CorMedix Inc 8-K, filed Nov 9, 2026
CorMedix Inc. (CRMD)
About this 8-K
CorMedix Inc filed this 8-K on November 9, 2026, reporting on events of November 8, 2026.
On November 8, 2026, CorMedix Inc. agreed to acquire substantially all Heron Therapeutics, Inc. assets for $145.0 million cash and 14,583,333 shares, plus contingent royalties and earn-outs. AI summary
Items reported
- Item 1.01: Entered into a material agreement
- Item 2.03: New debt or off-balance-sheet obligation
- Item 3.02: Unregistered sale of equity
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (I.R.S. Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s
telephone number, including area code: (
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement.
Asset Purchase Agreement
On November 8, 2026, CorMedix Inc., a Delaware corporation (the “Company,” “CorMedix,” “we,” “our” and “us”), and Heron Therapeutics, Inc., a Delaware corporation (the “Seller” or “Heron”), entered into an Asset Purchase Agreement (the “Purchase Agreement”), pursuant to which the Seller has agreed to sell substantially all of its assets to the Company, other than certain excluded assets, and the Company has agreed to acquire those assets and assume certain liabilities of the Seller as set forth in the Purchase Agreement (the “Asset Sale” or the “Proposed Transaction”).
As consideration for the Asset Sale, the Company has agreed to (i) issue to the Seller 14,583,333 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”) (the “Stock Consideration”), (ii) pay to the Seller a purchase price equal to $145.0 million in cash, subject to certain adjustments for the Seller’s closing cash and net working capital as set forth in the Purchase Agreement (the “Cash Consideration”), of which $2.0 million will be deposited into escrow with Citibank, N.A., as escrow agent, at the Closing to secure post-Closing adjustments to the Cash Consideration, which post-Closing adjustments may not exceed $10.0 million in either direction, (iii) pay to the Seller royalties equal to 5.0% of the amount, if any, by which aggregate annual net sales of CINVANTI®, SUSTOL® and the products covered by Seller’s multi-Product Development and License Agreement exceed $25.0 million in each of calendar years 2027, 2028 and 2029, if and when payable, on the terms set forth in the Purchase Agreement, (iv) pay to the Seller earn-out payments of $25.0 million if net sales of ZYNRELEF® for calendar year 2028 equal or exceed $65.0 million and an additional $30.0 million if such net sales equal or exceed $95.0 million, payable at the Company’s election in cash, shares of Common Stock or a combination thereof (provided that any portion that would cause the aggregate shares of Common Stock issued under the Purchase Agreement to exceed 19.9% of the Common Stock outstanding as of the closing of the Asset Sale (the “Closing”) will be paid in cash), if and when payable, on the terms set forth in the Purchase Agreement and (v) assume certain liabilities of the Seller as specified in the Purchase Agreement.
The Purchase Agreement contains customary representations, warranties and covenants of the parties, including covenants concerning the conduct of the Seller’s business prior to the Closing, certain restrictions on the Company prior to the Closing, including with respect to amendments to its organizational documents, recapitalizations, stock splits and share repurchases, and customary provisions regarding indemnification obligations of (i) the Seller with respect to liabilities retained by the Seller and the Seller’s post-Closing covenants and agreements in the Purchase Agreement and (ii) the Company with respect to liabilities assumed by the Company and the Company’s post-Closing covenants and agreements. Following the Closing, the Seller will be subject to certain restrictive covenants, including a five-year covenant not to engage in any business worldwide involving the treatment of chemotherapy-induced or post-operative nausea and vomiting with injectable products containing aprepitant or granisetron or the treatment of post-operative pain with non-opioid anesthetics containing bupivacaine or low-dose meloxicam, subject to certain exceptions, and a three-year covenant not to solicit employees who transfer to the Company, subject to certain exceptions. The Company has also agreed to a reciprocal three-year covenant not to solicit certain employees of the Seller, subject to certain exceptions. The representations and warranties of the parties do not survive the Closing, and the Seller will have no liability following the Closing for any breach of its representations and warranties, other than in the case of fraud. The Company and the Seller have agreed to use their reasonable best efforts to consummate the Asset Sale and the other transactions contemplated by the Purchase Agreement. The Company’s obligation to consummate the Asset Sale is not subject to any financing conditions.
Additionally, pursuant to the Purchase Agreement, the Seller has agreed, subject to certain exceptions with respect to unsolicited proposals, not to directly or indirectly solicit competing proposals or to enter into discussions concerning, or provide confidential information in connection with, any competing proposals. The Seller has also agreed to cease all existing discussions with third parties regarding any competing proposals.
1
However, at any time prior to obtaining the approval of the Seller’s stockholders, the Seller’s board of directors (the “Seller Board”) may, subject to certain conditions, change its recommendation in favor of approving the Purchase Agreement in response to a bona fide competing proposal that was not solicited in material breach of the non-solicit provisions set forth in the Purchase Agreement, if the Seller Board determines in good faith, after consulting with the Seller’s financial advisor and outside legal counsel, that the competing proposal is a superior proposal and determines in good faith that the failure to effect such a change in recommendation in response to such superior proposal would be reasonably likely to be inconsistent with the directors’ fiduciary duties under applicable law. The Seller may also terminate the Purchase Agreement in order to enter into a definitive agreement providing for a superior proposal, but only if (i) the Seller has complied in all material respects with its obligations, including the non-solicit provisions, set forth in the Purchase Agreement with respect to the superior proposal, (ii) the Seller pays the $4.0 million termination fee described below and (iii) the Seller Board has authorized the Seller to enter into a definitive agreement providing for the superior proposal.
The Seller Board also may, subject to certain conditions, change its recommendation in favor of approving the Purchase Agreement (but the Seller may not terminate the Purchase Agreement) in response to certain “intervening events” if it determines in good faith that the failure to effect such change in recommendation would be reasonably likely to be inconsistent with the directors’ fiduciary duties under applicable law.
The board of directors of the Company (the “Board”) has unanimously approved the Purchase Agreement, the Asset Sale and the other transactions contemplated by the Purchase Agreement and has agreed to recommend that the Company’s stockholders approve the Purchase Agreement, the Asset Sale and the other transactions contemplated by the Purchase Agreement. The Purchase Agreement, the Asset Sale and other transactions contemplated by the Purchase Agreement must also be approved by the holders of a majority of the issued and outstanding shares of the Seller’s common stock entitled to vote thereon (the “Seller Stockholder Approval”). No vote of the Company’s stockholders is required in connection with the Asset Sale or the issuance of the Stock Consideration. In addition to the receipt of the Seller Stockholder Approval, each party’s obligation to consummate the Asset Sale is conditioned upon certain other customary closing conditions, including the expiration or termination of any applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and any other required antitrust filings, the approval for listing on the Nasdaq Global Market of the shares of Common Stock issuable as Stock Consideration, the accuracy of the other party’s representations and warranties as of the Closing, subject, in certain instances, to certain materiality and other thresholds, the performance by the other party of its obligations and covenants under the Purchase Agreement in all material respects, the absence of a material adverse effect with respect to the other party, the delivery of certain documentation by the other party, and the absence of any injunction or other legal prohibitions preventing consummation of the Asset Sale.
If the Closing has not occurred by the date that is six months after the date of the Purchase Agreement (the “Outside Date”), the Seller Stockholder Approval is not obtained at a duly convened meeting of the Seller’s stockholders as discussed above or there shall be in place any final and non-appealable injunction or other legal prohibition permanently preventing consummation of the Asset Sale, either the Company or the Seller may terminate the Purchase Agreement. The Purchase Agreement contains certain additional termination rights for both the Company and the Seller, and further provides that, upon termination of the Purchase Agreement under specified circumstances, the Seller will be required to pay the Company a termination fee of $4.0 million. Those circumstances include, among others, (i) the termination of the Purchase Agreement by the Company following the Seller Board changing its recommendation in favor of the Asset Sale or approving or recommending a competing proposal, (ii) the termination of the Purchase Agreement by the Seller to enter into a definitive agreement with respect to a superior proposal, or (iii) the termination of the Purchase Agreement (a) by either party due to the failure of the Closing to occur by the Outside Date, if a competing proposal was publicly announced after the date of the Purchase Agreement and prior to such termination and was not publicly withdrawn prior to such termination, (b) by either party due to the failure to obtain the Seller Stockholder Approval, if a competing proposal was publicly announced after the date of the Purchase Agreement and prior to the stockholder vote and was not publicly withdrawn prior to the stockholder meeting, or (c) by the Company due to a breach by the Seller of any of its representations, warranties, covenants or agreements under the Purchase Agreement that would result in the failure of a closing condition and that is not cured within a specified period, in each case if a competing proposal was publicly announced after the date of the Purchase Agreement and prior to such breach and was not publicly withdrawn prior to such termination (or, in the case of the failure to obtain the Seller Stockholder Approval, prior to the stockholder meeting), and, in each case, within 12 months following such termination, the Seller enters into a definitive agreement with respect to, or consummates, a competing transaction with respect to such competing proposal. In addition, if the Purchase Agreement is terminated due to the failure to obtain the Seller Stockholder Approval, or is otherwise terminated at a time when the Company could have terminated it on that basis, the Seller will be required to reimburse the Company for its documented and reasonable out-of-pocket expenses, up to $2.5 million, which amount will be credited against any termination fee subsequently payable (and no such reimbursement will be payable if the termination fee has previously been paid). Notwithstanding any termination of the Purchase Agreement, each party remains liable to the other party for any willful breach of the Purchase Agreement prior to such termination.
2
At the Closing, the Company, the Seller and Rubric Capital Manager LP, as manager or sub-manager of certain funds and accounts (“Rubric”) will enter into a Registration Rights Agreement, substantially in the form attached as an exhibit to the Purchase Agreement (the “Registration Rights Agreement”), pursuant to which the Company will agree to file a registration statement covering the resale of the Stock Consideration within 90 days following the Closing and use commercially reasonable efforts to cause such registration statement to become effective within 60 days after such filing deadline (or earlier under certain circumstances as set forth in the Registration Rights Agreement). The Registration Rights Agreement also provides the Seller and Rubric with certain rights to participate in underwritten shelf takedown offerings, piggyback registrations and block trades subject to certain conditions.
Voting and Support Agreement
On November 8, 2026, the Company and the Seller entered into separate Voting and Support Agreements (the “Voting Agreements”) with Rubric and funds managed by Velan Capital Investment Management LP, and each of the Seller’s directors and executive officers (collectively, the “Supporting Stockholders”). Collectively, the Supporting Stockholders beneficially own approximately 22% of the outstanding shares of the Seller’s common stock. Each Supporting Stockholder entered into its Voting Agreement solely in its capacity as a stockholder of the Seller, and the Voting Agreements do not restrict the actions of any director or officer of the Seller in his or her capacity as a director or officer of the Seller.
Each Supporting Stockholder’s Voting Agreement generally requires that such Supporting Stockholder vote or cause to be voted all shares of the Seller’s common stock owned by such Supporting Stockholder (i) in favor of the adoption of the Purchase Agreement and the approval of the transactions contemplated thereby, any proposal to adjourn or postpone the stockholder meeting if there are not sufficient votes to obtain the Seller Stockholder Approval, and any other matters necessary to obtain the Seller Stockholder Approval, and (ii) against any competing proposal or competing transaction, any other action or agreement that would reasonably be expected to result in the failure of a closing condition under the Purchase Agreement or a material breach of the Seller’s obligations under the Purchase Agreement, and any other matter that would reasonably be expected to materially impede, frustrate, delay or interfere with the consummation of the Asset Sale. No Supporting Stockholder is required to vote in favor of the Purchase Agreement as amended by any amendment entered into without its consent that decreases the amount of, changes the form or terms of or delays the timing of payment or allocation of any portion of the consideration payable under the Purchase Agreement (including the royalty and earn-out payments), imposes material restrictions or additional material conditions on the consummation of the Asset Sale or the payment of such consideration, or is otherwise materially adverse to such Supporting Stockholder or the Seller’s other stockholders (an “Adverse Amendment”). In addition, until the termination of the Voting Agreements, each Voting Agreement restricts that Supporting Stockholder from transferring shares of the Seller’s common stock owned by that Supporting Stockholder, subject to certain exceptions, and requires that Supporting Stockholder to comply with the non-solicitation restrictions applicable to the Seller under the Purchase Agreement.
Generally, each Voting Agreement will terminate upon the earliest to occur of (a) the Closing, (b) the termination of the Purchase Agreement in accordance with its terms, (c) the entry into or adoption of an Adverse Amendment, (d) the mutual written agreement of the parties thereto and (e) a change in the Seller Board’s recommendation in favor of the Asset Sale, provided that such change in recommendation is made in compliance with the Seller’s obligations under the Purchase Agreement.
Seller Governance Agreement
Concurrently with the execution of the Purchase Agreement, the Company and the Seller entered into a Governance Agreement (the “Seller Governance Agreement”), which will become effective as of, and contingent upon, the Closing. Pursuant to the Seller Governance Agreement, for so long as the Seller beneficially owns at least 10% of the outstanding Common Stock, subject to certain adjustments, the Seller will be entitled to designate one individual who qualifies as independent and is reasonably acceptable to the Board for appointment or nomination to the Board. For so long as the Seller beneficially owns at least 1% of the outstanding Common Stock, the Seller has agreed to cause its shares to be present for quorum purposes at meetings of the Company’s stockholders, and, for so long as the Seller beneficially owns at least 5% of the outstanding Common Stock, the Seller has agreed to vote its shares of Common Stock in favor of the Board’s director nominees and otherwise in accordance with the recommendation of the Board, subject to certain exceptions, and, with respect to certain extraordinary transactions in the same proportion as the votes cast by the Company’s other stockholders, other than the Seller and the Company’s directors and executive officers and their respective affiliates. The Seller Governance Agreement also contains customary standstill provisions that apply until the Seller’s ownership falls below 1%, including a prohibition on the Seller acquiring beneficial ownership of, or an aggregate economic or voting interest in, more than 19.9% of the outstanding Common Stock, and prohibits the Seller from transferring the shares of Common Stock it receives as Stock Consideration for six months following the Closing, subject to certain exceptions. Following the expiration of such lock-up period, the Seller may distribute such shares pro rata to its stockholders, and the Seller’s open-market sales of Common Stock will be subject to certain volume limitations, which limitations will terminate if the registration statement covering the resale of the Stock Consideration is not timely declared effective or ceases to be available. The Seller has also agreed to restrictions on transfers to certain holders of more than 5% of the Common Stock, and to customary confidentiality and non-disparagement covenants. The Seller Governance Agreement will terminate upon the earliest to occur of (i) the third anniversary of the Closing, (ii) the consummation of a change of control of the Company, (iii) the first date on which the Seller’s ownership of Common Stock falls below 1% and (iv) the mutual written agreement of the parties, and will automatically terminate if the Purchase Agreement is terminated prior to the Closing.
3
Stockholder Governance Agreement
Concurrently with the execution of the Purchase Agreement, the Company entered into a Stockholder Governance Agreement (the “Stockholder Governance Agreement”) with Rubric, which, except for certain provisions, will become effective as of, and contingent upon, the Closing. In connection with the Asset Sale, the Seller and Rubric entered into an Exchange Agreement, dated November 8, 2026 (the “Exchange Agreement”), pursuant to which the Seller will transfer a portion of the Stock Consideration to Rubric and the other purchasers under the Note Purchase Agreement, dated as of August 8, 2025, among the Seller, Rubric, as agent, and such purchasers (the “Note Purchase Agreement”), in satisfaction of the Seller’s obligations thereunder (the shares so transferred, the “Rubric Stock Consideration”). Pursuant to the Stockholder Governance Agreement, Rubric, on behalf of itself and such purchasers, has consented to the Asset Sale for all purposes under the Note Purchase Agreement and has acknowledged that the Company will not assume any obligations thereunder. From the Closing until the earlier of the date on which all of the Rubric Stock Consideration has been transferred to Rubric and December 31, 2027 (the “Final Exchange Date”), and thereafter for so long as Rubric beneficially owns at least 1% of the outstanding Common Stock, Rubric has agreed to cause its shares to be present for quorum purposes at meetings of the Company’s stockholders. Through the Final Exchange Date, and thereafter for so long as Rubric beneficially owns at least 5% of the outstanding Common Stock, Rubric has agreed to vote its shares in favor of the Board’s director nominees and otherwise in accordance with the Board’s recommendations, subject to certain exceptions, issues a differing recommendation and with respect to certain amendments to the Company’s organizational documents that would adversely affect Rubric. Through the Final Exchange Date, and thereafter for so long as Rubric beneficially owns at least 1% of the outstanding Common Stock, Rubric has agreed to vote its shares on any extraordinary transaction in the same proportion as the votes cast by the Company’s other stockholders, other than Rubric and the Company’s directors and executive officers and their respective affiliates, and to be subject to customary standstill provisions, including a prohibition on acquiring beneficial ownership of, or an aggregate economic or voting interest in, more than 19.9% of the outstanding Common Stock. The Stockholder Governance Agreement prohibits Rubric from transferring the Rubric Stock Consideration for six months following the Closing, subject to certain exceptions. Following such lock-up period, Rubric’s open-market sales of Common Stock will be subject to certain volume limitations, which limitations will terminate if the registration statement covering the resale of the Stock Consideration is not timely declared effective or ceases to be available. Rubric has also agreed to restrictions on transfers to certain activist investors and holders of more than 5% of the Common Stock, and to customary confidentiality and non-disparagement covenants. The Stockholder Governance Agreement will terminate upon the earliest to occur of (i) the third anniversary of the Closing, (ii) the consummation of a change of control of the Company, (iii) the first date after the Final Exchange Date on which Rubric’s ownership of Common Stock falls below 1% and (iv) the mutual written agreement of the parties, and will automatically terminate if the Purchase Agreement is terminated prior to the Closing.
Loan Agreement
On November 8, 2026, CorMedix, certain subsidiaries of CorMedix party thereto as guarantors, BioPharma Credit PLC, as collateral agent, and each of BPCR Limited Partnership and BioPharma Credit Investments V (Master) LP, which are funds managed by Pharmakon Advisors, LP, as lenders (the “Lenders”), entered into that certain loan agreement (the “Loan Agreement”), which provides for a senior secured term loan facility in an aggregate principal amount of up to $150,000,000, consisting of two tranches: (i) a term loan in an aggregate principal amount of $75,000,000 (the “Tranche A Loan”), the proceeds of which are to be used to fund the Proposed Transaction, and (ii) a term loan in an aggregate principal amount of up to $75,000,000 (the “Tranche B Loan” and, together with the Tranche A Loan, the “Term Loans”), the proceeds of which may be used to fund certain other acquisitions or in-licensing transactions involving commercial-stage pharmaceutical products. The obligations of the Lenders to fund the Term Loans are subject to the satisfaction of customary closing conditions and certain other conditions specified in the Loan Agreement.
The Tranche A Loan is available to be funded on or prior to May 8, 2027, subject to the consummation of the Proposed Transaction and the satisfaction of the applicable funding conditions. The Tranche B Loan may be funded either before or after the Tranche A Loan. If the Tranche B Loan is funded before the Tranche A Loan, CorMedix must borrow between $50,000,000 and $75,000,000, so long as funded prior to July 30, 2028, subject to the satisfaction of the applicable funding conditions.
4
Maturity
The Term Loans mature on the fifth anniversary of the date on which the first Term Loan is funded (the “Maturity Date”), subject to a springing earlier maturity if on the date that is ninety (90) days before the Maturity Date, (x) consolidated total gross leverage of CorMedix and its subsidiaries exceeds 3.00x and (y) more than $25,000,000 of CorMedix’s 4.00% convertible senior notes due August 1, 2030 (the “2030 Convertible Notes”) remain outstanding (the “Maturity Date Acceleration Trigger”).
Interest and Fees
The Term Loans will bear interest at a rate equal to three-month Term SOFR, subject to a floor of 3.50%, plus 5.75% per annum. Interest on the Term Loans will be payable quarterly in arrears. CorMedix will be required to make equal quarterly principal payments beginning on the last day of the fiscal quarter ending on or immediately following the third anniversary of the initial funding date, with the remaining outstanding principal balance due on the Maturity Date; provided that, if either of (x) CorMedix’s revenues from REZZAYO have equaled or exceed $95,000,000 for the trailing twelve-month period ending September 30, 2029, or (y) the consolidated total gross leverage ratio of CorMedix and its subsidiaries does not exceed 3.0x as of September 30, 2029, CorMedix may elect to defer the commencement of scheduled principal amortization until the last day of the fiscal quarter ending on or immediately following the fourth anniversary of the initial funding date. CorMedix will also be required to pay additional consideration equal to 1.5% of the principal amount of each Term Loan upon the funding thereof.
Prepayments
CorMedix may voluntarily prepay the Term Loans, in whole or in part, subject to certain minimum prepayment amounts and notice requirements. The Loan Agreement also contains certain mandatory prepayment provisions upon the occurrence of certain events, including a change in control of CorMedix and certain prepayments, repurchases or redemptions of the 2030 Convertible Notes, subject to specified exceptions. Certain prepayments of the Term Loans will be required to be accompanied by a make-whole amount if made prior to the second anniversary of the funding date of the applicable Term Loan. The make-whole amount does not apply if such payment occurs as a result of the acceleration of the Maturity Date upon the occurrence of the Maturity Date Acceleration Trigger. Certain prepayments of the Term Loans will be subject to a prepayment premium equal to 3.0% of the principal amount prepaid prior to the third anniversary of the applicable funding date, 2.0% on or after the third anniversary but prior to the fourth anniversary, and 1.0% thereafter and prior to the Maturity Date.
Guarantees
All obligations under the Loan Agreement are unconditionally guaranteed jointly and severally, by: (a) CorMedix and (b) substantially all of the direct and indirect wholly owned subsidiaries of CorMedix, other than certain excluded subsidiaries (collectively, the “Guarantors”).
Security
Subject to certain limitations, the Term Loans are secured on a first priority basis by: (a) a perfected security interest in the equity interests of each direct and indirect subsidiary of CorMedix and each Guarantor under the Term Loans (subject to certain customary exceptions) and (b) perfected security interests in, and mortgages on, substantially all tangible and intangible personal property and real property of CorMedix and each of the Guarantors with a fair market value of over $5,000,000 under the Term Loans, subject, in each case, to certain exceptions.
Certain Covenants, Representations and Warranties, and Events of Default
The Loan Agreement contains certain affirmative and restrictive covenants, representations and warranties and events of default that are customary for financings of this type. CorMedix and any of its future subsidiaries are bound by certain affirmative covenants setting forth actions that are required during the term of the Loan Agreement, including, without limitation covenants relating to the maintenance of CorMedix’s existence, delivery of financial statements and other information, maintenance of insurance, compliance with applicable laws, protection of intellectual property, maintenance of regulatory approvals, and maintenance of manufacturing capacity for certain products. Additionally, CorMedix and any of its future subsidiaries are bound by certain restrictive covenants setting forth actions that are not permitted to be taken during the term of the Loan Agreement, including, without limitation, incurring additional indebtedness, creating liens, disposing of assets, making investments and acquisitions, paying dividends or making other distributions, merging or consolidating with other entities, and entering into certain transactions involving royalty arrangements or other financing obligations. The Loan Agreement also contains certain events of default, including with respect to the failure to make payments under the Term Loans, cross default, certain bankruptcy and insolvency events, the occurrence of a material adverse change and certain events relating to the withdrawal of regulatory approvals for specified pharmaceutical products.
5
The Loan Agreement does not contain any financial covenants.
The foregoing descriptions of the Purchase Agreement, the Voting Agreements, the Seller Governance Agreement, the Stockholder Governance Agreement and the Loan Agreement and the transactions contemplated thereby do not purport to be complete and are subject to, and qualified in their entirety by, the full texts of the Purchase Agreement, the form of Voting Agreement, the Seller Governance Agreement, the Stockholder Governance Agreement and the Loan Agreement, copies of which are attached hereto as Exhibits 2.1, 10.1, 10.2, 10.3 and 10.4, respectively, and are incorporated herein by reference. The Purchase Agreement has been included as an exhibit hereto solely to provide investors and stockholders with information regarding its terms. It is not intended to provide any other factual information about the Company or the Seller. The representations, warranties and covenants contained in the Purchase Agreement were made only for purposes of the Purchase Agreement as of the specific dates therein, were solely for the benefit of the parties to the Purchase Agreement, may be subject to qualifications and limitations agreed upon by the contracting parties, including being qualified by confidential disclosures made for the purposes of allocating contractual risk between the parties to the Purchase Agreement instead of establishing these matters as facts, and may be subject to standards of materiality applicable to the contracting parties that differ from those applicable to investors. Investors are not third-party beneficiaries under the Purchase Agreement and should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of the Company or the Seller. Moreover, information concerning the subject matter of the representations and warranties may change after the date of the Purchase Agreement, which subsequent information may or may not be fully reflected in the parties’ public disclosures.
Item 2.03 Creation of a Direct Financial Obligation.
The information set forth in Item 1.01 with respect to the Loan Agreement is incorporated herein by reference.
Item 3.02 Unregistered Sales of Equity Securities.
The information set forth in Item 1.01 of this Current Report on Form 8-K regarding the Stock Consideration and the earn-out payments is incorporated by reference into this Item 3.02. The shares of Common Stock to be issued as Stock Consideration, and any shares of Common Stock issued in satisfaction of the earn-out payments, will be issued in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), as a transaction by an issuer not involving a public offering.
Item 7.01 Regulation FD Disclosure.
On November 9, 2026, the Company and the Seller issued a joint press release announcing the execution of the Purchase Agreement. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1 and incorporated by reference herein.
The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.
Additional Information and Where to Find It
In connection with the proposed transaction by CorMedix to purchase substantially all of the assets of Heron (the “Proposed Transaction”), Heron intends to file with the SEC a proxy statement on Schedule 14A. Each of CorMedix and Heron may also file other relevant documents with the SEC regarding the Proposed Transaction. This Current Report on Form 8-K is not a substitute for the proxy statement or any other document that Heron may file with the SEC. Heron will mail the definitive proxy statement to its stockholders. INVESTORS AND STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and stockholders may obtain these documents free of charge at the SEC’s website, www.sec.gov, and on the Investors section of CorMedix’s investor relations website at https://cormedix.com/investors/ and Heron’s investor relations website at https://ir.herontx.com/.
6
Participants in the Solicitation
CorMedix, Heron and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from Heron’s stockholders in connection with the Proposed Transaction. Information about the directors and executive officers of Heron, including a description of their direct or indirect interests, by security holdings or otherwise, is set forth in its proxy statement for its 2026 annual meeting of stockholders, filed with the SEC on April 30, 2026, which is available online at https://www.sec.gov/ix?doc=/Archives/edgar/data/818033/000119312526196306/hrtx-20260430.htm, under the headings “Information Concerning the Board of Directors,” “Information Concerning Executive Officers,” “Corporate Governance – 2025 Director Compensation,” “Security Ownership of Certain Beneficial Owners and Management,” “Certain Relationships and Related Person Transactions” and “Executive Compensation,” and information about the directors and executive officers of CorMedix, including a description of their direct or indirect interests, by security holdings or otherwise, is set forth in its proxy statement for its 2026 annual meeting of stockholders, filed with the SEC on April 29, 2026, which is available online at https://www.sec.gov/ix?doc=/Archives/edgar/data/1410098/000121390026049311/ea0286136-05.htm, under the headings “Proposal No. 1 – Approval of the Director Election Proposal,” “Corporate Governance – Executive Officers,” “Security Ownership of Certain Beneficial Owners and Management,” “Director Compensation,” “Executive Compensation” and “Certain Relationships and Related Transactions,” and, in each case, in subsequently filed Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Forms 3, 4 and 5. Additional information regarding the interests of such participants will be included in the proxy statement and other relevant materials to be filed with the SEC when they become available.
Other information regarding the participants in the solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be set forth in Heron’s definitive proxy statement and other relevant materials to be filed with the SEC regarding the Proposed Transaction when such materials become available. Investors and stockholders should read the proxy statement carefully when it becomes available before making any voting or investment decisions. Copies of these documents may be obtained, free of charge, from the sources indicated above.
No Offer or Solicitation
This Current Report on Form 8-K is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The shares of CorMedix common stock to be issued to Heron in the Proposed Transaction will be issued in a private placement in reliance on an exemption from the registration requirements of the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration.
Forward-Looking Statements
This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Exchange Act, that are subject to risks and uncertainties. Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “guidance,” “intend,” “may,” “plan,” “potential,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions. All statements, other than statements of historical facts, should be considered forward-looking statements, including, but not limited to, statements regarding the Proposed Transaction; Heron’s ability to provide an additional revenue base of four FDA-approved commercial brands, with opportunities to drive future growth; the expected timing of closing; the anticipated benefits of the Proposed Transaction, including expected synergies, diversification of revenue base and the expectation that the Proposed Transaction will be accretive to earnings; statements regarding product strategy, growth and label expansion opportunities; development and expectations of CorMedix’s and Heron’s product pipeline, results of real-world studies, expectations regarding product utilization, reimbursement rates, and market access, including changes in CMS reimbursement methodology; the potential achievement of earn-out milestones and royalty payments; the commercial potential of ZYNRELEF and the other acquired products; the development of the acquired pipeline program; the terms, funding and availability of the Pharmakon term loan facility; CorMedix’s ability to pursue future business development transactions; estimates of total addressable market size; and Heron’s plans following the closing, including its expectation to remain a publicly traded company.
7
These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including: Heron’s failure to obtain stockholder approval or required regulatory clearances, or to satisfy other closing conditions, on a timely basis or at all; CorMedix’s ability to successfully integrate the acquired assets, achieve anticipated synergies or accretion, and EBITDA or Adjusted EBITDA on a timely basis or at all; the amount of any adjustments to the consideration under the asset purchase agreement; the occurrence of any event that could give rise to termination of the asset purchase agreement, including circumstances requiring Heron to pay a termination fee; the risk that CorMedix’s or Heron’s stock price may decline if the Proposed Transaction is not completed; fluctuations in the price of CorMedix common stock; dilution to CorMedix’s stockholders; disruption to CorMedix’s and Heron’s business relationships with customers, suppliers and employees, including as a result of the announcement or pendency of the Proposed Transaction, and diversion of management’s attention; restrictions on the conduct of Heron’s business while the Proposed Transaction is pending; unexpected costs, liabilities or delays relating to the Proposed Transaction and the acquired products; market acceptance and reimbursement of the acquired products, including continued eligibility for separate payment under the NOPAIN Act; changes to reimbursement rates and methodology, customer utilization, and other factors impacting the demand for CorMedix’s and Heron’s products; competition; manufacturing and supply risks; the incurrence of indebtedness and compliance with covenants under the Pharmakon facility; litigation relating to the Proposed Transaction; uncertainty about CorMedix’s or Heron’s business, operations and strategy after the consummation of the Proposed Transaction, including (i) the risk that Heron may not identify, pursue or complete an acquisition of, or investment in, another business, (ii) the risk that Heron may not find opportunities to utilize its NOLs after the consummation of the Proposed Transaction or that its ability to use its NOLs may be limited or lost, (iii) Heron’s plans with respect to shares of CorMedix common stock received by Heron as consideration in the Proposed Transaction, including uncertainty and timing of any sales, transfers or other distributions of such shares, (iv) the risk that the value of CorMedix common stock received by Heron as consideration in the Proposed Transaction may decline and that Heron may be unable to sell or otherwise monetize such shares when or at the price it expects and (v) Heron’s lack of operating revenues or material operations following the closing, the risk that Heron may not regain or maintain compliance with Nasdaq’s continued listing requirements, and the risk that Heron may be deemed an investment company under the Investment Company Act of 1940; and the other risks described in the periodic reports filed by CorMedix and Heron with the Securities and Exchange Commission (“SEC”), including their most recent Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, copies of which are available free of charge at the SEC’s website at www.sec.gov or upon request from CorMedix and Heron, as applicable. All forward-looking statements are expressly qualified in their entirety by this cautionary statement, and readers are cautioned not to place undue reliance on them. Forward-looking statements speak only as of the date of this Current Report on Form 8-K, and neither CorMedix nor Heron undertakes any obligation to update them, except as required by law.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| * | Certain schedules and exhibits to this agreement have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant will furnish copies of any such schedules and exhibits to the U.S. Securities and Exchange Commission upon request; however, the registrant may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any schedules so furnished. |
8
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CorMedix Inc. | |
| Date: November 9, 2026 | /s/ Joseph Todisco |
| Joseph Todisco | |
| Chief Executive Officer | |
9
Exhibit 2.1
Execution Version
ASSET PURCHASE AGREEMENT
by and between
HERON THERAPEUTICS, INC.,
as Seller
and
CORMEDIX INC.,
as Buyer
Dated as of November 8, 2026
TABLE OF CONTENTS
| Page | ||||
| ARTICLE I DEFINITIONS | 2 | |||
| Section 1.1 | Certain Defined Terms | 2 | ||
| Section 1.2 | Table of Definitions | 21 | ||
| ARTICLE II PURCHASE AND SALE | 24 | |||
| Section 2.1 | Purchase and Sale of Assets | 24 | ||
| Section 2.2 | Excluded Assets | 25 | ||
| Section 2.3 | Assumed Liabilities | 26 | ||
| Section 2.4 | Excluded Liabilities | 27 | ||
| Section 2.5 | Consents to Certain Assignments | 28 | ||
| Section 2.6 | Transaction Consideration | 29 | ||
| Section 2.7 | Closing | 29 | ||
| Section 2.8 | Withholding | 30 | ||
| Section 2.9 | Adjustments to Stock Consideration | 31 | ||
| Section 2.10 | Purchase Price Adjustment | 31 | ||
| Section 2.11 | Royalty Payments and Earn-Out Payments | 33 | ||
| ARTICLE III REPRESENTATIONS AND WARRANTIES OF SELLER | 33 | |||
| Section 3.1 | Organization and Qualification | 33 | ||
| Section 3.2 | Authority | 34 | ||
| Section 3.3 | No Conflict; Required Filings and Consents | 34 | ||
| Section 3.4 | Transferred Assets | 35 | ||
| Section 3.5 | Financial Information; SEC Filings | 35 | ||
| Section 3.6 | Absence of Certain Changes or Events | 38 | ||
| Section 3.7 | Compliance with Law; Permits | 38 | ||
| Section 3.8 | Litigation | 40 | ||
| Section 3.9 | FCPA; Anti-Corruption and Anti-Bribery Laws | 40 | ||
| Section 3.10 | Business Employees and Employee Plans | 41 | ||
| Section 3.11 | Labor and Employment Matters | 42 | ||
| Section 3.12 | Insurance | 43 | ||
| Section 3.13 | Intellectual Property | 43 | ||
| Section 3.14 | Privacy and Data Security | 46 | ||
| Section 3.15 | Taxes | 47 | ||
| Section 3.16 | Environmental Matters | 48 | ||
| Section 3.17 | Material Contracts | 48 | ||
| Section 3.18 | Customers and Suppliers | 49 | ||
| Section 3.19 | Transferred Inventory; Transferred Equipment | 50 | ||
| Section 3.20 | Affiliate Transactions | 50 | ||
| Section 3.21 | Brokers | 50 | ||
i
TABLE OF CONTENTS
(Continued)
| Page | ||||
| Section 3.22 | International Trade | 50 | ||
| Section 3.23 | Disclosure Documents | 51 | ||
| Section 3.24 | Solvency | 51 | ||
| Section 3.25 | Excluded Entity | 51 | ||
| Section 3.26 | No Shared Contracts | 52 | ||
| ARTICLE IV REPRESENTATIONS AND WARRANTIES OF BUYER | 52 | |||
| Section 4.1 | Organization and Qualifications | 52 | ||
| Section 4.2 | Authority | 53 | ||
| Section 4.3 | Buyer Subsidiaries; Equity Interests | 53 | ||
| Section 4.4 | Capitalization | 53 | ||
| Section 4.5 | No Conflict; Required Filings and Consents | 54 | ||
| Section 4.6 | Absence of Certain Changes or Events | 55 | ||
| Section 4.7 | Compliance with Law | 55 | ||
| Section 4.8 | Litigation | 55 | ||
| Section 4.9 | Financing | 55 | ||
| Section 4.10 | Brokers | 56 | ||
| Section 4.11 | SEC Filings; Financial Statements; and the Sarbanes-Oxley Act | 56 | ||
| Section 4.12 | Disclosure Documents | 57 | ||
| Section 4.13 | No Stockholder Vote Required | 58 | ||
| Section 4.14 | Takeover Statutes | 58 | ||
| ARTICLE V COVENANTS | 58 | |||
| Section 5.1 | Conduct of Business Prior to the Closing | 58 | ||
| Section 5.2 | Covenants Regarding Information | 62 | ||
| Section 5.3 | Acquisition Proposals | 63 | ||
| Section 5.4 | Proxy Statement | 67 | ||
| Section 5.5 | Stockholders Meeting | 67 | ||
| Section 5.6 | Regulatory Matters | 68 | ||
| Section 5.7 | Employee Benefits | 69 | ||
| Section 5.8 | Confidentiality | 71 | ||
| Section 5.9 | Consents and Filings | 72 | ||
| Section 5.10 | Further Assurances; Conveyance | 74 | ||
| Section 5.11 | No Solicitation | 74 | ||
| Section 5.12 | Non-Competition | 74 | ||
| Section 5.13 | Anti-Circumvention | 75 | ||
| Section 5.14 | Restrictive Covenant Remedies | 75 | ||
| Section 5.15 | Insurance | 76 | ||
| Section 5.16 | Public Announcements | 77 | ||
ii
TABLE OF CONTENTS
(Continued)
| Page | ||||
| Section 5.17 | Buyer R&W Insurance Policy | 77 | ||
| Section 5.18 | Affiliate Transactions | 77 | ||
| Section 5.19 | Transaction Litigation | 78 | ||
| Section 5.20 | NDC Transition | 78 | ||
| Section 5.21 | Rebates; Chargebacks; Returns; Government Pricing | 78 | ||
| Section 5.22 | Cooperation in Litigation | 80 | ||
| Section 5.23 | Use of Name | 82 | ||
| Section 5.24 | Debt Financing Cooperation | 83 | ||
| ARTICLE VI TAX MATTERS | 86 | |||
| Section 6.1 | Tax Matters | 86 | ||
| Section 6.2 | Straddle Periods | 87 | ||
| Section 6.3 | Cooperation on Tax Matters | 87 | ||
| Section 6.4 | Transfer Taxes | 87 | ||
| ARTICLE VII CONDITIONS TO CLOSING | 88 | |||
| Section 7.1 | General Conditions | 88 | ||
| Section 7.2 | Conditions to Obligations of the Seller Parties | 88 | ||
| Section 7.3 | Conditions to Obligations of the Buyer Parties | 89 | ||
| Section 7.4 | Frustration of Closing Conditions | 89 | ||
| ARTICLE VIII INDEMNIFICATION | 90 | |||
| Section 8.1 | Survival of Representations, Warranties and Covenants | 90 | ||
| Section 8.2 | Indemnification by Seller | 90 | ||
| Section 8.3 | Indemnification by Buyer | 90 | ||
| Section 8.4 | Procedures | 91 | ||
| Section 8.5 | Limits on Indemnification | 92 | ||
| Section 8.6 | Exclusive Remedy | 93 | ||
| Section 8.7 | Treatment of Indemnity Payments | 94 | ||
| ARTICLE IX TERMINATION | 94 | |||
| Section 9.1 | Termination | 94 | ||
| Section 9.2 | Effect of Termination | 94 | ||
| Section 9.3 | Termination Fee | 96 | ||
| ARTICLE X GENERAL PROVISIONS | 98 | |||
| Section 10.1 | Fees and Expenses | 98 | ||
| Section 10.2 | Amendment and Modification | 98 | ||
| Section 10.3 | Waiver; Extension | 98 | ||
iii
TABLE OF CONTENTS
(Continued)
| Page | ||||
| Section 10.4 | Notices | 99 | ||
| Section 10.5 | Interpretation | 100 | ||
| Section 10.6 | Entire Agreement | 100 | ||
| Section 10.7 | Parties in Interest | 100 | ||
| Section 10.8 | Governing Law; Jurisdiction; Waiver of Jury Trial | 101 | ||
| Section 10.9 | Non-Reliance | 103 | ||
| Section 10.10 | Disclosure Generally | 104 | ||
| Section 10.11 | Personal Liability | 104 | ||
| Section 10.12 | Assignment; Successors | 104 | ||
| Section 10.13 | Enforcement | 104 | ||
| Section 10.14 | Severability | 105 | ||
| Section 10.15 | Counterparts; Signatures | 105 | ||
| Section 10.16 | Conflicts; Privilege | 105 | ||
| Section 10.17 | Financing Sources | 106 | ||
iv
TABLE OF CONTENTS
(Continued)
| Page | ||
| EXHIBITS: | ||
| Exhibit A – | Form of Bill of Sale and Assignment and Assumption Agreement | A-1 |
| Exhibit B – | Form of Intellectual Property Assignment Agreement | B-1 |
| Exhibit C – | Form of Registration Rights Agreement | C-1 |
| Exhibit D – | Form of Escrow Agreement | D-1 |
SCHEDULES:
Seller Disclosure Schedules
| Schedule 1.1A – | Business Products |
| Schedule 1.1B – | Seller Knowledge Individuals |
| Schedule 1.1C – | Buyer Knowledge Individuals |
| Schedule 1.1D – | Required Antitrust Approvals |
| Schedule 1.1E – | Accounting Principles |
| Schedule 1.1F – | Illustrative Closing Statement |
| Schedule 1.1G – | Business Employees |
| Schedule 1.1H – | Specified Employees |
| Schedule 1.1I – | Excluded Employee |
| Schedule 1.1J – | Royalty and Earn-Out Payments |
| Schedule 1.1K – | Termination Eligible Employees |
| Schedule 6.1(a) – | Allocation Exhibit |
v
ASSET PURCHASE AGREEMENT
ASSET PURCHASE AGREEMENT (this “Agreement”), dated as of November 8, 2026 (the “Agreement Date”), by and between Heron Therapeutics, Inc., a Delaware corporation (“Seller”), and CorMedix Inc., a Delaware corporation (“Buyer”). Capitalized terms used herein shall have the meanings ascribed to them in Article I or elsewhere in this Agreement.
RECITALS
A. Seller, through itself or one or more Affiliates (any such Affiliate that owns or holds any interest in any Transferred Assets, is the obligor of any Assumed Liabilities or employs a Business Employee, together with Seller, each a “Seller Party”), is engaged in the Business at various locations around the world.
B. Seller wishes to sell, and cause the Seller Parties to sell, to Buyer or one or more of its Affiliates (any such Affiliate that purchases Transferred Assets or assumes Assumed Liabilities, together with Buyer, each a “Buyer Party”), and Buyer wishes to purchase, or to cause another Buyer Party to purchase, from the Seller Parties, the Transferred Assets, and, in connection therewith, the Buyer Parties are willing to assume the Assumed Liabilities, all upon the terms and subject to the conditions set forth herein (collectively, the “Asset Sale”).
C. As of the Agreement Date, the board of directors of Seller (the “Seller Board”) has unanimously (a) determined that this Agreement and the Asset Sale, the Buyer Stock Issuance (as defined below), and the other transactions contemplated by this Agreement and the Ancillary Agreements (the “Transactions”) are fair to, and in the best interests of, Seller and its stockholders, (b) approved and declared advisable the execution, delivery and performance of this Agreement and the consummation of the Transactions, (c) directed that this Agreement and the Transactions be submitted to a vote at a meeting of the holders of issued and outstanding shares of Seller’s common stock, par value $0.01 per share (“Seller Common Stock”), for approval and (d) resolved to recommend that Seller’s stockholders approve this Agreement and the Transactions.
D. Concurrently with the execution and delivery of this Agreement, and as a condition and inducement to the willingness of Buyer to enter into this Agreement, Seller is entering into a governance agreement, in the form mutually agreed upon between Buyer and Seller (the “Seller Governance Agreement”), effective as of the Closing, pursuant to which, among other things, Seller has agreed to certain obligations in respect of the voting of the Buyer Common Stock it shall be entitled to receive upon the consummation of the Transactions, upon the terms and subject to the conditions and limitations set forth in the Seller Governance Agreement.
E. Concurrently with the execution and delivery of this Agreement, and as a condition and inducement to the willingness of Buyer to enter into this Agreement, certain stockholders of Seller are entering into governance agreements, in the form mutually agreed upon among the parties thereto (the “Stockholder Governance Agreement”), pursuant to which, among other things, such stockholders have agreed to certain obligations in respect of the voting of Buyer Common Stock such stockholders may receive if the Buyer Common Stock is issued or distributed to such stockholders as a result of the Transactions at, or at any time following, the consummation of the Transactions, in each case, upon the terms and subject to the conditions and limitations set forth in the Stockholder Governance Agreement.
F. Concurrently with the execution and delivery of this Agreement, and as a condition and inducement to the willingness of Buyer to enter into this Agreement, certain stockholders of Seller and certain directors and officers of Seller are entering into voting and support agreements, in the form mutually agreed upon among the parties thereto (the “Voting Agreements”), pursuant to which, among other things, such stockholders, directors and officers have agreed to vote all of their shares in favor of the adoption of this Agreement and to take certain other actions in furtherance of the Transactions, in each case, upon the terms and subject to the conditions and limitations set forth in the Voting Agreements.
G. The board of directors of Buyer has unanimously approved the issuance of shares of Buyer’s common stock, par value $0.001 per share (“Buyer Common Stock”), in connection with the Asset Sale and on the terms and subject to the conditions set forth in this Agreement (the “Buyer Stock Issuance”).
AGREEMENT
In consideration of the foregoing and the mutual covenants and agreements herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows:
Article
I
DEFINITIONS
Section 1.1 Certain Defined Terms. For purposes of this Agreement:
“Acquisition Proposal” means any bona fide offer, proposal or similar indication of interest contemplating or otherwise relating to an Acquisition Transaction (other than an offer, proposal or similar indication of interest by the Buyer Parties).
“Acquisition Transaction” means any transaction or series of related transactions (other than the Transactions) involving: (a) any acquisition or purchase by any Person, directly or indirectly, of more than twenty percent (20%) of any class of outstanding voting or equity securities of Seller, or any tender offer (including a self-tender offer) or exchange offer that, if consummated, would result in such Person beneficially owning more than twenty percent (20%) of any class of outstanding voting or equity securities of Seller; (b) any merger, consolidation, share exchange, business combination, joint venture, recapitalization, reorganization or other similar transaction involving Seller and any Person that, if consummated, would result in such Person beneficially owning more than twenty percent (20%) of any class of outstanding voting or equity securities of Seller, but expressly excluding any transaction or series of transactions that exclusively relate to any Excluded Assets; or (c) any sale, lease, exchange, transfer or other disposition to any Person of more than twenty percent (20%) of the consolidated assets, revenue or net income of the Transferred Assets or the Business (with assets being measured by the fair market value thereof), but expressly excluding any transaction or series of transactions that exclusively relate to any Excluded Assets; provided, that, for the avoidance of doubt, all references to “Person” in this definition shall include any “group” as defined pursuant to Section 13(d) of the Exchange Act but shall exclude Buyer and any of its Affiliates or Representatives.
2
“Action” means any claim, complaint, charge, demand, assessment, litigation, injunction, suit, action, qui tam, whistleblower suit, proceeding, arbitration, mediation, audit, investigation, hearing, or administrative proceeding (in each case, whether civil, criminal, administrative or investigative) commenced, brought, conducted or heard by or before or otherwise involving, any Governmental Authority.
“Additional Employee” means any employee of Seller who is not listed on Schedule 1.1G as of the Agreement Date and whom Buyer designates, in accordance with Section 5.7(b), to be added as a Business Employee by making a Qualified Offer to such employee.
“Affiliate” means, with respect to any Person, any other Person that directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, such first Person.
“Ancillary Agreements” means the Bill of Sale and Assignment and Assumption Agreement, the Escrow Agreement, the Intellectual Property Assignment Agreement, the Registration Rights Agreement, the Seller Governance Agreement, the Stockholder Governance Agreement, and the Voting Agreements.
“Antitrust Laws” means the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, the HSR Act, and all other Laws, including any competition, merger control, antitrust or similar applicable Law of any jurisdiction outside of the United States, prohibiting, limiting, or promulgated or intended to govern conduct having the purpose or effect of monopolization, restraint of trade, or substantial lessening of competition.
“Base Cash Consideration” means $145,000,000 in cash.
“Bill of Sale and Assignment and Assumption Agreement” means one or more bill of sale and assignment and assumption agreements with a Seller Party substantially in the form of Exhibit A hereto.
“Books and Records” means the Seller Parties’ books and records relating to the Transferred Assets, including (i) promotional literature, regulatory submissions, clinical study reports, clinical data, nonclinical data or reports, manufacturing records, quality control records, adverse event files, operating records for the Business Products, (ii) customer sales records, (iii) financial books, records, statements or reports, (iv) legal and regulatory analyses and assessments, legal opinions and other records, including with respect to the prosecution of the Transferred Intellectual Property, and (v) all books and records relating to reimbursement, contracting, managed market activities and pricing, except, in each case, to the extent they are specifically included in the Transferred Marketing Records, Transferred Regulatory Documentation, Excluded Assets or Excluded Liabilities.
“Business” means the business of Seller related to the Exploitation of any Business Products, together with all related services, as conducted by the Seller Parties as of the Agreement Date or as of immediately prior to the Closing; provided, for the avoidance of doubt, Excluded Assets and Excluded Liabilities shall not be considered part of the Business.
3
“Business Day” means any day that is not a Saturday, a Sunday or other day on which banks are required or authorized by Law to be closed in Cary, North Carolina, Parsippany, New Jersey or New York, New York.
“Business Employee” means each employee of the Seller Parties set forth on Schedule 1.1G, as such Schedule may be updated by Buyer pursuant to Section 5.7(b) to reflect any Replacement Employee (and the removal of the applicable employee being replaced) or Additional Employee.
“Business Employee Severance Costs” means (A) plus (B) minus (C) where:
(A) is, in respect of each Business Employee (other than a Specified Employee) set forth on Schedule 1.1G as of the Agreement Date (and without regard to any subsequent changes to such schedule) who (x) does not receive a Qualified Offer prior to the Closing Date, (y) is terminated by the Seller Group without “cause” on or following the Closing Date and prior to the Termination Measurement Date or, if such Business Employee is added to Schedule 1.1K in accordance with Section 5.7(h) below only, after being added to such schedule and prior to the Closing Date, and (z) timely executes and delivers to Seller (a copy of which is promptly provided to Buyer) an effective release of claims in favor of each of Seller, Buyer and their respective Affiliates: (i) the aggregate cash severance payments actually paid or provided by the Seller Group to such Business Employee pursuant to, and in accordance with, the Specified Plan (as calculated as if such termination occurred after a “Change of Control” or “Change in Control”); provided that the amount of cash severance paid to any Business Employee shall be capped for purposes of this definition at the applicable amounts set forth for such Business Employee on Schedule 3.10(a)(i) of the Seller Disclosure Schedules based on the date of such Business Employee’s termination of employment (i.e., whether such termination occurs prior to, on or after, the next anniversary of such Business Employee’s date of hire following the Agreement Date); and (ii) the aggregate amount of COBRA premium payments, reimbursements and subsidies set forth on Schedule 3.10(a)(i) of the Seller Disclosure Schedules applicable to such Business Employee;
(B) is, in respect of each Specified Employee who (x) does not become an employee of Buyer (or its Affiliates) by the Termination Measurement Date, (y) is terminated by the Seller Group without “cause” on or following the Closing Date and prior to the Termination Measurement Date or, if such Business Employee is added to Schedule 1.1K in accordance with Section 5.7(h) below only, after being added to such schedule and prior to the Closing Date, and (z) timely executes and delivers to Seller (a copy of which is promptly provided to Buyer) an effective release of claims in favor of each of Seller, Buyer and their respective Affiliates, the aggregate cash severance payments and benefits set forth on Schedule 3.10(a)(i) of the Seller Disclosure Schedules actually paid by the Seller Group to such Specified Employee; and
(C) is, with respect to each Replacement Employee and Additional Employee who receives a Qualified Offer, (i) the aggregate cash severance, as set forth on Schedule 3.10(a)(i) of the Seller Disclosure Schedules applicable to such Replacement Employee or Additional Employee (assuming termination on the Closing Date); and (ii) the aggregate amount of COBRA premium payments, reimbursements and subsidies set forth on Schedule 3.10(a)(i) of the Seller Disclosure Schedules applicable to such Replacement Employee or Additional Employee.
4
In no event shall the Business Employee Severance Costs be less than zero, and to the extent the amount determined pursuant to clause (C) above would otherwise exceed the sum of the amounts determined pursuant to clauses (A) and (B) above, the Business Employee Severance Costs shall be deemed to equal zero. In no event shall the Business Employee Severance Costs include any costs relating to the accelerated vesting of any Seller Equity Awards, which will be borne exclusively by Seller. For the avoidance of doubt, (x) with respect to Business Employees other than Specified Employees, the Business Employee Severance Costs shall be determined by reference to the applicable level of severance benefits payable in connection with a termination made upon or following a “Change of Control” or “Change in Control” of Seller solely pursuant to the Specified Plan (and not pursuant to any contract, agreement, offer letter or other benefit plan other than the Specified Plan) and solely as set forth on Schedule 3.10(a)(i) of the Seller Disclosure Schedules regardless of whether such termination actually occurs prior to, on or following the Closing, and (y) with respect to Specified Employees, the Business Employee Severance Costs shall be determined by reference to the applicable level of severance benefits payable in connection with a termination made upon or following a “Change of Control” or “Change in Control” of Seller and solely as set forth on Schedule 3.10(a)(i) of the Seller Disclosure Schedules.
“Business Products” means the products that are listed on Schedule 1.1A under the heading “Business Products.”
“Buyer Equity Awards” means stock options, restricted stock units and all other compensatory equity awards granted to Buyer’s employees with respect to Buyer Common Stock, including such equity awards with performance vesting criteria.
“Buyer FDA Letters” means the letters, forms and other submissions from Buyer or its designated Affiliate to the FDA or such other instrument as may be necessary to effectuate the transfer of Transferred Regulatory Approvals from the Seller Parties, as applicable, to Buyer or its designated Affiliate in accordance with this Agreement, in a form reasonably satisfactory to Seller, duly executed by Buyer or its designated Affiliate.
“Buyer Fundamental Representations” means Section 4.1(a) (Organization), Section 4.2 (Authority), Section 4.4(a) (Capitalization), Section 4.5(a)(i) (No Conflict), and Section 4.10 (Brokers).
5
“Buyer Material Adverse Effect” means any event, change, occurrence or effect that, individually or in the aggregate, (i) would or would reasonably be expected to prevent, materially delay or materially impair the ability of any Buyer Party to consummate the Transactions or (ii) would or would reasonably be expected to have a material adverse effect on the business, assets, financial condition or results of operations of the Buyer Parties, taken as a whole; provided, in each case, that none of the following shall be deemed, either alone or in combination, to constitute or contribute to, and none of the following shall be taken into account in determining whether there is, or would reasonably be expected to be, a Buyer Material Adverse Effect: (a) general changes or developments in the industry, markets or territories in which the Buyer Group’s business operates, (b) changes in regional, national or international political conditions (including any outbreak or escalation of hostilities, any acts of war or terrorism or any other national or international crisis or emergency, and any escalation or general worsening of any of the foregoing) or in general economic, business, regulatory, technological, political or market conditions or in national or international financial markets, including any disruption of any financial, banking, securities or commodities markets or decline in the price of any security or any market index, (c) any man-made or natural disasters, hurricanes, earthquakes, floods or other natural disasters or any health crisis, public health event, epidemics, pandemics or disease outbreaks, the worsening of any of the foregoing or any governmental or other response or reaction to any of the foregoing, (d) changes after the Agreement Date in any applicable Laws, or applicable accounting regulations or principles or interpretations thereof, (e) the existence, announcement or pendency of this Agreement and the Transactions, including the initiation of litigation by any Person with respect to this Agreement, and including any termination of, reduction in or similar negative impact on relationships, contractual or otherwise, with any customers, suppliers, distributors, partners or employees of the Buyer Group’s business due to the existence, announcement and performance of this Agreement or the identity of the parties to this Agreement, or the performance of this Agreement and the Transactions, including compliance with the covenants set forth herein, (f) any action taken by the Buyer Parties which is expressly required to be taken by this Agreement, and (g) the failure of the Buyer Group’s business to meet any internal or published projections, clinical trial targets, product pricing or reimbursement levels, estimates, forecasts, budgets, metrics, milestones or expectation of financial or operating performance, but not the underlying causes of such failure unless such underlying causes would otherwise be exempted from this definition (provided that this clause (g) shall not be construed as implying that the Buyer Parties are making any representations or warranties regarding any projections, estimates, forecasts, budgets, metrics, milestones or expectation of financial or operating performance); provided that, in the case of clauses (a), (b), (c) and (d), such events, changes, occurrences or effects may be taken into account in determining whether a Buyer Material Adverse Effect has occurred to the extent the Buyer Group’s business is materially disproportionately affected thereby as compared with other participants in the industry in which the Buyer Group’s business operates (in which case only the incremental disproportionate impact or impacts may be taken into account in determining whether a Buyer Material Adverse Effect has occurred).
“Buyer Preferred Stock” means Buyer’s shares of preferred stock, par value $0.001 per share.
“Buyer Stock Plan” means Amended and Restated CorMedix Inc. 2019 Omnibus Stock Incentive Plan, as the same has been amended from time to time.
“Closing Cash” means, as of immediately prior to the Closing, without duplication, the aggregate amount of all cash and cash equivalents (including marketable securities) of the Seller Parties as of such time, calculated in accordance with GAAP and consistently with the Accounting Principles. Closing Cash shall include inbound wires in transit and checks and drafts deposited for the account of the Seller Parties, but shall be reduced by (i) the amount of all uncleared checks, outstanding withdrawals and other debits and payments of the Seller Parties in transit, and (ii) any Restricted Cash. Closing Cash shall not include any cash held as of immediately prior to the Closing in the Retained Bank Accounts.
6
“Closing Statement” means a statement setting forth Buyer’s good faith calculation of (a) the Net Working Capital and Closing Cash, each as of immediately prior to the Closing, and (b) the Final Cash Consideration derived therefrom, in each case, together with reasonable supporting detail, prepared in accordance with GAAP applied on a basis consistent with the Accounting Principles.
“Code” means the Internal Revenue Code of 1986, as amended, and the rules and regulations promulgated thereunder.
“Commercialization” means the conduct of activities undertaken following regulatory approval relating to the promotion, advertising, marketing, sale (including receiving, accepting, and filling product orders), offer for sale, and distribution (including importing, exporting, transporting, warehousing, and delivering) of the Business Products. “Commercialize” and “Commercializing” have correlative meanings.
“Confidential Information” means all non-public, confidential or proprietary information, in whatever form or medium, whether or not marked or identified as “confidential.”
“Confidentiality Agreement” means the Confidentiality Agreement, dated as of January 21, 2025, by and between Seller and Buyer.
“Consent” means any and all consents, approvals, clearances, ratifications, permissions, authorizations or waivers from any third party, including from any Governmental Authority.
“Contract” means any agreement, contract, subcontract, lease, understanding, instrument, note, bond, mortgage, indenture, option, warranty, insurance policy, benefit plan or other legally binding commitment together with modifications and amendments thereto (in each case, whether written or oral).
“control,” including the terms “controlled by” and “under common control with,” means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, as trustee or executor, as general partner or managing member, by contract or otherwise.
“Data” means any and all research data, pharmacology data, preclinical data, clinical data, including in each case, raw data, as well as marketing, Market Access, government price reporting, pharmacovigilance, and other data related to the Business Products, in each case, to the extent that such data is in the possession or control of the Seller Parties as of the Closing.
“Data Protection Laws” means with regard to the Transferred Assets, all applicable laws pertaining to data protection, data privacy, data security, cybersecurity, cross-border data transfer, and general consumer protection laws as applied in the context of data privacy, data breach notification, electronic communication, telephone and text message communications, marketing by email or other channels, and other similar laws, and includes the U.S. Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. Section 1320d et seq.), as amended.
7
“Data Protection Requirements” means (i) Data Protection Laws; (ii) Privacy Policies; (iii) any Contracts and/or codes of conduct relating to the collection, access, use, storage, disclosure, transmission, or cross-border transfer of Personal Data; and (iv) binding industry standards, including the Payment Card Industry Data Security Standard.
“Data Systems” means computer, electronic or telecommunications or network systems of any variety (including databases, websites, hardware, software, storage, switching and interconnection devices and mechanisms, whether on-premises or provided as a service by a third party).
“Debt Financing” means the debt financing contemplated by the Loan Agreement, together with any alternative debt financing obtained in accordance with this Agreement.
“DGCL” means Delaware General Corporation Law, as amended.
“Development” means all development activities for a pharmaceutical or biological product that are directed to obtaining regulatory approval(s) of such product and lifecycle management of such product, including non-clinical, preclinical, and clinical studies and trials; the preparation, filing, and prosecution of any regulatory approval for such product; development activities directed to label expansion and/or obtaining regulatory approval for one or more additional indications following initial regulatory approval; and all regulatory affairs related to any of the foregoing. “Develop,” “Developing” and “Developed” and similar variations have correlative meanings.
“Disclosure Schedules” means, as the context requires, the Seller Disclosure Schedules and/or the Buyer Disclosure Schedules.
“Earn-Out Payments” means the payments, payable by Buyer, subject to, and in accordance with Schedule 1.1J.
“Employee Plans” means all “employee benefit plans” within the meaning of Section 3(3) of ERISA, all multiemployer plans within the meaning of Section 3(37) of ERISA, all formal or informal, oral or written plans (whether or not subject to ERISA) and all other compensation and benefit plans, contracts, policies, programs, arrangements and payroll practices of the Seller Parties (other than routine administrative procedures) in which any Business Employees participate as of the Agreement Date, including all pension, profit sharing, savings and thrift, bonus, stock bonus, stock purchase, stock option, restricted stock or other cash or equity-based incentive or deferred compensation, severance, retention, employment, consulting, change-of-control, collective bargaining, employee loan, fringe benefit and medical and life insurance plans in which any of the Business Employees or their dependents participate, that is sponsored, maintained, contributed to or required to be contributed to by any Seller Party or under which any Seller Party has current or potential Liability (including any related funding mechanism now in effect or required in the future).
“Encumbrance” means any charge, claim, condition, easement, encroachment, equitable interest, lien (statutory or otherwise), mortgage, option, pledge, right of first refusal, right of first offer, preemptive right, security interest, conditional sale or other title retention agreement or other restriction or limitation of any kind, in each case, on or with respect to any property (real or personal) or property interest.
8
“Environmental Laws” means any Laws of any Governmental Authority in effect as of the Agreement Date relating to pollution, protection of the environment, natural resources, or human health and safety as relating to exposure to Hazardous Substances.
“Environmental Permits” means all Permits under any Environmental Law.
“ERISA” means the U.S. Employee Retirement Income Security Act of 1974, as amended, and the regulations promulgated thereunder.
“Estimated Cash Consideration” means an amount equal to (a) the Base Cash Consideration, plus (b) the estimated Closing Cash, plus (c) the estimated Working Capital Adjustment (based on the estimated Net Working Capital), in each case calculated in accordance with Schedule 1.1E and as set forth on the Estimated Closing Statement.
“Estimated Closing Statement” means a statement delivered by Seller to Buyer setting forth (a) Seller’s good faith estimates of the Net Working Capital and Closing Cash, each as of immediately prior to the Closing, and a calculation of the Estimated Cash Consideration derived therefrom, in each case with reasonable supporting detail prepared in accordance with GAAP applied on a basis consistent with the Accounting Principles, (b) the total amount of Net Sales during the Royalty Year (as defined in Schedule 1.1J) in which the Closing occurs but prior to the Closing, and (c) a funds flow memorandum identifying the wire transfer instructions corresponding to each payment to be made at the Closing (including the Purchase Price Escrow Amount).
“Exchange Act” means the U.S. Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.
“Excluded Employee Liabilities” means any and all Liabilities arising out of or relating to (i) any Employee Plan; (ii) the employment or engagement by Seller or any of its Affiliates, or the termination of such employment or engagement, of any current or former Business Employee or other individual service provider, including any Liabilities relating to wages, salaries, commissions, bonuses, incentive or deferred compensation, severance, accrued vacation, paid time off or other leave, employee benefits, expense reimbursements or other compensation or remuneration; (iii) the engagement by Seller or any of its Affiliates, or the termination of such engagement, of any current or former independent contractor or other individual service provider; (iv) any actual or alleged misclassification of any current or former employee, independent contractor or other individual service provider, including with respect to employment status or exemption from wage and hour requirements; (v) any employment, payroll, social security, unemployment or similar Taxes relating to any current or former Business Employee, independent contractor or other individual service provider; (vi) any workplace injury, workers’ compensation or similar claim arising out of events occurring on or prior to the Closing; (vii) any collective bargaining agreement or other agreement with any labor union, works council or similar employee representative body, or any grievance, unfair labor practice or other labor-related claim relating to any period on or prior to the Closing; (viii) the WARN Act or any similar state, local or foreign Law, in each case, to the extent resulting from any action taken by Seller or any of its Affiliates on or prior to the Closing; (ix) any equity or equity-based compensation or award granted or promised by Seller or any of its Affiliates (including any Seller Equity Awards); (x) except for the Business Employee Severance Costs, any severance, retention, change-in-control, transaction, sale or similar bonus, payment or benefit arising from or relating to the transactions contemplated hereby or any termination of employment or service occurring on or prior to the Closing; (xi) any amounts owed to any current or former Business Employee, other individual service provider or director as an indemnification or similar obligation whether under the organizational documents of Seller or any Affiliate thereof, by operation of Law or under any Contract related to the acts or omissions thereof occurring on or prior to the Closing; or (xii) any acts or omissions of any current or former Business Employee, independent contractor or other individual service provider relating to the Business outside of the ordinary course of business, including any workplace sexual harassment, illegal retaliation or discrimination, or unlawful conduct, in each case, regardless of when any such Liability is asserted, incurred, accrued, payable or otherwise arises; provided, notwithstanding the foregoing, Excluded Employee Liabilities shall not include (A) any Business Employee Severance Costs, (B) any Liabilities in respect of a Transferred Employee arising solely from such Transferred Employee’s employment with Buyer or its Affiliates from and after the Closing, or (C) any Liabilities in respect of accrued but unused vacation explicitly assumed by Buyer pursuant to Section 5.7(f) below.
9
“Excluded Employee” means the employee of the Seller Parties listed on Schedule 1.1I.
“Exploit,” and related terms such as “Exploitation,” means to make, have made, import, export, use, sell or offer for sale, including to Develop, Commercialize, Manufacture and have Manufactured.
“FDA” means the U.S. Food and Drug Administration, or any successor agency thereto.
“FDCA” means the U.S. Federal Food, Drug, and Cosmetic Act, as amended from time to time, together with any rules, regulations and requirements promulgated thereunder.
“FDI Laws” means any foreign direct investment or national security law, rule, statute, regulation, legally binding measure or all other Laws in any jurisdiction that relates to foreign direct investment or national security.
“Final Cash Consideration” means an amount equal to (a) the Base Cash Consideration, plus (b) the Closing Cash, plus (c) the Working Capital Adjustment, in each case as determined in accordance with Schedule 1.1E.
“Field” means the treatment of chemotherapy-induced or post-operative nausea and vomiting with injectable products containing aprepitant or granisetron or treatment of post-operative pain with non-opioid anesthetic containing bupivacaine or a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam.
“Financing Sources” means the Persons (other than Buyer and its Affiliates) that have committed to provide, arrange or otherwise entered into agreements in connection with the Debt Financing, including the collateral agent and the lenders party to the Loan Agreement (including BioPharma Credit PLC, BPCR Limited Partnership and BioPharma Credit Investments V (Master) LP), together with any joinder agreements, indentures, credit agreements or other definitive documents relating thereto, and their respective Affiliates, and the respective former, current and future officers, directors, employees, partners, members, managers, controlling persons, agents, advisors, investment managers, general partners, attorneys and other representatives of each of the foregoing, and their respective successors and assigns; provided that in no event shall Buyer or any of its Affiliates constitute a Financing Source.
10
“Financing Source Related Party” means each Financing Source and each of its Affiliates and its and their respective Representatives, and the successors and assigns of each of the foregoing.
“Fraud” means any actual and intentional fraud causes of action that require as an element an intent to deceive or scienter, but not any type of fraud cause of action based on recklessness, negligence or any similar constructive knowledge element, in the making of the representations and warranties set forth in Article III, Article IV, any Indemnification Ancillary Agreement or in any certificate delivered pursuant to Section 2.7(b)(ii) (solely to the extent confirming satisfaction of the condition specified in Section 7.3(a)) or Section 2.7(c)(iii) (solely to the extent confirming satisfaction of the condition specified in Section 7.2(a)).
“GAAP” means United States generally accepted accounting principles, as promulgated by the Financial Accounting Standards Board, or its predecessors or successors, as of the date or period of the statement to which such term refers.
“Government Official” means any director, officer, employee, representative, contractor, or agent acting in an official capacity for or on behalf of a (i) Governmental Authority or (ii) public international organization (as such term is defined by the FCPA). Government Official also includes any political party, political party official, and any foreign official (as such term is defined in the FCPA).
“Governmental Authority” means any national, federal, state, local or political subdivision thereof governmental, regulatory or administrative authority, agency, department, division, instrumentality, ministry, board, commission, court, subdivision, audit group, or commission or any judicial or arbitral body, domestic or foreign.
“Governmental Pricing Programs” means the 340B drug pricing program under the Public Health Service Act (42 U.S.C. § 256b),Veterans Affairs drug pricing program (38 U.S.C. § 8126), and, as applicable only to government drug price reporting requirements, any applicable “federal health care program”, as such term is defined in 42 U.S.C. § 1320a–7b(f).
“Hazardous Substance” means any pollutant, contaminant, hazardous substance, hazardous material, hazardous waste or petroleum products, and any other chemical waste, substance or material listed in or regulated or identified in any Environmental Law.
“HSR Act” means the U.S. Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the regulations promulgated thereunder.
11
“Independent Expert” means a nationally recognized independent accounting firm mutually agreed upon by Buyer and Seller.
“Intellectual Property” or “Intellectual Property Rights” means all intellectual and industrial property rights and proprietary and priority rights, whether protected, created or arising under the laws of the United States or any other jurisdiction or under any international convention, including (a) Patents, (b) Marks, (c) copyrights, mask work rights, mask work registrations and applications therefor, works of authorship, including rights in databases, data collections and moral rights and all registrations, applications, renewals, extensions and reversions of any of the foregoing (all of the foregoing in this subsection (c), “Copyrights”), (d) trade secrets and rights in confidential and proprietary information that derive economic value from being maintained as confidential and are subject to efforts reasonable under the circumstances to maintain their secrecy (“Trade Secrets”), (e) know how, methods and processes and (f) all registrations and applications for any of the foregoing and all rights to obtain renewals, continuations, divisions or other legal protections pertaining thereto.
“Intellectual Property Assignment Agreement” means one or more assignment agreements with the applicable Seller Party, substantially in the form of Exhibit B hereto, transferring all of the Seller Parties’ right, title and interest in and to the Registered IP of the Business Products to the Buyer Parties.
“Inventory” means all inventories of active pharmaceutical ingredient for the Business Products, all drug product for the Business Products, all raw and pack materials, work-in-process, finished goods, Business Products on stability, reference materials, warehoused stock, supplies, consumables and packaging materials relating to the Business Products or manufacture thereof.
“IRS” means the Internal Revenue Service of the United States.
“Knowledge” means (A) with respect to Seller, the actual knowledge, after due inquiry of their respective direct reports, of the Persons listed in Schedule 1.1B and (B) with respect to Buyer, the actual knowledge, after due inquiry of their respective direct reports, of the Persons listed in Schedule 1.1C.
“Law” means any statute, law (including the common law), constitution, treaty, ordinance, regulation, rule, code, injunction, judgment, decree, requirements or Order of any Governmental Authority.
“Liability” means any direct or indirect liabilities or obligations of any nature whatsoever, whether accrued, absolute, contingent or otherwise, whether known or unknown, whether due or to become due, whether called a liability, obligation, indebtedness, guaranty, claim or otherwise.
“Loan Agreement” means that certain Loan Agreement, dated as of the November 8, 2026, by and among Buyer, as borrower, the guarantors from time to time party thereto, BioPharma Credit PLC, as collateral agent, and the lenders from time to time party thereto (including all exhibits, schedules and annexes thereto), as the same may be amended, restated, supplemented or otherwise modified from time to time.
12
“Manufacture” and “Manufacturing” mean all activities related to the production, manufacture, processing, filling, finishing, packaging, labeling, and shipping of a product or any intermediate thereof, including process qualification and validation, pre-clinical, clinical and commercial manufacture, product characterization, stability testing, and quality assurance and quality control.
“Market Access” means any and all processes and activities conducted to establish, seek and maintain pricing and reimbursement for the Business Products, as well as country level, state, regional and local payor processes and activities to obtain and maintain local and regional patient access for the Business Products, including price setting, national mandatory rebate negotiations with applicable Governmental Authorities, preparing reimbursement and economic dossiers, and policy-related activities associated with any of the foregoing.
“Marketing Records” means all advertising, marketing, market research, market data, sales and promotional materials, pricing lists, consulting deliverables and other related literature, catalogs and materials (including customer lists), in each case, with respect to the Business Products.
“Marks” means fictitious business names, corporate names, trade names, logos, slogans, trade dress rights, registered and unregistered trademarks and service marks, Internet domain names, all other indications of source or origin and registrations and applications for any of the foregoing.
“Nasdaq” means the Nasdaq Stock Market LLC.
“Net Working Capital” means current assets minus current liabilities of the Business, but solely those current assets and current liabilities expressly set forth as being included as part of the Net Working Capital calculation in the illustrative closing statement attached hereto as Schedule 1.1F, in each case determined as of immediately prior to the Closing in accordance with the accounting principles set forth on Schedule 1.1E (the “Accounting Principles”).
“Net Sales” has the meaning set forth in Schedule 1.1J.
“New Drug Application” means, in the United States, a New Drug Application, as defined in the FDCA (21 U.S.C. § 355), and applicable regulations promulgated thereunder by the FDA, or any equivalent application that replaces such application.
“Non-Scheduled Contracts” means the following Contracts: (a) non-disclosure agreements under customary terms, (b) Privacy Policies, (c) non-exclusive licenses to Intellectual Property Rights entered into in the ordinary course of business under customary terms, including where such license is merely incidental to the transaction contemplated in such Contract, the commercial purpose of which is primarily for something other than such license, (d) Contracts with past and present employees, contractors, consultants, service providers entered into in the ordinary course of business under customary terms, and (e) purchase orders, statements of work, work orders, change orders, invoices, and similar confirmatory or administrative documents, schedules or addendums that are not material to the main contractual relationship between the parties to a particular Contract or group of Contracts.
13
“Order” means and includes any writ, law, rule, regulation, executive order or decree, decision, award, judgment, injunction, ruling, or other order, whether temporary, preliminary, or permanent enacted, issued, promulgated, enforced, or entered into by any Governmental Authority.
“Patents” means patents and patent applications, including all continuations, divisionals, continuations-in-part, and provisionals and patents issuing on any of the foregoing, and all reissues, reexaminations, substitutions, renewals and extensions of any of the foregoing, and comparable rights, however denominated, in any jurisdiction throughout the world.
“Permits” means all licenses, permits, franchises, approvals, certificates, accreditations, registrations, certifications, authorizations, exemptions, clearances, Consents or orders of, or from, any Governmental Authority.
“Permitted Exception” means (i) statutory liens for current Taxes not yet delinquent or which are being contested in good faith by appropriate proceedings, (ii) mechanics’, carriers’, workers’, repairers’ and other similar liens arising or incurred in the ordinary course of business relating to obligations as to which there is no default on the part of the Seller Parties, or the validity or amount of which is being contested in good faith by appropriate proceedings, or pledges, deposits or other liens securing the performance of bids, trade contracts, leases or statutory obligations (including workers’ compensation, unemployment insurance or other social security legislation), (iii) with respect to Intellectual Property, (x) non-exclusive licenses of Intellectual Property granted by any member of the Seller Group in the ordinary course of business and (y) restrictions or limitations associated with third party rights and licenses set forth in Contracts to which any member of the Seller Group is a party that do not materially restrict or limit the conduct of the Business in the ordinary course consistent with past practice and (iv) Encumbrances with respect to the Closing Date Seller Indebtedness that will be released at Closing.
“Person” means an individual, corporation, partnership, limited liability company, limited liability partnership, syndicate, person, trust, association, organization or other entity, including any Governmental Authority, and including any successor, by merger or otherwise, of any of the foregoing.
“Personal Data” means information that: (i) identifies or could reasonably be used to identify an individual (including names, signatures, addresses, telephone numbers, e-mail addresses and other unique identifiers); (ii) can be used to authenticate an individual (including employee identification numbers, government-issued identification numbers, passwords or PINs, financial account numbers, credit report information, biometric or health data, answers to security questions and other personal identifiers); or (iii) when referring to a Data Protection Requirement, has the same meaning as the similar or equivalent term defined thereunder.
“Post-Closing Tax Period” means any taxable period beginning after the Closing Date and the portion of any Straddle Period beginning after the Closing Date.
“Pre-Closing Tax Period” means any Tax period ending on or before the Closing Date and the portion of any Straddle Period ending on and including the Closing Date.
14
“Privacy Policies” means all published, posted and written internal policies, procedures and notices relating to the collection, use, storage, disclosure, destruction, or cross-border transfer of Personal Data.
“Purchase Price Escrow Amount” means an amount in cash equal to $2,000,000.
“Qualified Offer” means a written offer of employment by Buyer (or an Affiliate of Buyer) to a Business Employee, commencing effective as of the Closing, that provides for an annual base salary or base wage rate that is not less than the base salary or base wage rate set forth on Schedule 3.10(a)(i) of the Seller Disclosure Schedules.
“Registered IP” means all Intellectual Property Rights that are registered with any Governmental Authority, including applications for any of the foregoing, and domain names.
“Registration Rights Agreement” means the agreement substantially in the form attached hereto as Exhibit C.
“Regulatory Approval” means, with respect to the Business Products in any country or regulatory jurisdiction, any and all Permits, investigational new drug applications or any other authorizations for the Development and study of the Business Products from the applicable Regulatory Authority required for the import, distribution, marketing, use, offering for sale, sale, Development, testing and study (including nonclinical studies and human clinical trials) of the Business Products in such country or jurisdiction in accordance with applicable Laws, but excluding any applicable pricing and reimbursement approvals.
“Regulatory Authority” means any national or supranational Governmental Authority (including the FDA) that has regulatory responsibility and authority in one or more jurisdictions for review and approval of Exploitation of a Business Product.
“Regulatory Documentation” means all (a) Regulatory Filings and other registrations, licenses, authorizations, and approvals of or with Regulatory Authorities (including Regulatory Approvals); (b) correspondence and reports submitted to or received from Regulatory Authorities (including minutes and official contact reports relating to any communications with any Regulatory Authority) and all supporting documents with respect thereto, including all regulatory drug lists, advertising and promotion documents, adverse event files, and complaint files; (c) correspondence and documentation with any Regulatory Authority related to orphan drug designation and exclusivity or a foreign equivalent thereof; and (d) Data contained or relied upon in any of the foregoing, in each case, relating to the Exploitation of the Business Products in a particular country or jurisdiction.
“Regulatory Filings” means any and all regulatory applications and/or related documentation submitted on or before the Closing Date, to a Regulatory Authority with respect to the Business Products in connection with the initiation or conduct of clinical studies, and/or to seek Regulatory Approval for the Business Products, including any investigational new drug applications, drug master files, manufacturing master files, New Drug Applications or any supplements thereto.
15
“Regulatory Laws” means any Law related to the research, investigation, development, validation, marketing, distribution, storage, shipping, advertising, labeling, promotion, sale, safety, efficacy, or manufacturing of the Business Products, including: (a) applicable federal, state or local laws, rules, regulations, orders, ordinances, codes, statutes, and agency guidance related to Governmental Pricing Programs, as binding on either Party; (b) all health care-related fraud and abuse and patient inducement Laws, including the U.S. Anti-Kickback Statute (42 U.S.C. Section 1320a-7b(b)), the U.S. Civil False Claims Act (31 U.S.C. Section 3729 et seq.), Sections 1320a-7, 1320a-7a, and 1320a-7b of Title 42 of the United States Code and the regulations promulgated pursuant to such statutes; (c) Medicare (Title XVIII of the Social Security Act); (d) Medicaid (Title XIX of the Social Security Act); (e) TRICARE; (f)Veterans Health Care Act of 1992, its implementing regulations, including the Federal Acquisition Regulation (“FAR”) / Veterans Affairs Acquisition Regulations (“VAAR”) at 48 C.F.R. Chapters 1 and 8; (g) the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Pub. L. No. 108-173); (h) the Physician Payments Sunshine Act (42 U.S.C. § 1320a-7h); (i) reporting and disclosure requirements for health care items and services, including any arising under the Medicaid Drug Rebate Program (e.g., Monthly and Quarterly Average Manufacturer Price, Baseline Average Manufacturer Price, and Rebate Per Unit, as applicable), Medicare Part B (Quarterly Average Sales Price), Section 602 of the Veterans Health Care Act (Public Health Service 340B Quarterly Ceiling Price), Section 603 of the Veterans Health Care Act (Quarterly and Annual Non-Federal Average Manufacturer Price and Federal Ceiling Price), Best Price, Federal Supply Schedule Contract Prices and Tricare Retail Pharmacy Refunds, and Medicare Part D, as well as any requirements concerning disclosure of any other company information to the public, customers, prescribers or to state and local agencies under federal, state, or local laws; (j) the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010; (k) the FDCA; (l) the Public Health Service Act (42 U.S.C. § 201 et seq.); (m) the equivalent or analogous state or local laws; and (n) any and all amendments thereto. For clarity, the term “Regulatory Laws” does not include HIPAA.
“Replacement Employee” means any employee of Seller who is not listed on Schedule 1.1G as of the Agreement Date and whom Buyer designates, in accordance with Section 5.7(b), to replace a Business Employee by making a Qualified Offer to such employee.
“Representatives” means, with respect to any Person, the officers, directors, principals, employees, agents, auditors, advisors, bankers, financing sources and other representatives of such Person, in each case, acting in the scope of his, her or its service to such Person.
“Required Antitrust Approvals” means the approvals listed on Schedule 1.1D.
“Restricted Cash” means any cash and cash equivalents of the Seller Parties that, as of immediately prior to the Closing, are (a) designated, or that pursuant to GAAP should be designated, as restricted or otherwise unavailable cash on the balance sheet of any Seller Party, (b) held in escrow or in trust for the benefit of any other Person, (c) held as collateral, security deposit, margin or similar deposit in respect of obligations to any other Person, (d) subject to any contractual, regulatory or legal restriction on the use or distribution thereof (other than customary restrictions under credit agreements that will be released at or prior to the Closing), or (e) subject to withholding Tax or other impediment to repatriation or distribution to the Seller Parties.
16
“Sarbanes-Oxley Act” means the Sarbanes-Oxley Act of 2002, as amended.
“SEC” means the U.S. Securities and Exchange Commission.
“Securities Act” means the U.S. Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.
“Seller Equity Awards” means stock options, restricted stock units and all other compensatory equity awards granted to Business Employees with respect to Seller Common Stock, including such equity awards with performance vesting criteria, whether granted under the Seller 2007 Equity Plan, or granted outside of the Seller 2007 Equity Plan as “inducement” equity awards.
“Seller FDA Letters” means the letters, forms and other submissions from the Seller Parties, as applicable, to the FDA or such other instrument as may be necessary to effectuate the transfer of Transferred Regulatory Approvals to Buyer or its designated Affiliate in accordance with this Agreement, each in a form reasonably satisfactory to Buyer, duly executed by the Seller Parties, as applicable.
“Seller Fundamental Representations” means Section 3.1(a) (Organization and Qualification), Section 3.2 (Authority), Section 3.3(a)(i) (No Conflict), Section 3.4(a) (Title to Transferred Assets) and Section 3.21 (Brokers).
“Seller Group” means Seller and any Subsidiary of Seller.
“Seller Indebtedness” means, with respect to any Person, without duplication, (a) indebtedness for borrowed money or indebtedness issued or incurred in substitution or exchange for indebtedness for borrowed money, (b) amounts owing as deferred purchase price for property or services, including all seller notes and “earn-out” payments, (c) indebtedness evidenced by any note, bond, debenture, mortgage or other debt instrument or debt security, (d) commitments or obligations by which such Person assures a creditor against loss (including contingent reimbursement obligations with respect to letters of credit), (e) indebtedness secured by an Encumbrance on assets or properties of such Person, (f) obligations or commitments to repay deposits or other amounts advanced by and owing to third parties, (g) obligations under any interest rate, currency or other hedging agreement, (h) obligations under all capital leases and financing leases (as determined in accordance with GAAP), (i) all accrued but unpaid declared or undeclared dividends or distributions, and (j) guarantees or other contingent liabilities (including so called take-or-pay or keep-well agreements) with respect to any indebtedness, obligation, claim or liability of any other Person of a type described in clauses (a) through (i) above; provided that in no event shall Seller Indebtedness include trade payables and accruals and other current liabilities incurred in the ordinary course of business.
17
“Seller Material Adverse Effect” means any event, change, occurrence or effect that, individually or in the aggregate, (i) would or would reasonably be expected to prevent, materially delay or materially impair the ability of any Seller Party to consummate the Transactions or (ii) would or would reasonably be expected to have a material adverse effect on the business, assets, financial condition or results of operations of the Business, taken as a whole; provided, in each case, that none of the following shall be deemed, either alone or in combination, to constitute or contribute to, and none of the following shall be taken into account in determining whether there is, or would reasonably be expected to be, a Seller Material Adverse Effect: (a) general changes or developments in the industry, markets or territories in which the Business operates, (b) changes in regional, national or international political conditions (including any outbreak or escalation of hostilities, any acts of war or terrorism or any other national or international crisis or emergency, and any escalation or general worsening of any of the foregoing) or in general economic, business, regulatory, technological, political or market conditions or in national or international financial markets, including any disruption of any financial, banking, securities or commodities markets or decline in the price of any security or any market index, (c) any man-made or natural disasters, hurricanes, earthquakes, floods or other natural disasters or any health crisis, public health event, epidemics, pandemics or disease outbreaks, the worsening of any of the foregoing or any governmental or other response or reaction to any of the foregoing, (d) changes after the Agreement Date in any applicable Laws, or applicable accounting regulations or principles or interpretations thereof, (e) the existence, announcement or pendency of this Agreement and the Transactions, including the initiation of litigation by any Person with respect to this Agreement, and including any termination of, reduction in or similar negative impact on relationships, contractual or otherwise, with any customers, suppliers, distributors, partners or employees of the Business due to the existence, announcement and performance of this Agreement or the identity of the parties to this Agreement, or the performance of this Agreement and the Transactions, including compliance with the covenants set forth herein, (f) any action taken by the Seller Parties which is expressly required to be taken by this Agreement, and (g) the failure of the Business to meet any internal or published projections, clinical trial targets, product pricing or reimbursement levels, estimates, forecasts, budgets, metrics, milestones or expectation of financial or operating performance, but not the underlying causes of such failure unless such underlying causes would otherwise be exempted from this definition (provided that this clause (g) shall not be construed as implying that the Seller Parties are making any representations or warranties regarding any projections, estimates, forecasts, budgets, metrics, milestones or expectation of financial or operating performance); provided that, in the case of clauses (a), (b), (c) and (d), such events, changes, occurrences or effects may be taken into account in determining whether a Seller Material Adverse Effect has occurred to the extent the Business is materially disproportionately affected thereby as compared with other participants in the industry in which the Business operates (in which case only the incremental disproportionate impact or impacts may be taken into account in determining whether a Seller Material Adverse Effect has occurred).
“Seller Stockholder Approval” means the affirmative vote of a majority of the outstanding shares of Seller Common Stock entitled to vote thereon in favor of the adoption of this Agreement and approval of the Transactions.
“Seller Termination Fee” means an amount equal to $4,000,000.
“Specified Employees” means the employees listed on Schedule 1.1H.
“Specified Plan” means the Employee Plan set forth on Schedule 1.1 of the Seller Disclosure Schedules.
“Stock Consideration” means 14,583,333 shares of Buyer Common Stock to be issued to Seller.
18
“Straddle Period” means any taxable period beginning on or prior to and ending after the Closing Date.
“Subsidiary” means, with respect to any Person, any other Person of which at least fifty percent (50%) of the outstanding voting securities or other voting equity interests are owned, directly or indirectly, by such first Person.
“Superior Proposal” means a bona fide Acquisition Proposal that if consummated would result in a Person owning, directly or indirectly, (a) more than fifty percent (50%) of the outstanding shares of Seller Common Stock or (b) more than fifty percent (50%) of the consolidated assets of the Seller Group, taken as a whole, in either case, which the Seller Board determines in good faith, after consultation with its outside legal counsel and outside financial advisor, if consummated, would result in a transaction more favorable to Seller’s stockholders from a financial point of view than the Asset Sale, taking into account at the time of determination all circumstances deemed relevant by the Seller Board, including as the Seller Board deems relevant various legal, financial, regulatory and financing aspects of the Acquisition Proposal, all the terms and conditions of such Acquisition Proposal and this Agreement, any changes to the terms of this Agreement offered by Buyer in writing in response to such Acquisition Proposal, and the anticipated timing, conditions and the ability of the Person making such Acquisition Proposal to consummate the transactions contemplated by such Acquisition Proposal, and, if such Acquisition Proposal involves the payment of cash consideration (in whole or in part), the financing for which is then fully committed or reasonably determined by the Seller Board to be available.
“Target Net Working Capital” means $102,000,000.
“Tax Action” means any claim, action, suit, complaint, arbitration, audit, investigation, review, assessment, notice of deficiency or other proceeding relating to any Tax or Tax Return by or before any Tax Authority.
“Tax Authority” means any Governmental Authority responsible for the imposition, determination or collection of any Tax or the audit, investigation or review of any Tax Return.
“Tax Return” means any return, declaration, report, statement, information statement and other document filed or required to be filed with any Tax Authority with respect to Taxes.
“Taxes” means any and all taxes of any kind in the nature of a tax (together with any and all interest, penalties, additions to tax and additional amounts imposed with respect thereto) imposed by any Tax Authority, including any income, franchise, windfall or other profits, gross receipts, property, capital gains, sales, use, capital stock, payroll, employment, social security, workers’ compensation, unemployment compensation, net worth taxes, excise tax, withholding tax, ad valorem tax, business tax, transfer tax, stamp tax, estimated tax, surtax or value added tax.
“Termination Measurement Date” means the date that is sixty (60) days following the Closing Date.
19
“Transaction Expenses” means, without duplication, to the extent unpaid as of immediately prior to the Closing, any and all third-party fees, costs, expenses, payments and expenditures incurred by any Seller Party in connection with the negotiation, execution and consummation of the Transactions, this Agreement, and any Ancillary Agreement, whether or not billed or accrued, including (a) any fees, costs, expenses, payments and expenditures of legal counsel and accountants, and (b) any fees, costs, expenses, payments and expenditures payable to brokers, finders, financial advisors, investment bankers or similar Persons; provided that, notwithstanding the foregoing, Transaction Expenses shall not include the costs and expenses of the Escrow Agent.
“Transfer Agent” means VStock Transfer, LLC, Buyer’s duly appointed transfer agent for the Stock Consideration.
“Transfer Tax” means all transfer and similar Taxes imposed as a result of the Transactions, including documentary, recording, registration, stamp duty, transfer, real estate transfer, sales and use, value added tax, and all penalties, interest and additions thereto.
“Transferred Books and Records” means all Books and Records related to the Business Products that are owned by or in the possession or control of the Seller Parties as of the Closing.
“Transferred Marketing Records” means all Marketing Records related to the Business Products that are owned by the Seller Parties and in the possession or control of the Seller Parties as of the Closing, to the extent transferable in compliance with applicable Laws or Privacy Policies.
“Transferred Regulatory Documentation” means original documents or, to the extent original documents are not reasonably available, copies thereof, in any format in the possession or control of any of the Seller Parties as of the Closing, of all Regulatory Documentation, including documentation evidencing all Transferred Regulatory Approvals.
“WARN Act” means the Worker Adjustment and Retraining Notification Act of 1988 and any analogous Law.
“Working Capital Adjustment” means (a) if the Net Working Capital exceeds the Target Net Working Capital, a positive amount equal to such excess, and (b) if the Target Net Working Capital exceeds the Net Working Capital, a negative amount equal to such shortfall; provided, however, if the excess contemplated by clause (a) or the shortfall contemplated by clause (b) is less than $2,000,000, the Working Capital Adjustment shall be zero; provided, further, if the Net Working Capital equals the Target Net Working Capital, the Working Capital Adjustment shall be zero).
20
Section 1.2 Table of Definitions. The following terms have the meanings set forth in the Sections referenced below:
| Definition | Location | ||
| Acceptable Confidentiality Agreement | Section 5.3(b) | ||
| Adjustment Escrow Fund | Section 2.10(f)(ii) | ||
| Agreement | Preamble | ||
| Agreement Date | Preamble | ||
| Allocation Dispute Notice | Section 6.1(a) | ||
| Allocation Exhibit | Section 6.1(a) | ||
| Alternative Acquisition Agreement | Section 5.3(a)(iv) | ||
| Alternative Recovery | Section 8.5(b) | ||
| Anti-Corruption Laws | Section 3.9(a) | ||
| Arbiter | Section 6.1(a) | ||
| Asset Sale | Recitals | ||
| Assumed Contracts | Section 2.1(a) | ||
| Assumed Liabilities | Section 2.3 | ||
| Assumed Litigation | Section 5.22(a) | ||
| Assumed Litigation Expenses | Section 5.22(c) | ||
| Assumed Settlement Agreements | Section 5.22(a) | ||
| Buyer | Preamble | ||
| Buyer Balance Sheet | Section 4.11(h) | ||
| Buyer Common Stock | Recitals | ||
| Buyer Disclosure Schedules | Article IV | ||
| Buyer Entity | Section 4.1(a) | ||
| Buyer Group | Section 4.1(a) | ||
| Buyer Indemnified Parties | Section 8.2 | ||
| Buyer NDCs | Section 5.20(a) | ||
| Buyer Party | Recitals | ||
| Buyer R&W Insurance Policy | Section 5.17 | ||
| Buyer Savings Plan | Section 5.7(d) | ||
| Buyer SEC Documents | Article IV | ||
| Buyer Stock Issuance | Recitals | ||
| Buyer Welfare Benefit Plans | Section 5.7(e)(i) | ||
| Capitalization Date | Section 4.4(a) | ||
| Change of Recommendation | Section 5.3(d)(i) | ||
| Claim Information | Section 8.4(a) | ||
| Closing | Section 2.7(a) | ||
| Closing Date | Section 2.7(a) | ||
| Closing Date Seller Indebtedness | Section 2.7(b)(iii) | ||
| COBRA | Section 5.7(e)(ii) | ||
| Competing Business | Section 5.12(a) | ||
| Contributor | Section 3.13(f) | ||
| Determination Notice | Section 5.3(e)(ii) | ||
| Discussion Period | Section 6.1(a) | ||
| Dispute Notice | Section 2.10(b) | ||
| DLA Piper | Section 10.16 | ||
| Electronic Data Room | Section 10.5 | ||
| Escrow Agent | Section 2.10(f)(i) | ||
| Escrow Agreement | Section 2.10(f)(i) |
21
| Definition | Location | ||
| Excess Payment | Section 2.10(d)(ii) | ||
| Excluded Assets | Section 2.2 | ||
| Excluded Claims | Section 2.4(a) | ||
| Excluded Entity | Section 2.4(g) | ||
| Excluded Liabilities | Section 2.4 | ||
| Excluded Regulatory Approvals | Section 2.2(m) | ||
| Expense Reimbursement | Section 9.3(c)(iii) | ||
| FCPA | Section 3.9(a) | ||
| Final Allocation | Section 6.1(a) | ||
| Financing Source Provisions | Section 10.17 | ||
| Indemnification Ancillary Agreements | Section 8.1(a) | ||
| Indemnified Party | Section 8.4(a) | ||
| Indemnifying Party | Section 8.4(a) | ||
| Intended Tax Treatment | Section 6.1(b) | ||
| Interim Period | Section 5.1(a)(i) | ||
| Intervening Event | Section 5.3(e) | ||
| Legal Privileges and Protection | Section 10.16 | ||
| Legal Restraint | Section 7.1(a) | ||
| Losses | Section 8.2 | ||
| Material Contract | Section 3.17(a) | ||
| Materials | Section 5.23 | ||
| NDC | Section 5.20(a) | ||
| Non-Solicitation Period | Section 5.11(a) | ||
| Notice Period | Section 5.3(e)(ii) | ||
| Occurrence-Based Policy | Section 5.15 | ||
| Pre-Closing Occurrence | Section 5.15 | ||
| Pricing Program Obligations | Section 5.21(a) | ||
| Proposed Allocation | Section 6.1(a) | ||
| Proxy Statement | Section 5.4(a) | ||
| Related Person | Section 3.20 | ||
| Remedy Action | Section 5.9(b) | ||
| Required Filing | Section 5.9(a) | ||
| Restriction Period | Section 5.12(a) | ||
| Retained Bank Accounts | Section 2.2(b) | ||
| Retained Seller Insurance Policies | Section 2.2(j) | ||
| Royalty Payments | Section 2.11(a) | ||
| Sanctions | Section 3.22 | ||
| Security Incidents | Section 3.13(j) | ||
| Seller | Preamble | ||
| Seller Board | Recitals | ||
| Seller Board Recommendation | Section 3.2 | ||
| Seller Common Stock | Recitals | ||
| Seller Disclosure Schedules | Article III | ||
| Seller Employee | Section 5.11(b) | ||
| Seller Financial Information | Section 3.5(a) |
22
| Definition | Location | ||
| Seller Governance Agreement | Recitals | ||
| Seller Indemnified Parties | Section 8.3 | ||
| Seller NDC Products | Section 5.21(a) | ||
| Seller Party | Recitals | ||
| Seller Savings Plan | Section 5.7(d) | ||
| Seller SEC Documents | Section 3.5(f) | ||
| Seller Systems | Section 3.13(j) | ||
| Shortfall Payment | Section 2.10(d)(i) | ||
| Significant Customer | Section 3.18(a) | ||
| Significant Supplier | Section 3.18(a) | ||
| Specified Transaction | Section 5.9(d) | ||
| Stockholder Governance Agreement | Recitals | ||
| Stockholders Meeting | Section 5.5 | ||
| Tax Purchase Price | Section 6.1(a) | ||
| Termination Date | Section 9.1(b) | ||
| Termination Measurement Date | Section 1.1 | ||
| Third-Party Claim | Section 8.4(a) | ||
| Transaction Consideration | Section 2.6(a) | ||
| Transaction Litigation | Section 5.19 | ||
| Transactions | Recitals | ||
| Transferred Assets | Section 2.1 | ||
| Transferred Employees | Section 5.7(a) | ||
| Transferred Equipment | Section 2.1(d) | ||
| Transferred Intellectual Property | Section 2.1(c) | ||
| Transferred Inventory | Section 2.1(e) | ||
| Transferred Non-Patent Intellectual Property | Section 2.1(c) | ||
| Transferred Patents | Section 2.1(b) | ||
| Transferred Regulatory Approvals | Section 2.1(f) | ||
| Transferred Trademarks | Section 5.23 | ||
| Transition Date | Section 5.20(b) | ||
| Voting Agreements | Recitals |
23
Article
II
PURCHASE AND SALE
Section 2.1 Purchase and Sale of Assets. Upon the terms and subject to the conditions of this Agreement, at the Closing, the Seller Parties shall sell, assign, transfer, convey and deliver to Buyer, or one of the other Buyer Parties, all of the Seller Parties’ right, title and interest as of the Closing Date in and to all of the assets of Seller, as they exist at the time of the Closing, other than the Excluded Assets (the “Transferred Assets”), and Buyer, or one of the other Buyer Parties, shall purchase, acquire, accept and pay for the Transferred Assets and assume the Assumed Liabilities. Transferred Assets shall include, without duplication, all of the Seller Parties’ right, title and interest in and to the following enumerated assets (other than the Excluded Assets), as they exist at the time of the Closing, as set forth below:
(a) all of the Seller Parties’ Contracts (other than any Employee Plans) and rights thereunder (such Contracts, together with any purchase orders, change orders or work orders related thereto, collectively, the “Assumed Contracts”) relating to the Business or the other Transferred Assets, except the Contracts set forth on Schedule 2.2(c) of the Seller Disclosure Schedules;
(b) all Patents of the Seller Parties (the “Transferred Patents”);
(c) all Intellectual Property (other than Patents) of the Seller Parties (the “Transferred Non-Patent Intellectual Property” and, together with the Transferred Patents, the “Transferred Intellectual Property”);
(d) all machinery, equipment, vehicles and other items of tangible personal property and assets that are owned by the Seller Parties, wherever located (the “Transferred Equipment”), except the equipment set forth on Schedule 2.1(d) of the Seller Disclosure Schedules;
(e) all Inventory (the “Transferred Inventory”) of the Seller Parties;
(f) all Regulatory Approvals, to the extent permissible under Law, held by the Seller Parties relating to or used in the conduct of the Business (the “Transferred Regulatory Approvals”);
(g) all current assets of the Seller Parties, including accounts receivable, notes receivable, deposits and other amounts owed, in connection with the operation of the Business, and all Closing Cash;
(h) to the extent legally transferable, all third-party warranties, indemnities, guarantees and similar rights that have been made by any predecessors in title, manufacturers or suppliers and other third parties, to the extent relating to any Assumed Liabilities or the Transferred Assets;
(i) all goodwill associated with the Transferred Assets;
(j) the Transferred Marketing Records, Transferred Regulatory Documentation and Transferred Books and Records; provided, that the Seller Parties shall be entitled to retain a copy to the extent required by applicable Law or reasonably necessary for Tax, accounting, legal, compliance or insurance purposes or for the performance of their obligations under this Agreement or any Ancillary Agreement;
(k) all telephone numbers, facsimile numbers, e-mail addresses, internet domain names, social media accounts and URLs, in each case, used in the conduct of the Business (other than personal cellular telephone numbers of employees who are not Transferred Employees);
24
(l) all rights, claims, causes of action, choses in action, rights of recovery, rights of set-off, and rights of recoupment of any Seller Party, whether known or unknown, arising out of or relating to the Business or the Transferred Assets (other than any such rights, claims or causes of action to the extent relating to any Excluded Asset or Excluded Liability);
(m) all bank accounts of the Seller Parties other than the Retained Bank Accounts; and
(n) all data, databases, data compilations and collections, and all rights therein, in each case, owned by or licensed to any Seller Party and used in or held for use in the conduct of the Business.
Section 2.2 Excluded Assets. Notwithstanding anything contained in Section 2.1 to the contrary, the Seller Parties are not selling, and the Buyer Parties are not purchasing, the following assets of Seller, all of which shall be retained by Seller (collectively, the “Excluded Assets”):
(a) the Seller Parties’ charter and bylaws, corporate books and records of internal corporate proceedings, minute books, taxpayer and other identification numbers, Tax records (including Tax Returns), work papers and other documents, Permits and assets to the extent relating to the organization or maintenance of Seller’s corporate existence, its status as a reporting company under the Exchange Act or its continued listing on the Nasdaq Capital Market;
(b) the bank accounts of Seller set forth on Schedule 2.2(b) of the Seller Disclosure Schedules (the “Retained Bank Accounts”) and any cash, shares of Seller Common Stock or other contents, if any, therein;
(c) all rights of the Seller Parties with respect to the Contracts set forth on Schedule 2.2(c) of the Seller Disclosure Schedules;
(d) except as specifically provided in Section 5.7, any assets relating to any Employee Plan;
(e) all rights, claims and causes of action of any nature available to or being pursued by any Seller Party, whether arising by way of counterclaim or otherwise, to the extent in respect of any Excluded Asset or any Excluded Liability;
(f) all Actions and rights related thereto set forth on Schedule 2.2(f) of the Seller Disclosure Schedules;
(g) all records, correspondence and other materials prepared by or on behalf of any Seller Party in connection with the sale of the Transferred Assets to Buyer;
(h) all Legal Privileges and Protection maintained by any Seller Party;
(i) all Tax attributes, including all net operating loss carryforwards, Tax refunds, credits, and prepayments of Seller;
(j) any insurance policies of the Seller Parties, including all directors’ and officers’ liability insurance policies, and all rights, claims or causes of action thereunder and proceeds thereof (including in respect of any occurrences, acts or omissions prior to the Closing) (the “Retained Seller Insurance Policies”);
25
(k) all employment records and personnel files: (i) of employees of Seller who are not Transferred Employees, or (ii) of Transferred Employees who have not consented to the transfer of such employment records or personnel files to the extent required by applicable Law (it being understood and agreed that the Seller Parties shall use commercially reasonable efforts to promptly obtain any such required consents);
(l) any Books and Records which Seller is prohibited from disclosing or transferring to Buyer under applicable Law and is required by applicable Law to retain;
(m) the Regulatory Approvals that are not Transferred Regulatory Approvals (the “Excluded Regulatory Approvals”); and
(n) assets set forth on Schedule 2.2 of the Seller Disclosure Schedules.
Section 2.3 Assumed Liabilities. In connection with the purchase and sale of the Transferred Assets pursuant to this Agreement, at the Closing, Buyer, or one of the other Buyer Parties, shall assume and pay, discharge, perform or otherwise satisfy the Liabilities and obligations of the Seller Parties arising out of, relating to or otherwise in respect of the Business or the Transferred Assets, in each case, other than Excluded Liabilities (the “Assumed Liabilities”), including all Liabilities that may arise in connection with any of the following:
(a) all Liabilities accruing, arising out of or relating to the conduct or operation of the Business or the ownership or use of the Transferred Assets;
(b) all Liabilities with respect to the Transferred Regulatory Approvals or obtaining additional Permits or Regulatory Approvals for the Exploitation of the Business Products required by applicable Law in any country, territory or jurisdiction;
(c) all Liabilities of the Seller Parties under the Assumed Contracts;
(d) all Liabilities in respect of Business Products arising out of or relating to any Action, including any infringement or misappropriation of Intellectual Property Rights of any third party, or any warranty claims and manufacturing or product liability or similar claims by a third party to the extent such Liabilities relate to a Business Product;
(e) all Liabilities arising out of or relating to sales of the Business Products, including all Liabilities for rebates, chargebacks and/or returns associated with such sales;
(f) any Liability arising out of or relating to any product liability claim, personal injury claim, property damage claim, breach of warranty claim, or any recall, field correction or market withdrawal, in each case, to the extent arising out of or relating to the sale, distribution, marketing, manufacturing, packaging, labeling, storage, handling, or use of any Business Product prior to the Closing;
26
(g) all Actions and rights related thereto set forth on Schedule 2.3(g) of the Seller Disclosure Schedules;
(h) all current liabilities of the Seller Parties, including accounts payable, incurred in connection with the operation of the Business that are not otherwise Excluded Liabilities; and
(i) all Business Employee Severance Costs, any Liabilities in respect of a Transferred Employee arising solely from such Transferred Employee’s employment with Buyer or its Affiliates from and after the Closing, and, so long as explicitly assumed by Buyer pursuant to Section 5.7(f), any Liabilities in respect of accrued but unused vacation of any Business Employee.
Notwithstanding anything to the contrary herein, the assumption of the Assumed Liabilities by the Buyer Parties shall not enlarge any rights of third parties under Contracts or arrangements with any Seller Party or Buyer Party, and nothing herein shall prevent any Buyer Party or Seller Party from contesting in good faith any such Liabilities with any third party.
Section 2.4 Excluded Liabilities. Notwithstanding anything contained in Section 2.3 to the contrary, the Buyer Parties are not assuming, and the Seller Parties shall pay, perform or otherwise satisfy when due, the following Liabilities (the “Excluded Liabilities”):
(a) any Liability arising out of or otherwise relating to any Transaction Litigation or any other Action asserted or threatened against Seller or any of the Seller Parties by any stockholder, debtholder, or other constituent of Seller, to the extent arising under United States federal or state securities Laws or alleging breach of fiduciary duty (the “Excluded Claims”);
(b) all Liabilities of the Seller Parties for Seller Indebtedness;
(c) any Liability or obligation to the extent relating to or arising from an Excluded Asset, and any Liability in connection with the operations or activities of the Seller Parties following the Closing;
(d) all Excluded Employee Liabilities;
(e) any Liability arising under or relating to the Contracts set forth on Schedule 2.2(c) of the Seller Disclosure Schedules;
(f) any Taxes (x) of Seller, or (y) related to the ownership of the Transferred Assets or the Business prior to the Closing, in each case, to the extent apportioned to the Pre-Closing Tax Period pursuant to Section 6.2;
(g) all Liabilities of, by or related to Heron Therapeutics B.V. (the “Excluded Entity”);
(h) any Liabilities from Environmental Laws arising out of or relating to (x) the ownership, use or operation of the Business or the Transferred Assets prior to the Closing, (y) any real property formerly owned, operated or leased by any Seller Party, or (z) any off-site disposal, treatment, storage or release of Hazardous Substances by or on behalf of any Seller Party prior to the Closing;
27
(i) all Liabilities of the Seller Parties under any real property lease;
(j) any Liabilities of the Seller Parties to any of their Related Persons other than as expressly set forth in this Agreement or the Ancillary Agreements;
(k) all Transaction Expenses of the Seller Parties;
(l) all fees and expenses in respect of Seller’s legal counsel for services rendered prior to the Closing, except as set forth on Schedule 2.4(l) of the Seller Disclosure Schedules; and
(m) any Liabilities set forth on Schedule 2.4(m) of the Seller Disclosure Schedules.
Section 2.5 Consents to Certain Assignments.
(a) Notwithstanding anything in this Agreement or any Ancillary Agreement to the contrary, this Agreement and the Ancillary Agreements shall not constitute an agreement to transfer or assign any asset, claim or right or any benefit arising thereunder or resulting therefrom if an attempted assignment thereof, without the Consent of a third party, would constitute a breach or other contravention under any agreement or Law to which a Seller Party is a party or by which it is bound, or if any attempted assignment would adversely affect the rights of a Seller Party thereunder so that the Buyer Parties would not in fact receive all such rights.
(b) If any such Consent is not obtained prior to the Closing and as a result thereof the Buyer Parties shall be prevented by such third party from receiving the rights and benefits with respect to such Transferred Asset intended to be transferred hereunder, or if any attempted assignment would adversely affect the rights of a Seller Party thereunder so that the Buyer Parties would not in fact receive all such rights, Seller and Buyer shall cooperate in any lawful and commercially reasonable arrangement, as Seller and Buyer shall agree, under which the Buyer Parties would, for a period of no more than twenty-four (24) months following the Closing Date, obtain the economic claims, rights and benefits under such asset and assume the economic burdens and obligations with respect thereto in accordance with this Agreement, including by subcontracting, sublicensing or subleasing to Buyer; provided, that all reasonable out-of-pocket administrative expenses of such cooperation and related actions shall be borne solely by Buyer. Seller shall use its commercially reasonable efforts for a period of twelve (12) months following the Closing to obtain any Consents that were not obtained prior to the Closing; provided, for the avoidance of doubt, no party hereto shall be required to make any payments in respect of any Consent to assignment or any third-party license to be obtained by the Seller Parties, and, so long as Seller has complied with its obligations under this Section 2.5, the failure to obtain any such Consent shall not, in and of itself, constitute a breach of this Agreement or result in the failure of any condition set forth in Article VII. Seller shall promptly pay to Buyer when received all monies received by the Seller Parties under such Transferred Asset or any claim or right or any benefit arising thereunder.
28
(c) Notwithstanding anything in this Agreement to the contrary, this Section 2.5 shall not apply to the Excluded Regulatory Approvals.
Section 2.6 Transaction Consideration.
(a) In consideration for the Transferred Assets and other obligations of Seller pursuant to this Agreement, Buyer shall (i) pay or issue (A) to Seller, the Estimated Cash Consideration (as adjusted pursuant to Section 2.10), as paid in the manner set forth in Section 2.7(c); (B) to Seller, the Stock Consideration; (C) to Seller, the Royalty Payments, if and when payable, as provided in Section 2.11 and Schedule 1.1J and (D) to Seller, the Earn-Out Payments, if and when payable, as provided in Section 2.11 and Schedule 1.1J (the payments collectively contemplated by the foregoing clauses (A), (B), (C) and (D) being the “Transaction Consideration”); and (ii) assume the Assumed Liabilities.
(b) At least three (3) Business Days prior to the Closing Date, Seller shall deliver to Buyer the Estimated Closing Statement. Buyer shall have the right to review and comment on the Estimated Closing Statement, and Seller shall consider in good faith any such comments and make such revisions as are reasonably requested by Buyer and acceptable to Seller, acting reasonably.
Section 2.7 Closing.
(a) The sale and purchase of the Transferred Assets and the assumption of the Assumed Liabilities contemplated by this Agreement shall take place at a closing (the “Closing”) to be held remotely via electronic transmission of related documentation or other similar means, on the third (3rd) Business Day following the satisfaction or, to the extent permitted by applicable Law, waiver of all conditions to the obligations of the parties hereto set forth in Article VII (other than such conditions as may, by their terms, only be satisfied at the Closing or on the Closing Date, but subject to the satisfaction of such conditions on the Closing Date), or at such other place or at such other time or on such other date as Seller and Buyer mutually may agree in writing. The day on which the Closing takes place is referred to as the “Closing Date” and the Closing shall be deemed to have occurred at 12:01 a.m. on the Closing Date.
(b) At the Closing, Seller shall deliver or cause to be delivered to Buyer:
(i) the Transferred Assets free and clear of all Encumbrances other than Permitted Exceptions;
(ii) a certificate, dated as of the Closing Date, signed by a duly authorized officer of Seller, confirming the satisfaction of the conditions specified in Section 7.3(a), Section 7.3(b) and Section 7.3(c);
(iii) the payoff letters, in form and substance reasonably acceptable to Buyer, duly executed by or on behalf of the applicable lenders or other holders of Seller Indebtedness specified on Schedule 2.7(b)(iii) (the “Closing Date Seller Indebtedness”), together with a release of all Encumbrances thereunder on Transferred Assets;
(iv) a duly completed and executed IRS Form W-9 of Seller;
29
(v) an executed counterpart of each of the Ancillary Agreements (excluding the Seller Governance Agreement, the Stockholder Governance Agreement and the Voting Agreements) to which a Seller Party is a party, signed by Seller or its applicable Affiliate; and
(vi) a certificate of good standing with respect to Seller issued by the Secretary of State of the State of Delaware (or applicable jurisdiction of incorporation) dated no earlier than five (5) Business Days prior to the Closing Date.
(c) At the Closing, Buyer shall pay, discharge, or deliver, or cause to be paid, discharged, or delivered:
(i) to Seller, or to a party designated by Seller, by wire transfer of immediately available funds to the account(s) designated in the Estimated Closing Statement, the Estimated Cash Consideration less the Purchase Price Escrow Amount;
(ii) to Seller, evidence, in form and substance reasonably acceptable to Seller, of the issuance to Seller of an aggregate number of shares of Buyer Common Stock equal to the Stock Consideration, fully paid and non-assessable, and free and clear of all Encumbrances (other than those existing under securities Laws and the organizational documents of Buyer), credited to the book entry account maintained by the Transfer Agent;
(iii) to Seller, a certificate, dated as of the Closing Date, signed by a duly authorized officer of Buyer, confirming the satisfaction of the conditions specified in Section 7.2(a), Section 7.2(b), and Section 7.2(c);
(iv) to Seller, an executed counterpart of each of the Ancillary Agreements (excluding the Seller Governance Agreement, the Stockholder Governance Agreement and the Voting Agreements) to which a Buyer Party is a party, signed by Buyer or its applicable Affiliate; and
(v) to the Escrow Agent, the Purchase Price Escrow Amount by wire transfer of immediately available funds, to be held and released in accordance with Section 2.10(d).
Section 2.8 Withholding. The Buyer Parties shall be entitled to deduct and withhold from any amounts otherwise payable hereunder such amounts as are required to be deducted or withheld from such amounts under the Code or any provision of any other applicable Tax Law (including any state, local or foreign Tax Law); provided, however, that in the event that such withholding is required, the Buyer Parties shall (a) notify Seller of such determination in writing at least ten (10) days prior to the Closing Date, and (b) reasonably cooperate with Seller to claim any benefits or reduce and/or eliminate any such withholding Taxes. Buyer shall take all actions that may be necessary to ensure that any amounts so withheld are timely and properly remitted to the appropriate Tax Authority in accordance with the applicable Law. To the extent that amounts are so withheld and Buyer timely remits such amounts to the appropriate Tax Authority and provides Seller with evidence reasonably satisfactory to Seller with respect thereto, such amounts shall be treated for all purposes of this Agreement as having been paid to the party otherwise entitled to receive such payment pursuant to this Agreement.
30
Section 2.9 Adjustments to Stock Consideration. If at any time during the Interim Period, any change in the outstanding shares of capital stock of Buyer shall occur as a result of any reclassification, stock split (including reverse stock split) or combination, exchange or readjustment of shares, or any stock dividend or stock distribution with a record date during such period, the number of shares of Buyer Common Stock constituting the Stock Consideration shall be equitably adjusted.
Section 2.10 Purchase Price Adjustment.
(a) Closing Statement. Within sixty (60) days following the Closing Date, Buyer shall prepare and deliver to Seller the Closing Statement. From the Closing until final determination of the Final Cash Consideration pursuant to this Section 2.10, Buyer shall, and shall cause its Affiliates and Representatives to, provide Seller and its Representatives with reasonable access, during normal business hours upon reasonable advance notice, to the books, records, work papers and relevant personnel of Buyer and its Affiliates as may be reasonably requested in connection with its review of the Closing Statement. The Closing Statement shall (i) be based solely on facts and circumstances as they exist on or prior to the Closing and (ii) not include, reflect, or be based on, in any respect: (A) any of the plans, transactions or changes which Buyer intends to initiate or make, or cause to be initiated or made, after the Closing with respect to the Business or the Transferred Assets, (B) the effect of any decision by Buyer or its Affiliates, (C) purchase accounting adjustments or other adjustments arising from or resulting as a consequence of the Transactions, or (D) the introduction of any rules, guidelines, methods, policies, principles, practices, procedures, classifications or estimation methodologies different from those set forth in the Accounting Principles.
(b) Disputes. If Seller disagrees with any amount set forth in the Closing Statement, Seller shall, within thirty (30) days after receipt of the Closing Statement, deliver written notice (a “Dispute Notice”) to Buyer setting forth, in reasonable detail, each item in dispute, the basis for such dispute and Seller’s calculation of such disputed item (to the extent then reasonably determinable based on the information made available to Seller). If Seller does not deliver a Dispute Notice within such thirty (30)-day period, the Closing Statement as delivered by Buyer shall be final and binding on the parties for all purposes hereunder. If Seller timely delivers a Dispute Notice, the Closing Statement shall be deemed not final and Buyer and Seller shall use commercially reasonable efforts to resolve such disputed items within thirty (30) days following Buyer’s receipt of such Dispute Notice. If Buyer and Seller resolve all disputed items, the Closing Statement, as modified to reflect such resolution, shall be final and binding on the parties for all purposes hereunder. For the avoidance of doubt, any items in the Closing Statement not specifically disputed in the Dispute Notice shall be deemed accepted by Seller and shall be final and binding on the parties.
31
(c) Independent Expert. If Buyer and Seller are unable to resolve all disputed items within thirty (30) days following Buyer’s receipt of the Dispute Notice, either party hereto may submit any unresolved disputed items to the Independent Expert for resolution. The Independent Expert shall act as an expert and not as an arbitrator and shall determine, based solely on written submissions by Buyer and Seller (each to be submitted within ten (10) days of the submission of the dispute to the Independent Expert) and not by independent review, only those items remaining in dispute and shall render a written decision as to the disputed items and the resulting Final Cash Consideration as promptly as reasonably practicable, but in no event later than thirty (30) days after receipt of both parties’ submissions. Neither Buyer nor Seller (nor any of their respective Affiliates or Representatives) shall have any ex parte communications or meetings with the Independent Expert regarding the subject matter of the dispute without the prior written consent of the other party; provided that the foregoing shall not restrict (x) communications relating solely to the engagement, scheduling or other administrative matters, or (y) any party’s response to a written request for information from the Independent Expert, so long as a copy of any written communication delivered to the Independent Expert is concurrently delivered to the other party and the other party is given a reasonable opportunity to participate in any oral communication. The Independent Expert’s decision shall (i) be based solely on the definitions and other applicable terms of this Agreement and this Section 2.10, (ii) not assign a value to any item in dispute greater than the highest value claimed for such item or less than the lowest value claimed for such item, and (iii) be final and binding on the parties hereto for all purposes hereunder, absent fraud or manifest error. All fees and expenses of the Independent Expert shall be borne on a proportionate basis by Buyer, on the one hand, and Seller, on the other hand, based on the percentage that the portion of the contested amount not awarded in favor of such party bears to the amount actually contested by such party. For example, if Buyer’s calculations would have resulted in a $100,000 net payment to Buyer, and Seller’s calculations would have resulted in a $100,000 net payment to Seller, and the Independent Expert’s final determination results in an aggregate net payment of $50,000 to Seller, then Buyer and Seller would bear 75% and 25%, respectively, of such fees and expenses.
(d) Post-Closing Adjustment. Within three (3) Business Days after the Closing Statement becomes final and binding pursuant to this Section 2.10, the parties hereto shall cause the Escrow Agent holding the Purchase Price Escrow Amount to release such amount and shall make the applicable payment as follows:
(i) if the Final Cash Consideration exceeds the Estimated Cash Consideration (such amount, the “Shortfall Payment”), then the Escrow Agent shall release the Purchase Price Escrow Amount to Seller, and Buyer shall pay (or cause to be paid) to Seller, by wire transfer of immediately available funds to an account designated by Seller in writing, an amount equal to such Shortfall Payment in an amount not to exceed $10,000,000;
(ii) if the Estimated Cash Consideration exceeds the Final Cash Consideration (such amount, the “Excess Payment”), then the Escrow Agent shall release to Buyer an amount equal to the lesser of (I) the Purchase Price Escrow Amount and (II) such Excess Payment and any remaining balance of the Purchase Price Escrow Amount shall be released to Seller, and, if the Excess Payment exceeds the Purchase Price Escrow Amount, Seller shall pay (or cause to be paid) to Buyer, by wire transfer of immediately available funds to an account designated by Buyer in writing, an amount equal to such excess; provided, that in no event shall the aggregate Excess Payment (including any amounts released to Buyer from the Purchase Price Escrow Amount) exceed $10,000,000; and
(iii) if the Final Cash Consideration equals the Estimated Cash Consideration, the Escrow Agent shall release the Purchase Price Escrow Amount to Seller.
32
(e) Treatment of Adjustment Payments. Any payments made pursuant to this Section 2.10 shall be treated by the parties hereto, to the extent permitted by applicable Law, for federal income Tax and other applicable Tax purposes, as an adjustment to the Transaction Consideration.
(f) Adjustment Escrow Fund.
(i) On the Closing Date, Buyer shall withhold from the consideration otherwise payable to Seller hereunder and will deposit with Citibank, N.A., as escrow agent (the “Escrow Agent”), the Purchase Price Escrow Amount (any and all of such deposits to constitute escrow funds to be governed by the terms of the Escrow Agreement, in the form attached hereto as Exhibit D (the “Escrow Agreement”)), without any act of Seller.
(ii) The Purchase Price Escrow Amount plus any interest or earnings paid thereon in accordance with the Escrow Agreement (the “Adjustment Escrow Fund”) shall be governed by this Section 2.10 and the terms of the Escrow Agreement and shall, among other customary terms, secure Buyer’s right to receive the Excess Payment (if any) pursuant to Section 2.10(d); provided, that the Adjustment Escrow Fund shall not be the sole source of recovery for, or otherwise limit, the Excess Payment, subject to the cap set forth in Section 2.10(d)(ii).
Section 2.11 Royalty Payments and Earn-Out Payments.
(a) Buyer shall make (i) royalty payments to Seller based on Net Sales of the Business Products (the “Royalty Payments”) in accordance with the terms to be set forth in Schedule 1.1J and (ii) Earn-Out Payments in accordance with the terms to be set forth in Schedule 1.1J.
(b) Any payments made pursuant to this Section 2.11 and Schedule 1.1J shall be treated by the parties hereto as an adjustment to the Transaction Consideration for federal income Tax and other applicable Tax purposes.
Article
III
REPRESENTATIONS AND WARRANTIES OF SELLER
Except as set forth in (i) the reports, schedules, forms, registration statements, definitive proxy statements and other documents (including exhibits and all information incorporated by reference) filed or furnished by Seller with the SEC or filed or furnished by Seller to the SEC in connection with this Agreement or the Transactions prior to the Agreement Date (excluding, in each case, any disclosures contained under the captions “Risk Factors,” “Cautionary Statement,” “Quantitative and Qualitative Disclosures About Market Risk” and any other disclosures contained therein to the extent they are predictive, cautionary or forward-looking in nature) or (ii) the corresponding section of the Seller Disclosure Schedules (the “Seller Disclosure Schedules”) (giving effect to Section 10.10), Seller hereby represents and warrants to Buyer as of the Agreement Date as follows:
Section 3.1 Organization and Qualification.
(a) Each of the Seller Parties is duly organized, validly existing and in good standing under the Laws of its jurisdiction of incorporation and has all necessary corporate or equivalent company power and authority to (i) own, lease and operate the Transferred Assets owned by it and (ii) carry on the Business as it is now being conducted by it.
33
(b) Each Seller Party is duly qualified and licensed to do business as a foreign corporation in, and is in good standing (where such concept is applicable) in, each jurisdiction where the character of the properties owned, leased, or operated by it or the nature of its business, its ownership or its activities makes such qualification and licensing necessary, except, where the failure to be so qualified or licensed would not, individually or in the aggregate, have or reasonably be expected to have a Seller Material Adverse Effect.
Section 3.2 Authority. Seller has all requisite corporate or equivalent company power and authority to execute and deliver this Agreement and each of the Ancillary Agreements to which it will be a party, to perform its obligations hereunder and to consummate the Transactions. Each other Seller Party has all requisite power and authority to execute and deliver each of the Ancillary Agreements to which it will be a party, to perform its obligations thereunder and to consummate the Transactions. The execution, delivery and performance by Seller of this Agreement and by each Seller Party of each of the Ancillary Agreements to which it will be a party and the consummation by each Seller Party of the Transactions have been duly and validly authorized by all necessary corporate action on the part of Seller and each other Seller Party, other than, with respect to Seller, the Seller Stockholder Approval. The Seller Board has unanimously (a) determined that this Agreement and the Transactions are advisable, fair to and in the best interests of Seller and its stockholders, (b) approved and declared advisable the entry into this Agreement and the consummation of the Transactions, (c) recommended that Seller’s stockholders adopt this Agreement and approve the Transactions (the “Seller Board Recommendation”), and (d) directed that this Agreement and the Transactions be submitted to Seller’s stockholders for their adoption and approval. This Agreement has been, and upon their execution each of the Ancillary Agreements will have been, duly executed and delivered by each Seller Party that is a party thereto and, assuming due execution and delivery by each of the other parties hereto and thereto, this Agreement constitutes, and upon their execution each of the Ancillary Agreements will constitute, the legal, valid and binding obligation of each Seller Party that is a party thereto, enforceable against such Seller Party in accordance with their respective terms, except as enforcement may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally and by general principles of equity (regardless of whether considered in a proceeding in equity or at law).
Section 3.3 No Conflict; Required Filings and Consents.
(a) The execution, delivery and performance by Seller of this Agreement and by each Seller Party of each of the Ancillary Agreements to which it will be a party, and the consummation of the Transactions do not and will not, and the consummation of the Transactions and compliance with the terms hereof and thereof will not, conflict with, or result in any violation of, or default (with or without notice or lapse of time, or both) under, or give rise to a right of termination, cancelation or acceleration of any obligation or loss of a benefit under, or result in the creation of any Encumbrance other than any Permitted Exception upon any of the Transferred Assets, or require any Consent, exemption or other action by or notice to any other Person, under, any provision of:
(i) the certificate of incorporation or bylaws or similar organizational documents of any Seller Party;
34
(ii) any Law applicable to any Seller Party, the Business or any of the Transferred Assets or by which any Seller Party, the Business or any of the Transferred Assets may be bound or affected; or
(iii) any Material Contract;
except, in the case of clause (ii) or (iii), as would not, individually or in the aggregate, have or reasonably be expected to have a Seller Material Adverse Effect.
(b) The Seller Parties are not required to file, seek or obtain any notice, Permit or Consent of or with any Governmental Authority in connection with the execution, delivery and performance by the Seller Parties of this Agreement or any Ancillary Agreements or the consummation of the Transactions, except (i) the Required Antitrust Approvals; (ii) compliance with any applicable requirements of the Securities Act, the Exchange Act and any other applicable securities Laws, including the filing with the SEC of (A) the Proxy Statement and (B) such reports under, and other compliance with, the Exchange Act and the Securities Act as may be required in connection with this Agreement and the Transactions; (iii) compliance with any applicable rules of Nasdaq; or (iv) where failure to obtain such notice, Permit, or Consent, or to make such filing or notification, would not, individually or in the aggregate, have or reasonably be expected to have a Seller Material Adverse Effect.
Section 3.4 Transferred Assets.
(a) Except as would not, individually or in the aggregate, reasonably be expected to be material to the Business, the Seller Parties have good and valid title to, a valid leasehold interest (under an Assumed Contract) or a valid license (under an Assumed Contract) to, possess and use, all of the Transferred Assets, free and clear of all Encumbrances (including Encumbrances resulting from any Seller Indebtedness of any Seller Party), other than Permitted Exceptions.
(b) Assuming consent from the counterparty to assign the Transferred Assets is obtained where required, the Transferred Assets constitute all of the material assets of any nature whatsoever (whether tangible, intangible or mixed), (i) owned and used by any member of the Seller Group in the conduct of the Business or (ii) licensed to and used by any member of the Seller Group in the conduct of the Business, in each case, as currently conducted as of the Agreement Date, other than (x) the Excluded Assets, and (y) employees of the Seller Parties who are not Transferred Employees.
Section 3.5 Financial Information; SEC Filings.
(a) Each of (i) Seller’s audited financial statements for the period ended December 31, 2025, and (ii) Seller’s unaudited interim financial statements for the period ended June 30, 2026, are contained the Seller SEC Documents (collectively, the “Seller Financial Information”).
35
(b) The Seller Financial Information (i) has been prepared in accordance with GAAP, (ii) has been derived from the books and records maintained by Seller in the ordinary course of business, and (iii) fairly presents, in all material respects, the financial position and results of operations of Seller, for the periods indicated.
(c) Seller (as related to the Business or the Transferred Assets) has no material indebtedness or liability, absolute or contingent, known or unknown, required to be reflected or reserved against on, or disclosed in the notes to, a balance sheet prepared in accordance with GAAP, other than (i) as set forth in the Seller Financial Information, (ii) liabilities or obligations incurred in the ordinary course of business since the date of the most recent Seller Financial Information, (iii) liabilities that are executory performance obligations arising under Assumed Contracts (other than to the extent arising from a breach thereof by any Seller Party), (iv) liabilities or obligations incurred in connection with the Transactions and (v) as would not, individually or in the aggregate, have or reasonably be expected to have a Seller Material Adverse Effect.
(d) Seller has established and maintains a system of internal accounting controls and processes designed to provide reasonable assurances regarding the reliability of financial reporting and the preparation of financial statements in accordance with GAAP. Neither Seller nor, to the Knowledge of Seller, Seller’s independent auditors have identified since January 1, 2024, (i) any significant deficiency or material weakness in the design or operation of internal controls over financial reporting utilized by the Seller Parties with respect to the Business, (ii) any illegal act or fraud, whether or not material, that involves the management or other employees of the Seller Parties with respect to the Business, or (iii) improper, wrongful or fraudulent accounting or auditing practices, procedures, methodologies or methods with respect to the Business or any material inaccuracy in the Seller Financial Information, except, in each case, as would not, individually or in the aggregate, have or reasonably be expected to have a Seller Material Adverse Effect.
(e) All accounts receivable of the Seller Parties included in the Transferred Assets (i) are reflected on the books and records of the Seller Parties, (ii) represent valid obligations arising from bona fide arm’s-length transactions in the ordinary course of business, (iii) are the valid and legally binding obligations of the parties owing such amounts, (iv) to the Knowledge of Seller, are collectible in the ordinary course of business without the necessity of commencing any legal proceeding, (v) to the Knowledge of Seller, are not subject to counterclaim or setoff, (vi) are not in dispute and (vii) no credit, deduction, free goods or services, discount or other deferred price or quantity adjustment has been granted with respect to any such accounts receivable, except in the ordinary course of business consistent with past practice.
36
(f) Seller has timely filed with or furnished to the SEC (including following any extensions of time for filing provided by Rule 12b-25 promulgated under the Exchange Act) all material reports, schedules, forms, registration statements, definitive proxy statements and other documents (including exhibits and all information incorporated by reference) required to be filed or furnished by it under the Securities Act or the Exchange Act since January 1, 2024 (collectively, together with all amendments thereof and supplements thereto, the “Seller SEC Documents”). As of its filing date (or, if amended or supplemented, as of the date of the most recent amendment or supplement filed prior to the Agreement Date), each Seller SEC Document complied in all material respects with the applicable requirements of the Securities Act, the Exchange Act and the rules and regulations of the SEC promulgated thereunder, as the case may be. As of its filing date (or, if amended or supplemented, as of the date of the most recent amendment or supplement filed prior to the Agreement Date), no Seller SEC Document filed or furnished pursuant to the Exchange Act contained any untrue statement of a material fact or omitted to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. Each Seller SEC Document that is a registration statement, as amended or supplemented, if applicable, filed pursuant to the Securities Act, as of the date such registration statement or amendment became effective, did not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading. To the Knowledge of Seller, as of the Agreement Date, none of the Seller SEC Documents is the subject of ongoing SEC review or outstanding SEC investigation and there are no outstanding or unresolved comments received from the SEC with respect to any of the Seller SEC Documents.
(g) Seller has established and maintains disclosure controls and procedures (as defined in Rule 13a-15 under the Exchange Act). Such disclosure controls and procedures are designed to ensure that material information relating to Seller and the Business is made known to Seller’s principal executive officer and its principal financial officer by others within Seller, particularly during the periods in which periodic reports required under the Exchange Act are being prepared. Such disclosure controls and procedures are effective in all material respects.
(h) Seller has established and maintained a system of internal controls over financial reporting (as defined in Rule 13a-15 under the Exchange Act) sufficient to provide reasonable assurance regarding the reliability of Seller’s financial reporting and the preparation of Seller’s financial statements for external purposes in accordance with GAAP. Seller has disclosed, based on its most recent evaluation of internal controls prior to the Agreement Date, to Seller’s auditors and audit committee (i) any significant deficiencies and material weaknesses in the design or operation of internal controls which are reasonably likely to adversely affect Seller’s ability to record, process, summarize and report financial information, and (ii) any fraud, whether or not material, that involves management or other employees who have a significant role in internal controls.
(i) No Seller Party has extended or maintained credit, arranged for the extension of credit, or renewed an extension of credit, in the form of a personal loan to or for any executive officer (as defined in Rule 3b-7 under the Exchange Act) or director of Seller in violation of Section 402 of the Sarbanes-Oxley Act.
(j) Each of the principal executive officer and principal financial officer of Seller (or each former principal executive officer and principal financial officer of Seller, as applicable) has made all certifications required by Rules 13a-14 and 15d-14 under the Exchange Act and Sections 302 and 906 of the Sarbanes-Oxley Act and any related rules and regulations promulgated by the SEC and Nasdaq, and the statements contained in any such certifications are complete and correct in all material respects.
37
(k) Each of the consolidated financial statements (including, in each case, any notes and schedules thereto) contained in or incorporated by reference into the Seller SEC Documents (i) complied as to form in all material respects with the published rules and regulations of the SEC with respect thereto as of their respective dates, (ii) was prepared in accordance with GAAP applied on a consistent basis throughout the periods involved (except as may be indicated in the notes thereto and, in the case of unaudited interim financial statements, as may be permitted by the SEC for Quarterly Reports on Form 10-Q) and (iii) fairly presented in all material respects the consolidated financial position and the results of operations and cash flows of Seller and its consolidated Subsidiaries as of the respective dates of and for the periods referred to in such financial statements, subject, in the case of unaudited interim financial statements, to normal year-end audit adjustments as permitted by applicable rules and regulations of the SEC.
Section 3.6 Absence of Certain Changes or Events.
(a) Since June 30, 2026 through the Agreement Date, the Seller Parties have operated the Business in the ordinary course of business in all material respects.
(b) Since June 30, 2026 through the Agreement Date, there has not occurred any event that has had, or that would reasonably be expected to have, individually or in the aggregate, a Seller Material Adverse Effect.
Section 3.7 Compliance with Law; Permits.
(a) The Seller Parties are, and since January 1, 2023 have been, in compliance in all material respects with all applicable Laws (including Regulatory Laws) relating to the Transferred Assets, and no Seller Party is in violation of, or has, since January 1, 2023, violated, in any material respect nor, to the Knowledge of Seller, is under investigation with respect to or has, since January 1, 2023, been threatened in writing to be charged with or given written notice of any material violation of, any applicable Law (including Regulatory Laws) relating to the Transferred Assets or the conduct of the Business, and no Seller Party is in default in any material respect with respect to any Order relating to the Business.
(b) Each material Permit has been duly obtained, is valid and in full force and effect, and is not subject to any (i) pending, (ii) threatened in writing, or (iii) to the Knowledge of Seller, orally threatened, administrative or judicial proceeding to revoke, cancel, suspend or declare such Permit invalid in any respect. The Seller Parties are in possession of all material Permits necessary for them to continue to lawfully own, lease and operate the Transferred Assets and to lawfully carry on the Business as currently conducted.
(c) The Seller Parties have timely filed with the applicable Governmental Authority (including CMS and the FDA) all material filings, including applications, submissions, documents, statements, amendments, restatements, and supplements, required to be filed by the Seller Parties under Regulatory Law, except as would not, individually or in the aggregate, have or reasonably be expected to have a Seller Material Adverse Effect. Since January 1, 2023, all such filings were in material compliance with applicable Regulatory Law and were true and correct in all material respects as of the date of filing.
38
(d) Since January 1, 2023, the Seller Parties have not received any written notification of any (i) pending, (ii) threatened in writing, or (iii) to the Knowledge of Seller, orally threatened, Action alleging material non-compliance with any Permits or Regulatory Laws.
(e) Since January 1, 2023, no Business Product has been seized, withdrawn, recalled, detained, or been subject to a field correction, safety alert, or suspension of manufacturing, in each case, by a Governmental Authority, except as would not, individually or in the aggregate, reasonably be expected to be material to the Business. As of the Agreement Date, no proceedings in the United States seeking the withdrawal, recall, correction, suspension, detention or seizure of any Business Product are pending or, to the Knowledge of Seller, threatened in writing against a Seller Party.
(f) Since January 1, 2023, the Seller Parties have not received written notice or written threat of any action, including notice, warning, proceeding, review, or investigation, by a Governmental Authority, including any FDA Form 483, FDA warning letter or untitled letter or any similar notice, that asserted that a Seller Party materially violated any applicable Regulatory Laws or sought to withdraw a material marketing clearance or approval of, or materially change the labeling or classification of, any Business Product.
(g) Neither the Seller Parties nor, any of their officers, employees or, to the Knowledge of Seller, agents engaged in the Business (i) is or has been debarred under 21 U.S.C. § 335a, (ii) is excluded from participation in any federal health care program (as defined in 42 U.S.C. § 1320a–7b(f)), or (iii) has been convicted of any crime that would reasonably be expected to result in debarment under 21 U.S.C. § 335a or exclusion pursuant to 42 U.S.C. § 1320a-7.
(h) Neither the Seller Parties nor, to the Knowledge of Seller, any of their officers, employees or agents, has (i) made an untrue statement of material fact to the FDA or any other Governmental Authority, (ii) failed to disclose a material fact required to be disclosed to the FDA or any other Governmental Authority or (iii) otherwise committed an act, made a statement or failed to make a statement that, at the time such statement or disclosure was made (or, in the case of such failure, should have been made) or such act was committed, would reasonably be expected to constitute a material violation of any Regulatory Law. To the Knowledge of Seller, the Seller Parties have not been the subject of any pending or threatened investigation by the FDA pursuant to its policy on fraud, untrue statements of material facts, bribery and illegal gratuities or by any other Governmental Authority pursuant to any similar Law.
(i) Since January 1, 2023, each Seller Party has been in material compliance with all applicable healthcare fraud and abuse Laws (including the federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b) and the False Claims Act (31 U.S.C. §§ 3729-3733)), the Physician Payments Sunshine Act (42 U.S.C. § 1320a-7h) and any applicable state Law equivalents. No Seller Party has been assessed a civil monetary penalty under any Regulatory Law, been party to a corporate integrity agreement, deferred prosecution agreement, consent decree, received a subpoena, complaints, criminal information, civil investigative demands or monitoring agreement with any Governmental Authority, or, to the Knowledge of Seller, since January 1, 2023, received written notice from a Governmental Authority of any investigation or enforcement action relating to healthcare fraud or abuse.
39
(j) The Seller Group maintains policies and procedures reasonably designed to promote compliance by the Seller Group with, and to prevent breaches by the Seller Group of, the applicable healthcare fraud and abuse Laws, including the federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b), the False Claims Act (31 U.S.C. §§ 3729-3733), the Physician Payments Sunshine Act (42 U.S.C. § 1320a-7h), and any applicable state equivalents.
(k) Seller Parties maintain and, since January 1, 2023, have maintained a corporate compliance program.
Section 3.8 Litigation. As of the Agreement Date, and since January 1, 2024, there is and has not been any Action by or against the Seller Parties involving or relating to the Business, the Transferred Assets or the Transactions (a) pending, (b) threatened in writing, or (c) to the Knowledge of Seller, orally threatened that would, individually or in the aggregate, reasonably be expected to be material to the Business or the Transferred Assets, taken as a whole.
Section 3.9 FCPA; Anti-Corruption and Anti-Bribery Laws.
(a) Since January 1, 2021, the Seller Group has complied in all material respects with all applicable anti-bribery, anti-corruption and anti-money laundering Laws (the “Anti-Corruption Laws”), including the Foreign Corrupt Practices Act of 1977, as amended (“FCPA”), the UK Bribery Act 2010, as amended, applicable Laws enacted in accordance with the Organization for Economic Cooperation and Development Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, and any other applicable U.S. or non-U.S. laws relating to fraud, conflicts of interest, bribery, gratuities, or corruption (including mail or wire fraud, honest services fraud, or commercial bribery), or any rules or regulations promulgated thereunder.
(b) Since January 1, 2021, no member of the Seller Group, nor any of their respective directors or officers, nor, to the Knowledge of Seller, employees, agents, or other representatives (in each case, when acting on behalf of Seller or a Subsidiary) has been charged with violating, or received any notice, request, or citation of any investigation (formal or informal), inquiry, action, charge, or proceeding with regard to a violation or alleged violation of the Anti-Corruption Laws.
(c) Since January 1, 2021, no member of the Seller Group, nor any of their respective directors or officers, nor, to the Knowledge of Seller, employees, agents, or other representatives (in each case, when acting on behalf of Seller or a Subsidiary) has directly or indirectly, offered, paid, promised, or authorized the payment, promising, or offering of any money, gift, or other thing of value, regardless of form, (i) corruptly, to any Government Official, or to any Person while knowing that such Person had or would offer, pay, promise, or authorize the payment, promising or offering of any money, gift, or other thing of value to a Government Official, or (ii) to any prospective or actual customer or employee or agent of any business counterparty to induce or reward the improper performance of the recipient’s function or the breach of a duty owed by the recipient to his or her employer or principal, in violation of applicable Anti-Corruption Laws.
40
(d) Since January 1, 2021, no member of the Seller Group, nor any of their respective directors or officers, nor, to the Knowledge of Seller, employees, agents, or other representatives nor any direct, indirect, or beneficial owners of the foregoing, is or has been a Government Official.
(e) The Seller Group maintains policies and procedures reasonably designed to promote compliance by the Seller Group with, and to prevent breaches by the Seller Group of, the Anti-Corruption Laws.
(f) Since January 1, 2021, no member of the Seller Group, nor any of their respective directors or officers, nor, to the Knowledge of Seller, employees, agents or other third party representatives of a member of the Seller Group has, directly or indirectly, in connection with the business of any Seller Group member: (i) requested, agreed to receive, or accepted any financial or other advantage or inducement where such request, agreement to receive or acceptance would be unlawful under an applicable Anti-Corruption Law, or (ii) used any corporate funds for any unlawful contribution, gift, entertainment, or other unlawful expenses relating to political activity.
Section 3.10 Business Employees and Employee Plans.
(a) Schedule 3.10(a)(i) of the Seller Disclosure Schedules sets forth, as of the Agreement Date, to the extent permitted under applicable Law, a list of each employee of the Seller Group, such employee’s employing legal entity, job title, status as exempt/non-exempt from applicable wage and hour Laws and full or part-time status, base salary, bonus opportunities and commission payments payable to such employee in Seller’s fiscal year 2026, the employee’s date of hire, accrued vacation liability, visa/work permit type and status (as applicable), the total amount of cash severance payments and an estimate of the COBRA premium payments to which such employee would be entitled upon a termination of employment without “cause” in connection with the Transactions pursuant to the Specified Plan, in each case, both (A) assuming such termination occurs on the Agreement Date and (B) assuming such termination occurs on or after the next anniversary of such employee’s date of hire following the Agreement Date, and the primary geographic location of their employment with the Seller Parties, as of the Agreement Date, broken down into the following categories: (i) active, and (ii) on an approved leave of absence, the type of leave and the anticipated date of return. Schedule 3.10(a)(ii) of the Seller Disclosure Schedules lists all individuals who are currently working as consultants or independent contractors for or on behalf of any Seller Party or any of its Affiliates, who primarily provide services to the Business, with annualized fees above $50,000 for the fiscal year ended December 31, 2025, which list includes each such individual service provider’s name, location and compensation arrangement.
(b) Each individual providing services to the Seller Parties (including each employee and independent contractor) is properly classified by the Seller Parties as an employee or independent contractor, as applicable, under all applicable Laws. The Seller Parties have complied in all material respects with all applicable Laws relating to the employment of foreign citizens, including all requirements of Form I-9, and no Business Employee is employed by a Seller Party who was not permitted to work in the jurisdiction in which such Business Employee was employed.
41
(c) Schedule 3.10(c) of the Seller Disclosure Schedules sets forth a list of all material Employee Plans. Seller has provided or made available to Buyer a complete copy of each material Employee Plan.
(d) With respect to the Employee Plans: (i) no event has occurred and, to the Knowledge of Seller, there exists no condition or set of circumstances in connection with which the Seller Parties could be subject to any material Liability under the terms of such Employee Plan, ERISA or the Code, or other applicable Law in respect of any current or former Business Employees, (ii) each of the Employee Plans has been operated and administered in all material respects in accordance with its terms and applicable Law and (iii) each Employee Plan intending to be “qualified” within the meaning of Section 401(a) of the Code has received a favorable determination or opinion letter as to such qualification from the IRS and, to the Knowledge of Seller, no event has occurred, either by reason of any action or failure to act, which would cause the loss of any such qualification. All required contributions to Employee Plans have been made or properly accrued.
(e) None of the Employee Plans is a multiemployer plan (within the meaning of Section 3(37) or 4001(a)(3) of ERISA) or a single employer pension plan (within the meaning of Section 4001(a)(15) of ERISA), and the Seller Parties have no Liability relating to any such plan.
(f) Except where required by Law or as set forth on Schedule 3.10(f) of the Seller Disclosure Schedules, neither the execution and delivery of this Agreement nor the Transactions, either alone or in conjunction with any other event, will (i) result in any payment becoming due to any Business Employee, (ii) increase any benefits otherwise payable under any Employee Plan, or (iii) result in any acceleration of the time of payment, vesting or funding of any payment or benefit.
Section 3.11 Labor and Employment Matters.
(a) No Seller Party is a party to or bound by any labor or collective bargaining contract that pertains to any Business Employees, and no labor union, works council or similar labor organization represents or has within the three-year period prior to the Agreement Date represented any Business Employees. There are no pending or, to the Knowledge of Seller, threatened in writing Actions concerning labor matters with respect to the Business, except for such Actions that would not, individually or in the aggregate, reasonably be expected to be material to the Business or the Transferred Assets. To the Knowledge of Seller, there are no organizational campaigns in progress with respect to any Business Employees. No Seller Party has engaged in any material unfair labor practice with respect to any Business Employee.
(b) The Business is being conducted in material compliance with all applicable Laws regarding labor, employment and employment practices, and none of the Seller Parties is delinquent in payment to any Business Employees or former employees of the Business for any material services or amounts required to be reimbursed or otherwise paid.
(c) There are no pending or, to the Knowledge of Seller, threatened Actions against any Seller Party brought by or on behalf of any Business Employee or former employee of the Business, or by any Governmental Authority, relating to employment, employment practices, terms and conditions of employment, wages and hours, workplace safety, or workers’ compensation.
42
(d) To the Knowledge of Seller, no Business Employee is bound by any contract or subject to any judgment, decree, or order of any Governmental Authority that would materially interfere with such Business Employee’s ability to perform his or her duties for Buyer following the Closing or that would materially conflict with the Business as currently conducted.
(e) Since January 1, 2024, (i) there have been no allegations, complaints, charges or claims, whether written or oral, made against or involving any Business Employee relating to sexual harassment, sexual misconduct, discrimination, retaliation, or workplace violence, and (ii) no Seller Party has entered into any settlement, conciliation, consent decree, separation agreement or other agreement or arrangement resolving, or providing for any payment or other consideration in connection with, any such allegation, complaint, charge or claim involving any Business Employee.
Section 3.12 Insurance. Schedule 3.12 of the Seller Disclosure Schedules sets forth a true and complete list of all material insurance policies in force with respect to the Business and the Transferred Assets. Seller has made available to Buyer true and complete copies or summaries of such policies. All such policies are in full force and effect and all premiums due thereon have been paid. No written notice of cancellation or non-renewal of any such policy has been received by any Seller Party, other than in connection with ordinary-course renewals. No material claim under any such policy relating to the Business or the Transferred Assets is pending.
Section 3.13 Intellectual Property.
(a) Schedule 3.13(a) of the Seller Disclosure Schedules sets forth a true, complete and accurate list of all Registered IP, as of the Agreement Date, owned by or, to Seller’s Knowledge, exclusively licensed to the Seller Parties. The issued Patents, registered Copyrights and registered Marks in each case that are owned by a Seller Party and set forth in Schedule 3.13(a) of the Seller Disclosure Schedules are subsisting and, to the Knowledge of Seller, valid and enforceable. No Registered IP owned by a Seller Party is involved in any interference, reissue, reexamination, opposition, cancellation or similar proceeding that remains unresolved or is still pending and is reasonably expected to have a Seller Material Adverse Effect, and no such action is, or has been since January 1, 2024, threatened in writing with respect to any of the material Registered IP owned by a Seller Party, other than any such action that was resolved or is not reasonably expected to have a Seller Material Adverse Effect. With respect to the Transferred Intellectual Property that is material to the Business, one of the Seller Parties is the sole and exclusive and, as applicable, the record owner of the Transferred Intellectual Property, free and clear of all Encumbrances other than Permitted Exceptions. No third party has joint ownership of any issued patents or pending patent applications included in the Registered IP owned by a Seller Party that is material to the Business. The Transferred Intellectual Property comprises all Intellectual Property Rights owned by the Seller Parties and used in the conduct of the Business as of the Agreement Date, and, together with the Intellectual Property licensed or used pursuant to Assumed Contracts, comprises all material Intellectual Property used in the conduct of the Business as of the Agreement Date.
43
(b) As of the Agreement Date, there is no Action pending or, to the Knowledge of Seller, threatened in writing (other than office actions in the ordinary course of prosecution), and no Seller Party has received since January 1, 2024, any written claim, challenging the scope, validity, registrability or enforceability of, or the Seller Parties’ ownership of or right to use any Transferred Intellectual Property, in each case, other than office actions in the ordinary course of prosecution and any such claim that remains unresolved and is reasonably expected to have a Seller Material Adverse Effect.
(c) As of the Agreement Date, there is no Action pending or, to the Knowledge of Seller, threatened in writing against the Seller Parties, and no Seller Party has received any written claim, in the six (6)-year period preceding the Agreement Date alleging that the Business infringes, violates or misappropriates or has infringed, violated or misappropriated, Intellectual Property Rights of any Person in a manner that is reasonably expected to result in material liability to the Business, taken as a whole. As of the Agreement Date, there are no pending, unresolved written claims for indemnity by or against any Seller Party covering any Business Products.
(d) To the Knowledge of Seller, the Business as currently conducted does not infringe, violate or misappropriate, and in the six (6)-year period preceding the Agreement Date has not infringed, violated or misappropriated the Intellectual Property Rights of any Person. To the Knowledge of Seller, no Person is violating, misappropriating or infringing, or in the six (6)-year period preceding the Agreement Date has violated, misappropriated or infringed any Transferred Intellectual Property, and no such claims have been made in writing against any Person by any Seller Party that would reasonably be expected to be material to the Business, taken as a whole.
(e) The Seller Parties have taken measures reasonable under the circumstances to protect the material Trade Secrets included in the Transferred Intellectual Property. To the Knowledge of Seller, there has not been any disclosure or access to any Trade Secret included in the Transferred Intellectual Property to any Person other than pursuant to an agreement that such Trade Secrets be treated as confidential information, except as would not, individually or in the aggregate, be or reasonably be expected to be material to the Business.
(f) Except as would not, individually or in the aggregate, be or reasonably be expected to be material to the Business, each Person that has delivered, developed, contributed to, modified, or improved Transferred Intellectual Property owned or purported to be owned by the Seller Parties (other than any such Transferred Intellectual Property that is owned by a Seller Party by operation of law) (each, a “Contributor”) has executed a valid written agreement (i) presently assigning to Seller exclusive ownership of all such Contributor’s right, title, and interest in and to such Intellectual Property Rights that are legally assignable, and (ii) agreeing to hold all Trade Secrets and other confidential information of Seller Parties and the Business in confidence. No Contributor has excluded works or inventions that are material to the Business or the Business Products made prior to their employment or engagement with the Seller Group from their assignment of Intellectual Property Rights to a Seller Party. There is no uncured breach by a Seller Party or, to the Knowledge of Seller, the counterparty, under any such agreement that is reasonably expected to result in material liability to the Business or, to the Knowledge of Seller, the counterparty, as the case may be.
44
(g) All fees associated with obtaining, registering, maintaining and renewing any Transferred Intellectual Property for which any Seller Party has registered or applied for registration have been paid in full in a timely manner to the proper Governmental Authority, and all necessary documents and certificates in connection therewith have been timely filed with the relevant Intellectual Property office, domain name registrar or other authority in the United States or foreign jurisdictions, as the case may be, for the purpose of maintaining such Registered IP in full force and effect, except, in each case, where failure to do so would not be material to the Business, taken as a whole.
(h) No Transferred Intellectual Property is subject to any outstanding Consent or Order of any Governmental Authority restricting the use thereof consistent with past practices, except as would not be material to the Business, taken as a whole.
(i) Except as would not, individually or in the aggregate, have or reasonably be expected to be material to the Business, taken as a whole, no funding, facilities, personnel or resources of any Governmental Authority, university, college, hospital, foundation, institution or Person was used in the development of any Transferred Intellectual Property that has resulted in such entity owning or having license rights to any such Transferred Intellectual Property. No Seller Party is now or ever has been a member or promoter of, or contributor to, any industry standards bodies or similar organizations and participated in the development of a standard that requires or obligates any Seller Party to grant or offer to any Person any license or right to any material Transferred Intellectual Property.
(j) The software, firmware, hardware, networks, interfaces, and information technology systems, owned, leased or licensed by the Seller Parties or used by the Seller Parties (collectively, the “Seller Systems”) are reasonably sufficient in all material respects for the conduct of the Business as presently conducted. The Seller Parties and, to the Knowledge of Seller, their vendors and service providers, have taken commercially reasonable steps designed to protect the integrity, security and operation of the Seller Systems and information stored therein, processed thereon or transmitted therefrom from unauthorized access, disclosure, or use (“Security Incidents”). In the three (3) years prior to the Agreement Date, there has been no substantial disruption (whether due to failure, crash, or other unavailability of Seller Systems) or interruption in or to the use of, or, to the Knowledge of Seller, Security Incident materially and adversely affecting, any Seller Systems that remains unaddressed. The Seller Parties have established plans for the backup and recovery of material data and incident response, disaster recovery and business continuity, and, as applicable, test such plans and procedures on a regular basis. The Seller Parties have conducted regular security assessments of the Seller Systems, and have remediated all medium, high, and critical vulnerabilities identified in such assessments and penetration testing. No Seller Party in the three (3) years prior to the Agreement Date has paid, or has directed the payment of, any ransomware demand payment to any Person in connection with a Security Incident.
45
(k) Except as would not, individually or in the aggregate, be or reasonably be expected to be material to the Business, taken as a whole, and assuming consent to assignment is obtained from the counterparty where required, the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby will not, by reason of Contracts to which a member of the Seller Group is a party, (i) result in the breach of, or create on behalf of any Person the right to terminate or modify, any agreement as to which any Seller Party is a party and pursuant to which such Seller Party is authorized to use any Intellectual Property of any third party that is used in the Business as presently conducted, (ii) result in or require the grant, assignment or transfer to any other Person of any license or other right or interest under, to or in any of the Transferred Intellectual Property or (iii) cause a loss or impairment of any Transferred Intellectual Property. Immediately following the consummation of the transactions contemplated hereby and assuming consents to assignment and the contemplated transactions are obtained where required and except as would not, individually or in the aggregate, be or reasonably be expected to be material to the Business, taken as a whole, Buyer will have the right to exercise all of the rights in the Transferred Intellectual Property and the other Intellectual Property Rights material to the Business to the same extent the Seller Parties would have been able to had the transactions contemplated hereby not occurred.
Section 3.14 Privacy and Data Security.
(a) With regard to the Transferred Assets, each Seller Party complies with, and has at all times in the last three (3) years complied with, all applicable Data Protection Requirements in all material respects.
(b) With regard to the Transferred Assets, each Seller Party established and maintains, and has maintained, physical, technical, and administrative security measures and policies, in compliance in all material respects with applicable Data Protection Requirements, that (i) are designed to protect the confidentiality, integrity, security, and availability of its Data Systems and websites that are involved in the collection and/or processing of Personal Data; and (ii) are designed to protect against the loss or unauthorized access, use, modification, or disclosure of Personal Data in its possession or control.
(c) In the last three (3) years, with regard to the Transferred Assets, to the Knowledge of Seller, no Seller Party has experienced any Security Incident affecting Personal Data or Data Systems in the possession or control of the Seller Party that would require notification of individuals, other affected parties, law enforcement, or any Governmental Authority.
(d) In the last three (3) years, with regard to the Transferred Assets, no Seller Party has received any subpoenas, written demands, or other written notices from any Governmental Authority investigating, inquiring into, or otherwise relating to any actual or potential material violation of any Data Protection Requirement, and, to the Knowledge of Seller, no Seller Party is under investigation by any Governmental Authority for any actual or potential material violation of any Data Protection Law. In the last three (3) years, with regard to the Transferred Assets, no written notice, complaint, claim, inquiry, audit, enforcement action, proceeding, or litigation of any kind has been served on, initiated against any Seller Party or any of Seller’s officers, directors, or employees (in their capacity as such) by any private party or Governmental Authority, foreign or domestic, alleging a material violation of any Data Protection Requirement.
46
(e) The execution, delivery, and performance of this Agreement shall not cause, constitute, or result in a material breach or material violation of any Data Protection Requirement.
Section 3.15 Taxes.
(a) All Tax Returns required to have been filed by the Seller Parties with respect to the Transferred Assets or the Business have been duly and timely filed (taking into account all applicable extensions of time to file), and all such Tax Returns are true, correct and complete in all material respects.
(b) All material Taxes due and payable related to the Business or Transferred Assets, whether or not shown to be due on any Tax Return, have been timely paid in full.
(c) All material Tax deficiencies that have been claimed, proposed, or asserted in writing by any Tax Authority against any Seller Party with respect to the Transferred Assets or the Business have been fully paid or finally settled.
(d) No material Tax audits or administrative or judicial Tax Actions are being conducted with respect to any Transferred Asset or the Business. In the past three (3) years, Seller has not received from any Tax Authority any written notice of an intent to open an audit or other review with respect to material Taxes relating to the ownership of the Transferred Assets or the Business which audit or review remains unresolved.
(e) No claim has ever been made by an authority in a jurisdiction where a Seller Party does not file Tax Returns that such Seller Party may be subject to material taxation by that jurisdiction as a result of ownership of the Transferred Assets.
(f) Seller has complied in all material respects with its obligations under applicable Law to (x) withhold and pay all material Taxes required to have been withheld and paid in connection with any amounts paid or owing to any service provider, equity interest holder, or other third party, and (y) complete and timely file (taking into account all applicable extensions of time to file) all IRS Forms W-2 and 1099 required with respect thereto, in each case of clauses (x) and (y), with respect to the Transferred Assets and the Business.
(g) There is no material Tax Action pending with respect to any Tax or Tax Return with respect to the Business or the Transferred Assets.
(h) Seller has complied in all material respects with its obligations under applicable Law to (x) properly and timely collect and remit all sales, use, excise and similar Taxes in accordance with applicable Law, or (y) collect and maintain all exemption certificates required to qualify for any exemption from the collection of any such Taxes, in each case of clauses (x) and (y), with respect to the Transferred Assets and the Business.
(i) There are no material Encumbrances for Taxes (except Permitted Exceptions) on any of the Transferred Assets.
(j) None of the Transferred Assets are entities for federal, state, local or foreign Tax purposes.
47
(k) Seller has complied in all material respects with its payment and remittance obligations under applicable escheat and unclaimed property Laws with respect to the Business and the Transferred Assets.
Section 3.16 Environmental Matters. Except as would not, individually or in the aggregate, have or reasonably be expected to have a Seller Material Adverse Effect, (i) the Seller Parties are in compliance with all applicable Environmental Laws and have obtained and are in compliance with all Environmental Permits in connection with the conduct or operation of the Business and the ownership or use of the Transferred Assets and (ii) there are no written claims alleging violation of or Liability pursuant to any Environmental Law pending or threatened against the Seller Parties in connection with the conduct or operation of the Business or the ownership or use of the Transferred Assets.
Section 3.17 Material Contracts.
(a) Except (x) any Employee Plans, or (y) Non-Scheduled Contracts, Schedule 3.17 of the Seller Disclosure Schedules lists each of the following written Contracts as of the Agreement Date (each, a “Material Contract”):
(i) all Assumed Contracts with aggregate annual consideration above $1,000,000 for the fiscal year ended December 31, 2025 with (A) any contract manufacturing organization, (B) contract research organization, or (C) other service provider material to the Exploitation of any Business Product;
(ii) all Assumed Contracts that limit or purport to limit the ability of a Seller Party to compete in any material respect consistent with past practice in any line of business or with any Person or in any geographic area or during any period of time, or that, in connection with the Business, restrict the right of Seller in any material respect consistent with past practice to sell to or purchase from any Person, or that grant the other party or any third person “most favored nation” status that is material to the Exploitation of the Business Products;
(iii) all material joint venture, partnership or similar Assumed Contracts regarding ownership of or investments in any Person, business or enterprise;
(iv) all Assumed Contracts (A) that grant licenses, covenants or other rights to any Person in, to or under any Transferred Intellectual Property or (B) that grant licenses, covenants or other rights to any Seller Party in, to or under any Intellectual Property Rights, in each case, where material to the Business;
(v) all material Assumed Contracts that involve the lease of equipment;
(vi) all Assumed Contracts that in any material manner restrict any Seller Party’s ability to own, use, register, apply to register, disclose or enforce any Transferred Intellectual Property;
(vii) all Assumed Contracts with a Significant Customer or Significant Supplier and all material Assumed Contracts with a Governmental Authority;
48
(viii) all Assumed Contracts that involve an obligation to purchase a minimum quantity of goods or services material to the Business;
(ix) any collective bargaining agreements or other agreements with a trade union, works council or other similar labor organization to which a Seller Party is a party or otherwise bound that would affect any Business Employees after the Closing;
(x) all Assumed Contracts that are Contracts between Related Persons;
(xi) any settlement agreement under which any Seller Party has any continuing material obligations (other than confidentiality obligations) relating to the Business or the Transferred Assets; and
(xii) all Assumed Contracts involving indebtedness for borrowed money, any guarantee, letter of credit, indenture, note, swap or similar arrangement, or any Contract evidencing, providing for the creation of, or granting any Encumbrance upon any Transferred Asset.
(b) Seller has delivered to Buyer a true, correct and complete copy of each Material Contract (or, to the extent that a Material Contract is oral, an accurate description of the material terms thereof is included in Schedule 3.17(b)). Each Material Contract (and any Contract that if entered into as of the Agreement Date would have been a Material Contract) is valid and binding on the applicable Seller Party that is a party thereto and, to the Knowledge of Seller, the counterparties thereto, and is in full force and effect, in each case, except as enforcement may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally and by general principles of equity. No Seller Party is in breach of, or default under, any Material Contract to which it is a party, except for such breaches or defaults that would not, individually or in the aggregate, have or reasonably be expected to have a Seller Material Adverse Effect. To the Knowledge of Seller, no other party to any Material Contract is in material default in respect thereof. As of the Agreement Date, Seller has not received any written (or, to the Knowledge of Seller, oral) notice of intention of any party to terminate or amend in any material respect any Material Contracts or received any request for proposal with respect to any existing Material Contract or been informed by any counterparty to any Material Contract that such counterparty intends to exercise an option not to renew such Material Contract.
Section 3.18 Customers and Suppliers.
(a) Schedule 3.18 of the Seller Disclosure Schedules sets forth a true and complete list of the names of the eight (8) largest specialty distributor and full line wholesaler customers (based on gross revenue recognized during the applicable time period) to whom the Business has sold products during the year ended December 31, 2025 and the gross revenue received from each such customer for such period (each a “Significant Customer”), and the ten (10) largest suppliers or service providers (based on amounts paid during the applicable time period) from whom the Business has purchased supplies or services during the year ended December 31, 2025 and the amount paid to such Person for such period (each a “Significant Supplier”).
49
(b) In the twelve (12) months prior to the Agreement Date, none of the Significant Customers or the Significant Suppliers have canceled, materially modified or otherwise terminated, not renewed or otherwise indicated to Seller in writing or, to the Knowledge of Seller, orally, that it intends to cancel, materially modify or otherwise terminate or not renew, any Contract or other agreement or arrangement to which such Significant Customer or Significant Supplier is a party with any Seller Party. To the Knowledge of Seller, as of the Agreement Date, there are no existing facts, circumstances, or events that would reasonably be expected to result in a material change to the relationship between any Significant Customer or Significant Supplier and the Seller Parties, or a material increase or change to the rate or price of products or services provided by any Significant Customer or Significant Supplier to the Seller Parties.
Section 3.19 Transferred Inventory; Transferred Equipment.
(a) Except as would not, individually or in the aggregate, reasonably be expected to be material to the Business, all Transferred Inventory included in the Transferred Assets is in all material respects of good and merchantable quality and is usable and saleable in the ordinary course of business in all material respects, except for obsolete materials and materials of below standard quality in amounts consistent with past practice. None of the Transferred Inventory is held on consignment by third parties or by distributors.
(b) Except as would not, individually or in the aggregate, reasonably be expected to be material to the Business, the Transferred Equipment is in good operating condition and repair, subject to ordinary wear and tear considering the age and ordinary course of use of such Transferred Equipment and routine maintenance.
Section 3.20 Affiliate Transactions. To the Knowledge of Seller, no director, officer, employee, Affiliate, “associate” or member of any of their “immediate family” (as such terms are respectively defined in Rule 12b-2 and Rule 16a-1 of the Exchange Act) of Seller or its Affiliates (each of the foregoing, a “Related Person”), other than in its capacity as a director, officer or employee of Seller or any of its Affiliates, (a) is a party to any material Contract relating to the Business or the Transferred Assets, or (b) directly or indirectly owns any material Transferred Asset.
Section 3.21 Brokers. Except for Leerink Partners LLC, the fees, commissions and expenses of which constitute a Transaction Expense, no broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission in connection with the Transactions based upon arrangements made by or on behalf of the Seller Parties.
Section 3.22 International Trade. Neither Seller nor its Subsidiary, nor, to the Knowledge of Seller, any of their respective directors, officers, agents, affiliates, employees or representatives acting on behalf of Seller or its Subsidiary is, or is owned or controlled by one or more Persons that are, currently the subject or the target of any sanctions administered or enforced by the U.S. government (including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of State), the United Nations Security Council, the European Union, His Majesty’s Treasury, or other relevant sanctions authority (collectively, “Sanctions”). Neither Seller nor its Subsidiary is located, organized, or resident in a country or territory that is the subject of comprehensive Sanctions, including, without limitation, the Crimea Region of Ukraine, the so-called Donetsk People’s Republic, the so-called Luhansk People’s Republic, or any other covered region of Ukraine, Cuba, Iran, North Korea and Syria (with respect to Syria, only until July 1, 2025). Since April 24, 2019, Seller and its Subsidiary have not engaged in any dealings or transactions with any Person, or in any country or territory, that at the time of the dealing or transaction is, or whose government is, the subject or the target of Sanctions. Since January 1, 2021, Seller and its Subsidiary have been in material compliance with all applicable Sanctions and export control laws. Since April 24, 2019, Seller has not received from any Governmental Authority any written or, to the Knowledge of Seller, oral notice, inquiry or allegation, or made any voluntary or involuntary disclosure to a Governmental Authority related to Sanctions or export control laws.
50
Section 3.23 Disclosure Documents. The information supplied or to be supplied by or on behalf of any Seller Party for inclusion or incorporation by reference in the Proxy Statement will, when the Proxy Statement, or any amendment or supplement thereto, is first disseminated to Seller’s stockholders and at the time of the Stockholders Meeting, comply in all material respects with the applicable requirements of the Exchange Act. None of the information supplied or to be supplied by or on behalf of the Seller Parties expressly for inclusion or incorporation by reference in the Proxy Statement will, at the time such Proxy Statement, or any amendment or supplement thereto, is first disseminated to Seller’s stockholders or at the time of the Stockholders Meeting, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they are made, not misleading. The representations and warranties contained in this Section 3.23 shall not apply to statements or omissions included or incorporated by reference in the Proxy Statement based upon information supplied by the Buyer Parties or any of their respective Representatives specifically for use or incorporation by reference therein.
Section 3.24 Solvency. Seller is not a party to any bankruptcy, insolvency, reorganization, dissolution, liquidation, wind-up or moratorium action, claim, or similar proceeding, no circumstances exist which would require Seller to apply for the opening of such proceedings, and, to the Knowledge of Seller, no such action, claim, or proceeding is contemplated or threatened in writing against Seller or has been filed before any Governmental Authority.
Section 3.25 Excluded Entity.
(a) Schedule 3.25(a) of the Seller Disclosure Schedules lists each Subsidiary of Seller, its form and jurisdiction of organization. All the outstanding shares of capital stock of, or other voting securities or ownership interests in, each Subsidiary of Seller have been validly issued and are fully paid and nonassessable and are owned by Seller, free and clear of all Encumbrances except for Encumbrances for Taxes that are not yet due and payable, and free of any other restriction (including any restriction on the right to vote, sell or otherwise dispose of such capital stock or other ownership interests), except for restrictions imposed by applicable securities Laws.
(b) Except for its interests in the Subsidiary of Seller, neither Seller nor the Subsidiary of Seller owns, directly or indirectly, any equity or similar interest in, or any interest convertible into or exchangeable or exercisable for, any corporation, partnership, joint venture or other business association or entity.
51
(c) The Excluded Entity does not have any (i) material assets, (ii) material Liabilities or obligations (whether absolute, accrued, contingent or otherwise) and (iii) employees, in each case, related to the Business or any Transferred Asset. The Excluded Entity is not a party to any Contract related to the Business or any Transferred Asset. The Excluded Entity does not own, license or have any rights in or to any Intellectual Property Rights related to the Business or any Business Product.
(d) The Excluded Entity does not hold any Permits, Regulatory Approvals or other governmental authorizations related to the Business or any Business Product. There is no Action pending or, to the Knowledge of Seller, threatened against or by the Excluded Entity relating to the Business, any Business Product or any Transferred Asset.
Section 3.26 No Shared Contracts. No Assumed Contract includes a material Excluded Asset or material Excluded Liability.
Article
IV
REPRESENTATIONS AND WARRANTIES OF BUYER
Except as set forth in (i) the reports, schedules, forms, registration statements, definitive proxy statements and other documents (including exhibits and all information incorporated by reference) filed or furnished by Buyer with the SEC or filed or furnished by Buyer to the SEC in connection with this Agreement or the Transactions (collectively, the “Buyer SEC Documents”) prior to the Agreement Date (excluding, in each case, any disclosures contained under the captions “Risk Factors,” “Cautionary Statement,” “Quantitative and Qualitative Disclosures About Market Risk” and any other disclosures contained therein to the extent they are predictive, cautionary or forward-looking in nature) or (ii) the corresponding section of the Buyer Disclosure Schedules (collectively, the “Buyer Disclosure Schedules”) (giving effect to Section 10.10), Buyer hereby represents and warrants to Seller as of the Agreement Date as follows:
Section 4.1 Organization and Qualifications.
(a) Each of Buyer and the Subsidiaries of Buyer (each, a “Buyer Entity,” and collectively, the “Buyer Group”) is duly organized, validly existing and in good standing under the Laws of its jurisdiction of incorporation and has all necessary corporate or equivalent company power and authority to (i) own, lease and operate its assets and (ii) carry on its business as it is now being conducted.
(b) Each Buyer Entity is duly qualified and licensed to do business as a foreign corporation in, and is in good standing (where such concept is applicable) in, each jurisdiction where the character of the properties owned, leased, or operated by it or the nature of its activities makes such qualification or licensing necessary, except, in each case, where the failure to be so qualified, licensed or in good standing would not, individually or in the aggregate, have or reasonably be expected to have a Buyer Material Adverse Effect.
52
Section 4.2 Authority. Buyer has the corporate or equivalent company power and authority to execute and deliver this Agreement and each of the Ancillary Agreements to which it will be a party, to perform its obligations hereunder and to consummate the Transactions. Each other Buyer Entity has full corporate or equivalent company power and authority to execute and deliver each of the Ancillary Agreements to which it will be a party, to perform its obligations thereunder and to consummate the Transactions. The execution, delivery and performance by Buyer of this Agreement and by each Buyer Entity of each of the Ancillary Agreements to which it will be a party and the consummation by each Buyer Entity of the Transactions have been duly and validly authorized by all necessary corporate action. This Agreement has been, and upon their execution each of the Ancillary Agreements will have been, duly executed and delivered by each Buyer Entity that is a party thereto and, assuming due execution and delivery by each of the other parties hereto, this Agreement constitutes, and upon their execution each of the Ancillary Agreements will constitute, the legal, valid and binding obligations of each Buyer Entity, enforceable against such Buyer Entity in accordance with its terms, except as enforcement may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally and by general principles of equity (regardless of whether considered in a proceeding in equity or at law).
Section 4.3 Buyer Subsidiaries; Equity Interests.
(a) Schedule 4.3(a) of the Buyer Disclosure Schedules lists each Subsidiary of Buyer, its form and its jurisdiction of organization. All the outstanding shares of capital stock of, or other voting securities or ownership interests in, each Subsidiary of Buyer have been validly issued and are fully paid and nonassessable and are owned by Buyer, by another Subsidiary of Buyer or by Buyer and another Subsidiary of Buyer, free and clear of all Encumbrances except for Encumbrances for Taxes that are not yet due and payable, and free of any other restriction (including any restriction on the right to vote, sell or otherwise dispose of such capital stock or other ownership interests), except for restrictions imposed by applicable securities Laws.
(b) Except for its interests in the Subsidiaries of Buyer, neither Buyer nor any Subsidiary of Buyer owns, directly or indirectly, any equity or similar interest in, or any interest convertible into or exchangeable or exercisable for, any corporation, partnership, joint venture or other business association or entity.
Section 4.4 Capitalization.
(a) The authorized capital stock of Buyer consists of (i) 160,000,000 shares of Buyer Common Stock and (ii) 2,000,000 shares of Buyer Preferred Stock. As of the close of business on November 4, 2026 (the “Capitalization Date”): (i) 79,477,190 shares of Buyer Common Stock and (ii) 91,623 shares of Buyer Preferred Stock are issued and outstanding. Such issued and outstanding shares of Buyer Common Stock have been, and all shares that may be issued pursuant to any Buyer Stock Plan or as contemplated or permitted by this Agreement will be, when issued in accordance with the respective terms thereof, duly authorized and validly issued, fully paid and nonassessable and free of preemptive rights. As of the Agreement Date, there are no outstanding contractual obligations of Buyer of any kind to redeem, purchase or otherwise acquire any equity interests of Buyer. Other than the Buyer Common Stock, as of the Agreement Date, there are no outstanding bonds, debentures, notes or other indebtedness or securities of Buyer having the right to vote (or, other than the outstanding Buyer Equity Awards, convertible into, or exchangeable for, securities having the right to vote) on any matters on which stockholders of Buyer may vote. As of the Agreement Date, no Buyer Entity is a party to any voting agreement with respect to any of its equity interests, other than as may be set forth in the organizational documents of any wholly-owned Subsidiary of Buyer.
53
(b) Except as set forth in Section 4.4(a), as of the Capitalization Date, no equity interests of Buyer were issued, reserved for issuance or outstanding. Since the Capitalization Date through the Agreement Date, Buyer has not issued any equity interests of Buyer (other than in connection with the exercise, settlement or vesting of Buyer Equity Awards in accordance with their respective terms) or granted any Buyer Equity Awards. Except as set forth in Section 4.4(a), as of the Agreement Date, there are no outstanding commitments, agreements, arrangements or undertakings of any kind to which Buyer is a party or by which it is bound (i) obligating Buyer to issue, deliver or sell, or cause to be issued, delivered or sold, any equity interests in Buyer or (ii) obligating Buyer to issue, grant, extend or enter into any such security, option, warrant, call, right, commitment, agreement, arrangement or undertaking.
Section 4.5 No Conflict; Required Filings and Consents.
(a) The execution, delivery and performance by Buyer of this Agreement and the execution, delivery and performance by each Buyer Entity of each of the Ancillary Agreements to which it will be a party, and the consummation of the Transactions do not and will not, and the consummation of the Transactions and compliance with the terms hereof and thereof will not, conflict with, or result in any violation of, or default (with or without notice or lapse of time, or both) under, or give rise to a right of termination, cancelation or acceleration of any obligation or loss of a benefit under, or require any Consent, exemption or other action by or notice to any other Person, under, any provision of:
(i) the certificate of incorporation or bylaws of any Buyer Entity;
(ii) any Law applicable to the Buyer Group or by which any property or asset of the Buyer Group is bound or affected; or
(iii) any material contract or agreement to which any Buyer Entity is a party;
except, in the case of clause (ii) or (iii), for any such conflicts, violations, breaches, defaults or other occurrences that would not, individually or in the aggregate, have or reasonably be expected to have a Buyer Material Adverse Effect.
(b) The Buyer Group is not required to file, seek or obtain any notice, Permit or Consent of or with any Governmental Authority in connection with the execution, delivery and performance by the Buyer Group of this Agreement and each of the Ancillary Agreements to which it will be a party or the consummation of the Transactions, except (i) the Required Antitrust Approvals; (ii) compliance with any applicable requirements of the Securities Act, the Exchange Act and any other applicable securities Laws, including the filing with the SEC of (A) any resale registration statement pursuant to the Registration Rights Agreement and (B) such reports under, and other compliance with, the Exchange Act and the Securities Act as may be required in connection with this Agreement and the Transactions; (iii) where failure to obtain such notice, Permit or Consent, or to make such filing or notification, would not, individually or in the aggregate, have or reasonably be expected to have a Buyer Material Adverse Effect; or (iv) as may be necessary solely as a result of any facts or circumstances relating to Seller or any of its Affiliates.
54
Section 4.6 Absence of Certain Changes or Events. Except as expressly contemplated by this Agreement:
(a) Since June 30, 2026 through the Agreement Date, the business of the Buyer Group has been operated in the ordinary course of business in all material respects.
(b) Since June 30, 2026 through the Agreement Date, there has not occurred any event that would reasonably be expected to have, individually or in the aggregate, a Buyer Material Adverse Effect.
Section 4.7 Compliance with Law. The operation of the Buyer Group’s business by Buyer is, and since January 1, 2023, has been, in compliance in all material respects with all applicable Laws (including Regulatory Laws), and the Buyer Group is not in violation of any such Laws in respect of the Buyer Group’s business.
Section 4.8 Litigation. As of the Agreement Date, there is no civil, criminal or administrative Action by or against the Buyer Group with respect to Buyer’s business (i) pending, (ii) threatened in writing, or (iii) to the Knowledge of Buyer, orally threatened that would, individually or in the aggregate, reasonably be expected to be material to the Buyer Group’s business, taken as a whole. As of the Agreement Date, there is no Action pending, or to the Knowledge of Buyer, threatened in writing, seeking to prohibit the Transactions.
Section 4.9 Financing. Buyer has on the Agreement Date, and will have at the Closing, the financial capability to consummate the Transactions on the terms and subject to the conditions set forth in this Agreement and the Ancillary Agreements, as applicable, and to pay all related fees and expenses. Buyer will at the Closing have sufficient authorized shares of Buyer Common Stock to issue the Stock Consideration. Buyer has delivered to Seller a true, correct and complete copy of the executed Loan Agreement. The obligations to fund the commitments under the Loan Agreement are not subject to any condition, other than the conditions expressly set forth in the Loan Agreement, and other than the Loan Agreement, there are no side letters or other agreements, contracts or arrangements related to the Debt Financing that could affect the availability, conditionality or amount of the Debt Financing. The Loan Agreement has been duly executed by Buyer and, to the Knowledge of Buyer, each other Person party thereto, is in full force and effect and constitutes the legal, valid and binding obligations of Buyer and, to the Knowledge of Buyer, each other Person party thereto. As of the Agreement Date, the Loan Agreement has not been amended or modified, no such amendment or modification is contemplated, and the commitments contained therein have not been withdrawn or rescinded in any respect. As of the Agreement Date, (x) no event has occurred or circumstance exists which, with or without notice, lapse of time or both, would or would reasonably be expected to constitute a default or breach under the Loan Agreement and (y) Buyer has no reason to believe that any of the conditions to the Debt Financing will not be satisfied on a timely basis or that the Debt Financing will not be made available to Buyer on the Closing Date. Buyer has fully paid any and all fees required by the Loan Agreement to be paid on or before the Agreement Date.
55
Section 4.10 Brokers. Except for Moelis & Company, the fees, commissions and expenses of which will be paid by Buyer, no broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission in connection with the Transactions based upon arrangements made by or on behalf of the Buyer Group.
Section 4.11 SEC Filings; Financial Statements; and the Sarbanes-Oxley Act.
(a) Buyer has timely filed with or furnished to the SEC (including following any extensions of time for filing provided by Rule 12b-25 promulgated under the Exchange Act) the Buyer SEC Documents. As of its filing date (or, if amended or supplemented, as of the date of the most recent amendment or supplement filed prior to the Agreement Date), each Buyer SEC Document complied in all material respects with the applicable requirements of the Securities Act and the Exchange Act and the Sarbanes-Oxley Act, and any rules and regulations promulgated thereunder, as the case may be. As of its filing date (or, if amended or supplemented, as of the date of the most recent amendment or supplement filed prior to the Agreement Date), each Buyer SEC Document filed or furnished pursuant to the Exchange Act did not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading in any material respect. Each Buyer SEC Document that is a registration statement, as amended or supplemented, if applicable, filed pursuant to the Securities Act, as of the date such registration statement or amendment became effective, and as of the date of such supplement, did not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading in any material respect. To the Knowledge of Buyer, as of the Agreement Date, none of the Buyer SEC Documents is the subject of ongoing SEC review or outstanding SEC investigation and there are no outstanding or unresolved comments received from the SEC with respect to any of the Buyer SEC Documents.
(b) Buyer has established and maintains disclosure controls and procedures (as defined in Rule 13a-15 under the Exchange Act). Such disclosure controls and procedures are reasonably designed to ensure that material information relating to Buyer, including its consolidated Subsidiaries, is made known to Buyer’s principal executive officer and its principal financial officer by others within those entities, particularly during the periods in which the periodic reports required under the Exchange Act are being prepared, and such disclosure controls and procedures are reasonably designed to ensure all such information is communicated in a timely fashion to Buyer’s principal executive officer and principal financial officer to allow timely decisions regarding the disclosure of such information in Buyer’s periodic and current reports required under the Exchange Act.
(c) The Buyer Group has established and maintained a system of internal controls over financial reporting (as defined in Rule 13a-15 under the Exchange Act) sufficient to provide reasonable assurance regarding the reliability of the Buyer Group’s financial reporting and the preparation of the Buyer Group’s financial statements for external purposes in accordance with GAAP. Buyer has disclosed, based on its most recent evaluation of internal controls prior to the Agreement Date, to Buyer’s auditors and audit committee (i) any significant deficiencies and material weaknesses in the design or operation of internal controls which are reasonably likely to adversely affect Buyer’s ability to record, process, summarize and report financial information and (ii) to the Knowledge of Buyer, any fraud, whether or not material, that involves management or other employees who have a significant role in internal controls.
56
(d) No Buyer Entity has extended or maintained credit, arranged for the extension of credit, or renewed an extension of credit, in the form of a personal loan to or for any executive officer (as defined in Rule 3b-7 under the Exchange Act) or director of Buyer in violation of Section 402 of the Sarbanes-Oxley Act.
(e) Buyer is in compliance, and has complied since June 30, 2026, in each case, in all material respects, with (i) the applicable provisions of the Sarbanes-Oxley Act and (ii) the applicable listing and corporate governance rules and regulations of Nasdaq.
(f) Each of the principal executive officer and principal financial officer of Buyer (or each former principal executive officer and principal financial officer of Buyer, as applicable) has made all certifications required by Rules 13a-14 and 15d-14 under the Exchange Act and Sections 302 and 906 of the Sarbanes-Oxley Act and any related rules and regulations promulgated by the SEC and Nasdaq, and the statements contained in any such certifications are complete and correct in all material respects.
(g) Each of the consolidated financial statements (including, in each case, any notes and schedules thereto) contained in or incorporated by reference into the Buyer SEC Documents: (i) complied as to form in all material respects with the published rules and regulations of the SEC with respect thereto as of their respective dates; (ii) was prepared in accordance with GAAP applied on a consistent basis throughout the periods involved (except as may be indicated in the notes thereto and, in the case of unaudited interim financial statements, as may be permitted by the SEC for Quarterly Reports on Form 10-Q or other rules and regulations of the SEC); and (iii) fairly presented in all material respects the consolidated financial position and the results of operations and cash flows of Buyer and its consolidated Subsidiaries as of the respective dates of and for the periods referred to in such financial statements, subject, in the case of unaudited interim financial statements, to normal year-end audit adjustments as permitted by the applicable rules and regulations of the SEC (but only if the effect of such adjustments would not, individually or in the aggregate, be material).
(h) The audited balance sheet of Buyer dated as of December 31, 2025, contained in the Buyer SEC Documents filed prior to the Agreement Date is hereinafter referred to as the “Buyer Balance Sheet.” The Buyer Group does not have any Liabilities other than Liabilities that: (i) are reflected or reserved against in the Buyer Balance Sheet (including in the notes thereto); (ii) were incurred since the date of the Buyer Balance Sheet in the ordinary course of business consistent with past practice; (iii) are incurred in connection with the Transactions; or (iv) would not reasonably be expected to have, individually or in the aggregate, a Buyer Material Adverse Effect.
Section 4.12 Disclosure Documents. The information supplied or to be supplied by or on behalf of any Buyer Entity for inclusion or incorporation by reference in the Proxy Statement will, when the Proxy Statement, or any amendment or supplement thereto, is first disseminated to Seller’s stockholders, and at the time of the Stockholders Meeting, comply in all material respects with the applicable requirements of the Exchange Act. None of the information supplied or to be supplied by or on behalf of a Buyer Entity expressly for inclusion or incorporation by reference in the Proxy Statement will, at the time such Proxy Statement, or any amendment or supplement thereto, is first disseminated to Seller’s stockholders or at the time of the Stockholders Meeting, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they are made, not misleading. The representations and warranties contained in this Section 4.12 shall not apply to statements or omissions included or incorporated by reference in the Proxy Statement based upon information supplied by Seller or any of its Representatives specifically for use or incorporation by reference therein.
57
Section 4.13 No Stockholder Vote Required. No vote of the stockholders of Buyer or the holders of any other securities of Buyer (equities or otherwise) is required by Law, the certificate of incorporation or bylaws of Buyer or the applicable rules of the Nasdaq Global Market in order for Buyer to issue shares of Buyer Common Stock pursuant to the terms of this Agreement or to consummate the Transactions.
Section 4.14 Takeover Statutes.
(a) The board of directors of Buyer has taken all action necessary so that the restrictions on “business combinations” (as defined in Section 203 of the DGCL )set forth in Section 203 of the DGCL shall not apply to (i) the execution, delivery or performance of this Agreement or the Ancillary Agreements, or the consummation of the Transactions, including the Buyer Stock Issuance and the issuance of the Stock Consideration to Seller at the Closing, or (ii) Seller or any of its Affiliates or “associates” (as defined in Section 203 of the DGCL) by reason of Seller becoming the owner of the Stock Consideration pursuant to this Agreement or any subsequent distribution of the Stock Consideration by Seller to its stockholders.
(b) No other “fair price,” “moratorium,” “control share acquisition,” “business combination,” “interested stockholder” or other similar anti-takeover statute or regulation under any Law, and no anti-takeover provision in the certificate of incorporation or bylaws of Buyer, applies or purports to apply to Buyer with respect to this Agreement, the Ancillary Agreements or the Transactions, including the Buyer Stock Issuance, or that would prohibit, restrict or delay the issuance of the Stock Consideration to Seller at the Closing.
Article
V
COVENANTS
Section 5.1 Conduct of Business Prior to the Closing.
(a) Conduct of Business by Seller.
(i) Except as otherwise contemplated by this Agreement or as set forth on Schedule 5.1(a) of the Seller Disclosure Schedules, between the Agreement Date and the Closing Date or the earlier termination of this Agreement in accordance with its terms (the “Interim Period”), unless Buyer shall otherwise provide its prior written consent (which consent shall not be unreasonably withheld, conditioned or delayed), Seller shall, and shall cause the other Seller Parties to, use their commercially reasonable efforts to (i) conduct the Business in the ordinary course of business in all material respects and (ii) preserve in all material respects the present commercial relationships with key Persons with whom the Seller Parties deal in connection with the conduct of the Business in the ordinary course.
58
(ii) During the Interim Period, except (w) as otherwise contemplated by this Agreement, (x) as set forth on Schedule 5.1(a) of the Seller Disclosure Schedules, (y) with the prior consent of Buyer (which consent shall not be unreasonably withheld, conditioned or delayed), or (z) as expressly required by applicable Law, Seller shall not, and shall not permit the other Seller Parties to, in connection with the Business and the Transferred Assets:
(A) sell, assign, transfer, lease, sublease, license, encumber (other than a Permitted Exception), abandon, allow to lapse or expire, or otherwise dispose of any Transferred Assets or any interest therein, or grant an option to do any of the foregoing, other than Transferred Inventory sold or disposed of, or non-exclusive licenses granted, in each case, in the ordinary course of business;
(B) change the nature or scope of the Business in any material respect;
(C) create, assume or incur, or agree to create, assume or incur, any obligation or liability (contractual or otherwise, including any indebtedness) that would constitute an Assumed Liability, except in the ordinary course of business;
(D) (i) amend, terminate, modify, cancel any material provision of, or waive any rights under or otherwise alter or change any of the material terms or provisions of any material Assumed Contract or Material Contract or (ii) create any material default under the terms of any material Assumed Contract or Material Contract, except, in each case, in the ordinary course of business;
(E) cancel, compromise, waive or release any material claims or rights that relate to the Business, the Transferred Assets or the Assumed Liabilities;
(F) other than in the ordinary course of business, enter into any material Contract relating to the Business or the Transferred Assets;
(G) commence, settle or offer or propose to settle, any Action material to the Exploitation of the Business Products, the Business, the Transferred Assets or the Assumed Liabilities, other than any settlement or compromise involving solely monetary damages not in excess of $500,000;
(H) acquire any corporation, partnership, limited liability company, other business organization or any division or substantially all of the assets thereof;
(I) enter into any Contract that would be reasonably likely to, after the Closing Date, limit or restrict in any material respect the Buyer Group or the operation of the Business;
(J) enter into any material Contract with any Related Person of any Seller Party in connection with or materially affecting the Business or the Transferred Assets;
59
(K) other than as required by an Employee Plan set forth on Schedule 3.10(c) of the Seller Disclosure Schedules, (i) increase the compensation or benefits of any Business Employee or any independent contractor of Seller or any of its Affiliates, (ii) accelerate the vesting or payment of any compensation or benefits of any Business Employee or any independent contractor of Seller or any of its Affiliates, provided that Seller may provide for the acceleration of vesting of Seller Equity Awards, and may elect to satisfy the tax withholding for such Seller Equity Awards via net share settlement, as determined by Seller in its discretion, (iii) enter into, amend or terminate any Employee Plan (or any plan, program, agreement or arrangement that would be an Employee Plan if in effect on the Agreement Date) or grant, amend or terminate any awards thereunder, in each case, with respect to any Business Employee, (iv) except as provided in Section 5.7(h), terminate without “cause” (as determined consistent with past practice) any Business Employee or any independent contractor of Seller or any of its Affiliates, (v) make or forgive any loan to any Business Employee or any independent contractor of Seller or any of its Affiliates (other than advancement of expenses in the ordinary course of business consistent with past practices), (vi) enter into, amend or terminate any collective bargaining agreement or other agreement with a labor union, works council or similar employee or labor organization (or enter into negotiations to do any of the foregoing), (vii) recognize or certify any labor union, works council, bargaining representative, or any other similar organization as the bargaining representative for any Business Employee, (viii) implement or announce any employee layoffs, furloughs, reductions in force, reductions in compensation, hours or benefits, work schedule changes or similar actions that could implicate the WARN Act, or (ix) waive or release any noncompetition, nonsolicitation, nondisclosure, noninterference, nondisparagement, or other restrictive covenant obligation of any Business Employee or any independent contractor of Seller or any of its Affiliates;
(L) except to the extent such actions are consistent with past practice or are otherwise required by applicable Law or GAAP: (i) make or change any material Tax election, (ii) change any annual Tax accounting period, (iii) file any amended Tax Return in respect of a material amount of Taxes, (iv) enter into any closing agreement or settle any Tax claim or assessment material to the Exploitation of the Business Products, the Business, the Transferred Assets or the Assumed Liabilities, other than any settlement or compromise involving solely monetary damages not in excess of $500,000, (v) consent to any extension or waiver (other than as a result of an automatic extension) of the limitation period applicable to any Tax claim or assessment in respect of a material amount of Taxes, or (vi) adopt or change any material accounting methods, principles or practices as they relate to the Business, except in accordance with changes made by Seller affecting its financial statements generally;
(M) sell or agree to sell Transferred Inventory outside of the ordinary course of business;
(N) (i) offer, grant or agree to any trade, cash, volume, free-goods, slotting or other promotional discount, rebate, allowance, chargeback, early-payment incentive or extended payment, credit or return term with respect to any Business Product that is not in the ordinary course of business in all material respects; (ii) accelerate the shipment, invoicing or recognition of revenue of any Business Product, or take any other action with the primary purpose of front-loading, pulling in or artificially increasing sales of any Business Product prior to the Closing (including by soliciting orders in advance of the customer’s normal purchasing cycle, shipping product in quantities materially exceeding customers’ historical ordering patterns, or extending payment terms beyond those customary in the ordinary course of business); or (iii) materially increase or decrease the levels of Transferred Inventory as compared to levels maintained in the ordinary course of business, other than normal seasonal fluctuations, changes in response to bona fide customer demand and changes resulting from supply chain disruptions outside the reasonable control of the Seller Parties; or
60
(O) authorize, resolve, commit or agree (by Contract or otherwise) to do any of the foregoing.
(b) Conduct of Business by Buyer.
(i) Except as otherwise contemplated by this Agreement or as set forth on Schedule 5.1(b) of the Buyer Disclosure Schedules, during the Interim Period, unless Seller shall otherwise provide its prior written consent (which consent shall not be unreasonably withheld, conditioned or delayed), Buyer shall, and shall cause the other Buyer Parties to, use their commercially reasonable efforts to (i) conduct Buyer’s business in the ordinary course of business in all material respects and (ii) preserve in all material respects the present commercial relationships with key Persons with whom the Buyer Group deals in connection with the conduct of Buyer’s business in the ordinary course.
(ii) During the Interim Period, except (w) as otherwise contemplated by this Agreement, (x) as set forth on Schedule 5.1(b) of the Buyer Disclosure Schedules, (y) with the prior consent of Seller (which consent shall not be unreasonably withheld, conditioned or delayed), or (z) as expressly required by applicable Law, Buyer shall not, and shall not permit the other Buyer Parties to, in connection with Buyer’s business:
(A) amend the certificate of incorporation or bylaws of Buyer or any of its Subsidiaries in a manner that would (i) have a material and adverse impact on the value of Buyer Common Stock or (ii) adversely affect Seller relative to the other holders of Buyer Common Stock;
(B) adopt, propose or effect a plan of complete or partial liquidation, restructuring, recapitalization or other reorganization, or resolutions providing for or authorizing such a liquidation, dissolution, restructuring, recapitalization or other reorganization of Buyer;
(C) (i) split, combine, subdivide or reclassify any of its capital stock, other equity interests, securities convertible into or exercisable or exchangeable for capital stock or other equity interests or issue or authorize the issuance of any other securities in respect of, in lieu of or in substitution for shares of Buyer’s capital stock; or (ii) repurchase, redeem or otherwise acquire, or offer to repurchase, redeem or otherwise acquire any shares of capital stock of Buyer or any Subsidiary of Buyer or any other securities thereof or any rights, warrants or options to acquire such shares or other securities except in accordance with the Buyer Stock Plan in the ordinary course of business; or
(D) authorize, resolve, commit or agree (by Contract or otherwise) to do any of the foregoing.
61
(c) No Control of Other Party’s Business. Nothing contained in this Agreement shall give Buyer or its Affiliates, directly or indirectly, the right to control or direct Seller’s or its Subsidiaries’ operations prior to the Closing. Prior to the Closing, each of Buyer and Seller shall exercise, consistent with the terms and conditions of this Agreement, complete control and supervision over its and its Subsidiaries’ respective businesses, assets, and operations.
Section 5.2 Covenants Regarding Information.
(a) During the Interim Period, except as prohibited by applicable Law, Seller shall, and shall cause the Seller Parties to, (i) afford to Buyer and its Representatives, upon reasonable advance written notice, reasonable access during normal business hours to the properties, books, Contracts, commitments, personnel and records related to the Business, (ii) furnish to Buyer copies of all reports, schedules, registration statements and other documents filed by any Seller Party pursuant to applicable securities Laws as Buyer may reasonably request, and (iii) use commercially reasonable efforts to cooperate with and assist Buyer and its Representatives in the preparation of any pro forma financial statements or other pro forma financial information required or advisable in connection with any SEC filing or financing, including by providing reasonable access to the Seller Parties’ financial personnel, accountants and auditors, furnishing historical financial information and data, and providing customary auditor consents. Any access or cooperation under this Section 5.2(a) shall be conducted at Buyer’s expense, during normal business hours, under the supervision of Seller’s personnel and in such a manner as not to unreasonably interfere with the normal operations of the Seller Parties.
(b) For a period of seven (7) years after the Closing, the Seller Parties shall, and shall cause their Affiliates to, (i) retain the books and records (which shall not otherwise have been delivered to Buyer) to the extent relating to the Business, the Transferred Assets and the Assumed Liabilities relating to periods prior to the Closing and (ii) upon reasonable advance written notice, afford the Representatives of Buyer reasonable access (including the right to make photocopies), during normal business hours, to such books and records to the extent relating to the Business, the Transferred Assets and the Assumed Liabilities, provided, however, that any such access shall be conducted at Buyer’s expense and in such a manner as not to unreasonably interfere with the normal business operations of any Seller Party.
(c) For a period of seven (7) years after the Closing, Buyer shall, and shall cause its Affiliates to, at Seller’s expense, promptly furnish to Seller such financial and other information regarding the Business, the Transferred Assets and the Assumed Liabilities (including reasonable access to the Transferred Employees and, upon Seller’s request, to Buyer’s independent registered public accounting firm and its work papers), and provide such other assistance, as Seller may reasonably request solely (i) in connection with the preparation, audit or review of any financial statements of the Business or any pro forma financial information required to be included in any filing that Seller is required to furnish or file with the SEC, (ii) in connection with the preparation and filing of, any report, schedule, form, statement, registration statement, proxy statement or other document that Seller is required to furnish or file with the SEC or Nasdaq, or is otherwise required to make available to its stockholders under applicable Law or the rules of Nasdaq, including any consent of Buyer’s independent registered public accounting firm required in connection therewith, or (iii) for use in any other judicial, regulatory, administrative or other Action or in order to satisfy audit, accounting, claims, regulatory, litigation or other similar requirements arising from or relating to the Excluded Liabilities; provided, that such cooperation shall not unreasonably interfere with Buyer’s business operations. In order to facilitate the prosecution or protection of Intellectual Property Rights that are Excluded Assets and that have a Transferred Employee named as an inventor, or for any Actions where access to Transferred Employees is necessary, for a period of seven (7) years following the Closing Date, at Seller’s expense, Buyer shall afford Seller and its Representatives reasonable access upon reasonable advance written notice, to the Transferred Employees to execute any documents and take any other reasonable actions requested by Seller in connection with such Actions or such prosecution or protection of Intellectual Property Rights.
62
(d) Notwithstanding anything to the contrary in this Agreement, neither the Seller Parties nor the Buyer Parties shall be required to provide access to any information to the other party or its Representatives if (i) such access would jeopardize any attorney-client or other legal privilege, (ii) such access would contravene any applicable Laws, fiduciary duty or binding agreement (including any confidentiality agreement) entered into prior to the Agreement Date, (iii) the information to be accessed is pertinent to any Action in which the Seller Parties, on the one hand, and Buyer or any of its Affiliates, on the other hand, are engaged, (iv) the information to be accessed should not be disclosed due to its competitively sensitive nature, or (v) the information to be accessed relates to any consolidated, combined or unitary Tax Return filed by such party or any of its respective predecessor entities. Notwithstanding the foregoing, if any information is withheld pursuant to clauses (i) through (v) above, the withholding party shall, at the requesting party’s expense, use commercially reasonable efforts to provide the requesting party with access to summaries, redactions or portions of the withheld information as may be reasonably practicable without implicating the applicable limitation.
Section 5.3 Acquisition Proposals.
(a) No Solicitation. During the Interim Period, neither the Seller Group nor any of the directors and officers of any member of the Seller Group shall, and Seller shall instruct the Seller Group and its other Representatives not to, directly or indirectly:
(i) initiate, solicit, endorse, knowingly encourage or knowingly facilitate (including by way of furnishing information), or take any other action intentionally designed to promote any inquiries or the making of any proposal or offer that constitutes, or would reasonably be expected to lead to, any Acquisition Proposal (other than discussions solely to clarify whether such proposal or offer constitutes an Acquisition Proposal or informing such Person of the provisions contained in this Section 5.3(a));
(ii) engage in, continue or otherwise participate in any discussions or negotiations regarding, or provide any non-public information or data to any Person relating to, any Acquisition Proposal or any proposal or offer that would reasonably be expected to lead to an Acquisition Proposal (other than discussions solely to clarify whether such proposal or offer constitutes an Acquisition Proposal or informing such Person of the provisions contained in this Section 5.3(a));
(iii) take any action to make the provisions of any takeover statute inapplicable to any transactions contemplated by an Acquisition Proposal; or
63
(iv) approve, execute or enter into any letter of intent, agreement in principle, term sheet, memorandum of understanding, merger agreement, acquisition agreement or other similar Contract providing for an Acquisition Proposal (other than an Acceptable Confidentiality Agreement) (an “Alternative Acquisition Agreement”).
(b) Exceptions. Notwithstanding anything to the contrary in this Agreement, at any time prior to the time the Seller Stockholder Approval is obtained, Seller and its Representatives may (i) provide information in response to a request therefor by a Person who has made an Acquisition Proposal if Seller did not materially violate Section 5.3(a) in respect of such Person and receives from such Person an executed confidentiality agreement on terms that, taken as a whole, are not materially less restrictive to the other party than those contained in the Confidentiality Agreement and that permits the sharing of information by Seller to Buyer in accordance with this Section 5.3 (it being understood that such confidentiality agreement need not contain a standstill provision or otherwise prohibit the making, or amendment, of an Acquisition Proposal (any confidentiality agreement satisfying the criteria of this clause (i) being an “Acceptable Confidentiality Agreement”)), and promptly (and in any event within forty-eight (48) hours thereafter) makes available to Buyer any material non-public information concerning the Seller Group that Seller provides to any such Person that was not previously made available to Buyer; (ii) engage or participate in any discussions or negotiations with any Person who has made such an Acquisition Proposal (so long as such Person has executed an Acceptable Confidentiality Agreement); or (iii) after having complied with Section 5.3(e), authorize, adopt, approve, recommend or otherwise declare advisable or execute or enter into or propose to authorize, adopt, approve, recommend or declare advisable (publicly or otherwise) such an Acquisition Proposal, if and only to the extent that, (A) prior to taking any action described in clause (i), (ii) or (iii) above, the Seller Board determines in good faith, after consultation with its outside legal counsel, that failure to take such action would be reasonably likely to be inconsistent with the directors’ fiduciary duties under applicable Law, (B) in each such case referred to in clause (i), (ii) or (iii) above, the Seller Board determines in good faith based on the information then available, after consultation with its outside financial advisor and legal counsel, that such Acquisition Proposal either constitutes a Superior Proposal or is reasonably likely to result in a Superior Proposal and (C) in the case referred to in clause (iii) above, the Seller Board determines in good faith that such Acquisition Proposal is a Superior Proposal.
(c) Notice of Acquisition Proposals. Seller agrees that it will promptly (and, in any event, within twenty-four (24) hours) notify Buyer of any written proposals or offers received with respect to an Acquisition Proposal and, in connection with such notice, Seller will provide the identity of the Person making such written proposal or offer and the material terms and conditions of any such proposals or offers (including, if applicable, unredacted copies of any written proposals or offers, including proposed agreements). Thereafter, Seller shall keep Buyer reasonably informed, on a prompt basis (and in any event within twenty-four (24) hours of any material developments), of the status and material terms of any such proposals or offers (including any amendments thereto) and the status of any such discussions or negotiations.
64
(d) No Change of Recommendation or Alternative Acquisition Agreement. Subject to and except as provided in Section 5.3(e), the Seller Board and each committee of the Seller Board shall not:
(i) (A) withhold, withdraw, qualify or modify (or publicly propose to withhold, withdraw, qualify or modify), in a manner adverse to Buyer, the Seller Board Recommendation with respect to the Asset Sale, (B) approve, adopt or recommend (publicly or otherwise) an Acquisition Proposal, (C) fail to include the Seller Board Recommendation in the Proxy Statement, (D) fail to recommend, in a solicitation/recommendation statement on Schedule 14D-9, against any Acquisition Proposal that is a tender offer or exchange offer subject to Regulation 14D promulgated under the Exchange Act (other than any tender offer or exchange offer by Buyer) within ten (10) Business Days after the commencement (within the meaning of Rule 14d-2 under the Exchange Act) of such tender offer or exchange offer (it being understood and agreed that any communication made in accordance with Section 5.3(f)(ii) shall not be deemed a Change of Recommendation if such communication is made prior to the tenth (10th) Business Day after the commencement (within the meaning of Rule 14d-2 under the Exchange Act) of such tender offer or exchange offer), or (E) fail to issue, within ten (10) Business Days after Buyer’s written request therefor following the public announcement of an Acquisition Proposal (or, if such request is delivered fewer than ten (10) Business Days prior to the date of the Stockholders Meeting (as it may be postponed or adjourned pursuant to this Agreement), as promptly as reasonably practicable and in any event prior to the Stockholders Meeting), a press release reaffirming the Seller Board Recommendation, which request may not be made (and Seller shall not be obligated to reaffirm the Seller Board Recommendation) more than two (2) times in respect of any specific Acquisition Proposal (it being understood that any material amendment or modification of such Acquisition Proposal shall not be deemed a new Acquisition Proposal for such purpose) (any action described in clauses (A) through (E), a “Change of Recommendation”); or
(ii) cause or permit any member of the Seller Group to enter into an Alternative Acquisition Agreement (other than any Acceptable Confidentiality Agreement) relating to any Acquisition Proposal.
(e) Change of Recommendation / Superior Proposal Termination. Notwithstanding anything to the contrary in this Agreement, (i) at any time prior to the time the Seller Stockholder Approval is obtained, the Seller Board may make a Change of Recommendation (A) in connection with a Superior Proposal or (B) other than in connection with an Acquisition Proposal, in response to an event, change, occurrence or effect occurring after the Agreement Date that was not known to or reasonably foreseeable by the Seller Board as of the Agreement Date, or if known or reasonably foreseeable as of the Agreement Date, the magnitude or consequences of which were not known or reasonably foreseeable as of the Agreement Date (an “Intervening Event”), in either case of (A) or (B), only if the Seller Board determines in good faith that the failure to take such action would be reasonably likely to be inconsistent with the directors’ fiduciary duties under applicable Law and (ii) if the Seller Board is permitted to make a Change of Recommendation pursuant to clause (i), Seller may also terminate this Agreement pursuant to Section 9.1(e) to enter into an Alternative Acquisition Agreement with respect to the applicable Superior Proposal; provided, however, that neither the Seller Board nor Seller shall take any of the foregoing actions unless:
(i) Seller did not materially violate Section 5.3(a) in respect of such Superior Proposal;
65
(ii) Seller shall have provided prior written notice (a “Determination Notice”) to Buyer at least four (4) Business Days in advance (the “Notice Period”) to the effect that the Seller Board intends to take such action and specifying in reasonable detail the circumstances giving rise to such proposed action, including, in the case such action is proposed to be taken in connection with an Acquisition Proposal, the information specified by Section 5.3(c) with respect to such Acquisition Proposal (it being understood and agreed that the delivery of a Determination Notice shall not, in and of itself, be deemed a Change of Recommendation); provided, however, that any material revision to the terms of any Superior Proposal shall require a new Determination Notice and the Notice Period shall be extended by an additional two (2) Business Days from the date of receipt of such new Determination Notice;
(iii) Seller shall have during the Notice Period negotiated with Buyer and its Representatives in good faith (to the extent Buyer desires to negotiate) to make such adjustments in the terms and conditions of this Agreement such that with respect to any such action to be taken in connection with (A) an Acquisition Proposal, such Acquisition Proposal ceases to constitute a Superior Proposal (provided, however, that in the event of any material revision to the terms of such Superior Proposal, Seller shall be required to deliver a new Determination Notice to Buyer and to comply with the requirements of Section 5.3(e)(ii) and this Section 5.3(e)(iii) with respect to such new Determination Notice and the revised Superior Proposal contemplated thereby) or (B) an Intervening Event, the Seller Board could no longer make a determination that taking such action would be reasonably likely to be inconsistent with the directors’ fiduciary duties under applicable Law; and
(iv) at or following the end of such Notice Period, the Seller Board shall have determined in good faith based on the information then available that with respect to any such action to be taken in connection with an Acquisition Proposal, such Acquisition Proposal continues to constitute a Superior Proposal and that the failure to take such action would be reasonably likely to be inconsistent with the directors’ fiduciary duties under applicable Law, in each case, taking into account any revisions to this Agreement made or proposed in writing by Buyer prior to the time of such determination pursuant to clause (iii) above.
(f)
Certain Permitted Disclosure. Nothing contained in this Section 5.3 shall be deemed to prohibit Seller or the Seller
Board from (i)(i) complying with its disclosure obligations under applicable Law with regard to an Acquisition Proposal,
including taking and disclosing to Seller’s stockholders a position contemplated by Rule 14d-9 or Rule 14e-2(a) promulgated under
the Exchange Act (or any similar communication to Seller’s stockholders), or (ii)(ii) making any “stop-look-and-listen”
communication to Seller’s stockholders pursuant to Rule 14d-9(f) under the Exchange Act (or any similar communications to Seller’s
stockholders); provided, however, that the Seller Board shall not make a Change of Recommendation except in accordance with
Section 5.3(e).
(g) Existing Discussions. Subject to Section 5.3(b) and Section 5.3(e), upon execution and delivery of this Agreement, Seller agrees that it will (i) immediately cease and cause to be terminated any activities, discussions or negotiations with any parties conducted with respect to any Acquisition Proposal, (ii) immediately cease providing any information to any such Person or its Representatives, (iii) immediately terminate all access granted to any such Person and its Representatives to any physical or electronic data room, and (iv) within two (2) Business Days following the Agreement Date, request the prompt return or destruction of all confidential information that has been provided in any such discussions or negotiations.
66
Section 5.4 Proxy Statement.
(a) As promptly as reasonably practicable after the Agreement Date, Seller shall, and shall use reasonable best efforts within forty-five (45) calendar days after the Agreement Date to, file with the SEC a proxy statement in preliminary form relating to the Stockholders Meeting (such proxy statement, including any amendment or supplement thereto, the “Proxy Statement”), and, subject to Section 5.3, shall include the Seller Board Recommendation in the Proxy Statement. Each of Seller and Buyer shall provide the other with the information as may be reasonably necessary or advisable in connection with the Proxy Statement and shall otherwise reasonably assist and cooperate with the other in connection with any of the actions contemplated by this Section 5.4, including the preparation, filing and distribution of the Proxy Statement and the resolution of any comments in respect thereof received from the SEC. No filing of, or amendment or supplement to, the Proxy Statement will be made by Seller without providing Buyer with a reasonable opportunity to review and comment thereon.
(b) Seller shall promptly notify Buyer of the receipt of any comments of the SEC with respect to the Proxy Statement and of any request by the SEC for any amendment or supplement thereto or for additional information and shall promptly provide to Buyer copies of all correspondence between Seller or any of its Representatives and the SEC with respect to the Proxy Statement. Seller agrees to permit Buyer and its counsel to participate in all substantive meetings and conferences with the SEC relating to the Proxy Statement. Seller and Buyer shall each use its reasonable best efforts to promptly provide responses to the SEC with respect to all comments received in respect of the Proxy Statement, and Seller shall cause the definitive Proxy Statement to be mailed as promptly as reasonably practicable after the date the SEC staff advises that it has no further comments thereon or that Seller may commence mailing the Proxy Statement. Seller and Buyer shall ensure that the Proxy Statement complies as to form in all material respects with the provisions of the Securities Act and the Exchange Act. If at any time prior to the Stockholders Meeting, any fact, event or circumstance relating to Seller or Buyer or any of their respective Affiliates is discovered by Seller or Buyer, which such fact, event or circumstance is required, pursuant to the Exchange Act, to be set forth in an amendment or supplement to the Proxy Statement, (i) the applicable party shall promptly inform the other parties hereto and (ii) Seller shall promptly amend or supplement the Proxy Statement to include disclosure of such fact, event or circumstance.
(c) Each of Seller and Buyer agrees to correct any information provided by it for use in the Proxy Statement which shall have become materially false or misleading.
Section 5.5 Stockholders Meeting. Subject to Section 5.4(a), Seller shall use its reasonable best efforts to take, in accordance with applicable Law and the organizational documents of Seller, all action necessary to convene a meeting of the holders of Seller Common Stock (the “Stockholders Meeting”) to consider and vote upon the adoption of this Agreement as promptly as reasonably practicable after the date the SEC staff advises that it has no further comments on the Proxy Statement or that Seller may commence mailing the Proxy Statement. Following the mailing of the Proxy Statement pursuant to Section 5.4, the date of the Stockholders Meeting may not be changed, and the Stockholders Meeting may not otherwise be adjourned or postponed, without the consent of Buyer (not to be unreasonably withheld, conditioned or delayed) or as required by applicable Law; provided, however, that Seller may, without the written consent of Buyer, adjourn, recess or postpone the Stockholders Meeting (a) if Seller believes in good faith it will not receive proxies sufficient to obtain the Seller Stockholder Approval, whether or not a quorum is present (provided that, Seller may not, without the prior written consent of Buyer (not to be unreasonably withheld, delayed or conditioned), adjourn or postpone the Stockholders Meeting more than ten (10) Business Days in the aggregate from the then-scheduled date of the Stockholders Meeting), (b) if it is necessary to adjourn or postpone the Stockholders Meeting to ensure that any required supplement or amendment to the Proxy Statement is delivered, or (c) if and to the extent such adjournment or postponement of the Stockholders Meeting is required by Law. Seller shall, through the Seller Board (unless the Seller Board has made a Change of Recommendation in compliance with Section 5.3) (i) use its reasonable best efforts to solicit the Seller Stockholder Approval (including adjourning the Stockholders Meeting as necessary in accordance with the foregoing clause (a)); and (ii) include the Seller Board Recommendation in the Proxy Statement.
67
Section 5.6 Regulatory Matters.
(a) Prior to or on the Closing Date, Buyer and Seller shall submit all documentation, including filing with the FDA the Buyer FDA Letters and the Seller FDA Letters (and providing a copy to the other party), and subsequently, take all other actions reasonably necessary to effectuate the transfer to Buyer of ownership of the Transferred Regulatory Approvals.
(b) Seller shall (i) transfer to Buyer the Transferred Regulatory Documentation, Transferred Marketing Records and Transferred Books and Records within fifteen (15) Business Days following the Closing Date via virtual data room or other file-share platform reasonably acceptable to Buyer (or such other method as mutually agreed by the parties hereto) and (ii) solely to the extent any Transferred Regulatory Documentation, Transferred Marketing Records and Transferred Books and Records held by or on behalf of the Seller Parties is only available in paper format, deliver to Buyer (or such other location as Buyer may designate in advance of such delivery) such documents in paper format as soon as reasonably practicable following the Closing Date and in any event within forty-five (45) days following the Closing Date. Notwithstanding anything to the contrary, Seller may retain an archival copy of all such Transferred Regulatory Documentation, Transferred Marketing Records and Transferred Books and Records.
(c) Buyer shall be responsible for responding to any complaint related to any Business Product that is received by either Buyer or Seller on any date following the Closing Date from any source and for investigating and analyzing such product complaint and making required reports to the FDA and equivalent foreign Governmental Authorities, regardless of whether the Business Products involved were sold by Seller or Buyer. Each party hereto shall promptly notify the other in the event such party receives such a product complaint relating to a Business Product lot manufactured by Seller, and Seller shall, and shall cause the other Seller Parties to, notify Buyer of all product complaints received by the Seller Parties relating to the Business Products. A product complaint received by the Seller Parties that also involves an adverse experience report shall be reported by the Seller Parties to Buyer. Buyer and Seller shall, and Seller shall cause the other Seller Parties to, cooperate with each other in connection with any investigation and response to any product complaint.
68
(d) Buyer shall be responsible for determining what change of ownership requirements, new licensure requirements, renewal requirements and notice requirements are necessary for Buyer to obtain all licenses and other Permits needed by Buyer in connection with the Transferred Assets and/or the Transactions.
(e) Upon reasonable request by Buyer and reasonable notice to Seller, Seller shall use commercially reasonable efforts to cooperate with Buyer to effect the application for licenses and all pharmacy and other Permits needed by Buyer in connection with the Transferred Assets and/or the Transactions.
Section 5.7 Employee Benefits.
(a) Transferred Employees.
(i) Buyer (or an Affiliate of Buyer) may, in its sole discretion, make Qualified Offers to Business Employees (including any Replacement Employee or Additional Employee) at any time during the period commencing on the Agreement Date and ending ten (10) days prior to the Closing Date. Notwithstanding anything to the contrary in this Agreement, neither Buyer nor any of its Affiliates shall make any offer of employment to the Excluded Employee at any time prior to the first anniversary of the Closing Date, and the Excluded Employee may not be designated as a Replacement Employee or Additional Employee. Business Employees who accept Qualified Offers and commence work with Buyer and its Affiliates immediately following the Closing are referred to herein as “Transferred Employees.” Such employment by Buyer or an Affiliate thereof shall commence effective as of the Closing, and shall be deemed for all purposes to have occurred with no interruption or break in service. Immediately prior to the Closing, Buyer shall provide Seller with a list of Business Employees who have received Qualified Offers and separately identify whether or not such Business Employee accepted such offer.
(ii) Buyer agrees to, or to cause an Affiliate of Buyer to, offer each Business Employee (including any Replacement Employee or Additional Employee) who receives a Qualified Offer pursuant to subsection (i) above a lump sum cash payment of $500 in exchange for the Business Employee’s execution, delivery and non-revocation of a general release of claims in favor of Seller, Buyer and their respective Affiliates, directors, officers and employees in a form reasonably acceptable to Buyer and Seller. Buyer agrees to provide Seller with a copy of any such releases that are executed and non-revocable by a Business Employee promptly following the date on which such release becomes effective and irrevocable.
(b) Replacement Employees; Additional Employees; Business Employee Severance Cost Reimbursement. No later than ten (10) days prior to the Closing Date, Buyer may, in its discretion, elect to replace one or more Business Employees with a Replacement Employee, or to add one or more Additional Employees, by delivering written notice to Seller and making a Qualified Offer to such Replacement Employee or Additional Employee, in which case such Replacement Employee or Additional Employee shall be deemed a Business Employee for purposes of this Agreement, and Schedule 1.1G shall be deemed updated accordingly. Subject to receipt of a reasonably detailed inventory and copies of all applicable releases, within thirty (30) days following the Termination Measurement Date, Buyer shall reimburse Seller for all Business Employee Severance Costs.
69
(c) Service Credit. Subject and in addition to any requirements imposed by applicable Law, the Transferred Employees shall receive credit for all periods of employment and/or service with the Seller Parties (including service with predecessor employers, where such credit was provided by the Seller Parties) prior to the Closing Date for purposes of eligibility and vesting (including with respect to accrual of vacation and any severance benefits) under Buyer’s relevant plans and policies; provided, that such service shall not be recognized to the extent such credit would result in a duplication of benefits under any plan or for purposes of any defined benefit pension plan, nonqualified deferred compensation plan or retiree medical or other retiree welfare plan sponsored or maintained by Buyer or its Affiliates.
(d) Defined Contribution Plans. Buyer agrees to have in effect (or cause an Affiliate to have in effect) on the Closing Date a defined contribution plan or plans with a salary reduction arrangement that covers Transferred Employees in the United States, the terms of which meet the requirements of Sections 401(a) and 401(k) of the Code (such plan or plans, the “Buyer Savings Plan”). Each Transferred Employee in the United States who is eligible to contribute to Seller’s defined contribution plan (the “Seller Savings Plan”) on the Closing Date shall be eligible to contribute to the Buyer Savings Plan commencing as soon as administratively practicable after the Closing Date. The Transferred Employees in the United States shall be permitted to roll over their account balances (excluding loan balances) from the Seller Savings Plan accrued through the Closing Date into their new accounts under the Buyer Savings Plan promptly after the Closing Date, subject to the terms and conditions of such plan, but in no event later than ninety (90) days after the Closing Date or in contravention of ERISA or the Code.
(e) Welfare Benefit Plans.
(i) For those Transferred Employees who reside in the United States, Buyer shall use commercially reasonable efforts to (A) waive all waiting periods and pre-existing condition clauses under the welfare benefit plans, including medical, dental, life insurance, and short- and long-term disability (all of such welfare plans, the “Buyer Welfare Benefit Plans”) maintained by Buyer and its Affiliates for the Transferred Employees and their eligible dependents who were participating in comparable welfare benefit plans and programs of the Seller Parties before the Closing Date; and (B) cause the Buyer Welfare Benefit Plans to recognize any out-of-pocket medical and dental expenses incurred by each of the Transferred Employees and their eligible dependents prior to the Closing Date and during the calendar year in which the Closing Date occurs for purposes of determining deductibles and out-of-pocket maximums under the Buyer Welfare Benefit Plans; provided that Seller provides all such information to Buyer prior to, at or within five (5) days following the Closing in a format reasonably acceptable to Buyer and its insurers.
(ii) Seller shall maintain its welfare benefit plans with respect to which employees could potentially elect continuation coverage under Sections 601 et seq. of ERISA (“COBRA”) and shall be solely responsible for all continuation coverage obligations under COBRA and any state continuation coverage requirements with respect to all current and former Business Employees and their dependents and beneficiaries; provided, however, that Buyer shall bear the cost of any COBRA premium payments or subsidies constituting Business Employee Severance Costs.
70
(f) Vacation Benefits. Seller shall, no later than ten (10) days following the Closing Date (or such earlier date as may be required by applicable Law), pay out all accrued but unused vacation for all Business Employees (whether or not such Business Employees become Transferred Employees) that the Seller Parties are required by applicable Law or pursuant to Seller’s paid time off policy set forth on Schedule 3.10(c) of the Seller Disclosure Schedules to pay out as a result of the termination of such Business Employee’s employment in connection with the Transactions. Within five (5) days following such payment, Seller shall deliver to Buyer a reasonably detailed invoice setting forth the amount of accrued but unused vacation actually paid by the Seller Parties pursuant to the immediately preceding sentence and promptly thereafter, Buyer shall reimburse Seller for up to $300,000 of such payments. To the extent that payout is not required by applicable Law or pursuant to Seller’s paid time off policy set forth on Schedule 3.10(c) of the Seller Disclosure Schedules, all remaining accrued but unused vacation for Transferred Employees shall be Assumed Liabilities (and shall not constitute Excluded Employee Liabilities) and shall be fully recognized and governed by Buyer’s vacation policy as in effect from time to time.
(g) No Third-Party Beneficiaries. Notwithstanding any other superseding provision herein, nothing herein express or implied by this Agreement shall (i) confer upon any Business Employee, or legal representative thereof, any rights or remedies, including any right to employment or benefits for any specified period, of any nature or kind whatsoever, under or by reason of this Agreement or (ii) be treated as an amendment to, or prevent the termination of any employee benefit plan, program, arrangement or agreement.
(h) Amendment to Termination Eligible Employee. Upon the written request of Seller delivered no earlier than thirty (30) days following the date of this Agreement, Buyer shall consider in good faith and discuss with Seller its hiring expectations and to the extent that Buyer conclusively determines that it will not provide an offer of employment to certain employees of Seller, and further determines in good faith and acting reasonably that such employees are not necessary to the continued operation of the Business through the Closing, Buyer will agree to amend Schedule 1.1K to include such employees. The Seller Group may terminate the employment of any employee listed on Schedule 1.1K at any time prior to the Closing, as determined in the Seller Group’s discretion.
Section 5.8 Confidentiality.
(a) From and after the Closing, Buyer shall, and shall cause its Affiliates and its and their respective Representatives to, maintain in confidence and not disclose, and not use for any purpose other than as reasonably necessary in connection with the enforcement of its rights under this Agreement or the Ancillary Agreements, any Confidential Information of Seller or its Affiliates (other than Confidential Information exclusively relating to the Business, the Transferred Assets or the Assumed Liabilities).
71
(b) From and after the Closing, Seller shall, and shall cause its Affiliates and its and their respective Representatives to, maintain in confidence and not disclose, and not use for any purpose other than as reasonably necessary in connection with the enforcement of its rights under this Agreement or the Ancillary Agreements, any Confidential Information exclusively relating to the Business, the Transferred Assets or the Assumed Liabilities.
(c) The obligations set forth in this Section 5.8 shall not apply to Confidential Information that (i) is or becomes generally available to the public other than as a result of a disclosure by the receiving party hereto or its Representatives in violation of this Section 5.8, (ii) was available to the receiving party on a non-confidential basis prior to disclosure by the disclosing party, (iii) becomes available to the receiving party on a non-confidential basis from a source other than the disclosing party or its Representatives, provided that such source is not known by the receiving party to be bound by a confidentiality obligation to the disclosing party with respect to such information, or (iv) is independently developed by the receiving party or its Representatives without use of or reference to the Confidential Information of the disclosing party.
(d) Notwithstanding anything to the contrary in this Section 5.8, a party hereto or its Representatives may disclose Confidential Information to the extent required by applicable Law or Order; provided that, to the extent legally permitted, the disclosing party shall (i) provide the other party with prompt written notice of such requirement so that such other party, at such other party’s cost, may seek a protective order or other appropriate remedy, and (ii) cooperate with the other party in seeking such protective order or other remedy. If such protective order or other remedy is not obtained, the disclosing party shall disclose only that portion of the Confidential Information that, on the advice of its legal counsel, is legally required to be disclosed.
(e) The obligations of the parties hereto under this Section 5.8 shall survive the Closing for a period of five (5) years following the Closing Date.
(f) The presence of any Confidential Information that is not a Transferred Asset on any servers, computers or other equipment that is a Transferred Asset does not grant any title to or effect any assignment of such Confidential Information to Buyer or its Affiliates. The presence after Closing of any Confidential Information that is a Transferred Asset on any servers, computers or other equipment that is not a Transferred Asset does not grant any title to or effect any assignment of such Confidential Information to the Seller Parties.
Section 5.9 Consents and Filings.
(a) Each of the parties hereto shall use reasonable best efforts to take, or cause to be taken, all appropriate action to do, or cause to be done, all things necessary, proper or advisable under applicable Law or otherwise to consummate and make effective the Transactions as promptly as practicable and, in any event, no later than the Termination Date, including to (i) obtain from Governmental Authorities all Consents, qualifications and Orders as are necessary for the consummation of the Transactions and supply promptly any additional information and documentary material that may be requested by a Governmental Authority under any applicable Law (including promptly making available any information and appropriate personnel in response to any queries made by a Governmental Authority) and (ii) make all necessary filings, seeking (unless prohibited by Law) expedited treatment thereof or early termination of any applicable waiting periods related thereto, within ten (10) Business Days of the Agreement Date, and thereafter make any other required submissions, with respect to this Agreement if the parties hereto reasonably determine that such a filing is required or advisable under applicable Antitrust Laws and FDI Laws, including the Required Antitrust Approvals (any such filing, a “Required Filing”), and Buyer and Seller shall, and shall cause their respective Affiliates to, cooperate fully with the other parties to that end. Subject to applicable Law, Buyer shall, in consultation with Seller, have the right to (A) determine the strategy and direction of all matters with any Governmental Authority in connection with any Required Filing relating to the Transactions and (B) review and comment upon any filing, application, notification or other document to be submitted by Seller to any Governmental Authority under any applicable Law in advance of such submissions, and Seller shall consider Buyer’s comments thereon in good faith. Buyer shall pay all administrative filing fees due in connection with any Required Filing.
72
(b) Without limiting the generality of the undertakings of the parties hereto pursuant to Section 5.9(a), Buyer agrees to, and to cause each of its Affiliates to, use its reasonable best efforts and to take any and all actions necessary to avoid or eliminate each and every impediment under any applicable Antitrust Laws or FDI Laws that may be asserted by any Governmental Authority or any other party so as to enable the parties hereto to close the Transactions as promptly as practicable and in no event later than the Termination Date, including proposing, negotiating, committing to and effecting, by consent decree, hold separate orders, or otherwise, (i) the sale, divestiture, license or other disposition of Buyer’s or its Affiliates’ assets, properties or businesses or of the assets, properties or businesses to be acquired by it pursuant hereto, or (ii) the establishment, termination or modification of any contractual arrangements, obligations, or other conduct remedies, in each case, as required in order to obtain any Consent, clearance, action or non-action from a Governmental Authority, or to avoid any injunction (or to effect the dissolution thereof), temporary restraining order or other order or decision in any suit, investigation or proceeding, which would otherwise have the effect of materially delaying or preventing the consummation of the Transactions (any of the actions described in the foregoing clauses (i) and (ii), a “Remedy Action”); provided that, (I) neither Buyer nor its Affiliates shall be required to take any action with respect to any of their assets or operations other than the Transferred Assets, (II) in no event shall Buyer or any of its Affiliates be required to take, or agree to take, any Remedy Action that would, or would reasonably be expected to, individually or in the aggregate, result in a material adverse impact on the business, assets, financial condition or results of operations of the business to be acquired by Buyer hereunder, (III) any Remedy Action required to be taken shall be conditioned upon the consummation of the Transactions and (IV) it is expressly understood and agreed that neither Buyer nor any of its Affiliates shall have any obligation to defend or bring any Action challenging any of the Transactions as violative of applicable Law or enter into any consent decree with any Governmental Authority.
(c) Each of the parties hereto shall promptly notify the other party of any communication it or any of its Affiliates receives from any Governmental Authority relating to the matters that are the subject of this Agreement and permit the other party to review in advance any proposed communication by such party to any Governmental Authority relating to the matters that are the subject of this Agreement. Neither party to this Agreement shall agree to participate in any meeting with any Governmental Authority in respect of any filings, investigation or other inquiry unless it consults with the other party in advance and, unless prohibited by such Governmental Authority, gives the other party the opportunity to attend and participate at such meeting. Subject to the Confidentiality Agreement and applicable Law, the parties hereto will coordinate and cooperate fully with each other in exchanging such information and providing such assistance as the other party may reasonably request in connection with the foregoing and in seeking early termination of any applicable waiting periods including under any Required Filing. Subject to the Confidentiality Agreement and applicable Law, the parties hereto will provide each other with copies of all correspondence, filings or communications between them or any of their Representatives, on the one hand, and any Governmental Authority or members of its staff, on the other hand, with respect to this Agreement and the Transactions; provided, that the parties hereto may withhold, redact, or provide information on an outside-counsel-only basis to the extent necessary to prevent violations of Law or protect reasonable privilege or confidentiality interests.
(d) Buyer shall not, and shall not permit any of its Affiliates to, take any action (including acquiring or agreeing to acquire by merging or consolidating with, or by purchasing the assets of or equity in, or by any other manner, any Person or portion thereof, or otherwise acquiring or agreeing to acquire any assets) that would reasonably be expected to have the effect of (i) materially delaying, impairing, or impeding the receipt of, or materially increasing the risk of not receiving, any approval or clearance in respect of any Required Filings, (ii) materially delaying, impairing, or impeding the expiration of any applicable waiting period with respect to the Required Filings, (iii) materially increasing the risk of any Governmental Authority entering an Order permanently prohibiting the consummation of any of the Transactions, or (iv) otherwise materially delaying the consummation of any of the Transactions; provided, that, notwithstanding the foregoing, neither Buyer nor any of its Affiliates shall be deemed to be in breach of this Section 5.9(d) solely as a result of pursuing, negotiating, entering into or consummating the Specified Transaction, solely to the extent such Specified Transaction materially delays the consummation of any of the Transactions; provided, further, that (x) the foregoing proviso shall not limit, condition or otherwise affect Buyer’s obligations under Section 5.9(a) and Section 5.9(b) (including with respect to any impediment arising out of the Specified Transaction), Seller’s rights under Section 9.1(b) or any other right or remedy of Seller hereunder, and (y) Buyer shall, through its outside counsel and solely on an outside counsel-to-outside counsel basis, keep Seller’s outside counsel reasonably informed on a current basis of the status of any regulatory review of the Specified Transaction to the extent such review would reasonably be expected to affect the timing of the Closing or the receipt of any approval or clearance in respect of the Required Filings. For purposes of this Agreement, “Specified Transaction” means the transaction involving the target whose name was confidentially provided by Buyer’s counsel to Seller’s counsel prior to the Agreement Date.
73
Section 5.10 Further Assurances; Conveyance. After the Closing Date, each party hereto shall use its commercially reasonable efforts from time to time to execute and deliver at the reasonable written request of the other party such additional documents and instruments, data, and information, and to take, or refrain from taking, such other actions, as may be reasonably required to give effect to this Agreement, the Ancillary Agreements and the Transactions, and to comply with requirements under Regulatory Laws.
Section 5.11 No Solicitation.
(a) Seller agrees that it will not, and will cause the other members of the Seller Group not to, for a period of three (3) years following the Closing Date (the “Non-Solicitation Period”) personally or through others, directly or indirectly, encourage, induce, attempt to induce, solicit or attempt to solicit (on their own behalf or on behalf of any other Person) any Transferred Employee to leave his or her employment with Buyer or its Affiliates; provided, that no member of the Seller Group shall be restricted from (i) making a general solicitation that is not targeted specifically to any Transferred Employee or group of Transferred Employees, (ii) responding to any Transferred Employee who contacts it at his or her own initiative without the prior direct or indirect encouragement or solicitation by any member of the Seller Group, or (iii) hiring persons (x) who are referred by search firms or employment agencies or similar entities so long as such entities have not been instructed by any member of the Seller Group to solicit any Transferred Employee or (y) to whom any member of the Seller Group may respond pursuant to clause (i) or (ii). Any violation of this Section 5.11(a) by any member of the Seller Group shall be deemed a violation by Seller. The restrictions set forth in this Section 5.11(a) shall not apply to any third Person or any of such third Person’s current or future Affiliates that acquires, via a merger or business combination, any member of the Seller Group; provided, for the avoidance of doubt, such restrictions shall continue to apply to any acquired member of the Seller Group (or, if applicable, the surviving entity of a merger or business combination involving any member of the Seller Group).
(b) Buyer agrees that it will not, and will cause the other members of the Buyer Group not to, for the Non-Solicitation Period personally or through others, directly or indirectly, encourage, induce, attempt to induce, solicit or attempt to solicit (on their own behalf or on behalf of any other Person) any employee of the Seller Parties (other than the Business Employees) (a “Seller Employee”) to leave his or her employment with Seller or its Affiliates; provided, that no member of the Buyer Group shall be restricted from (i) making a general solicitation that is not targeted specifically to any Seller Employee or group of Seller Employees, (ii) responding to any Seller Employee who contacts it at his or her own initiative without the prior direct or indirect encouragement or solicitation by any member of the Buyer Group, or (iii) hiring persons (x) who are referred by search firms or employment agencies or similar entities so long as such entities have not been instructed by any member of the Buyer Group to solicit any Seller Employee or (y) to whom any member of the Buyer Group may respond pursuant to clause (i) or (ii). Any violation of this Section 5.11(b) by any member of the Buyer Group shall be deemed a violation by Buyer. The restrictions set forth in this Section 5.11(b) shall not apply to any third Person or any of such third Person’s current or future Affiliates that acquires, via a merger or business combination, any member of the Buyer Group; provided, for the avoidance of doubt, such restrictions shall continue to apply to any acquired member of the Buyer Group (or, if applicable, the surviving entity of a merger or business combination involving any member of the Buyer Group).
Section 5.12 Non-Competition.
(a) Except with the prior written consent of Buyer, for a period of five (5) years following the Closing Date (the “Restriction Period”), Seller shall not, and shall cause the members of the Seller Group not to, own, manage, engage in, operate or control, any business in the Field, including the Exploitation of any product in the Field (such business, as so conducted, a “Competing Business”) in any jurisdiction in the entire world.
74
(b) Notwithstanding any provision to the contrary in this Section 5.12, Seller may, and may cause members of the Seller Group to, directly or indirectly:
(i) purchase or otherwise acquire by merger, purchase of assets, stock or equity interest or otherwise (and thereafter operate) any Person or business the acquisition of which would otherwise cause non-compliance with Section 5.12(a) so long as twenty percent (20%) or more of the revenues of such Person or business are not derived from the Competing Business;
(ii) acquire, own or manage for the account of third parties indirectly through a mutual fund, employee benefit plan, trust account not controlled by the Seller Group or similar investment pool or vehicle as a passive investment, any class of security of any Person (not to exceed 5% of such class of security) regardless of whether such Person engages in a Competing Business; and
(iii) the actions set forth on Schedule 5.12(b) of the Seller Disclosure Schedules.
(c) The restrictions set forth in this Section 5.12 shall not apply to any third Person or any of such third Person’s current or future Affiliates that acquires, via a merger or business combination, any member of the Seller Group; provided, for the avoidance of doubt, such restrictions shall continue to apply to any acquired member of the Seller Group (or, if applicable, the surviving entity of a merger or business combination involving any member of the Seller Group).
(d) If any of the provisions of this Section 5.12 is invalid in part, the parties hereto agree that the restrictions stated herein shall be curtailed in scope and geographic location to the minimum extent required for its validity under applicable Law and shall be binding and enforceable with respect to the restricted party, and its Affiliates (as the case may be), as so curtailed.
Section 5.13 Anti-Circumvention. During the Restriction Period, Seller shall not, and shall cause each member of the Seller Group not to, directly or indirectly, (a) knowingly induce or knowingly encourage any customer, supplier, licensor, or licensee of the Business to terminate, curtail, or materially and adversely modify its relationship with respect to the Business Products, or (b) take any action for the purpose of circumventing the restrictions set forth in Section 5.11 or Section 5.12; provided, that nothing in this Section 5.13 shall restrict (i) any action or activity expressly permitted under Section 5.11 or Section 5.12 (including Section 5.12(b) and Section 5.12(c)), (ii) any action taken in the ordinary course of business with respect to any business of the Seller Group that is not a Competing Business, or (iii) any general advertisement or solicitation not specifically targeted at the business relations of the Business.
Section 5.14 Restrictive Covenant Remedies. Without intending to limit the remedies available to any Buyer Party or any Seller Party, each of Seller and Buyer acknowledges that a breach of any of the covenants contained in Section 5.11 and Section 5.12 may result in material irreparable injury to Buyer, Seller or any of their respective Affiliates for which there is no adequate remedy at law, that it will not be possible to measure damages for such injuries precisely and that, in the event of such a breach or threat thereof, Buyer, Seller or any of their respective Affiliates shall be entitled to obtain a temporary restraining order and/or a preliminary or permanent injunction, without the necessity of proving irreparable harm or injury as a result of such breach or threatened breach of Section 5.11 or Section 5.12 and without the requirement to secure or post a bond in connection with such remedy, restraining the applicable member of the Seller Group or Buyer Group, as applicable, from engaging in activities prohibited by Section 5.11 and Section 5.12 or such other relief as may be required specifically to enforce any of the covenants set forth in Section 5.11 and Section 5.12.
75
Section 5.15 Insurance. As of the Closing Date, the coverage under all Retained Seller Insurance Policies shall continue in force only for the benefit of the Seller Parties, and not for the benefit of Buyer or any of its Representatives. From and after the Closing Date, Buyer shall be solely responsible for arranging, at its sole cost and expense, its own insurance policies with respect to the Business, the Transferred Assets and the Assumed Liabilities covering all periods and agrees not to seek, through any means, to benefit from any of the Seller Parties’ insurance policies which may provide coverage for claims relating in any way to the Business, the Transferred Assets or the Assumed Liabilities, except as expressly set forth in this Section 5.15. With respect to occurrences, acts or omissions occurring prior to the Closing relating to the Business, the Transferred Assets or the Assumed Liabilities (other than to the extent giving rise to any Excluded Liability) (each, a “Pre-Closing Occurrence”) that are covered by any Retained Seller Insurance Policy written on an occurrence basis (and not on a claims-made basis) (each, an “Occurrence-Based Policy”), following the Closing, Buyer may submit to Seller and Seller will, on behalf of the Business, use (and cause its Affiliates to use) commercially reasonable efforts to make claims or otherwise exercise rights under such Occurrence-Based Policies subject to the terms and conditions of such Occurrence-Based Policies (or any contractual rights or obligations relating thereto) and pay to Buyer the amounts actually received by any Seller Party in respect of such claims under such Occurrence-Based Policies, to the extent such coverage and limits are available under such policies and programs less any reasonable and documented out-of-pocket expenses incurred in connection therewith, it being agreed that (a) no such payments will be made in respect of any self-insurance provided by any Seller Party (or any other Person that holds any such Retained Seller Insurance Policy) or in respect of any deductibles or retention included in or that apply to any such Retained Seller Insurance Policy, and Buyer shall bear all such deductibles, retentions and self-insured amounts and any Losses not actually recovered under such Retained Seller Insurance Policies, (b) in no event will any Seller Party be required to commence, or threaten to commence, any Action or otherwise pursue any dispute with any insurer in connection with the foregoing, and (c) in no event will any Seller Party be required to take any action that would violate the terms of, or jeopardize coverage under, any Retained Seller Insurance Policy; provided, however, that Buyer will indemnify Seller and its Affiliates, and pay, and, if requested advance, to them the amount of any reasonable and documented out-of-pocket fees and expenses or other Losses (as well as any increased insurance premiums) incurred by Seller and its Affiliates or other relevant Persons in connection with or as a result of the making of any such claims or otherwise complying with the terms set forth in this Section 5.15. Nothing in this Section 5.15 will require Seller or any of its Affiliates to maintain, renew, continue or obtain any Retained Seller Insurance Policy or other insurance or prevent Seller or any of its Affiliates from amending the terms of or terminating any such Retained Seller Insurance Policy or any other Contracts relating thereto; provided, however, Seller shall not, and shall cause its Affiliates not to, affirmatively commute, buy back, release or otherwise compromise any Occurrence-Based Policy, in whole or in part, in a manner that would materially prejudice the coverage available thereunder for such Pre-Closing Occurrence. Subject to the immediately preceding proviso, Seller and its Affiliates shall retain sole and exclusive control over the Retained Seller Insurance Policies, including the exclusive right to administer, adjust, settle, compromise, amend, terminate, cancel, commute, buy back, release or otherwise resolve any claim or coverage thereunder, and no such action shall give rise to any liability of any Seller Party to Buyer or any of its Affiliates. Seller makes no representation or warranty as to the availability, scope or adequacy of coverage under, or the collectability of any amounts from, any Retained Seller Insurance Policy. Seller’s obligations under this Section 5.15 shall terminate on the earlier of (i) the date that is twenty-four (24) months following the Closing Date and (ii) the date on which the applicable Retained Seller Insurance Policy expires or is terminated in accordance with its terms.
76
Section 5.16 Public Announcements. The initial press release regarding this Agreement shall be a joint press release in a form agreed to by the parties hereto. Thereafter, Seller and Buyer each shall consult with the other prior to them or their Affiliates issuing any press releases or otherwise making public statements with respect to this Agreement, the Asset Sale and the other Transactions and shall not issue (and not have their respective Affiliates issue) any such press release or make any such public statement without the prior consent of the other party (which consent shall not be unreasonably withheld, conditioned, or delayed); provided, that a party may, without the prior consent of the other party, issue such press release or make such public statement (a) so long as such statements are consistent with previous public statements made in compliance with this Agreement or otherwise agreed to between Seller and Buyer or (b) after prior consultation (to the extent practicable in the circumstances) to the extent required by Law or by obligations pursuant to any listing agreement with or rules of any national securities exchange or interdealer quotation service or by the request of any Governmental Authority. None of the limitations set forth in this Section 5.16 shall apply to the disclosure of any information or communications (i) by Seller regarding an Acquisition Proposal or from and after a Change of Recommendation effected in accordance with Section 5.3, or by Buyer in response thereto, or (ii) in connection with any dispute between the parties hereto relating to this Agreement or the Transactions.
Section 5.17 Buyer R&W Insurance Policy. Prior to the Closing, Buyer may obtain and bind, on terms and conditions reasonably satisfactory to Buyer, a buyer-side representation and warranty insurance policy in connection with the transactions contemplated herein (the “Buyer R&W Insurance Policy”). The premium, costs and expenses of the Buyer R&W Insurance Policy will be borne by Buyer. Buyer agrees that any Buyer R&W Insurance Policy shall provide that none of Seller or its controlled Affiliates shall be liable to the insurer, and the insurer shall waive all rights of subrogation, other than in the event of Fraud (and then only against the Person who committed such Fraud), and that Seller and its Affiliates are express third party beneficiaries of such provision. The failure to obtain or maintain the Buyer R&W Insurance Policy, or any denial of coverage, insufficiency of limits, or insolvency of the insurer thereunder, shall not expand or otherwise affect the liability of Seller or any of its Affiliates under this Agreement or any Ancillary Agreement.
Section 5.18 Affiliate Transactions. Prior to Closing, Seller shall have terminated or caused to be terminated without liability to any Buyer Party any Contract between Seller or any of its Affiliates, on the one hand, and any Related Person, on the other hand, solely to the extent related to the Business or the Transferred Assets. For the avoidance of doubt, any Liabilities related to any such Contracts or the termination thereof shall constitute an Excluded Liability.
77
Section 5.19 Transaction Litigation. During the Interim Period, Seller shall promptly notify Buyer of all Actions commenced or threatened in writing against Seller or any of the Seller Parties, in each case, in connection with, arising from or otherwise relating to the Transactions (“Transaction Litigation”) (including by providing copies of all pleadings with respect thereto) and thereafter keep Buyer reasonably informed with respect to the status thereof. For the avoidance of doubt, any Liabilities related to any Transaction Litigation shall constitute an Excluded Claim.
Section 5.20 NDC Transition.
(a) No later than fifteen (15) Business Days after the Closing Date, Buyer shall submit to the FDA drug listing information for the Business Products that includes national drug code numbers (each, an “NDC”) reflecting Buyer’s labeler codes (the “Buyer NDCs”). Buyer shall notify Seller promptly after submission thereof, including a copy of the forms submitted to the FDA.
(b) Buyer shall use commercially reasonable efforts to apply Buyer NDCs to all inventory of the Business Products packaged after the submission under Section 5.20(a); provided that, following the Closing Date, Buyer may continue to distribute inventory of each Business Product labeled with Seller’s NDCs until the earlier of (i) the date on which all such inventory of such Business Product has been sold or otherwise depleted and (ii) the expiration date of such inventory (the “Transition Date”).
Section 5.21 Rebates; Chargebacks; Returns; Government Pricing. From and after the Closing:
(a) Rebates. Buyer shall bear, and shall pay, or, to the extent Seller pays on Buyer’s behalf, reimburse Seller for, the cost of all rebates, discounts, refunds, fees and other payment obligations arising under (i) the Medicaid Drug Rebate Program, (ii) the Medicare Part D Manufacturer Discount Program, (iii) the Medicare Part B and Part D inflation rebate programs under 42 U.S.C. §§ 1395w-3a(i) and 1395w-114b, (iv) the Medicare Drug Price Negotiation Program, (v) the TRICARE Retail Pharmacy Refund Program, (vi) the 340B Drug Pricing Program, (vii) the Veterans Health Care Act of 1992 and any Federal Supply Schedule contract, (viii) any other state or federal health care program, (ix) any commercial, managed care, pharmacy benefit manager, GPO or similar rebate or administrative fee agreement, and (x) any patient assistance, copay assistance, coupon or similar program (collectively, “Pricing Program Obligations”), each with respect to the Business Products bearing Seller’s or its Affiliates’ NDCs (“Seller NDC Products”), regardless of whether the applicable pharmacy claim payment date falls before, on, or after the Closing Date. Nothwithstanding the foregoing, Seller shall bear and pay for, or, to the extent Buyer pays on Seller’s behalf, reimburse Buyer for, the cost of rebates, discounts, refunds, fees, and other payment obligations arising from the Medicaid Drug Rebate Program restatement covering the period May 2017 through September 2019, including any liabilities under the 340B Drug Pricing and Medicaid Part B Programs.
(b) Chargebacks. Buyer shall bear the cost of all chargebacks for the Seller NDC Products, or Buyer’s or its Affiliates’ NDCs regardless of whether the Business Products are sold by a wholesaler or distributor to an end purchaser customer before, on, or after the Closing Date.
78
(c) Seller shall, promptly, and in no event later than five (5) Business Days after receipt, forward to Buyer any invoice, demand, or claim for a rebate or chargeback claim for which Buyer is financially responsible under Sections 5.21(a) and 5.21(b), together with all supporting documentation in its possession, and shall not pay, satisfy, or otherwise resolve such invoice, demand, or claim without Buyer’s prior written consent, except as required by applicable Law or the terms of a rebate agreement. Buyer shall immediately (but no more than five (5) Business Days after receipt of a reimbursement request and reasonable supporting documentation), reimburse Seller for any amounts properly paid on Buyer’s behalf, failing which interest shall accrue on the unpaid amount at a rate of ten percent (10%) per annum from the date of the reimbursement request until paid. Buyer shall have the right, upon reasonable notice (but no less than five (5) Business Days), to audit Seller’s books and records to the extent reasonably necessary to verify amounts invoiced or claimed under Sections 5.21(a) and 5.21(b). Buyer shall process and pay, or reimburse Seller for, all amounts for which Buyer is financially responsible under Sections 5.21(a) and 5.21(b) in the ordinary course of business consistent with past practice and in compliance with applicable Law, and Buyer shall indemnify and hold harmless Seller Parties and its Affiliates from and against any civil monetary penalty, program exclusion, interest, or other liability or other Losses arising from Buyer’s failure to timely pay, report or reimburse any such amount. Seller shall have the right, upon reasonable notice, to audit Buyer’s books and records to the extent reasonably necessary to verify amounts invoiced or claimed under Sections 5.21(a) and 5.21(b). Seller shall use reasonable best efforts to provide all necessary data, information, reports, calculations in order for Buyer to make timely reports and payments under Sections 5.21(a) and 5.21(b). To facilitate reports and payments under Sections 5.21(a) and 5.21(b), Buyer shall assume and gain access to Seller’s government price reporting-related systems as well as facilitate the assignment to Buyer of Seller’s contracts for vendors that report and calculate government price reporting.
(d) All returns of the Business Products bearing Seller’s or its Affiliates’ NDCs whether received before, on or after the Closing Date, shall be the responsibility of Buyer.
(e) Buyer shall be responsible for complying with reporting requirements under all Laws and Regulatory Laws applicable to the Business Products, including for the entire reporting period that includes the Closing Date, regardless of whether such reporting period commenced prior the Closing Date. The parties hereto shall reasonably cooperate with one another in connection with the transition of such reporting obligations, including amending applicable Contracts and agency records to reflect Buyer as owner of the Business Products and any other Transferred Regulatory Approvals. Buyer will use reasonable best efforts, acting in good faith, to use Seller’s methodology to calculate payment obligations in accordance with the first sentence of Section 5.21(e); provided that, Buyer will discuss any material deviation with Seller before Buyer adopts a new methodology. Buyer shall indemnify and hold harmless Seller Parties and their Affiliates from and against any civil monetary penalty, program exclusion, interest, or other liability or other Losses arising from or related to (i) Buyer’s failure to timely and accurately comply with reporting requirements; (ii) any inaccuracy in a price report filed by the Buyer (with respect to Seller NDC Products); (iii) any Pricing Program Obligation for which Buyer is responsible under this Section 5.21(e); or (iv) any other breach of this Section 5.21(e) by Buyer. Seller shall have the right, upon reasonable notice, to audit Buyer’s books and records, and access Buyer’s relevant systems and personnel, to the extent reasonably necessary to verify the price report calculations and all underlying transactional data, assumptions and supporting documentation.
79
Section 5.22 Cooperation in Litigation.
(a) Following the Closing, Seller and Buyer shall use their respective commercially reasonable efforts to cause Buyer (or its designated Affiliate) to intervene, be substituted for, or joined with or in place of, any member of the Seller Group that is a party to any Action pending as of the Closing relating to the infringement, violation, misappropriation, validity, enforceability or ownership of any Transferred Intellectual Property, including any Action arising out of or related to the settlement agreements set forth on Schedule 5.22 of the Seller Disclosure Schedules (clause (ii), collectively, the “Assumed Settlement Agreements”, and collectively the “Assumed Litigation”), including by executing and delivering such additional documents and instruments, and making such filings with the applicable Governmental Authority, as may be reasonably required to effect such substitution.
(b) Following the Closing, Seller and Buyer shall use their respective commercially reasonable efforts to cooperate with regard to the Assumed Litigation, including by providing reasonable access to employees, records, documents, and other information in their respective possessions or control that is reasonably related to the Assumed Litigation, provided that (i) such cooperation shall not unreasonably interfere with any cooperating party’s business or operations, (ii) neither Seller nor Buyer shall be required to disclose any Legal Privileges and Protection, and (iii) all access shall be granted during normal business hours in a manner reasonably calculated to minimize disruption. Notwithstanding anything to the contrary in this Section 5.22, neither Seller nor Buyer shall have any obligation to cooperate or disclose any documents or information pursuant to this Section 5.22 if Buyer or any of its Affiliates, on the one hand, and Seller or any of its Affiliates, on the other hand, are adverse parties in any Action and such cooperation or information is reasonably pertinent thereto; provided, further, that nothing in this Section 5.22(b) shall limit the rights of any party hereto with respect to discovery in connection with any such Action.
(c) From and after the Closing, (i) Buyer shall have the sole right to control, direct and conduct the prosecution, defense and settlement of the Assumed Litigation, including the selection of counsel, and the applicable member of the Seller Group shall take, or refrain from taking, such actions in connection therewith as Buyer may reasonably request (subject to the limitations set forth in Section 5.22(b)), and (ii) all reasonable and documented fees, costs and expenses (including reasonable attorneys’ fees, expert fees, court reporter expenses, electronic discovery expenses, filing fees and any other expenses) or any other fees, costs and expenses incurred at Buyer’s request or with Buyer’s consent (including any fees of a third party engaged at Buyer’s request or with Buyer’s consent) in connection with the Assumed Litigation pursuant to this Section 5.22 (collectively, the “Assumed Litigation Expenses”) incurred by any member of the Seller Group in connection with such Assumed Litigation (including the settlement thereof) or such cooperation and related actions shall be borne solely by Buyer. No member of the Seller Group shall have any obligation to fund, direct or participate in the management of any Assumed Litigation, except as expressly set forth in this Section 5.22. For the avoidance of doubt, Buyer shall promptly pay any Assumed Litigation Expenses in the first instance, and Seller shall not be required to pay any Assumed Litigation Expenses in the first instance and then seek reimbursement from Buyer. From and after the Closing, Seller shall, as promptly as reasonably practicable following receipt thereof, pay to Buyer any monies actually received by the Seller Parties in respect of any Assumed Litigation settlement payments.
80
(d) Buyer shall indemnify, defend, and hold harmless the Seller Indemnified Parties from and against any and all Losses arising out of or relating to any Assumed Litigation, including any judgment, verdict, award, settlement amount, sanction, fine, penalty, fee award, or other monetary obligation that any Seller Indemnified Party is obligated to pay in connection with any Assumed Litigation. Buyer shall pay any such amount in the first instance, and no Seller Indemnified Party shall be required to pay any such amount and thereafter seek reimbursement from Buyer. Notwithstanding the foregoing, if Buyer is not or cannot be substituted, pursuant to Section 5.22(a), for each member of the Seller Group that is a party to any Assumed Litigation, Seller reserves the right, at Seller’s cost and expense (but subject to the proviso that immediately follows), to retain independent legal counsel to monitor and participate in the prosecution or defense of such Assumed Litigation; provided, however, if Buyer (i) is not or cannot be substituted, pursuant to Section 5.22(a), for each member of the Seller Group that is a party to any Assumed Litigation, and (ii) either (A) has failed to prosecute or provide a defense of such Assumed Litigation as required by the immediately preceding sentence and such failure has not been cured within fifteen (15) days following written notice from Seller, or (B) has filed, or had filed against it, a petition under Title 11 of the United States Code or any similar state or foreign insolvency Law, then, in each such case, Seller reserves the right, at Buyer’s cost and expense, to retain or re-assume control over or otherwise participate in the prosecution or defense of such Assumed Litigation with counsel selected by Seller. From and after the Closing with respect to any Assumed Litigation, and unless and until Buyer has been fully substituted for each member of the Seller Group that is a named party to such Assumed Litigation, Buyer shall provide, or cause legal counsel to provide to Seller, and independent counsel retained by Seller (if any), with (1) reasonable written updates regarding the status of each Assumed Litigation, and (2) reasonable advance notice of any material hearings, depositions, mediations, or trial proceedings in connection therewith.
(e) From and after the Closing with respect to any Assumed Litigation, and unless and until Buyer has been fully substituted for each member of the Seller Group that is a named party to such Assumed Litigation, Buyer shall not settle any Assumed Litigation without Seller’s prior written consent unless (i) the settlement provides for a full and complete release of all Seller Indemnified Parties, (ii) the settlement does not involve any admission of a violation of Law or any admission of guilt, fault, wrongdoing, or liability on the part of any Seller Indemnified Party, and (iii) the settlement does not impose any injunction, consent order, decree, or non-monetary obligation on any Seller Indemnified Party (other than customary confidentiality obligations). Seller’s prior written consent, if necessary, shall not be unreasonably withheld, conditioned, or delayed.
(f) From and after the Closing, (i) Seller shall promptly notify Buyer of any new Actions related to a Transferred Asset, the Business, or an Assumed Liability in which Seller or one of its Affiliates is named as a party, and (ii) Buyer shall promptly notify Seller of any new Action commenced by Buyer within the scope of the Assumed Litigation and of any Assumed Litigation in which any member of the Seller Group is named.
81
(g) The provisions of this Section 5.22 shall survive the Closing until the final resolution (including exhaustion or expiration of all appeals) of all Assumed Litigation and the satisfaction in full of all obligations of Buyer under this Section 5.22.
Section 5.23 Use of Name. Except as expressly contemplated and permitted by this Agreement, promptly following the Closing (but not later than ninety (90) days following the Closing), each Seller Party shall, and shall cause its respective Affiliates to, (i) cease and discontinue any and all uses of the Marks included in the Transferred Intellectual Property (collectively, the “Transferred Trademarks”), or any confusingly similar Mark, (ii) to the extent practicable, remove, destroy or strike over the labeling, stationery, forms, supplies, displays, advertising and promotional materials, manuals, and other materials (collectively, “Materials”) existing as of the Closing that are not Transferred Assets that bear any Transferred Trademarks or alter any such Materials so as to remove the Transferred Trademarks, and (iii) to the extent practicable, remove all Transferred Trademarks from all assets, websites, email and other online materials and from all signage and other displays. Notwithstanding the foregoing promptly following the Closing (but not later than ninety (90) days following the Closing), each Seller Party shall, and shall cause its respective Affiliates to, use commercially reasonable efforts to change all corporate names (including each Seller Party’s or its respective Affiliates’ corporate names) with all applicable Governmental Authorities to corporate names that do not encompass or include any Transferred Trademarks or any confusingly similar Mark. The foregoing notwithstanding, Seller and its Affiliates may continue to use the Marks on all Inventory to be sold under its NDC following the Closing, as contemplated by Section 5.20. Nothing in this Agreement shall prohibit or restrict the Seller Parties or their Affiliates from using, referencing or displaying the Transferred Trademarks (including any corporate, trade or business names that include any Transferred Trademarks) in a non-trademark manner, including: (a) in filings, returns, reports, registrations, notices and other submissions with or to any Governmental Authority (including tax returns, financial statements and securities filings), and in connection with any Permits, licenses or registrations held by the Seller Parties or their Affiliates, in each case to the extent relating to periods prior to the Closing or prior to the completion of any change of corporate name contemplated by this Section; (b) as required by applicable Law, any Governmental Authority, any Order or the rules of any securities exchange; (c) in a plain-text, non-trademark, factual or historical manner, including to accurately describe or refer to the historical ownership or operation of the Business, the transactions contemplated by this Agreement, or the history of the Seller Parties or their Affiliates; (d) in or in connection with any Action, dispute, audit, investigation or inquiry, or the enforcement or defense of any right or obligation under this Agreement or any Ancillary Agreement; (e) in books, records, contracts, invoices, correspondence, archives and other documents and materials created or existing prior to the Closing (or prior to the completion of the applicable name change), including in connection with the collection of receivables and the performance or wind-down of obligations arising prior to the Closing; (f) in internal, non-public materials and communications; and (g) in any other manner that would constitute fair use (including in correspondence to inform others regarding the transition of Seller’s Business to Buyer and its Affiliates), provided that in no event shall the Seller Parties or their Affiliates use the Transferred Trademarks as a source identifier for any products or services offered after the Closing other than as permitted under clauses (a) through (g). Each Seller Party and their respective Affiliates hereby acknowledge that all right, title and interest in and to the Transferred Trademarks, together with all goodwill associated with any of the foregoing, and all other Intellectual Property Rights of any kind owned by Seller Parties related to the Business prior to the Closing, are, after the Closing, owned exclusively by Buyer or its Affiliates. Neither the Seller Parties nor their respective Affiliates shall seek to register in any jurisdiction any trade, corporate or business name, Mark or other name or source identifier that is the same as or confusingly similar to, any Transferred Trademarks and shall not knowingly and voluntarily challenge Buyer’s or its Affiliates’ ownership thereof.
82
Section 5.24 Debt Financing Cooperation.
(a) During the Interim Period, Seller shall use its commercially reasonable efforts, and shall cause each of the Seller Parties to use its respective commercially reasonable efforts, in each case, at Buyer’s sole cost and expense, to provide Buyer with such customary cooperation as is reasonably requested by Buyer to arrange, syndicate, and obtain the Debt Financing, including using commercially reasonable efforts in the following (it being understood that the Seller Parties’ obligations under this Section 5.24 shall be limited to the provision of information that is reasonably available to the Seller Parties without undue burden or expense):
(i) causing management of the Seller Parties to participate in, upon reasonable advance notice, a reasonable number of telephonic meetings, presentations, road shows, due diligence sessions, drafting sessions and sessions (upon reasonable request) with rating agencies and other customary syndication activities in connection with the Debt Financing at times and locations to be mutually agreed;
(ii) providing reasonable and customary assistance to Buyer with the preparation of customary rating agency presentations, bank information memoranda required in connection with the Debt Financing and similar documents (it being understood that Buyer and the Financing Sources shall be responsible for the preparation of such materials), including execution and delivery of customary authorization letters related thereto authorizing the distribution of information to prospective lenders who have agreed to maintain the confidentiality thereof for the benefit of the Seller Parties, which authorization letters shall include customary language exculpating the Seller Parties and their Representatives from liability in connection with the use of the information contained therein and shall not include any representation as to the accuracy or completeness of such information (other than with respect to customary 10b-5 representation and the presence or absence of material non-public information), and providing reasonable cooperation with the due diligence efforts of the Financing Sources, in each case, to the extent reasonable and customary for financings of the type of the Debt Financing;
(iii) obtaining the payoff letters and other customary release and termination documentation for the Closing Date Seller Indebtedness;
(iv) providing, as promptly as reasonably practicable (and in any event, no less than three (3) Business Days prior to the Closing Date), all documentation and other information required by bank regulatory authorities under applicable “know your customer” and anti-money laundering rules and regulations, including (A) the USA Patriot Act of 2001 and (B) a certification regarding beneficial ownership as required by 31 C.F.R. §1010.230 to any Financing Source that has requested such certification, relating to any Seller Party, in each case, as reasonably requested of such Seller Party in writing by Buyer or the Financing Sources at least ten (10) Business Days prior to the Closing Date;
83
(v) furnishing Buyer as promptly as reasonably practicable, such other financial and other pertinent information in the Seller Parties’ (or their respective advisors’) possession and reasonably available to the Seller Parties, pertaining to the Seller Parties, as may be customarily required and reasonably requested by Buyer for completion of the Debt Financing (for the avoidance of doubt, Seller shall not be responsible for the preparation of any pro forma financial statements or other financial information that places undue burden on Seller (including, for the avoidance of doubt, preparation of financial information in a form not customarily prepared by Seller)); and
(vi) assisting in the taking of all actions, subject to the occurrence of the Closing, reasonably required by Buyer that are necessary to permit the consummation of the Debt Financing on the Closing Date and to permit the proceeds thereof to be made available at the Closing.
(b) Nothing in this Section 5.24 will require any Seller Party to (i) waive or amend any terms of this Agreement or agree to pay any fees or reimburse any expenses prior to the Closing; (ii) except with respect to the provision of authorization letters referred to in clause (a)(ii) above and except with respect to “know-your-customer” information referred to in clause (a)(iv) above, enter into any definitive agreement or documentation, the effectiveness of which is not conditioned upon the Closing; (iii) give any indemnities or incur any fees or other liabilities that are effective prior to the Closing; (iv) take any action that would unreasonably or materially interfere with the conduct of the Business, breach any confidentiality obligations or create a risk of damage or destruction to the Business or any Transferred Asset; (v) provide any information the disclosure of which is prohibited under applicable Law or would jeopardize any attorney-client privilege; (vi) take any action that would conflict with or violate its organizational documents, any applicable Law or any Contract, or cause any representation or warranty in this Agreement to be breached or any condition to Closing to fail to be satisfied; (vii) prepare any pro forma financial statements or pro forma adjustments, or financial statements or information in a form not customarily prepared by Seller in the ordinary course of business; or (viii) be an issuer, borrower, guarantor or other obligor with respect to the Debt Financing. In addition, no action, liability or obligation of any Seller Party or any of their respective Representatives pursuant to any certificate, agreement, arrangement, document or instrument relating to the Debt Financing will be effective until the Closing, and no Seller Party will be required to take any action pursuant to any certificate, agreement, arrangement, document or instrument that is not contingent on the occurrence of the Closing or that becomes effective prior to the Closing. Nothing in this Section 5.24 will require the Seller Parties or their respective directors, officers or employees to execute, deliver or enter into, or perform any agreement, document or instrument (except with respect to the provision of authorization letters referred to in clause (a)(ii) above and except with respect to “know-your-customer” information referred to in clause (a)(iv) above) including any definitive financing document, with respect to any debt financing or adopt resolutions approving the agreements, documents and/or instruments pursuant to which any debt financing is obtained or pledge any collateral with respect to the Debt Financing. Nothing in this Section 5.24 shall require (A) any officer, director, stockholder or Representative of any Seller Party to deliver any certificate or take any other action under this Section 5.24 that would reasonably be expected to result in personal liability to such Person; or (B) the Seller Board to approve any financing or Contracts related thereto. The Seller Parties and their respective Representatives shall not be required to deliver any legal opinions or solvency certificates. In no event shall any Seller Party be in breach of this Agreement because of the failure to deliver any financial or other information that is not readily available to the Seller Parties or not otherwise prepared in the ordinary course of business at the time requested (other than, for the avoidance of doubt, the Seller Financial Information). Notwithstanding anything to the contrary in this Agreement, the condition set forth in Section 7.3(b), as it applies to Seller’s obligations relating to the Debt Financing, shall be deemed satisfied, and Seller shall not be deemed to have breached or failed to perform or observe any covenants, obligations or other agreements contained in this Section 5.24 relating to the Debt Financing, in each case, unless the failure of any condition precedent to the funding of the Debt Financing is caused by Seller’s willful and material breach of its obligations under this Section 5.24 and is a direct and proximate cause of the failure of Buyer to obtain Debt Financing, which breach has not been cured on or prior to the fifth Business Day after Buyer has provided written notice of such breach (it being understood that in no event shall the Debt Financing or any breach of this Section 5.24 give rise to any right of Buyer to delay or refuse to consummate the Closing).
84
(c)
(i) Seller hereby consents to the use of any logos related to the Business in connection with the Debt Financing so long as such logos (A) are used solely in a manner that is not intended to, or reasonably likely to, harm or disparage the Seller Parties or the reputation or goodwill of the Seller Parties; and (B) are used solely in connection with a description of the Seller Parties, the Business or the Transactions.
(ii) Notwithstanding anything to the contrary herein, Buyer will be permitted to disclose any non-public or other confidential information provided by the Seller Parties to any Financing Sources or prospective financing sources and other financial institutions and investors that are or may become parties to the Debt Financing and to any underwriters, initial purchasers or placement agents or ratings agencies in connection with the Debt Financing (and, in each case, to their respective counsel and auditors) so long as such Persons (A) agree to be bound by the Confidentiality Agreement as if parties thereto; or (B) are subject to other confidentiality undertakings reasonably satisfactory to Seller and of which Seller is an express third-party beneficiary.
(iii) Promptly (and in any event within ten (10) Business Days) upon request by Seller, Buyer shall reimburse Seller for reasonable and documented out-of-pocket costs and expenses (including attorneys’ and accountants’ fees) incurred by any Seller Party or any of their respective Representatives in connection with the cooperation or obligations of such Seller Party and their Representatives contemplated by this Section 5.24 whether or not the Closing occurs; provided, that Buyer shall not be required to reimburse such Seller Party for costs and expenses incurred in connection with the preparation of financial statements, financial information or other materials, in each case, prepared prior to the Agreement Date or, after the Agreement Date, that such Seller Party would have prepared in the ordinary course of business.
(iv) The Seller Parties and their respective Affiliates and Representatives shall be indemnified and held harmless by Buyer from and against any and all liabilities, losses, damages, claims, costs, expenses (including attorneys’ fees), interest, awards, judgments, fines, penalties and amounts paid in settlement suffered or incurred by them in connection with the Debt Financing pursuant to this Agreement, including any action taken by them at the request of Buyer pursuant to this Section 5.24, or the provision of information utilized in connection therewith (except in the case of the Seller Parties’ and their respective Representatives’ Fraud, gross negligence or bad faith, as determined by a final, non-appealable judgment of a court of competent jurisdiction). The obligations of Buyer under this clause (iv) and clause (iii) above shall survive the Closing and any termination of this Agreement.
85
(d) Buyer acknowledges and agrees that obtaining the Debt Financing or any other financing is not a condition to the Closing or to any of Buyer's obligations under this Agreement and shall not excuse or delay Buyer’s performance of its obligations under this Agreement. Buyer shall have, at the Closing, and shall pay or cause to be paid at the Closing, in immediately available funds, all amounts required to be paid by Buyer at the Closing under this Agreement, in each case whether or not the Debt Financing has been funded or is available.
Article
VI
TAX MATTERS
Section 6.1 Tax Matters.
(a) For all Tax purposes, the Transaction Consideration (plus any Assumed Liabilities that are treated as consideration for the Transferred Assets for U.S. federal income tax purposes, but excluding any imputed interest attributable to the Earn-Out Payments (if any) and Royalty Payments (if any)) (the “Tax Purchase Price”) shall be allocated among each of the Seller Parties and Transferred Assets, as applicable, in accordance with Section 1060 of the Code and the methodology and principles described in Schedule 6.1(a) (the “Allocation Exhibit”). Within sixty (60) days following the Closing Date, Buyer shall prepare and deliver to Seller a written schedule (the “Proposed Allocation”) allocating the Tax Purchase Price among each of the Seller Parties and Transferred Assets in accordance with the methodology and principles described in the Allocation Exhibit. If Seller disagrees with the Proposed Allocation, Seller may, within thirty (30) days after Seller’s receipt of the Proposed Allocation, deliver a written notice (the “Allocation Dispute Notice”) to Buyer to such effect, specifying those items as to which Seller disagrees and setting forth Seller’s proposed allocation. Buyer and Seller shall use commercially reasonable efforts to reach agreement on the disputed items or amounts within fifteen (15) days of Buyer’s receipt of the Allocation Dispute Notice (the “Discussion Period”). If Buyer and Seller are unable to resolve any differences identified in the Allocation Dispute Notice within the Discussion Period, then any disputed items shall be referred to a nationally recognized accounting firm mutually agreed upon by Buyer and Seller (the “Arbiter”) for resolution within thirty (30) days of having the item referred to the Arbiter, and the determination of the Arbiter shall be final and binding upon Seller and Buyer. The fees and expenses of the Arbiter shall be paid fifty percent (50%) by Seller and fifty percent (50%) by Buyer. The allocation, as prepared by Buyer if no Allocation Dispute Notice has been given, as adjusted pursuant to any mutual agreement between Buyer and Seller, or as determined by the Arbiter shall be the final allocation (the “Final Allocation”). The Final Allocation shall be revised to take into account subsequent adjustments to the Transaction Consideration as determined for applicable Tax purposes.
(b) The parties agree that, for U.S. federal income tax purposes, the purchase and sale of the Transferred Assets in exchange for the Transaction Consideration pursuant to this Agreement shall be treated as the taxable acquisition by Buyer of assets held by (or treated for U.S. federal income tax purposes as held by) the applicable Seller Parties pursuant to Section 1001 of the Code (the “Intended Tax Treatment”).
86
(c) Each party hereto agrees to (i) be bound by the Final Allocation and the Intended Tax Treatment, (ii) act in strict accordance with the Final Allocation and the Intended Tax Treatment in the preparation and filing of all Tax Returns, (iii) to the extent each party is required, timely file an IRS Form 8594 reflecting the Final Allocation for the taxable year that includes the Closing Date and to make any timely comparable filings required by applicable state or local Law and (iv) not take any position inconsistent with the Final Allocation or the Intended Tax Treatment for any Tax purpose, unless required by a “final determination” within the meaning of Section 1313(a) of the Code resulting from a Tax Action initiated by a Tax Authority challenging the Final Allocation or the Intended Tax Treatment, as applicable. If any Tax Authority challenges the Final Allocation (or any allocation resulting therefrom) or the Intended Tax Treatment, the party hereto receiving notice of such challenge shall give the other parties prompt written notice thereof and the parties hereto shall use reasonable efforts to preserve the effectiveness of the Final Allocation and/or the Intended Tax Treatment, as applicable.
Section 6.2 Straddle Periods. For purposes of this Agreement, all personal property Taxes, real property Taxes, and similar ad valorem obligations levied with respect to the Transferred Assets for a Straddle Period shall be apportioned between the Pre-Closing Tax Period and the Post-Closing Tax Period as of the Closing Date based on the number of days of such taxable period included in the Pre-Closing Tax Period and the number of days of such taxable period included in the Post-Closing Tax Period.
Section 6.3 Cooperation on Tax Matters. Buyer and Seller agree to use commercially reasonable efforts to furnish or cause to be furnished to each other, upon reasonable written request, as promptly as practicable, such information and assistance relating to the Transferred Assets (including access to books and records) as is reasonably necessary for the filing of all Tax Returns, the making of any election relating to Taxes, the preparation for any audit by any Tax Authority and the prosecution or defense of any claims, suit or proceeding relating to any Tax and the payment of any amounts pursuant to Section 6.4 between Buyer and Seller. Notwithstanding anything to the contrary in this Agreement, no Seller Party shall be required to provide any portion of any Tax Return filed on an affiliated, combined, consolidated or unitary basis, and no Buyer Party (or any other Person) shall be entitled to any such Tax Return.
Section 6.4 Transfer Taxes. All Transfer Taxes levied on the parties hereto resulting from the Transactions shall be borne by Seller and remitted to the applicable Governmental Authority when due. Each of the parties hereto shall use commercially reasonable efforts to cooperate, as reasonably requested by the other party, in order to minimize Transfer Taxes. Seller shall timely prepare and file (or cause to be timely prepared and filed) any Tax Return or other documentation in respect of such Transfer Taxes, and Buyer shall reasonably cooperate with respect thereto.
87
Article
VII
CONDITIONS TO CLOSING
Section 7.1 General Conditions. The respective obligations of the Buyer Parties and the Seller Parties to consummate the Transactions shall be subject to the fulfillment, at or prior to the Closing, of each of the following conditions, any of which may, to the extent permitted by applicable Law, be waived in writing by either party in its sole discretion (provided, that such waiver shall only be effective as to the obligations of such party):
(a) No Governmental Authority of competent jurisdiction shall have enacted, issued, promulgated, enforced or entered any Law (whether temporary, preliminary or permanent) (any such Law, a “Legal Restraint”) that is then in effect and that enjoins, restrains, makes illegal or otherwise prohibits the consummation of the Transactions.
(b) Any waiting period (and any extension thereof) under any Required Filing shall have expired or shall have been terminated.
(c) The Seller Stockholder Approval shall have been obtained.
(d) The shares of Buyer Common Stock issuable as Stock Consideration pursuant to this Agreement shall have been approved for listing on the Nasdaq Global Market, subject to official notice of issuance.
Section 7.2 Conditions to Obligations of the Seller Parties. The obligations of the Seller Parties to consummate the Transactions shall be subject to the fulfillment, at or prior to the Closing, of each of the following conditions, any of which may be waived in writing by Seller in its sole discretion:
(a) Representations and Warranties. The Buyer Fundamental Representations shall be true and correct both as of the Agreement Date and as of the Closing Date, or in the case of representations and warranties that are made as of a specified date, such representations and warranties shall be true and correct as of such specified date (without giving effect to any limitation or qualification as to “materiality” (including the word “material”) or “Buyer Material Adverse Effect” set forth therein), in all material respects. The representations and warranties of Buyer contained in this Agreement, other than the Buyer Fundamental Representations, shall be true and correct both as of the Agreement Date and as of the Closing Date, or in the case of representations and warranties that are made as of a specified date, such representations and warranties shall be true and correct as of such specified date (without giving effect to any limitation or qualification as to “materiality” (including the word “material”) or “Buyer Material Adverse Effect” set forth therein), except as would not have a Buyer Material Adverse Effect.
(b) Compliance with Covenants. The Buyer Parties shall have performed and complied with in all material respects all agreements and covenants required by this Agreement to be performed or complied with by them prior to or at the Closing.
88
(c) No Material Adverse Effect. Since the Agreement Date, there shall not have occurred and be continuing a Buyer Material Adverse Effect.
(d) Closing Deliverables. Seller shall have received the items to be delivered by the Buyer Parties pursuant to Section 2.7(c).
Section 7.3 Conditions to Obligations of the Buyer Parties. The obligations of the Buyer Parties to consummate the Transactions shall be subject to the fulfillment, at or prior to the Closing, of each of the following conditions, any of which may be waived in writing by Buyer in its sole discretion:
(a) Representations and Warranties. The Seller Fundamental Representations shall be true and correct both as of the Agreement Date and as of the Closing Date, or in the case of representations and warranties that are made as of a specified date, such representations and warranties shall be true and correct as of such specified date (without giving effect to any limitation or qualification as to “materiality” (including the word “material”) or “Seller Material Adverse Effect” set forth therein), in all material respects. The representations and warranties of the Seller Parties set forth in Section 3.6(b) (Absence of Certain Changes or Events) shall be true and correct in all respects as of the Closing Date as though made on and as of the Closing Date. The representations and warranties of Seller contained in this Agreement, other than the Seller Fundamental Representations, shall be true and correct both as of the Agreement Date and as of the Closing Date, or in the case of representations and warranties that are made as of a specified date, such representations and warranties shall be true and correct as of such specified date (without giving effect to any limitation or qualification as to “materiality” (including the word “material”) or “Seller Material Adverse Effect” set forth therein), except as would not have a Seller Material Adverse Effect.
(b) Compliance with Covenants. The Seller Parties shall have performed and complied with in all material respects all agreements and covenants required by this Agreement (other than pursuant to Section 5.24) to be performed or complied with by them prior to or at the Closing.
(c) No Material Adverse Effect. Since the Agreement Date, there shall not have occurred and be continuing a Seller Material Adverse Effect.
(d) Closing Deliverables. Buyer shall have received the items to be delivered by the Seller Parties pursuant to Section 2.7(b).
Section 7.4 Frustration of Closing Conditions . No party may rely on the failure of any condition set forth in this Article VII to be satisfied if such failure was caused by such party’s failure to use efforts to cause the Closing to occur as required by Section 5.9.
89
Article
VIII
INDEMNIFICATION
Section 8.1 Survival of Representations, Warranties and Covenants.
(a) The representations and warranties of Seller and Buyer contained in this Agreement and the Bill of Sale and Assignment and Assumption Agreement (the “Indemnification Ancillary Agreements”) shall terminate effective as of the Closing and shall not survive the Closing for any purpose. The foregoing shall not prevent any party hereto from obtaining any remedies to which such party hereto or its Affiliates may be entitled from an insurance carrier under the Buyer R&W Insurance Policy. Notwithstanding the foregoing, nothing in this Section 8.1 shall limit in any way any claim for Fraud.
(b) The covenants and agreements of Seller and Buyer contained in this Agreement that by their terms are required to be performed prior to the Closing shall terminate on the Closing solely to the extent such obligations are to be performed prior to the Closing. The covenants and agreements contained in this Agreement and the Indemnification Ancillary Agreements that by their terms contemplate performance in whole or in part after the Closing shall survive the Closing until fully performed in accordance with their terms or, if no express performance date is specified, until the expiration of the applicable statute of limitations. Notwithstanding the foregoing, any claim for indemnification with respect to a breach of a surviving covenant or agreement herein that is validly asserted in writing prior to the expiration of the applicable survival period shall survive until finally resolved.
(c) The survival periods set forth in Section 8.1(a) and Section 8.1(b) are in lieu of, and the parties expressly waive, any otherwise applicable statute of limitations, whether arising at law or in equity. No claim for breach of any representation, warranty, covenant or agreement may be brought after expiration of the survival periods set forth in Section 8.1(a) and Section 8.1(b), as applicable; provided, however, the survival periods set forth herein shall not apply to, and nothing herein shall limit the rights of Buyer or any of its Affiliates under, the Buyer R&W Insurance Policy; provided, further, that the foregoing proviso shall not create, extend or revive any right, claim or recourse against Seller or any of its Affiliates, and shall not be construed to limit Section 8.5(a)(i).
Section 8.2 Indemnification by Seller. From and after the Closing, Seller shall indemnify and hold harmless Buyer, its Affiliates, and its and their respective officers, directors, employees and agents (collectively, the “Buyer Indemnified Parties”) from and against any and all losses, Liabilities, damages, judgments, settlements, penalties, fines, interest, fees (including reasonable attorneys’ fees), costs and expenses (hereinafter collectively, “Losses”) to the extent arising out of or resulting from:
(a) any breach of any covenant or agreement of any Seller Party made by a Seller Party contained in this Agreement or any Indemnification Ancillary Agreement, in each case, that by its terms contemplates performance in whole or in part after the Closing; and
(b) any Excluded Liability.
Section 8.3 Indemnification by Buyer. From and after the Closing, Buyer shall indemnify and hold harmless Seller, its Affiliates, and its and their respective officers, directors, employees and agents (collectively, the “Seller Indemnified Parties”) from and against any and all Losses to the extent arising out of or resulting from:
(a) any breach of any covenant or agreement of any Buyer Party contained in this Agreement or any Indemnification Ancillary Agreement, in each case, that by its terms contemplates performance in whole or in part after the Closing; and
(b) any Assumed Liability.
90
Section 8.4 Procedures.
(a) In order for a Buyer Indemnified Party or Seller Indemnified Party (the “Indemnified Party”) to be entitled to any indemnification provided for under this Agreement as a result of a Loss or a claim or demand made by any third Person against the Indemnified Party (a “Third-Party Claim”), such Indemnified Party shall deliver notice thereof to the party against whom indemnity is sought (the “Indemnifying Party”) promptly after receipt by such Indemnified Party of written notice of the Third-Party Claim, with such notice describing in reasonable detail (to the extent known) (i) the facts giving rise to any claim for indemnification hereunder, (ii) the amount or method of computation of the amount of such claim, (iii) each individual item of Loss included in the amount so stated, to the extent known, (iv) the date such item was paid or properly accrued, and (v) the nature of the breach with respect to which such Indemnified Party claims to be entitled to indemnification hereunder (all of the foregoing, the “Claim Information”), and shall provide any other information with respect thereto as the Indemnifying Party may reasonably request. The failure to provide such notice, however, shall not release the Indemnifying Party from any of its obligations under this Article VIII except to the extent that the Indemnifying Party is prejudiced by such failure.
(b) The Indemnifying Party shall have the right to assume the defense of a Third-Party Claim at the expense of the Indemnifying Party with counsel selected by the Indemnifying Party, unless the Indemnifying Party has by written notice to the Indemnified Party declined to assume such defense within thirty (30) days after receipt of notice from the Indemnified Party of the commencement of such Third-Party Claim, and subject to the Indemnified Party’s right to control the defense of certain Third-Party Claims as set forth below. The Indemnified Party shall be entitled to employ separate counsel and to participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of the Indemnified Party, except that the reasonable fees and expenses of such separate counsel shall be borne by the Indemnifying Party if the Indemnified Party has been advised by outside counsel that a reasonable likelihood exists of a conflict of interest between the Indemnifying Party and the Indemnified Party. The Indemnified Party shall cooperate with the Indemnifying Party in such defense and make available to the Indemnifying Party all witnesses, pertinent records, materials and information in the Indemnified Party’s possession or under the Indemnified Party’s control relating thereto as is reasonably required by the Indemnifying Party. If the Indemnifying Party has assumed the control and defense of a Third-Party Claim, the Indemnifying Party will not enter into any settlement, compromise or discharge of any Third-Party Claim without the Indemnified Party’s consent. The Indemnified Party shall consent to any settlement, compromise or discharge of such Third-Party Claim that the Indemnifying Party may recommend; provided, that such settlement (i) by its terms obligates the Indemnifying Party to pay the full amount of the Liability in connection with such Third-Party Claim, (ii) releases the Indemnified Party completely and unconditionally from all Liability in connection with such Third-Party Claim, (iii) other than with respect to any Tax Action, does not involve any finding or admission of any violation of Law or any rights of any Person by the Indemnified Party and (iv) does not impose any injunctive or other non-monetary relief on the Indemnified Party. Notwithstanding the foregoing, the Indemnified Party shall have the right to control the defense of any Third-Party Claim that (A) seeks injunctive or equitable relief against the Indemnified Party (other than relief that is incidental to a claim for monetary damages), (B) involves an allegation of a violation of Law (including any criminal matter), (C) is brought by a Governmental Authority or relates to any regulatory examination, enforcement Action or other proceeding, or (D) relates to the conduct of the Business following the Closing; provided, that (1) the Indemnifying Party shall be entitled to participate in the defense thereof at its own expense and (2) the Indemnified Party shall keep the Indemnifying Party reasonably informed of, and consult in good faith with the Indemnifying Party regarding, the defense thereof, and (3) the Indemnifying Party shall bear the reasonable and documented out-of-pocket fees and expenses of such defense only to the extent such Third-Party Claim is indemnifiable under this Article VIII, subject to the limitations set forth in Section 8.5. The Indemnified Party shall not admit any Liability with respect to, or settle, compromise or discharge, or offer to settle, compromise or discharge, such Third-Party Claim without the Indemnifying Party’s prior written consent (which consent shall not be unreasonably withheld).
91
(c) In the event any Indemnified Party should have a claim against any Indemnifying Party hereunder that does not involve a Third-Party Claim being asserted against or sought to be collected from such Indemnified Party, the Indemnified Party shall deliver notice of such claim containing the Claim Information promptly to the Indemnifying Party. The failure to provide such notice, however, shall not release the Indemnifying Party from any of its obligations under this Article VIII, except to the extent that the Indemnifying Party is prejudiced by such failure. The Indemnified Party shall provide information reasonably requested by the Indemnifying Party for purposes of determining the validity of any claim for indemnity by the Indemnified Party; provided that in no event shall the Indemnified Party be required to provide information subject to attorney-client or similar privilege. For the avoidance of doubt, the Indemnified Party shall not be entitled to commence any Action against the Indemnifying Party for indemnification pursuant to this Section 8.4(c) unless the notice and procedural provisions set forth herein shall have been satisfied prior thereto.
Section 8.5 Limits on Indemnification.
(a) Notwithstanding anything to the contrary contained in this Agreement, other than in the event of Fraud:
(i) The sole and exclusive source of recovery available to any Buyer Indemnified Party for any breach of, or inaccuracy in, any representation or warranty of the Seller Parties set forth in Article III of this Agreement or arising out of or relating to this Agreement or any Indemnification Ancillary Agreement shall be recovery under the Buyer R&W Insurance Policy, and no Seller Party shall have any Liability to any Buyer Indemnified Party in respect of any such breach or inaccuracy, whether or not such breach or inaccuracy is covered by, or recoverable under, the Buyer R&W Insurance Policy (including as a result of any failure by Buyer to obtain, bind or maintain such policy or to pursue a claim thereunder, any retention, deductible, exclusion or policy limit thereunder, or the insolvency of the insurer(s)); and
(ii) No party hereto shall have any Liability under any provision of this Agreement for any punitive, consequential or incidental damages or special or indirect damages, including business interruption, diminution of value, loss of future revenue, profits or income, or loss of business reputation or opportunity relating to the breach or alleged breach of this Agreement or any Indemnification Ancillary Agreement; provided, that the foregoing limitation shall not apply to (A) any such damages to the extent paid or payable to a third party in connection with a Third-Party Claim or (B) Losses arising from Fraud.
92
(b) The amount of any and all Losses under this Article VIII shall be determined net of any insurance, indemnity, reimbursement arrangement, contract or other recovery actually received by the Indemnified Party or its Affiliates in connection with the facts giving rise to the right of indemnification (further net of any increases in premiums or cost of collecting such amounts under any policy other than the Buyer R&W Insurance Policy) (each, an “Alternative Recovery”). Except for Fraud, each party hereto hereby waives, to the extent permitted under its applicable insurance policies, any subrogation rights that its insurer(s) may have with respect to any indemnifiable Losses. No Seller Party shall have any obligation to maintain, obtain or renew any insurance policy, and the obligation of the Seller Indemnified Parties with respect to insurance in connection with any Assumed Liability shall be limited to using commercially reasonable efforts to access coverage available under any then-existing Retained Seller Insurance Policy, it being agreed that no Seller Indemnified Party shall be required to commence or threaten any Action against any insurer. In the event that the Indemnified Party receives recovery of any amount pursuant to an Alternative Recovery for which it has already been indemnified by the Indemnifying Party hereunder, the Indemnified Party will promptly refund an equal amount to the Indemnifying Party.
(c) Each of Buyer and Seller shall use commercially reasonable efforts to mitigate any claim or Loss for which indemnification may be sought hereunder (subject, in the case of the Seller Indemnified Parties with respect to insurance, to Section 8.5(b)), and, in the case of Buyer, such efforts shall include seeking coverage under the Buyer R&W Insurance Policy to the extent coverage under the Buyer R&W Insurance Policy is available with respect to any claim for which a Buyer Indemnified Party seeks indemnification under Section 8.2. In the event that Buyer or Seller shall fail to make such commercially reasonable efforts, then notwithstanding anything else to the contrary contained herein, the other party shall not be required to indemnify any Person for any claim or Loss that could reasonably be expected to have been avoided if such efforts had been made. Nothing in the foregoing shall require a party hereto to waive the attorney-client privilege, work product protection or similar privilege or protection.
(d) Notwithstanding anything to the contrary herein, in no event shall (i) Seller or any Seller Party be liable to the Buyer Indemnified Parties, or (ii) Buyer or any Buyer Party be liable to the Seller Indemnified Parties, in each case, in an aggregate amount in excess of $250,000,000; provided, that the foregoing limitations shall not apply to Losses arising from Fraud or willful breach of any covenant or agreement contained in this Agreement.
Section 8.6 Exclusive Remedy.
(a) Except (x) as specifically set forth in this Agreement or (y) in the case of Fraud, effective as of the Closing, Buyer, on behalf of itself and the other Buyer Indemnified Parties, and Seller, on behalf of itself and the other Seller Indemnified Parties, waives any rights and claims any Buyer Indemnified Party or Seller Indemnified Party, as the case may be, may have against the Seller Parties or the Buyer Parties, respectively, regardless of the Law or legal theory under which such Liability or obligation may be sought to be imposed, whether at law, in equity, contract, tort or otherwise, relating to the Business, the Transferred Assets or the Assumed Liabilities, in each case, occurring or arising on or prior to the Closing Date. The rights and claims waived by Buyer, on behalf of itself and the other Buyer Indemnified Parties, and Seller, on behalf of itself and the other Seller Indemnified Parties, include, to the fullest extent permitted under applicable Law, claims for contribution or other rights of recovery arising out of or relating to any Law, claims for breach of contract, for breach (negligent or otherwise) of representation or warranty, and claims for breach of duty. After the Closing, subject to Section 8.6(b), this Article VIII will provide the exclusive remedy against Seller and its Affiliates, in the case of Buyer Indemnified Parties, and against Buyer and its Affiliates, in the case of Seller Indemnified Parties, for any breach of any representation, warranty, covenant or other claim arising out of or relating to this Agreement or any Indemnification Ancillary Agreement and/or the transactions contemplated hereby or thereby. Notwithstanding the foregoing, nothing in this Section 8.6(a) shall affect the rights of Buyer under any Buyer R&W Insurance Policy.
93
(b) Notwithstanding anything to the contrary set forth in this Agreement, nothing in this Agreement shall preclude a party from bringing any action seeking specific performance or other equitable remedy to require any other party to perform its obligations under this Agreement or an Indemnification Ancillary Agreement.
(c) The parties hereto agree that the provisions in this Agreement relating to indemnification, and the limits imposed on such parties’ remedies with respect to this Agreement and the Transactions were specifically bargained for between sophisticated parties and were specifically taken into account in the determination of the terms of this Agreement and the Ancillary Agreements.
Section 8.7 Treatment of Indemnity Payments. Following the Closing, any payment made pursuant to this Article VIII shall be treated by the parties hereto, to the extent permitted by Law, for federal income Tax and other applicable Tax purposes, as an adjustment to the Transaction Consideration received by the Seller Parties in the Transactions.
Article
IX
TERMINATION
Section 9.1 Termination. This Agreement may be terminated at any time prior to the Closing:
(a) by mutual written consent of Buyer and Seller;
(b) by either Seller or Buyer if the Closing shall not have occurred by the date which is six (6) months from the Agreement Date (the “Termination Date”); provided that the right to terminate this Agreement under this Section 9.1(b) shall not be available if the failure of the party so requesting termination to fulfill any obligation under this Agreement shall have been the cause of the failure of the Closing to occur on or prior to such date;
(c) by either Seller or Buyer if any Legal Restraint permanently restraining, enjoining or otherwise prohibiting consummation of the Transactions shall become final and nonappealable; provided, however, that the right to terminate this Agreement under this Section 9.1(c) shall not be available to the party hereto whose failure to perform its covenants or agreements contained in this Agreement has been the cause of or has resulted in the imposition of such Legal Restraint or the failure of such Legal Restraint to be resisted, resolved or lifted;
94
(d) by either Seller or Buyer if the Seller Stockholder Approval shall not have been obtained at the Stockholders Meeting duly convened therefor (including any adjournment or postponement thereof) at which a vote on the Seller Stockholder Approval was taken;
(e) by Seller, at any time prior to the time the Seller Stockholder Approval is obtained, if (i) the Seller Board authorizes Seller to enter into an Alternative Acquisition Agreement with respect to a Superior Proposal (subject to complying in all material respects with the terms of Section 5.3 with respect to such Superior Proposal); and (ii) Seller pays to Buyer (or its designee) the Seller Termination Fee in accordance with Section 9.3(a);
(f) by Seller, in the event that (i) Seller has not then materially breached this Agreement and (ii) (A) Buyer shall have breached, failed to perform or violated its covenants or agreements under this Agreement, or (B) any of the representations and warranties of Buyer set forth in this Agreement shall have become inaccurate, and in either case of clause (A) or clause (B) where such breach, failure to perform, violation or inaccuracy (I) would result in the failure of the condition set forth in Section 7.2(a) or Section 7.2(b) to be satisfied, and (II) is not capable of being cured by the Termination Date or, if capable of being cured by the Termination Date, is not cured by Buyer before the earlier of (x) the Business Day immediately prior to the Termination Date and (y) the thirtieth (30th) calendar day following receipt of written notice from Seller of such breach, failure to perform, violation or inaccuracy;
(g) by Buyer, at any time prior to the time the Seller Stockholder Approval is obtained, in the event that the Seller Board (or any committee thereof) shall have effected and not withdrawn a Change of Recommendation; or
(h) by Buyer, in the event that (i) Buyer has not then materially breached this Agreement and (ii) (A) Seller shall have breached, failed to perform or violated its covenants or agreements under this Agreement, or (B) any of the representations and warranties of Seller set forth in this Agreement shall have become inaccurate, and in either case of clause (A) or clause (B) where such breach, failure to perform, violation or inaccuracy (I) would result in the failure of the condition set forth in Section 7.3(a) or Section 7.3(b) to be satisfied, and (II) is not capable of being cured by the Termination Date or, if capable of being cured by the Termination Date, is not cured by Seller before the earlier of (x) the Business Day immediately prior to the Termination Date and (y) the thirtieth (30th) calendar day following receipt of written notice from Buyer of such breach, failure to perform, violation or inaccuracy.
Section 9.2 Effect of Termination. In the event of termination of this Agreement as provided in Section 9.1, this Agreement shall forthwith become void and there shall be no Liability on the part of either party hereto except (a) for the provisions of Section 3.21 and Section 4.10 relating to broker’s fees and finder’s fees, Section 5.8 relating to confidentiality, Section 5.11 relating to nonsolicitation, Section 5.16 relating to public announcements, Section 5.24(c)(iii)-Section 5.24(c)(iv) related to the reimbursement of and indemnification with respect to Seller’s costs and expenses in connection with certain Debt Financing matters, this Section 9.2, Section 9.3, Section 10.17 and the other Financing Source Provisions, and Article X and the related definitions, in each case, and (b) that nothing herein shall relieve either party from Liability for any willful breach of this Agreement prior to such termination.
95
Section 9.3 Termination Fee.
(a) Seller Termination Fee.
(i) In the event that this Agreement is terminated pursuant to Section 9.1(e) or Section 9.1(g), then within two (2) Business Days following such termination, Seller shall pay to Buyer (or its designee) the Seller Termination Fee by wire transfer of immediately available funds to an account or accounts designated in writing by Buyer.
(ii) In the event that (A) this Agreement is terminated by (1) either party pursuant to Section 9.1(b), and after the Agreement Date and prior to such termination, an Acquisition Proposal shall have been publicly proposed, announced or otherwise communicated publicly and is not publicly withdrawn prior to the termination of this Agreement, (2) either party pursuant to Section 9.1(d), and after the Agreement Date and prior to the time at which a vote is taken on the adoption of this Agreement at the Stockholders Meeting (or an adjournment or postponement thereof), an Acquisition Proposal is publicly proposed, announced or otherwise communicated publicly and is not publicly withdrawn prior to the Stockholders Meeting, or (3) Buyer pursuant to Section 9.1(h) and after the Agreement Date and prior to a material breach by Seller that gives rise to Buyer’s termination right pursuant to Section 9.1(h), an Acquisition Proposal shall have been publicly proposed, announced or otherwise communicated publicly and is not publicly withdrawn prior to the termination of this Agreement, and (B) in any such cases of clauses (1), (2), or (3), within twelve (12) months of such termination, Seller enters into a definitive agreement with respect to, or consummates, an Acquisition Transaction with respect to such Acquisition Proposal, then Seller shall pay to Buyer (or its designee) the Seller Termination Fee within two (2) Business Days following the earlier of the execution of such definitive agreement or the consummation of such Acquisition Transaction. For purposes of this Section 9.3(a)(ii), any reference in the definition of Acquisition Transaction to “more than twenty percent (20%)” shall be deemed a reference to “more than fifty percent (50%).”
(iii) The parties hereto acknowledge and hereby agree that in no event shall Seller be required to pay the Seller Termination Fee on more than one occasion, or pay the Expense Reimbursement on more than one occasion, whether or not the Seller Termination Fee or the Expense Reimbursement may be payable under more than one provision of this Agreement at the same or at different times and the occurrence of different events. In the event that the Expense Reimbursement has been made, and Buyer is subsequently entitled to the Seller Termination Fee, the Seller Termination Fee shall be reduced dollar for dollar, by the amount of the Expense Reimbursement actually paid. If the Seller Termination Fee is paid, Buyer shall not simultaneously or subsequently be entitled to the Expense Reimbursement.
(b) Recovery. Seller hereby acknowledges that the covenants set forth in this Section 9.3 are an integral part of this Agreement and the Asset Sale, and that, without these agreements, Buyer would not have entered into this Agreement. Accordingly, if Seller fails to promptly pay any amounts due pursuant to this Section 9.3 and, in order to obtain such payment, Buyer commences an Action that results in a judgment against Seller for the amount set forth in this Section 9.3 or any portion thereof, Seller will pay to Buyer its out-of-pocket costs and expenses (including reasonable attorneys’ fees and costs) in connection with such Action, together with interest on such amount or portion thereof at the annual rate equal to the prime rate as published in The Wall Street Journal in effect on the date that such payment or portion thereof was required to be made through the date that such payment or portion thereof was actually received, plus two percent (2%) per annum, or a lesser rate that is the maximum permitted by applicable Law.
96
(c) Acknowledgement. Each of the parties hereto acknowledges and agrees that:
(i) The damages resulting from termination of this Agreement under circumstances where the Seller Termination Fee or the Expense Reimbursement is payable are uncertain and incapable of accurate calculation and therefore, the amounts payable pursuant to Section 9.3(a) are not a penalty but rather constitute liquidated damages in a reasonable amount that will compensate Buyer for the efforts and resources expended and opportunities foregone while negotiating this Agreement and in reliance on this Agreement and on the expectation of the consummation of the Transactions.
(ii) Notwithstanding anything to the contrary in this Agreement, under the circumstances in which the Seller Termination Fee is payable pursuant to this Section 9.3, Buyer’s right to receive the Seller Termination Fee pursuant to this Section 9.3 shall be the sole and exclusive remedy (whether at law, in equity, in contract, tort, through piercing of the corporate veil or otherwise) of Buyer against Seller, its Affiliates, or its or their respective Representatives, in each case, for any Losses or Liabilities of any kind (including any Losses of any such Person for the benefit of the bargain, opportunity cost, loss of premium, time value of money or otherwise, or for any consequential, special, expectancy, indirect or punitive damages) suffered or incurred by Buyer or its Affiliates as a result of any breach of any representation, warranty, covenant or agreement or the failure of the Closing or otherwise in connection with this Agreement, the Transactions (and the abandonment or termination thereof) or any matter forming the basis for such termination (other than Liability for Seller’s willful and material breach), and Buyer shall not be entitled to assert, bring or maintain, any Action against Seller, its Affiliates or its or their respective Representatives or the Transactions (and the abandonment or termination thereof) or any matter forming the basis for such termination, whether by or through attempted piercing of the corporate veil or any legal or equitable proceeding whether at law, in equity, in contract, in tort or otherwise (other than Liability for Seller’s willful and material breach). For the avoidance of doubt, nothing in this Section 9.3 shall limit or impair Buyer’s right to seek specific performance or other equitable relief pursuant to Section 10.8 to compel Seller to consummate the Closing, and Buyer’s right to seek specific performance shall not be conditioned on or affected by the availability of the Seller Termination Fee.
(iii) Expense Reimbursement. In the event that this Agreement is terminated pursuant to Section 9.1(d), or is terminated pursuant to any other subsection of Section 9.1 and at the time of such termination, Buyer could have terminated this Agreement under Section 9.1(d), Seller shall reimburse Buyer for all documented and reasonable out-of-pocket expenses (including legal fees) incurred by Buyer in connection with this Agreement and the Transactions (the “Expense Reimbursement”); provided, that such reimbursement shall not exceed $2,500,000 in the aggregate. Within two (2) Business Days following such termination, Seller shall pay to Buyer (or its designee) the aggregate amount of such expenses by wire transfer of immediately available funds to an account or accounts designated in writing by Buyer. In no event shall Buyer be required to disclose any information subject to the attorney-client or similar privilege (including narrative time entries) in connection with seeking or obtaining the Expense Reimbursement hereunder; provided, that for all documented and reasonable out-of-pocket expense amounts sought or obtained in connection with the Expense Reimbursement, Buyer shall deliver to Seller a reasonably satisfactory statement or statements, including a summary of any invoices received by Buyer, which such summary may be redacted as necessary to avoid the waiver of any privilege accorded by applicable Law.
97
Article
X
GENERAL PROVISIONS
Section 10.1 Fees and Expenses. Except as otherwise provided herein, all fees and expenses incurred in connection with or related to this Agreement and the Ancillary Agreements and the Transactions shall be paid by the party hereto incurring such fees or expenses, whether or not such Transactions are consummated.
Section 10.2 Amendment and Modification. This Agreement may not be amended, modified or supplemented in any manner, whether by course of conduct or otherwise, except by an instrument in writing specifically designated as an amendment hereto, signed on behalf of each party. Notwithstanding the foregoing, no amendment, modification, supplement or waiver of any Financing Source Provision (or of any other provision of this Agreement to the extent such amendment, modification, supplement or waiver would modify the substance of any Financing Source Provision) that is adverse to any Financing Source or Financing Source Related Party shall be effective without the prior written consent of the collateral agent under the Loan Agreement (acting at the direction of the requisite lenders thereunder).
Section 10.3 Waiver; Extension. Seller, on the one hand, and Buyer, on the other hand, may (a) extend the time for performance of any of the obligations or other acts of the other party contained herein, (b) waive any inaccuracies in the representations and warranties of the other party contained herein or in any document, certificate or writing delivered by such party pursuant hereto, or (c) waive compliance by the other party with any of the agreements or conditions contained herein. Any agreement on the part of any party hereto to any such extension or waiver shall be valid only if set forth in a written agreement signed on behalf of such party. No failure or delay of either party in exercising any right or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right or power, or any abandonment or discontinuance of steps to enforce such right or power, or any course of conduct, preclude any other or further exercise thereof or the exercise of any other right or power. Any agreement on the part of either party hereto to any such waiver shall be valid only if set forth in a written instrument executed and delivered by a duly authorized officer on behalf of such party. Notwithstanding the foregoing, no waiver of any Financing Source Provision (or of any other provision of this Agreement to the extent such waiver would modify the substance of any Financing Source Provision) that is adverse to any Financing Source or Financing Source Related Party shall be effective without the prior written consent of the collateral agent under the Loan Agreement (acting at the direction of the requisite lenders thereunder).
98
Section 10.4 Notices. All notices, requests, consents, claims, demands, waivers and other communications hereunder shall be in writing and shall be deemed to have been given (a) when delivered by hand (with proof of delivery); (b) when received by the addressee if sent by a nationally recognized overnight courier (receipt requested); or (c) on the date sent by e-mail (notice deemed given upon transmission so long as there is no return error message or other notification of non-delivery received by the sender) if sent during normal business hours of the recipient, and on the next Business Day if sent after normal business hours of the recipient. Such communications must be sent to the respective parties at the following addresses (or at such other address for a party as shall be specified in a notice given in accordance with this Section 10.4):
(i) if to Seller, to:
Heron Therapeutics, Inc.
25 Fenton Main Street, Suite 300
Cary, NC 27511
| Attention: | General Counsel | |
| Email: | [***] |
with a copy (which shall not constitute notice) to:
DLA Piper LLP (US)
51 John F. Kennedy Parkway, Suite 120
Short Hills, New Jersey 07078-2704
| Attention: | Andrew P. Gilbert | |
| Jeffrey Scharfstein, P.C. | ||
| Carina Meleca | ||
| E-mail: | [***] |
(ii) if to Buyer, to:
CorMedix Inc.
389 Interpace Pkwy, Suite 450
Parsippany, New Jersey 07054
| Attention: | Joseph Todisco | |
| Beth Zelnick Kaufman | ||
| Email: | [***] |
with a copy (which shall not constitute notice) to:
Willkie Farr & Gallagher LLP
787 7th Avenue
New York, New York 10019
| Attention: | Jared Fertman | |
| Andrew Marmer | ||
| Email: | [***] |
99
Section 10.5 Interpretation. For purposes of this Agreement and any Ancillary Agreement, whenever the context requires: (a) the singular number shall include the plural, and vice versa; (b) the masculine gender shall include the feminine and neuter genders; (c) the feminine gender shall include the masculine and neuter genders; and (d) the neuter gender shall include the masculine and feminine genders. The parties hereto agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting party shall not be applied in the construction or interpretation of this Agreement. As used in this Agreement and the Ancillary Agreements, (i) the words “include” and “including,” and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words “without limitation,” (ii) the word “extent” in the phrase “to the extent” shall mean the degree to which a subject or other thing extends, and such phrase shall not mean simply “if,” (iii) the word “or” shall not be exclusive, (iv) the word “will” shall be construed to have the same meaning as the word “shall” and (v) the words “herein,” “hereof” and “hereunder,” and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof. Except as otherwise indicated, all references in this Agreement to “Sections” and “Exhibits” are intended to refer to Sections of this Agreement and Exhibits to this Agreement. The headings contained in this Agreement and in the table of contents to this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. The phrases “made available to,” “provided to,” “furnished to,” by Seller, and phrases of similar import when used in this Agreement, unless the context otherwise requires, mean that a copy of the information or material referred to (i) has been provided by Seller to Buyer, including by means of being provided for review in the electronic data room hosted by Seller in connection with the Transactions (the “Electronic Data Room”), in connection with this Agreement or (ii) has been filed by Seller in the Electronic Data Gathering, Analysis, and Retrieval (EDGAR) Database for the SEC. When calculating the period of time before which, within which or after which any act is to be done or step taken pursuant to this Agreement, (i) the date that is the reference date in calculating such period shall be excluded and (ii) if the last day of such period is not a Business Day, the period in question shall end on the next succeeding Business Day. All references in this Agreement to a number of days are to such number of calendar days unless Business Days are specified. Unless otherwise specifically indicated, any reference in this Agreement or any Ancillary Agreement to $ means U.S. dollars. References to a Person are also to its permitted successors and assigns.
Section 10.6 Entire Agreement. This Agreement (including the Exhibits and Schedules hereto), the Ancillary Agreements and the Confidentiality Agreement constitute the entire agreement, and supersede all prior written agreements, arrangements, communications and understandings and all prior and contemporaneous oral agreements, arrangements, communications and understandings between the parties hereto with respect to the subject matter hereof and thereof. Neither this Agreement nor any Ancillary Agreement shall be deemed to contain or imply any restriction, covenant, representation, warranty, agreement or undertaking of any party with respect to the Transactions other than those expressly set forth herein or therein or in any document required to be delivered hereunder or thereunder and none shall be deemed to exist or be inferred with respect to the subject matter hereof.
Section 10.7 Parties in Interest. This Agreement shall be binding upon and inure solely to the benefit of each party hereto, and nothing in this Agreement, express or implied, is intended to or shall confer upon any Person other than the parties hereto and their respective successors and permitted assigns any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Agreement, except (i) with respect to the provisions of Article VIII, which shall inure to the benefit of the Indemnified Parties who are intended to be third-party beneficiaries thereof, (ii) the provisions of Section 5.15 and Section 5.17, which shall inure to the benefit of the Affiliates of Seller who are intended to be third-party beneficiaries thereof, and (iii) the Financing Source Provisions, which shall inure to the benefit of, and be enforceable by, the Financing Sources and Financing Source Related Parties, who are intended to be third-party beneficiaries thereof.
100
Section 10.8 Governing Law; Jurisdiction; Waiver of Jury Trial. Except as otherwise provided in Section 10.17, this Agreement and all disputes or controversies arising out of or relating to this Agreement or the Transactions shall be governed by, and construed in accordance with, the internal laws of the State of Delaware, without regard to the laws of any other jurisdiction that might be applied because of the conflicts of laws principles of the State of Delaware or any other jurisdiction.
(a) EXCEPT AS OTHERWISE PROVIDED IN SECTION 10.17, THIS AGREEMENT SHALL BE DEEMED TO BE MADE AND ALL CLAIMS OR CAUSES OF ACTION (WHETHER IN CONTRACT OR TORT) THAT MAY BE BASED UPON, ARISE OUT OF OR RELATE TO THIS AGREEMENT, OR THE NEGOTIATION, EXECUTION OR PERFORMANCE OF THIS AGREEMENT OR THE ASSET SALE, SHALL BE INTERPRETED, CONSTRUED AND GOVERNED IN ALL RESPECTS BY AND IN ACCORDANCE WITH THE LAWS OF THE STATE OF DELAWARE, REGARDLESS OF THE LAWS THAT MIGHT OTHERWISE GOVERN UNDER APPLICABLE CONFLICTS OF LAW PRINCIPLES. The parties hereto hereby irrevocably submit to the personal jurisdiction of the Court of Chancery of the State of Delaware or, if such Court of Chancery shall lack subject matter jurisdiction, the federal courts of the United States of America located in the County of New Castle, Delaware, solely in respect of the interpretation and enforcement of the provisions of (and any claim or cause of action arising under or relating to) this Agreement and of the documents referred to in this Agreement, and in respect of the Transactions, and hereby waive, and agree not to assert, as a defense in any action, suit or proceeding for the interpretation or enforcement hereof or of any such document, that it is not subject thereto or that such action, suit or proceeding may not be brought or is not maintainable in said courts or that the venue thereof may not be appropriate or that this Agreement or any such document may not be enforced in or by such courts, and the parties hereto irrevocably agree that all claims relating to such action, suit or proceeding shall be heard and determined in such courts. The parties hereto hereby consent to and grant any such court jurisdiction over the person of such parties and, to the extent permitted by Law, over the subject matter of such dispute and agree that mailing of process or other papers in connection with any such action, suit or proceeding in the manner provided in Section 10.4 or in such other manner as may be permitted by Law shall be valid and sufficient service thereof.
(b) EXCEPT AS OTHERWISE PROVIDED IN SECTION 10.17, EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES TO THE FULLEST EXTENT PERMITTED BY LAW ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY ACTION, SUIT OR PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE ANCILLARY AGREEMENTS, OR THE TRANSACTIONS. EACH PARTY HEREBY CERTIFIES AND ACKNOWLEDGES THAT (i) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF ANY ACTION, SUIT OR PROCEEDING, SEEK TO ENFORCE THE FOREGOING WAIVER, (ii) EACH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (iii) EACH PARTY MAKES THIS WAIVER VOLUNTARILY AND (iv) EACH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE TRANSACTIONS BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS CONTAINED IN THIS SECTION 10.8.
101
(c) The parties hereto agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy would occur in the event that the parties hereto do not perform the provisions of this Agreement (including any party hereto failing to take such actions as are required of it hereunder in order to consummate this Agreement) in accordance with its specified terms or otherwise breach such provisions. The parties hereto acknowledge and agree that: (i) the parties hereto will be entitled, in addition to any other remedy to which they are entitled at law or in equity, to an injunction, specific performance and other equitable relief to prevent breaches (or threatened breaches) of this Agreement and to enforce specifically the terms and provisions hereof; (ii) the provisions of Section 9.3 are not intended to and do not adequately compensate the parties hereto for the harm that would result from a breach of this Agreement, and will not be construed to diminish or otherwise impair in any respect any party’s right to an injunction, specific performance and other equitable relief; and (iii) the right to an injunction, specific enforcement and other equitable relief is an integral part of the Transactions and without that right, none of the parties hereto would have entered into this Agreement.
(d) The parties hereto hereby agree not to raise any objections to the availability of the equitable remedy of specific performance to prevent or restrain breaches or threatened breaches of this Agreement by any party hereto, and to specifically enforce the terms and provisions of this Agreement to prevent breaches or threatened breaches of, or to enforce compliance with, the covenants and obligations of any party under this Agreement. Any party hereto seeking an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement will not be required to provide any bond or other security in connection with such injunction or enforcement, and each party hereto irrevocably waives any right that it may have to require the obtaining, furnishing or posting of any such bond or other security. The parties hereto further agree that (i) by seeking the remedies provided for in this Section 10.8, a party hereto shall not in any respect waive its right to seek any other form of relief that may be available to a party under this Agreement in the event that this Agreement has been terminated or in the event that the remedies provided for in this Section 10.8 are not available or otherwise are not granted, and (ii) nothing set forth in this Section 10.8 shall require any party hereto to institute any proceeding for (or limit any party’s right to institute any proceeding for) specific performance under this Section 10.8 prior or as a condition to exercising any termination right under Article IX (and pursuing damages after such termination), nor shall the commencement of any Action pursuant to this Section 10.8 or anything set forth in this Section 10.8 restrict or limit any party’s right to terminate this Agreement in accordance with the terms of Article IX or pursue any other remedies under this Agreement that may be available then or thereafter; provided, that under no circumstances will Buyer be permitted or entitled to receive both a grant of injunction, specific performance or other equitable remedy to consummate the Closing on the one hand, and payment of any amount pursuant to Section 9.3 (whether in the form of money damages or the Seller Termination Fee), on the other hand; provided, further, that, notwithstanding anything to the contrary in this Section 10.8 or in Section 10.13, no party shall be entitled to specific performance or other equitable relief against any Financing Source or Financing Source Related Party, as provided in Section 10.17.
102
(e) Notwithstanding anything to the contrary in this Agreement, to the extent any party hereto brings an action, suit or proceeding to enforce specifically the performance of the terms and provisions of this Agreement (other than an action to specifically enforce any provision that expressly survives termination of this Agreement) when expressly available to such party pursuant to the terms of this Agreement, the Termination Date shall automatically be extended (if it would otherwise have passed) to (i) the twentieth (20th) Business Day following the resolution of such action, suit or proceeding, or (ii) such other time period established by the court presiding over such action, suit or proceeding.
Section 10.9 Non-Reliance.
(a) Each of the Buyer Parties hereby acknowledges and agrees (each for itself and on behalf of its Affiliates and Representatives) that, as of the Agreement Date, each Buyer Party and their respective Affiliates and Representatives (i) have received full access to (A) such books and records, facilities, equipment, contracts and other assets of the Seller Group that each Buyer Party and their respective Affiliates and Representatives, as of the Agreement Date, have requested to review and (B) the Electronic Data Room, and (ii) have had the full opportunity to meet with the management of Seller and to discuss the Business, the Transferred Assets, the Assumed Liabilities and the Transactions.
(b) In connection with the due diligence investigation of Seller, the Business, the Transferred Assets, the Assumed Liabilities and the Transactions by the Buyer Parties and their respective Affiliates and Representatives, the Buyer Parties and their respective Affiliates and Representatives have received and may continue to receive after the Agreement Date from the Seller Parties and their respective Representatives certain estimates, projections, forecasts and other forward-looking information, as well as certain business plan information, regarding Seller, the Business, the Transferred Assets, and the Assumed Liabilities. Each Buyer Party hereby acknowledges and agrees that: (i) there are uncertainties inherent in attempting to make such estimates, projections, forecasts and other forward-looking statements, as well as in such business plans, with which the Buyer Parties are familiar; and (ii) the Buyer Parties are taking full responsibility for making their own evaluation of the adequacy and accuracy of all estimates, projections, forecasts and other forward-looking information, as well as such business plans, so furnished to them (including the reasonableness of the assumptions underlying such estimates, projections, forecasts, forward-looking information or business plans). Accordingly, the Buyer Parties hereby acknowledge and agree that no Seller Party or member of the Seller Group, or any of their respective Affiliates or Representatives, has made or is making any express or implied representation or warranty with respect to such estimates, projections, forecasts, forward-looking statements or business plans (including the reasonableness of the assumptions underlying such estimates, projections, forecasts, forward-looking statements or business plans).
(c) Except as and only to the extent expressly set forth in the representations and warranties made by Seller and contained in Article III, the Buyer Parties hereby acknowledge and agree that none of the Seller Parties, nor any of their respective Affiliates or Representatives or any other Person, has made or is making any other express or implied representation or warranty with respect to any Seller Party, the Business, the Transferred Assets or the Assumed Liabilities, including with respect to any information provided or made available to the Buyer Parties or any of their respective Affiliates or Representatives or any other Person. In addition, and notwithstanding anything herein to the contrary, the Buyer Parties hereby acknowledge and agree that none of the Seller Parties, nor any of their respective Affiliates or Representatives or any other Person, has made or is making any other express or implied representation or warranty with respect to the Excluded Assets or Excluded Liabilities.
103
(d) Except as and only to the extent expressly set forth in the representations and warranties made by Buyer and contained in Article IV, the Seller Parties hereby acknowledge and agree that none of the Buyer Parties, nor any of their respective Affiliates or Representatives or any other Person, has made or is making any other express or implied representation or warranty with respect to any Buyer Party, the Business, the Transferred Assets or the Assumed Liabilities, including with respect to any information provided or made available to the Seller Parties or any of their respective Affiliates or Representatives or any other Person.
Section 10.10 Disclosure Generally. Notwithstanding anything to the contrary contained in the Disclosure Schedules or in this Agreement, the information and disclosures contained in any Disclosure Schedule shall be deemed to be disclosed and incorporated by reference in any other Disclosure Schedule as though fully set forth in such Disclosure Schedule for which applicability of such information and disclosure is reasonably apparent on its face. The fact that any item of information is disclosed in any Disclosure Schedule shall not be construed to mean that such information is required to be disclosed by this Agreement. Such information and the dollar thresholds set forth herein shall not be used as a basis for interpreting the terms “material” or “Material Adverse Effect” or other similar terms in this Agreement.
Section 10.11 Personal Liability. This Agreement shall not create or be deemed to create or permit any personal Liability or obligation on the part of any direct or indirect stockholder of Seller or Buyer, any Financing Source or Financing Source Related Party, or any officer, director, employee, Representative or investor of either party hereto.
Section 10.12 Assignment; Successors. Neither this Agreement nor any of the rights, interests or obligations under this Agreement may be assigned or delegated, in whole or in part, by operation of law or otherwise, by either party without the prior written consent of the other party; provided, that Buyer may, with Seller’s consent (which consent shall not be unreasonably withheld, conditioned or delayed), (i) assign its rights, but not its obligations, under this Agreement, in whole or in part, to any Affiliate of Buyer and (ii) collaterally assign any or all of its rights and interests hereunder to one or more Financing Sources (including the collateral agent under the Loan Agreement), and following the Closing, any Financing Source may exercise such rights and interests in connection with the exercise of remedies under the Loan Agreement; provided, further, that no such assignment shall relieve Buyer of its obligations hereunder. Subject to the preceding sentence, this Agreement will be binding upon, inure to the benefit of, and be enforceable by, the parties hereto and their respective successors and assigns.
Section 10.13 Enforcement. Subject to Section 10.17, the parties hereto agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. Accordingly, each of the parties hereto shall be entitled to specific performance of the terms hereof, including an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement, this being in addition to any other remedy to which such party is entitled at law or in equity. Each of the parties hereto hereby further waives (a) any defense in any action for specific performance that a remedy at law would be adequate and (b) any requirement under any law to post security as a prerequisite to obtaining equitable relief.
104
Section 10.14 Severability. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the parties hereto agree that the court making such determination shall have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the parties hereto agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision.
Section 10.15 Counterparts; Signatures. This Agreement may be executed in one (1) or more counterparts, each of which shall be deemed an original but all of which together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each of the parties hereto and delivered to the other party, it being understood that the parties hereto need not sign the same counterpart. This Agreement may be executed and delivered by facsimile transmission, by electronic mail in “portable document format” (“.pdf”) form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, or by combination of such means.
Section 10.16 Conflicts; Privilege. Recognizing that DLA Piper LLP (US) (together with the various separate and distinct legal entities through which the global law firm DLA Piper operates, “DLA Piper”) has acted as legal counsel to the Seller Parties and their respective Affiliates, and that DLA Piper intends to act as legal counsel to Seller and its Affiliates after the Closing, Buyer hereby waives, on its own behalf and agrees to cause its Affiliates to waive, any conflicts that may arise in connection with DLA Piper representing any Seller Party or its Affiliates prior to the Closing or after the Closing as such representation may relate to any Seller Party and its Affiliates or the Transactions. In addition, all attorney-client privilege, attorney work-product protections and other privilege or protection held by any Seller Party and its Affiliates prior to the Closing (collectively, the “Legal Privileges and Protection”), including those in connection with legal advice rendered to any Seller Party and its Affiliates or concerning the Transactions, this Agreement or any Ancillary Agreement, shall be deemed to be attorney-client confidences that belong solely to the Seller Parties and their Affiliates. Accordingly, each Buyer Party and its Affiliates shall not control the privilege with respect to any such communications or their access to the files of DLA Piper relating to such engagement from and after the Closing. Notwithstanding the foregoing, and with regard to both extant litigation or other disputes with third parties as well as any future other such litigation or disputes that relate to the Assumed Liabilities or Transferred Assets, Buyer and Seller recognize that a common interest currently exists and shall exist between themselves as against any such third party, such that Buyer and Seller may confidentially communicate and preserve, and do not waive, any privilege or protection (including the attorney-client privilege, work-product protections, taxpayer-advisor privilege or other privilege or protection) as against such third party. Seller and Buyer agree to cooperate to ensure that privileges and protections are maintained and, to the extent that they may be at risk, to communicate necessary information through another method to minimize potential risk to such privileges and protections. Such future cooperation may include Buyer and Seller entering into a separate common interest agreement memorializing the currently recognized and extant common interest as set forth above.
105
Section 10.17 Financing Sources. Notwithstanding anything in this Agreement or any Ancillary Agreement to the contrary, each of the parties hereto, on behalf of itself and its Affiliates and its and their respective Representatives (and, in the case of Seller, on behalf of each Seller Party and the Seller Indemnified Parties), hereby: (a) agrees that none of the Financing Sources or Financing Source Related Parties shall have any liability or obligation (whether in contract, tort, equity or otherwise, and whether at law or in equity) to Seller, any Seller Party or any of their respective Affiliates, equityholders or Representatives relating to or arising out of this Agreement, any Ancillary Agreement, the Debt Financing, the Loan Agreement or any of the transactions contemplated hereby or thereby, or the performance of any services thereunder, and Seller, on behalf of itself and each other Seller Party and their respective Affiliates, equityholders and Representatives, hereby waives, releases and agrees not to assert any and all such rights, claims, causes of action and remedies against any Financing Source or Financing Source Related Party; (b) agrees that any claim, action, suit, cause of action or proceeding of any kind or description, whether at law or in equity, whether in contract, tort or otherwise, involving any Financing Source or Financing Source Related Party arising out of or relating to this Agreement, the Debt Financing, the Loan Agreement or any of the transactions contemplated hereby or thereby, or the performance of any services thereunder, shall be subject to the exclusive jurisdiction of any state court of the State of New York sitting in the Borough of Manhattan, New York County, or of the United States District Court for the Southern District of New York (and, in each case, any appellate court thereof), and each party hereto irrevocably submits itself and its property to the exclusive jurisdiction of such courts with respect to any such claim, action, suit, cause of action or proceeding, and agrees that it will not bring or support any such claim, action, suit, cause of action or proceeding in any other court; (c) agrees that any such claim, action, suit, cause of action or proceeding described in clause (b) above shall be governed by, and construed in accordance with, the laws of the State of New York, without regard to any conflict of laws principles that would result in the application of the laws of another jurisdiction (except as otherwise expressly provided in the Loan Agreement); (d) KNOWINGLY, INTENTIONALLY AND VOLUNTARILY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY CLAIM, ACTION, SUIT, CAUSE OF ACTION OR PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE DEBT FINANCING, THE LOAN AGREEMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY, OR THE PERFORMANCE OF ANY SERVICES THEREUNDER, IN EACH CASE, INVOLVING ANY FINANCING SOURCE OR FINANCING SOURCE RELATED PARTY; (e) agrees that service of process upon Seller or any Seller Party in any such claim, action, suit, cause of action or proceeding shall be effective if notice is given in accordance with Section 10.4; (f) agrees that (i) no Financing Source or Financing Source Related Party shall be subject to any special, consequential, punitive, indirect or exemplary damages, or damages of a tortious nature, in connection with the foregoing, and (ii) none of Seller, any Seller Party or any of their respective Affiliates shall be entitled to seek or obtain specific performance, injunctive relief or any other equitable remedy against any Financing Source or Financing Source Related Party, or to cause Buyer or any of its Affiliates to enforce, or seek to enforce, any of their rights against any Financing Source under the Loan Agreement or otherwise in connection with the Debt Financing; (g) agrees that the Financing Sources and Financing Source Related Parties are express third-party beneficiaries of, and may rely upon and enforce, this Section 10.17, Section 9.2 (solely to the extent relating to this Section 10.17), Section 10.2, Section 10.3, Section 10.7, Section 10.11 and Section 10.12, in each case, solely to the extent relating to the Financing Sources or Financing Source Related Parties, and the related definitions (collectively, the “Financing Source Provisions”); and (h) agrees that the Financing Source Provisions (and any other provision of this Agreement to the extent an amendment, waiver or other modification of such provision would modify the substance of any Financing Source Provision) may not be amended, waived, supplemented or otherwise modified in any manner adverse to any Financing Source or Financing Source Related Party without the prior written consent of the collateral agent under the Loan Agreement (acting at the direction of the requisite lenders thereunder). Notwithstanding the foregoing, nothing in this Section 10.17 shall (x) limit or modify the rights and obligations of Buyer or any of its Affiliates under the Loan Agreement or any other agreement with any Financing Source, or the rights of any Financing Source against Buyer or any of its Affiliates thereunder, or (y) limit any party’s rights or remedies against Buyer under this Agreement.
[The remainder of this page is intentionally left blank.]
106
IN WITNESS WHEREOF, Seller and Buyer have caused this Agreement to be executed as of the date first written above by their respective officers thereunto duly authorized.
| CORMEDIX INC. | ||
| By: | /s/ Joseph Todisco | |
| Name: | Joseph Todisco | |
| Title: | Chief Executive Officer | |
[Signature Page to Asset Purchase Agreement]
IN WITNESS WHEREOF, Seller and Buyer have caused this Agreement to be executed as of the date first written above by their respective officers thereunto duly authorized.
| HERON THERAPEUTICS, INC. | ||
| By: | /s/ Craig Collard | |
| Name: | Craig Collard | |
| Title: | Chief Executive Officer | |
[Signature Page to Asset Purchase Agreement]
EXHIBIT A
Form of Bill of Sale and Assignment and Assumption Agreement
[Omitted]
A-1
EXHIBIT B
Form of Intellectual Property Assignment Agreement
[Omitted]
B-1
EXHIBIT C
Form of Registration Rights Agreement
[See attached]
Final Form
REGISTRATION RIGHTS AGREEMENT
REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of [●] by and among CorMedix Inc., a Delaware corporation (the “Company”), Heron Therapeutics, Inc., a Delaware corporation (“Heron” or the “Initial Holder”), Rubric Capital Management LP, a Delaware limited partnership (“Rubric”), and each other Holder (as defined below) from time to time signatory hereto.
WHEREAS:
A. In accordance with the Asset Purchase Agreement, dated as of November 8, 2026 (as the same may be amended, restated, amended and restated or otherwise modified from time to time, the “Asset Purchase Agreement”), by and between the Company and Heron, the Company issued (or will issue, by book-entry credit through the Company’s transfer agent) to the Initial Holder an aggregate of 14,583,333 shares (consisting of the Stock Consideration issued to Heron) (the “APA Shares”) of the common stock, par value $0.001 per share (“Common Stock”), of the Company.
B. In connection with the Asset Purchase Agreement, Heron will transfer to Rubric, in accordance with the terms of that certain Exchange Agreement, dated as of November 8, 2026 (the “Exchange Agreement”), by and between Heron and Rubric, such number of shares of the Stock Consideration as set forth in the Exchange Agreement, consisting of shares of Common Stock, in full satisfaction and discharge of all indebtedness and other obligations owed by Heron and any other Seller Party to Rubric (the “Rubric Stock Consideration”), including under that certain Note Purchase Agreement, dated as of August 8, 2025, by and among Heron, the purchasers from time to time party thereto (the “Purchasers”) and Rubric, as agent for the Purchasers (as it may be amended from time to time).
C. In order to induce Heron to enter into the Asset Purchase Agreement and Rubric to deliver the Rubric Payoff Letter (as defined in the Exchange Agreement) and accept the Rubric Stock Consideration in full satisfaction of the Rubric Payoff, and as a condition to the consummation of the transactions contemplated by the Asset Purchase Agreement, the Company has agreed to provide certain registration rights under the Securities Act of 1933, as amended, and the rules and regulations thereunder, or any similar successor statute (collectively, the “Securities Act”), and applicable state securities laws.
NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company, the Initial Holder and Rubric hereby agree as follows:
1. DEFINITIONS.
a. As used in this Agreement, the following terms shall have the following meanings (all capitalized terms used and not otherwise defined herein having the respective meanings set forth in the Asset Purchase Agreement):
(i) “Additional Filing Deadline” means, with respect to any Registration Statements that may be required pursuant to Section 2(a)(ii), (A) the thirtieth (30th) day following the first date on which such Registrable Securities may then be included in a Registration Statement if such Registration Statement is required to be filed because the United States Securities and Exchange Commission (the “SEC”) shall have notified the Company in writing that certain Registrable Securities were not eligible for inclusion in a previously filed Registration Statement, or (B) if such additional Registration Statement is required for a reason other than as described in (A) above, the thirtieth (30th) day following the date on which the Company first knows that such additional Registration Statement is required.
(ii) “Applicable Securities Laws” means all applicable securities laws in all jurisdictions relevant to the Company, the Company’s securities or the issuance of securities of the Company pursuant to the terms of this Agreement, including but not limited to, the Securities Act, the Exchange Act, and the rules, regulations and policies of the SEC and the Nasdaq Global Market.
C-1
(iii) “Business Day” means any day, except a Saturday, Sunday or legal holiday, on which banking institutions in the city of New York, New York are authorized or obligated by law or executive order to close; provided, however, for clarification, banking institutions shall not be deemed to be authorized or obligated by law or executive order to remain closed so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in the city of New York, New York generally are open for use by customers on such day.
(iv) “Closing Date” means the date of closing of the transactions contemplated under the Asset Purchase Agreement.
(v) “Exchange Act” means the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated thereunder, and any successor statute.
(vi) “Filing Deadline” for the Registration Statement required pursuant to Section 2(a)(i), means the ninetieth (90th) calendar day following the Closing Date (the “Initial Filing Deadline”), and for each Registration Statement required pursuant to Section 2(a)(ii) means the Additional Filing Deadline.
(vii) “FINRA” means the Financial Industry Regulatory Authority, Inc. (or successor thereto).
(viii) “Holder” means the Initial Holder, Rubric and any transferee or assignee who agrees in writing to become bound by the provisions of this Agreement in accordance with Section 13(f) hereof.
(ix) “Lock-Up” has the meaning set forth in (a) the Seller Governance Agreement, dated as of November 8, 2026, by and between the Company and Heron; and (b) the Stockholder Governance Agreement, dated as of November 8, 2026, by and between the Company and Rubric (collectively, the “Governance Agreements”).
(x) “Lock-Up Period” has the meaning set forth in the Governance Agreements.
(xi) “Person” means and includes any natural person, partnership, joint venture, corporation, trust, limited liability company, limited company, joint stock company, unincorporated organization, government entity or any political subdivision or agency thereof, or any other entity.
(xii) “Prospectus” means (i) any prospectus (preliminary or final) included in any Registration Statement, as may be amended or supplemented by any prospectus supplement with respect to the terms of the offering of any portion of the Registrable Securities covered by such Registration Statement and by all other amendments and supplements to such prospectus, including post-effective amendments, and all material incorporated by reference in such prospectus, and (ii) any “free writing prospectus” as defined in Rule 405 under the Securities Act relating to any offering of Registrable Securities pursuant to a Registration Statement.
(xiii) “Register,” “Registered,” and “Registration” refer to a registration effected by preparing and filing a Registration Statement or Statements in compliance with the Securities Act and pursuant to Rule 415, and such Registration Statement becoming effective under the Securities Act (to the extent required, by declaration or ordering of effectiveness, of such Registration Statement by the SEC).
(xiv) “Registrable Securities” means (a) the APA Shares and (b) any securities issued or issuable upon any stock split, dividend, distribution, recapitalization, reorganization, reclassification or similar event with respect to any of the foregoing; provided that any securities that would otherwise qualify as Registrable Securities but (i) have been sold pursuant to a Registration Statement or pursuant to Rule 144 or (ii) may be immediately sold to the public without registration or restriction (including without limitation as to volume by each holder thereof) and without compliance with any “current public information” requirement, pursuant to Rule 144 under the Securities Act, shall cease to be a “Registrable Security.”
(xv) “Registration Deadline” means, for purposes of any Registration Statement required pursuant to Sections 2(a)(i) and 2(a)(ii), the date that is (x) sixty (60) days after the applicable Filing Deadline or (y) if earlier than the date described in clause (x) of this definition, five (5) Trading Days after the Company is first notified by the SEC that such Registration Statement will not be reviewed or is no longer subject to further review and comment. Any Registration Deadline (or any extension thereof) shall be automatically extended if the Company has, and continues to use, its commercially reasonable efforts to respond to and resolve any comments to the Registration Statement received from the SEC.
C-2
(xvi) “Registration Effective Date” means the date that the first Registration Statement covering the Registrable Securities that the Company is required to file pursuant to this Agreement has been declared effective by the SEC or otherwise become effective under the Securities Act.
(xvii) “Registration Statement(s)” means any registration statement(s) of the Company filed under the Securities Act that covers the resale of any of the Registrable Securities pursuant to the provisions of this Agreement, all amendments and supplements to such Registration Statement, including post-effective amendments, and all exhibits to, and all material incorporated by reference in, such Registration Statement.
(xviii) “Required Holders” means Holders of a majority in interest of then-outstanding Registrable Securities.
(xix) “Restricted Shares” means the APA Shares; provided, that such shares shall cease to be Restricted Shares upon the expiration of the Lock-Up Period or on such earlier date as is provided under the Governance Agreements. For the avoidance of doubt, no shares of Common Stock or any other securities of the Company acquired by any Holder other than pursuant to the Asset Purchase Agreement will be deemed Restricted Shares or subject to the Lock-Up (as defined above).
(xx) “Rule 415” means Rule 415 under the Securities Act or any successor rule providing for the offering of securities on a continuous basis.
(xxi) “Trading Day” means any day on which the Common Stock is traded for any period on the Nasdaq Global Market or, if not the Nasdaq Global Market, the principal securities exchange or other securities market on which the Common Stock is then being traded.
(xxii) “Underwriter” means a securities dealer who purchases any Registrable Securities as principal in an Underwritten Offering and not as part of such dealer’s market-making activities.
(xxiii) “Underwritten Offering” means a Registration in which securities of the Company are sold to an Underwriter in a firm commitment underwriting for distribution to the public.
2. REGISTRATION.
a. MANDATORY REGISTRATION.
(i) Following the date of this Agreement, the Company shall prepare, and, on or prior to the applicable Filing Deadline, file with the SEC a Registration Statement (the “Mandatory Registration Statement”) on Form S-3 (or, if Form S-3 is not then available, on such other form of Registration Statement as is then available to effect a Registration of all of the Registrable Securities, subject to the consent of the Initial Holder, which consent shall not be unreasonably withheld), covering the resale of all of the Registrable Securities, which shall include the total number of the APA Shares, and which shall name the Initial Holder as a selling stockholder therein.
(ii) If for any reason, despite the Company’s use of its commercially reasonable efforts to include all of the Registrable Securities requested or required to be included in any Registration Statement filed pursuant to Section 2(a)(i) (and subject to Section 3(p) below), the SEC does not permit all such Registrable Securities to be included in such Registration Statement, or for any other reason any such Registrable Securities are not then included in a Registration Statement, then the Company shall prepare, and, as soon as practicable but in no event later than the Additional Filing Deadline, file with the SEC an additional Registration Statement on Form S-3 (or, if Form S-3 is not then available, on such form of Registration Statement as is then available to effect a Registration of the Registrable Securities, subject to the consent of the Initial Holder, which consent shall not be unreasonably withheld) covering the resale of all Registrable Securities requested or required to be included in such Registration Statement filed pursuant to Section 2(a)(i) and not already covered by an existing and effective Registration Statement for an offering to be made on a continuous basis pursuant to Rule 415.
C-3
(iii) Subject to any SEC comments, any Registration Statement pursuant to this Section 2(a) shall include a “plan of distribution” approved by the Required Holders of the Registrable Securities to be included in such Registration Statement. No Holder shall be named as an “underwriter” in the Registration Statement without the Holder’s prior written consent. Each Registration Statement (and each amendment or supplement thereto, and each request for acceleration of effectiveness thereof) shall be provided to, and shall be subject to the approval, which shall not be unreasonably withheld or delayed, of the Holders prior to its filing or other submission; provided, that, notwithstanding any other provision in this Agreement, if despite the Company’s compliance with Section 3(p), the SEC or the Securities Act requires such Holder(s) to be named as an “underwriter” in the Registration Statement and such Holder(s) withhold written consent to be so named, the Company’s failure to fulfill its obligations under this Section 2(a) solely as a result thereof shall not constitute a violation of this Agreement.
b. UNDERWRITTEN SHELF TAKEDOWNS.
(i) At any time and from time to time when an effective Registration Statement filed pursuant to Section 2(a) is on file with the SEC, the Holders (each such Holder making such request, the “Demanding Holder” and, collectively, the “Demanding Holders”) may request to sell all or any portion of their Registrable Securities in an Underwritten Offering that is registered pursuant to such Registration Statement (each, an “Underwritten Shelf Takedown”); provided that the Company shall only be obligated to effect an Underwritten Shelf Takedown if such offering shall include Registrable Securities proposed to be sold by the Demanding Holders, with a total offering price reasonably expected to exceed, in the aggregate, $30 million (the “Minimum Takedown Threshold”). Notwithstanding the foregoing, if the Demanding Holders cannot use the Registration Statement filed pursuant to Section 2(a) to effect an Underwritten Shelf Takedown, then the Company and such Demanding Holders will work together in good faith to (A) file a new Registration Statement or (B) amend or supplement the Registration Statement filed pursuant to Section 2(a), in each case in a form approved by the Company (such approval not to be unreasonably withheld, conditioned or delayed).
(ii) All requests for Underwritten Shelf Takedowns shall be made by giving written notice to the Company, specifying the approximate number of Registrable Securities proposed to be sold in the Underwritten Shelf Takedown. The Company shall, within three (3) Business Days after receipt of such request, give written notice of the proposed Underwritten Shelf Takedown to all of the other Holders, which notice shall offer to such Holders the opportunity to include in such registered offering such number of Registrable Securities as such Holders may request in writing within three (3) Business Days after receipt of such written notice (with each Holder requesting inclusion in such Underwritten Shelf Takedown, a “Requesting Holder”).
(iii) The Demanding Holders shall have the right to select the lead managing Underwriter for such offering (which shall consist of one or more reputable nationally recognized investment banks), subject to the Company’s prior approval (which shall not be unreasonably withheld, conditioned or delayed). The Company shall have the right to select any co-managing Underwriters for such offering, subject to the Demanding Holders’ prior approval (which shall not be unreasonably withheld, conditioned or delayed). In no event shall the Company be required, in connection with any Underwritten Shelf Takedown, to agree to any lock-up or similar restriction on the offer or sale of its securities for a period in excess of sixty (60) days following the pricing of such Underwritten Shelf Takedown, and any such restriction shall be subject to customary exceptions, including for issuances under equity incentive plans, issuances in connection with mergers, acquisitions, collaborations or other strategic transactions, and the filing of registration statements on Form S-4 or Form S-8.
(iv) Subject to Section 2(d), the Holders may demand not more than two (2) Underwritten Shelf Takedowns or Block Trades, taken together, in any twelve (12) month period and not more than four (4) Underwritten Shelf Takedowns and Block Trades, taken together, in the aggregate (collectively, the “Limit”); provided, however, that (A) any Underwritten Shelf Takedown that is not consummated for any reason other than the voluntary withdrawal by the Demanding Holders (without cause attributable to the Company or its Underwriters) shall not count against the Limit, and (B) if the Holders are unable to sell at least 50% of the Registrable Securities requested to be included in an Underwritten Shelf Takedown due to a cutback pursuant to Section 2(b)(v), such Underwritten Shelf Takedown shall not count against the Limit.
C-4
(v) If the managing Underwriter or Underwriters in an Underwritten Shelf Takedown, in good faith, advise the Company, the Demanding Holders and the Requesting Holders (if any) that the dollar amount or number of Registrable Securities that the Demanding Holders and the Requesting Holders (if any) desire to sell, taken together with all other shares of Common Stock or other equity securities that the Company desires to sell and all other shares of Common Stock or other equity securities, if any, that have been requested to be sold in such Underwritten Offering pursuant to separate written contractual piggyback registration rights held by any other stockholders, exceeds the maximum dollar amount or maximum number of equity securities that can be sold in the Underwritten Offering without adversely affecting the proposed offering price, the timing, the distribution method, or the probability of success of such offering (such maximum dollar amount or maximum number of such securities, as applicable, the “Maximum Number of Securities”), then the Company shall include in such Underwritten Offering, before including any shares of Common Stock or other equity securities proposed to be sold by the Company or by other holders of shares of Common Stock or other equity securities, the Registrable Securities of the Demanding Holders and Requesting Holders (pro rata based on the respective number of Registrable Securities that each such Holder has requested be included in such Underwritten Shelf Takedown) that can be sold without exceeding the Maximum Number of Securities.
(vi) Prior to the filing of the applicable “red herring” Prospectus or any Prospectus supplement used for marketing such Underwritten Shelf Takedown, any Demanding Holder initiating an Underwritten Shelf Takedown shall have the right to withdraw from such Underwritten Shelf Takedown for any or no reason whatsoever upon written notification (a “Withdrawal Notice”) to the Company and the Underwriter or Underwriters (if any) of its intention to withdraw from such Underwritten Shelf Takedown; provided that the Requesting Holders may elect to have the Company continue an Underwritten Shelf Takedown if the Minimum Takedown Threshold would still be satisfied by the Registrable Securities proposed to be sold in the Underwritten Shelf Takedown by the Requesting Holders. If withdrawn, a demand for an Underwritten Shelf Takedown shall constitute a demand for an Underwritten Shelf Takedown by the withdrawing Demanding Holder for purposes of the Limit, unless such withdrawal is the result of a notice delivered pursuant to Section 3(e) or 3(f) or a Grace Period pursuant to Section 3(r). Following the receipt of any Withdrawal Notice, the Company shall promptly forward such Withdrawal Notice to any other Holders that had elected to participate in such Underwritten Shelf Takedown. Notwithstanding anything to the contrary in this Agreement, if a Demanding Holder withdraws from an Underwritten Shelf Takedown pursuant to this Section 2(b)(vi) other than as a result of a notice delivered pursuant to Section 3(e) or 3(f) or a Grace Period pursuant to Section 3(r), the withdrawing Demanding Holder(s) shall reimburse the Company (pro rata based on the respective number of Registrable Securities that each withdrawing Demanding Holder requested be included therein) for the expenses described in Section 6 incurred in connection with such Underwritten Shelf Takedown prior to its withdrawal (unless the Requesting Holders elect to continue such Underwritten Shelf Takedown as provided above); otherwise, the Company shall be responsible for such expenses.
c. BLOCK TRADES. Notwithstanding any other provision of this Section 2, at any time and from time to time when an effective Registration Statement filed pursuant to Section 2(a) is on file with the SEC, if a Demanding Holder wishes to engage in an underwritten registered offering not involving a “roadshow,” an offer commonly known as a “block trade” (a “Block Trade”), with a total offering price reasonably expected to exceed, in the aggregate, the Minimum Takedown Threshold, then such Demanding Holder shall notify the Company of the Block Trade at least five (5) Business Days prior to the day such offering is to commence and the Company shall use its commercially reasonable efforts to facilitate such Block Trade; provided that the Demanding Holders representing a majority of the Registrable Securities wishing to engage in the Block Trade shall use commercially reasonable efforts to work with the Company and any Underwriters prior to making such request in order to facilitate preparation of the Registration Statement, Prospectus and other offering documentation related to the Block Trade. The Company shall give written notice of the proposed Block Trade to all of the other Holders within one (1) Business Day after receipt of the Demanding Holder’s notice, which notice shall offer to such Holders the opportunity to include in such Block Trade such number of Registrable Securities as such Holders may request in writing within one (1) Business Day after receipt of such written notice (with any reductions in such number of securities to be included in such Block Trade to be governed by Section 2(b)(v)). Each Holder agrees to keep confidential the receipt of any notice pursuant to Section 2(b) or this Section 2(c) and the information contained therein until the proposed offering has been publicly announced. Prior to the filing of the applicable “red herring” Prospectus or any Prospectus supplement used in connection with a Block Trade, any Demanding Holder initiating such Block Trade shall have the right to submit a Withdrawal Notice to the Company and the Underwriter or Underwriters (if any) of its intention to withdraw from such Block Trade, and the provisions of Section 2(b)(vi) regarding the counting of withdrawn demands and the reimbursement of expenses shall apply mutatis mutandis to any such withdrawal. The Demanding Holder in a Block Trade shall have the right to select the Underwriters for such Block Trade (which shall consist of one or more reputable nationally recognized investment banks), subject to the Company’s prior approval (which shall not be unreasonably withheld, conditioned or delayed). In no event shall the Company be required, in connection with any Block Trade, to agree to any lock-up or similar restriction on the offer or sale of its securities for a period in excess of thirty (30) days following the pricing of such Block Trade. Any Block Trade effected pursuant to this Section 2(c) shall count toward each of the limitations comprising the Limit and toward the limitations set forth in Section 2(d).
C-5
d. AGGREGATE DEMAND LIMIT; CERTAIN LIMITATIONS. Notwithstanding anything to the contrary in this Agreement, (i) in no event may the number of Block Trades demanded pursuant to Section 2(c) plus the number of Underwritten Shelf Takedowns demanded pursuant to Section 2(b) exceed a total of two (2) demands in any twelve (12) month period, (ii) the Company shall not be obligated to effect any Underwritten Shelf Takedown or Block Trade (A) within ninety (90) days after the pricing of any prior Underwritten Shelf Takedown, Block Trade or underwritten public offering of the Company’s equity securities or (B) during any Allowable Grace Period, and (iii) no Restricted Shares may be included in any Underwritten Shelf Takedown, Block Trade or registration pursuant to Section 2(e) while such shares remain subject to the Lock-Up. Nothing in this Agreement shall permit any transfer of Registrable Securities in violation of the transfer restrictions in the Governance Agreements, and in the event of any conflict between this Agreement and the transfer restrictions contemplated in the Governance Agreements, the Governance Agreements shall control.
e. PIGGYBACK REGISTRATION.
(i) If at any time, or from time to time, the Company shall determine to make an underwritten public offering of its Common Stock for cash (whether pursuant to a newly filed registration statement or a previously filed registration statement), whether or not for its own account (other than (1) a registration statement on Form S-4, Form S-8 or any successor forms, (2) a registration relating solely to employee benefit plans, any dividend or distribution reinvestment plan or any rights offering to the Company’s existing securityholders, (3) a registration relating to an exchange offer or an offering of debt securities or securities convertible into or exchangeable for Common Stock, (4) any “at-the-market” offering, (5) a Registration Statement filed pursuant to Section 2(a), or (6) an Underwritten Shelf Takedown or a Block Trade), the Company will (A) promptly give to the Holders written notice thereof, which notice shall be given, to the extent reasonably practicable, no less than five (5) Business Days prior to the filing or launch date (except in the case of an offering that is an “overnight offering,” in which case such notice must be given no later than one (1) Business Day prior to the filing or launch date); and (B) subject to Section 2(e)(iii), include in such Underwritten Offering (and any related qualification under blue sky laws or other compliance) all the Registrable Securities specified in a written request or requests made within three (3) Business Days (or, in the case of an “overnight offering,” one (1) Business Day) after receipt of such written notice from the Company by the Holders. Each Holder agrees to keep confidential the receipt of any notice pursuant to this Section 2(e) and the information contained therein until the proposed offering has been publicly announced by the Company.
(ii) The right of any Holder to registration pursuant to this Section 2(e) shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of Registrable Securities in the underwriting to the extent provided herein. Each Holder proposing to distribute its securities through such underwriting shall (together with the Company and the other holders distributing their securities through such underwriting) enter into and perform such Holder’s obligations under an underwriting agreement with the managing underwriter selected for such underwriting by the Company or by the stockholders of the Company who have the right to select the underwriters (such underwriting agreement to be in the form negotiated by the Company or such stockholders, as the case may be).
(iii) Notwithstanding any other provision of this Section 2(e), if the managing underwriter or underwriters of a proposed Underwritten Offering with respect to which Holders of Registrable Securities have exercised their piggyback registration rights advise the board of directors of the Company that in its or their opinion the number of Registrable Securities requested to be included in the offering thereby and all other securities proposed to be sold in the offering exceeds the number which can be sold in such Underwritten Offering in light of market conditions, the Registrable Securities and such other securities to be included in such Underwritten Offering shall be allocated, (A) first, (1) in the event such offering was initiated by the Company, up to the total number of securities that the Company has requested to be included in such registration, (2) in the event such offering was initiated by the holders of securities (other than the Holders) who have exercised their demand registration rights, up to the total number of securities that such holders of such securities have requested to be included in such offering, and (3) in the event such offering was initiated by the Holders who have exercised their demand registration rights, up to the total number of securities that such Holders have requested to be included in such offering, (B) second, and only if all the securities referred to in clause (A) have been included, up to the total number of securities that the Holders and other holders of securities that have contractual rights to be included in such registration have requested to be included in such offering (pro rata based upon the number of securities that each of them shall have requested to be included in such offering) and (C) third, and only if all the securities referred to in clause (B) have been included, all other securities proposed to be included in such offering that, in the opinion of the managing underwriter or underwriters, can be sold without having such adverse effect.
C-6
(iv) If any Holder disapproves of the terms of any such underwriting, such Holder may elect to withdraw therefrom by written notice to the Company and the managing underwriter or underwriters. Any securities excluded or withdrawn from such underwriting shall be withdrawn from such registration.
(v) The Company or the holders of securities who have caused a registration statement to be filed as contemplated by this Section 2(e), as the case may be, shall have the right to have any registration initiated by it or them under this Section 2(e) terminated or withdrawn prior to pricing, whether or not any Holder has elected to include securities in such registration.
3. OBLIGATIONS OF THE COMPANY. In connection with any Registration of the Registrable Securities hereunder, the Company shall have the following obligations:
a. The Company shall prepare promptly, and file with the SEC as soon as practicable after such registration obligation arises hereunder (but in no event later than the applicable Filing Deadline), such Registration Statements with respect to the Registrable Securities as provided in Section 2, and thereafter use its commercially reasonable efforts to cause each such Registration Statement relating to Registrable Securities to become effective as soon as possible after such filing, but in any event shall use its commercially reasonable efforts to cause each such Registration Statement relating to Registrable Securities to become effective no later than the applicable Registration Deadline, and shall use its commercially reasonable efforts to keep such Registration Statement current and effective pursuant to Rule 415 at all times after its effective date until the date on which all of the securities included in such Registration Statement no longer constitute Registrable Securities (the “Registration Period”), and shall use its commercially reasonable efforts to ensure that such Registration Statement (including any amendments or supplements thereto and Prospectuses contained therein or related thereto), except for information provided in writing by a Holder pursuant to Section 4(a), does not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein, or necessary to make the statements therein not misleading. In the event that Form S-3 is not available for the registration of the resale of any Registrable Securities hereunder (but, for the avoidance of doubt, without in any way affecting the Company’s obligation to Register the resale of the Registrable Securities on such other form as is available, as provided in Section 2(a)), (i) the Company shall undertake to file, within twenty (20) days of such time as such form is available for such Registration, a post-effective amendment to the Registration Statement then in effect, or otherwise file a Registration Statement on Form S-3, registering such Registrable Securities on Form S-3; provided that the Company shall maintain the effectiveness of the Registration Statement then in effect until such time as a Registration Statement (or post-effective amendment) on Form S-3 covering such Registrable Securities has been declared effective by the SEC, and (ii) the Company shall provide that any Registration Statement on Form S-1 filed hereunder shall incorporate documents by reference (including by way of forward incorporation by reference) to the maximum extent possible. If the Company is a “well-known seasoned issuer” (as defined in Rule 405 under the Securities Act) at the time the Company is requested or required hereunder to file a Registration Statement or amendment to a Registration Statement hereunder (including pursuant to Section 3(b)), the Company shall use its commercially reasonable efforts to file the Registration Statement or amendment as an “automatic shelf registration statement” (as defined in Rule 405 under the Securities Act); provided that nothing in this Agreement shall require the Company to file or maintain an automatic shelf registration statement or to take any action to obtain or maintain its status as a well-known seasoned issuer, and the Company’s obligations hereunder shall be fully satisfied by the filing and effectiveness of a Registration Statement on Form S-3 that is not an automatic shelf registration statement.
C-7
b. The Company shall prepare and file with the SEC such amendments (including post-effective amendments) and supplements to each Registration Statement and the Prospectus used in connection with each Registration Statement as may be necessary to keep each Registration Statement (or, as applicable, another Registration Statement covering the Registrable Securities) current and effective at all times during the Registration Period, and, during the Registration Period, shall comply with the provisions of the Securities Act with respect to the disposition of all Registrable Securities covered by each Registration Statement until such time as all of such Registrable Securities have been disposed of in accordance with the intended methods of disposition by the seller or sellers thereof as set forth in such Registration Statement. In the event that on any Trading Day (the “Registration Trigger Date”) the number of shares available under the Registration Statements filed pursuant to this Agreement is insufficient to cover all of the Registrable Securities, the Company shall amend the Registration Statements, or file a new Registration Statement (on the short form available therefor, if applicable), or both, so as to cover the total number of Registrable Securities so issued or issuable as of the Registration Trigger Date as soon as practicable, but in any event within twenty (20) days after the Registration Trigger Date. The Company shall use its commercially reasonable efforts to cause such amendment and/or new Registration Statement to become effective as soon as practicable following the filing thereof, but in any event the Company shall use commercially reasonable efforts to cause such amendment and/or new Registration Statement to become effective within sixty (60) days of the Registration Trigger Date (or, if earlier, five (5) Trading Days after the Company is first notified by the SEC that such Registration Statement will not be reviewed or is no longer subject to further review and comment) or as promptly as practicable in the event the Company is required to increase its authorized shares.
c. The Company shall furnish to each Holder and Legal Counsel (i) promptly after the same is prepared and publicly distributed, publicly filed with the SEC or received by the Company, one copy of each Registration Statement and any amendment thereto (other than the Company’s filings under the Exchange Act and other than any amendment or supplement to a Registration Statement that is substantially similar to the Company’s filings under the Exchange Act), each preliminary Prospectus and Prospectus and each amendment or supplement thereto, each letter written by or on behalf of the Company to the SEC or the staff of the SEC, and each item of correspondence from the SEC or the staff of the SEC, in each case relating to such Registration Statement (other than any portion thereof which contains information for which the Company has sought or intends to seek confidential treatment or which contains or reflects any material non-public information with respect to the Company or its securities), and (ii) such number of copies of a Prospectus, including a preliminary Prospectus, and all amendments and supplements thereto and such other documents as a Holder may reasonably request in order to facilitate the disposition of the Registrable Securities owned by such Holder; provided that the Company may provide any such copies in electronic form only. The Company will promptly notify each of the Holders by electronic mail of the effectiveness of each Registration Statement or any post-effective amendment thereto. The Company shall use commercially reasonable efforts to promptly respond to any and all comments received from the SEC with respect to any Registration Statement filed pursuant to this Agreement, with a view towards causing each Registration Statement or any amendment thereto to become effective (to the extent required, by declaration or ordering of effectiveness, of such Registration Statement or amendment by the SEC) as soon as practicable, and, as soon as practicable, but in no event later than five (5) Business Days, following the resolution or clearance of all SEC comments or, if applicable, following notification by the SEC that any such Registration Statement or any amendment thereto will not be subject to review, shall file a request for acceleration of effectiveness of such Registration Statement (to the extent required for such Registration Statement or amendment to become effective, by declaration or ordering of effectiveness, of such Registration Statement or amendment by the SEC) to a time and date not later than two (2) Business Days after the submission of such request. No later than one (1) Business Day after the Registration Statement becomes effective, the Company shall file with the SEC the final Prospectus included in the Registration Statement pursuant to Rule 424 (or successor thereto) under the Securities Act.
d. The Company shall use its commercially reasonable efforts to (i) register and qualify, in any jurisdiction where registration and/or qualification is required, the Registrable Securities covered by the Registration Statements under such other securities or “blue sky” laws of such jurisdictions in the United States as the Holders shall reasonably request, (ii) prepare and file in those jurisdictions such amendments (including post-effective amendments) and supplements to such registrations and qualifications as may be reasonably necessary to maintain the effectiveness thereof during the Registration Period, (iii) take such other actions as may be reasonably necessary to maintain such registrations and qualifications in effect at all times during the Registration Period, and (iv) take all other actions reasonably necessary or advisable to qualify the Registrable Securities for sale in such jurisdictions; except that in no event shall the Company be required to qualify to do business as a foreign corporation in any jurisdiction where it would not, but for the requirements of this Section 3(d), be required to be so qualified, to subject itself to taxation in any such jurisdiction or to consent to general service of process in any such jurisdiction, except where the Company is then already required to be so qualified, already subject to taxation or required to consent to general service of process, as applicable.
C-8
e. As promptly as practicable after becoming aware of such event, the Company shall (i) notify each Holder that holds Registrable Securities of the happening of any event, of which the Company has knowledge, as a result of which the Prospectus included in any Registration Statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading, and, subject to Section 3(r), (ii) use its commercially reasonable efforts to promptly prepare a supplement or amendment to any Registration Statement to correct such untrue statement or omission, and (iii) deliver such number of copies of such supplement or amendment to each Holder as such Holder may reasonably request.
f. The Company shall use its commercially reasonable efforts to prevent the issuance of any stop order or other suspension of effectiveness of any Registration Statement and, if such an order is issued, to obtain the withdrawal of such order as promptly as reasonably practicable and to notify each Holder that holds Registrable Securities (and, in the event of an underwritten offering, the managing underwriters) of the issuance of such order and the resolution thereof, in each case as promptly as reasonably practicable.
g. The Company shall permit one outside legal counsel designated by the Holders (which shall be DLA Piper LLP (US) (Attn: [***]) or such other counsel as shall have been designated by the Required Holders) (“Legal Counsel”) to review such Registration Statement and all amendments and supplements thereto (as well as all requests for acceleration or effectiveness thereof but excluding the Company’s filings under the Exchange Act and excluding any amendment or supplement to a Registration Statement that is substantially similar to the Company’s filings under the Exchange Act), a reasonable period of time prior to their filing with the SEC (not less than three (3) Business Days prior to such filing), and the Company shall consider in good faith any reasonable comments of Legal Counsel received within such period; provided that, notwithstanding the foregoing, in no event shall the Company be (i) required to file any document with the SEC which in the view of the Company or its counsel contains any untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make any statement therein not misleading or (ii) prohibited from filing any document with the SEC which the Company or its counsel reasonably believes to be required by law to be so filed.
h. The Company shall hold in confidence and not make any disclosure of information concerning a Holder provided to the Company unless (i) disclosure of such information is necessary to comply with federal or state securities laws or otherwise required in the context of any Registration Statement or offering of securities in which any Holder participates, (ii) the disclosure of such information is necessary to avoid or correct a misstatement or omission in any Registration Statement, (iii) the release of such information is ordered pursuant to a subpoena or other order from a court or governmental body of competent jurisdiction, or (iv) such information has been made generally available to the public other than by disclosure in violation of this Agreement or any other agreement. The Company agrees that it shall, upon learning that disclosure of such information concerning any Holder is sought in or by a court or governmental body of competent jurisdiction or through other means, give prompt notice to such Holder prior to making such disclosure, and allow such Holder, at its expense, to undertake appropriate action to prevent disclosure of, or to obtain a protective order for, such information.
i. The Company shall use its commercially reasonable efforts to cause all the Registrable Securities covered by each Registration Statement to be listed on each securities exchange on which securities of the same class or series issued by the Company are then listed, and to arrange for at least two market makers to register with FINRA as such with respect to such Registrable Securities.
j. The Company shall provide a transfer agent and registrar, which may be a single entity, for the Registrable Securities not later than the effective date of the initial Registration Statement.
C-9
k. The Company shall cooperate with each Holder that holds Registrable Securities being offered to facilitate the timely (i) preparation and delivery of certificates (not bearing any restrictive legends) representing Registrable Securities to be offered pursuant to such Registration Statement, and enable such certificates to be registered in such names and in such denominations or amounts, as the case may be, or (ii) crediting of the Registrable Securities to be offered pursuant to a Registration Statement to the applicable account (or accounts) with The Depository Trust Company (“DTC”) through its Deposit/Withdrawal At Custodian (DWAC) system, in any such case as such Holder may reasonably request.
l. At the reasonable request of a Holder, the Company shall prepare and file with the SEC such amendments (including post-effective amendments) and supplements to a Registration Statement and any Prospectus used in connection with the Registration Statement as may be necessary in order to change the plan of distribution set forth in such Registration Statement, in each case as promptly as is reasonably practicable.
m. The Company shall not, and shall not agree to, allow the holders of any Common Stock or other securities of the Company to include any of their securities (other than Registrable Securities) in any Registration Statement filed pursuant to Section 2(a) or any amendment or supplement thereto under Section 3(b) hereof without the consent of the Required Holders. In addition, the Company shall not include any securities for its own account or the account of others in any Registration Statement filed pursuant to Section 2(a) or any amendment or supplement thereto filed pursuant to Section 3(b) hereof without the consent of the Required Holders.
n. The Company shall comply in all material respects with all applicable laws related to a Registration Statement and offering and sale of securities and all applicable rules and regulations of governmental authorities in connection therewith (including the Securities Act and the Exchange Act and the rules and regulations promulgated by the SEC).
o. If required by the FINRA Corporate Financing Department, the Company shall promptly effect a filing with FINRA pursuant to FINRA Rule 5110 (or successor thereto) with respect to the public offering contemplated by resales of securities under the Registration Statement (an “Issuer Filing”), and pay the filing fee required by such Issuer Filing. The Company shall use its commercially reasonable efforts to pursue the Issuer Filing until FINRA issues a letter confirming that it does not object to the terms of the offering contemplated by the Registration Statement.
p. If at any time the SEC advises the Company in writing that the offering of some or all of the Registrable Securities in a Registration Statement is not eligible to be made on a delayed or continuous basis under the provisions of Rule 415 under the Securities Act, the Company shall use its commercially reasonable efforts to persuade the SEC that the offering contemplated by a Registration Statement is a bona fide secondary offering and not an offering “by or on behalf of the issuer” as defined in Rule 415 and that none of the Holders is an “underwriter.” The Holders shall have the right to participate or have one legal counsel on behalf of all Holders participate in any meetings or discussions with the SEC regarding the SEC’s position and to comment or have their respective counsel comment on any written submission made to the SEC with respect thereto. In the event that, despite the Company’s commercially reasonable efforts and compliance with the terms of this Section 3(p), the SEC refuses to alter its position, the Company shall remove from the Registration Statement such portion of the Registrable Securities as the SEC requires in writing be removed therefrom. Any such cutback imposed by the SEC as contemplated by this Section 3(p) shall be imposed on such Registrable Securities as the Required Holders may elect, on a pro rata basis (based upon the applicable type of Registrable Securities held by each of the Holders), except to the extent otherwise required by the SEC.
q. Subject to the limitations contained herein, the Company shall use its commercially reasonable efforts to take all other reasonable actions arising out of its obligations under this Agreement and necessary to facilitate the disposition by the Holders of the Registrable Securities pursuant to a Registration Statement; provided that, in connection with any Underwritten Shelf Takedown or Block Trade, the Company’s obligations shall be limited to (i) entering into a customary underwriting agreement, (ii) causing the delivery of customary legal opinions, negative assurance letters and accountants’ comfort letters, (iii) making available for customary due diligence its books, records and personnel, subject to customary confidentiality undertakings, and (iv) solely in connection with a marketed Underwritten Shelf Takedown, making members of its senior management reasonably available to participate in a customary roadshow not exceeding two (2) Business Days in the aggregate.
C-10
r. Notwithstanding anything to the contrary in Section 3(e), the Company may postpone effecting (including postponing the filing of, or any request for effectiveness of) a Registration with respect to any Registration Statements that may be required pursuant to Section 2 or Section 3(b), may postpone or suspend any Underwritten Shelf Takedown or Block Trade or, at any time after the effective date of the applicable Registration Statement, the Company may suspend the use of any Prospectus forming a part of such Registration Statement if the Company determines, based on the advice of counsel, that it would otherwise be required to disclose material non-public information concerning the Company, the disclosure of which (i) is not otherwise required (based on the advice of counsel) and which the Company has a bona fide business purpose for preserving in confidence and (ii) at the time is not, in the good faith opinion of the Company and its counsel, in the best interests of the Company (the period of such postponement or suspension, a “Grace Period”); provided, that the Company shall (x) promptly notify the Holders in writing of the existence of material non-public information giving rise to a Grace Period (provided that in each notice the Company shall not disclose the content of such material non-public information to any Holder unless otherwise requested in writing by such Holder) and the date on which the Grace Period will begin, and (y) as soon as such date may be determined, promptly notify the Holders in writing of the date on which the Grace Period ends; and, provided, further, that (A) no Grace Period shall exceed forty-five (45) consecutive days, (B) during any three hundred sixty-five (365) day period, such Grace Periods shall not exceed an aggregate of ninety (90) days, and (C) the first day of any Grace Period must be at least forty-five (45) days after the last day of any prior Grace Period (each Grace Period that satisfies all of the requirements of this Section 3(r) being referred to as an “Allowable Grace Period”). For purposes of determining the length of a Grace Period above, the Grace Period shall begin on and include the date the Holders receive the notice referred to in clause (x) and shall end on and include the later of the date the Holders receive the notice referred to in clause (y) and the date referred to in such notice. The provisions of Section 3(e) hereof shall not be applicable during the period of any Allowable Grace Period. Upon expiration of the Grace Period, the Company shall again be bound by the first sentence of Section 3(e) with respect to the information giving rise thereto unless such material non-public information is no longer applicable. Each applicable Filing Deadline, Additional Filing Deadline and Registration Deadline shall be extended by the number of days in any Allowable Grace Period occurring prior to such deadline, and no Allowable Grace Period shall constitute a breach of this Agreement.
s. The Company shall not grant any Person any registration rights with respect to shares of Common Stock or any other securities of the Company other than registration rights that will not adversely affect the rights of the Holders hereunder (including by limiting in any way the number of Registrable Securities that could be included in any Registration Statement pursuant to Rule 415); provided that (i) the grant of registration rights (including demand, shelf and piggyback registration rights that are pari passu with or subordinate to the rights of the Holders hereunder) to other current or future securityholders shall not in and of itself be deemed to adversely affect the rights of the Holders and (ii) nothing herein shall restrict the Company from performing its obligations under any registration rights agreement in effect as of the date hereof, including the Registration Rights Agreement, dated as of August 29, 2025, by and among the Company and the holders party thereto.
t. At all times during the Registration Period, (i) the Common Stock shall be eligible for clearing through DTC, through its Deposit/Withdrawal At Custodian (DWAC) system; (ii) the Company shall be eligible and participating in the Direct Registration System (DRS) of DTC with respect to the Common Stock; (iii) the transfer agent for the Common Stock shall be a participant in, and the Common Stock shall be eligible for transfer pursuant to, DTC’s Fast Automated Securities Transfer Program (or successor thereto); and (iv) the Company shall use its commercially reasonable efforts to cause the Common Stock to not at any time be subject to any DTC “chill,” “freeze” or similar restriction with respect to any DTC services, including the clearing of shares of Common Stock through DTC, and, in the event the Common Stock becomes subject to any DTC “chill,” “freeze” or similar restriction with respect to any DTC services, the Company shall use its commercially reasonable efforts to cause any such “chill,” “freeze” or similar restriction to be removed at the earliest possible time.
C-11
4. OBLIGATIONS OF THE HOLDERS.
a. It shall be a condition precedent to the obligations of the Company to complete the Registration pursuant to this Agreement with respect to the Registrable Securities of a Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it and the intended method of disposition of the Registrable Securities held by it as shall be reasonably required to effect the Registration of such Registrable Securities and shall execute such documents in connection with such registration as the Company may reasonably request. At least five (5) Business Days prior to the first anticipated filing date of a Registration Statement, the Company shall notify each Holder of the information the Company requires from such Holder. Any such information shall not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein, or necessary to make the statements therein not misleading.
b. Each Holder agrees that, upon receipt of any notice from the Company of the happening of any event of the kind described in Sections 3(e) or 3(f) or of the commencement of a Grace Period pursuant to Section 3(r), such Holder will immediately discontinue disposition of Registrable Securities pursuant to the Registration Statement covering such Registrable Securities until such Holder’s receipt of the copies of the supplemented or amended Prospectus contemplated by Sections 3(e) or 3(f) or written notice from the Company that such Grace Period has ended, as applicable; provided, however, that the foregoing shall not prohibit or require the Holder to discontinue the settlement of any sale of Registrable Securities with respect to which a Holder has entered into a contract for sale prior to the Holder’s receipt of such notice from the Company.
c. In connection with any underwritten public offering of the Company’s equity securities (including any Underwritten Shelf Takedown) in which a Holder participates and sells Registrable Securities, each such participating Holder agrees, if requested by the managing underwriter(s), to enter into a customary lock-up agreement with the underwriters restricting public sales of Common Stock for a period not to exceed sixty (60) days (or such shorter period as the managing underwriter(s) may agree) following the pricing of such offering, on terms no less favorable to such Holder than those applicable to the Company’s directors and executive officers; provided, that if the Company or the managing underwriter(s) release any director or executive officer from such restrictions, in whole or in part, each such Holder shall be released on a pro rata basis.
d. Each Holder shall comply with all laws applicable to its distribution of Registrable Securities, including Regulation M under the Exchange Act and the Prospectus delivery requirements of the Securities Act, and shall not use any “free writing Prospectus” in connection with the sale of Registrable Securities without the prior written consent of the Company. The Company may exclude from any Registration Statement or offering hereunder the Registrable Securities of any Holder that fails to timely furnish the information required pursuant to Section 4(a).
5. RESERVED
6. EXPENSES OF REGISTRATION. All reasonable expenses, other than underwriting discounts and commissions or other charges of any broker-dealer acting on behalf of the Holders, incurred in connection with Registrations, filings or qualifications pursuant to Section 2, including all registration, listing and qualification fees, printing and accounting fees, and the fees and disbursements of counsel for the Company shall be borne by the Company, subject to Section 2(b)(vi). The Company shall also reimburse the Holders for the reasonable fees and disbursements of Legal Counsel in the aggregate amount up to $35,000 per Registration in connection with Registrations pursuant to Sections 2 or 3 of this Agreement.
C-12
7. INDEMNIFICATION. In the event any Registrable Securities are included in a Registration Statement under this Agreement:
a. The Company will indemnify, hold harmless and defend (i) each Holder and (ii) the directors, officers, partners, managers, members, employees and agents of each Holder, and each Person who controls any Holder within the meaning of the Securities Act or the Exchange Act, if any, (each, an “Indemnified Person”), against any joint or several losses, claims, damages, liabilities or expenses (collectively, together with actions, proceedings or inquiries by any regulatory or self-regulatory organization, whether commenced or threatened, in respect thereof, “Claims”) to which any of them may become subject insofar as such Claims arise out of or are based upon: (i) any untrue statement or alleged untrue statement of a material fact in any Registration Statement, or any amendment or supplement thereto, or any filing made under state securities laws as required hereby, or the omission or alleged omission to state therein a material fact required to be stated or necessary to make the statements therein not misleading; (ii) any untrue statement or alleged untrue statement of a material fact contained in any Prospectus, or any amendment or supplement thereto, or the omission or alleged omission to state therein any material fact necessary to make the statements made therein, in the light of the circumstances under which the statements therein were made, not misleading; or (iii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act or any state securities law, or any rule or regulation thereunder, in each case in connection with the offer or sale of the Registrable Securities pursuant to a Registration Statement (the matters in the foregoing clauses (i) through (iii) being, collectively, “Violations”). The Company shall reimburse the Indemnified Person, promptly as such expenses are incurred and are due and payable, for any reasonable and documented legal fees and other reasonable and documented expenses incurred by them in connection with investigating or defending any such Claim. Notwithstanding anything to the contrary contained herein, the indemnification agreement contained in this Section 7(a) shall not apply (A) to a Claim by any Indemnified Person arising out of or based upon a Violation to the extent that such Violation occurs in reliance upon and in conformity with information furnished in writing to the Company by or on behalf of any Indemnified Person expressly for use in connection with the preparation of such Registration Statement or related Prospectus or any such amendment thereof or supplement thereto, (B) to a Claim to the extent arising out of or based upon the use by or on behalf of a Holder of a Prospectus (1) after the Company has notified such Holder in writing of the happening of an event of the kind described in Section 3(e) or 3(f) or of the commencement of a Grace Period, and prior to such Holder’s receipt of the supplemented or amended Prospectus contemplated by Section 3(e) or 3(f) or written notice from the Company that such Grace Period has ended, as applicable, or (2) that has been superseded or corrected by an amended or supplemented Prospectus made available to such Holder prior to the confirmation of the sale giving rise to such Claim, (C) to a Claim to the extent arising out of or based upon any sale or other disposition of Registrable Securities by or on behalf of a Holder in breach of Section 4(b) or Section 4(d), or (D) to any amounts paid in settlement of any Claim effected without the prior written consent of the Company, which consent shall not be unreasonably withheld, conditioned or delayed. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of the Indemnified Person and shall survive the transfer of the Registrable Securities by any of the Holders.
b. Promptly after receipt by an Indemnified Person under this Section 7 of notice of the commencement of any action (including any governmental action), such Indemnified Person shall, if a Claim in respect thereof is to be made against the Company under this Section 7, deliver to the Company a written notice of the commencement thereof, and the Company shall have the right to participate in, and, to the extent the Company so desires, to assume control of the defense thereof with counsel selected by the Company and reasonably satisfactory to the Indemnified Person; provided, however, that an Indemnified Person shall have the right to retain its own counsel with the reasonable and documented fees and expenses to be paid by the Company if the Indemnified Person reasonably determines, based upon the written advice of its outside counsel, that representation of such Indemnified Person and the Company by the same counsel would be inappropriate due to an actual conflict of interest between such Indemnified Person and the Company or any other party represented by such counsel in such proceeding. The Company shall pay for only one separate legal counsel (plus one local counsel in each applicable jurisdiction, if necessary) for all Indemnified Persons, taken together, and such legal counsel shall be selected by the Required Holders. The failure to deliver written notice to the Company within a reasonable time of the commencement of any such action shall not relieve the Company of any liability to the Indemnified Person under this Section 7, except to the extent that the Company is actually prejudiced by such failure in its ability to defend such action, and shall not relieve the Company of any liability to the Indemnified Person otherwise than pursuant to this Section 7. The Company shall not, without the prior written consent of the Indemnified Persons, consent to entry of any judgment or enter into any settlement or other compromise with respect to any Claim in respect of which indemnification or contribution may be or has been sought hereunder (whether or not any such Indemnified Person is an actual or potential party to such action or claim) which does not include as an unconditional term thereof the giving by the claimant or plaintiff to the Indemnified Persons of a full release from all liability with respect to such Claim or which includes any admission as to fault, culpability or failure to act on the part of any Indemnified Person. The indemnification required by this Section 7 shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as any expense, loss, damage or liability is incurred.
C-13
c. Each Holder will, severally and not jointly, indemnify, hold harmless and defend (i) the Company, (ii) the directors, officers (including each officer of the Company who signs the Registration Statement), partners, managers, members, employees and agents of the Company, (iii) each Person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act, and (iv) each Underwriter, if any, of Registrable Securities sold by such Holder and each Person, if any, who controls such Underwriter within the meaning of the Securities Act or the Exchange Act (each, a “Company Indemnified Person”), against any Claims to which any of them may become subject insofar as such Claims arise out of or are based upon (A) any untrue statement or alleged untrue statement of a material fact contained in any Registration Statement or Prospectus, or any amendment or supplement thereto, or the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus, in the light of the circumstances under which they were made) not misleading, in each case to the extent, and only to the extent, that such untrue statement or omission occurs in reliance upon and in conformity with information furnished in writing to the Company by or on behalf of such Holder expressly for inclusion in such Registration Statement or Prospectus, (B) any sale or other disposition of Registrable Securities by or on behalf of such Holder in breach of Section 4(b), including the use by or on behalf of such Holder of a Prospectus in the circumstances described in clause (B) of the third sentence of Section 7(a), (C) the use by or on behalf of such Holder of any “free writing prospectus” in violation of Section 4(d), or (D) any violation or alleged violation by such Holder of the Securities Act, the Exchange Act or any state securities law, or any rule or regulation thereunder (including Regulation M and applicable Prospectus delivery requirements), in connection with the offer or sale of Registrable Securities by or on behalf of such Holder. Each Holder shall reimburse the applicable Company Indemnified Person, promptly as such expenses are incurred and are due and payable, for any reasonable and documented legal fees and other reasonable and documented expenses incurred in connection with investigating or defending any such Claim. Notwithstanding anything herein to the contrary, the indemnity agreement contained in this Section 7(c) shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the prior written consent of such Holder, which consent shall not be unreasonably withheld, conditioned or delayed; and provided, however, that a Holder shall be liable under this Section 7(c) for only that amount of a Claim as does not exceed the net amount of proceeds received by such Holder as a result of the sale of Registrable Securities pursuant to such Registration Statement.
d. Promptly after receipt by a Company Indemnified Person under this Section 7 of notice of the commencement of any action (including any governmental action), such Company Indemnified Person shall, if a Claim in respect thereof is to be made against any Holder under this Section 7, deliver to such Holder a written notice of the commencement thereof, and such Holder shall have the right to participate in, and, to the extent such Holder so desires, to assume control of the defense thereof with counsel mutually satisfactory to such Holder and such Company Indemnified Person. No Holder shall, without the prior written consent of the Company, consent to entry of any judgment or enter into any settlement or other compromise with respect to any Claim in respect of which indemnification or contribution may be or has been sought by any Company Indemnified Person hereunder (whether or not any such Company Indemnified Person is an actual or potential party to such action or claim) which does not include as an unconditional term thereof the giving by the claimant or plaintiff to the Company Indemnified Persons of a full release from all liability with respect to such Claim or which includes any admission as to fault, culpability or failure to act on the part of any Company Indemnified Person.
e. Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in any underwriting agreement entered into in connection with an Underwritten Offering are in conflict with the provisions of this Section 7 or Section 8, the provisions in such underwriting agreement shall control.
C-14
8. CONTRIBUTION. If for any reason the indemnification provided for in Sections 7(a) or 7(c) (as applicable) is unavailable to an Indemnified Person or Company Indemnified Person (as applicable) or insufficient to hold it harmless, other than as expressly specified therein, then the indemnifying party shall contribute to the amount paid or payable by the Indemnified Person or Company Indemnified Person (as applicable) as a result of the Claim in such proportion as is appropriate to reflect the relative fault of the Indemnified Person or Company Indemnified Person (as applicable) and the indemnifying party (provided that the relative fault of any Company Indemnified Person (other than any Underwriter or any Person who controls an Underwriter) shall be deemed to include the fault of all other such Company Indemnified Persons), as well as any other relevant equitable considerations. The parties agree that it would not be just and equitable if contribution pursuant to this Section 8 were determined by pro rata allocation or by any other method of allocation that does not take account of the equitable considerations referred to in this Section 8. No Person guilty of fraudulent misrepresentation within the meaning of Section 11(f) of the Securities Act shall be entitled to contribution from any Person not guilty of such fraudulent misrepresentation. In no event shall the contribution obligation of a Holder be greater in amount than the net amount of proceeds received by such Holder as a result of the sale of Registrable Securities giving rise to such contribution obligation pursuant to the applicable Registration Statement (net of the aggregate amount of any damages or other amounts such Holder has otherwise been required to pay (pursuant to Section 7(c) or otherwise) by reason of such Holder’s untrue or alleged untrue statement or omission or alleged omission).
9. REPORTS UNDER THE EXCHANGE ACT. With a view to making available to the Holders the benefits of Rule 144 promulgated under the Securities Act or any other similar rule or regulation of the SEC that may at any time permit the Holders to sell securities of the Company to the public without registration, the Company agrees to, during the period when there are Registrable Securities outstanding (or deemed hereunder to be outstanding):
a. make and keep public information available, as those terms are understood and defined in Rule 144;
b. file with the SEC in a timely manner (without giving effect to any extensions pursuant to Rule 12b-25 under the Exchange Act) all reports and other documents required of the Company under the Exchange Act so long as the Company remains subject to such requirements and the filing of such reports and other documents is required for the applicable provisions of Rule 144;
c. remain continuously subject to the reporting requirements under the Exchange Act; and
d. so long as any of the Holders owns Registrable Securities, promptly upon request, furnish to such Holder (i) a written statement by the Company that it has complied with the reporting requirements of the Exchange Act as required for applicable provisions of Rule 144 and (ii) such other information as may be reasonably requested to permit such Holder to sell such Registrable Securities pursuant to Rule 144 without registration.
C-15
10. LEGEND REMOVAL.
a. The Registrable Securities held by any Holder (and any certificates or electronic book entries evidencing the Registrable Securities) shall not contain or be subject to (and such Holder shall be entitled to removal of) any legend (or stop transfer or similar instruction) restricting the transfer thereof (including any legend pertaining to restrictions on transfer under Applicable Securities Laws) if: (i) (A) a Registration Statement covering the sale or resale of such securities is effective under the Securities Act, or (B) such Holder provides customary paperwork to the effect that it has sold, or is selling substantially contemporaneously with the delivery of such paperwork, such securities pursuant to such a Registration Statement or Rule 144 under the Securities Act, or (C) such securities are eligible for sale under Rule 144(b)(1) under the Securities Act as set forth in customary, non-affiliate certifications provided by such Holder, or (D) at any time on or after the date hereof such Holder certifies that it is not an “affiliate” (within the meaning of such term under Rule 144 under the Securities Act) of the Company (a “Rule 144 Affiliate”), and has not been a Rule 144 Affiliate for the preceding three (3) months, and that such Holder’s holding period for purposes of Rule 144 (including, for the avoidance of doubt, subsection (d)(3)(ii) thereof) is at least six (6) months, and if such holding period is less than one (1) year, the current public information requirement of Rule 144(b)(1) is then met, or (E) such legend is not otherwise required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the SEC) as determined in good faith by counsel to the Company and (ii) in each case, such Registrable Securities are not subject to the Lock-Up, to the extent applicable (collectively, the “Unrestricted Conditions”). The Company shall cause its counsel to issue a legal opinion to the transfer agent for the Common Stock (the “Transfer Agent”) (with a copy to each Holder), as soon as practicable (and in any event within two (2) Business Days) after such time as any of the Unrestricted Conditions has been satisfied with respect to any Registrable Securities (which in the case of Registrable Securities that are not subject to the Lock-Up, shall be the Registration Effective Date), if the Transfer Agent requires such an opinion to effect the issuance of such Registrable Securities, as applicable, without a restrictive legend or removal of the legend hereunder.
b. The Company agrees that at such time as any of the Unrestricted Conditions is met or such legend is otherwise no longer required under this Section 10 in respect of any Registrable Securities, which in the case of Registrable Securities that are not subject to the Lock-Up shall include any time following the Registration Effective Date, it will, no later than the earlier of (x) one (1) Trading Day and (y) the number of Trading Days comprising the standard settlement period, in each case following the delivery by a Holder to the Company or the Transfer Agent of a written legend removal request (together with, if applicable, the deliverables required by the Unrestricted Conditions and such other documentation as the Company may reasonably request from such Holder to the extent necessary to effect such legend removal) or of the Registrable Securities issued with a restrictive legend (such date, the “Legend Removal Date”), deliver or cause to be delivered to such Holder or its designee the Registrable Securities free from all restrictive and other legends (or similar notations) by crediting the account of such Holder’s prime broker with DTC, through its DWAC system.
11. RESERVED.
12. MATERIAL NON-PUBLIC INFORMATION.
a. From and after the date hereof, with respect to each Holder other than Heron and its Affiliates, and with respect to Heron and its Affiliates solely during any period in which Heron does not have a designee on the board of directors of the Company:
i. The Company shall not, and shall cause each of its Affiliates, representatives and agents to not, provide any Holder or any Holder’s Affiliates, representatives or agents, with any material non-public information regarding the Company, any of its Affiliates or any other Person (“MNPI”) without the express prior written consent of such Holder. Each Holder acknowledges that it is aware, and will advise its Affiliates, representatives and agents who receive MNPI, that applicable securities laws prohibit any Person who has received MNPI regarding the Company from purchasing or selling securities of the Company in violation of such laws, and nothing in this Agreement shall be construed to permit any Holder or any of its Affiliates to trade in securities of the Company while in possession of MNPI.
C-16
ii. Notwithstanding anything to the contrary herein, in the event that the Company believes that a notice or communication to any Holder or any Holder’s Affiliates, attorneys, agents or representatives contains MNPI, the Company shall, prior to the delivery of such notice or communication, (i) so indicate to such Holder, and such indication shall provide such Holder the means to refuse to receive such notice or communication, and in the absence of any such indication, such Holder, the other holders of the Registrable Securities and their respective Affiliates, agents and representatives shall be allowed to presume that all matters relating to such notice or communication do not constitute MNPI and (ii) provide such notice or communication to counsel to such Holder (which shall be as set forth on such Holder’s signature page to this Agreement or such other counsel as shall have been designated in writing by such Holder). In the event that the Company either (A) fails to indicate that a notice or communication to a Holder contains MNPI or otherwise provides any Holder with MNPI without such Holder’s prior written consent or (B) provides such notice or communication to any Holder notwithstanding any such Holder’s refusal in writing to receive such notice or communication, such Holder shall have the right, following delivery of written notice to the Company identifying the applicable MNPI and the failure of the Company to publicly disclose such MNPI within two (2) Business Days after receipt of such notice, to make a public disclosure in the form of a press release, public advertisement or otherwise of the applicable MNPI without the prior approval by the Company or any of its Affiliates, or any of its or their respective officers, directors (or equivalent persons), employees, attorneys, representatives or agents, and no Holder (nor any of its Affiliates, agents or representatives) shall have any liability to the Company or any of its Affiliates or any of its or their respective officers, directors (or equivalent persons), employees, stockholders, attorneys, representatives or agents for any such disclosure.
iii. Notwithstanding the foregoing, to the extent the Company reasonably and in good faith determines that it is necessary to disclose MNPI to any Holder for purposes relating to this Agreement or the Asset Purchase Agreement (a “Necessary Disclosure”), the Company shall inform counsel to such Holder (which shall be as set forth on such Holder’s signature page to this Agreement or such other counsel as shall have been designated in writing by such Holder) of such determination without disclosing the applicable MNPI, and the Company and such counsel on behalf of such Holder shall endeavor to agree upon a process for making such Necessary Disclosure to the applicable Holder or its representatives that is mutually acceptable to such Holder and the Company (an “Agreed Disclosure Process”). Thereafter, the Company shall be permitted to make such Necessary Disclosure (only) in accordance with the Agreed Disclosure Process. The Company acknowledges and agrees that the Holders and their Affiliates will rely upon the foregoing representations, warranties and agreements and the other disclosure obligations of the Company hereunder in effecting transactions in Common Stock and other securities of the Company and other Persons.
b. For so long as Heron has a designee on the board of directors of the Company, (i) Section 12(a) shall not apply to Heron or its Affiliates, and information received by such designee in his or her capacity as a director shall be subject to such designee’s fiduciary and confidentiality obligations to the Company and the Company’s policies applicable to directors; (ii) Heron and its Affiliates shall comply with the Company’s insider trading policy, including any applicable blackout periods and pre-clearance procedures, with respect to any sale of Registrable Securities (including pursuant to Sections 2(b) or 2(c)), other than sales pursuant to a trading plan adopted in accordance with Rule 10b5-1 under the Exchange Act; and (iii) Heron acknowledges that it may be deemed a Rule 144 Affiliate and that, accordingly, the Registrable Securities held by Heron and its Affiliates may not cease to be Registrable Securities pursuant to clause (ii) of the proviso to the definition thereof, but shall remain subject to clause (i) of such proviso.
13. MISCELLANEOUS.
a. A Person is deemed to hold, and be a holder of, shares of Common Stock or other Registrable Securities whenever such Person owns of record or beneficially through a “street name” holder such shares of Common Stock or other Registrable Securities. If the Company receives conflicting instructions, notices or elections from two or more Persons with respect to the same Registrable Securities, the Company shall act upon the basis of instructions, notice or election received from the registered owner of such Registrable Securities.
C-17
b. Any notices required or permitted to be given under the terms hereof shall be delivered personally or by courier (including a recognized overnight delivery service) or by electronic mail and shall be effective upon receipt, in each case addressed to a party. The addresses for such communications shall be:
If to the Company:
CorMedix Inc.
389 Interpace Pkwy, Suite 450
Parsippany, New Jersey 07054
Attention: [***]
Email: [***]
with a copy (which shall not constitute notice) to:
Willkie Farr & Gallagher LLP
787 7th Avenue
New York, New York 10019
Attention: [***]
Email: [***]
If to a Holder, to the address set forth in such Holder’s signature page to this Agreement.
The Company shall provide notice to each Holder, and each Holder shall provide notice to the Company, of any change in such party’s address.
c. Failure of any party to exercise any right or remedy under this Agreement or otherwise, or delay by a party in exercising such right or remedy, shall not operate as a waiver thereof.
d. Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with, and all disputes arising out of or in connection with this Agreement shall be resolved under, the internal laws of the State of Delaware, without regard to the principles of conflicts of law thereof that would result in the application of the substantive laws of any other jurisdiction. Each party agrees that all legal proceedings concerning the interpretation, enforcement and defense of the transactions contemplated by this Agreement (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, employees or agents) shall be commenced exclusively in the Delaware Court of Chancery or, solely if the Delaware Court of Chancery does not have subject matter jurisdiction thereof, any other court of the State of Delaware or any federal court sitting in the State of Delaware. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the State of Delaware for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. The parties hereby waive all rights to a trial by jury.
C-18
e. This Agreement, the Asset Purchase Agreement, and any other Ancillary Agreements (collectively, the “Transaction Documents”), constitute the entire agreement among the parties hereto with respect to the subject matter hereof and thereof. This Agreement and the other Transaction Documents (including all schedules and exhibits hereto and thereto) supersede all prior agreements and understandings among the parties hereto with respect to the subject matter hereof and thereof.
f. This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns of each of the parties hereto, and the provisions of Sections 7 and 8 hereof shall inure to the benefit of, and be enforceable by, each Indemnified Person and Company Indemnified Person (as applicable). No Holder may assign this Agreement or any of its rights or obligations hereunder, in whole or in part, to any Person (including any transferee of Registrable Securities, whether by sale, distribution in kind to its equityholders or otherwise), and any purported assignment in violation of this Section 13(f) shall be null and void; provided that a Holder may assign its rights hereunder, together with the related Registrable Securities, to any of its controlled Affiliates that (i) acquires such Registrable Securities in a transfer permitted under the Governance Agreements and (ii) agrees in writing with the Company to be bound by all of the provisions hereof applicable to a Holder, with written notice of such assignment (including the name and address of the assignee and the Registrable Securities assigned) delivered to the Company within five (5) Business Days thereafter. The Company shall not assign this Agreement or any rights or obligations hereunder, except after obtaining the prior written consent of the Required Holders; provided that no such consent shall be required in connection with an assignment to a successor to the Company by merger, consolidation or sale of all or substantially all of its assets that assumes the Company’s obligations hereunder.
g. Provisions of this Agreement may be amended and the observance thereof may be waived (either generally or in a particular instance and either retroactively or prospectively), only with written consent of the Company and the Required Holders. Any amendment or waiver effected in accordance with this Section 13(g) shall be binding upon each of the Holders and the Company.
h. The headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning hereof.
i. This Agreement and any amendments hereto may be executed and delivered in two or more counterparts, and by the different parties hereto in separate counterparts, each of which when executed shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement, and shall become effective when counterparts have been signed by each party hereto and delivered to the other parties hereto, it being understood that all parties need not sign the same counterpart. In the event that any signature to this Agreement or any amendment hereto is delivered by facsimile transmission, by e-mail delivery of a “.pdf” format data file or by other electronic means, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile, “.pdf” or other electronic signature page were an original thereof. No party hereto shall raise the use of a facsimile machine, e-mail delivery of a “.pdf” format data file or other electronic means to deliver a signature to this Agreement or any amendment hereto or the fact that such signature was transmitted or communicated through the use of a facsimile machine, e-mail delivery of a “.pdf” format data file or other electronic means as a defense to the formation or enforceability of a contract, and each party hereto forever waives any such defense.
j. Each of the parties hereto acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the non-breaching part(y)(ies) hereto by vitiating the intent and purpose of the transactions contemplated hereby. Accordingly, the parties acknowledge that the remedy at law for breach of its obligations hereunder will be inadequate and agree, in the event of a breach or threatened breach by any party hereto of any of the provisions hereunder, that the non-breaching party shall be entitled, in addition to all other available remedies in law or in equity, to an injunction or injunctions to prevent or cure breaches of the provisions of this Agreement and to enforce specifically the terms and provisions hereof, without the necessity of showing economic loss and without any bond or other security being required.
C-19
k. The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rule of strict construction will be applied against any party.
l. In the event that any provision of this Agreement is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any provision hereof which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision hereof.
m. There shall be no oral modifications or amendments to this Agreement. This Agreement may be modified or amended only in writing signed by the Company and the Required Holders, and any amendment or modification so adopted shall be binding upon all of the Holders.
n. The obligations of each Holder hereunder are several and not joint with the obligations of any other Holder, and no provision of this Agreement (or any other Transaction Document) is intended to confer any obligations on any Holder vis-à-vis any other Holder. Nothing contained herein (or in any Transaction Document), and no action taken by any Holder pursuant hereto (or thereto), shall be deemed to constitute the Holders as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Holders are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated herein (or therein).
o. Unless the context otherwise requires, (i) all references to Sections, Schedules or Exhibits are to Sections, Schedules or Exhibits contained in or attached to this Agreement, (ii) words in the singular or plural include the singular and plural, and pronouns stated in either the masculine, the feminine or neuter gender shall include the masculine, feminine and neuter, (iii) the use of the word “include,” “includes” and “including” in this Agreement shall be by way of example rather than limitation, and (iv) the word “or” is not exclusive (i.e., “or” shall mean “and/or”).
p. The provisions of this Agreement that refer to a number of shares of Common Stock or a number of Registrable Securities shall be appropriately adjusted for any stock split or other subdivision of outstanding Common Stock, combination of outstanding Common Stock (including by reverse stock split), payment of a stock dividend in shares of Common Stock, or other similar transaction of such character that outstanding shares of Common Stock shall be changed into or become exchangeable for a larger or smaller number of shares of Common Stock.
q. This Agreement shall terminate with respect to any Holder on the date on which such Holder no longer holds any Registrable Securities, and shall terminate in its entirety on the date on which no Registrable Securities remain outstanding; provided that the provisions of Sections 6, 7, 8 and 13 shall survive any such termination, and no such termination shall relieve any party of liability for any breach of this Agreement occurring prior thereto.
[Remainder of page left intentionally blank]
[Signature page follows]
C-20
IN WITNESS WHEREOF, the undersigned Holders and the Company have caused this Registration Rights Agreement to be duly executed as of the date first written above.
| COMPANY: | ||
| CORMEDIX INC. | ||
| By: | ||
| Name: | [***] | |
| Title: | [***] | |
[SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT]
C-21
IN WITNESS WHEREOF, the undersigned Holders and the Company have caused this Registration Rights Agreement to be duly executed as of the date first written above.
| HOLDERS: | ||
| HERON THERAPEUTICS, INC. | ||
| By: | ||
| Name: | [***] | |
| Title: | [***] | |
Heron Therapeutics, Inc.
25 Fenton Main Street, Suite 300
Cary, North Carolina 27511
Attn: [***]
E-mail: [***]
with a copy (which shall not constitute notice) to:
DLA Piper LLP (US)
51 John F. Kennedy Parkway, Suite 120
Short Hills, NJ 07078
Attn: [***]
Email: [***]
[SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT]
C-22
IN WITNESS WHEREOF, the undersigned Holders and the Company have caused this Registration Rights Agreement to be duly executed as of the date first written above.
| HOLDERS: | ||
| RUBRIC CAPITAL MANAGEMENT LP | ||
| By: | Rubric Capital Management GP LLC | |
| Its General Partner | ||
| By: | ||
| Name: | [***] | |
| Title: | [***] | |
c/o Rubric Capital Management LP
155 East 44th St, Suite 1630
New York, New York 10017
Attn: [***]
E-mail: [***]
with a copy (which shall not constitute notice) to:
Seward & Kissel LLP
One Battery Park Plaza
New York, NY 10004
Attn: [***]
Email: [***]
[SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT]
C-23
EXHIBIT D
Form of Escrow Agreement
[Omitted]
D-1
Schedule 1.1A
Business Products
Cinvanti®
Zynrelef®
Sustol®
Aponvie®
Schedule 1.1B
Seller Knowledge Individuals
[Omitted]
Schedule 1.1C
Buyer Knowledge Individuals
[Omitted]
Schedule 1.1D
Required Antitrust Approvals
The filing of a Notification and Report Form under the HSR Act.
Schedule 1.1E
Accounting Principles
All financial statements, financial information and calculations delivered or made pursuant to this Agreement shall be prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), consistently applied, and using accounting policies, principles, practices, methodologies and procedures consistent with those historically used by Seller, except to the extent not inconsistent with GAAP, consistently applied.
Schedule 1.1F
Illustrative Closing Statement
[Omitted]
Schedule 1.1G
Business Employees
[Omitted]
Schedule 1.1H
Specified Employees
[Omitted]
Schedule 1.1I
Excluded Employee
[Omitted]
Schedule 1.1J
Royalty and Earn-Out Payments
See attached.
Final Form
SCHEDULE 1
1. DEFINITIONS
Section 1.1 Certain Defined Terms. Capitalized terms used but not defined in this Schedule 1 have the meanings given to them in the Asset Purchase Agreement to which this Schedule 1 is attached (the “Agreement”).
“Buyer Rights Chain Group” means, collectively, (a) Buyer and its Affiliates, (b) any Person to which Buyer or any of its Affiliates directly or indirectly licenses, sublicenses or otherwise grants rights to develop, manufacture, commercialize, distribute or sell any Business Product (including through co-promotion or distribution arrangements), (c) any Royalty Product Purchaser and (d) any successor or assign of any of the foregoing with respect to its interest in any Business Product.
“Earn-Out Event” means each of the First Earn-Out Event and the Second Earn-Out Event, as described in Section 3.1.
“Earn-Out Payment” means each payment payable upon the achievement of an Earn-Out Event.
“Earn-Out Product” means the Business Product marketed as ZYNRELEF® (bupivacaine and meloxicam extended-release solution), including all formulations, dosages, strengths and forms of administration thereof.
“Exchange Cap” means the maximum number of shares of Buyer Common Stock that may be issued pursuant to the Agreement and this Schedule 1 (including the Stock Consideration and any Earn-Out Shares) without exceeding nineteen and nine-tenths percent (19.9%) of the total issued and outstanding shares of Buyer Common Stock as of the Closing, or such lesser number as would require approval of Buyer’s stockholders under the applicable rules of Nasdaq.
“Net Sales” means, with respect to any Business Product, the gross amount invoiced, billed or otherwise recorded for sales or other dispositions of such Business Product by or on behalf of any member of the Buyer Rights Chain Group to a third party, less the following amounts, in each case to the extent actually incurred, allowed, paid or accrued by the applicable member of the Buyer Rights Chain Group with respect to such Business Product, determined in accordance with GAAP, consistently applied, and not otherwise recovered by or reimbursed to such member:
(a) reasonable and customary rebates, chargebacks, quantity and other discounts, credits and allowances and other price reductions granted, allowed, incurred or paid, in each case insofar as applied to sales of such Business Product;
(b) reasonable and customary credits, adjustments and allowances granted on account of price adjustments, billing errors, damaged goods and the rejection, return or recall of such Business Product;
(c) reasonable and customary freight, shipping and insurance costs incurred with respect to the shipment of such Business Product to customers, in each case to the extent included in the gross amount invoiced;
(d) sales, use, value-added, and excise taxes, in each case that the applicable member of the Buyer Rights Chain Group allocates to sales of such Business Product in accordance with its standard policies and procedures consistently applied across its products, and in each case to the extent not paid by a third party; and
(e) amounts actually written off as uncollectible with respect to sales of such Business Product; provided that if any such amount is thereafter paid, the corresponding amount shall be added to the Net Sales of the period during which it is paid.
No other deduction shall be taken in determining Net Sales, and no amount shall be deducted more than once. For clarity, Net Sales shall not include sales or dispositions of any Business Product between or among members of the Buyer Rights Chain Group; provided that any subsequent sale or disposition of such Business Product by a member of the Buyer Rights Chain Group to a third party shall be included in the calculation of Net Sales. Amounts invoiced in a currency other than U.S. dollars shall be converted into U.S. dollars at rates of exchange determined in a manner consistent with Buyer’s method for calculating rates of exchange in the preparation of its annual financial statements in accordance with GAAP, consistently applied.
“Promote” means, with respect to any product, direct communication (whether in person, telephonically or via written communication) with healthcare professionals for the purposes of causing such product to be prescribed for treatment of patients. For the avoidance of doubt, commercialization of any product shall not, in itself, be deemed to be Promotion of such product.
“Royalty Products” means (a) the Business Products marketed as CINVANTI® (aprepitant injectable emulsion) and SUSTOL® (granisetron extended-release injection), (b) [***] and (c) [***].
“Royalty Rate” means five percent (5.0%).
“Royalty Threshold” means twenty-five million U.S. dollars ($25,000,000).
“Royalty Year” means each of the calendar years ending December 31, 2027, December 31, 2028 and December 31, 2029.
“VWAP Price” means the arithmetic average of the volume weighted average price per share of Buyer Common Stock on Nasdaq (as reported by Bloomberg Finance L.P. or, if not reported thereby, another authoritative source mutually agreed by Buyer and Seller) for each of the five (5) consecutive Trading Days ending on (and including) the Trading Day immediately prior to the earlier of (a) the date on which the applicable Earn-Out Statement is delivered pursuant to Section 3.3 and (b) the date on which such Earn-Out Statement is required to be delivered pursuant to Section 3.3; provided that if a Stock Event occurs during such period or after such period but prior to the issuance of the applicable Earn-Out Shares, the VWAP Price shall be equitably adjusted to reflect such Stock Event. “Trading Day” means any day on which Nasdaq is open for trading, and “Stock Event” means any stock split, reverse stock split, combination, reclassification, stock dividend, recapitalization or similar transaction affecting the Buyer Common Stock.
Section 1.2 Determination of Net Sales. Net Sales shall be determined in accordance with the definition thereof and, to the extent not inconsistent therewith, Buyer’s accounting policies used in preparing its consolidated financial statements filed with the SEC (or, if Buyer is not then a reporting company, its audited consolidated financial statements); in the event of any conflict, the definition of Net Sales shall control. Sales between or among members of the Buyer Rights Chain Group shall be disregarded, and Net Sales shall be determined only on the subsequent sale to a third party. Net Sales of the Royalty Products shall be aggregated for purposes of Section 2. No amount shall be counted more than once in calculating Net Sales, and any GAAP true-up of estimates made in a later period shall be reflected in the period in which such true-up is recorded. Deductions taken in calculating Net Sales shall be determined in accordance with Buyer’s usual and customary accounting methods, consistently applied across its product portfolio, and shall be fairly and equitably allocated such that the Business Products do not bear a disproportionate portion of any deduction allocable across multiple products.
2. ROYALTY PAYMENTS
Section 2.1 Royalty Payments. Subject to the terms and conditions of the Agreement and this Schedule 1, in respect of each Royalty Year, Buyer shall pay, or cause to be paid, to Seller an amount in cash (each, a “Royalty Payment”) equal to the product of (a) the Royalty Rate multiplied by (b) the amount, if any, by which the aggregate Net Sales of all Royalty Products during such Royalty Year exceed the Royalty Threshold. If aggregate Net Sales of the Royalty Products for a Royalty Year are equal to or less than the Royalty Threshold, no Royalty Payment shall be payable in respect of such Royalty Year. Notwithstanding the foregoing, no Royalty Payment shall be due and payable to Seller in respect of any Net Sales occurring prior to the Closing; provided that, for the avoidance of doubt, Net Sales occurring during the Royalty Year but prior to the Closing shall be included for purposes of determining whether the Royalty Threshold has been exceeded.
Section 2.2 Royalty Reports and Payment. Within the earlier of (a) one (1) Business Day following the filing with the SEC by Buyer of its Annual Report on Form 10-K for the fiscal year that includes a Royalty Year and (b) ninety (90) days following the end of such Royalty Year, Buyer shall deliver to Seller a written report (each, a “Royalty Report”) setting forth in reasonable detail (i) the gross sales and the Net Sales of each Royalty Product during such Royalty Year, together with an itemized calculation of the deductions taken in determining Net Sales, (ii) the aggregate Net Sales of all Royalty Products during such Royalty Year, and (iii) Buyer’s calculation of the Royalty Payment, if any, in respect of such Royalty Year. Within thirty (30) days after receipt of any Royalty Report, Seller may request one (1) meeting (by telephone or videoconference) per calendar year with the Chief Executive Officer or Chief Financial Officer of Buyer or, at their election, one or more representatives of Buyer having direct knowledge of the commercialization and sale of the Business Products, for the purpose of inquiring about the contents of such report, and Buyer shall schedule such meeting within thirty (30) days of Seller’s request. Buyer shall pay the Royalty Payment set forth in the Royalty Report concurrently with delivery of such Royalty Report, and any additional amount finally determined to be payable pursuant to Section 5 in accordance therewith. Any Royalty Payment (or portion thereof) that is not paid when due in accordance with this Section 2.2 shall accrue interest, from the date such payment was due until the date such payment is made, at a rate equal to the prime rate as published in The Wall Street Journal in effect on the date such payment was required to be made plus two percent (2%) per annum from the date originally due until paid, calculated on the total number of days payment is delinquent.
Section 2.3 Disclosure. Seller acknowledges that Royalty Reports, Earn-Out Statements and any information made available pursuant to Section 5 may contain material non-public information regarding Buyer, and Seller shall hold such information in confidence in accordance with Section 5.8 (Confidentiality) of the Agreement and shall comply with applicable securities Laws with respect thereto. Buyer shall not be required to deliver any Royalty Report or Earn-Out Statement prior to the public filing of the corresponding Buyer financial statements.
3. EARN-OUT PAYMENTS
Section 3.1 Earn-Out Events and Payments. Subject to the terms and conditions of the Agreement and this Schedule 1 and subject to and, if applicable, payable in accordance with Section 3.4:
(a) if the Net Sales of the Earn-Out Product for the calendar year ending December 31, 2028 equal or exceed sixty-five million U.S. dollars ($65,000,000) (the “First Earn-Out Event”), Buyer shall pay, or cause to be paid, to Seller a one-time payment of twenty-five million U.S. dollars ($25,000,000) (the “First Earn-Out Payment”); and
(b) if the Net Sales of the Earn-Out Product for the calendar year ending December 31, 2028 equal or exceed ninety-five million U.S. dollars ($95,000,000) (the “Second Earn-Out Event”), Buyer shall pay, or cause to be paid, to Seller a one-time payment of thirty million U.S. dollars ($30,000,000) (the “Second Earn-Out Payment”), which shall be in addition to the First Earn-Out Payment. For clarity, if the Net Sales of the Earn-Out Product for the calendar year ending December 31, 2028 equal or exceed ninety-five million U.S. dollars ($95,000,000), Earn-Out Payments totaling fifty-five million U.S. dollars ($55,000,000) shall be paid to Seller.
Section 3.2 Single Measurement Period; Maximum Amount. Each Earn-Out Payment shall be payable, if at all, only once and only in respect of Net Sales of the Earn-Out Product during the calendar year ending December 31, 2028. There shall be no partial, pro rata or interpolated payment if Net Sales fall between or below the thresholds set forth in Section 3.1, and no Earn-Out Payment shall be payable based on Net Sales in any other period. In no event shall the aggregate Earn-Out Payments exceed fifty-five million U.S. dollars ($55,000,000).
Section 3.3 Earn-Out Statement. Within the earlier of (a) one (1) Business Day following the filing with the SEC by Buyer of its Annual Report on Form 10-K for fiscal year 2028 and (b) April 2, 2029, Buyer shall deliver to Seller a written statement (the “Earn-Out Statement”) setting forth in reasonable detail the gross sales and the Net Sales of the Earn-Out Product for the calendar year ending December 31, 2028, an itemized calculation of the deductions taken in determining such Net Sales, and whether each Earn-Out Event has been achieved. The Earn-Out Statement may be combined with the Royalty Report for the Royalty Year ending December 31, 2028.
Section 3.4 Form of Payment. Each Earn-Out Payment that becomes payable shall be paid, at Buyer’s election in its sole discretion (which election shall be set forth in the Earn-Out Statement), (a) in cash by wire transfer of immediately available funds to the account designated in writing by Seller to Buyer not less than five (5) Business Days prior to the applicable payment date, (b) in shares of Buyer Common Stock (“Earn-Out Shares”), or (c) in any combination of cash and Earn-Out Shares. For purposes of the foregoing, (i) the number of Earn-Out Shares to be issued shall equal the dollar amount of the Earn-Out Payment elected to be paid in Earn-Out Shares divided by the VWAP Price, rounded down to the nearest whole share, with cash paid in lieu of any fractional share; and (ii) in no event shall Buyer issue Earn-Out Shares to the extent that such issuance, together with all other shares of Buyer Common Stock issued pursuant to the Agreement and this Schedule 1, would exceed the Exchange Cap, and any portion of an Earn-Out Payment that would otherwise be paid in Earn-Out Shares in excess of the Exchange Cap shall instead be paid in cash.
Section 3.5 Payment Timing; Share Issuance. Each Earn-Out Payment, to the extent payable, shall be paid (in cash or shares, as applicable) as soon as reasonably practicable and in no event later than ten (10) days after the Earn-Out Statement becomes final and binding pursuant to Section 5. Earn-Out Shares shall be issued by book-entry issuance through the Transfer Agent, shall be duly authorized, validly issued, fully paid and non-assessable, shall constitute “Registrable Securities” (or the equivalent term) under the Registration Rights Agreement, and shall be subject to the Seller Governance Agreement to the same extent as the Seller Stock Consideration (as if such Earn-Out Shares were issued on the Closing Date). Any Earn-Out Payment (or portion thereof) that is not paid when due in accordance with this Section 3.5 shall accrue interest, from the date such payment was due until the date such payment is made, at a rate equal to the prime rate as published in The Wall Street Journal in effect on the date such payment was required to be made plus two percent (2%) per annum from the date originally due until paid, calculated on the total number of days payment is delinquent, and such accrued interest shall be paid together with, and in the same manner as, the related Earn-Out Payment.
4. OPERATION OF THE BUSINESS
Section 4.1 Buyer Discretion. From and after the Closing, subject to Section 4.2 and Section 4.3, Buyer shall have the sole and exclusive right to make all decisions regarding the marketing, promotion, pricing, distribution, and commercialization of the Business Products, including the right to determine in its sole discretion the markets in which to commercialize the Business Products, the resources allocated thereto, and the terms and conditions of any contracts entered into in connection therewith. Subject to Section 4.2 and Section 4.3, no provision of this Section 4.1 or the Agreement or any related agreement shall be construed to limit Buyer’s operational control over the Business Products.
Section 4.2 Marketing Efforts. From the Closing until the date of payment of the final Royalty Payment and the final Earn-Out Payment, as applicable, Buyer shall, and shall cause its Affiliates to, use commercially reasonable efforts to achieve the Milestones for the Royalty Products and the Earn-Out Product, including by allocating appropriate personnel, funding and other resources thereto. Seller acknowledges and agrees that (a) except as expressly provided in the first sentence of this Section 4.2 and in Section 4.3, neither Buyer nor any of its Affiliates has any obligation to use any higher level of efforts (including “diligent efforts,” “best efforts” or any similar standard) to achieve any Earn-Out Event, to generate any level of Net Sales or otherwise to cause any Royalty Payment or Earn-Out Payment to become payable; (b) subject to the first and last sentences of this Section 4.2 and to Section 4.3, Buyer and its Affiliates may (i) operate their respective businesses, including the Business Products, in their sole discretion and in their own best interests, and (ii) develop, acquire, in-license or commercialize products that compete with the Business Products, and (c) there is no assurance that any Royalty Payment or Earn-Out Payment will become payable. Notwithstanding subsection (b), from the Closing until the earlier of (A) the date on which the final Earn-Out Payment (if any) is paid or the Earn-Out Statement becomes final and binding reflecting that no Earn-Out Payment is payable and (B) December 31, 2028, Buyer shall not, and shall cause its Affiliates not to, Promote in the United States any non-opioid product indicated for the management of post-surgical pain, other than the Earn-Out Product; provided that such restriction on Promotion shall not apply to any non-opioid pain drug that can be Promoted for use in combination or concurrent administration with the Earn-Out Product, or for post-operative conditions in which the Earn-Out Product is not indicated.
Section 4.3 Bad Faith. Notwithstanding Section 4.1 and Section 4.2, Buyer covenants and agrees that it shall not take any action, or fail to take any action, whose primary purpose is to avoid the achievement of the Milestones or the payment of the Royalty Payments and Earn-Out Payments.
Section 4.4 Progress Reporting; Access. From the Closing until December 31, 2029, within fourteen (14) days after the filing with the SEC of Buyer’s Quarterly Report on Form 10-Q for each of the first three (3) calendar quarters of each calendar year (or, if Buyer is not then a reporting company, within sixty (60) days after the end of each such calendar quarter), Buyer shall, and shall cause the other members of the Buyer Rights Chain Group to provide to Buyer such information as is necessary to permit Buyer to, deliver to Seller a written report setting forth the Net Sales of each Royalty Product and the Earn-Out Product for such calendar quarter and for the year-to-date period, together with, for each month in such calendar quarter and for each Royalty Product and the Earn-Out Product, by NDC (SKU), at least (a) the unit volume sold and (b) the net selling price per unit. Such reports are provided for informational purposes only, shall not constitute Payment Statements and shall not be subject to Section 5. The fourth calendar quarter shall be addressed solely in the applicable Royalty Report or Earn-Out Statement.
5. DISPUTE RESOLUTION FOR ROYALTY AND EARN-OUT PAYMENTS
Section 5.1 Payment Dispute Notice.
| (a) | If Seller disagrees with the calculation of Net Sales or of any Royalty Payment or Earn-Out Payment set forth in any Royalty Report or the Earn-Out Statement (each, a “Payment Statement”), Seller shall, within sixty (60) days after Seller’s receipt of such Payment Statement (the “Payment Dispute Period”), deliver written notice (a “Payment Dispute Notice”) to Buyer setting forth, in reasonable detail, each item in dispute, the basis for such dispute and Seller’s calculation of such disputed item, to the extent known. Any items in a Payment Statement not specifically disputed in the Payment Dispute Notice shall be deemed accepted by Seller and shall be final and binding on the parties. Following the expiration of the Payment Dispute Period, the Payment Statement shall be final and binding on the parties. Following delivery of any Payment Statement and during the Payment Dispute Period, Buyer shall, and shall cause the other members of the Buyer Rights Chain Group (including any Transferee) to, provide Seller and its Representatives with reasonable access, during normal business hours upon reasonable advance notice, to the work papers and underlying records used in preparing the applicable Payment Statement, subject to customary confidentiality and access letters. |
| (b) | Following delivery of any Payment Statement and during the Payment Dispute Period, Seller shall have the right, at its own expense and upon reasonable advance written notice, to engage a nationally recognized independent certified public accounting firm (reasonably acceptable to Buyer and subject to customary confidentiality obligations to Buyer) to review, during normal business hours, the books and records of Buyer and the other members of the Buyer Rights Chain Group (including any Transferee) solely to the extent necessary to verify the calculation of Net Sales and the Royalty Payment or Earn-Out Payment set forth in such Payment Statement. Any such review (i) may be conducted only once with respect to each Payment Statement, (ii) shall be limited to the calendar year covered by such Payment Statement, and (iii) shall not cover any period covered by a Payment Statement that has become final and binding. Such accountant shall report to Seller only whether there has been an underpayment or overpayment and, if so, the amount thereof, and any such finding shall be asserted, if at all, solely through a Payment Dispute Notice delivered within the Payment Dispute Period and resolved in accordance with Section 5.2 and Section 5.3. Buyer shall, and shall cause the other members of the Buyer Rights Chain Group (including any Transferee) to, maintain books and records sufficient to verify the calculation of Net Sales for each calendar year until the date on which the Payment Statement for such calendar year becomes final and binding. If the amount finally determined pursuant to this Section 5 reflects an underpayment of more than five percent (5%) of the amount set forth in the applicable Payment Statement, Buyer shall reimburse Seller for the reasonable and documented fees of such accountant. |
Section 5.2 Negotiation. If Seller timely delivers a Payment Dispute Notice, Buyer and Seller shall use commercially reasonable efforts to resolve such disputed items within thirty (30) days following Buyer’s receipt of such Payment Dispute Notice. If Buyer and Seller resolve all disputed items, the Payment Statement, as modified to reflect such resolution, shall be final and binding on the parties for all purposes hereunder.
Section 5.3 Independent Expert. If Buyer and Seller are unable to resolve all disputed items within thirty (30) days following Buyer’s receipt of the Payment Dispute Notice, either party may submit any unresolved disputed items to the Independent Expert for resolution. The Independent Expert shall act as an expert and not as an arbitrator and shall determine, based solely on written submissions by Buyer and Seller (each to be submitted within ten (10) days of the submission of the dispute to the Independent Expert, and each party may deliver one written reply to the other party’s submission within ten (10) days after receipt thereof), and not by independent review, only those items remaining in dispute and shall render a written decision as to the disputed items and the resulting Net Sales, Royalty Payment or Earn-Out Payment, as applicable, as promptly as reasonably practicable, but in no event later than thirty (30) days after receipt of both parties’ final submissions. The Independent Expert may request in writing such additional information as it reasonably requires, and Buyer shall, and shall cause its Affiliates to, provide such information within ten (10) Business Days after such request. Neither Buyer nor Seller (nor any of their respective Affiliates or Representatives) shall have any ex parte communications or meetings with the Independent Expert regarding the subject matter of the dispute without the prior written consent of the other party; provided that the foregoing shall not restrict (x) communications relating solely to the engagement, scheduling or other administrative matters, or (y) any party’s response to a written request for information from the Independent Expert, so long as a copy of any written communication delivered to the Independent Expert is concurrently delivered to the other party and the other party is given a reasonable opportunity to participate in any oral communication. The Independent Expert’s decision shall (i) be based solely on the definitions and other applicable terms of the Agreement and this Schedule 1 (including, in the case of Net Sales, GAAP, consistently applied), (ii) not assign a value to any item in dispute greater than the highest value claimed for such item or less than the lowest value claimed for such item, and (iii) be final and binding on the parties for all purposes hereunder, absent fraud or manifest error. All fees and expenses of the Independent Expert shall be borne on a proportional basis by Buyer, on the one hand, and Seller, on the other hand, based on the percentage that the portion of the contested amount not awarded in favor of such party bears to the amount actually contested by such party. For example, if Buyer’s calculations would have resulted in a $100,000 net payment to Buyer, and Seller’s calculations would have resulted in a $100,000 net payment to Seller, and the Independent Expert’s final determination results in an aggregate payment of $50,000 to Seller, then Buyer and Seller would bear 75% and 25%, respectively, of such fees and expenses. The provisions of Sections 5.1 through 5.3 shall apply mutatis mutandis to any dispute by Buyer of the findings of an audit conducted under Section 5.1(b), with references to Seller, the Payment Statement and the Payment Dispute Notice being read as references to Buyer, the accountant’s report and Buyer’s written notice of dispute, respectively.
Section 5.4 Payment Following Resolution; Interest. Any underpayment finally determined pursuant to Section 5 shall be paid by Buyer to Seller within fifteen (15) Business Days after such determination. Any overpayment so determined shall, at Buyer’s election, be repaid by Seller to Buyer within fifteen (15) Business Days after such determination or credited against any future payments owing to Seller under this Schedule 1. Any amount not paid when due (including any amount finally determined pursuant to Section 5 to have been payable on an earlier date) shall bear simple interest at the prime rate as published in The Wall Street Journal in effect on the date such payment was required to be made plus two percent (2%) per annum from the date originally due until paid.
Section 5.5 Exclusive Remedy. The procedures set forth in this Section 5 shall be the sole and exclusive method for resolving any dispute regarding the calculation of Net Sales or the amount of any Royalty Payment or Earn-Out Payment; provided that any dispute as to whether Buyer has breached Section 4.2 or Section 4.3, and any action to enforce a final determination of the Independent Expert, shall be resolved in accordance with Section 10.8 (Governing Law; Jurisdiction) of the Agreement.
6. GENERAL
Section 6.1 Nature of Rights. The right of Seller to receive the Royalty Payments and the Earn-Out Payments (a) is solely a contractual right and is not a security for purposes of any federal or state securities Laws, (b) will not be evidenced by any certificate or other instrument, (c) does not represent any equity or ownership interest in Buyer or any of its Affiliates or in the Business Products, (d) is an unsecured obligation of Buyer, and (e) may not be sold, assigned, transferred, pledged, encumbered or otherwise disposed of, in whole or in part, by Seller (other than by operation of Law or to a successor to all or substantially all of the assets of Seller) without the prior written consent of Buyer, and any purported transfer in violation of this Section 6.1 shall be null and void ab initio.
Section 6.2 Withholding. Buyer shall be entitled to deduct and withhold from any amount payable under this Schedule 1 such amounts as are required to be deducted and withheld under applicable Tax Law, in accordance with Section 2.8 (Withholding) of the Agreement.
Section 6.3 Set-Off. Buyer shall be entitled to set off against any Royalty Payment or Earn-Out Payment otherwise payable to Seller (a) any amount finally determined to be owed by Seller to Buyer pursuant to the purchase price adjustment provisions of the Agreement, (b) any overpayment finally determined pursuant to Section 5, and (c) any other amount finally determined to be owed by Seller to Buyer or any Buyer Indemnified Party under the Agreement or any Ancillary Agreement, in each case of clauses (a), (b) and (c), solely to the extent such amount is then due and payable and is not the subject of a good faith dispute.
Section 6.4 Incorporation. This Schedule 1 forms part of, and shall be construed in accordance with, the Agreement, and Article X (General Provisions) of the Agreement (including provisions regarding notices, governing law, jurisdiction, waiver of jury trial, specific performance, amendment and waiver, and interpretation) shall apply to this Schedule 1 mutatis mutandis. In the event of any conflict between this Schedule 1 and the body of the Agreement with respect to the Royalty Payments or the Earn-Out Payments, this Schedule 1 shall control.
Section 6.5 Transfer of the Obligation; Divestment.
| (a) | Buyer shall not, and shall cause its Affiliates not to, consummate any sale, assignment, transfer or exclusive license (a “Transfer”) to any Person (other than Buyer or any of its Affiliates) of all or substantially all of the rights to commercialize any Business Product in the United States (a “Divestment Transaction”) unless, in (i) the case of a Transfer of all of the Royalty Products or the Earn-Out Product, as applicable, prior to or concurrently with such consummation, the transferee (the “Transferee”) shall expressly assume in writing Buyer’s obligations under this Schedule 1 solely with respect to the Business Product(s) subject to such Divestment Transaction (the “Transferred Products”) and agree in writing to provide the information and access contemplated by Section 4.4 and Section 5 (including Section 5.1(b)) with respect to the Transferred Products, (ii) the case of a Transfer of less than all of the Royalty Products, Buyer shall obtain from the Transferee (a “Royalty Product Purchaser”) written agreement and assumption by such Transferee of all reporting and information requirements of Buyer under this Schedule 1 to Seller and provide to Seller information regarding the sales of such Royalty Product(s) sufficient to allow Buyer to calculate Net Sales and provide Royalty Reports as provided herein, and the information and access contemplated by Section 4.4 and Section 5 (including Section 5.1(b)), and (iii) each case, the Transferee (or its ultimate parent entity) shall be a Qualified Transferee. Buyer shall deliver to Seller a copy of such written assumption or agreement within fifteen (15) Business Days after the consummation of such Divestment Transaction. Notwithstanding clause (iii) of the first sentence of this Section 6.5(a), Buyer and its Affiliates may consummate a Divestment Transaction with respect to SUSTOL® (granisetron extended-release injection) with any Person, regardless of whether such Person is a Qualified Transferee, subject only to compliance with clause (i) or (ii) (as applicable) of such sentence. Upon the consummation of a Divestment Transaction in compliance with this Section 6.5(a), Net Sales of the Transferred Products by the Transferee shall continue to be included in Net Sales for purposes of this Schedule 1. For the avoidance of doubt, none of (A) any license or sublicense that is not a Divestment Transaction, (B) any transaction with or among Buyer and its Affiliates, or (C) any change of control of Buyer shall constitute a Divestment Transaction. “Qualified Transferee” means a Person that, as of the date of execution of the definitive agreement for the applicable Divestment Transaction, has (x) if such Person or its ultimate parent entity has publicly listed equity securities, a market capitalization, or (y) otherwise, net assets as reflected on its most recent audited balance sheet, in either case at least equal to the market capitalization or net assets (as applicable) of Buyer as of such date. |
| (b) | Buyer may assign or delegate its obligations under this Schedule 1, in whole or in part, to any wholly owned Affiliate of Buyer without Seller’s consent; provided that no such assignment or delegation shall relieve Buyer of, and Buyer shall remain fully liable for, its obligations under this Schedule 1. For the avoidance of doubt, no Divestment Transaction, and no license, sublicense or other grant of rights to any Person, shall reduce or impair Seller’s right to receive the Royalty Payments and the Earn-Out Payments calculated on Net Sales of the Business Products by or on behalf of any member of the Buyer Rights Chain Group. |
| (c) | The obligations of Buyer under this Schedule 1 shall survive any merger, consolidation, sale of equity securities or other transaction resulting in a change of control of Buyer, and Buyer shall remain bound by, and responsible for the performance of, such obligations as a continuing entity following any such transaction (or, if Buyer is not the surviving entity of a merger or consolidation, such obligations shall be binding upon the surviving entity by operation of Law). Buyer shall provide written notice to Seller upon the occurrence of any change of control. |
Schedule 1.1K
Termination Eligible Employees
[Omitted]
Schedule 6.1(a)
Allocation Exhibit
[Omitted]
Exhibit 10.1
Execution Version
VOTING AND SUPPORT AGREEMENT
This Voting and Support Agreement (this “Agreement”) is made and entered into as of November 8, 2026 (the “Agreement Date”), by and among CorMedix Inc., a Delaware corporation (“Buyer”), Heron Therapeutics, Inc., a Delaware corporation (“Seller”), and the undersigned stockholder of Seller (the “Stockholder”). Each of Buyer, Seller and the Stockholder is sometimes referred to herein as a “Party.” Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Purchase Agreement (as defined below).
RECITALS
1. Concurrently with the execution and delivery of this Agreement, Buyer and Seller are entering into an Asset Purchase Agreement (as it may be amended, supplemented or otherwise modified from time to time, the “Purchase Agreement”) that, among other things and subject to the terms and conditions set forth therein, provides for the sale by Seller of the Transferred Assets to, and assumption of the Assumed Liabilities by, Buyer, in each case, on the terms and subject to the conditions set forth therein (the “Asset Sale”).
2. As of the Agreement Date, the Stockholder is the record and/or “beneficial owner” (within the meaning of Rule 13d-3 under the Exchange Act) of the number of shares of common stock, par value $0.01 per share, of Seller (“Seller Common Stock”), set forth next to the Stockholder’s name on Schedule A hereto (the “Owned Shares,” and together with such additional shares of capital stock of Seller that become beneficially owned (within the meaning of Rule 13d-3 under the Exchange Act) by the Stockholder, whether upon the receipt of dividends, conversion of convertible securities or otherwise, after the Agreement Date until the Expiration Time, the “Covered Shares”).
3. In connection with Buyer’s entry into the Purchase Agreement, as a condition and inducement to the willingness of Buyer to enter into the Purchase Agreement, the Stockholder has agreed to enter into this Agreement with respect to the Stockholder’s Covered Shares.
NOW, THEREFORE, in consideration of the foregoing and the respective representations, warranties, covenants and agreements set forth below and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as follows:
1. Agreement to Vote the Covered Shares.
1.1 Voting Agreement. From the Agreement Date until the Expiration Time (as defined below), at every meeting of Seller’s stockholders (whether annual, special or otherwise) at which any of the following matters are to be voted on (and at every adjournment, recess or postponement thereof), and in connection with any action by written consent of Seller’s stockholders, the Stockholder shall, and shall cause any Affiliate controlled by the Stockholder that is a holder of record of any Covered Shares to, vote (including via proxy) or execute consents with respect to all of the Stockholder’s Covered Shares: (a) in favor of (i) the adoption of the Purchase Agreement and the approval of the Transactions, (ii) any proposal to adjourn or postpone any meeting of Seller’s stockholders to a later date if there are not sufficient votes to obtain the Seller Stockholder Approval and (iii) any other matters necessary to secure the Seller Stockholder Approval; and (b) against (i) any action or agreement that would reasonably be expected to (x) result in any of the conditions set forth in Article VII of the Purchase Agreement not being satisfied or (y) result in a material breach of any covenant, representation or warranty or any other obligation or agreement of Seller under the Purchase Agreement, (ii) any Acquisition Proposal or Acquisition Transaction, and (iii) any other agreement, transaction or other matter that is intended to, or would reasonably be expected to, materially impede, frustrate, delay, or interfere with, or materially and adversely affect, the consummation of the Asset Sale and the other Transactions (clauses (a) and (b), the “Covered Proposals”).
1.2 Adverse Amendment. For the avoidance of doubt, nothing in this Agreement shall require the Stockholder to vote in favor of the adoption of the Purchase Agreement as amended by any amendment to the Purchase Agreement, entered into after the Agreement Date without the prior written consent of the Stockholder, that (A) decreases the amount of, changes the form or terms of or delays the timing of payment or allocation of, any portion of the Transaction Consideration (including the Royalty Payments and the Earn-Out Payments); (B) imposes any material restrictions or any additional material conditions on the consummation of the Asset Sale or the payment of the Transaction Consideration to Seller; or (C) is otherwise materially adverse to the Stockholder in particular or to any other of Seller’s stockholders (each of the foregoing, an “Adverse Amendment”).
1.3 Quorum. Until the Expiration Time, at every meeting of Seller’s stockholders (and at every adjournment or postponement thereof) at which a Covered Proposal is to be voted upon, the Stockholder shall be represented in person or by proxy at such meeting (or cause the holders of record on any applicable record date to be represented in person or by proxy at such meeting) in order for the Stockholder’s Covered Shares to be counted as present for purposes of establishing a quorum.
1.4 No Transfer of Shares. The Stockholder covenants and agrees that during the period from the Agreement Date until the Expiration Time, the Stockholder will not, directly or indirectly, (a) transfer, assign, sell, pledge, encumber, hypothecate or otherwise dispose (whether by sale, liquidation, dissolution, dividend or distribution) of or consent to any of the foregoing (“Transfer”), or cause to be Transferred, any of the Stockholder’s Covered Shares, (b) deposit any of the Stockholder’s Covered Shares into a voting trust or enter into a voting agreement or arrangement with respect to such Covered Shares or grant any proxy or power of attorney with respect thereto, (c) enter into any contract, option or other arrangement or undertaking with respect to the Transfer of any of the Stockholder’s Covered Shares, (d) enter into any swap (including a total return swap) or similar derivative transaction with respect to any of the Stockholder’s Covered Shares or (e) take any other action or enter into any agreement or undertaking that would reasonably be expected to restrict, limit or interfere with the performance of the Stockholder’s obligations hereunder; provided, however, that the Stockholder may Transfer any such Covered Shares (i) pursuant to any sell-to-cover or net settlement transactions executed for the purpose of satisfying any Tax withholding obligations or exercise price in connection with the vesting, exercise or settlement of any stock options, restricted stock units or other equity awards granted by Seller that are held by such Stockholder (including pursuant to any trading plan intended to satisfy Rule 10b5-1(c) under the Exchange Act that is in effect as of the Agreement Date); or (ii) (A) if the Stockholder is an individual, to any member of the Stockholder’s immediate family or to a trust for the benefit of the Stockholder or any member of the Stockholder’s immediate family or (B) if the Stockholder is not an individual, to any Affiliate controlled by the Stockholder, in each case, only if prior to such transfer the transferee of such Covered Shares evidences in a writing reasonably satisfactory to Buyer such transferee’s agreement to be bound by and subject to the terms and provisions hereof to the same effect as the transferring Stockholder, and no such Transfer shall relieve the transferring Stockholder of its obligations hereunder; provided that any such writing shall not be required in connection with ordinary course monthly rebalancings, if any, between Stockholder’s Affiliates. Any Transfer or attempted Transfer of any Covered Shares in violation of this Section 1.4 shall be null and void and of no effect whatsoever, and Seller shall not register any such Transfer. For the avoidance of doubt, the fact, in and of itself, that any Covered Shares are held in a margin account or pledged pursuant to the terms thereof shall not be deemed a breach or violation of any representation, warranty or covenant contained herein; provided no event has occurred that, with or without notice or lapse of time or both, would result in foreclosure on the Covered Shares.
| 2 |
1.5 Expiration Time. For purposes of this Agreement, “Expiration Time” means the earliest to occur of (a) the Closing, (b) such date and time as the Purchase Agreement is validly terminated in accordance with its terms, (c) the entry into or adoption of an Adverse Amendment, (d) the written agreement of the Stockholder, Buyer and Seller to terminate this Agreement, and (e) a Change of Recommendation, provided that such Change of Recommendation is made in compliance with Seller’s obligations under the Purchase Agreement.
1.6 Certain Other Covenants. From the Agreement Date until the Expiration Time, (a) the Stockholder shall, in its capacity as a stockholder of Seller, comply with the restrictions set forth in Section 5.3(a) of the Purchase Agreement as if it were a party thereto, subject to the exceptions set forth in Section 5.3 of the Purchase Agreement that are applicable to Seller (which shall apply to the Stockholder to the same extent applicable to Seller), and (b) the Stockholder shall not commence or participate in any Action against Buyer, Seller or any of their respective Affiliates challenging the validity of, or seeking to enjoin the operation of, any provision of this Agreement or the Purchase Agreement (other than any Action to enforce the terms of this Agreement).
2. Representations and Warranties of the Stockholder. The Stockholder hereby represents and warrants to Buyer and Seller that:
2.1 Organization; Due Authority. If the Stockholder is not an individual, it is duly organized, validly existing and in good standing under the Laws of the jurisdiction in which it is incorporated, formed, organized or constituted, and the execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereby are within the Stockholder’s corporate, limited liability company or organizational powers and have been duly authorized by all necessary corporate, limited liability company or organizational actions on the part of the Stockholder. If the Stockholder is an individual, the Stockholder has full legal capacity, right and authority to execute and deliver this Agreement and to perform his or her obligations hereunder. This Agreement has been duly and validly executed and delivered by the Stockholder and constitutes a valid and binding obligation of the Stockholder enforceable against it in accordance with its terms (assuming due and valid execution by Seller and Buyer), except as enforcement may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors’ rights generally and by general principles of equity.
2.2 Ownership of the Covered Shares. (a) The Stockholder is, as of the Agreement Date, the beneficial or record owner of, and has good and marketable title to, the Stockholder’s Owned Shares, free and clear of any proxy, voting restriction, adverse claim, or other Encumbrances, other than any of the foregoing created by this Agreement and restrictions on transfer under applicable securities Laws and (b) as of the Agreement Date, except as set forth on Schedule A (including any voting power shared with any Affiliate, general partner, investment manager, managing member or other Person, as described thereon), the Stockholder has sole voting power over all of such Owned Shares beneficially owned by the Stockholder. As of the Agreement Date, the Stockholder does not own, beneficially or of record, any Seller Common Stock (or any securities convertible, exercisable or exchangeable for, or rights to purchase or acquire, any Seller Common Stock) other than (i) the Owned Shares, (ii) any stock options, restricted stock units or other equity awards granted by Seller and held by the Stockholder, and (iii) any warrants (including pre-funded warrants), convertible preferred stock, convertible notes or other securities convertible into, or exercisable or exchangeable for, Seller Common Stock, in each case of clauses (ii) and (iii), set forth opposite the Stockholder’s name on Schedule A (the securities described in clauses (ii) and (iii), collectively, the “Other Seller Securities”). As of the Agreement Date, other than pursuant to the terms of any Other Seller Securities, any trading plan intended to satisfy Rule 10b5-1(c) under the Exchange Act that is in effect as of the Agreement Date or as otherwise set forth on Schedule A, there are no agreements or arrangements of any kind, contingent or otherwise, obligating the Stockholder to Transfer, or cause to be Transferred, any of the Owned Shares and no Person has any contractual or other right or obligation to purchase or otherwise acquire any of such Owned Shares.
| 3 |
2.3 No Conflict; Consents.
a. The execution and delivery of this Agreement by the Stockholder does not, and the performance by the Stockholder of such Stockholder’s obligations under this Agreement and the compliance by the Stockholder with any provisions hereof does not and will not: (i) conflict with or violate any laws applicable to the Stockholder; or (ii) result in any breach of or constitute a default (or an event that with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, or result in the creation of an Encumbrance on any of the Owned Shares beneficially owned by the Stockholder pursuant to, any Contract or obligation to which the Stockholder is a party or by which the Stockholder is subject, except, in each case, as would not, individually or in the aggregate, reasonably be expected to prevent or materially impair or delay the Stockholder’s ability to perform its obligations hereunder.
b. No consent, approval, order or authorization of, or registration, declaration or, except as required by the rules and regulations promulgated under the Exchange Act, filing with, any Governmental Authority or any other Person, is required by or with respect to the Stockholder in connection with the execution and delivery of this Agreement or the consummation by it of the transactions contemplated hereby.
2.4 Litigation. As of the Agreement Date, there is no Action pending or, to the knowledge of the Stockholder, threatened against the Stockholder that in any manner questions or challenges the beneficial or record ownership of the Stockholder’s Owned Shares, the validity of this Agreement or any action taken or to be taken by the Stockholder in connection with this Agreement.
3. Representations and Warranties of Buyer. Buyer hereby represents and warrants to the Stockholder and Seller that:
3.1 Due Authority. Buyer has the full power and capacity to make, enter into and carry out the terms of this Agreement. Buyer is duly organized, validly existing and in good standing in accordance with the laws of its jurisdiction of formation. The execution and delivery of this Agreement, the performance of Buyer’s obligations hereunder, and the consummation of the transactions contemplated hereby have been validly authorized, and no other consents or authorizations are required to give effect to this Agreement or the transactions contemplated by this Agreement. This Agreement has been duly and validly executed and delivered by Buyer and constitutes a valid and binding obligation of Buyer enforceable against it in accordance with its terms (assuming due and valid execution by the Stockholder and Seller), except as enforcement may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors’ rights generally and by general principles of equity.
| 4 |
3.2 No Conflict; Consents.
a. The execution and delivery of this Agreement by Buyer does not, and the performance by Buyer of its obligations under this Agreement and the compliance by Buyer with the provisions hereof do not and will not: (i) conflict with or violate any laws applicable to Buyer; or (ii) result in any breach of or constitute a default (or an event that with notice or lapse of time or both would become a material default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any Contract or obligation to which Buyer is a party or by which Buyer is subject, except, in the case of clause (ii), as would not, individually or in the aggregate, reasonably be expected to prevent or materially impair or delay Buyer’s ability to perform its obligations hereunder.
b. No consent, approval, order or authorization of, or registration, declaration or, except as required by the rules and regulations promulgated under the Exchange Act, filing with, any Governmental Authority or any other Person, is required by or with respect to Buyer in connection with the execution and delivery of this Agreement or the consummation by Buyer of the transactions contemplated hereby.
4. Representations and Warranties of Seller. Seller hereby represents and warrants to Buyer and the Stockholder that:
4.1 Due Authority. Seller has the full power and capacity to make, enter into and carry out the terms of this Agreement. Seller is duly organized, validly existing and in good standing in accordance with the laws of its jurisdiction of formation. The execution and delivery of this Agreement, the performance of Seller’s obligations hereunder, and the consummation of the transactions contemplated hereby have been validly authorized, and no other consents or authorizations are required to give effect to this Agreement or the transactions contemplated by this Agreement. This Agreement has been duly and validly executed and delivered by Seller and constitutes a valid and binding obligation of Seller enforceable against it in accordance with its terms (assuming due and valid execution by the Stockholder and Buyer), except as enforcement may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors’ rights generally and by general principles of equity.
4.2 No Conflict; Consents.
a. The execution and delivery of this Agreement by Seller does not, and the performance by Seller of its obligations under this Agreement and the compliance by Seller with the provisions hereof do not and will not: (i) conflict with or violate any laws applicable to Seller; or (ii) result in any breach of or constitute a default (or an event that with notice or lapse of time or both would become a material default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any Contract or obligation to which Seller is a party or by which Seller is subject, except, in the case of clause (ii), as would not, individually or in the aggregate, reasonably be expected to prevent or materially impair or delay Seller’s ability to perform its obligations hereunder.
| 5 |
b. No consent, approval, order or authorization of, or registration, declaration or, except as required by the rules and regulations promulgated under the Exchange Act, filing with, any Governmental Authority or any other Person, is required by or with respect to Seller in connection with the execution and delivery of this Agreement or the consummation by Seller of the transactions contemplated hereby.
5. Miscellaneous.
5.1 No Ownership Interest. Nothing contained in this Agreement shall be deemed to vest in Buyer or Seller any direct or indirect ownership or incidence of ownership of or with respect to the Covered Shares. All rights, ownership and economic benefits of and relating to the Covered Shares shall remain vested in and belong to the Stockholder, and Buyer and Seller shall have no authority to direct the Stockholder in the voting or disposition of any of the Covered Shares, except as otherwise provided herein.
5.2 Certain Adjustments. In the event of any change in Seller Common Stock by reason of any split-up, reverse share split, recapitalization, combination, reclassification, exchange of shares or the like, the terms “Seller Common Stock,” “Owned Shares” and “Covered Shares” shall be deemed to refer to and include such shares as well as any securities into which or for which any or all of such shares may be changed or exchanged or which are received in such transaction.
5.3 Amendment and Modification; Waiver. This Agreement may not be amended, modified or supplemented in any manner, whether by course of conduct or otherwise, except by an instrument in writing specifically designated as an amendment hereto, signed on behalf of each Party. No failure or delay of any Party in exercising any right or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right or power, or any abandonment or discontinuance of steps to enforce such right or power, or any course of conduct, preclude any other or further exercise thereof or the exercise of any other right or power. Any agreement on the part of any Party to any such waiver shall be valid only if set forth in a written instrument executed and delivered by such Party (or, in the case of a Party that is not an individual, by a duly authorized officer on behalf of such Party).
5.4 Fees and Expenses. All fees and expenses incurred in connection with or related to this Agreement and the transactions contemplated hereby shall be paid by the Party incurring such fees or expenses, whether or not the Transactions are consummated.
| 6 |
5.5 Notices. All notices, requests, consents, claims, demands, waivers and other communications hereunder shall be in writing and shall be deemed to have been given (i) when delivered by hand (with proof of delivery); (ii) when received by the addressee if sent by a nationally recognized overnight courier (receipt requested); or (iii) on the date sent by e-mail (notice deemed given upon transmission so long as there is no return error message or other notification of non-delivery received by the sender) if sent during normal business hours of the recipient, and on the next Business Day if sent after normal business hours of the recipient. Such communications must be sent to the respective Parties at the following addresses (or at such other address for a Party as shall be specified in a notice given in accordance with this Section 5.5):
| a. | if to the Stockholder, to the address and recipient set forth on Schedule A attached hereto. |
| b. | if to Buyer, to: |
CorMedix Inc. 389 Interpace Pkwy, Suite 450 Parsippany, New Jersey 07054 Attention: [***] Email: [***]
with a copy (which shall not constitute notice) to:
Willkie Farr & Gallagher LLP 787 7th Avenue New York, New York 10019 Attention: [***] Email: [***] |
| c. | if to Seller, to: |
Heron Therapeutics, Inc. 25 Fenton Main Street, Suite 300 Cary, NC 27511 Attention: General Counsel Email: [***]
with a copy (which shall not constitute notice) to: DLA
Piper LLP (US) Short
Hills, New Jersey 07078-2704 |
|
| Email: [***] |
| 7 |
5.6 Governing Law; Jurisdiction; Waiver of Jury Trial. This Agreement and all disputes or controversies arising out of or relating to this Agreement or the Transactions shall be governed by, and construed in accordance with, the internal laws of the State of Delaware, without regard to the laws of any other jurisdiction that might be applied because of the conflicts of laws principles of the State of Delaware or any other jurisdiction.
a. THIS AGREEMENT SHALL BE DEEMED TO BE MADE AND ALL CLAIMS OR CAUSES OF ACTION (WHETHER IN CONTRACT OR TORT) THAT MAY BE BASED UPON, ARISE OUT OF OR RELATE TO THIS AGREEMENT, OR THE NEGOTIATION, EXECUTION OR PERFORMANCE OF THIS AGREEMENT OR THE ASSET SALE, SHALL BE INTERPRETED, CONSTRUED AND GOVERNED IN ALL RESPECTS BY AND IN ACCORDANCE WITH THE LAWS OF THE STATE OF DELAWARE, REGARDLESS OF THE LAWS THAT MIGHT OTHERWISE GOVERN UNDER APPLICABLE CONFLICTS OF LAW PRINCIPLES. The Parties hereby irrevocably submit to the personal jurisdiction of the Court of Chancery of the State of Delaware or, if such Court of Chancery shall lack subject matter jurisdiction, the federal courts of the United States of America located in the County of New Castle, Delaware, solely in respect of the interpretation and enforcement of the provisions of (and any claim or cause of action arising under or relating to) this Agreement and of the documents referred to in this Agreement, and in respect of the Transactions, and hereby waive, and agree not to assert, as a defense in any action, suit or proceeding for the interpretation or enforcement hereof or of any such document, that it is not subject thereto or that such action, suit or proceeding may not be brought or is not maintainable in said courts or that the venue thereof may not be appropriate or that this Agreement or any such document may not be enforced in or by such courts, and the Parties irrevocably agree that all claims relating to such action, suit or proceeding shall be heard and determined in such courts. The Parties hereby consent to and grant any such court jurisdiction over the person of such Parties and, to the extent permitted by Law, over the subject matter of such dispute and agree that mailing of process or other papers in connection with any such action, suit or proceeding in the manner provided in Section 5.5 or in such other manner as may be permitted by Law shall be valid and sufficient service thereof.
b. EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES TO THE FULLEST EXTENT PERMITTED BY LAW ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY ACTION, SUIT OR PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS. EACH PARTY HEREBY CERTIFIES AND ACKNOWLEDGES THAT (i) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF ANY ACTION, SUIT OR PROCEEDING, SEEK TO ENFORCE THE FOREGOING WAIVER, (ii) EACH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (iii) EACH PARTY MAKES THIS WAIVER VOLUNTARILY AND (iv) EACH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE TRANSACTIONS BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS CONTAINED IN THIS SECTION 5.6.
| 8 |
5.7 Documentation and Information. The Stockholder consents to and authorizes the publication and disclosure by Buyer and Seller of the Stockholder’s identity and holding of the Covered Shares, and the terms of this Agreement (including, for the avoidance of doubt, the disclosure of this Agreement), in the Proxy Statement and any other disclosure document required in connection with the Purchase Agreement, the Asset Sale and the other Transactions.
5.8 Further Assurances. The Stockholder agrees, from time to time, at Buyer’s reasonable request, to execute and deliver such additional documents and take all such further action as may be reasonably required to consummate and make effective, in the most expeditious manner practicable, the transactions contemplated by this Agreement; provided that the Stockholder shall not be required to take any action, or refrain from taking any action, that is inconsistent with, or that expands or increases any of, the Stockholder’s obligations under this Agreement.
5.9 Enforcement. The Parties agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. Accordingly, each of the Parties shall be entitled to specific performance of the terms hereof, including an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement, this being in addition to any other remedy to which such Party is entitled at law or in equity. Each of the Parties hereby further waives (a) any defense in any action for specific performance that a remedy at law would be adequate and (b) any requirement under any law to post security as a prerequisite to obtaining equitable relief.
5.10 Entire Agreement. This Agreement (including the Schedule hereto) constitutes the entire agreement, and supersedes all prior written agreements, arrangements, communications and understandings and all prior and contemporaneous oral agreements, arrangements, communications and understandings among the Parties with respect to the subject matter hereof. This Agreement shall not be deemed to contain or imply any restriction, covenant, representation, warranty, agreement or undertaking of any Party with respect to the subject matter hereof other than those expressly set forth herein, and none shall be deemed to exist or be inferred with respect to the subject matter hereof. For the avoidance of doubt, nothing in this Agreement shall be deemed to amend, alter or modify, in any respect, any of the provisions of the Purchase Agreement.
| 9 |
5.11 Interpretation. For purposes of this Agreement, whenever the context requires: (a) the singular number shall include the plural, and vice versa; (b) the masculine gender shall include the feminine and neuter genders; (c) the feminine gender shall include the masculine and neuter genders; and (d) the neuter gender shall include the masculine and feminine genders. The Parties agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting party shall not be applied in the construction or interpretation of this Agreement. As used in this Agreement, (i) the words “include” and “including,” and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words “without limitation,” (ii) the word “extent” in the phrase “to the extent” shall mean the degree to which a subject or other thing extends, and such phrase shall not mean simply “if,” (iii) the word “or” shall not be exclusive, (iv) the word “will” shall be construed to have the same meaning as the word “shall” and (v) the words “herein,” “hereof” and “hereunder,” and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof. Except as otherwise indicated, all references in this Agreement to “Sections” and “Schedules” are intended to refer to Sections of this Agreement and Schedules to this Agreement. The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. When calculating the period of time before which, within which or after which any act is to be done or step taken pursuant to this Agreement, (i) the date that is the reference date in calculating such period shall be excluded and (ii) if the last day of such period is not a Business Day, the period in question shall end on the next succeeding Business Day. All references in this Agreement to a number of days are to such number of calendar days unless Business Days are specified. Unless otherwise specifically indicated, any reference in this Agreement to $ means U.S. dollars. References to a Person are also to its permitted successors and assigns. The Parties agree that they have been represented by counsel during the negotiation, drafting, preparation and execution of this Agreement and, therefore, waive the application of any law or rule of construction providing that ambiguities in an agreement or other document will be construed against the Party drafting such agreement or document.
5.12 Assignment; Successors; Parties in Interest. Neither this Agreement nor any of the rights, interests or obligations under this Agreement may be assigned or delegated, in whole or in part, by operation of law or otherwise, by any Party without the prior written consent of the other Parties; provided, that Buyer may, with Seller’s consent (which consent shall not be unreasonably withheld, conditioned or delayed), assign its rights, but not its obligations, under this Agreement, in whole or in part, to any Affiliate of Buyer; provided, further, that no such assignment shall relieve Buyer of its obligations hereunder. Subject to the preceding sentence, this Agreement will be binding upon, inure to the benefit of, and be enforceable by, the Parties and their respective successors and assigns. This Agreement shall be binding upon and inure solely to the benefit of each Party, and nothing in this Agreement, express or implied, is intended to or shall confer upon any Person other than the Parties and their respective successors and permitted assigns any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.
| 10 |
5.13 Severability. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the Parties agree that the court making such determination shall have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the Parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision.
5.14 Counterparts; Signatures. This Agreement may be executed in one (1) or more counterparts, each of which shall be deemed an original but all of which together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each of the Parties and delivered to the other Parties, it being understood that the Parties need not sign the same counterpart. This Agreement may be executed and delivered by facsimile transmission, by electronic mail in “portable document format” (“.pdf”) form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, or by combination of such means.
5.15 Non-survival of Representations and Warranties. None of the representations and warranties in this Agreement or in any schedule, instrument or other document delivered pursuant to this Agreement shall survive the Expiration Time.
5.16 Termination. This Agreement shall automatically terminate without further action by any of the Parties and shall have no further force or effect as of the Expiration Time; provided that the provisions of this Section 5 (other than Section 5.8) shall survive any such termination. Notwithstanding the foregoing, termination of this Agreement shall not prevent any Party from seeking any remedies (at law or in equity) against any other Party for that Party’s willful breach of any of the terms of this Agreement prior to the date of termination in accordance with Section 5.9.
5.17 Fiduciary Duties. The Stockholder has entered into this Agreement solely in the Stockholder’s capacity as the record and/or beneficial owner of the Covered Shares (and not in any other capacity, including any capacity as a director or officer of Seller or a Seller Party). Nothing in this Agreement: (a) will limit or affect any actions or omissions taken by the Stockholder or any of its Affiliates in the Stockholder’s or such Affiliate’s capacity as a director or officer of Seller or a Seller Party, including in exercising rights under the Purchase Agreement, and no such actions or omissions shall be deemed a breach of this Agreement; or (b) will be construed to prohibit, limit, or restrict the Stockholder or any of its Affiliates from exercising the Stockholder’s or such Affiliates’ fiduciary duties as a director or officer to Seller, a Seller Party, or their respective stockholders; provided that nothing in this Section shall limit or affect the Stockholder’s obligations under Section 1 in its capacity as a holder of Covered Shares.
[Signature Page Follows]
| 11 |
IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed and delivered on the date and year first above written.
| CORMEDIX INC. | ||
| By: | ||
| Name: | ||
| Title: | ||
[Signature Page – Voting and Support Agreement]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed and delivered on the date and year first above written.
| HERON THERAPEUTICS, INC. | ||
| By: | ||
| Name: | ||
| Title: | ||
[Signature Page – Voting and Support Agreement]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed and delivered on the date and year first above written.
| RUBRIC CAPITAL MANAGEMENT LP, as Manager or Sub-Manager of its Funds and Accounts | ||
| By: | ||
| Name: | ||
| Title: | Authorized Signatory | |
[Signature Page – Voting and Support Agreement]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed and delivered on the date and year first above written.
| [______] | ||
| By: | ||
| Name: | ||
| Title: | ||
[Signature Page – Voting and Support Agreement]
Schedule A
| Name | Owned Shares |
Other Seller Securities | Shared Voting Arrangements | Address | ||||
| [Stockholder] | [●] | c/o: Email: |
Exhibit 10.2
Execution Version
GOVERNANCE AGREEMENT
This Governance Agreement, dated as of November 8, 2026 (this “Agreement”), is by and between CorMedix Inc., a Delaware corporation (the “Company”), and Heron Therapeutics, Inc., a Delaware corporation (“Heron”).
WHEREAS, the Company and Heron are, concurrently with the execution and delivery of this Agreement, entering into that certain Asset Purchase Agreement, dated as of the date hereof (as it may be amended from time to time, the “Purchase Agreement”), pursuant to which, among other things, the Company will issue to Heron at the Closing (as defined in the Purchase Agreement) the Seller Stock Consideration (as defined in the Purchase Agreement), consisting of shares of common stock of the Company, par value $0.001 per share (the “Common Stock”);
WHEREAS, as a condition and inducement to the willingness of the Company to enter into the Purchase Agreement, Heron has agreed to enter into this Agreement, which shall become effective as of, and contingent upon, the Closing; and
WHEREAS, the Company and Heron have mutually determined to reflect their agreements on matters relating to the representation of Heron on the Company’s Board of Directors (the “Board”), the voting and disposition of the Voting Securities (as defined below) held by Heron and its Affiliates and certain other matters, as provided in this Agreement.
NOW, THEREFORE, in consideration of and reliance upon the mutual covenants and agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:
| 1. | Definitions. |
As used in this Agreement:
| (a) | the term “Affiliate” shall have the meaning set forth in Rule 12b-2 promulgated by the SEC under the Exchange Act; provided that none of the Company or its Affiliates, on the one hand, and Heron and its Affiliates, on the other hand, shall be deemed to be “Affiliates” with respect to the other for purposes of this Agreement; provided, further, that Affiliates of a person shall not include any entity solely by reason of the fact that one or more of such person’s employees or principals serves as a member of its board of directors or similar governing body; |
| (b) | the terms “Beneficial Ownership,” “Beneficially Own” and “Beneficial Owner” of Common Stock or Voting Securities, in each case, as applicable, mean ownership of: (i) Common Stock or Voting Securities, in each case, as applicable, and (ii) rights or options to own or acquire any Common Stock or Voting Securities, in each case, as applicable (whether such right or option is exercisable immediately or only after the passage of time or upon the satisfaction of one or more conditions (whether or not within the control of such person), compliance with regulatory requirements or otherwise); provided that no person shall be deemed to Beneficially Own any securities beneficially owned by any director of the Company to the extent such securities were acquired directly from the Company by such director as or pursuant to director compensation for serving as a director of the Company; |
| (c) | the term “Change of Control Transaction” means (x) any transaction pursuant to which any person becomes a Beneficial Owner, directly or indirectly, of securities of the Company representing more than 50% of the Company’s then-outstanding equity interests and voting power, (y) any merger or stock-for-stock transaction with a Third Party whereby immediately after the consummation of the transaction, the Company’s stockholders retain less than 50% of the equity interests and voting power of the surviving entity’s then-outstanding equity securities or (z) the sale of all or substantially all of the Company’s assets to a Third Party; |
| (d) | the term “Company Interests” means (x) any Voting Securities, (y) any other direct or indirect interest in any securities of the Company or any direct or indirect rights, warrants or options to acquire, or securities convertible into or exchangeable for, any securities of the Company, or (z) any contracts or rights in any way related to the acquisition or price of securities or interests of the Company (whether Beneficially, constructively or synthetically through any derivative or trading position or otherwise); |
| (e) | the term “Competing Acquisition” means any acquisition of (whether by merger, purchase of assets or equity, exclusive license or otherwise), or any investment in, any person or business engaged in a Competing Business; |
| (f) | the term “Competing Business” shall have the meaning set forth in the Purchase Agreement; |
| (g) | the term “Confidential Information” shall have the meaning set forth in Section 6(a); |
| (h) | the term “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder; it being agreed that references to Exchange Act provisions or other provisions of securities law shall refer to such provisions as in effect on the date hereof; |
| (i) | the term “Extraordinary Transaction” means any tender offer or exchange offer, merger, acquisition, consolidation, business combination, sale or other disposition of all or a material amount of the assets or businesses of the Company, reorganization, restructuring, recapitalization, dissolution, liquidation or other similar transaction involving the Company or any of its subsidiaries; |
| (j) | the term “Lock-Up Period” shall have the meaning set forth in Section 5(a); |
| (k) | the term “Ownership Percentage” means, as of any date of determination, the percentage obtained by dividing (x) the aggregate number of shares of Common Stock Beneficially Owned by Heron by (y) the total number of shares of Common Stock issued and outstanding as of such date, as set forth in the Company’s most recent filing with the SEC disclosing such number (as adjusted for any issuance or repurchase of which Heron has been notified in writing by the Company); |
| (l) | the term “Permitted Transferee” means Velan Capital Management LLC and Rubric Capital Management LP and, in each case, its controlled Affiliates and the investment funds and accounts managed or advised by it; |
| 2 |
| (m) | the term “Proxy Advisory Firms” means Institutional Shareholder Services Inc. and Glass, Lewis & Co., LLC (including any successor thereto); |
| (n) | the terms “person” or “persons” mean any individual, corporation (including not-for-profit), general or limited partnership, limited liability or unlimited liability company, joint venture, estate, trust, association, organization or other entity of any kind or nature; |
| (o) | the term “SEC” means the U.S. Securities and Exchange Commission; |
| (p) | the term “Third Party” means any person that is not a party to this Agreement or an Affiliate of a party to this Agreement; |
| (q) | the term “Transfer” means any direct or indirect sale, assignment, transfer, conveyance, gift, exchange, distribution or other disposition (including by operation of law), or the entry into any contract, option or other arrangement with respect to any of the foregoing, of any Company Interests or any economic, voting or other rights therein, including by means of any short sale, swap, hedge or other derivative transaction; provided that a Permitted Pledge (as defined in Section 5(a)) shall not constitute a Transfer; and |
| (r) | the term “Voting Securities” shall mean the Common Stock, and any other securities of the Company entitled to vote in the election of directors, or securities convertible into, or exercisable or exchangeable for Common Stock or such other securities, whether or not subject to the passage of time or other contingencies; provided that as it pertains to any obligations of Heron hereunder, Voting Securities will not include any securities contained in any index fund, exchange traded fund, benchmark fund or broad basket of securities which may contain or otherwise reflect the performance of, but not primarily consist of, securities or other interests of the Company. |
Capitalized terms used but not defined herein shall have the meanings given to them in the Purchase Agreement.
| 2. | Board Representation and Board Matters. |
| (a) | Board Designee. From and after the Closing and for so long as the Ownership Percentage is at least 10%, excluding the issuance by the Company of any Voting Securities from the date of this Agreement through December 31, 2027 (the “Board Threshold”), Heron shall be entitled, but not obligated, to designate one (1) individual for appointment or nomination to the Board (the “Heron Designee”). Any individual designated by Heron as the Heron Designee (including any Replacement Designee) must (i) qualify as “independent” of the Company under the rules and regulations of the SEC and the listing standards of the Nasdaq Stock Market, (ii) be reasonably acceptable to the Board (acting through its Nominating and Corporate Governance Committee (the “Nominating Committee”)), it being understood that the Board shall not unreasonably withhold, condition or delay its acceptance, (iii) satisfy the Company’s generally applicable director qualification standards and policies and complete the Company’s customary director questionnaire and background check, and (iv) not be, and not have been within the three (3) years prior to designation, an officer, director, employee or consultant of Heron or of any person engaged in a Competing Business. |
| 3 |
| (b) | Nomination and Support. For so long as Heron is entitled to designate a Heron Designee pursuant to Section 2(a), the Company will include the Heron Designee on the Company’s slate of nominees for election to the Board at each annual meeting of stockholders at which the Heron Designee’s term expires and will recommend, support and solicit proxies for the election of the Heron Designee in a manner no less rigorous and favorable than the manner in which the Company supports its other nominees in the aggregate; provided that any recommendation of the Board shall be subject in each case to the good faith exercise of the Board’s fiduciary duties under applicable Law. In addition, for so long as Heron is entitled to designate a Heron Designee pursuant to Section 2(a), upon Heron’s written request, the Company shall cause the Heron Designee to be appointed to one or more committees of the Board, which committee shall be designated by the Board in its sole discretion, in each case, subject in each case to the approval of the Board, applicable committee charters and eligibility requirements, the rules and regulations of the SEC and the listing standards of the Nasdaq Stock Market. |
| (c) | Replacement. If the Heron Designee is unable to serve as a director due to death, disability, resignation or incapacity, and as long as Heron remains entitled to designate a Heron Designee pursuant to Section 2(a), Heron shall be entitled to designate a replacement satisfying the requirements of Section 2(a) (a “Replacement Designee”), and the Board and all applicable committees thereof shall take such actions as are necessary, subject in each case to the good faith exercise of the Board’s fiduciary duties under applicable Law, to appoint the Replacement Designee to serve as a director for the remainder of such Heron Designee’s term, and such Replacement Designee, once appointed to the Board, shall be deemed the Heron Designee for all purposes hereunder. |
| (d) | Company Policies. Heron acknowledges that, at all times while serving as a member of the Board, the Heron Designee is required to comply with all policies, procedures, processes, codes, rules, standards and guidelines generally applicable to Board members, including the Company’s corporate code of ethics, securities trading policies, Regulation FD-related policies, director confidentiality policies and corporate governance standards, in each case that have been provided in writing to such director, and to preserve the confidentiality of Company business and information, including discussions or matters considered in meetings of the Board or Board committees. |
| (e) | Compensation. The Heron Designee will be entitled to the same compensation, director indemnity and insurance and other benefits as are accorded to the other non-employee directors of the Company. |
| (f) | Recusal. The Heron Designee shall recuse himself or herself from, and the Company shall be entitled to exclude the Heron Designee from, any portion of any meeting of the Board or any committee thereof (and from receipt of related materials) at which the Board or such committee is evaluating or taking action with respect to (i) this Agreement, the Purchase Agreement or any other Ancillary Agreement (including the Royalty Payments and Earn-Out Payments thereunder), (ii) any dispute or transaction between the Company or any of its Affiliates, on the one hand, and Heron or any of its Affiliates, on the other hand, or (iii) any matter as to which the Board reasonably determines in good faith, upon the advice of outside counsel, that such recusal is necessary or advisable to preserve attorney-client privilege or to avoid a conflict of interest. |
| 4 |
| (g) | Termination of Board Rights. The Company’s obligations under this Section 2 shall terminate automatically, without further action, at such time as the Ownership Percentage first falls below the Board Threshold or upon the execution of a definitive agreement with respect to, or consummation of, a Competing Acquisition by Heron; provided, however, that notwithstanding the foregoing, Heron and the Company may mutually agree in writing that the Heron Designee shall continue to serve on the Board for the remainder of his or her then-current term following the occurrence of any of the foregoing events, and the Company may, in its sole discretion, thereafter renominate such individual for election to the Board. Prior to, and as a condition of, the appointment or nomination of the Heron Designee, the Heron Designee shall deliver to the Company an irrevocable resignation letter, pursuant to which the Heron Designee shall resign from the Board and all committees thereof, effective upon the occurrence of the foregoing, unless Heron and the Company have agreed in accordance with the immediately preceding proviso that the Heron Designee shall continue to serve. Once terminated, the rights of Heron under this Section 2 shall not be revived, notwithstanding any subsequent increase in the Ownership Percentage. |
| (h) | Non-Assignability. The rights of Heron under this Section 2 are personal to Heron and may not be assigned or transferred (by operation of law or otherwise) to any person, including any transferee of Voting Securities. |
| 3. | Voting. |
| (a) | Quorum. For so long as the Ownership Percentage is at least 1% (the “Quorum Threshold”), at each annual or special meeting of the stockholders of the Company (and at every adjournment or postponement thereof), Heron shall cause all Voting Securities Beneficially Owned by Heron as of the applicable record date to be present (in person or by proxy) for quorum purposes and to be voted (or consented) in accordance with this Section 3. |
| (b) | Voting in Accordance with Board Recommendation. For so long as the Ownership Percentage is at least 5% (the “Voting Threshold”), and subject to Sections 3(c) and 3(d), Heron shall vote all Voting Securities Beneficially Owned by Heron (i) in favor of each director nominated and recommended by the Board for election at any such meeting, (ii) against any stockholder nominations for directors that are not approved and recommended by the Board and against any proposal or resolution to remove any member of the Board, and (iii) with respect to all other proposals submitted to the stockholders of the Company (other than any proposal relating to an Extraordinary Transaction, which is subject to Section 3(d) below), in favor of each proposal recommended by the Board and against each proposal that the Board recommends against. |
| (c) | Exceptions. Notwithstanding Section 3(b): |
| (i) | in the event that either of the Proxy Advisory Firms issues a voting recommendation that differs from the voting recommendation of the Board with respect to any proposal submitted to stockholders, Heron shall be permitted to vote in accordance with any such Proxy Advisory Firm recommendation on such proposal; and |
| 5 |
| (ii) | Heron shall be permitted to vote in its sole discretion with respect to (x) any proposal to amend the Company’s certificate of incorporation or bylaws that would (A) adversely affect the rights of Heron under this Agreement or the Purchase Agreement or (B) treat Heron or the Voting Securities held by Heron differently from, or disproportionately relative to, other holders of Common Stock or (y) any proposal relating specifically to this Agreement or the Purchase Agreement. |
| (d) | Extraordinary Transactions. For so long as the Ownership Percentage is at least 5% (the “Transaction Voting Threshold”), with respect to any proposal relating to an Extraordinary Transaction submitted to the stockholders of the Company, Heron shall vote all Voting Securities Beneficially Owned by it in favor of, against or abstaining from such proposal in the same proportion as the votes cast in favor of, against or abstaining from such proposal by holders of Common Stock other than (i) Heron and (ii) the Company’s directors and executive officers and their respective Affiliates. The parties shall cooperate in good faith to determine appropriate procedures and mechanics to facilitate such proportionate voting. |
| (e) | No Other Voting Arrangements. Heron shall not grant any proxy or enter into any voting agreement, voting trust or similar arrangement with respect to Voting Securities that is inconsistent with this Section 3 or otherwise take any action that is designed to or has the effect of circumventing this Section 3. |
| 4. | Standstill. |
| (a) | From and after the Closing until the earlier of (x) the date on which the Ownership Percentage first falls below 1% and (y) the termination of this Agreement in accordance with Section 8 (such period, the “Standstill Period”), Heron shall not, directly or indirectly, except as may otherwise be required by the voting provisions set forth herein: |
| (i) | solicit proxies or written consents of stockholders or conduct any other type of referendum (binding or non-binding) with respect to, or from the holders of, the Voting Securities, or become a “participant” (as such term is defined in Instruction 3 to Item 4 of Schedule 14A promulgated under the Exchange Act) in or knowingly assist any Third Party in any “solicitation” of any proxy, consent or other authority (as such terms are defined under the Exchange Act) to vote any shares of the Voting Securities other than such encouragement or advice that is consistent with the Board’s recommendation in connection with such matter (it being understood that voting the Voting Securities held by Heron, or publicly announcing how Heron intends to vote, in each case in accordance with Section 3, shall not be deemed a violation of this clause); |
| (ii) | form or join any partnership, limited partnership, syndicate or other group, including a “group” as defined under Section 13(d) of the Exchange Act, with respect to the Voting Securities (it being understood that neither this Agreement, in and of itself, nor Heron acting in concert solely with its controlled Affiliates shall be deemed to constitute the formation of a “group”); |
| 6 |
| (iii) | (A) call or seek to call (publicly or otherwise), alone or in concert with others, a meeting of the Company’s stockholders (or the setting of a record date therefor), (B) present at any annual meeting or any special meeting of the Company’s stockholders any proposal for consideration for action by stockholders or seek the removal of any member of the Board or, except as expressly contemplated by Section 2, propose any nominee for election to the Board or seek, alone or in concert with others, representation on the Board, or (C) conduct a referendum of stockholders of the Company or engage in any “withhold” or similar campaign; |
| (iv) | grant any proxy, consent or other authority to vote any Voting Securities (other than to the named proxies included in the Company’s proxy card for any annual meeting or special meeting of stockholders or to any controlled Affiliate of Heron) or deposit any Voting Securities in a voting trust or subject them to a voting agreement or other arrangement of similar effect (excluding customary brokerage accounts, margin accounts, prime brokerage accounts and the like and any Permitted Pledge); |
| (v) | make any request for a stockholder list or similar materials or other books and records of the Company or any of its subsidiaries under Section 220 of the Delaware General Corporation Law or otherwise; |
| (vi) | without the prior written approval of the Board, separately or in conjunction with any other person, publicly propose or effect, or publicly announce any intention to propose or effect, any Extraordinary Transaction, or actively encourage, initiate or support any Third Party in any such activity, in each case either publicly or in a manner that would reasonably be expected to require public disclosure by the Company or Heron (it being understood that the foregoing shall not restrict Heron from tendering shares, receiving payment for shares or otherwise participating in any Extraordinary Transaction on the same basis as other stockholders of the Company, subject to Sections 3(d) and 5); |
| (vii) | knowingly encourage or advise any other person or knowingly assist any Third Party in so encouraging or assisting any person with respect to the giving or withholding of any proxy, consent or other authority to vote any shares of the Voting Securities or in conducting any type of referendum with respect to the Voting Securities (other than such encouragement or advice that is consistent with the Board’s recommendation in connection with such matter); |
| (viii) | acquire, offer or propose to acquire, solicit an offer to acquire, or agree to acquire, alone or in concert with any Third Party, any Company Interests, in each case, if such acquisition, offer, agreement or transaction would result in Heron having Beneficial Ownership of, or an aggregate economic or voting interest in, more than 19.9% of the Common Stock outstanding at such time, whether Beneficially Owned or held through any other Company Interests, including any derivative, swap, option or other synthetic position; |
| 7 |
| (ix) | engage in any short sale or any purchase, sale or grant of any option, warrant, convertible security, share appreciation right or other similar right (including any put or call option or “swap” transaction) with respect to any security (other than any index fund, exchange traded fund, benchmark fund or broad basket of securities) that includes, relates to, or derives any significant part of its value from a decline in the market price or value of any of the securities of the Company, or otherwise hedge its economic exposure to the Common Stock; |
| (x) | institute, solicit or join as a party any litigation, arbitration or other proceeding against or involving the Company or any of its subsidiaries or any of its or their respective current or former directors or officers (including derivative actions), in order to effect or take any of the actions prohibited by this Section 4 or with the intent of circumventing any of the provisions of this Section 4; provided, however, that the foregoing shall not prevent Heron from (A) bringing litigation to enforce any provision of this Agreement, the Purchase Agreement or any other Ancillary Agreement, (B) making counterclaims with respect to any proceeding initiated by, or on behalf of, the Company or its Affiliates against Heron, (C) bringing or participating in bona fide commercial or legal disputes that do not relate to the subject matter of this Section 4, (D) exercising statutory appraisal rights, (E) responding to or complying with validly issued legal process, (F) bringing any claim based on fraud by the Company or (G) participating as a member of a class (but not as a named plaintiff or lead plaintiff) in any class action commenced and maintained by persons other than Heron or its Affiliates; |
| (xi) | enter into any discussions, negotiations, agreements or understandings (whether written or oral) with, or advise, finance, assist or knowingly encourage, any Third Party in connection with any of the foregoing; or |
| (xii) | request, directly or indirectly, any amendment or waiver of the terms of this Agreement (including this clause (xii)) in a manner that would be reasonably likely to require public disclosure by Heron or the Company. |
| (b) | Notwithstanding anything to the contrary in this Agreement, nothing in this Agreement will prohibit or restrict Heron from (A) making any factual statement to comply with any subpoena or other legal process or respond to a request for information from any governmental authority with jurisdiction over such person, (B) entering into any Permitted Pledge, (C) negotiating, evaluating or trading in any index fund, exchange traded fund, benchmark fund or broad basket of securities which may contain or otherwise reflect the performance of, but not primarily consist of, securities of the Company, (D) providing its views privately to the Board or the Company’s senior executives in a manner that would not reasonably be expected to require public disclosure, or (E) complying with its reporting obligations under the Exchange Act or its obligations to its own stockholders under applicable Law and the rules of any stock exchange (including in connection with any Distribution permitted by Section 5(c)(i)). |
| 8 |
| 5. | Transfer Restrictions. |
| (a) | Lock-Up. During the period commencing on the Closing Date and ending at 11:59 p.m., New York City time, on the date that is six (6) months following the Closing Date (the “Lock-Up Period”), Heron shall not, directly or indirectly, Transfer any shares of Common Stock issued to Heron pursuant to the Purchase Agreement (together with any securities issued in respect thereof by way of stock dividend, stock split, recapitalization or similar event, the “Subject Shares”), other than pursuant to Section 5(c). Notwithstanding the foregoing, Heron may pledge, hypothecate or grant a security interest in the Subject Shares to one or more bona fide lenders as collateral for indebtedness pursuant to customary loan or margin arrangements (a “Permitted Pledge”), and such Permitted Pledge shall not constitute a Transfer; provided that Heron shall provide the Company with written notice of any Permitted Pledge (including the identity of the pledgee and the number of Subject Shares pledged) within five (5) Business Days following the entry into such Permitted Pledge. |
| (b) | Post-Lock-Up Volume Limitation. During the period commencing upon the expiration of the Lock-Up Period and continuing for the remainder of the term of this Agreement, Heron may Transfer Subject Shares at any time and from time to time in its discretion; provided that sales by Heron in open-market brokerage transactions on any single trading day shall not exceed ten percent (10%) of the greater of (i) the consolidated trading volume of the Common Stock on such trading day and (ii) the average daily consolidated trading volume of the Common Stock over the thirty (30) trading days immediately preceding such trading day (the “Volume Limitation”). The Volume Limitation applies only to open-market brokerage sales and shall not apply to or restrict: (A) any underwritten offering of Common Stock (an “Underwritten Secondary”), but only if either (x) the Company participates in such underwritten offering or (y) the Company has approved such underwritten offering in advance in writing (it being understood that any underwritten offering that satisfies neither clause (x) nor clause (y) shall not be excluded from, and shall be subject to, the Volume Limitation as if it were an open-market brokerage sale); (B) sales in privately negotiated transactions exempt from the registration requirements of the Securities Act of 1933, as amended; (C) sales or tenders into any tender offer, exchange offer, merger, consolidation or other business combination involving the Company; (D) any Distribution permitted by Section 5(c)(i); (E) any Permitted Pledge or any Transfer upon foreclosure of a Permitted Pledge; or (F) Transfers to controlled Affiliates of Heron that agree in writing to be bound by this Agreement as if they were Heron. The Volume Limitation shall automatically terminate and be of no further force or effect if the resale registration statement required under the Registration Rights Agreement is not declared effective by the deadline set forth therein, or if such registration statement thereafter ceases to be effective or available for use by Heron (other than during any blackout period expressly permitted under the Registration Rights Agreement). |
| (c) | Permitted Transfers. Notwithstanding Sections 5(a) and 5(b), Heron may Transfer Subject Shares: |
| (i) | by way of a pro rata distribution in kind to the holders of Heron’s common stock (a “Distribution”); provided that (A) no Distribution shall be effected prior to the expiration of the Lock-Up Period, and (B) Heron shall provide the Company with not less than five (5) Business Days’ prior written notice of any Distribution and shall reasonably cooperate with the Company with respect to the timing and public announcement thereof; |
| 9 |
| (ii) | in connection with any tender offer, exchange offer, merger or other Extraordinary Transaction that has been approved or recommended by the Board, on the same terms as other holders of Common Stock; |
| (iii) | to the Company or any of its subsidiaries; or |
| (iv) | with the prior written consent of the Board. |
| (d) | Restricted Transferees. Without the prior written consent of the Board (which consent shall not be unreasonably withheld, conditioned or delayed; it being agreed that it shall be reasonable for the Board to withhold consent if the proposed transferee or any of its Affiliates has, within the five (5) years prior to the proposed Transfer, engaged in any solicitation of proxies, nominated directors, publicly proposed an Extraordinary Transaction or otherwise engaged in any activity of the type restricted by Section 4(a) with respect to any public company), Heron shall not Transfer any Voting Securities (other than in an Underwritten Secondary or in anonymous open-market brokers’ transactions in compliance with Section 5(b)) to any person that (i) has, within the five (5) years prior to the proposed Transfer, filed a Schedule 13D with respect to the Company or any other issuer, or (ii) would, to Heron’s knowledge after reasonable inquiry, Beneficially Own more than 5% of the outstanding Common Stock after giving pro forma effect to such Transfer; provided that, for purposes of clarity, a Transfer to a Permitted Transferee shall not be prohibited by this Section 5(d). |
| (e) | Void Transfers; Legends. Any purported Transfer in violation of this Section 5 shall be null and void ab initio, and the Company shall not, and shall instruct its transfer agent not to, register any such Transfer. Each book-entry position representing Subject Shares shall bear a customary restrictive notation referring to this Agreement, which the Company shall promptly cause to be removed with respect to any Subject Shares upon the termination of this Section 5 or upon any Transfer of such Subject Shares permitted hereunder to a person not bound by this Agreement. |
| 6. | Confidentiality; Non-Disparagement. |
| (a) | Confidentiality. Heron shall, and shall cause its Representatives to, maintain in confidence and not disclose, and not use for any purpose other than monitoring its investment in the Company or enforcing its rights under this Agreement, the Purchase Agreement or the other Ancillary Agreements, any non-public, confidential or proprietary information of or relating to the Company or any of its subsidiaries (“Confidential Information”). The obligations set forth in this Section 6(a) shall not apply to Confidential Information that (i) is or becomes generally available to the public other than as a result of a disclosure by Heron or its Representatives in violation of this Section 6, (ii) was available to Heron on a non-confidential basis prior to its disclosure by or on behalf of the Company, (iii) becomes available to Heron on a non-confidential basis from a source other than the Company or its Representatives, provided that such source is not known by Heron to be bound by a confidentiality obligation to the Company with respect to such information, or (iv) is independently developed by Heron or its Representatives without use of or reference to the Confidential Information. |
| 10 |
| (b) | Permitted Disclosure. Notwithstanding anything to the contrary in this Section 6, Heron or its Representatives may disclose Confidential Information to the extent required by applicable Law or Order; provided that, to the extent legally permitted, Heron shall (i) provide the Company with prompt written notice of such requirement so that the Company, at its cost, may seek a protective order or other appropriate remedy, and (ii) reasonably cooperate with the Company in seeking such protective order or other remedy. If such protective order or other remedy is not obtained, Heron shall disclose only that portion of the Confidential Information that, on the advice of its legal counsel, is legally required to be disclosed. |
| (c) | Non-Disparagement. For so long as the Ownership Percentage is greater than 10% and for one (1) year thereafter (the “Non-Disparagement Period”), Heron shall not, and shall cause its directors and executive officers not to, make, or cause to be made, any statement or announcement that relates to and constitutes an ad hominem attack on, or that disparages, defames or slanders (in each case as distinct from objective statements reflecting business criticism), the Company or its business, products, operations or financial performance, its officers or its directors or any person who has served as an officer or director of the Company (in each case in such person’s capacity as such), (A) in any document or report filed with or furnished to the SEC or any other governmental agency or (B) in any press release or other publicly available format. Nothing in this Section 6(c) shall (1) restrict the ability of any person to comply with a subpoena or other legal process or respond to a request for information from any governmental or regulatory authority with jurisdiction over such person, (2) limit or preclude a party hereto from exercising or enforcing any rights under this Agreement, the Purchase Agreement or any other Ancillary Agreement, or from asserting any counterclaim in any proceeding initiated by the other party, or (3) preclude Heron from making any statement required by applicable Law or stock exchange rules in its own periodic reports or proxy materials. |
| (d) | Relationship to Other Agreements. The obligations in this Section 6 are in addition to, and not in limitation of, Heron’s obligations under Section 5.8 (Confidentiality) of the Purchase Agreement and the Confidentiality Agreement. |
| 7. | Representations and Warranties. |
| (a) | Representations and Warranties of All Parties. Each of the parties hereto represents and warrants to the other party hereto that: (i) such party has all requisite power and authority to execute and deliver this Agreement and to perform its obligations hereunder; (ii) this Agreement has been duly and validly authorized, executed and delivered by such party and, assuming the valid execution and delivery hereof by the other party, is a valid and binding obligation of such party, enforceable against such party in accordance with its terms; and (iii) the execution, delivery and performance of this Agreement does not and will not (A) violate or conflict with any law, rule, regulation, order, judgment or decree applicable to such party, or (B) result in any breach or violation of or constitute a default (or an event which with notice or lapse of time or both could constitute a breach, violation or default) under or pursuant to, or result in the loss of a material benefit under, or give any right of termination, amendment, acceleration or cancellation of, any organizational document, agreement, contract, commitment, understanding or arrangement to which such party is a party or by which it is bound. |
| 11 |
| (b) | Representations and Warranties of Heron. Heron represents and warrants that, as of the date of this Agreement: (i) other than as contemplated by the Purchase Agreement, Heron does not Beneficially Own, or have any economic exposure to, any Voting Securities or other Company Interests; and (ii) Heron is not party to any agreement, arrangement or understanding (whether written or oral) with any Third Party with respect to the acquisition, holding, voting or disposition of any Company Interests, other than the Stockholder Governance Agreement, the Voting Agreements and the Purchase Agreement. |
| 8. | Termination. |
| (a) | This Agreement shall become effective as of the Closing and shall automatically terminate and be of no further force or effect, without any action by any party, upon the termination of the Purchase Agreement in accordance with its terms prior to the Closing. |
| (b) | Following the Closing, this Agreement shall terminate upon the earliest to occur of: (i) the third (3rd) anniversary of the Closing Date; (ii) the consummation of a Change of Control Transaction; provided that Heron shall have complied with its obligations under Section 3 in connection with any vote of the Company’s stockholders with respect to such Change of Control Transaction; (iii) the first date on which the Ownership Percentage is less than 1%, provided, that all obligations contained herein that expressly survive following termination, as set forth in Section 8(d) below, shall continue to survive for the duration set forth herein, and provided further that no Transfer restriction in Section 5 then in effect has been breached; and (iv) the mutual written agreement of the Company and Heron. |
| (c) | Individual provisions of this Agreement shall cease to apply upon the Ownership Percentage falling below the applicable ownership threshold or the expiration of the applicable period specified therein, as follows: Section 2 (Board Representation) upon the Ownership Percentage first falling below the Board Threshold or a Competing Acquisition; Sections 3(b) through 3(d) (Voting) upon the Ownership Percentage first falling below the Voting Threshold or the Transaction Voting Threshold, as applicable; Section 3(a) (Quorum) and Section 4 (Standstill) upon the Ownership Percentage first falling below the Quorum Threshold; Section 5(a) upon expiration of the Lock-Up Period; Section 5(b) (Volume Limitation) upon the automatic termination of the Volume Limitation in accordance with Section 5(b); and Section 6(c) upon expiration of the Non-Disparagement Period. Once the Ownership Percentage has fallen below the applicable ownership threshold, the corresponding provisions shall not be revived by any subsequent increase in the Ownership Percentage. |
| (d) | Upon termination, this Agreement shall have no further force and effect; provided that (i) Sections 6(a), 6(b) and 6(d) shall survive any termination of this Agreement for a period of two (2) years (or, with respect to Confidential Information constituting a trade secret, for so long as such information constitutes a trade secret under applicable Law), (ii) Sections 1 and 9 shall survive any termination of this Agreement, and (iii) no termination of this Agreement shall relieve any party of liability for any breach of this Agreement arising prior to such termination. |
| 12 |
| 9. | Miscellaneous. |
| (a) | Specific Performance. The parties hereto recognize and agree that if for any reason any of the provisions of this Agreement are not performed in accordance with their specific terms or are otherwise breached, immediate and irreparable harm or injury would be caused for which money damages would not be an adequate remedy. Accordingly, each party hereto agrees that, in addition to any other remedies to which the other party hereto may be entitled at law or in equity, the other party hereto shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement exclusively in the Court of Chancery of the State of Delaware (or, if such court lacks subject matter jurisdiction, the federal or state courts located in the State of Delaware), without proof of actual damages and without any requirement to post a bond or other security. |
| (b) | Venue. Each of the parties hereto (i) consents to submit itself to the personal jurisdiction of the Court of Chancery of the State of Delaware (or, if such court lacks subject matter jurisdiction, the federal or state courts located in the State of Delaware) in the event any dispute arises out of this Agreement or the transactions contemplated by this Agreement, (ii) agrees that it shall not attempt to deny or defeat such personal jurisdiction by motion or other request for leave from any such court, (iii) agrees that it shall not bring any action relating to this Agreement or the transactions contemplated by this Agreement in any court other than the Court of Chancery of the State of Delaware (or, if such court lacks subject matter jurisdiction, the federal or state courts located in the State of Delaware), and (iv) irrevocably consents to service of process by a reputable overnight mail delivery service, signature requested, to the address of such party’s principal place of business or as otherwise provided by applicable Law. |
| (c) | Governing Law. This Agreement shall be governed in all respects, including validity, interpretation and effect, by the laws of the State of Delaware applicable to contracts executed and to be performed wholly within such State without giving effect to the choice of law principles of such State. |
| (d) | Waiver of Jury Trial. EACH OF THE PARTIES HERETO, AFTER CONSULTING OR HAVING HAD THE OPPORTUNITY TO CONSULT WITH COUNSEL, KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVES ANY RIGHT THAT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN ANY LITIGATION BASED UPON OR ARISING OUT OF THIS AGREEMENT OR ANY RELATED INSTRUMENT OR AGREEMENT, OR ANY OF THE TRANSACTIONS CONTEMPLATED THEREBY, OR ANY COURSE OF CONDUCT, DEALING, STATEMENTS (WHETHER ORAL OR WRITTEN), OR ACTIONS OF ANY OF THEM. No party hereto shall seek to consolidate, by counterclaim or otherwise, any action in which a jury trial has been waived with any other action in which a jury trial cannot be or has not been waived. |
| 13 |
| (e) | No Waiver. Any waiver by any party hereto of a breach of any provision of this Agreement shall not operate as or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of this Agreement. The failure of a party hereto to insist upon strict adherence to any term of this Agreement on one or more occasions shall not be considered a waiver or deprive that party of the right thereafter to insist upon strict adherence to that term or any other term of this Agreement. Any waiver or consent by the Company hereunder shall be effective only if approved by the Board (excluding the Heron Designee). |
| (f) | Entire Agreement; Amendment. This Agreement (together with Schedule A hereto), the Purchase Agreement and the other Ancillary Agreements contain the entire understanding of the parties hereto with respect to the subject matter hereof and supersede any and all prior and contemporaneous agreements, memoranda, arrangements and understandings, both written and oral, between the parties, or any of them, with respect to the subject matter of this Agreement, including any term sheet relating to the subject matter hereof. This Agreement may be amended only by an agreement in writing executed by the parties hereto. |
| (g) | Notices. All notices, consents, requests, instructions, approvals and other communications provided for herein and all legal process in regard to this Agreement will be in writing and will be deemed validly given, made or served, (i) if delivered in person, when delivered in person, (ii) if given by email, when such email is sent to the email address set forth in Schedule A hereto during normal business hours and appropriate confirmation is received (provided such confirmation is not automatically generated), or (iii) if given by any other means, when actually received during normal business hours at the address specified in Schedule A hereto. |
| (h) | Severability. If at any time subsequent to the date hereof, any provision of this Agreement is held by any court of competent jurisdiction to be illegal, void or unenforceable, such provision will be of no force and effect, but the illegality or unenforceability of such provision will have no effect upon the legality or enforceability of any other provision of this Agreement. In addition, the parties hereto agree to use their best efforts to agree upon and substitute a valid and enforceable provision for any provision that is held illegal, void or unenforceable by a court of competent jurisdiction. |
| (i) | Counterparts. This Agreement may be executed in one or more counterparts and by scanned computer image (such as .pdf), each of which will be deemed to be an original copy of this Agreement. For the avoidance of doubt, no party hereto shall be bound by any contractual obligation to the other party hereto until all counterparts to this Agreement have been duly executed by each of the parties hereto and delivered to the other party hereto (including by means of electronic delivery). |
| (j) | Successors and Assigns. This Agreement shall not be assignable by any of the parties to this Agreement, and, without limiting the foregoing, the rights of Heron under Section 2 shall not be assignable in any circumstance. This Agreement, however, shall be binding on successors of the parties hereto, including any successor to Heron by merger, consolidation, dissolution or liquidation or any person acquiring all or substantially all of Heron’s assets (which successor shall be bound by the obligations, but shall not be entitled to the rights under Section 2, of Heron hereunder). |
| 14 |
| (k) | No Third Party Beneficiaries. This Agreement is solely for the benefit of the parties hereto and is not enforceable by any other persons. |
| (l) | Fees and Expenses. Each party to this Agreement will bear and pay all fees, costs and expenses that have been incurred or that are incurred in the future by such party in connection with, relating to or resulting from the negotiation, execution and performance of this Agreement. |
| (m) | Interpretation and Construction. Each of the parties hereto acknowledges that it has been represented by counsel of its choice throughout all negotiations that have preceded the execution of this Agreement, and that it has executed the same with the advice of such counsel. Each party hereto and its counsel cooperated and participated in the drafting and preparation of this Agreement and the documents referred to herein, and any and all drafts relating thereto exchanged among the parties hereto shall be deemed the work product of all of the parties hereto and may not be construed against any party hereto by reason of its drafting or preparation. Accordingly, any rule of law or any legal decision that would require interpretation of any ambiguities in this Agreement against any party hereto that drafted or prepared it is of no application and is hereby expressly waived by each of the parties hereto, and any controversy over interpretations of this Agreement will be decided without regard to events of drafting or preparation. The section headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. The terms “include,” “includes” and “including” shall be deemed to be followed by the words “without limitation” in all instances. |
| (n) | Adjustments. All share numbers and thresholds based on numbers of shares of Common Stock shall be equitably adjusted to reflect any stock split, reverse stock split, stock dividend, recapitalization, reclassification or similar event affecting the Common Stock. |
[Signature Page Follows]
| 15 |
IN WITNESS WHEREOF, each of the parties hereto has executed this Agreement, or caused the same to be executed by its duly authorized representative as of the date first above written.
| CORMEDIX INC. | ||
| By: | ||
| Name: | [●] | |
| Title: | [●] | |
| HERON THERAPEUTICS, INC. | ||
| By: | ||
| Name: | [●] | |
| Title: | [●] | |
SCHEDULE A
NOTICE INFORMATION
If to the Company: CorMedix Inc., 389 Interpace Pkwy, Suite 450, Parsippany, New Jersey 07054, Attention: [***], Email: [***]
With a copy to (which shall not constitute notice): Willkie Farr & Gallagher LLP, 787 Seventh Avenue, New York, New York 10019, Attention: [***], Email: [***]
If to Heron: Heron Therapeutics, Inc., 25 Fenton Main Street, Suite 300, Cary, North Carolina 27511, Attention: [***], Email: [***]
With a copy to (which shall not constitute notice): DLA Piper LLP (US), 51 John F. Kennedy Parkway, Suite 120, Short Hills, New Jersey 07078-2704, Attention: [***], Email: [***]
Exhibit 10.3
Execution Version
STOCKHOLDER GOVERNANCE AGREEMENT
This Stockholder Governance Agreement, dated as of November 8, 2026 (this “Agreement”), is by and between CorMedix Inc., a Delaware corporation (the “Company”), and Rubric Capital Management LP, a Delaware limited partnership (“Rubric”).
WHEREAS, the Company and Heron Therapeutics, Inc., a Delaware corporation (“Heron”), are, concurrently with the execution and delivery of this Agreement, entering into that certain Asset Purchase Agreement, dated as of the date hereof (as it may be amended from time to time, the “Purchase Agreement”), pursuant to which, among other things, the Company will issue to Heron at the Closing (as defined in the Purchase Agreement) shares of common stock of the Company, par value $0.001 per share (the “Common Stock”);
WHEREAS, Heron, Rubric and certain other purchasers (the “Purchasers”) are parties to that certain Note Purchase Agreement, dated as of August 8, 2025 (as it may be amended from time to time, the “Note Purchase Agreement”);
WHEREAS, in connection with the transactions contemplated by the Purchase Agreement, Heron and Rubric have entered into that certain Exchange Agreement, dated as of the date hereof and attached hereto as Exhibit A, pursuant to which Heron will satisfy its obligations owed under the Note Purchase Agreement by transferring certain shares of Common Stock to Rubric and the other Purchasers (the “Rubric Stock Consideration”), subject to the terms and conditions therein (the “Exchange Agreement”);
WHEREAS, as a condition and inducement to the willingness of the Company to enter into the Purchase Agreement, Rubric has agreed to enter into this Agreement, which (except as set forth in Section 8(a)) shall become effective as of, and contingent upon, the Closing; and
WHEREAS, the Company and Rubric have mutually determined to reflect their agreements on matters relating to the voting and disposition of the Voting Securities (as defined below) held by Rubric and its Affiliates, including with respect to the election of members of the Company’s Board of Directors (the “Board”), and certain other matters, as provided in this Agreement.
NOW, THEREFORE, in consideration of and reliance upon the mutual covenants and agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:
| 1. | Definitions. |
As used in this Agreement:
| (a) | the term “Affiliate” shall have the meaning set forth in Rule 12b-2 promulgated by the SEC under the Exchange Act; provided that none of the Company or its Affiliates, on the one hand, and Rubric and its Affiliates, on the other hand, shall be deemed to be “Affiliates” with respect to the other for purposes of this Agreement; provided, further, that Affiliates of a person shall not include any entity solely by reason of the fact that one or more of such person’s employees or principals serves as a member of its board of directors or similar governing body; |
| (b) | the terms “Beneficial Ownership,” “Beneficially Own” and “Beneficial Owner” of Common Stock or Voting Securities, in each case, as applicable, mean ownership of: (i) Common Stock or Voting Securities, in each case, as applicable, and (ii) rights or options to own or acquire any Common Stock or Voting Securities, in each case, as applicable (whether such right or option is exercisable immediately or only after the passage of time or upon the satisfaction of one or more conditions (whether or not within the control of such person), compliance with regulatory requirements or otherwise); provided that no person shall be deemed to Beneficially Own any securities beneficially owned by any director of the Company to the extent such securities were acquired directly from the Company by such director as or pursuant to director compensation for serving as a director of the Company; |
| (c) | the term “Change of Control Transaction” means (x) any transaction pursuant to which any person becomes a Beneficial Owner, directly or indirectly, of securities of the Company representing more than 50% of the Company’s then-outstanding equity interests and voting power, (y) any merger or stock-for-stock transaction with a Third Party whereby immediately after the consummation of the transaction, the Company’s stockholders retain less than 50% of the equity interests and voting power of the surviving entity’s then-outstanding equity securities or (z) the sale of all or substantially all of the Company’s assets to a Third Party; |
| (d) | the term “Company Interests” means (x) any Voting Securities, (y) any other direct or indirect interest in any securities of the Company or any direct or indirect rights, warrants or options to acquire, or securities convertible into or exchangeable for, any securities of the Company, or (z) any contracts or rights in any way related to the acquisition or price of securities or interests of the Company (whether Beneficially, constructively or synthetically through any derivative or trading position or otherwise); |
| (e) | the term “Confidential Information” shall have the meaning set forth in Section 6(a); |
| (f) | the term “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder; it being agreed that references to Exchange Act provisions or other provisions of securities law shall refer to such provisions as in effect on the date hereof; |
| (g) | the term “Extraordinary Transaction” means any tender offer or exchange offer, merger, acquisition, consolidation, business combination, sale or other disposition of all or a material amount of the assets or businesses of the Company, reorganization, restructuring, recapitalization, dissolution, liquidation or other similar transaction involving the Company or any of its subsidiaries; |
| (h) | the term “Lock-Up Period” shall have the meaning set forth in Section 5(a); |
| (i) | the term “Ownership Percentage” means, as of any date of determination, the percentage obtained by dividing (x) the aggregate number of shares of Common Stock Beneficially Owned by Rubric by (y) the total number of shares of Common Stock issued and outstanding as of such date, as set forth in the Company’s most recent filing with the SEC disclosing such number (as adjusted for any issuance or repurchase of which Rubric has been notified in writing by the Company); |
2
| (j) | the term “Permitted Transferee” means any controlled Affiliate of Rubric and any investment fund or account managed or advised by Rubric or any of its controlled Affiliates, in each case, that agrees in writing to be bound by this Agreement as if it were Rubric; |
| (k) | the term “Proxy Advisory Firms” means Institutional Shareholder Services Inc. and Glass, Lewis & Co., LLC (including any successor thereto); |
| (l) | the terms “person” or “persons” mean any individual, corporation (including not-for-profit), general or limited partnership, limited liability or unlimited liability company, joint venture, estate, trust, association, organization or other entity of any kind or nature; |
| (m) | the term “SEC” means the U.S. Securities and Exchange Commission; |
| (n) | the term “Third Party” means any person that is not a party to this Agreement or an Affiliate of a party to this Agreement; |
| (o) | the term “Transfer” means any direct or indirect sale, assignment, transfer, conveyance, gift, exchange, distribution or other disposition (including by operation of law), or the entry into any contract, option or other arrangement with respect to any of the foregoing, of any Company Interests or any economic, voting or other rights therein, including by means of any short sale, swap, hedge or other derivative transaction; provided that a Permitted Pledge (as defined in Section 5(a)) shall not constitute a Transfer; and |
| (p) | the term “Voting Securities” means the Common Stock, and any other securities of the Company entitled to vote in the election of directors, or securities convertible into, or exercisable or exchangeable for Common Stock or such other securities, whether or not subject to the passage of time or other contingencies; provided that as it pertains to any obligations of Rubric hereunder, Voting Securities will not include any securities contained in any index fund, exchange traded fund, benchmark fund or broad basket of securities which may contain or otherwise reflect the performance of, but not primarily consist of, securities or other interests of the Company. |
Capitalized terms used but not defined herein shall have the meanings given to them in the Purchase Agreement.
| 2. | Consents. |
| (a) | Rubric Consent. Rubric, on behalf of itself, the Purchasers and their respective Affiliates, hereby consents to, and approves, the Purchase Agreement and the transactions contemplated thereby, including the transfer of the Transferred Assets thereunder, for all purposes under the Note Purchase Agreement, any related agreement or otherwise. Without limiting the generality of the foregoing, Rubric, on behalf of itself, the Purchasers and their respective Affiliates, acknowledges and agrees that any obligations under the Note Purchase Agreement shall be the sole and exclusive obligation of Heron and that neither the Company nor any Affiliate thereof assumes any liability or obligation to Rubric or the other Purchasers under the Note Purchase Agreement, any related agreement or otherwise (except for the obligations expressly set forth herein). Rubric, on behalf of itself, the Purchasers and their respective Affiliates, further acknowledges and agrees that its obligations under this Agreement are not contingent in any way on Heron’s performance under the Exchange Agreement or the satisfaction of the obligations owed to Rubric or the other Purchasers under the Note Purchase Agreement. |
| (b) | CorMedix Consent. The Company hereby consents to, and approves, the transfer of Common Stock from Heron to Rubric and the other Purchasers in accordance with and subject to the terms set forth in the Exchange Agreement attached hereto as Exhibit A and acknowledges that any such transfer shall not be deemed a breach of this Agreement. |
3
| 3. | Voting. |
| (a) | Quorum. From and after (i) the Closing until the date on which all shares of the Rubric Stock Consideration have been transferred to Rubric pursuant to the Exchange Agreement (the “Final Exchange Date”) and (ii) thereafter, for so long as the Ownership Percentage is at least 1% (the “Quorum Threshold”), at each annual or special meeting of the stockholders of the Company (and at every adjournment or postponement thereof), Rubric shall cause all Voting Securities Beneficially Owned by Rubric as of the applicable record date to be present (in person or by proxy) for quorum purposes and to be voted (or consented) in accordance with this Section 3. |
| (b) | Voting in Accordance with Board Recommendation. From and after (i) the Closing until the Final Exchange Date and (ii) thereafter, for so long as the Ownership Percentage is at least 5% (the “Voting Threshold”), subject to Sections 3(c) and 3(d), Rubric shall vote all Voting Securities Beneficially Owned by Rubric (i) in favor of each director nominated and recommended by the Board for election at any such meeting, (ii) against any stockholder nominations for directors that are not approved and recommended by the Board and against any proposal or resolution to remove any member of the Board, and (iii) with respect to all other proposals submitted to the stockholders of the Company (other than any proposal relating to an Extraordinary Transaction, which is subject to Section 3(d) below), in favor of each proposal recommended by the Board and against each proposal that the Board recommends against. |
| (c) | Exceptions. Notwithstanding Section 3(b): |
| (i) | in the event that either of the Proxy Advisory Firms issues a voting recommendation that differs from the voting recommendation of the Board with respect to any proposal submitted to stockholders, Rubric shall be permitted to vote in accordance with any such Proxy Advisory Firm recommendation on such proposal; and |
| (ii) | Rubric shall be permitted to vote in its sole discretion with respect to (x) any proposal to amend the Company’s certificate of incorporation or bylaws that would (A) adversely affect the rights of Rubric under this Agreement or (B) treat Rubric or the Voting Securities held by Rubric differently from, or disproportionately relative to, other holders of Common Stock or (y) any proposal relating specifically to this Agreement or the Purchase Agreement. |
| (d) | Extraordinary Transactions. From and after (i) the Closing until the Final Exchange Date and (ii) thereafter, for so long as the Ownership Percentage is at least 5% (the “Transaction Voting Threshold”), with respect to any proposal relating to an Extraordinary Transaction submitted to the stockholders of the Company, Rubric shall vote all Voting Securities Beneficially Owned by it in favor of, against or abstaining from such proposal in the same proportion as the votes cast in favor of, against or abstaining from such proposal by holders of Common Stock other than (i) Rubric (if permitted pursuant to Section 4) and (ii) the Company’s directors and executive officers and their respective Affiliates. The parties shall cooperate in good faith to determine appropriate procedures and mechanics to facilitate such proportionate voting. |
4
| (e) | No Other Voting Arrangements. Rubric shall not grant any proxy or enter into any voting agreement, voting trust or similar arrangement with respect to Voting Securities that is inconsistent with this Section 3 or otherwise take any action that is designed to or has the effect of circumventing this Section 3. |
| 4. | Standstill. |
| (a) | From and after (i) the Closing until the Final Exchange Date and (ii) thereafter, for so long as the Ownership Percentage is at least 1%, Rubric shall not, directly or indirectly, except as may otherwise be required by the voting provisions set forth herein: |
| (i) | solicit proxies or written consents of stockholders or conduct any other type of referendum (binding or non-binding) with respect to, or from the holders of, the Voting Securities, or become a “participant” (as such term is defined in Instruction 3 to Item 4 of Schedule 14A promulgated under the Exchange Act) in or knowingly assist any Third Party in any “solicitation” of any proxy, consent or other authority (as such terms are defined under the Exchange Act) to vote any shares of the Voting Securities other than such encouragement or advice that is consistent with the Board’s recommendation in connection with such matter (it being understood that voting the Voting Securities held by Rubric, or publicly announcing how Rubric intends to vote, in each case in accordance with Section 3, shall not be deemed a violation of this clause); |
| (ii) | form or join any partnership, limited partnership, syndicate or other group, including a “group” as defined under Section 13(d) of the Exchange Act, with respect to the Voting Securities (it being understood that neither this Agreement, in and of itself, nor Rubric acting in concert solely with its controlled Affiliates shall be deemed to constitute the formation of a “group”); |
| (iii) | (A) call or seek to call (publicly or otherwise), alone or in concert with others, a meeting of the Company’s stockholders (or the setting of a record date therefor), (B) present at any annual meeting or any special meeting of the Company’s stockholders any proposal for consideration for action by stockholders or seek the removal of any member of the Board or propose any nominee for election to the Board or seek, alone or in concert with others, representation on the Board, or (C) conduct a referendum of stockholders of the Company or engage in any “withhold” or similar campaign; |
| (iv) | grant any proxy, consent or other authority to vote any Voting Securities (other than to the named proxies included in the Company’s proxy card for any annual meeting or special meeting of stockholders or to any controlled Affiliate of Rubric) or deposit any Voting Securities in a voting trust or subject them to a voting agreement or other arrangement of similar effect (excluding customary brokerage accounts, margin accounts, prime brokerage accounts and the like and any Permitted Pledge); |
| (v) | make any request for a stockholder list or similar materials or other books and records of the Company or any of its subsidiaries under Section 220 of the Delaware General Corporation Law or otherwise; |
5
| (vi) | without the prior written approval of the Board, separately or in conjunction with any other person, publicly propose or effect, or publicly announce any intention to propose or effect, any Extraordinary Transaction, or actively encourage, initiate or support any Third Party in any such activity, in each case either publicly or in a manner that would reasonably be expected to require public disclosure by the Company or Rubric (it being understood that the foregoing shall not restrict Rubric from tendering shares, receiving payment for shares or otherwise participating in any Extraordinary Transaction on the same basis as other stockholders of the Company, subject to Sections 3(d) and 5); |
| (vii) | knowingly encourage or advise any other person or knowingly assist any Third Party in so encouraging or assisting any person with respect to the giving or withholding of any proxy, consent or other authority to vote any shares of the Voting Securities or in conducting any type of referendum with respect to the Voting Securities (other than such encouragement or advice that is consistent with the Board’s recommendation in connection with such matter); |
| (viii) | acquire, offer or propose to acquire, solicit an offer to acquire, or agree to acquire, alone or in concert with any Third Party, any Company Interests, in each case, if such acquisition, offer, agreement or transaction would result in Rubric having Beneficial Ownership of, or an aggregate economic or voting interest in, more than 19.9% of the Common Stock outstanding at such time, whether Beneficially Owned or held through any other Company Interests, including any derivative, swap, option or other synthetic position; |
| (ix) | engage in any short sale or any purchase, sale or grant of any option, warrant, convertible security, share appreciation right or other similar right (including any put or call option or “swap” transaction) with respect to any security (other than any index fund, exchange traded fund, benchmark fund or broad basket of securities) that includes, relates to, or derives any significant part of its value from a decline in the market price or value of any of the securities of the Company, or otherwise hedge its economic exposure to the Common Stock; |
| (x) | institute, solicit or join as a party any litigation, arbitration or other proceeding against or involving the Company or any of its subsidiaries or any of its or their respective current or former directors or officers (including derivative actions), in order to effect or take any of the actions prohibited by this Section 4 or with the intent of circumventing any of the provisions of this Section 4; provided, however, that the foregoing shall not prevent Rubric from (A) bringing litigation to enforce any provision of this Agreement, (B) making counterclaims with respect to any proceeding initiated by, or on behalf of, the Company or its Affiliates against Rubric, (C) bringing or participating in bona fide commercial or legal disputes that do not relate to the subject matter of this Section 4, (D) exercising statutory appraisal rights, (E) responding to or complying with validly issued legal process, (F) bringing any claim based on fraud by the Company or (G) participating as a member of a class (but not as a named plaintiff or lead plaintiff) in any class action commenced and maintained by persons other than Rubric or its Affiliates; |
| (xi) | enter into any discussions, negotiations, agreements or understandings (whether written or oral) with, or advise, finance, assist or knowingly encourage, any Third Party in connection with any of the foregoing; or |
6
| (xii) | request, directly or indirectly, any amendment or waiver of the terms of this Agreement (including this clause (xii)) in a manner that would be reasonably likely to require public disclosure by Rubric or the Company. |
| (b) | Notwithstanding anything to the contrary in this Agreement, nothing in this Agreement will prohibit or restrict Rubric from (A) making any factual statement to comply with any subpoena or other legal process or respond to a request for information from any governmental authority with jurisdiction over such person, (B) entering into any Permitted Pledge, (C) negotiating, evaluating or trading in any index fund, exchange traded fund, benchmark fund or broad basket of securities which may contain or otherwise reflect the performance of, but not primarily consist of, securities of the Company, (D) providing its views privately to the Board or the Company’s senior executives in a manner that would not reasonably be expected to require public disclosure, or (E) complying with its reporting obligations under the Exchange Act or its obligations to its investors under applicable Law and the rules of any stock exchange. |
| 5. | Transfer Restrictions. |
| (a) | Lock-Up. During the period commencing on the Closing Date and ending at 11:59 p.m., New York City time, on the date that is six (6) months following the Closing Date (the “Lock-Up Period”), Rubric shall not, directly or indirectly, Transfer any shares of Common Stock comprising the Rubric Stock Consideration (together with any securities issued in respect thereof by way of stock dividend, stock split, recapitalization or similar event, the “Subject Shares”), other than pursuant to Section 5(c). Notwithstanding the foregoing, Rubric may pledge, hypothecate or grant a security interest in the Subject Shares to one or more bona fide lenders as collateral for indebtedness pursuant to customary loan or margin arrangements (a “Permitted Pledge”), and such Permitted Pledge shall not constitute a Transfer; provided that Rubric shall provide the Company with written notice of any Permitted Pledge (including the identity of the pledgee and the number of Subject Shares pledged) within five (5) Business Days following the entry into such Permitted Pledge. |
| (b) | Post-Lock-Up Volume Limitation. During the period commencing upon the expiration of the Lock-Up Period and continuing for the remainder of the term of this Agreement, Rubric may Transfer Subject Shares at any time and from time to time in its discretion; provided that sales by Rubric in open-market brokerage transactions on any single trading day shall not exceed ten percent (10%) of the greater of (i) the consolidated trading volume of the Common Stock on such trading day and (ii) the average daily consolidated trading volume of the Common Stock over the thirty (30) trading days immediately preceding such trading day (the “Volume Limitation”). The Volume Limitation applies only to open-market brokerage sales and shall not apply to or restrict: (A) any underwritten offering of Common Stock (an “Underwritten Secondary”), but only if either (x) the Company participates in such underwritten offering or (y) the Company has approved such underwritten offering in advance in writing (it being understood that any underwritten offering that satisfies neither clause (x) nor clause (y) shall not be excluded from, and shall be subject to, the Volume Limitation as if it were an open-market brokerage sale); (B) sales in privately negotiated transactions exempt from the registration requirements of the Securities Act of 1933, as amended; (C) sales or tenders into any tender offer, exchange offer, merger, consolidation or other business combination involving the Company; (D) any Transfer to a Permitted Transferee permitted by Section 5(c)(i); or (E) any Permitted Pledge or any Transfer upon foreclosure of a Permitted Pledge. |
7
| (c) | Permitted Transfers. Notwithstanding Sections 5(a) and 5(b), Rubric may Transfer Subject Shares: |
| (i) | to any Permitted Transferee; provided that (A) Rubric shall provide the Company with written notice of any such Transfer (including the identity of the Permitted Transferee and the number of Subject Shares Transferred) within five (5) Business Days following such Transfer, (B) any Subject Shares so Transferred shall remain subject to this Agreement and (C) Rubric shall remain responsible for any breach of this Agreement by any such Permitted Transferee; |
| (ii) | in connection with any tender offer, exchange offer, merger or other Extraordinary Transaction that has been approved or recommended by the Board, on the same terms as other holders of Common Stock; |
| (iii) | to the Company or any of its subsidiaries; or |
| (iv) | with the prior written consent of the Board. |
| (d) | Restricted Transferees. Without the prior written consent of the Board (which consent shall not be unreasonably withheld, conditioned or delayed; it being agreed that it shall be reasonable for the Board to withhold consent if the proposed transferee or any of its Affiliates has, within the five (5) years prior to the proposed Transfer, engaged in any solicitation of proxies, nominated directors, publicly proposed an Extraordinary Transaction or otherwise engaged in any activity of the type restricted by Section 4(a) with respect to any public company), Rubric shall not Transfer any Voting Securities (other than in an Underwritten Secondary or in anonymous open-market brokers’ transactions in compliance with Section 5(b)) to any person that (i) has, within the five (5) years prior to the proposed Transfer, filed a Schedule 13D with respect to the Company or any other issuer, or (ii) would, to Rubric’s knowledge after reasonable inquiry, Beneficially Own more than 5% of the outstanding Common Stock after giving pro forma effect to such Transfer; provided that, for the avoidance of doubt, a Transfer to a Permitted Transferee shall not be prohibited by this Section 5(d). |
| (e) | Void Transfers; Legends. Any purported Transfer in violation of this Section 5 shall be null and void ab initio, and the Company shall not, and shall instruct its transfer agent not to, register any such Transfer. Each book-entry position representing Subject Shares shall bear a customary restrictive notation referring to this Agreement, which the Company shall promptly cause to be removed with respect to any Subject Shares upon the termination of this Section 5 or upon any Transfer of such Subject Shares permitted hereunder to a person not bound by this Agreement. |
| 6. | Confidentiality; Non-Disparagement. |
| (a) | Confidentiality. Rubric shall, and shall cause its Representatives to, maintain in confidence and not disclose, and not use for any purpose other than monitoring its investment in the Company or enforcing its rights under this Agreement, any non-public, confidential or proprietary information of or relating to the Company or any of its subsidiaries (“Confidential Information”). The obligations set forth in this Section 6(a) shall not apply to Confidential Information that (i) is or becomes generally available to the public other than as a result of a disclosure by Rubric or its Representatives in violation of this Section 6, (ii) was available to Rubric on a non-confidential basis prior to its disclosure by or on behalf of the Company, (iii) becomes available to Rubric on a non-confidential basis from a source other than the Company or its Representatives, provided that such source is not known by Rubric to be bound by a confidentiality obligation to the Company with respect to such information, or (iv) is independently developed by Rubric or its Representatives without use of or reference to the Confidential Information. |
8
| (b) | Permitted Disclosure. Notwithstanding anything to the contrary in this Section 6, Rubric or its Representatives may disclose Confidential Information to the extent required by applicable Law or Order; provided that, to the extent legally permitted, Rubric shall (i) provide the Company with prompt written notice of such requirement so that the Company, at its cost, may seek a protective order or other appropriate remedy, and (ii) reasonably cooperate with the Company in seeking such protective order or other remedy. If such protective order or other remedy is not obtained, Rubric shall disclose only that portion of the Confidential Information that, on the advice of its legal counsel, is legally required to be disclosed. |
| (c) | Non-Disparagement. From and after (i) the Closing until the Final Exchange Date and (ii) thereafter, for so long as the Ownership Percentage is greater than 10%, and for one (1) year thereafter (the “Non-Disparagement Period”), Rubric shall not, and shall cause its general partner and its and its general partner’s respective principals and executive officers not to, make, or cause to be made, any statement or announcement that relates to and constitutes an ad hominem attack on, or that disparages, defames or slanders (in each case as distinct from objective statements reflecting business criticism), the Company or its business, products, operations or financial performance, its officers or its directors or any person who has served as an officer or director of the Company (in each case in such person’s capacity as such), (A) in any document or report filed with or furnished to the SEC or any other governmental agency or (B) in any press release or other publicly available format. Nothing in this Section 6(c) shall (1) restrict the ability of any person to comply with a subpoena or other legal process or respond to a request for information from any governmental or regulatory authority with jurisdiction over such person, (2) limit or preclude a party hereto from exercising or enforcing any rights under this Agreement, or from asserting any counterclaim in any proceeding initiated by the other party, or (3) preclude Rubric from making any statement required by applicable Law or stock exchange rules in its own filings with the SEC or other regulatory filings. |
| 7. | Representations and Warranties. |
| (a) | Representations and Warranties of All Parties. Each of the parties hereto represents and warrants to the other party hereto that: (i) such party has all requisite power and authority to execute and deliver this Agreement and to perform its obligations hereunder; (ii) this Agreement has been duly and validly authorized, executed and delivered by such party and, assuming the valid execution and delivery hereof by the other party, is a valid and binding obligation of such party, enforceable against such party in accordance with its terms; and (iii) the execution, delivery and performance of this Agreement does not and will not (A) violate or conflict with any law, rule, regulation, order, judgment or decree applicable to such party, or (B) result in any breach or violation of or constitute a default (or an event which with notice or lapse of time or both could constitute a breach, violation or default) under or pursuant to, or result in the loss of a material benefit under, or give any right of termination, amendment, acceleration or cancellation of, any organizational document, agreement, contract, commitment, understanding or arrangement to which such party is a party or by which it is bound. |
9
| (b) | Representations and Warranties of Rubric. Rubric represents and warrants that, as of the date of this Agreement: (i) other than the right to receive Common Stock pursuant to the Exchange Agreement, neither Rubric nor any of its Affiliates Beneficially Owns, or has any economic exposure to, any Voting Securities or other Company Interests; (ii) Rubric is not party to any agreement, arrangement or understanding (whether written or oral) with any Third Party with respect to the acquisition, holding, voting or disposition of any Company Interests, other than the Note Purchase Agreement; (iii) Rubric is the duly appointed agent for the Purchasers under the Note Purchase Agreement and has full power and authority to act on behalf of, and to bind, each of the Purchasers for purposes of this Agreement; and (iv) Rubric and the Purchasers are the sole holders of the Heron Obligations, and none of Rubric, the Purchasers or any of their respective Affiliates has sold, assigned, transferred, participated or otherwise disposed of any Heron Obligations or any interest in the Note Purchase Agreement. |
| 8. | Termination. |
| (a) | Sections 2, 7 and 9 shall become effective upon the execution and delivery of this Agreement, and the remainder of this Agreement shall become effective as of the Closing. This Agreement shall automatically terminate and be of no further force or effect, without any action by any party, upon the termination of the Purchase Agreement in accordance with its terms prior to the Closing. |
| (b) | Following the Closing, this Agreement shall terminate upon the earliest to occur of: (i) the third (3rd) anniversary of the Closing Date; (ii) the consummation of a Change of Control Transaction; provided that Rubric shall have complied with its obligations under Section 3 in connection with any vote of the Company’s stockholders with respect to such Change of Control Transaction and that no Transfer restriction in Section 5 then in effect has been breached; (iii) the first date after the Final Exchange Date on which the Ownership Percentage is less than 1%; provided that all obligations contained herein expressly survive following termination, as set forth in Section 8(d), shall continue to survive for the duration set forth herein, and provided further that no Transfer restriction in Section 5 then in effect has been breached; or (iv) the mutual written agreement of the Company and Rubric; provided, further, that all obligations contained herein that expressly survive following termination shall continue to survive for the duration set forth herein. |
| (c) | Individual provisions of this Agreement shall cease to apply upon the Ownership Percentage falling below the applicable ownership threshold (which, for the avoidance of doubt, shall be measured only after the expiration of the Lock-Up Period) or the expiration of the applicable period specified therein, as follows: Sections 3(b) through 3(d) (Voting) upon the Ownership Percentage first falling below the Voting Threshold or the Transaction Voting Threshold, as applicable; Section 3(a) (Quorum) and Section 4 (Standstill) upon the Ownership Percentage first falling below the Quorum Threshold; Section 5(a) upon expiration of the Lock-Up Period; Section 5(b) (Volume Limitation) upon the automatic termination of the Volume Limitation in accordance with Section 5(b); and Section 6(c) upon expiration of the Non-Disparagement Period. Once the Ownership Percentage has fallen below the applicable ownership threshold, the corresponding provisions shall not be revived by any subsequent increase in the Ownership Percentage. |
10
| (d) | Upon termination, this Agreement shall have no further force and effect; provided that (i) Sections 6(a) and 6(b) shall survive any termination of this Agreement for a period of two (2) years (or, with respect to Confidential Information constituting a trade secret, for so long as such information constitutes a trade secret under applicable Law), (ii) Sections 1, 2 and 9 shall survive any termination of this Agreement following the Closing, (iii) Section 6(c) shall survive for the remainder of the Non-Disparagement Period and (iv) no termination of this Agreement shall relieve any party of liability for any breach of this Agreement arising prior to such termination. |
| 9. | Miscellaneous. |
| (a) | Specific Performance. The parties hereto recognize and agree that if for any reason any of the provisions of this Agreement are not performed in accordance with their specific terms or are otherwise breached, immediate and irreparable harm or injury would be caused for which money damages would not be an adequate remedy. Accordingly, each party hereto agrees that, in addition to any other remedies to which the other party hereto may be entitled at law or in equity, the other party hereto shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement exclusively in the Court of Chancery of the State of Delaware (or, if such court lacks subject matter jurisdiction, the federal or state courts located in the State of Delaware), without proof of actual damages and without any requirement to post a bond or other security. |
| (b) | Venue. Each of the parties hereto (i) consents to submit itself to the personal jurisdiction of the Court of Chancery of the State of Delaware (or, if such court lacks subject matter jurisdiction, the federal or state courts located in the State of Delaware) in the event any dispute arises out of this Agreement or the transactions contemplated by this Agreement, (ii) agrees that it shall not attempt to deny or defeat such personal jurisdiction by motion or other request for leave from any such court, (iii) agrees that it shall not bring any action relating to this Agreement or the transactions contemplated by this Agreement in any court other than the Court of Chancery of the State of Delaware (or, if such court lacks subject matter jurisdiction, the federal or state courts located in the State of Delaware), and (iv) irrevocably consents to service of process by a reputable overnight mail delivery service, signature requested, to the address of such party’s principal place of business or as otherwise provided by applicable Law. |
| (c) | Governing Law. This Agreement shall be governed in all respects, including validity, interpretation and effect, by the laws of the State of Delaware applicable to contracts executed and to be performed wholly within such State without giving effect to the choice of law principles of such State. |
| (d) | Waiver of Jury Trial. EACH OF THE PARTIES HERETO, AFTER CONSULTING OR HAVING HAD THE OPPORTUNITY TO CONSULT WITH COUNSEL, KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVES ANY RIGHT THAT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN ANY LITIGATION BASED UPON OR ARISING OUT OF THIS AGREEMENT OR ANY RELATED INSTRUMENT OR AGREEMENT, OR ANY OF THE TRANSACTIONS CONTEMPLATED THEREBY, OR ANY COURSE OF CONDUCT, DEALING, STATEMENTS (WHETHER ORAL OR WRITTEN), OR ACTIONS OF ANY OF THEM. No party hereto shall seek to consolidate, by counterclaim or otherwise, any action in which a jury trial has been waived with any other action in which a jury trial cannot be or has not been waived. |
11
| (e) | No Waiver. Any waiver by any party hereto of a breach of any provision of this Agreement shall not operate as or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of this Agreement. The failure of a party hereto to insist upon strict adherence to any term of this Agreement on one or more occasions shall not be considered a waiver or deprive that party of the right thereafter to insist upon strict adherence to that term or any other term of this Agreement. Any waiver or consent by the Company hereunder shall be effective only if approved by the Board. |
| (f) | Entire Agreement; Amendment. This Agreement (together with Schedule A and Exhibit A hereto) contains the entire understanding of the parties hereto with respect to the subject matter hereof and supersede any and all prior and contemporaneous agreements, memoranda, arrangements and understandings, both written and oral, between the parties, or any of them, with respect to the subject matter of this Agreement, including any term sheet relating to the subject matter hereof. This Agreement may be amended only by an agreement in writing executed by the parties hereto. |
| (g) | Notices. All notices, consents, requests, instructions, approvals and other communications provided for herein and all legal process in regard to this Agreement will be in writing and will be deemed validly given, made or served, (i) if delivered in person, when delivered in person, (ii) if given by email, when such email is sent to the email address set forth in Schedule A hereto during normal business hours and appropriate confirmation is received (provided such confirmation is not automatically generated), or (iii) if given by any other means, when actually received during normal business hours at the address specified in Schedule A hereto. |
| (h) | Severability. If at any time subsequent to the date hereof, any provision of this Agreement is held by any court of competent jurisdiction to be illegal, void or unenforceable, such provision will be of no force and effect, but the illegality or unenforceability of such provision will have no effect upon the legality or enforceability of any other provision of this Agreement. In addition, the parties hereto agree to use their best efforts to agree upon and substitute a valid and enforceable provision for any provision that is held illegal, void or unenforceable by a court of competent jurisdiction. |
| (i) | Counterparts. This Agreement may be executed in one or more counterparts and by scanned computer image (such as .pdf), each of which will be deemed to be an original copy of this Agreement. For the avoidance of doubt, no party hereto shall be bound by any contractual obligation to the other party hereto until all counterparts to this Agreement have been duly executed by each of the parties hereto and delivered to the other party hereto (including by means of electronic delivery). |
| (j) | Successors and Assigns. This Agreement shall not be assignable by any of the parties to this Agreement. This Agreement, however, shall be binding on successors of the parties hereto, including any successor to Rubric by merger, consolidation, dissolution or liquidation or any person acquiring all or substantially all of Rubric’s assets (which successor shall be bound by the obligations of Rubric hereunder). |
| (k) | No Third Party Beneficiaries. This Agreement is solely for the benefit of the parties hereto and is not enforceable by any other persons. |
12
| (l) | Fees and Expenses. Each party to this Agreement will bear and pay all fees, costs and expenses that have been incurred or that are incurred in the future by such party in connection with, relating to or resulting from the negotiation, execution and performance of this Agreement. |
| (m) | Interpretation and Construction. Each of the parties hereto acknowledges that it has been represented by counsel of its choice throughout all negotiations that have preceded the execution of this Agreement, and that it has executed the same with the advice of such counsel. Each party hereto and its counsel cooperated and participated in the drafting and preparation of this Agreement and the documents referred to herein, and any and all drafts relating thereto exchanged among the parties hereto shall be deemed the work product of all of the parties hereto and may not be construed against any party hereto by reason of its drafting or preparation. Accordingly, any rule of law or any legal decision that would require interpretation of any ambiguities in this Agreement against any party hereto that drafted or prepared it is of no application and is hereby expressly waived by each of the parties hereto, and any controversy over interpretations of this Agreement will be decided without regard to events of drafting or preparation. The section headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. The terms “include,” “includes” and “including” shall be deemed to be followed by the words “without limitation” in all instances. |
| (n) | Adjustments. All share numbers and thresholds based on numbers of shares of Common Stock shall be equitably adjusted to reflect any stock split, reverse stock split, stock dividend, recapitalization, reclassification or similar event affecting the Common Stock. |
[Signature Page Follows]
13
IN WITNESS WHEREOF, each of the parties hereto has executed this Agreement, or caused the same to be executed by its duly authorized representative as of the date first above written.
| CORMEDIX INC. | ||
| By: | ||
| Name: | [●] | |
| Title: | [●] | |
| RUBRIC CAPITAL MANAGEMENT LP | ||
| By: | ||
| Name: | [●] | |
| Title: | [●] | |
SCHEDULE A
NOTICE INFORMATION
If to the Company: CorMedix Inc., 389 Interpace Pkwy, Suite 450, Parsippany, New Jersey 07054, Attention: [***], Email: [***]
With a copy to (which shall not constitute notice): Willkie Farr & Gallagher LLP, 787 Seventh Avenue, New York, New York 10019, Attention: [***], Email: [***]
If to Rubric: Rubric Capital Management LP, 155 East 44th St, Suite 1630, New York, New York 10017, Attention: [***], Email: [***]
With a copy to (which shall not constitute notice): Seward & Kissel LLP, One Battery Park Plaza, New York, New York 10004, Attention: [***], Email: [***]
EXHIBIT A
EXCHANGE AGREEMENT
[See attached.]
Exhibit 10.4
Execution Version
LOAN AGREEMENT
Dated as of November 8, 2026
among
CORMEDIX INC.
(as Borrower and a Credit Party),
THE GUARANTORS SIGNATORY HERETO OR OTHERWISE PARTY HERETO FROM TIME TO TIME
(as additional Credit Parties),
BIOPHARMA CREDIT PLC
(as Collateral Agent),
BPCR LIMITED PARTNERSHIP
(as a Lender)
and
BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP
(as a Lender)
Table of Contents
| Page | ||||
| 1. | ACCOUNTING AND OTHER TERMS | 1 | ||
| 1.1 | Accounting | 1 | ||
| 1.2 | Defined Terms | 1 | ||
| 1.3 | Currency | 1 | ||
| 1.4 | SOFR | 1 | ||
| 2. | LOANS AND TERMS OF PAYMENT | 2 | ||
| 2.1 | Promise to Pay | 2 | ||
| 2.2 | Term Loans | 2 | ||
| 2.3 | Payment of Interest on Credit Extensions | 7 | ||
| 2.4 | Expenses | 9 | ||
| 2.5 | Requirements of Law; Increased Costs | 9 | ||
| 2.6 | Taxes; Withholding, Etc | 10 | ||
| 2.7 | Additional Consideration | 13 | ||
| 2.8 | Evidence of Debt; Note Register; Term Loan Notes | 13 | ||
| 3. | CONDITIONS TO TERM LOANS | 14 | ||
| 3.1 | Conditions Precedent to First Closing Date | 14 | ||
| 3.2 | Conditions Precedent to Second Closing Date | 20 | ||
| 3.3 | Additional Conditions Precedent to Term Loans | 24 | ||
| 3.4 | Covenant to Deliver | 24 | ||
| 3.5 | Procedures for Borrowing | 24 | ||
| 4. | REPRESENTATIONS AND WARRANTIES | 25 | ||
| 4.1 | Due Organization, Existence, Power and Authority | 25 | ||
| 4.2 | Equity Interests | 25 | ||
| 4.3 | Authorization; No Conflict | 25 | ||
| 4.4 | Government Consents; Third-Party Consents | 26 | ||
| 4.5 | Binding Obligation | 26 | ||
| 4.6 | Collateral | 26 | ||
| 4.7 | Adverse Proceedings, Compliance with Laws | 31 | ||
| 4.8 | Exchange Act Documents; Financial Statements; Financial Condition; No Material Adverse Change; Books and Records | 32 | ||
| 4.9 | Solvency | 33 | ||
| 4.10 | Payment of Taxes | 33 | ||
| 4.11 | Environmental Matters | 33 | ||
| 4.12 | Material Contracts | 33 | ||
| 4.13 | Regulatory Compliance | 34 | ||
| 4.14 | Margin Stock | 34 | ||
| 4.15 | Subsidiaries; Capitalization | 34 | ||
| 4.16 | Employee Matters | 34 | ||
| 4.17 | Full Disclosure | 34 | ||
| 4.18 | Anti-Corruption Laws; Anti-Money Laundering Laws; Sanctions; Export and Import Laws | 35 | ||
| 4.19 | Health Care Matters | 36 | ||
| 4.20 | Regulatory Approvals or Licensures | 39 | ||
| 4.21 | Supply and Manufacturing | 41 | ||
| 4.22 | Cybersecurity and Data Protection | 42 | ||
| 4.23 | Additional Representations and Warranties | 43 | ||
| 4.24 | Permitted Royalty Agreement; Permitted Royalty Financing; Permitted Other Royalty Financing; Permitted Acquisition Royalty Documents | 44 | ||
i
| 5. | AFFIRMATIVE COVENANTS | 44 | ||
| 5.1 | Maintenance of Existence | 44 | ||
| 5.2 | Financial Statements, Notices | 45 | ||
| 5.3 | Taxes | 48 | ||
| 5.4 | Insurance | 49 | ||
| 5.5 | Operating Accounts | 49 | ||
| 5.6 | Compliance with Laws | 50 | ||
| 5.7 | Protection of Intellectual Property Rights | 50 | ||
| 5.8 | Books and Records | 52 | ||
| 5.9 | Access to Collateral; Audits | 52 | ||
| 5.10 | Use of Proceeds | 52 | ||
| 5.11 | Further Assurances | 52 | ||
| 5.12 | Additional Collateral | 52 | ||
| 5.13 | Formation or Acquisition of Subsidiaries; Designated Guarantors | 54 | ||
| 5.14 | Post-Closing Requirements | 54 | ||
| 5.15 | Environmental | 55 | ||
| 5.16 | Inventory; Returns; Maintenance of Properties | 56 | ||
| 5.17 | Regulatory Obligations; Maintenance of Regulatory Approval; Manufacturing, Marketing and Distribution | 56 | ||
| 5.18 | Material Contracts; Collateral Documents; Permitted Royalty Agreement Documents; Permitted Royalty Financing Documents; Permitted Acquisition Royalty Documents | 56 | ||
| 5.19 | Protection of Regulatory Materials | 57 | ||
| 5.20 | Privacy, Cybersecurity, and Data Protection | 57 | ||
| 6. | NEGATIVE COVENANTS | 58 | ||
| 6.1 | Dispositions | 58 | ||
| 6.2 | Fundamental Changes; Location of Collateral | 58 | ||
| 6.3 | Mergers, Acquisitions, Liquidations or Dissolutions | 59 | ||
| 6.4 | Indebtedness | 59 | ||
| 6.5 | Encumbrances | 59 | ||
| 6.6 | No Further Negative Pledges; Negative Pledge | 60 | ||
| 6.7 | Maintenance of Collateral Accounts | 60 | ||
| 6.8 | Distributions; Investments | 60 | ||
| 6.9 | No Restrictions on Subsidiary Distributions | 60 | ||
| 6.10 | Subordinated Debt; Permitted Convertible Indebtedness; Permitted Royalty Agreement Documents; Permitted Royalty Financing; Permitted Other Royalty Financing; Permitted Acquisition Royalty Documents | 61 | ||
| 6.11 | Amendments or Waivers of Organizational Documents | 63 | ||
| 6.12 | Compliance | 63 | ||
| 6.13 | Compliance with Sanctions, Export and Import Laws, Anti-Corruption Laws and Anti-Money Laundering Laws | 63 | ||
| 6.14 | Material Contracts | 64 | ||
| 7. | EVENTS OF DEFAULT | 65 | ||
| 7.1 | Payment Default | 65 | ||
| 7.2 | Covenant Default | 65 | ||
| 7.3 | Withdrawal Event; Material Adverse Change | 66 | ||
| 7.4 | Attachment; Levy; Restraint on Business | 66 | ||
| 7.5 | Insolvency | 66 | ||
| 7.6 | Other Agreements | 67 | ||
| 7.7 | Judgments | 68 | ||
| 7.8 | Misrepresentations | 68 | ||
| 7.9 | Loan Documents; Collateral | 68 | ||
| 7.10 | ERISA Event | 68 | ||
| 7.11 | Intercreditor Agreements | 69 | ||
| 8. | RIGHTS AND REMEDIES UPON AN EVENT OF DEFAULT | 69 | ||
| 8.1 | Rights and Remedies | 69 | ||
| 8.2 | Power of Attorney | 71 | ||
| 8.3 | Application of Payments and Proceeds Upon Default | 71 | ||
| 8.4 | Collateral Agent’s Liability for Collateral | 71 | ||
| 8.5 | No Waiver; Remedies Cumulative | 71 | ||
| 8.6 | Demand Waiver; Makewhole Amount; Prepayment Premium; Additional Consideration | 72 | ||
ii
| 9. | NOTICES | 72 | ||
| 10. | CHOICE OF LAW, VENUE, AND JURY TRIAL WAIVER | 74 | ||
| 11. | GENERAL PROVISIONS | 74 | ||
| 11.1 | Successors and Assigns | 74 | ||
| 11.2 | Indemnification | 75 | ||
| 11.3 | Severability of Provisions | 76 | ||
| 11.4 | Correction of Loan Documents | 76 | ||
| 11.5 | Amendments in Writing; Integration | 76 | ||
| 11.6 | Counterparts | 77 | ||
| 11.7 | Survival; Termination | 77 | ||
| 11.8 | Confidentiality | 77 | ||
| 11.9 | Attorneys’ Fees, Costs and Expenses | 78 | ||
| 11.10 | Right of Setoff | 78 | ||
| 11.11 | Marshalling; Payments Set Aside | 78 | ||
| 11.12 | Electronic Execution of Documents | 78 | ||
| 11.13 | Captions | 78 | ||
| 11.14 | Construction of Agreement | 79 | ||
| 11.15 | Third Parties | 79 | ||
| 11.16 | No Advisory or Fiduciary Duty | 79 | ||
| 11.17 | Credit Parties’ Agent | 79 | ||
| 12. | COLLATERAL AGENT | 80 | ||
| 12.1 | Appointment and Authority | 80 | ||
| 12.2 | Rights as a Lender | 80 | ||
| 12.3 | Exculpatory Provisions | 80 | ||
| 12.4 | Reliance by Collateral Agent | 81 | ||
| 12.5 | Delegation of Duties | 81 | ||
| 12.6 | Resignation of Collateral Agent | 81 | ||
| 12.7 | Non-Reliance on Collateral Agent and Other Lenders | 82 | ||
| 12.8 | Collateral and Guaranty Matters | 82 | ||
| 12.9 | Reimbursement by Lenders | 83 | ||
| 12.10 | Notices and Items to Lenders | 83 | ||
| 13. | DEFINITIONS | 84 | ||
| 13.1 | Definitions | 84 | ||
Exhibit A: Loan Advance Request Form
Exhibit B-1: Form of Tranche A Term Loan Note
Exhibit B-2: Form of Tranche B Term Loan Note
Exhibit C: Form of Security Agreement
Exhibit D: Commitments; Notice Addresses
Exhibit E: Form of Compliance Certificate
Exhibit F-1: Form of U.S. Tax Compliance Certificate for Foreign Lenders that Are Not Partnerships for U.S. Federal Income Tax Purposes
Exhibit F-2: Form of U.S. Tax Compliance Certificate for Foreign Participants that Are Not Partnerships for U.S. Federal Income Tax Purposes
Exhibit F-3: Form of U.S. Tax Compliance Certificate for Foreign Participants that Are Partnerships for U.S. Federal Income Tax Purposes
Exhibit F-4: Form of U.S. Tax Compliance Certificate for Foreign Lenders that Are Partnerships for U.S. Federal Income Tax Purposes
iii
LOAN AGREEMENT
THIS LOAN AGREEMENT (this “Agreement”), dated as of November 8, 2026 (the “Effective Date”) by and among CORMEDIX INC., a Delaware corporation (as “Borrower” and a Credit Party), the Guarantors signatory hereto or otherwise party hereto from time to time, as additional Credit Parties, BIOPHARMA CREDIT PLC, a public limited company incorporated under the laws of England and Wales with company number 10443190 (as the “Collateral Agent”), BPCR LIMITED PARTNERSHIP, a limited partnership established under the laws of England and Wales with registration number LP020944 (as a “Lender”) and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP, a Cayman Islands exempted limited partnership acting by its general partner, BioPharma Credit Investments V GP LLC (as a “Lender”), provides the terms on which each Lender shall make, and Borrower shall repay, the Credit Extensions (as hereinafter defined).
1. ACCOUNTING AND OTHER TERMS
1.1 Accounting. Except as otherwise expressly provided herein, all accounting terms not otherwise defined in this Agreement shall have the meanings assigned to them in conformity with GAAP. Calculations and determinations must be made following GAAP. If at any time any change in GAAP would affect the computation of any financial requirement set forth in any Loan Document (including for purposes of measuring compliance with any provision of Section 6), and either Borrower or the Collateral Agent shall so request, the Collateral Agent and Borrower shall negotiate in good faith to amend such requirement to preserve the original intent thereof in light of such change in GAAP; provided, that, until so amended, (x) such requirement shall continue to be computed in accordance with GAAP prior to such change therein and (y) all financial statements, Compliance Certificates and similar documents provided, delivered or submitted hereunder shall be provided, delivered or submitted together with a reconciliation between the calculations and amounts set forth therein before and after giving effect to such change in GAAP. Notwithstanding any other provision contained herein, all terms of an accounting or financial nature used herein shall be construed, and all computations of amounts referred to herein, including in Section 5 and Section 6 shall be made, without giving effect to any election under ASC 825-10 (or any other Financial Accounting Standards Board Accounting Standards Codification (“ASC”) or Financial Accounting Standard or Applicable Accounting Standard (including IFRS 9) having a similar result or effect) to value any Indebtedness or other liabilities of any Credit Party or any Subsidiary of any Credit Party at “fair value”. Notwithstanding anything to the contrary above or in the definition of “Capital Lease Obligations”, all obligations of any Person that are or would have been treated as operating leases for purposes of GAAP prior to the effectiveness of ASC 842 shall continue to be accounted for as operating leases for all purposes hereunder or under any other Loan Documents (whether or not such operating lease obligations were in effect on such date) notwithstanding the fact that such obligations are required in accordance with ASC 842 (on a prospective or retroactive basis or otherwise) to be treated as Capital Leases.
1.2 Defined Terms. Capitalized terms not otherwise defined in this Agreement shall have the meanings set forth in Section 13. All other terms contained in this Agreement, unless otherwise indicated, shall have the meaning provided by the Code to the extent such terms are defined therein. All references to “Dollars” or “$” are United States Dollars, unless otherwise noted.
1.3 Currency. For purposes of Sections 5 and 6 hereof and solely with respect to the amount of any Indebtedness, Investment or other transaction made or consummated in a currency other than Dollars, no Default or Event of Default shall be deemed to have occurred after the time such Indebtedness, Investment or other transaction is incurred, made or consummated (so long as such Indebtedness, Investment or other transaction, at the time incurred, made or consummated, was permitted hereunder) solely as a result of changes in rates of currency exchange occurring over time.
1.4 SOFR. The Collateral Agent does not warrant or accept responsibility for, and shall not have any liability with respect to (a) the continuation of, administration of, submission of, calculation of or any other matter related to the Term SOFR Reference Rate or Term SOFR, or any component definition thereof or rates referred to in the definition thereof, or any alternative, successor or replacement rate thereto (including any Benchmark Replacement), including whether the composition or characteristics of any such alternative, successor or replacement rate (including any Benchmark Replacement) will be similar to, or produce the same value or economic equivalence of, or have the same volume or liquidity as, the Term SOFR Reference Rate, Term SOFR or any other Benchmark prior to its discontinuance or unavailability, or (b) the effect, implementation or composition of any Conforming Changes. The Collateral Agent and its affiliates or other related entities may engage in transactions that affect the calculation of the Term SOFR Reference Rate, Term SOFR, any alternative, successor or replacement rate (including any Benchmark Replacement) or any relevant adjustments thereto, in each case, in a manner adverse to Borrower. The Collateral Agent may select information sources or services in its reasonable discretion to ascertain the Term SOFR Reference Rate, Term SOFR or any other Benchmark, in each case pursuant to the terms of this Agreement, and shall have no liability to Borrower, any Lender or any other Person for damages of any kind, including direct or indirect, special, punitive, incidental or consequential damages, costs, losses or expenses (whether in tort, contract or otherwise and whether at law or in equity), for any error or calculation of any such rate (or component thereof) provided by any such information source or service.
-1-
2. LOANS AND TERMS OF PAYMENT
2.1 Promise to Pay. Borrower hereby unconditionally promises to pay each Lender the outstanding principal amount of the Term Loans advanced to Borrower by such Lender and accrued and unpaid interest thereon and any other amounts due hereunder as and when due in accordance with this Agreement.
2.2 Term Loans.
(a) Availability. Subject to the terms and conditions of this Agreement (including Sections 3.1, 3.2, 3.3, 3.4 and 3.5):
(i) (A) Borrower agrees to request the Tranche A Loan Amount in accordance with Section 3.5, and each Lender severally agrees to make a term loan to Borrower on the Tranche A Closing Date in an original principal amount equal to such Lender’s Applicable Percentage of the Tranche A Loan Amount and, for the avoidance of doubt, not greater than such Lender’s Tranche A Commitment (the “Tranche A Loan”); provided, however, that the parties hereto hereby agree that if Borrower does not deliver the completed and duly executed Advance Request Form for the Tranche A Loan pursuant to Section 3.1(a)(ii) and Borrower or any of its Subsidiaries consummates the Heron Acquisition Transaction or any other transaction involving the acquisition, directly or indirectly, of one or more of the Heron Acquisition Products on or before the Tranche A Commitment End Date, Borrower shall be and is deemed to have requested the Tranche A Loan in accordance with Section 2.2(h) and Section 3.5.
(ii) (A) if the Tranche B Closing Date is the First Closing Date and the use of proceeds thereof are to fund the Other Acquisition Transaction, Borrower agrees to request the Tranche B Loan Amount in accordance with Section 3.5, and each Lender severally agrees to make a term loan to Borrower on the Tranche B Closing Date in an original principal amount equal to such Lender’s Applicable Percentage of the Tranche B Loan Amount and, for the avoidance of doubt, not greater than such Lender’s Tranche B Commitment (the “Tranche B Loan”); provided, however, that the parties hereto hereby agree that if Borrower does not deliver the completed and duly executed Advance Request Form for the Tranche B Loan pursuant to Section 3.1(a)(ii) and Borrower or any of its Subsidiaries consummates the Other Acquisition Transaction or any other transaction involving the acquisition, directly or indirectly, of one or more of the Other Acquisition Products on or before the Tranche B Commitment End Date, Borrower shall be and is deemed to have requested the Tranche B Loan in accordance with Section 2.2(h) and Section 3.5; and (B) if the Tranche B Closing Date is the Second Closing Date, at Borrower’s election pursuant to Section 3.5, each Lender severally agrees to make a term loan to Borrower on the Tranche B Closing Date in an original principal amount equal to such Lender’s Applicable Percentage of the Tranche B Loan Amount and, for the avoidance of doubt, not greater than such Lender’s Tranche B Commitment (the “Tranche B Loan”).
(iii) After repayment or prepayment (in whole or in part), no Term Loan (or any portion thereof) may be re-borrowed.
-2-
(b) Repayment.
(i) Borrower shall make equal quarterly payments of principal of each Term Loan, commencing on the Initial Payment Date and continuing quarterly on each of the next seven (7) consecutive Payment Dates thereafter and on the Term Loan Maturity Date; provided, however, that, notwithstanding the foregoing, upon the occurrence of the Amortization Adjustment Trigger, Borrower shall have the right to elect, by delivery of written notice thereof to the Collateral Agent no later than November 30, 2029, to make equal quarterly payments of principal of each Term Loan, commencing on the Initial Payment Date and continuing quarterly on each of the next three (3) consecutive Payment Dates thereafter and on the Term Loan Maturity Date.
(ii) The Term Loans, including all unpaid principal thereunder (and, for the avoidance of doubt, all accrued and unpaid interest, all due and unpaid Lender Expenses and any and all other outstanding amounts payable under the Loan Documents), are due and payable in full on the Term Loan Maturity Date.
(iii) The Term Loans may be prepaid only in accordance with Section 2.2(c), except as provided in Section 8.1.
(c) Prepayment of Term Loans.
(i) Borrower shall have the option, at any time after the First Closing Date, to prepay, outstanding principal amounts under the Term Loans advanced by Lenders under this Agreement, in whole or in part, in multiples of no less than $25,000,000 per prepayment (unless the then-outstanding principal amount of the Term Loans is less than $25,000,000, in which case such Term Loans shall be prepaid in whole); provided, that, (A) Borrower provides written notice to the Collateral Agent of its election to prepay the Term Loans at least five (5) Business Days prior to such prepayment (which notice shall be irrevocable and shall include the amount of the outstanding principal amount of the Term Loans to be prepaid), and (B) the prepayment of such principal amount shall be accompanied by any and all accrued and unpaid interest thereon through the date of prepayment, any and all amounts payable in connection with such prepayment pursuant to Section 2.2(e) and Section 2.2(f), as applicable, and any and all other amounts payable and not yet paid under this Agreement and the other Loan Documents (including pursuant to Section 2.4). The Collateral Agent will promptly notify each Lender of its receipt of such notice, and the amount of such Lender’s Applicable Percentage of such prepayment. Notwithstanding anything in this Section 2.2(c)(i) to the contrary, Borrower may rescind any notice of prepayment under this Section 2.2(c)(i) if such prepayment would have resulted from a refinancing of the Term Loans or other contingent transaction, which refinancing or transaction shall not be consummated or shall otherwise be delayed (in which case the date of prepayment may be extended with the consent of the Collateral Agent or the Required Lenders (not to be unreasonably withheld, conditioned or delayed) or a new notice shall be required to be sent in connection with any subsequent prepayment).
(ii) Borrower shall promptly, and in any event no later than ten (10) Business Days prior (or immediately if known fewer than ten (10) Business Days prior) to the consummation of such Change in Control, notify the Collateral Agent in writing of the occurrence (or anticipated occurrence) of a Change in Control, which notice shall include reasonable detail as to the nature, timing and other circumstances of such Change in Control (such notice, a “Change in Control Notice”). Borrower shall prepay in full all of the Term Loans advanced by Lenders under this Agreement, immediately upon (and concurrent with) the consummation of such Change in Control, in an amount equal to the sum of (A) all unpaid principal and any and all accrued and unpaid interest thereon through the date of prepayment (such interest to be calculated based on Term SOFR for the Interest Period during which such Change in Control is consummated), and (B) any and all amounts payable with respect to the prepayment under this Section 2.2(c)(ii) pursuant to Section 2.2(e) and Section 2.2(f), as applicable, together with any and all other amounts payable or accrued and not yet paid under this Agreement and the other Loan Documents (including pursuant to Section 2.4). The Collateral Agent will promptly notify each Lender of its receipt of the Change in Control Notice, and the amount of such Lender’s Applicable Percentage of such prepayment.
-3-
(iii) Prior to any prepayment, repurchase, redemption or similar action, of the Permitted Convertible Indebtedness in accordance with its terms (the “Convertible Indebtedness Redemption”) that occurs prior to the Term Loan Maturity Date, Borrower shall promptly, and in any event no later than five (5) days prior to the consummation of such Convertible Indebtedness Redemption, notify the Collateral Agent in writing of the expected occurrence of such Convertible Indebtedness Redemption, which notice shall include reasonable detail as to the nature, timing and other circumstances of such Convertible Indebtedness Redemption (such notice, a “Convertible Indebtedness Redemption Notice”). Borrower shall prepay in full all of the Term Loans advanced by Lenders under this Agreement no later than concurrently with such Convertible Indebtedness Redemption, in an amount equal to the sum of (A) all unpaid and outstanding principal and any and all accrued and unpaid interest with respect to the Term Loans, and (B) any and all amounts payable with respect to the prepayment under this Section 2.2(c)(iii) pursuant to Section 2.2(e) and Section 2.2(f), as applicable, together with any and all other amounts payable or accrued and not yet paid under this Agreement and the other Loan Documents (including pursuant to Section 2.4). The Collateral Agent will promptly notify each Lender of its receipt of the Convertible Indebtedness Redemption Notice, and the amount of such Lender’s Applicable Percentage of such prepayment. Notwithstanding the foregoing, none of the following shall be deemed to be a Convertible Indebtedness Redemption: (w) the conversion to Equity Interests (and payment of cash in lieu of fractional shares) by holders of Permitted Convertible Indebtedness (including any cash payment upon conversion) or required payment of any interest with respect to any Permitted Convertible Indebtedness, in each case, in accordance with the terms of the indenture or other documentation governing such Permitted Convertible Indebtedness; (x) delivery of Equity Interests and cash in lieu of fractional shares or in respect of accrued and unpaid interest to any holder of Permitted Convertible Indebtedness to induce such holder to convert Permitted Convertible Indebtedness in accordance with the terms of the indenture governing such Permitted Convertible Indebtedness; (y) any prepayment, repurchase, redemption or similar action of the Permitted Convertible Indebtedness using cash proceeds of (1) any issuance of Permitted Convertible Indebtedness (and any cash proceeds received pursuant to the exercise, early unwind or termination of any Permitted Equity Derivatives in connection with such prepayment, repurchase, redemption or action) or (2) any issuance of Equity Interests of Borrower occurring within thirty (30) days prior to such prepayment, repurchase, redemption or similar action and no later than the Maturity Date Acceleration Trigger; or (z) the exchange of existing Permitted Convertible Indebtedness for (1) Indebtedness constituting new Permitted Convertible Indebtedness (the “Refinancing Convertible Debt”) (or the cash proceeds from the issuance of such Refinancing Convertible Debt) to the extent such Refinancing Convertible Debt is permitted to be issued under the terms of this Agreement, (2) Equity Interests, (3) the cash proceeds, if any, received pursuant to the exercise, early unwind or termination of any Permitted Equity Derivatives entered into in connection with such existing Permitted Convertible Indebtedness, or (4) cash in respect of accrued and unpaid interest on such exchanged existing Permitted Convertible Indebtedness (any such transaction described in sub-clauses (w) through (z) above, a “Permitted Transaction” and collectively, the “Permitted Transactions”).
(d) Prepayment Application. Any prepayment of the Term Loans pursuant to Section 2.2(c) or as a result of the acceleration of the maturity of the Term Loans pursuant to Section 8.1(a) (together with the accompanying Makewhole Amount and Prepayment Premium that is payable pursuant to Section 2.2(e) and Section 2.2(f), as applicable), shall be paid to Lenders in accordance with their respective Applicable Percentages for application to the Obligations in the following order: (i) first, to due and unpaid Lender Expenses; (ii) second, to accrued and unpaid interest at the Default Rate incurred pursuant to Section 2.3(b), with respect to past due amounts, if any; (iii) third, without duplication of amounts paid pursuant to sub-clause (ii) above, to accrued and unpaid interest at the Term Loan Rate; (iv) fourth, to accrued and unpaid Additional Consideration, if any; (v) fifth, to the Prepayment Premium; (vi) sixth, to the Makewhole Amount, if applicable; (vii) seventh, to the outstanding principal amount of the Term Loans being prepaid, provided, that, unless otherwise determined by the Collateral Agent in its sole discretion, such prepayment shall be applied first to reduce the principal amount of the Term Loans funded on the Second Closing Date, then to reduce the principal amount of the Term Loans funded on the First Closing Date; and (viii) eighth, to any remaining amounts then due and payable under this Agreement and the other Loan Documents.
-4-
(e) Makewhole Amount.
(i) Any (A) prepayment of the Tranche A Loan by Borrower (1) pursuant to Section 2.2(c) or (2) as a result of the acceleration of the maturity of the Term Loans pursuant to Section 8.1(a) (but not, for the avoidance of doubt, as a result of the acceleration of the maturity of the Term Loans upon the occurrence of the Maturity Date Acceleration Trigger), in either case occurring prior to the 2nd-year anniversary of the Tranche A Closing Date, or (B) in the case where the Tranche A Loan is deemed to have been requested by Borrower and to have been advanced by Lenders pursuant to Sections 2.2(a)(i), 2.2(h) and 3.5, any deemed prepayment of the Tranche A Loan by Borrower pursuant to Section 2.2(h), shall in either case of sub-clause (A) or (B) above, be accompanied by payment of an amount equal to the Tranche A Makewhole Amount.
(ii) Any (A) prepayment of the Tranche B Loan by Borrower (1) pursuant to Section 2.2(c) or (2) as a result of the acceleration of the maturity of the Term Loans pursuant to Section 8.1(a) (but not, for the avoidance of doubt, as a result of the acceleration of the maturity of the Term Loans upon the occurrence of the Maturity Date Acceleration Trigger), in either case occurring prior to the 2nd-year anniversary of the Tranche B Closing Date, or (B) in the case where the Tranche B Loan is deemed to have been requested by Borrower and to have been advanced by Lenders pursuant to Sections 2.2(a)(ii), 2.2(h) and 3.5, any deemed prepayment of the Tranche B Loan by Borrower pursuant to Section 2.2(h), shall in either case of sub-clause (A) or (B) above, be accompanied by payment of an amount equal to the Tranche B Makewhole Amount.
(f) Prepayment Premium.
(i) Any (A) prepayment of the Tranche A Loan by Borrower (1) pursuant to Section 2.2(c) or (2) as a result of the acceleration of the maturity of the Term Loans pursuant to Section 8.1(a) (including, for the avoidance of doubt, as a result of the acceleration of the maturity of the Term Loans upon the occurrence of the Maturity Date Acceleration Trigger), or (B) in the case where the Tranche A Loan is deemed to have been requested by Borrower and to have been advanced by Lenders pursuant to Sections 2.2(a)(i), 2.2(h) and 3.5, any deemed prepayment of the Tranche A Loan by Borrower pursuant to Section 2.2(h), shall in either case of sub-clause (A) or (B) above, be accompanied by payment of an amount equal to the Tranche A Prepayment Premium.
(ii) Any (A) prepayment of the Tranche B Loan by Borrower (1) pursuant to Section 2.2(c) or (2) as a result of the acceleration of the maturity of the Term Loans pursuant to Section 8.1(a) (including, for the avoidance of doubt, as a result of the acceleration of the maturity of the Term Loans upon the occurrence of the Maturity Date Acceleration Trigger), or (B) in the case where the Tranche B Loan is deemed to have been requested by Borrower and to have been advanced by Lenders pursuant to Sections 2.2(a)(ii), 2.2(h) and 3.5, any deemed prepayment of the Tranche B Loan by Borrower pursuant to Section 2.2(h), shall in either case of sub-clause (A) or (B) above, be accompanied by payment of an amount equal to the Tranche B Prepayment Premium.
-5-
(g) Any Makewhole Amount or Prepayment Premium or, if applicable pursuant to Section 2.2(h) below, Tranche A Additional Consideration or Tranche B Additional Consideration, payable as a result of any prepayment of the Term Loans pursuant to Section 2.2(c) or as a result of the acceleration of the maturity of the Term Loans pursuant to Section 8.1(a), or any deemed prepayment of the Tranche A Loan by Borrower pursuant to Section 2.2(h) below or any deemed prepayment of the Tranche B Loan by Borrower pursuant to Section 2.2(h) below, shall be presumed to be the liquidated damages sustained by each applicable Lender as the result of the early redemption and repayment of such Term Loan Notes and Borrower agrees that it is reasonable under the circumstances currently existing. BORROWER EXPRESSLY WAIVES (TO THE FULLEST EXTENT IT MAY LAWFULLY DO SO) THE PROVISIONS OF ANY PRESENT OR FUTURE REQUIREMENTS OF LAW THAT PROHIBITS OR MAY PROHIBIT THE COLLECTION OF ANY MAKEWHOLE AMOUNT OR PREPAYMENT PREMIUM OR TRANCHE A ADDITIONAL CONSIDERATION OR TRANCHE B ADDITIONAL CONSIDERATION IN CONNECTION WITH ANY SUCH PREPAYMENT OR ACCELERATION OR OTHERWISE. Borrower expressly agrees that (to the fullest extent it may lawfully do so) that: (i) each Makewhole Amount and Prepayment Premium and, if applicable pursuant to Section 2.2(h) below, Tranche A Additional Consideration and Tranche B Additional Consideration, is reasonable and is the product of an arm’s-length transaction among sophisticated business people, ably represented by counsel; (ii) each Makewhole Amount and Prepayment Premium and, if applicable pursuant to Section 2.2(h) below, Tranche A Additional Consideration and Tranche B Additional Consideration, shall be payable notwithstanding the then-prevailing market rates at the time payment thereof is made; (iii) there has been a course of conduct among Lenders and Borrower giving specific consideration in this transaction for such agreement to pay each Makewhole Amount and Prepayment Premium and, if applicable pursuant to Section 2.2(h) below, Tranche A Additional Consideration and Tranche B Additional Consideration; and (iv) Borrower shall be estopped hereafter from claiming differently than as agreed to in this Section 2.2(g), Section 2.2(h) and Section 8.6. Borrower expressly acknowledges that its agreement to pay the Makewhole Amount and Prepayment Premium and, as may be applicable pursuant to Section 2.7, Tranche A Additional Consideration and Tranche B Additional Consideration, to applicable Lenders as herein described is a material inducement to such Lenders to make any Credit Extension. Without affecting any of any Lender’s rights or remedies hereunder or in respect hereof, if Borrower fails to pay the applicable Makewhole Amount or Prepayment Premium or, as may be applicable pursuant to Section 2.2(h) below, Tranche A Additional Consideration or Tranche B Additional Consideration, when due, then the amount thereof shall thereafter bear interest until paid in full at the Default Rate.
(h) (i) The parties hereto hereby agree that if Borrower does not deliver the completed and duly executed Advance Request Form for the Tranche A Loan pursuant to Section 3.1(a)(ii) and Borrower or any of its Subsidiaries consummates the Heron Acquisition Transaction or any other transaction involving the acquisition, directly or indirectly, of one or more of the Heron Acquisition Products on or before the Tranche A Commitment End Date (such consummation date, the “Tranche A Loan Trigger Date”): (a) Borrower shall be deemed to have requested the Tranche A Loan based on the Tranche A Loan Amount on the Business Day immediately preceding such Tranche A Loan Trigger Date; (b) each Lender shall be and is deemed to have advanced its Applicable Percentage of the Tranche A Loan Amount to Borrower on the Business Day immediately preceding such Tranche A Loan Trigger Date; (c) Borrower shall be deemed to have prepaid in full the Tranche A Loan pursuant to Section 2.2(c)(i) on such Tranche A Loan Trigger Date; (d) each of the Tranche A Additional Consideration, Tranche A Makewhole Amount and Tranche A Prepayment Premium shall be due and payable on such Tranche A Loan Trigger Date, without any notice, demand or other action by the Collateral Agent or any Lender (calculated based on the Tranche A Loan Amount deemed to have been requested by Borrower and advanced by Lenders pursuant to this clause (h) and Sections 2.2 and 3.5 hereof); and (e) Borrower shall pay each Lender its Applicable Percentage of the Tranche A Additional Consideration, Tranche A Makewhole Amount and Tranche A Prepayment Premium that is payable pursuant to Section 2.2 and Section 2.7, as applicable, on such Tranche A Loan Trigger Date; and
-6-
(ii) If the Tranche B Closing Date is the First Closing Date and the use of proceeds thereof are to fund the Other Acquisition Transaction, the parties hereto hereby agree that if Borrower does not deliver the completed and duly executed Advance Request Form for the Tranche B Loan pursuant to Section 3.1(a)(ii) and Borrower or any of its Subsidiaries consummates the Other Acquisition Transaction or any other transaction involving the acquisition, directly or indirectly, of one or more of the Other Acquisition Products on or before the Tranche B Commitment End Date (such consummation date, the “Tranche B Loan Trigger Date”): (a) Borrower shall be deemed to have requested the Tranche B Loan based on the Tranche B Loan Amount of $50,000,000.00 on the Business Day immediately preceding such Tranche B Loan Trigger Date; (b) each Lender shall be and is deemed to have advanced its Applicable Percentage of the Tranche B Loan Amount to Borrower on the Business Day immediately preceding such Tranche B Loan Trigger Date; (c) Borrower shall be deemed to have prepaid in full the Tranche B Loan pursuant to Section 2.2(c)(i) on such Tranche B Loan Trigger Date; (d) each of the Tranche B Additional Consideration, Tranche B Makewhole Amount and Tranche B Prepayment Premium shall be due and payable on such Tranche B Loan Trigger Date, without any notice, demand or other action by the Collateral Agent or any Lender (calculated based on the Tranche B Loan Amount deemed to have been requested by Borrower and advanced by Lenders pursuant to this clause (h) and Sections 2.2 and 3.5 hereof); and (e) Borrower shall pay each Lender its Applicable Percentage of the Tranche B Additional Consideration, Tranche B Makewhole Amount and Tranche B Prepayment Premium that is payable pursuant to Section 2.2 and Section 2.7, as applicable, on such Tranche B Loan Trigger Date.
2.3 Payment of Interest on Credit Extensions.
(a) Interest Rate.
(i) Subject to Section 2.3(b) below, the principal amount outstanding under each Term Loan shall accrue interest at a per annum rate equal to Term SOFR for the Interest Period therefor plus the Applicable Margin (the “Term Loan Rate”), which interest shall be payable quarterly in arrears in accordance with this Section 2.3.
(ii) Interest shall accrue on each Term Loan commencing on, and including, the day on which such Term Loan is made, and shall accrue on such Term Loan, or any portion thereof, through and including the day on which such Term Loan or such portion is paid.
(iii) Interest is due and payable quarterly on each Interest Date, as calculated by the Collateral Agent (which calculations shall be deemed correct absent manifest error, provided that the Collateral Agent shall provide evidence of such calculation upon Borrower’s written request); provided, however, that if any such date is not a Business Day, the applicable interest shall be due and payable on the immediately preceding Business Day.
(b) Default Rate. In the event Borrower fails to pay any of the Obligations when due (after giving effect to any applicable grace or cure period), or upon the commencement and during the continuance of an Insolvency Proceeding of Borrower, or upon the occurrence and during the continuance of any other Event of Default, immediately (and without notice or demand by any Lender or the Collateral Agent for payment thereof to Borrower), any past due Obligations shall accrue interest at a rate per annum which is three percentage points (3.00%) above the rate that is otherwise applicable thereto (the “Default Rate”), and, notwithstanding anything to the contrary in Section 2.3(a) above, such interest shall be payable entirely in cash on demand of the Collateral Agent; provided, however, that, with respect to any Event of Default of the type described in Section 7, other than Sections 7.1 and 7.5, the Collateral Agent shall notify Borrower in writing regarding the accrual of interest at the Default Rate in respect of any such Obligations as promptly as practicable following the occurrence of such Event of Default; provided, further, that the failure of the Collateral Agent to deliver such notice to Borrower shall not constitute a waiver of any such Event of Default or affect the right of any Lender or the Collateral Agent to collect or demand such accrued interest with respect to any time prior to the giving of such notice or otherwise prejudice or limit any rights or remedies of the Collateral Agent or any Lender. Payment or acceptance of the increased interest rate provided in this Section 2.3(b) is not a permitted alternative to timely payment of any Obligations and shall not constitute a waiver of any Event of Default or otherwise prejudice or limit any rights or remedies of the Collateral Agent or any Lender.
-7-
(c) 360-Day Year. Interest payable under each Term Loan shall be computed on the basis of a year of 360 days, and in each case shall be payable for the actual number of days elapsed.
(d) Payments. Except as otherwise expressly provided herein, all Term Loan payments and any other payments hereunder by (or on behalf of) Borrower shall be made on the date specified herein to such bank account of each applicable Lender as such Lender (or the Collateral Agent) shall have designated in a written notice to Borrower delivered on or before the First Closing Date (which such notice may be updated by such Lender (or the Collateral Agent) by written notice to Borrower from time to time after the First Closing Date on two (2) Business Days’ notice). Except as otherwise expressly provided herein, interest is payable quarterly on each Interest Date; provided, however, that if any such date is not a Business Day, the applicable interest shall be due and payable on the immediately preceding Business Day. Payments of principal or interest received after 11:00 a.m. New York City time on such date are considered received at the opening of business on the next Business Day. When any payment is due on a day that is not a Business Day, such payment is due on the immediately preceding Business Day. All payments to be made by Borrower hereunder or under any other Loan Document, including payments of principal and interest made hereunder and pursuant to any other Loan Document, and all fees, expenses, indemnities and reimbursements, shall be made without setoff, recoupment or counterclaim, in lawful money of the United States and in immediately available funds.
(e) Conforming Changes. In connection with the use or administration of Term SOFR, the Collateral Agent, in consultation with Borrower, will have the right to make Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any other Loan Document, any amendments implementing such Conforming Changes will become effective without any further action or consent of any other party to this Agreement or any other Loan Document. The Collateral Agent will promptly notify Borrower and the Lenders of the effectiveness of any Conforming Changes in connection with the use or administration of Term SOFR.
(f) Benchmark Replacement Setting. Notwithstanding anything to the contrary herein or in any other Loan Document:
(i) Benchmark Replacement. Notwithstanding anything herein or in any other Loan Document to the contrary, if a Benchmark Transition Event and its related Benchmark Replacement Date have occurred prior to any setting of the then-current Benchmark, then (x) if a Benchmark Replacement is determined in accordance with clause (a) of the definition of Benchmark Replacement for such Benchmark Replacement Date, such Benchmark Replacement will replace such Benchmark for all purposes hereunder and under any Loan Document in respect of such Benchmark setting and subsequent Benchmark settings without any amendment to, or further action or consent of any other party to, this Agreement or any other Loan Document and (y) if a Benchmark Replacement is determined in accordance with clause (b) of the definition of Benchmark Replacement for such Benchmark Replacement Date, such Benchmark Replacement will replace such Benchmark for all purposes hereunder and under any Loan Document in respect of any Benchmark setting at or after 5:00 p.m. (New York City time) on the fifth (5th) Business Day after the date notice of such Benchmark Replacement is provided to Lenders without any amendment to, or further action or consent of any other party to, this Agreement or any other Loan Document so long as the Collateral Agent has not received, by such time, written notice of objection to such Benchmark Replacement from Lenders comprising the Required Lenders. For the avoidance of doubt, if the Benchmark Replacement is Daily Simple SOFR, all interest payments will be payable on a quarterly basis.
-8-
(ii) Conforming Changes. In connection with the implementation and administration of a Benchmark Replacement, the Collateral Agent, in consultation with Borrower, will have the right to make Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any other Loan Document, any amendments implementing such Conforming Changes will become effective without any further action or consent of any other party to this Agreement or any other Loan Document.
(iii) Notices; Standards for Decisions and Determinations. The Collateral Agent will promptly notify Borrower and the Lenders of (A) the implementation of any Benchmark Replacement and (B) the effectiveness of any Conforming Changes in connection with the use, administration, adoption or implementation of a Benchmark Replacement. The Collateral Agent will notify Borrower of (x) the removal or reinstatement of any tenor of a Benchmark pursuant to sub-clause (iv) below and (y) the commencement of any Benchmark Unavailability Period. Any determination, decision or election that may be made by the Collateral Agent or, if applicable, any Lender (or group of Lenders) pursuant to this Section 2.3(f), including any determination with respect to a tenor, rate or adjustment or of the occurrence or non-occurrence of an event, circumstance or date and any decision to take or refrain from taking any action, will be conclusive and binding absent manifest error and may be made in its or their sole discretion and without consent from any other party to this Agreement or any other Loan Document, except, in each case, as expressly required pursuant to this Section 2.3(f).
(iv) Unavailability of Tenor of Benchmark. Notwithstanding anything to the contrary herein or in any other Loan Document, at any time (including in connection with the implementation of a Benchmark Replacement), (A) if the then-current Benchmark is a term rate (including the Term SOFR Reference Rate) and either (1) any tenor for such Benchmark is not displayed on a screen or other information service that publishes such rate from time to time as selected by the Collateral Agent in its reasonable discretion or (2) the regulatory supervisor for the administrator of such Benchmark has provided a public statement or publication of information announcing that any tenor for such Benchmark is not or will not be representative, then the Collateral Agent may modify the definition of “Interest Period” (or any similar or analogous definition) for any Benchmark settings at or after such time to remove such unavailable or non-representative tenor and (B) if a tenor that was removed pursuant to sub-clause (A) above either (1) is subsequently displayed on a screen or information service for a Benchmark (including a Benchmark Replacement) or (2) is not, or is no longer, subject to an announcement that it is not or will not be representative for a Benchmark (including a Benchmark Replacement), then the Collateral Agent may modify the definition of “Interest Period” (or any similar or analogous definition) for all Benchmark settings at or after such time to reinstate such previously removed tenor.
2.4 Expenses. Borrower shall pay to or reimburse (or pay directly on behalf of) each Lender and the Collateral Agent, as applicable, all of such Person’s reasonable and documented Lender Expenses incurred through and after the Effective Date, promptly after receipt of a written demand therefor by such Lender or the Collateral Agent (with, in the case of any Lender, a copy of such demand to the Collateral Agent), setting forth in reasonable detail such Person’s Lender Expenses.
2.5 Requirements of Law; Increased Costs. In the event that any applicable Change in Law:
(a) does or shall subject any Lender to any Tax of any kind whatsoever with respect to this Agreement or any other Loan Documents or the Term Loans made hereunder (except, in each case, Indemnified Taxes, Taxes described in clause (b) through (d) of the definition of Excluded Taxes, and Connection Income Taxes);
(b) does or shall impose, modify or hold applicable any reserve, capital requirement, special deposit, compulsory loan, insurance charge or similar requirements against assets held by, or deposits or other liabilities in or for the account of, advances or loans by, or other credit extended by, or any other acquisition of funds by, any Lender; or
-9-
(c) does or shall impose on any Lender any other condition (other than Taxes, which are addressed in clause (a) above); and the result of any of the foregoing is to increase the cost to such Lender (as determined by such Lender in good faith using calculation methods customary in the industry) of making, renewing or maintaining the Term Loans or to reduce any amount receivable in respect thereof or to reduce the rate of return on the capital of such Lender or any Person controlling such Lender, then, in any such case, Borrower shall promptly pay to the applicable Lender, within ten (10) Business Days of its receipt of the certificate described below, any additional amounts necessary to compensate such Lender for such additional cost or reduced amounts receivable or rate of return as reasonably determined by such Lender with respect to this Agreement or the Term Loans made hereunder. If any Lender becomes entitled to claim any additional amounts pursuant to this Section 2.5, it shall notify Borrower in writing of the event by reason of which it has become so entitled (with a copy of such notice to the Collateral Agent), and a certificate as to any additional amounts payable pursuant to the foregoing sentence containing the calculation thereof in reasonable detail submitted by such Lender to Borrower (with a copy of such certificate to the Collateral Agent) shall be conclusive in the absence of manifest error. The provisions hereof shall survive the termination of this Agreement and the payment of the outstanding Term Loans and all other Obligations. Failure or delay on the part of any Lender to demand compensation for any increased costs or reduction in amounts received or receivable or reduction in return on capital under this Section 2.5 shall not constitute a waiver of such Lender’s right to demand such compensation; provided that Borrower shall not be under any obligation to compensate such Lender under this Section 2.5 with respect to increased costs or reductions with respect to any period prior to the date that is 180 days prior to the date of the delivery of the notice required pursuant to the foregoing provisions of this clause (c); provided, further, that if the Change in Law giving rise to such increased costs or reductions is retroactive, then the 180-day period referred to above shall be extended to include the period of retroactive effect thereof.
2.6 Taxes; Withholding, Etc.
(a) All sums payable by any Credit Party hereunder and under the other Loan Documents shall (except to the extent required by Requirements of Law) be paid free and clear of, and without any deduction or withholding on account of, any Tax imposed, levied, collected, withheld or assessed by any Governmental Authority. In addition, the Credit Parties shall pay, in a timely manner, to the relevant Governmental Authority in accordance with Requirements of Law, Other Taxes, and Borrower shall furnish, in a timely manner, to each Lender (as applicable, with a copy to the Collateral Agent) the original or a certified copy of a receipt evidencing payment thereof or other evidence reasonably satisfactory to the Collateral Agent of such payment and of the remittance thereof to the relevant taxing or other Governmental Authority.
(b) If any Credit Party or any other Person (in either case, a “Withholding Agent”) is required by Requirements of Law to make any deduction or withholding on account of any Tax (as determined in the good faith discretion of such Withholding Agent) from any sum paid or payable by any Credit Party to any Lender under any of the Loan Documents: (i) such Withholding Agent shall make any such withholding or deduction; (ii) such Withholding Agent shall timely pay the full amount deducted or withheld to the relevant Governmental Authority in accordance with Requirements of Law; (iii) if the Tax is an Indemnified Tax, the sum payable by such Withholding Agent in respect of which the relevant deduction, withholding or payment of Indemnified Tax is required shall be increased to the extent necessary to ensure that, after the making of that deduction, withholding or payment (including any deductions for Indemnified Taxes applicable to additional sums payable under this Section 2.6(b)), such Lender receives on the due date a net sum equal to what it would have received had no such deduction, withholding or payment of Indemnified Tax been required or made; and (iv) Borrower shall (or shall cause such Withholding Agent, if not Borrower, to) deliver to such Lender (with a copy to the Collateral Agent) the original or a certified copy of a receipt evidencing payment thereof or other evidence reasonably satisfactory to such Lender of such deduction, withholding or payment and of the remittance thereof to the relevant taxing or other Governmental Authority.
-10-
(c) The Credit Parties shall jointly and severally indemnify each Lender for the full amount of any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable under this Section 2.6(c)) paid by such Lender and any liability (including any reasonable expenses) arising therefrom or with respect thereto whether or not such Indemnified Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. Any indemnification payment pursuant to this Section 2.6(c) shall be made to the applicable Lender within ten (10) days of written demand therefor. A certificate as to the amount of such payment or liability delivered to the Credit Parties by a Lender (with a copy to the Withholding Agent, if not a Credit Party), or by the Withholding Agent on its own behalf or on behalf of a Lender, shall be conclusive absent manifest error.
(d) Any Lender that is entitled to an exemption from or reduction of withholding Tax with respect to payments made under any Loan Document shall deliver, as soon as practicable, to Borrower, at the times reasonably requested in writing by Borrower, such properly completed and executed documentation as will permit such payments to be made without withholding or at a reduced rate of withholding. In addition, such Lender, if reasonably requested in writing by Borrower, shall deliver, as soon as practicable, such other documentation prescribed by Requirements of Law or otherwise reasonably requested by Borrower to enable Borrower to determine whether or not such Lender is subject to backup withholding or information reporting requirements. Notwithstanding anything to the contrary in the preceding two sentences, the completion, execution and submission of such documentation (other than such documentation set forth in Section 2.6(d)(i), (ii) or (iv) below) shall not be required if in such Lender’s reasonable judgment such completion, execution or submission would subject such Lender to any material unreimbursed cost or expense or would materially prejudice the legal or commercial position of such Lender. For the avoidance of doubt, for the purposes of this Section 2.6(d), the term “Lender” shall include each applicable assignee thereof. Without limiting the generality of the foregoing, each Lender shall deliver, and shall cause each applicable assignee thereof to deliver, to Borrower, on or prior to the First Closing Date or on or prior to the applicable date of assignment, as applicable, and at such other times as may be necessary in the determination of Borrower, upon reasonable request in writing by Borrower:
(i) If such Lender or applicable assignee is organized under the laws of the United States, two (2) executed copies of IRS Form W-9 certifying that such Lender is exempt from U.S. federal backup withholding tax.
(ii) If such Lender or assignee is a Foreign Lender:
(1) in the case of a Foreign Lender claiming the benefits of an income tax treaty to which the United States is a party (x) with respect to payments of interest under any Loan Document, a properly completed and duly executed copy of IRS Form W-8BEN or IRS Form W-8BEN-E, as applicable, establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the “interest” article of such tax treaty and (y) with respect to any other applicable payments under any Loan Document, a properly completed and duly executed copy of IRS Form W-8BEN or IRS Form W-8BEN-E, as applicable, establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the “business profits” or “other income” article of such tax treaty;
(2) a completed and duly executed copy of IRS Form W-8ECI;
(3) to the extent that such Foreign Lender is not the beneficial owner, a properly completed and duly executed copy of IRS Form W-8IMY and a certificate substantially in the form of Exhibit F-2 or Exhibit F-3 (a “U.S. Tax Compliance Certificate”), along with IRS Form W-9, W-8BEN-E, W-8BEN, W-8ECI or other certification documents from each beneficial owner, as applicable; provided that if the Foreign Lender is a partnership and one or more direct or indirect partners of such Foreign Lender are claiming the portfolio interest exemption, such Foreign Lender may provide a U.S. Tax Compliance Certificate substantially in the form of Exhibit F-4 on behalf of each such direct and indirect partner; or
(4) in the case of a Foreign Lender claiming the benefits of the exemption for “portfolio interest” under Section 881(c) of the IRC, a properly completed and duly executed copy of IRS Form W-8BEN-E or IRS Form W-8BEN, as applicable, and U.S. Tax Compliance Certificate substantially in the form of Exhibit F-1 to the effect that such Foreign Lender is not a “bank” within the meaning of Section 881(c)(3)(A) of the IRC, a “10 percent shareholder” of Borrower within the meaning of Section 871(h)(3)(B) of the IRC, or a “controlled foreign corporation” related to Borrower as described in Section 881(c)(3)(C) of the IRC.
-11-
(iii) If any Lender is a Foreign Lender it shall, to the extent it is legally entitled to do so, deliver to Borrower (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a party to this Agreement (and from time to time thereafter upon the reasonable request of Borrower), executed copies of any other form prescribed by applicable law as a basis for claiming exemption from or a reduction in U.S. federal withholding Tax, duly completed, together with such supplementary documentation as may be prescribed by applicable law to permit Borrower to determine the withholding or deduction required to be made.
(iv) If a payment made to any Lender under any Loan Document would be subject to U.S. federal withholding Tax imposed by FATCA if such Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section 1471(b) or 1472(b) of the IRC, as applicable), such Lender shall deliver to Borrower at the time or times prescribed by law and at such time or times reasonably requested by Borrower such documentation prescribed by applicable law (including as prescribed by Section 1471(b)(3)(C)(i) of the IRC) and such additional documentation reasonably requested by Borrower as may be necessary for Borrower to comply with their obligations under FATCA and to determine that Lender has complied with its obligations under FATCA or to determine the amount to deduct and withhold from such payment. Solely for purposes of this sub-clause (iv), “FATCA” shall include any amendments made to FATCA after the date of this Agreement.
(v) Each Lender agrees that if any form or certification it previously delivered pursuant to this Section 2.6 expires or becomes obsolete or inaccurate in any respect, it shall update such form or certification, provide such successor form, or promptly notify Borrower and Collateral Agent in writing of its legal inability to do so.
(e) If any party hereto determines, in its discretion exercised in good faith, that it has received a refund of any Taxes as to which it has been indemnified pursuant to this Section 2.6 (including by the payment of additional amounts pursuant to this Section 2.6), it shall pay to the indemnifying party an amount equal to such refund (but only to the extent of indemnity payments made, or additional amounts paid, under this Section 2.6 with respect to the Taxes giving rise to such refund), net of all out-of-pocket expenses (including Taxes) of such indemnified party and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund). Such indemnifying party, upon the request of such indemnified party, shall repay to such indemnified party the amount paid over pursuant to this clause (e) (plus any penalties, interest or other charges imposed by the relevant Governmental Authority) in the event that such indemnified party is required to repay such refund to such Governmental Authority. Notwithstanding anything to the contrary in this clause (e), in no event will the indemnified party be required to pay any amount to an indemnifying party pursuant to this clause (e) if the payment of such amount would place the indemnified party in a less favorable net after-Tax position than the indemnified party would have been in if the indemnification payments or additional amounts giving rise to such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional amounts with respect to such Tax had never been paid. This clause (e) shall not be construed to require any indemnified party to make available its Tax returns (or any other information relating to its Taxes that it deems confidential) to the indemnifying party or any other Person.
(f) Borrower is currently treated as a corporation for U.S. federal income tax purposes. Borrower shall provide the Required Lenders with a prior written notice before taking any affirmative action (including making any election under Section 301.7701-3(c) of the Treasury Regulations (or any successor provision) by way of filing an IRS Form 8832) to change its U.S. entity tax classification.
(g) Borrower shall use commercially reasonable efforts to furnish upon reasonable request any information to assist any Lender (i) in the computation of accruals with respect to any “original issue discount” or “market discount” arising with respect to the Term Loans for U.S. federal income tax and GAAP purposes, and (ii) with its compliance with any associated tax reporting or filing requirements of such Lender or its partners, members or beneficial owners.
-12-
(h) If any Lender requests compensation under Section 2.5, or requires Borrower to pay any Indemnified Taxes or additional amounts to any Lender or any Governmental Authority for the account of any Lender pursuant to Section 2.6, then such Lender shall (at the request of Borrower) use reasonable efforts to designate a different lending office for funding or booking its Term Loans hereunder or to assign its rights and obligations hereunder to another of its offices, branches or affiliates, if, in the judgment of such Lender, such designation or assignment (i) would eliminate or reduce amounts payable pursuant to Section 2.5 or 2.6, as the case may be, in the future, and (ii) would not subject such Lender to any unreimbursed cost or expense and would not otherwise be disadvantageous to such Lender. Borrower hereby agrees to pay all reasonable costs and expenses incurred by any Lender in connection with any such designation or assignment.
(i) Each party’s obligations under this Section 2.6 shall survive any assignment of rights by, or the replacement of, a Lender, the termination of the Term Loan Commitments and the repayment, satisfaction or discharge of all obligations under any Loan Document.
2.7 Additional Consideration. As additional consideration for the obligation of each Lender to fund (deemed or otherwise) its Applicable Percentage of the Term Loans pursuant to Section 2.2(a), Section 2.2(h) and Section 3.5 on the applicable Closing Date:
(a) on the Tranche A Closing Date, Borrower shall pay to each Lender an amount equal to the product of (x) such Lender’s Applicable Percentage of the Tranche A Loan Amount actually funded (or deemed to have been funded pursuant to Section 2.2(h)), multiplied by (y) 0.015 (such product, the “Tranche A Additional Consideration”); and
(b) on the Tranche B Closing Date, Borrower shall pay to each Lender an amount equal to the product of (x) such Lender’s Applicable Percentage of the Tranche B Loan Amount actually funded (or deemed to have been funded pursuant to Section 2.2(h)), multiplied by (y) 0.015 (such product, the “Tranche B Additional Consideration”).
Any and all Additional Consideration shall be fully earned when paid and shall not be refundable for any reason whatsoever. Except, solely in the case where the Tranche A Additional Consideration or Tranche B Additional Consideration becomes payable pursuant to Section 2.2(h), as applicable, all Additional Consideration shall be treated as original issue discount with respect to the applicable Term Loan for U.S. federal income tax purposes, unless otherwise required by Requirements of Law. The Additional Consideration payable hereunder shall be deducted, as applicable, from the proceeds of the applicable Term Loans to be advanced to Borrower pursuant to Section 2.2(a) and Section 3.5.
2.8 Evidence of Debt; Note Register; Term Loan Notes.
(a) Evidence of Debt; Register. Borrower will maintain at all times at its principal executive office, a register that identifies each beneficial owner that is entitled to a payment of principal and stated interest on each Term Loan (the “Note Register”) and provides for the registration and transfer of Term Loan Notes so that each Term Loan is at all times in “registered form” within the meaning of Section 5f.103-1(c) of the United States Treasury Regulations (or any amended or successor version) and Section 163(f), 871(h)(2) and 881(c)(2) of the IRC and any related regulations (and any other relevant or successor provisions of the IRC or such regulations). Each Term Loan: (i) shall, pursuant to this clause (a), be registered as to both principal and any stated interest with Borrower or its agent, and (ii) shall be transferred or exchanged by any Lender only through a book entry system maintained by Borrower. Any Term Loan Note issued in exchange for any other Term Loan Note or upon transfer thereof shall carry the rights to unpaid interest and interest to accrue that were carried by the Term Loan Note so exchanged or transferred, and neither gain nor loss of interest shall result from any such transfer or exchange. Any stamp, documentary, transfer or similar tax or governmental charge or fee relating to such transaction shall be paid by the party requesting the exchange. The entries in the Note Register shall be conclusive and binding for all purposes, including as to the outstanding principal amount of the Term Loan Note and the payment of interest, principal and other sums due hereunder absent manifest error and Borrower, Lenders and any of their respective agents shall treat the Person recorded in the Note Register as the sole and exclusive record and beneficial holder and owner of such Term Loan Note or any other Loan Document (including this Agreement), and a Lender hereunder, for all purposes whatsoever.
-13-
(b) Term Loan Notes. Borrower shall execute and deliver to each Lender to evidence such Lender’s Term Loan, (i) on the Tranche A Closing Date, a Tranche A Note, and (ii) on the Tranche B Closing Date (if any), a Tranche B Note. All amounts due under the Term Loan Notes shall be repayable as set forth in this Agreement and interest shall accrue on the principal amount of the Term Loans represented by the Term Loan Notes, in each case, in accordance with the terms of this Agreement. All Term Loan Notes shall rank for all purposes pari passu with each other.
3. CONDITIONS TO TERM LOANS
3.1 Conditions Precedent to First Closing Date. Each Lender’s obligation to advance its Applicable Percentage of the Tranche A Loan Amount or the Tranche B Loan Amount, as applicable, is subject to the satisfaction (or waiver in Lenders’ sole discretion in accordance with Section 11.5 hereof) of the following conditions:
(a) the Collateral Agent’s and each Lender’s receipt of:
(i) on the Effective Date:
(1) copies of the Loan Agreement, the Disclosure Letter, and the Perfection Certificate for the Credit Parties, in each case (x) dated as of the Effective Date, (y) executed (where applicable) and delivered by each applicable Credit Party, and (z) in form and substance reasonably satisfactory to the Collateral Agent;
(2) true, correct and complete copies of each Permitted Royalty Agreement and other Permitted Royalty Agreement Documents, in the form duly executed (as applicable) and delivered by all parties thereto;
(3) true, correct and complete copies of the Permitted Royalty Financing Agreement and other Permitted Royalty Financing Agreement Documents, if any, (x) substantially in form and substance to be duly executed (as applicable) by all parties thereto, and (y) in form and substance reasonably satisfactory to the Required Lenders (as confirmed by the Required Lenders in writing delivered to Borrower);
(4) true, correct and complete copies of any Permitted Acquisition Royalty Agreements and other Permitted Acquisition Royalty Agreement Documents, if any, (x) to be duly executed (as applicable) by all parties thereto and (y) in form and substance reasonably satisfactory to the Required Lenders (which such satisfaction shall be deemed if and only so long as the terms and conditions of each such Permitted Acquisition Royalty Agreement and other Permitted Acquisition Royalty Agreement Document do not and would not contravene any of the provisions of Section 6.10 or Section 6.14(c), as applicable);
(5) a true, correct and complete copy of the Heron Acquisition Agreement substantially in form and substance to be duly executed (as applicable) by all parties thereto;
(6) [reserved]; and
-14-
(7) a Secretary’s Certificate in relation to each Credit Party, dated the Effective Date, certifying that:
| a. | attached to such certificate is a true, correct, and complete copy of the Borrowing Resolutions then in full force and effect authorizing and ratifying the execution, delivery, and performance by such Credit Party of the Loan Documents to which it is a party; |
| b. | the name(s) and title(s) of the officers or other signatories of such Credit Party authorized to execute the Loan Documents to which such Credit Party is a party on behalf of such Credit Party, together with a sample of the true signature(s) of each such signatory; and |
| c. | the Collateral Agent and each Lender may conclusively rely on such certificate with respect to the authority of such officers unless and until such Credit Party shall have delivered to the Collateral Agent a further certificate, canceling or amending such prior certificate; or, as applicable; |
(ii) Prior to the First Closing Date, and in no event later than thirty (30) days prior to the First Closing Date:
(1) the completed Advance Request Form for the Tranche A Loan or the Tranche B Loan, as applicable, (x) executed and delivered by Borrower and (y) in form and substance reasonably satisfactory to the Collateral Agent;
(2) if the First Closing Date will be the Tranche A Closing Date, true, correct and complete copies of the Permitted Royalty Financing Agreement and other Permitted Royalty Financing Agreement Documents, (x) substantially in form and substance to be duly executed (as applicable) by all parties thereto, and (y) in form and substance reasonably satisfactory to the Required Lenders, as confirmed by the Required Lenders in writing delivered to Borrower prior to the Tranche A Closing Date, which such satisfaction shall be deemed only if (A) such Permitted Royalty Financing Agreement and other Permitted Royalty Financing Agreement Documents are in form and substance the same or substantially similar in all material respects to the versions delivered to the Collateral Agent and Lenders pursuant to Section 3.1(a)(i)(3) above, or (B) there have been no supplements or modifications thereto that would contravene any of the provisions of Section 6.10 or Section 6.14(c), as applicable, or are materially adverse when taken as a whole to the interests of Lenders (unless confirmed by the Required Lenders in writing delivered to Borrower prior to the First Closing Date);
(3) true, correct and complete copies of any Permitted Acquisition Royalty Agreement and other Permitted Acquisition Royalty Agreement Documents, if any, (x) substantially in form and substance to be duly executed by all parties thereto, and (y) in form and substance reasonably satisfactory to the Required Lenders (which such satisfaction shall be deemed if and only so long as (A) (aa) such Permitted Acquisition Royalty Agreement and other Permitted Acquisition Royalty Agreement Documents are in form and substance the same or substantially similar in all material respects to the versions delivered to the Collateral Agent and Lenders pursuant to Section 3.1(a)(i)(4) above, or (bb) there have been no supplements or modifications thereto since the Effective Date that would contravene any of the provisions of Section 6.10 or Section 6.14(c), as applicable or are materially adverse when taken as a whole to the interests of Lenders unless confirmed by the Required Lenders in writing delivered to Borrower prior to the First Closing Date) or, if not so delivered, (B) the terms and conditions of each such Permitted Acquisition Royalty Agreement and other Permitted Acquisition Royalty Agreement Document do not and would not contravene any of the provisions of Section 6.10 or Section 6.14(c), as applicable (unless confirmed by the Required Lenders in writing delivered to Borrower prior to the First Closing Date);
-15-
(4) true, correct and complete copies of any Permitted Other Royalty Financing Agreement and other Permitted Other Royalty Financing Agreement Documents, if any, (x) substantially in form and substance to be duly executed (as applicable) by all parties thereto, and (y) in form and substance reasonably satisfactory to the Required Lenders (as confirmed by the Required Lenders in writing delivered to Borrower prior to the date that is thirty (30) days prior to the First Closing Date);
(5) if the First Closing Date will be the Tranche A Closing Date, a true, correct and complete copy of the Heron Acquisition Agreement (x) substantially in form and substance to be duly executed by all parties thereto, and (y) in form and substance reasonably satisfactory to the Required Lenders, which such satisfaction shall be deemed if (A) the Heron Acquisition Agreement is in form and substance the same or substantially similar to the version delivered to the Collateral Agent and Lenders pursuant to Section 3.1(a)(i)(5) above, or (B) there have been no supplements or modifications thereto since the Effective Date that are materially adverse when taken as a whole to the interests of Lenders (unless confirmed by the Required Lenders in writing delivered to Borrower prior to the First Closing Date), it being understood that (aa) no reduction of up to ten percent (10.0%) of the purchase price payable under the Heron Acquisition Transaction shall be deemed to be materially adverse to the interests of Lenders, and (bb) any increase in the purchase price payable under the Heron Acquisition Transaction shall be deemed to be materially adverse to the interests of Lenders (including in connection with any purchase price, working capital or similar adjustment set forth in the Heron Acquisition Agreement), other than any increase in the cash purchase price in connection with working capital adjustments that does not exceed $5,000,000; and
(6) If the First Closing will be the Tranche B Closing Date and the use of proceeds thereof are to fund the Other Acquisition Transaction, true, correct and complete copies of the Other Acquisition Agreement (x) substantially in form and substance to be duly executed by all parties thereto, and (y) in form and substance reasonably satisfactory to the Required Lenders;
(iii) on or prior to the First Closing Date, copies of the other Loan Documents (including the schedules and exhibits thereto), including the Collateral Documents (but excluding any Loan Documents described in Schedule 5.14 of the Disclosure Letter to be delivered after the First Closing Date), the Tranche A Notes or the Tranche B Notes, as applicable, executed by Borrower and a Disclosure Letter and Perfection Certificate updated as necessary for the period between the Effective Date and the First Closing Date (provided, that, if the Second Closing Date is the Tranche A Closing Date, such Disclosure Letter and Perfection Certificate shall include the Heron Acquisition Products; provided, further, if the Second Closing Date is the Tranche B Closing Date, such Disclosure Letter and Perfection Certificate shall include the Other Acquisition Products; provided, finally, that in no event may the Disclosure Letter or the Perfection Certificate be updated in a manner that would reflect or evidence a Default or an Event of Default (with or without such update)), in each case (x) dated as of the First Closing Date, (y) executed (where applicable) and delivered by each applicable Credit Party, and (z) in form and substance reasonably satisfactory to the Collateral Agent;
-16-
(b) the Collateral Agent’s receipt of (i) true, correct, complete and up-to-date copies of the Operating Documents of each of the Credit Parties and (ii) a Secretary’s Certificate, dated the First Closing Date, certifying that the foregoing copies are true, correct and complete (such Secretary’s Certificate (as applicable) to be in form and substance reasonably satisfactory to the Collateral Agent);
(c) the Collateral Agent’s receipt of a good standing certificate for each Credit Party (where applicable in the subject jurisdiction), certified (where available) by the Secretary of State (or the equivalent thereof) of the jurisdiction of incorporation, formation or organization of such Person as of a date no earlier than thirty (30) days prior to the First Closing Date;
(d) the Collateral Agent’s receipt of a Secretary’s Certificate in relation to each Credit Party, dated the First Closing Date, certifying that:
(i) either (A) the Borrowing Resolutions previously delivered to the Collateral Agent pursuant to clause (a) above authorize the Tranche A Loan or the Tranche B Loan, as applicable, and have not been modified and remain in full force and effect or, alternatively, (B) attached to such certificate is a true, correct, and complete copy of the Borrowing Resolutions then in full force and effect authorizing the Tranche A Loan or the Tranche B Loan, as applicable, together with the name(s) and title(s) of the officers or other signatories of such Credit Party authorized to execute the Loan Documents to which such Credit Party is a party on behalf of such Credit Party, together with a sample of the true signature(s) of each such signatory; and
(ii) the Collateral Agent and each Lender may conclusively rely on such certificate with respect to the authority of such officers unless and until such Credit Party shall have delivered to the Collateral Agent a further certificate canceling or amending such prior certificate; or, as applicable,
(e) each Credit Party shall have obtained all Governmental Approvals, if any, and all consents of other Persons, if any, in each case that are necessary in connection with the transactions contemplated by the Loan Documents and each of the foregoing shall be in full force and effect and in form and substance reasonably satisfactory to the Collateral Agent;
(f) the Collateral Agent’s receipt on the First Closing Date of an opinion of Willkie Farr & Gallagher LLP, in its capacity as counsel to the Credit Parties, in form and substance reasonably satisfactory to the Collateral Agent;
(g) subject to Section 5.14, the Collateral Agent’s receipt of (i) evidence that any products liability and general liability insurance policies maintained regarding any Collateral are in full force and effect and (ii) appropriate evidence showing the Collateral Agent, for the benefit of Lenders and the other Secured Parties, having been named as additional insured or loss payee, as applicable (such evidence to be in form and substance reasonably satisfactory to the Collateral Agent) with respect to any products liability and general liability insurance policies maintained in the United States regarding any Collateral;
(h) the Collateral Agent’s receipt prior to the First Closing Date of Borrower’s U.S. tax forms and all documentation and other information required by bank regulatory authorities under applicable “know-your-customer” and anti-money laundering rules and regulations, including the U.S.A. Patriot Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)) (the “Patriot Act”);
-17-
(i) concurrent with the funding of the Tranche A Loan or the Tranche B Loan, as applicable, payment of (i) Lender Expenses then due as specified in Section 2.4 hereof for which Borrower has received an invoice at least one (1) Business Day prior, and (ii) payment of the Tranche A Additional Consideration or the Tranche B Additional Consideration, as applicable, which such payments in each case of sub-clause (i) and (ii) above shall be deducted from the proceeds of the Tranche A Loan or the Tranche B Loan, as applicable;
(j) if the First Closing Date is the Tranche A Closing Date, the Collateral Agent’s and each Lender’s receipt on the Tranche A Closing Date of (i) a true, correct and complete copy of the Heron Acquisition Agreement in the form duly executed by all parties thereto, and in form and substance reasonably satisfactory to the Required Lenders, which such satisfaction shall be deemed if (A) the Heron Acquisition Agreement is in form and substance the same or substantially similar to the version delivered to the Collateral Agent and Lenders pursuant to Section 3.1(a)(ii)(5) above, or (B) there have been no waivers, amendments, consents or other modifications thereto or thereof that are materially adverse when taken as a whole to the interests of Lenders (unless confirmed by the Required Lenders in writing delivered to Borrower prior to the First Closing Date), it being understood that (aa) no reduction of up to ten percent (10.0%) of the purchase price payable under the Heron Acquisition Transaction shall be deemed to be materially adverse to the interests of Lenders, and (bb) any increase in the purchase price payable under the Heron Acquisition Transaction shall be deemed to be materially adverse to the interests of Lenders (including in connection with any purchase price, working capital or similar adjustment set forth in the Heron Acquisition Agreement), other than any increase in the cash purchase price in connection with working capital adjustments that does not exceed $5,000,000, and (ii) the Collateral Agent’s receipt of a certificate, dated the Tranche A Closing Date and signed by a Responsible Officer of Borrower, confirming as of the date thereof, that the Heron Acquisition Transaction has been consummated substantially concurrently with the funding of the Tranche A Loan hereunder in accordance in all material respects with the Heron Acquisition Agreement, without any waivers, amendments, consents or other modifications thereto or thereof that are materially adverse when taken as a whole to the interests of Lenders (unless confirmed by the Required Lenders in writing delivered to Borrower prior to the First Closing Date), it being understood that (A) no reduction of up to ten percent (10.0%) of the purchase price payable under the Heron Acquisition Transaction shall be deemed to be materially adverse to the interests of Lenders, and (B) any increase in the purchase price payable under the Heron Acquisition Transaction shall be deemed to be materially adverse to the interests of Lenders (including in connection with any purchase price, working capital or similar adjustment set forth in the Heron Acquisition Agreement), other than any increase in the cash purchase price in connection with working capital adjustments that does not exceed $5,000,000;
(k) if the First Closing Date is the Tranche B Closing Date and the use of proceeds thereof is to fund the Other Acquisition Transaction, the Collateral Agent’s and each Lender’s receipt on the Tranche B Closing Date of (i) true, correct and complete copies of the Other Acquisition Agreement in the form duly executed by all parties thereto, and in form and substance reasonably satisfactory to the Required Lenders, which such satisfaction shall be deemed if (A) the Other Acquisition Agreement is in form and substance the same or substantially similar to the version delivered to the Collateral Agent and Lenders pursuant to Section 3.1(a)(ii)(6) above, or (B) there have been no waivers, amendments, consents or other modifications thereto or thereof that are materially adverse when taken as a whole to the interests of Lenders (unless confirmed by the Required Lenders in writing delivered to Borrower prior to the First Closing Date), it being understood that no reduction of up to ten percent (10.0%) of the purchase price payable under the Other Acquisition Transaction shall be deemed to be materially adverse to the interests of Lenders, and (ii) the Collateral Agent’s receipt of a certificate, dated the Tranche B Closing Date and signed by a Responsible Officer of Borrower, confirming as of the date thereof, that the Other Acquisition Transaction has been consummated substantially concurrently with the funding of the Tranche B Loan hereunder in accordance in all material respects with the Other Acquisition Agreement, without any waivers, amendments, consents or other modifications thereto or thereof that are materially adverse when taken as a whole to the interests of Lenders (unless confirmed by the Required Lenders in writing delivered to Borrower prior to the First Closing Date), it being understood that no reduction of up to ten percent (10.0%) of the purchase price payable under the Other Acquisition Transaction shall be deemed to be materially adverse to the interests of Lenders;
-18-
(l) the Collateral Agent’s and each Lender’s receipt on the First Closing Date of (i) if the First Closing Date is the Tranche A Closing Date, true, correct and complete copies the Permitted Royalty Financing Agreement and other Permitted Royalty Financing Documents in the forms duly executed (as applicable) by all parties thereto, and in form and substance reasonably satisfactory to the Required Lenders, which such satisfaction shall be deemed if (A) such Permitted Royalty Financing Agreement and other Permitted Royalty Financing Agreement Documents are in form and substance the same or substantially similar in all material respects to the versions previously approved by the Required Lenders pursuant to Section 3.1(a)(i)(3) or Section 3.1(a)(ii)(2) above (as the case may be), or (B) there have been no waivers, amendments, consents or other modifications thereto or thereof that relate to any royalty or milestone payment or similar contingent payment (or any royalty sale, synthetic royalty financing or similar financing) thereunder that would contravene any of the provisions of Section 6.10 or Section 6.14(c), as applicable, or are materially adverse when taken as a whole to the interests of Lenders (unless confirmed by the Required Lenders in writing delivered to Borrower prior to the Tranche A Closing Date), (ii) true, correct and complete copies any Permitted Other Royalty Financing Agreement and other Permitted Other Royalty Financing Documents in the forms duly executed (as applicable) by all parties thereto, and in form and substance reasonably satisfactory to the Required Lenders, which such satisfaction shall be deemed if (A) such Permitted Other Royalty Financing Agreement and other Permitted Other Royalty Financing Agreement Documents are in form and substance the same or substantially similar in all material respects to the versions previously approved by the Required Lenders pursuant to Section 3.1(a)(ii)(4) above, or (B) there have been no waivers, amendments, consents or other modifications thereto or thereof that relate to any royalty or milestone payment or similar contingent payment (or any royalty sale, synthetic royalty financing or similar financing) thereunder that would contravene any of the provisions of Section 6.10 or Section 6.14(c), as applicable, or are materially adverse when taken as a whole to the interests of Lenders (unless confirmed by the Required Lenders in writing delivered to Borrower prior to the Tranche A Closing Date), and (iii) the Collateral Agent’s receipt of a certificate, dated the First Closing Date and signed by a Responsible Officer of Borrower, confirming as of the date thereof, that the transactions underlying such Permitted Royalty Financing Agreement and other Permitted Royalty Financing Documents and such Permitted Other Royalty Financing Agreement and other Permitted Other Royalty Financing Documents, as applicable, have been consummated substantially concurrently with the funding of the Tranche A Loan, in accordance in all material respects with such Permitted Royalty Financing Agreement and other Permitted Royalty Financing Documents and such Permitted Other Royalty Financing Agreement and other Permitted Other Royalty Financing Documents, as applicable, without any waivers, amendments, consents or other modifications thereto or thereof that relate to any royalty or milestone payment or similar contingent payment (or any royalty sale, synthetic royalty financing or similar financing) thereunder that would contravene any of the provisions of Section 6.10 or Section 6.14(c), as applicable, or are materially adverse when taken as a whole to the interests of Lenders (unless confirmed by the Required Lenders in writing delivered to Borrower prior to the Tranche A Closing Date);
(m) the Collateral Agent’s and each Lender’s receipt on the First Closing Date of (i) true, correct and complete copies of any Permitted Acquisition Royalty Agreement and other Permitted Acquisition Royalty Agreement Documents in the forms duly executed by all parties thereto, if any, and in form and substance reasonably satisfactory to the Required Lenders (which such satisfaction shall be deemed if and only so long as (A) the terms and conditions of each such Permitted Acquisition Royalty Agreement and other Permitted Acquisition Royalty Agreement Document is in form and substance the same or substantially similar to the version delivered to the Collateral Agent and Lenders pursuant to Section 3.1(a)(i)(4) or Section 3.1(a)(ii)(3) above, or (B) there have been no supplements or modifications thereto that would contravene any of the provisions of Section 6.10 or Section 6.14(c), as applicable, or are materially adverse when taken as a whole to the interests of Lenders (unless confirmed by the Required Lenders in writing delivered to Borrower prior to the First Closing Date), and (ii) the Collateral Agent’s receipt of a certificate, dated the First Closing Date and signed by a Responsible Officer of Borrower, confirming as of the date thereof, that the transactions underlying such Permitted Acquisition Royalty Agreement and other Permitted Acquisition Royalty Agreement Documents have been consummated substantially concurrently with the funding of the Tranche A Loan or Tranche B Loan hereunder, as applicable, in accordance in all material respects with such Permitted Acquisition Royalty Agreement and other Permitted Acquisition Royalty Agreement Documents, without any waivers, amendments, consents or other modifications thereto or thereof that relate to any royalty or milestone payment or similar contingent payment (or any royalty sale, synthetic royalty financing or similar financing) thereunder that would contravene any of the provisions of Section 6.10 or Section 6.14(c), as applicable, or are materially adverse when taken as a whole to the interests of Lenders (unless confirmed by the Required Lenders in writing delivered to Borrower prior to the First Closing Date); and
(n) the Collateral Agent’s receipt of a certificate, dated the First Closing Date and signed by a Responsible Officer of Borrower, confirming as of the date thereof: (i) there is no Adverse Proceeding pending or, to the Knowledge of Borrower, threatened, that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Change, except as set forth on Schedule 4.7 of the Disclosure Letter delivered in accordance with Section 3.1(a); (ii) assuming the Collateral Agent’s and each Lender’s satisfaction with any matter as to which such satisfaction is required, the satisfaction of the other conditions precedent set forth in this Section 3.1 and in Section 3.3, Section 3.4 and Section 3.5 (such certificate to be in form and substance reasonably satisfactory to the Collateral Agent); and (iii) that the organizational structure or list of the names of Borrower and each of its Subsidiaries and the ownership therein held by Borrower or its applicable Subsidiary is as described on Schedule 4.15 of the Disclosure Letter as at the First Closing Date.
-19-
3.2 Conditions Precedent to Second Closing Date. Each Lender’s obligation to advance its Applicable Percentage of the Tranche A Loan Amount or the Tranche B Loan Amount, as applicable, is subject to the satisfaction (or waiver in accordance with Section 11.5 hereof) of the following conditions:
(a) the Collateral Agent’s and each Lender’s receipt, on (or prior to) the Second Closing Date, of the Tranche A Note or the Tranche B Note, as applicable, executed by Borrower, and, if and to the extent any update thereto is necessary between the First Closing Date and the Second Closing Date, an updated Disclosure Letter or Perfection Certificate (provided, that, if the Second Closing Date is the Tranche A Closing Date, such Disclosure Letter and Perfection Certificate shall include the Heron Acquisition Products; provided, further, if the Second Closing Date is the Tranche B Closing Date, such Disclosure Letter and Perfection Certificate shall include the Other Acquisition Products; provided, finally, that in no event may the Disclosure Letter or the Perfection Certificate be updated in a manner that would reflect or evidence a Default or an Event of Default (with or without such update)), in each case (x) dated as of the Second Closing Date, (y) executed (where applicable) and delivered by each applicable Credit Party, and (z) in form and substance reasonably satisfactory to the Collateral Agent;
(b) Prior to the Second Closing Date, and in no event later than thirty (30) days prior to the Second Closing Date:
(i) the completed Advance Request Form for the Tranche A Loan or the Tranche B Loan, as applicable, (x) executed and delivered by Borrower and (y) in form and substance reasonably satisfactory to the Collateral Agent;
(ii) if the Second Closing Date will be the Tranche A Closing Date, true, correct and complete copies of the Permitted Royalty Financing Agreement and other Permitted Royalty Financing Agreement Documents, (x) substantially in form and substance to be duly executed (as applicable) by all parties thereto, and (y) in form and substance reasonably satisfactory to the Required Lenders, as confirmed by the Required Lenders in writing delivered to Borrower prior to the Tranche A Closing Date, which such satisfaction shall be deemed only if (A) such Permitted Royalty Financing Agreement and other Permitted Royalty Financing Agreement Documents are in form and substance the same or substantially similar in all material respects to the versions delivered to the Collateral Agent and Lenders pursuant to Section 3.1(a)(i)(3) or Section 3.1(a)(ii)(2) above (as the case may be), or (B) there have been no supplements or modifications thereto since the Effective Date that are materially adverse when taken as a whole to the interests of Lenders, that would contravene any of the provisions of Section 6.10 or Section 6.14(c), as applicable, or are materially adverse when taken as a whole to the interests of Lenders (unless confirmed by the Required Lenders in writing delivered to Borrower prior to the First Closing Date);
(iii) true, correct and complete copies of any Permitted Acquisition Royalty Agreement and other Permitted Acquisition Royalty Agreement Documents, if any, (x) substantially in form and substance to be duly executed by all parties thereto, and (y) in form and substance reasonably satisfactory to the Required Lenders (which such satisfaction shall be deemed if and only so long as the terms and conditions of each such Permitted Acquisition Royalty Agreement and other Permitted Acquisition Royalty Agreement Document do not and would not contravene Section 6.10 or Section 6.14(c), as applicable); and
(iv) true, correct and complete copies of any Permitted Other Royalty Financing Agreement and other Permitted Other Royalty Financing Agreement Documents, (x) substantially in form and substance to be duly executed (as applicable) by all parties thereto, and (y) in form and substance reasonably satisfactory to the Required Lenders, as confirmed by the Required Lenders in writing delivered to Borrower prior to the Second Closing Date;
-20-
(v) if the Second Closing Date will be the Tranche A Closing Date, a true, correct and complete copy of the Heron Acquisition Agreement (x) substantially in form and substance to be duly executed by all parties thereto, and (y) in form and substance reasonably satisfactory to the Required Lenders, which such satisfaction shall be deemed if (A) the Heron Acquisition Agreement is in form and substance the same or substantially similar to the version delivered to the Collateral Agent and Lenders pursuant to Section 3.1(a)(i)(5) above, or (B) there have been no supplements or modifications thereto since the Effective Date that are materially adverse when taken as a whole to the interests of Lenders (unless confirmed by the Required Lenders in writing delivered to Borrower prior to the First Closing Date), it being understood that (aa) no reduction of up to ten percent (10.0%) of the purchase price payable under the Heron Acquisition Transaction shall be deemed to be materially adverse to the interests of Lenders, and (bb) any increase in the purchase price payable under the Heron Acquisition Transaction shall be deemed to be materially adverse to the interests of Lenders (including in connection with any purchase price, working capital or similar adjustment set forth in the Heron Acquisition Agreement, other than any increase in the cash purchase price in connection with working capital adjustments that does not exceed $5,000,000; and
(vi) If the Second Closing will be the Tranche B Closing Date and the proceeds thereof are to fund the Other Acquisition Transaction, true, correct and complete copies any Other Acquisition Agreement (x) substantially in form and substance to be duly executed by all parties thereto, and (y) in form and substance reasonably satisfactory to the Required Lenders, which such satisfaction shall be deemed if (A) such Other Acquisition Agreement is in form and substance the same or substantially similar to the version delivered to the Collateral Agent and Lenders pursuant to Section 3.1(a)(ii)(6) above, or (B) there have been no supplements or modifications thereto since the Effective Date that are materially adverse when taken as a whole to the interests of Lenders (unless confirmed by the Required Lenders in writing delivered to Borrower prior to the First Closing Date), it being understood that no reduction of up to ten percent (10.0%) of the purchase price payable under the Other Acquisition Transaction shall be deemed to be materially adverse to the interests of Lenders;
(c) if the Second Closing Date is the Tranche A Closing Date, the Collateral Agent’s and each Lender’s receipt on the Tranche A Closing Date of (i) a true, correct and complete copy of the Heron Acquisition Agreement in the form duly executed by all parties thereto, and in form and substance reasonably satisfactory to the Required Lenders, which such satisfaction shall be deemed if (A) the Heron Acquisition Agreement is in form and substance the same or substantially similar to the version delivered to the Collateral Agent and Lenders pursuant to Section 3.2(b)(v) above, or (B) there have been no waivers, amendments, consents or other modifications thereto or thereof that are materially adverse when taken as a whole to the interests of Lenders (unless confirmed by the Required Lenders in writing delivered to Borrower prior to the Second Closing Date), it being understood that (aa) no reduction of up to ten percent (10.0%) of the purchase price payable under the Heron Acquisition Transaction shall be deemed to be materially adverse to the interests of Lenders, and (bb) any increase in the purchase price payable under the Heron Acquisition Transaction shall be deemed to be materially adverse to the interests of Lenders (including in connection with any purchase price, working capital or similar adjustment set forth in the Heron Acquisition Agreement), other than any increase in the cash purchase price in connection with working capital adjustments that does not exceed $5,000,000, and (ii) the Collateral Agent’s receipt of a certificate, dated the Tranche A Closing Date and signed by a Responsible Officer of Borrower, confirming as of the date thereof, that the Heron Acquisition Transaction has been consummated substantially concurrently with the funding of the Tranche A Loan hereunder in accordance in all material respects with the Heron Acquisition Agreement, without any waivers, amendments, consents or other modifications thereto or thereof that are materially adverse when taken as a whole to the interests of Lenders (unless confirmed by the Required Lenders in writing delivered to Borrower prior to the Second Closing Date), it being understood that (A) no reduction of up to ten percent (10.0%) of the purchase price payable under the Heron Acquisition Transaction shall be deemed to be materially adverse to the interests of Lenders, and (B) any increase in the purchase price payable under the Heron Acquisition Transaction shall be deemed to be materially adverse to the interests of Lenders (including in connection with any purchase price, working capital or similar adjustment set forth in the Heron Acquisition Agreement, other than any increase in the cash purchase price in connection with working capital adjustments that does not exceed $5,000,000;
-21-
(d) if the Second Closing Date is the Tranche B Closing Date and the use of proceeds thereof is to fund the Other Acquisition Transaction, the Collateral Agent’s and each Lender’s receipt on the Tranche B Closing Date of (i) true, correct and complete copies of the Other Acquisition Agreement in the form duly executed by all parties thereto, and in form and substance reasonably satisfactory to the Required Lenders, which such satisfaction shall be deemed if (A) the Other Acquisition Agreement is in form and substance the same or substantially similar to the version delivered to the Collateral Agent and Lenders pursuant to Section 3.2(b)(vi) above, or (B) there have been no waivers, amendments, consents or other modifications thereto or thereof that are materially adverse when taken as a whole to the interests of Lenders, it being understood that no reduction of up to ten percent (10.0%) of the purchase price payable under the Other Acquisition Transaction shall be deemed to be materially adverse to the interests of Lenders, and (ii) the Collateral Agent’s receipt of a certificate, dated the Tranche B Closing Date and signed by a Responsible Officer of Borrower, confirming as of the date thereof, that the Other Acquisition Transaction has been consummated substantially concurrently with the funding of the Tranche B Loan hereunder in accordance in all material respects with the Other Acquisition Agreement, without any waivers, amendments, consents or other modifications thereto or thereof that are materially adverse when taken as a whole to the interests of Lenders (unless confirmed by the Required Lenders in writing delivered to Borrower prior to the Second Closing Date), it being understood that no reduction of up to ten percent (10.0%) of the purchase price payable under the Other Acquisition Transaction shall be deemed to be materially adverse to the interests of Lenders;
(e) the Collateral Agent’s and each Lender’s receipt on the Second Closing Date of (i) if the Second Closing Date is the Tranche A Closing Date, true, correct and complete copies the Permitted Royalty Financing Agreement and other Permitted Royalty Financing Documents in the forms duly executed (as applicable) by all parties thereto, and in form and substance reasonably satisfactory to the Required Lenders, which such satisfaction shall be deemed if (A) such Permitted Royalty Financing Agreement and other Permitted Royalty Financing Agreement Documents are in form and substance the same or substantially similar in all material respects to the versions delivered to the Collateral Agent and Lenders pursuant to Section 3.2(b)(ii) above, or (B) there have been no waivers, amendments, consents or other modifications thereto or thereof that relate to any royalty or milestone payment or similar contingent payment (or any royalty sale, synthetic royalty financing or similar financing) thereunder that would contravene any of the provisions of Section 6.10 or Section 6.14(c), as applicable, or are materially adverse when taken as a whole to the interests of Lenders (unless confirmed by the Required Lenders in writing delivered to Borrower prior to the Tranche A Closing Date), (ii) true, correct and complete copies of any Permitted Other Royalty Financing Agreement and other Permitted Other Royalty Financing Documents in the forms duly executed (as applicable) by all parties thereto, and in form and substance reasonably satisfactory to the Required Lenders, which such satisfaction shall be deemed if (A) such Permitted Other Royalty Financing Agreement and other Permitted Other Royalty Financing Agreement Documents are in form and substance the same or substantially similar in all material respects to the versions delivered to the Collateral Agent and Lenders pursuant to Section 3.2(b)(iv) above, or (B) there have been no waivers, amendments, consents or other modifications thereto or thereof that relate to any royalty or milestone payment or similar contingent payment (or any royalty sale, synthetic royalty financing or similar financing) thereunder that would contravene any of the provisions of Section 6.10 or Section 6.14(c), as applicable, or are materially adverse when taken as a whole to the interests of Lenders (unless confirmed by the Required Lenders in writing delivered to Borrower prior to the Second Closing Date), and (iii) the Collateral Agent’s receipt of a certificate, dated the Second Closing Date and signed by a Responsible Officer of Borrower, confirming as of the date thereof, that the transactions underlying such Permitted Royalty Financing Agreement and other Permitted Royalty Financing Documents and such Permitted Other Royalty Financing Agreement and other Permitted Other Royalty Financing Documents have been consummated substantially concurrently with the funding of the Tranche A Loan or Tranche B Loan hereunder, as applicable, in accordance in all material respects with such Permitted Royalty Financing Agreement and other Permitted Royalty Financing Documents, without any waivers, amendments, consents or other modifications thereto or thereof that relate to any royalty or milestone payment or similar contingent payment (or any royalty sale, synthetic royalty financing or similar financing) thereunder that that would contravene any of the provisions of Section 6.10 or Section 6.14(c), as applicable, or are materially adverse when taken as a whole to the interests of Lenders are materially adverse when taken as a whole to the interests of Lenders (unless confirmed by the Required Lenders in writing delivered to Borrower prior to the Second Closing Date);
-22-
(f) the Collateral Agent’s and each Lender’s receipt on the Second Closing Date of (i) true, correct and complete copies of any Permitted Acquisition Royalty Agreement and other Permitted Acquisition Royalty Agreement Documents in the forms duly executed by all parties thereto, if any, and in form and substance reasonably satisfactory to the Required Lenders (which such satisfaction shall be deemed if and only so long as (A) the terms and conditions of each such Permitted Acquisition Royalty Agreement and other Permitted Acquisition Royalty Agreement Document is in form and substance the same or substantially similar to the version delivered to the Collateral Agent and Lenders pursuant to Section 3.2(b)(iii) above, or (B) there have been no supplements or modifications thereto that would contravene any of the provisions of Section 6.10 or Section 6.14(c), as applicable, or are materially adverse when taken as a whole to the interests of Lenders (unless confirmed by the Required Lenders in writing delivered to Borrower prior to the Second Closing Date), and (ii) the Collateral Agent’s receipt of a certificate, dated the Second Closing Date and signed by a Responsible Officer of Borrower, confirming as of the date thereof, that the transactions underlying such Permitted Acquisition Royalty Agreement and other Permitted Acquisition Royalty Agreement Documents have been consummated substantially concurrently with the funding of the Tranche A Loan or Tranche B Loan hereunder, as applicable, in accordance in all material respects with such Permitted Acquisition Royalty Agreement and other Permitted Acquisition Royalty Agreement Documents, without any waivers, amendments, consents or other modifications thereto or thereof that relate to any royalty or milestone payment or similar contingent payment (or any royalty sale, synthetic royalty financing or similar financing) thereunder that would contravene any of the provisions of Section 6.10 or Section 6.14(c), as applicable, or are materially adverse when taken as a whole to the interests of Lenders (unless confirmed by the Required Lenders in writing delivered to Borrower prior to the Second Closing Date);
(g) the Collateral Agent’s receipt of a Secretary’s Certificate in relation to each Credit Party, dated the Second Closing Date, certifying that:
(i) (A) the Borrowing Resolutions authorizing the Term Loans and previously delivered to the Collateral Agent pursuant to Section 3.1 above have not been modified and remain in full force and effect or, alternatively, (B) attached to such certificate is a true, correct, and complete copy of the Borrowing Resolutions then in full force and effect authorizing the Tranche A Loan or the Tranche B Loan, as applicable; and
(ii) the Collateral Agent and each Lender may conclusively rely on such certificate with respect to the authority of such officers unless and until such Credit Party shall have delivered to the Collateral Agent a further certificate canceling or amending such prior certificate;
(h) there has been no prepayment or repayment of any Term Loan funded hereunder on the First Closing Date, in whole or in part, other than the deemed prepayment thereof pursuant to Section 2.2(h), provided, that, Borrower has paid in full all amounts that are payable pursuant to Section 2.2 and Section 2.7, as applicable, in accordance with Section 2.2(h);
(i) concurrent with the funding of the Tranche A Loan or the Tranche B Loan, as applicable, payment of Lender Expenses then due as specified in Section 2.4 hereof for which Borrower has received an invoice at least one (1) Business Day prior, and payment of the Tranche A Additional Consideration or the Tranche B Additional Consideration, as applicable, in accordance with Section 2.7, which such payments shall be deducted from the proceeds of the Tranche A Loan or the Tranche B Loan, as applicable; and
(j) the Collateral Agent’s receipt of a certificate, dated the Second Closing Date and signed by a Responsible Officer of Borrower, confirming: (i) there is no Adverse Proceeding pending or, to the Knowledge of Borrower, threatened, that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Change, except as set forth on Schedule 4.7 of the Disclosure Letter delivered in accordance with Section 3.1(a) or Section 3.2(a), as applicable; and (ii) assuming the Collateral Agent’s and each Lender’s satisfaction with any matter as to which such satisfaction is required, the satisfaction of the conditions precedent set forth in this Section 3.2 and in Section 3.3, Section 3.4 and Section 3.5 (such certificate to be in form and substance reasonably satisfactory to the Collateral Agent).
-23-
3.3 Additional Conditions Precedent to Term Loans. The obligation of each Lender to advance its Applicable Percentage of each Term Loan is subject to the following additional conditions precedent:
(a) the representations and warranties made by the Credit Parties in Section 4 of this Agreement and in the other Loan Documents are true and correct in all material respects on the applicable Closing Date, unless any such representation or warranty is stated to relate to a specific earlier date, in which case such representation or warranty shall be true and correct in all material respects as of such earlier date (it being understood that any representation or warranty that is qualified as to “materiality,” “Material Adverse Change,” or similar language shall be true and correct in all respects, in each case, on the applicable Closing Date (both with and without giving effect to the Term Loans to be borrowed on such Closing Date) or as of such earlier date, as applicable); and
(b) there shall not have occurred any Default, that is then continuing, or any Event of Default (including, for the avoidance of doubt, any Material Adverse Change or Withdrawal Event).
3.4 Covenant to Deliver. The Credit Parties agree to deliver to the Collateral Agent or each Lender, as applicable, each item required to be delivered to Collateral Agent or each Lender, as applicable, under this Agreement as a condition precedent to any Credit Extension; provided, however, that any such items set forth on Schedule 5.14 of the Disclosure Letter shall be delivered to the Collateral Agent within the time period prescribed therefor on such schedule. The Credit Parties expressly agree that a Credit Extension made prior to the receipt by the Collateral Agent or any Lender, as applicable, of any such item shall not constitute a waiver by the Collateral Agent or any Lender of the Credit Parties’ obligation to deliver such item, and the making of any Credit Extension in the absence of any such item required to have been delivered by the date of such Credit Extension shall be in the applicable Lender’s sole discretion.
3.5 Procedures for Borrowing. Subject to the prior satisfaction of all other applicable conditions to the making of each Term Loan set forth in this Agreement, to obtain any Term Loan, Borrower shall deliver to the Collateral Agent and Lenders by electronic mail or facsimile a completed Advance Request Form (but for the funds flow to be attached thereto, if any) for such Term Loan executed by a Responsible Officer of Borrower (which notice shall be irrevocable on and after the date on which such notice is given and Borrower shall be bound to make a borrowing in accordance therewith, in which case each Lender agrees to advance its Applicable Percentage of such Term Loan to Borrower on the Tranche A Closing Date or the Tranche B Closing Date, as applicable, by wire transfer of same day funds in Dollars, to such account(s) in the United States as may be designated in writing to the Collateral Agent by Borrower at least two (2) Business Days prior to the Tranche A Closing Date or the Tranche B Closing Date, respectively; provided, however, that with respect to the Tranche A Loan, Borrower shall deliver to the Collateral Agent and Lenders by electronic mail or facsimile, the completed Advance Request Form for the Tranche A Loan no later than thirty (30) days prior to the Tranche A Commitment End Date; provided, further, that, with respect to the Tranche A Loan and notwithstanding anything to the contrary herein, if Borrower does not deliver the completed and duly executed Advance Request Form for the Tranche A Loan pursuant to Section 3.1(a)(ii) and Borrower or any of its Subsidiaries consummates the Heron Acquisition Transaction or any other transaction involving the acquisition, directly or indirectly, of one or more of the Heron Acquisition Products on or before the Tranche A Commitment End Date, Borrower shall be deemed to have delivered to the Collateral Agent and Lenders such completed and duly executed Advance Request Form on the Business Day immediately preceding the Tranche A Loan Trigger Date; provided, further, that with respect to the Tranche B Loan, Borrower shall deliver to the Collateral Agent and Lenders by electronic mail or facsimile, at its option should it wish to obtain the Tranche B Loan, the completed Advance Request Form for the Tranche B Loan no later than the date that is thirty (30) days prior to the Tranche B Commitment End Date provided, finally, that, with respect to the Tranche B Loan and notwithstanding anything to the contrary herein, if the Tranche B Closing Date is the First Closing Date and the use of proceeds thereof is to fund the Other Acquisition Transaction, if Borrower does not deliver the completed and duly executed Advance Request Form for the Tranche B Loan pursuant to Section 3.1(a)(ii) and Borrower or any of its Subsidiaries consummates the Other Acquisition Transaction or any other transaction involving the acquisition, directly or indirectly, of one or more of the Other Acquisition Products on or before the Tranche B Commitment End Date, Borrower shall be deemed to have delivered to the Collateral Agent and Lenders such completed and duly executed Advance Request Form on the Business Day immediately preceding the Tranche B Loan Trigger Date. For the avoidance of doubt, and notwithstanding anything herein to the contrary, the parties hereto hereby agree that (x) each Lender’s Tranche A Commitment, and any obligations of such Lender hereunder with respect thereto, shall terminate automatically without any further action by any party hereto and be of no further force and effect if (1) the Heron Acquisition Transaction is not consummated pursuant to the Heron Acquisition Agreement in substantially the same form and substance as the version delivered pursuant to Section 3.1(j) or Section 3.2(c), as applicable, on or before the Tranche A Commitment End Date, or (2) such Heron Acquisition Agreement (and the underlying Heron Acquisition Transaction) is terminated by any party thereto on or before the Tranche A Commitment End Date, and (y) upon the occurrence of any event described in the foregoing clause (x), unless the Tranche B Closing Date shall have occurred on or before the Tranche A Commitment End Date, each Lender’s Tranche B Commitment, and any obligations of such Lender hereunder with respect thereto, shall terminate automatically on the Tranche A Commitment End Date without any further action by any party hereto and be of no further force and effect. Notwithstanding anything in this Section 3.5 to the contrary, if the Advance Request Form provides that the proceeds of the Term Loans will be used to consummate the Heron Acquisition Transaction or any Other Acquisition Transaction, Borrower may rescind such Advance Request Form if the Heron Acquisition Transaction or such Other Acquisition Transaction is terminated and shall not be consummated.
-24-
4. REPRESENTATIONS AND WARRANTIES
In order to induce each Lender and the Collateral Agent to enter into this Agreement and for each Lender to make the Credit Extensions to be made on each applicable Closing Date, each Credit Party, jointly and severally with each other Credit Party, represents and warrants to each Lender and the Collateral Agent that the following statements are true and correct as of the Effective Date and each applicable Closing Date on which a Term Loan is made (both with and without giving effect to the Term Loans) except as otherwise specified below; provided, that, for purposes of this Section 4 (including the Disclosure Letter and the Perfection Certificate), each reference to “Products” (and to Company IP, Current Company IP, Material Agreements and other matters to the extent relating to any Product) shall be deemed to refer to: (a) when made as of the Effective Date, the Effective Date Products; (b) when made as of the Tranche A Closing Date, (i) the Effective Date Products, (ii) the Heron Acquisition Products acquired on or concurrent with the Tranche A Closing Date pursuant to the Heron Acquisition Transaction (after giving effect thereto), and, if the Tranche B Closing Date precedes the Tranche A Closing Date, the Other Acquisition Products; and (c) when made as of the Tranche B Closing Date, (i) the Effective Date Products, (ii) the Other Acquisition Products acquired on or concurrent with the Tranche B Closing Date pursuant to the Other Acquisition Transaction (after giving effect thereto), and (iii) if the Tranche A Closing Date precedes the Tranche B Closing Date, the Heron Acquisition Products; provided, further, that each representation and warranty in Section 4.6 relating to Intellectual Property, including Company IP, Current Company IP, Current Product IP and Third-Party IP, (A) to the extent made as of the Tranche A Closing Date with respect to any Heron Acquisition Product acquired by Borrower or any of its Subsidiaries pursuant to the Heron Acquisition Agreement on or concurrently with the Tranche A Closing Date or (B) to the extent made as of the Tranche B Closing Date with respect to any Other Acquisition Product acquired by Borrower or any of its Subsidiaries pursuant to the Other Acquisition Agreement on or concurrently with the Tranche B Closing Date, is, in each case of sub-clause (A) and (B) above, made solely to the Knowledge of the Credit Parties.
4.1 Due Organization, Existence, Power and Authority. Borrower and each of its Subsidiaries (a) is duly incorporated, organized or formed, and validly existing and, to the extent the concept is applicable in such jurisdiction, in good standing, under the laws of its jurisdiction of incorporation, organization or formation identified on Schedule 4.15 of the Disclosure Letter, (b) has all requisite power and authority to (i) own, lease, license and operate its assets and properties and to carry on its business as currently conducted and (ii) execute and deliver the Loan Documents to which it is a party and to perform its obligations thereunder and otherwise carry out the transactions contemplated thereby, (c) is duly qualified and, to the extent the concept is applicable in such jurisdiction, in good standing, under the laws of each jurisdiction where its ownership, lease, license or operation of assets or properties or the conduct of its business requires such qualification, and (d) has all requisite Governmental Approvals to operate its business as currently conducted; except in each case referred to clauses (a) (other than with respect to Borrower and any other Credit Party), (b)(i), (c) or (d) above, to the extent that failure to do so could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change.
4.2 Equity Interests. All of the outstanding Equity Interests in each Subsidiary of Borrower which are required to be pledged pursuant to the Collateral Documents have been duly authorized and validly issued, are (where required by Requirements of Law to be) fully paid and, in the case of Equity Interests representing corporate interests, are non-assessable, and all such Equity Interests owned directly by Borrower or any other Credit Party are owned free and clear of all Liens except for Permitted Liens. Schedule 4.2 of the Disclosure Letter identifies each Person, the Equity Interests in which as of the applicable Closing Date are required to be pledged pursuant to the Collateral Documents.
4.3 Authorization; No Conflict. Except as set forth on Schedule 4.3 of the Disclosure Letter, the execution, delivery and performance by each Credit Party of the Loan Documents to which it is a party, and the consummation of the transactions contemplated thereby, (a) have been duly authorized by all necessary corporate or other organizational action and (b) do not and will not (i) contravene the terms of any of such Credit Party’s Operating Documents, (ii) conflict with or result in any breach or contravention of, or require any payment to be made under (A) any provision of any security issued by such Person or of any agreement, instrument or other undertaking to which such Credit Party is a party or affecting such Credit Party or the assets or properties of such Credit Party or any of its Subsidiaries or (B) any order, writ, judgment, injunction, decree, determination or award of any Governmental Authority by which such Credit Party or any of its properties or assets are subject, (iii) result in the creation of any Lien (other than under or otherwise permitted under the Loan Documents) or (iv) violate any Requirements of Law, except, in the cases of clauses (b)(ii) and (b)(iv) above, to the extent that such conflict, breach, contravention, payment or violation could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change.
-25-
4.4 Government Consents; Third-Party Consents. Except as set forth on Schedule 4.4 of the Disclosure Letter, no Governmental Approval or other approval, consent, exemption or authorization, or other action by, or notice to, or filing with, any Governmental Authority or any other Person (including any counterparty to any Company IP Agreement or other Material Contract) is necessary or required in connection with (a) the execution, delivery or performance by, or enforcement against, any Credit Party of this Agreement or any other Loan Document, or for the consummation of the transactions contemplated hereby or thereby, (b) the grant by any Credit Party of the Liens granted by it pursuant to the Collateral Documents, (c) the perfection or maintenance of the Liens created under the Collateral Documents (including the priority thereof) or (d) the exercise by the Collateral Agent or any Lender of its rights under the Loan Documents or the remedies in respect of the Collateral pursuant to the Collateral Documents, except in each case of clause (a) through (d) above, for (i) filings or registrations necessary to perfect the Liens on the Collateral granted by the Credit Parties to the Collateral Agent for the benefit of Lenders and the other Secured Parties, (ii) the approvals, consents, exemptions, authorizations, actions, notices and filings which have been duly obtained, taken, given or made and are in full force and effect, (iii) filings under state or federal securities laws, (iv) notices required to be delivered by the Collateral Agent or any Lender in connection with, or the cooperation of any third Person (that is not an Affiliate of any Credit Party) that is required for, any exercise of any of the rights or remedies by the Collateral Agent or any Lender, and (v) those approvals, consents, exemptions, authorizations or other actions, notices or filings, the failure of which to obtain or make could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change.
4.5 Binding Obligation. This Agreement has been duly executed and delivered by Borrower and each other Credit Party that is a party hereto and each other Loan Document has been duly executed and delivered by each Credit Party that is a party thereto, constitutes a legal, valid and binding obligation of Borrower or such Credit Party (as applicable), enforceable against Borrower or such Credit Party (as applicable) in accordance with its respective terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or limiting creditors’ rights generally, by general principles of equity.
4.6 Collateral. In connection with this Agreement, Borrower has delivered to the Collateral Agent a completed certificate signed by a Responsible Officer of Borrower (as may be updated from time to time in accordance with the terms herein, the “Perfection Certificate”). Each Credit Party, jointly and severally, represents and warrants to the Collateral Agent and each Lender that:
(a) (i) Its exact legal name is that indicated on the Perfection Certificate; (ii) it is an organization or company of the type and is organized or incorporated in the jurisdiction set forth in the Perfection Certificate; (iii) the Perfection Certificate accurately sets forth its organizational identification or registration number or accurately states that it has none; (iv) the Perfection Certificate accurately sets forth its place of business or registered office address, or, if more than one, its chief executive office or registered office address, as well as its mailing address (if different than its chief executive office or registered office address); (v) except as set forth in the Perfection Certificate, it (and each of its predecessors) has not, in the five (5) years prior to the Effective Date or applicable Closing Date, changed its jurisdiction of formation, organizational structure or type, or any organizational number assigned by its jurisdiction; and (vi) all other information set forth on the Perfection Certificate pertaining to it and each of its Subsidiaries is accurate and complete in all material respects.
(b) (i) It has good and valid title to, has the rights it purports to have in, and subject to Permitted Subsidiary Distribution Restrictions, Permitted Negative Pledges and the occurrence of the applicable Closing Date, the power to transfer, each item of the Collateral (including each item of Current Company IP included therein) upon which it purports to grant a Lien under any Collateral Document, free and clear of any and all Liens except Permitted Liens and except for such irregularities or defects in title as could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change, and (ii) it has no deposit accounts maintained at a bank or other depository or financial institution which are not Excluded Accounts other than the deposit accounts described in the Perfection Certificate delivered to the Collateral Agent pursuant to Section 3 hereof or as otherwise disclosed to the Collateral Agent in writing from time to time (including in any Compliance Certificate delivered to the Collateral Agent pursuant to Section 5.2(a)(iii) hereof).
-26-
(c) A true, correct and complete list of each: (I) pending, registered, or issued or in-licensed Patent, Copyright and Trademark in the Territory that is owned by or in-licensed to a Credit Party and that relates to any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, packaging, labeling, promotion, advertising, offer for sale or lease, distribution (including for investigational use) or sale or lease of any Key Product in the Territory; (II) pending, registered or issued or in-licensed Patent, Copyright and Trademark in the Territory that is owned by or in-licensed to a Credit Party and that is related to any material aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, packaging, labeling, promotion, advertising, offer for sale or lease, distribution (including for investigational use) or sale or lease of any other Product in the Territory; (III) regulatory exclusivities that are listed in FDA’s so called “Orange Book” as covering any Key Product in the Territory; (IV) regulatory exclusivities that are listed in FDA’s so called “Orange Book” as covering any other Product in the Territory; and (V) any other pending, registered, issued or in-licensed Patent, Copyright or Trademark in the Territory or regulatory exclusivity that, individually or taken together with any other such Patent, Copyright or Trademarks or regulatory exclusivity, is material to the business of Borrower and its Subsidiaries, taken as a whole, but excluding, in each case, any Patents, Copyrights or Trademarks for off-the-shelf and other commercially available products that are non-exclusively in-licensed (the foregoing sub-clauses (I) and (III) above, collectively, the “Current Key Product IP”; and the foregoing sub-clauses (II) and (IV) above, collectively, the “Current Other Product IP”, and the foregoing sub-clauses (I) through (IV) above, collectively the “Current Product IP”; and the foregoing sub-clauses (I) through (V) above, the “Current Company IP”), including its name/title, current owner or co-owners, registration, patent or application number, and registration or application date, is set forth on Schedule 4.6(c) of the Disclosure Letter. Except as set forth on Schedule 4.6(c) of the Disclosure Letter:
(i) (A) to such Credit Party’s Knowledge, each item of Current Company IP owned or co-owned by a Credit Party or any of its Subsidiaries (x) is valid, subsisting and enforceable, (y) has not in any respect lapsed, expired, been cancelled, held unpatentable, held unenforceable or held invalidated or become abandoned or unenforceable, in each case, except in accordance with its statutory term or in the exercise of normal prosecution practices and reasonable business judgment, and (z) no circumstance or grounds exist that would invalidate or reduce, in whole or in part, the validity, enforceability, subsistence or scope of any such Current Company IP, or reduce or otherwise materially limit the ownership or use of such Current Company IP, by any Credit Party or any of its Subsidiaries, and (B) no written notice has been received by any Credit Party or any of its Subsidiaries challenging the validity, patentability, enforceability, inventorship or ownership (other than from patent and trademark and other intellectual property offices through the normal prosecution practices), or relating to any lapse, expiration, invalidation, cancellation, abandonment or unenforceability (other than from patent and trademark and other intellectual property offices through the normal prosecution practices or relating to the expiration of Current Company IP in accordance with its statutory term), of any such item of Current Company IP owned or co-owned by a Credit Party or any of its Subsidiaries;
(ii) (A) to the Knowledge of such Credit Party, each item of Current Company IP that is exclusively in-licensed by a Credit Party or any of its Subsidiaries from another Person is valid, subsisting and enforceable and no item of such Current Company IP has in any respect lapsed, expired, been cancelled, held unpatentable, held unenforceable or held invalidated, or become abandoned (in each case other than in accordance with its statutory term or through the exercise of normal prosecution practices or reasonable business judgment of the applicable licensor), and (B) no written notice has been received by any Credit Party or any of its Subsidiaries challenging the validity, patentability, enforceability, inventorship or ownership, or relating to any lapse, expiration, invalidation, cancellation, abandonment or unenforceability, of any item of Current Company IP that is exclusively in-licensed by a Credit Party or any of its Subsidiaries (in each case, other than from patent and trademark and other intellectual property offices through the applicable licensor’s normal prosecution practices or relating to the expiration of Current Company IP in accordance with its statutory term);
-27-
(iii) to the Knowledge of each Credit Party, all prior art references (including published patents, published patent applications and published articles) known to the Credit Party and reasonably believed to be material to patentability of one or more claims of each Patent included in the Current Product IP that is owned or co-owned by a Credit Party were disclosed to the U.S. Patent and Trademark Office and, to the Knowledge of each Credit Party, any Product as approved by FDA does not infringe the claims of an issued U.S. patent or the currently pending claims of a published U.S. patent application as of the Effective Date or applicable Closing Date if the currently pending claims were to issue and were valid except as would not be reasonably expected to materially adversely affect the exploitation of such Product;
(iv) (A) each Person who has or has had any rights in or to any Current Company IP or any trade secrets, in each case, owned by any Credit Party or any of its Subsidiaries relating to any material aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, packaging, labeling, promotion, advertising, offer for sale, distribution or sale of any Product in the Territory, including each such Person who is an inventor named on the Patents within such owned Current Company IP, has executed an agreement assigning his, her or its entire right, title and interest in and to such owned Current Company IP and such trade secrets, and the inventions, ideas, discoveries, writings, works of authorship, information and other intellectual property embodied, described or claimed therein, to the stated owner thereof, and (B) to the Knowledge of each Credit Party, no such Person has any contractual or other obligation that would preclude or conflict with such assignment or the exploitation of any Product in the Territory or entitle such Person to ongoing payments; and
(v) no item of Current Company IP that is non-exclusively in-licensed from another Person is material to or necessary for research, development, manufacturing, production, use, commercialization, marketing, importing, storage, transport, packaging, labeling, promotion, advertising, offering for sale, distribution or selling any Product in the Territory.
(d) (i) Each Credit Party or any of its Subsidiaries possesses valid title to the Current Company IP for which it is listed as the owner or co-owner, as applicable, on Schedule 4.6(c) of the Disclosure Letter; and (ii) there are no Liens on any Current Company IP, other than Permitted Liens.
(e) There are no maintenance, annuity or renewal fees that are currently overdue beyond their allotted grace period for any of the Current Product IP that is owned by or, exclusively licensed to any Credit Party or any of its Subsidiaries; to the Knowledge of the Credit Parties, there are no maintenance, annuity or renewal fees that are currently overdue beyond their allotted grace period for any of the Current Company IP (other than Current Product IP) that is owned by or, exclusively licensed to any Credit Party or any of its Subsidiaries.
(f) There are no unpaid fees, royalties or indemnification payments under any Company IP Agreement that have become, or are reasonably expected to become, due or overdue. Each Company IP Agreement is in full force and effect and, to the Knowledge of each Credit Party, is legal, valid, binding, and enforceable in accordance with its respective terms, except as may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or limiting creditors’ rights generally or by equitable principles relating to enforceability. Except as set forth on Schedule 4.6(f) of the Disclosure Letter, no Credit Party or any of its Subsidiaries is in breach of or default under any Company IP Agreement to which it is a party or is otherwise bound, and to the Knowledge of each Credit Party, no circumstances or grounds exist that could give rise to a claim of breach or right of rescission, termination, non-renewal, revision, or amendment of any of the Company IP Agreements, including the execution, delivery and performance of this Agreement and the other Loan Documents.
(g) Except as set forth on Schedule 4.6(g) of the Disclosure Letter, no payments by any Credit Party or any of its Subsidiaries are due to any other Person in respect of the Current Company IP, other than (i) pursuant to (A) the Company IP Agreements (including, for the avoidance of doubt, that certain License and Assignment Agreement, dated January 30, 2008, between ND Partners, LLP and Borrower, as may be amended, restated, supplemented, modified or replaced, or renewed or altered (including pursuant to any waiver, consent or approval) from time to time), (B) any Permitted Royalty Agreement Document, (C) any Permitted Royalty Financing Document or Permitted Other Royalty Financing Document, or (D) any Permitted Acquisition Royalty Document and (ii) those fees for which a Credit Party is responsible that are payable to the U.S. Patent and Trademark Office or the U.S. Copyright Office in connection with the prosecution and maintenance of the Current Company IP and associated attorney fees.
-28-
(h) (A) (i) No Credit Party or any of its Subsidiaries has knowingly undertaken or omitted to undertake any acts, and (ii) to the Knowledge of such Credit Party in the case of Current Product IP owned or co-owned by or exclusively or non-exclusively licensed to any Credit Party or any of its Subsidiaries, no circumstance or grounds exist, that, in either case of sub-clause (i) or (ii) above, would invalidate, impair the validity of or reduce, in whole or in part, the enforceability or scope of any Credit Party’s or any of its Subsidiary’s right or entitlement to the Current Company IP in any manner that could reasonably be expected to materially adversely affect any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, packaging, labelling, promotion, advertising, offer for sale, distribution or sale of any Product in the Territory, except as set forth on Schedule 4.6(h)(A) of the Disclosure Letter; (B) (i) to the Knowledge of each Credit Party, no Credit Party or any of its Subsidiaries has undertaken or omitted to undertake any acts, and (ii) to the Knowledge of such Credit Party in the case of Current Company IP (other than Current Product IP) owned or co-owned by or exclusively or non-exclusively licensed to any Credit Party or any of its Subsidiaries, no circumstances or grounds exist that, in either case of sub-clause (i) or (ii) above, would invalidate, impair the validity of or reduce, in whole or in part, the enforceability or scope of any Credit Party’s or any Subsidiary’s right or entitlement to the Current Company IP in any manner that could reasonably be expected to materially adversely affect any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, packaging, labelling, promotion, advertising, offer for sale, distribution or sale of any Product in the Territory, except as set forth on Schedule 4.6(h)(B) of the Disclosure Letter.
(i) Except as noted on Schedule 4.6(i) of the Disclosure Letter, to the Knowledge of any Credit Party, there is no product or other technology of any third-party that infringes a Patent within the Current Company IP.
(j) As of the Effective Date and each applicable Closing Date, (i) no Credit Party is a party to, nor is it bound by, any Restricted License and (ii) except as noted on Schedule 4.6(j)(ii) of the Disclosure Letter, no Credit Party nor any of its Subsidiaries is a party to, nor is it bound by, any Excluded License.
(k) Except as set forth on Schedule 4.6(k) of the Disclosure Letter, in each case where an issued U.S. Patent within the Current Company IP is owned or co-owned by any Credit Party or its Subsidiaries by assignment, the assignment has been duly recorded with the U.S. Patent and Trademark Office, and if applicable the assignment has been duly recorded or will be recorded promptly with all similar offices and agencies anywhere in the world in which foreign counterparts are registered, filed or issued.
(l) Except as set forth on Schedule 4.6(l) of the Disclosure Letter, there are no pending or, to the Knowledge of each Credit Party, threatened (in writing) claims against Borrower or any of its Subsidiaries alleging (i) that any research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, packaging, labelling, promotion, advertising, offer for sale, distribution or sale of any Product in any Territory infringes or violates (or in the past infringed or violated), or form a reasonable basis for a claim of infringement or violation of, any of the rights of any third parties in or to any Intellectual Property (“Third-Party IP”) or constitutes a misappropriation of (or in the past constituted a misappropriation of) any Third-Party IP, or (ii) that any Current Company IP is invalid, unpatentable or unenforceable (other than from patent and trademark offices through the normal prosecution practices).
(m) Except as set forth on Schedule 4.6(m) of the Disclosure Letter, to the Knowledge of each Credit Party, the manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of any Product in the Territory has not in the past and does not (i) infringe or violate (or in the past infringed or violated), or form a reasonable basis for a claim of infringement or violation of, any of the rights of third parties in or to any Third-Party IP, or (ii) constitute (or in the past constituted) a misappropriation of any Third-Party IP.
(n) Except as set forth on Schedule 4.6(n) of the Disclosure Letter, there are no settlements, covenants not to sue, consents, judgments, orders or similar obligations, that: (i) restrict the rights of any Credit Party or any of its Subsidiaries to use any Intellectual Property owned, exclusively licensed or, to the Knowledge of each Credit Party, non-exclusively licensed, by such Credit Party relating to any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, packaging, labeling, promotion, advertising, offer for sale, distribution or sale of any Product in the Territory (in order to accommodate any Third-Party IP or otherwise), or (ii) permit any third parties to use any Company IP owned, exclusively licensed or, to the Knowledge of each Credit Party, non-exclusively licensed, by such Credit Party existing as of the Effective Date and on the applicable Closing Date.
-29-
(o) Except as set forth on Schedule 4.6(o) of the Disclosure Letter, to the Knowledge of each Credit Party, (i) there is no, nor has there been any, infringement or violation by any Person of any of the Company IP or the rights therein and (ii) there is no, nor has there been any, misappropriation by any Person of any of the Company IP or the subject matter thereof.
(p) Each Credit Party and each of its Subsidiaries has taken commercially reasonable measures customary in the health and life sciences sector to protect the confidentiality and value of trade secrets owned or licensed by such Credit Party or any of its Subsidiaries, or used or held for use by such Credit Party or any of its Subsidiaries, in each case (i) relating to any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, packaging, labeling, promotion, advertising, offer for sale, distribution or sale of any Key Product in the Territory or (ii) material to any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, packaging, labeling, promotion, advertising, offer for sale, distribution or sale of any other Product in the Territory. Any use or disclosure by a Credit Party or any of its Subsidiaries of any trade secrets to any third-party has been pursuant to the terms of a written agreement including appropriate confidentiality, access, use and non-disclosure provisions with such third-party, and, to the Knowledge of the Credit Party, no Credit Party or any of its Subsidiaries has suffered any material data breach or other incident that has resulted in any loss, unauthorized access, use, disclosure or modification of any such trade secrets.
(q) Except as set forth on Schedule 4.6(q) of the Disclosure Letter, units of any Product made, used or sold in the Territory under the Patents within the Current Company IP have been marked with the proper patent notice (where required by Requirements of Law).
(r) To the Knowledge of each Credit Party, (i) at the time of any shipment of any Key Product occurring prior to the Effective Date or applicable Closing Date, the units thereof so shipped complied with their relevant specifications and were developed, manufactured, stored and shipped (A) in accordance with then applicable FDA Good Manufacturing Practices, FDA Good Clinical Practices and FDA Good Laboratory Practices, and (B) in all material respects in accordance with all other Requirements of Law, and (ii) at the time of any shipment of any other Product occurring prior to the Effective Date or applicable Closing Date, the units thereof so shipped complied in all material respects with their relevant specifications and were developed, manufactured, stored and shipped (A) in accordance with then applicable FDA Good Manufacturing Practices, FDA Good Clinical Practices and FDA Good Laboratory Practices, and (B) in all material respects in accordance with all other Requirements of Law.
(s) Except as set forth on Schedule 4.6(s) of the Disclosure Letter:
(i) [Reserved];
(ii) (A) with respect to the Current Product IP consisting of Patents, subsequent to the issuance of such Patents, no Credit Party nor any Subsidiary nor any of their respective predecessors-in-interest, has filed any disclaimer or made or permitted any other voluntary reduction in the scope of the inventions claimed in such Patents, and (B) with respect to the Current Company IP (other than Current Product IP) consisting of Patents, subsequent to the issuance of such Patents, to the Knowledge of the Credit Parties, no Credit Party nor any Subsidiary nor any of their respective predecessors-in-interest, has filed any disclaimer or made or permitted any other voluntary reduction in the scope of the inventions claimed in such Patents;
(iii) with respect to the Current Company IP consisting of Patents, to the Knowledge of such Credit Party, no subject matter of such Patents that is designated allowable or allowed by the U.S. Patent and Trademark Office is subject to any competing conception claims of subject matter of any patent applications or patents of any third-party in the Territory and have not been the subject of any interference or derivation proceeding, and such Patents are not and have not been the subject of any re-examination, opposition or any other post-grant proceedings in the Territory;
-30-
(iv) with respect to the Current Company IP consisting of Patents and except as set forth on Schedule 4.6(s) of the Disclosure Letter, if any of such Patents is terminally disclaimed to another patent or patent application, all patents and patent applications subject to such terminal disclaimer are included in the Collateral; and
(v) with respect to the Current Company IP consisting of Patents, neither any Credit Party nor any Subsidiaries has received advice from legal counsel expressing an opinion, including a preliminary or qualified opinion, that concludes that a challenge to the validity or enforceability, subsistence or scope of any such Patents is more likely than not to succeed.
(t) (A) Neither any Credit Party nor any Subsidiary nor, to the Knowledge of such Credit Party, any of their respective agents or representatives, have (i) engaged in any conduct, the result of which would invalidate or render unpatentable or unenforceable or materially reduce, in whole or in part, the validity, enforceability, subsistence or scope of any Patent included within Current Company IP, or (ii) omitted to perform any necessary act to maintain the validity, patentability, enforceability, subsistence or scope of any such Patent, and (B) to the Knowledge of such Credit Party, no prior owner of any such Patent of any Credit Party or any of its Subsidiaries, nor any of such prior owner’s agents or representatives, have (i) engaged in any conduct, the result of which would invalidate or render unpatentable or unenforceable or materially reduce, in whole or in part, the validity, enforceability, subsistence or scope of any such Patent, or (ii) omitted to perform any necessary act to maintain the validity, patentability, enforceability, subsistence or scope of any such Patent, in each case of sub-clause (A) and (B) above, except in the reasonable exercise of normal prosecution practices or reasonable business judgment.
(u) The Collateral Documents create in favor of the Collateral Agent, for the benefit of Lenders and the other Secured Parties, a valid and continuing and, upon the making of the filings and the taking of the actions required under the terms of the Loan Documents, perfected Lien on and security interest in the Collateral (in each case, solely to the extent perfection is available under Requirements of Law through the making of such filings and taking of such actions and except to the extent expressly not required to be perfected pursuant to the terms of the Loan Documents), securing the payment of the Obligations, and having priority over all other Liens on and security interests in the Collateral (except Permitted Liens).
Notwithstanding anything set forth to the contrary herein: (A) each representation and warranty in Section 4.6 relating to Intellectual Property, including Company IP, Current Company IP, Current Product IP and Third-Party IP, to the extent made as of the Tranche A Closing Date with respect to any Heron Acquisition Product acquired by Borrower or any of its Subsidiaries pursuant to the Heron Acquisition Agreement on or concurrently with the Tranche A Closing Date, is made solely to the Knowledge of the Credit Parties; and (B) each representation and warranty in Section 4.6 relating to Intellectual Property, including Company IP, Current Company IP, Current Product IP and Third-Party IP, to the extent made as of the Tranche B Closing Date with respect to any Other Acquisition Product acquired by Borrower or any of its Subsidiaries pursuant to the Other Acquisition Agreement on or concurrently with the Tranche B Closing Date, is made solely to the Knowledge of the Credit Parties.
4.7 Adverse Proceedings, Compliance with Laws.
(a) As of the Effective Date and the Tranche A Closing Date, except as set forth on Schedule 4.7 of the Disclosure Letter, (i) there are no Adverse Proceedings pending or, to the Knowledge of such Credit Party, threatened in writing, at law, in equity, in arbitration or before any Governmental Authority, by or against Borrower or any of Borrower’s Subsidiaries; and (ii) neither Borrower nor any of Borrower’s Subsidiaries (A) is in material violation of any Requirements of Law, excluding any Requirement of Law which is being contested in good faith by appropriate proceedings, or (B) is subject to or in default with respect to any final judgments, orders, writs, injunctions, settlement agreements, decrees, rules or regulations of any court or any federal, state, municipal or other governmental department, commission, board, bureau, agency, instrumentality, or other Governmental Authority, domestic or foreign.
(b) As of each Closing Date other than the Tranche A Closing Date, (i) except as set forth on Schedule 4.7 of the Disclosure Letter, there are no Adverse Proceedings pending or, to the Knowledge of any Credit Party, threatened in writing, at law, in equity, in arbitration or before any Governmental Authority, by or against Borrower or any of Borrower’s Subsidiaries, which, if adversely determined, either individually or in the aggregate, could reasonably be expected to result in a Material Adverse Change; and (ii) neither Borrower nor any of Borrower’s Subsidiaries (A) is in violation of any Requirements of Law, excluding any Requirement of Law which is being contested in good faith by appropriate proceedings, where such violation could reasonably be expected to result in uninsured damages, penalties or costs to Borrower or any of Borrower’s Subsidiaries in an amount in excess of the materiality thresholds applied by Borrower in accordance with the Exchange Act and related regulations and standards for purposes of its Exchange Act reporting or (B) is subject to or in default with respect to any final judgment, order, writ, injunction, settlement agreement, decree, rule or regulation of any court or any federal, state, municipal or other governmental department, commission, board, bureau, agency, instrumentality, or other Governmental Authority, domestic or foreign that could reasonably be expected to result in uninsured damages, penalties or costs to Borrower or any of its Subsidiaries in an amount in excess of the materiality thresholds applied by Borrower in accordance with the Exchange Act and related regulations and standards for purposes of its Exchange Act reporting.
-31-
(c) Each of Borrower and its Subsidiaries, to the Knowledge of each such Credit Party, is in compliance in all material respects with the terms of all settlement agreements relating to any Adverse Proceeding to which Borrower or any Subsidiary is a party.
4.8 Exchange Act Documents; Financial Statements; Financial Condition; No Material Adverse Change; Books and Records.
(a) The Exchange Act Documents filed by Borrower with the SEC since December 31, 2025, when they were filed with the SEC, conformed in all material respects to the requirements of the Exchange Act, and as of the time they were filed with the SEC, none of such documents contained any untrue statement of a material fact or omitted to state a material fact necessary to make the statements therein (excluding any projections and forward-looking statements, estimates, budgets and general economic or industry data of a general nature), in the light of the circumstances under which they were made, not misleading; provided, that, with respect to projected financial information, Borrower represents only that such information was prepared in good faith based upon assumptions believed to be reasonable at the time (it being understood that such projections are not a guarantee of financial performance and are subject to uncertainties and contingencies, many of which are beyond the control of Borrower or any Subsidiary, and neither Borrower nor any Subsidiary can give any assurance that such projections will be attained, that actual results may differ in a material manner from such projections and any failure to meet such projections shall not be deemed to be a breach of any representation or covenant herein).
(b) Borrower’s audited annual financial statements as of December 31, 2025 and unaudited quarterly financial statements as of March 31, 2026 and June 30, 2026 (in each case, including the related notes thereto) of Borrower and its Subsidiaries included in the Exchange Act Documents present fairly in all material respects the consolidated financial condition of Borrower and such Subsidiaries and their consolidated results of operations as of the dates indicated and the results of their operations and the changes in their cash flows for the periods specified. Such financial statements have been prepared in conformity with GAAP applied on a consistent basis throughout the periods covered thereby, except as otherwise disclosed therein and, in the case of unaudited, interim financial statements, subject to normal year-end audit adjustments and the exclusion of certain footnotes.
(c) Borrower acknowledges that its management is responsible for the preparation and fair presentation of the financial statements of Borrower and each of its Subsidiaries delivered to the Collateral Agent pursuant to Section 5.2(a), in each case, in conformance, in all material respects, with GAAP. Borrower has, suitable for a company of its size and stage of development, designed, implemented and maintained internal controls relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.
(d) Since December 31, 2025, there has not occurred any change or event that has had or could reasonably be expected to have, either alone or in conjunction with any other change(s), event(s) or failure(s), a Material Adverse Change.
(e) Except as described on Schedule 4.8(e) of the Disclosure Letter, since December 31, 2025, there has not occurred any Transfer by Borrower or any Subsidiary, voluntary or involuntary, of any material part of the business, assets or property of Borrower or any of its Subsidiaries, and no purchase or other acquisition by any of them of any business, assets or property (including any Equity Interests of any other Person) material to Borrower or any Subsidiary, in each case, which is not reflected in the financial statements of Borrower and its Subsidiaries included in the Exchange Act Documents (or in the notes thereto) and has not otherwise been disclosed in writing to the Collateral Agent or Lenders on or prior to the applicable Closing Date.
(f) The Books of Borrower and each of its Subsidiaries in existence immediately prior to the Effective Date and each applicable Closing Date contain full, true and correct entries of all dealings and transactions in relation to its business and activities in conformity with GAAP and Requirements of Law in all material respects.
-32-
4.9 Solvency. The Credit Parties and their Subsidiaries, on a consolidated basis, are Solvent. Without limiting the generality of the foregoing, there has been no proposal made or resolution adopted by any competent corporate body for the dissolution or liquidation of any Credit Party, nor do any circumstances exist which may result in the dissolution or liquidation of any Credit Party (other than in respect of a dissolution or liquidation expressly permitted under Section 6.3(a)(iii)).
4.10 Payment of Taxes. All U.S. federal, state, local and non-U.S. income and other material Tax returns and reports (or extensions thereof) of each Credit Party and each of its Subsidiaries required to be filed by any of them have been timely filed (taking into account valid extensions) and are correct, in all material respects, and all U.S. federal, state, local and non-U.S. income and other Taxes which are due and payable by any Credit Party or any of its Subsidiaries and all assessments, fees and other governmental charges upon any Credit Party or any of its Subsidiaries and upon their respective properties, assets, income, businesses and franchises which are due and payable in each case have been paid when due and payable, provided, that, no such Tax or any claim for Taxes that have become due and payable shall be required to be paid if (i) the validity or amount thereof is being contested in good faith by appropriate proceedings and the applicable Credit Party has set aside on its books adequate reserves therefor in conformity with GAAP or (ii) the failure to pay such Taxes, individually or in the aggregate, does not result or could not reasonably be expected to result in a Material Adverse Change. To the Knowledge of such Credit Party, there is no proposed Tax assessment against any Credit Party or any of its Subsidiaries that would reasonably be expected to result in a Material Adverse Change.
4.11 Environmental Matters. Neither Borrower nor any of its Subsidiaries nor any of their respective Facilities or operations is subject to any outstanding written order, consent decree or settlement agreement with any Person relating to any Environmental Law, any Environmental Claim, or any Hazardous Materials Activity that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Change. There are and, to the Knowledge of such Credit Party, have been, no conditions, occurrences, or Hazardous Materials Activities that would reasonably be expected to form the basis of an Environmental Claim against Borrower or any of its Subsidiaries that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Change. To the Knowledge of such Credit Party, no predecessor of Borrower or any of its Subsidiaries has filed any notice under any Environmental Law indicating past or present treatment of Hazardous Materials at any Facility, which could reasonably be expected to form the basis of an Environmental Claim against Borrower or any of its Subsidiaries that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Change (but, for the avoidance of doubt, neither Borrower nor any of its Subsidiaries has, directly or indirectly, undertaken any investigation of or made any inquiries to, or relating to, any of its or its Subsidiaries’ predecessors), and neither Borrower’s nor any of its Subsidiaries’ operations involves the generation, transportation, treatment, storage or disposal of hazardous waste, as defined under 40 C.F.R. Parts 260–270 or any foreign or United States state equivalents, which could reasonably be expected to form the basis of an Environmental Claim against Borrower or any of its Subsidiaries that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Change. No event or condition has occurred or is occurring with respect to any Credit Party relating to any Environmental Law, any Release of Hazardous Materials, or any Hazardous Materials Activity that, individually or in the aggregate, has resulted in, or could reasonably be expected to result in, a Material Adverse Change.
4.12 Material Contracts. As of the Effective Date and each applicable Closing Date after giving effect to the consummation of the transactions contemplated by this Agreement, except as described on Schedule 4.12 of the Disclosure Letter, each Material Contract is a valid and binding obligation of the applicable Credit Party and, to the Knowledge of such Credit Party, each other party thereto, and is in full force and effect, and neither the applicable Credit Party nor, to the Knowledge of such Credit Party, any other party thereto is in material breach thereof or default thereunder, except where such breach or default (which default has not been cured or waived) could not reasonably be expected to give rise to any cancellation, termination or acceleration right of the applicable counterparty thereto. As of the Effective Date and each applicable Closing Date, except as described on Schedule 4.12 of the Disclosure Letter, no Credit Party or any of its Subsidiaries has received any written notice from any party to any Material Contract asserting or to the Knowledge of such Credit Party, threatening in writing to assert, circumstances that could reasonably be expected to result in the cancellation, termination or invalidation of any Material Contract (or any provision thereof) or the acceleration of such Credit Party’s or Subsidiary’s obligations thereunder.
-33-
4.13 Regulatory Compliance. No Credit Party is or is required to be registered as, or is a company “controlled” by, an “investment company” as defined in, or is subject to regulation under, the Investment Company Act of 1940, as amended. Except as could not reasonably be expected to result in a Material Adverse Change, each Credit Party has complied with the Federal Fair Labor Standards Act (and any foreign or United States state equivalent, as applicable). Except as could not, either individually or in the aggregate, reasonably be expected to result in a Material Adverse Change, each Plan is in compliance with the applicable provisions of ERISA, the IRC and other U.S. federal or state or foreign Requirements of Law, respectively. (i) No ERISA Event has occurred or is reasonably expected to occur; (ii) neither any Credit Party nor any ERISA Affiliate has incurred, or reasonably expects to incur, any liability (and no event has occurred which, with the giving of notice under Section 4219 of ERISA, would result in such liability) under Section 4201 et seq. of ERISA with respect to a Multiemployer Plan; and (iii) neither any Credit Party (to the extent applicable) nor any ERISA Affiliate has engaged in a transaction that would be subject to Section 4069 or 4212(c) of ERISA, except, with respect to each of clauses (i), (ii) and (iii) above, as could not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change.
4.14 Margin Stock. No Credit Party is engaged principally, or as one of its important activities, in extending credit for the purpose of, whether immediate or ultimate, purchasing or carrying Margin Stock. No Credit Party owns any Margin Stock. No Credit Party or any of its Subsidiaries has taken or permitted to be taken any action that might cause any Loan Document to violate Regulation T, U or X of the Federal Reserve Board.
4.15 Subsidiaries; Capitalization. Schedule 4.15 of the Disclosure Letter includes a complete and accurate list, as of the Effective Date or each applicable Closing Date, of Borrower and each of its Subsidiaries, setting forth (a) its name and jurisdiction of incorporation, organization or formation, (b) in the case of each Credit Party (other than Borrower), the number of authorized and issued shares (or equivalent) of each class (where applicable) of its Equity Interests outstanding, and (c) the percentage of its outstanding shares of each class owned (directly or indirectly) by Borrower or any of its Subsidiaries and the certificate numbers(s) for the same (if any), and (d) the number and effect, if exercised, of all of its outstanding options, warrants, rights of conversion or purchase and all other similar rights with respect thereto. Except as set forth on Schedule 4.15 of the Disclosure Letter, each Credit Party is a Registered Organization.
4.16 Employee Matters. Neither Borrower nor any of its Subsidiaries is engaged in any unfair labor practice that could reasonably be expected to result in a Material Adverse Change. There is (a) no unfair labor practice complaint pending against Borrower or any of its Subsidiaries or, to the Knowledge of such Credit Party, threatened in writing against any of them in each case before the National Labor Relations Board, and no grievance or arbitration proceeding arising out of or under any collective bargaining agreement that is pending against Borrower or any of its Subsidiaries or, to the Knowledge of such Credit Party, threatened in writing against any of them, (b) no strike or work stoppage in existence or, to the Knowledge of such Credit Party, threatened in writing involving Borrower or any of its Subsidiaries, and (c) to the Knowledge of such Credit Party, no union representation question existing with respect to the employees of Borrower or any of its Subsidiaries and, to the Knowledge of such Credit Party, no union organization activity that is taking place that in each case specified in any of clauses (a), (b) and (c) above, individually or taken together with any other matter specified in clause (a), (b) or (c) above, could reasonably be expected to result in a Material Adverse Change.
4.17 Full Disclosure. None of the documents, certificates or written statements (excluding any projections and forward-looking statements, estimates, budgets and general economic or industry data of a general nature) furnished or otherwise made available to the Collateral Agent or any Lender by or on behalf of any Credit Party for use in connection with the transactions contemplated hereby (in each case, taken as a whole and as modified or supplemented by other information so furnished promptly after the same becomes available) contains any untrue statement of a material fact or omits to state a material fact necessary in order to make the statements contained herein or therein, as of the time when made or delivered, not misleading in light of the circumstances in which the same were made; provided, that, with respect to projected financial information, Borrower represents only that such information was prepared in good faith based upon assumptions believed to be reasonable at the time (it being understood that such projections are not a guarantee of financial performance and are subject to uncertainties and contingencies, many of which are beyond the control of Borrower or any Subsidiary, and neither Borrower nor any Subsidiary can give any assurance that such projections will be attained, that actual results may differ in a material manner from such projections and any failure to meet such projections shall not be deemed to be a breach of any representation or covenant herein). To the Knowledge of such Credit Party, there are no facts (other than matters of a general economic or industry nature) that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Change and that have not been disclosed herein or in such other documents, certificates and written statements furnished or made available to the Collateral Agent or any Lender for use in connection with the transactions contemplated hereby.
-34-
4.18 Anti-Corruption Laws; Anti-Money Laundering Laws; Sanctions; Export and Import Laws.
(a) In the last five (5) years, none of Borrower or any of its Subsidiaries, or any of their respective directors, officers, affiliates or employees, or, to the Knowledge of such Credit Party, any agent of Borrower or any of its Subsidiaries, has (i) used any corporate funds of Borrower or any of its Subsidiaries for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity, (ii) made any direct or, to the Knowledge of such Credit Party, indirect unlawful payment to any foreign or domestic government official or employee or any Person from corporate funds of Borrower or any of its Subsidiaries, (iii) violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”), the U.K. Bribery Act of 2010, or any other applicable anti-corruption laws (collectively, “Anti-Corruption Laws”) or (iv) made any bribe, improper rebate, payoff, influence payment, kickback or other unlawful payment, and no part of the proceeds of any Credit Extension will be used, directly or, to the Knowledge of such Credit Party, indirectly, for any payments to any governmental official or employee, political party, official of a political party, candidate for political office or anyone else acting in an official capacity, in order to obtain, retain or direct business, or to obtain any improper advantage, in violation of Anti-Corruption Laws. No action, suit or proceeding by or before any Governmental Authority or any arbitrator involving Borrower or any of its Subsidiaries, with respect to Anti-Corruption Laws is pending or to the Knowledge of such Credit Party, is or has been threatened in writing nor, to the Knowledge of Borrower, is there a basis for such action, suit, or proceeding.
(b) (i) The operations of Borrower and each of its Subsidiaries are and have been conducted at all times in the last five (5) years in compliance with applicable financial recordkeeping and reporting requirements of the Bank Secrecy Act of 1970 (as amended by Title III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism (USA PATRIOT) Act of 2001) and the anti-money laundering laws and counterterrorist financing, rules and regulations of each jurisdiction (foreign or domestic) in which Borrower and its Subsidiaries, is subject to such jurisdiction’s Requirements of Law (collectively, “Anti-Money Laundering Laws”) and (ii) no action, suit or proceeding by or before any Governmental Authority or any arbitrator involving Borrower or its Subsidiaries, with respect to the Anti-Money Laundering Laws is pending or to the Knowledge of such Credit Party, threatened in writing.
(c) None of Borrower or any of its Subsidiaries or controlled Affiliates, or any of their respective directors, officers or employees, or, to the Knowledge of such Credit Party, any non-controlled Affiliates or agents of such Credit Party, is, or is collectively 50% or more owned or, where applicable, controlled, by one or more Persons that are, the target or subject of any economic, trade or financial sanctions or restrictive measures administered and enforced by the Office of Foreign Assets Control of the U.S. Department of the Treasury (“OFAC”), the U.S. Department of State, the United Nations Security Council, the European Union and each of its member states or His Majesty’s Treasury of the United Kingdom, or other relevant Governmental Authority (collectively “Sanctions”). Except as permitted by applicable Sanctions laws, neither Borrower nor its Subsidiaries: (i) has assets located in, or otherwise directly or indirectly derives revenues from or engages in, investments, dealings, activities, or transactions in or with, any Sanctioned Country; or (ii) directly or indirectly derives revenues from, conducts any business or engages in investments, dealings, activities, or transactions with, any Blocked Person, including the making or receiving of any contribution of funds, goods or services to or for the benefit of any Blocked Person. Borrower and its Subsidiaries will not, directly or indirectly (including through an agent or any other Person), use the proceeds of any Credit Extension, or lend, contribute or otherwise make available such proceeds to any Subsidiary, joint venture partner or other Person, for (x) the purpose of financing the activities of any Person that is the target or subject of Sanctions or in any Sanctioned Country, except as permitted by applicable Sanctions laws, (y) use in any Sanctioned Country except as permitted by applicable Sanctions laws, or (z) any purpose that could cause any Person to be in violation of Sanctions. No action, suit or proceeding by or before any Governmental Authority or any arbitrator involving Borrower or any of its Subsidiaries, with respect to Sanctions is pending or to the Knowledge of such Credit Party, threatened in writing, nor, to the Knowledge of Borrower, is there a basis for such action, suit or proceeding.
-35-
(d) Borrower will not, directly or indirectly (including through an agent or any other Person), use the proceeds of any Credit Extension, or lend, contribute or otherwise make available the proceeds of any Credit Extension to any Subsidiary, joint venture partner or other Person (i) for any payments to any government official or employee, political party, official of a political party, candidate for political office or other Person, in order to obtain, retain or direct business, or to obtain any improper advantage in violation of Anti-Corruption Laws, (ii) in violation of any Anti-Money Laundering Laws, or (iii) in violation of Sanctions. Except as set forth in clause (d) of Schedule 5.14 of the Disclosure Letter, Borrower and each of its Subsidiaries have instituted and maintain policies and procedures reasonably designed to ensure compliance with Sanctions, Anti-Money Laundering Laws, Export and Import Laws, and Anti-Corruption Laws.
(e) Since April 25, 2019, Borrower and each of its Subsidiaries, and, acting in such capacity and on behalf of Borrower or one or more of its Subsidiaries, their respective officers, directors, employees and, to the Knowledge of Borrower, any agent of Borrower or any of its Subsidiaries, are and have been in compliance in all respects with Sanctions.
(f) Borrower and each of its Subsidiaries are (i) in compliance in all material respects with Export and Import Laws and Anti-Corruption Laws, and (ii) in compliance in all respects with Sanctions and Anti-Money Laundering Laws.
4.19 Health Care Matters.
(a) Compliance with Health Care Laws. Except as set forth on Schedule 4.19(a) of the Disclosure Letter, each Credit Party and, to the Knowledge of such Credit Party, each of its Subsidiaries, and each officer, Affiliate, and employee when acting on behalf of such Credit Party or any of its Subsidiaries, is in compliance in all material respects with all Health Care Laws applicable to such Credit Party or Subsidiary.
(b) Compliance with Regulatory Requirements. Each Credit Party and, to the Knowledge of such Credit Party, each of its Subsidiaries, and each of its licensing partners, is in compliance in all material respects with applicable FDA Laws; and any and all applicable Requirements of Law (including any other designations sought, including Orphan Drug Designation, Fast Track Designation, Priority Review Designation, Qualified Infection Disease Product Designation, and Rare Pediatric Disease Designation) governing or otherwise germane to the research, development, testing, approval, licensure, clearance, authorization, designations, exclusivity, post-approval (or post-licensure, post-authorization, as applicable) monitoring and requirements, reporting, manufacture, production, packaging, labeling, use, commercialization, marketing, promotion, advertising, importing, exporting, storage, transport, offer for sale, distribution (including for investigational use) or sale of any Product in the Territory. Except as set forth on Schedule 4.19(b) of the Disclosure Letter, any unit of any Product that has been distributed, including for investigational use, or sold in the Territory at all times during the past five (5) years has been (i) manufactured and developed in all material respects in accordance with all applicable FDA Good Manufacturing Practices, FDA Good Clinical Practices and FDA Good Laboratory Practices (as applicable) and any foreign equivalents thereof, and (ii) if and to the extent any Product is required to be approved, licensed, or cleared by the relevant Governmental Authority pursuant to FDA Laws in order to be legally marketed in the Territory for any Product’s intended uses, any such Product has been approved, licensed, or cleared for such intended uses, meets in all material respects any additional conditions of approval, clearance, authorization, or licensure by the competent Governmental Authority, and except as has been set forth in Schedule 4.19(b) of the Disclosure Letter during the past five (5) years no inquiries regarding material non-compliance of any Credit Party and, to the Knowledge of such Credit Party, any of its Subsidiaries, with any of the foregoing Requirements of Law have been initiated by or on behalf of FDA or any comparable Governmental Authority.
(c) Applicability of Controlled Substances Act. No Product contains a controlled substance (as that term is defined under the Controlled Substances Act (21 U.S.C. § 801 et seq.)).
-36-
(d) Material Statements. Within the past five (5) years, neither any Credit Party, nor, to the Knowledge of such Credit Party, any Subsidiary or any officer or employee of any Credit Party or Subsidiary in its capacity as a Subsidiary or as an officer, employee of a Credit Party or Subsidiary (as applicable), nor, to the Knowledge of such Credit Party, any agent of any Credit Party or Subsidiary in its capacity as such, (i) has made an untrue statement of a material fact or a fraudulent statement to any Governmental Authority under any applicable Health Care Law, (ii) has failed to disclose a material fact, to the extent disclosure is required, to any Governmental Authority under any applicable Health Care Law, or (iii) has otherwise committed an act, made a statement or failed to make a statement that, at the time such statement or disclosure was made (or, in the case of such failure, should have been made) or such act was committed, could reasonably be expected to constitute a material violation of any applicable Health Care Law. Each Credit Party and each of its Subsidiaries has implemented reasonable and appropriate policies and procedures designed to ensure compliance with all applicable Health Care Laws concerning the types of statements, disclosures, acts, and omissions described in sub-clauses (i), (ii) or (iii) above.
(e) Proceedings; Audits. Except as has been set forth on Schedule 4.19(e) of the Disclosure Letter, there is no Adverse Proceeding pending or, to the Knowledge of such Credit Party, threatened in writing, against any Credit Party or any of its Subsidiaries relating to any allegations of non-compliance with any applicable Health Care Laws, Data Protection Laws, FDA Laws, EU Laws, or U.K. Laws (or foreign equivalents), in each case, to the extent applicable to any Product in the Territory.
(f) Recalls, Safety Notices, Etc. Except as has been set forth on Schedule 4.19(f) of the Disclosure Letter, neither any Credit Party nor any of its Subsidiaries has initiated or otherwise engaged in any recalls, field notifications, safety warnings, “dear doctor” letters, investigator notices, safety alerts or other notices of action, relating to an alleged lack of safety or regulatory compliance of any Product. Except as set forth on Schedule 4.19(f), neither any Credit Party nor any of its Subsidiaries has a reasonable expectation that there are grounds for imposition of a clinical hold or a withdrawal of applicable designations of any Product.
(g) Preclinical Studies / Clinical Trials. All pre-clinical and clinical studies (including trials) relating to any Product conducted by or on behalf of any Credit Party or any of its Subsidiaries have been, or are being, conducted in material compliance with all applicable Requirements of Law. No research involving human subjects (including clinical trials) relating to any Product conducted by or sponsored by any Credit Party or any of its Subsidiaries has been conducted by or supported by any U.S. federal department or agency, and none are subject to regulation under 45 C.F.R. Part 46. Except as set forth on Schedule 4.19(g) of the Disclosure Letter, during the past five (5) years, no clinical study involving any Product conducted by or on behalf of any Credit Party or any of its Subsidiaries has been terminated or suspended by any Regulatory Agency and neither any Credit Party nor any of its Subsidiaries has received any written notice that FDA (or foreign equivalent), any other Governmental Authority or any institutional review board, ethics committee or safety monitoring committee (or foreign equivalent) has recommended, initiated or, to the Knowledge of such Credit Party, threatened to initiate, any action to suspend or terminate any clinical trial conducted by or on behalf of any Credit Party or any of its Subsidiaries or to otherwise materially restrict the preclinical research on or clinical study of any Product. Except as set forth on Schedule 4.19(g) of the Disclosure Letter, no safety or efficacy issues have been raised by a Governmental Authority in the context of a clinical hold (or foreign equivalent) placed on products under development by any Credit Party or any of its Subsidiaries. Except as set forth on Schedule 4.19(g) of the Disclosure Letter, no clinical hold (or foreign equivalent) has been placed on products under development by any Credit Party or any of its Subsidiaries, and no clinical trials undertaken by or on behalf of any Credit Party or any of its Subsidiaries have been terminated.
(h) Advertising/Promotion. Each Credit Party and, to the Knowledge of such Credit Party, each of its Subsidiaries, officers, employees and agents has advertised, promoted, marketed and distributed (in each case, if applicable) any Product in the Territory in compliance in all material respects with FDA Laws and other Requirements of Law. Neither any Credit Party nor any of its Subsidiaries, officers, employees nor, to the Knowledge of any such Credit Party, agents, has received any written notice of or is subject to any civil, criminal or administrative action, suit, demand, claim, complaint, hearing, investigation, demand letter, Warning Letter, Untitled Letter, proceeding or request for information from FDA (or foreign equivalents) or any other Governmental Authority concerning noncompliance with any applicable FDA Laws, or other Requirements of Law, with regard to advertising, promoting, marketing or distributing (including for investigational use) any Product in the Territory.
-37-
(i) Recordkeeping / Reporting. Each Credit Party and, to the Knowledge of such Credit Party, each of its Subsidiaries, has maintained records required to be maintained under any applicable FDA Laws or other applicable Health Care Laws or comparable Requirements of Law, relating to the research, development, testing, manufacture, recall, production, handling, labeling, packaging, storage, supply, promotion, distribution (including for investigational use), marketing, commercialization, import, export or sale of any Product in the Territory in compliance in all material respects with all applicable FDA Laws, applicable Health Care Laws, and other applicable Requirements of Law. Each Credit Party and, to the Knowledge of such Credit Party, each of its Subsidiaries, has submitted to FDA (or foreign equivalents) and other Governmental Authorities (including Regulatory Agencies) in a timely manner all material notices and annual or other material reports required to be made under any applicable FDA Laws or other applicable Health Care Laws or comparable Requirements of Law, including any adverse experience reports, medical device reports, annual reports specific to holders of Orphan Drug designations and safety reports for any Product.
(j) Prohibited Transactions; No Whistleblowers. Except as set forth on Schedule 4.19(j) of the Disclosure Letter, within the past ten (10) years, to the Knowledge of such Credit Party, no Credit Party, Subsidiary, Affiliate or officer or employee of a Credit Party or Subsidiary, nor, to the Knowledge of such Credit Party, any other Person acting on behalf of such Credit Party has (i) offered or paid any remuneration, in cash or in kind, to, or made any financial arrangements with, any past, present or potential patient, supplier, physician or contractor, in order to illegally obtain business or payments from such Person in material violation of any applicable Health Care Law; (ii) given or made, or is party to any illegal agreement to give or make, any illegal gift or gratuitous payment of any kind, nature or description (whether in money, property or services) to any past, present or potential patient, supplier, physician or contractor, or any other Person in material violation of any applicable Health Care Law; (iii) presented, or caused to be presented, a claim for any designated health service pursuant to a referral to an entity from a physician who has (or whose immediate family member has) a financial relationship with that entity, in material violation of any applicable Health Care Law; (iv) given or made, or is party to any agreement to give or make on behalf of any Credit Party or any of its Subsidiaries, any contribution, payment or gift of funds or property to, or for the private use of, any governmental official, employee or agent where either the contribution, payment or gift or the purpose of such contribution, payment or gift is or was a material violation of the laws of any Governmental Authority having jurisdiction over such payment, contribution or gift; (v) established or maintained any unrecorded fund or asset for any purpose or made any materially misleading, false or artificial entries on any of its books or records for any reason; or (vi) made, or is party to any agreement to make, any payment to any Person with the intention or understanding that any part of such payment would be in material violation of any applicable Health Care Law. Except as set forth on Schedule 4.19(j) of the Disclosure Letter, to the Knowledge of such Credit Party, there are no actions pending or threatened (in writing) against any Credit Party or any of its Subsidiaries or any of their respective Affiliates under any foreign, federal or United States state healthcare whistleblower statute, including under the False Claims Act of 1863 (31 U.S.C. § 3729 et seq.).
(k) Exclusion. Except as set forth on Schedule 4.19(k) of the Disclosure Letter, neither any Credit Party nor, to the Knowledge of such Credit Party, any Subsidiary or any officer, employee or Affiliate of a Credit Party or Subsidiary having authority to act on behalf of any Credit Party or any Subsidiary, is or, to the Knowledge of such Credit Party, has been threatened in writing to be (i) debarred, disqualified, suspended or excluded from participation in Medicare, Medicaid or any other Governmental Payor Programs (including pursuant to 42 U.S.C. § 1320a-7 and related statutes and regulations and for violations of 42 U.S.C. § 1320a-7b)) or is listed on the General Services Administration list of excluded parties; (ii) “suspended” or “debarred” from selling any products to the U.S. government or its agencies pursuant to the Federal Acquisition Regulation relating to debarment and suspension applicable to federal government agencies generally (42 C.F.R. Subpart 9.4), or other U.S. Requirements of Law; (iii) debarred by FDA (or foreign equivalent); or (iv) a party to any other action or proceeding by any Governmental Authority that would prohibit the applicable Credit Party or Subsidiary from distributing or selling any Product in the Territory or providing any services to any governmental or other purchaser pursuant to any Health Care Laws.
(l) Health Information. Each Credit Party and, to the Knowledge of such Credit Party, each of its Subsidiaries, to the extent applicable, is in material compliance with all applicable Data Protection Laws. Each Credit Party and, to the Knowledge of such Credit Party, each of its Subsidiaries, to the extent applicable, has implemented all written policies and procedures, and has provided such training for its personnel as are reasonable and customary in the pharmaceutical industry that satisfy in all material respects all applicable Data Protection Laws, and that are otherwise designed to assure continued compliance and to detect non-compliance with applicable Data Protection Laws. Neither any Credit Party, nor any Subsidiary that is not a Credit Party, is a “covered entity” or “business associate” as defined in HIPAA (45 C.F.R. § 160.103).
-38-
(m) Corporate Integrity Agreement. Neither any Credit Party or Subsidiary or any of its controlled Affiliates nor, to the Knowledge of such Credit Party, any of their respective non-controlled Affiliates, officers, directors, managing employees or agents, is, or in the reasonable business judgment of Borrower probably (as defined in ASC 450-20-20) will become within ninety (90) days of the Effective Date or applicable Closing Date, a party to, or has any ongoing reporting or disclosure obligations under, or is otherwise subject to, any order, individual integrity agreement, corporate integrity agreement, monitoring agreement, deferred prosecution agreement, consent decree, corrective action plan, settlement agreement or order or other similar agreements, or any order, in each case imposed by any Governmental Authority concerning compliance with Health Care Laws, rules, or regulations issued under or in connection with Governmental Payor Programs.
4.20 Regulatory Approvals or Licensures.
(a) Except as set forth on Schedule 4.20(a)(i) of the Disclosure Letter, each Credit Party and each Subsidiary thereof involved in research, development, testing, post-approval (or post-licensure, post-authorization, as applicable) monitoring and requirements, manufacture, production, packaging, labeling, use, commercialization, marketing, promotion, advertising, importing, exporting, storage, transport, offer for sale, distribution (including for investigational use) or sale of any Product in the Territory has all Regulatory Approvals or Licensures necessary or material to the conduct of its business as currently conducted. Borrower or one of its Subsidiaries solely and exclusively owns or possesses valid title to or right to use or exploit any and all Regulatory Submission Material owned or purported to be owned by Borrower or any of its Subsidiaries (including without limitation the regulatory exclusivities set forth on Schedule 4.20(a)(ii) of the Disclosure Letter, collectively the “Covered Regulatory Materials”), free and clear of all Liens other than Permitted Liens.
(i) (A) (x) Except as set forth on Schedule 4.20(a)(i)(A) of the Disclosure Letter, each item of Covered Regulatory Materials is valid, subsisting and enforceable, (y) no such item of Covered Regulatory Materials has in any respect lapsed, expired, been cancelled, held unenforceable or held invalidated or become abandoned or unenforceable, and (z) to each Credit Party’s Knowledge, no circumstance or grounds exist that would invalidate or reduce, in whole or in part, the validity, enforceability, subsistence or scope of any such Covered Regulatory Materials, or reduce the use of such Covered Regulatory Materials, by any Credit Party or any of its Subsidiaries, and (B) no written notice has been received by any Credit Party or any of its Subsidiaries challenging the validity or enforceability, or relating to any lapse, expiration, invalidation, cancellation, abandonment or unenforceability, of any such item of Covered Regulatory Materials.
(ii) (A) (x) No Credit Party or any of its Subsidiaries has undertaken or omitted to undertake any acts, and (y) to the Knowledge of such Credit Party in the case of Covered Regulatory Materials, no circumstance or grounds exist, that, in either case of sub-clause (x) or (y) above, would invalidate or reduce, in whole or in part, the enforceability or scope of any Credit Party’s or any of its Subsidiary’s right or entitlement to the Covered Regulatory Materials in any manner that could reasonably be expected to materially adversely affect any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, packaging, labelling, promotion, advertising, offer for sale, distribution (including for investigational use) or sale of any Product in the Territory; and (B) (x) no Credit Party or any of its Subsidiaries has omitted to undertake any acts necessary to maintain, and (y) to the Knowledge of such Credit Party in the case of Covered Regulatory Materials, no circumstances or grounds exist that would impair the validity or, in whole or in part, the enforceability or scope of, in either case of sub-clause (x) or (y) above, any Credit Party’s or any of its Subsidiary’s right or entitlement to the Covered Regulatory Materials in any manner that could reasonably be expected to materially adversely affect any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, packaging, labelling, promotion, advertising, offer for sale, distribution (including for investigational use) or sale of any Product in the Territory.
-39-
(iii) There are no pending or, to the Knowledge of each Credit Party, threatened (in writing) claims against Borrower or any of its Subsidiaries alleging (i) that any research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, packaging, labelling, promotion, advertising, offer for sale, distribution (including for investigational use) or sale of any Product in the Territory infringes or violates (or in the past infringed or violated) any of the rights of any third parties in or to any regulatory filings, submissions, approvals, licensures, and authorizations (“Third-Party Regulatory Materials”), or (ii) that any Covered Regulatory Materials are invalid or unenforceable.
(iv) To the Knowledge of each Credit Party, the manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution (including for investigational use) or sale of any Product in the Territory does not (i) infringe or violate (or in the past infringed or violated) any of the rights of third parties in or to any Third-Party Regulatory Materials, or (ii) constitute (or constituted) a misappropriation of any Third-Party Regulatory Materials.
(v) There are no settlements, covenants not to sue, consents, judgments, orders or similar obligations, in each case, that were undertaken in connection with the avoidance, resolution or disposition of an actual, anticipated or potential Adverse Proceeding (or any actual or potential basis or grounds therefor) which: (i) restrict the rights of any Credit Party or any of its Subsidiaries to use any Covered Regulatory Materials relating to any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, packaging, labeling, promotion, advertising, offer for sale, distribution (including for investigational use) or sale of any Product in the Territory (in order to accommodate any Third-Party Regulatory Materials or otherwise), or (ii) permit any third parties to use or otherwise exploit any Covered Regulatory Materials.
(vi) To the Knowledge of each Credit Party, there is no, nor has there been any, infringement or violation by any Person in the five (5) years prior to the Effective Date of any of the Covered Regulatory Materials or the rights therein.
(vii) (A) Neither any Credit Party nor any Subsidiary, nor, to the Knowledge of such Credit Party, any of their respective agents or representatives, have (i) engaged in any conduct, the result of which would invalidate or render unenforceable or materially reduce, in whole or in part, the validity, enforceability, subsistence or scope of any Covered Regulatory Materials, or (ii) omitted to perform any necessary act to maintain the validity, enforceability, subsistence or scope of any such Covered Regulatory Materials.
(b) Except as set forth on Schedule 4.20(b) of the Disclosure Letter, to the Knowledge of any Credit Party, no event or circumstance (or series of related events or circumstances) has occurred, or, in the reasonable business judgment of such Credit Party, is reasonably likely to occur, that would cause, or could reasonably be expected to cause, (i) the termination of any applicable Regulatory Approvals or Licensures or designations for Product, or (ii) Product to no longer materially meet the requirements of, or criteria for, any applicable Regulatory Approvals or Licensures or designations.
(c) Each Credit Party, and, to the Knowledge of such Credit Party, each Subsidiary thereof, is in compliance with, and at all times during the past five (5) years, has complied with, all applicable foreign, federal, state and local laws, rules and regulations governing any aspect of the research, development, testing, approval, licensure, clearance, authorization, post-approval (or post-licensure, post-authorization, or post-clearance, as applicable) monitoring and requirements, reporting, manufacture, production, packaging, labeling, use, commercialization, designation, exclusivity, marketing, promotion, advertising, importing, exporting, storage, transport, offer for sale, distribution (including for investigational use) or sale of any Product in the Territory, including all such regulations promulgated by each applicable Regulatory Agency (including FDA, the European Commission, the EMA, the competent authorities of the EU Member States or any other foreign equivalents), except where any instance of failure to comply with any such laws, rules or regulations could not, whether individually or taken together with any other such failures, reasonably be expected to result in a Material Adverse Change. Except as set forth on Schedule 4.20(c) of the Disclosure Letter, no Credit Party or its Subsidiaries has received any written notice from any Regulatory Agency citing action or inaction by any Credit Party or any of its Subsidiaries regarding a violation of any applicable foreign, federal, state or local laws, rules, or regulations, including a Warning Letter or Untitled Letter from FDA (or equivalent communication from any other Regulatory Agency).
-40-
4.21 Supply and Manufacturing.
(a) As of the Effective Date and the Tranche A Closing Date, except as set forth on Schedule 4.21(a) of the Disclosure Letter, to the Knowledge of any Credit Party:
(i) each Product has at all times during the past five (5) years been manufactured in sufficient quantities and of a sufficient quality to satisfy demand of such Product in the Territory, without the occurrence of any event or series of related events causing inventory of such Product to have become exhausted prior to satisfying such demand; and
(ii) no event or circumstances (or series of related events or circumstances) has occurred or is occurring that could reasonably be expected to cause (A) any Product to be manufactured in a quantity or of a quality insufficient to satisfy current or future demand of such Product in the Territory or (B) inventory of any Product in the Territory to become or have become exhausted prior to satisfying such demand of such Product in the Territory.
(b) As of the Tranche B Closing Date, except as set forth on Schedule 4.21(b) of the Disclosure Letter, to the Knowledge of any Credit Party:
(i) each Key Product has at all times during the past five (5) years been manufactured in sufficient quantities and of a sufficient quality to satisfy demand of such Key Product in the Territory, without the occurrence of any event or series of related events causing inventory of such Key Product to have become exhausted prior to satisfying such demand; and
(ii) no event or circumstances (or series of related events or circumstances) has occurred or is occurring that could reasonably be expected to cause (A) any Key Product to be manufactured in a quantity or of a quality insufficient to satisfy current or future demand of such Key Product in the Territory, or (B) inventory of any Key Product in the Territory to become or have become exhausted prior to satisfying such demand of such Key Product in the Territory;
(c) As of the Effective Date and each Closing Date, except as set forth on Schedule 4.21(c) of the Disclosure Letter, to the Knowledge of any Credit Party, no event or circumstances (or series of related events or circumstances) has occurred or is occurring that could reasonably be expected to cause any Product in the Territory not to be manufactured in any calendar year in sufficient quantities to satisfy the expected needs of patients with the disease or condition for which such Product was designated as an Orphan Drug for such calendar year, as reasonably determined by a Responsible Officer of Borrower in good faith (provided such calendar year occurs during the full 7-year term of orphan drug exclusive approval granted for any Product under 21 C.F.R. § 316.34);
(d) Except as set forth on Schedule 4.21(d) of the Disclosure Letter, to the Knowledge of any Credit Party, (i) no manufacturer (including a contract manufacturer) or producer of, or licensing partner of or for any Product has been for the last five (5) years or is currently subject to a material Regulatory Agency shutdown or voluntary shutdown (other than shutdowns for routine maintenance), material restriction, or import or export prohibition, (ii) no manufacturer (including a contract manufacturer) or producer of, or licensing partner of any Product has received in the last five (5) years a Form 483 with respect to or otherwise impacting such Product or is currently subject to (1) a Form 483, (2) other written Regulatory Agency notice of inspectional observations (other than routine inspections) with respect to such Product, Warning Letter, Untitled Letter or other correspondence requiring changes to be made to such Product that could reasonably be expected to, impact such Product, in either case of sub-clause (1) or (2) above with respect to any facility manufacturing such Product for import, export, distribution (including for investigational use) or sale in the Territory, and (iii) with respect to each such Form 483 received (if any) or other similar written Regulatory Agency notice (if any), all violations or other observations relating to FDA Good Manufacturing Practice requirements, or foreign equivalents, documented therein, and any disputes regarding any such violations or issues, have been corrected or otherwise resolved.
(e) Except as disclosed in Schedule 4.21(d) of the Disclosure Letter, no Credit Party or any of its Subsidiaries has received any written or, to the Knowledge of such Credit Party, other notice from any party to any Manufacturing Agreement containing any indication by or intent or threat of, such party to reduce or cease, in any material respect, the supply of any Product in the Territory or the materials (including raw materials), components (including component raw materials and other component materials), or any other element needed to fulfill its contractual obligations related to such Product for the Territory in any Manufacturing Agreement through calendar year 2031 (or such earlier date in accordance with the terms and conditions of such Manufacturing Agreement, as applicable).
-41-
4.22 Cybersecurity and Data Protection.
(a) Systems. Except as set forth in Schedule 4.22(a) of the Disclosure Letter, to the Knowledge of any Credit Party, the information technology systems (including software, hardware and related infrastructure) used in, and the operational technology systems (including industrial control systems) and related infrastructure material to, the business of each of Borrower and its Subsidiaries, including any technology systems made available by Borrower or any of its Subsidiaries to any medical partners, physicians, patients, payors, patient assistance programs, or other third parties in connection with any Product (altogether, “Systems”), operate and perform in all material respects as required to permit each of Borrower and its Subsidiaries to conduct their respective businesses as presently conducted in the Territory. Each of Borrower and its Subsidiaries has implemented and maintains commercially reasonable administrative, physical, and technical security controls and safeguards designed to protect the confidentiality, integrity, availability, and security of Sensitive Information and the Systems. To the Knowledge of such Credit Party, no System contains any material ransomware, disabling codes or instructions, spyware, Trojan horses, worms, viruses or other software routines that are designed or intended to delete, destroy, disable, disrupt, impair, interfere with, perform unauthorized modifications to, or provide unauthorized access to, any data, files, software, system, network or other device. Borrower and its Subsidiaries have and maintain commercially reasonable back-up systems designed to provide continuing availability of the material functionality provided by the Systems in the event of any malfunction of, or other event interrupting access to or the functionality of, such Systems. Except as set forth in Schedule 4.22(a) of the Disclosure Letter, Borrower and each of its Subsidiaries use commercially reasonable efforts to maintain System security, including promptly implementing, or requiring service providers responsible for System maintenance to promptly implement, material security patches that are generally available for the Systems, as applicable.
(b) Security Program. Except as set forth in clause (e) of Schedule 5.14 of the Disclosure Letter, Borrower and each of its Subsidiaries has implemented and maintains a commercially reasonable, enterprise-wide privacy and information security program, with plans, policies, procedures, and training for privacy and physical and cyber security (altogether, “Security Program”). The Security Program includes commercially reasonable and appropriate administrative, technical, and physical safeguards designed to protect the confidentiality, integrity, availability, and security of the Systems, consistent with generally accepted practices in the pharmaceutical industry of companies of the Borrower’s size and maturity, and designed to protect against:
(i) unauthorized, accidental, or unlawful access to or acquisition, use, disclosure, transmission, retention, processing, loss, destruction, corruption, exfiltration, interception, encryption, manipulation, erasure, unavailability, or modification of Personal Data (each, a “Personal Data Breach”) or any other Sensitive Information; and
(ii) any security incident (including cyber-attacks, ransomware, malware, denial-of-service attacks, credential compromise, business email compromise, and phishing schemes such as spear phishing or voice- or text-based phishing through any mode of communication) that would, or would reasonably be expected to, result in unauthorized, accidental, or unlawful access to or acquisition, use, control, disruption, destruction, encryption, impairment, unavailability, degradation, compromise, or modification of any of the Systems, or that would, or would reasonably be expected to, result in other losses or liabilities, to the extent that such security incident could reasonably be expected to result in a material and adverse effect on the operation of Borrower’s or any of its Subsidiaries’ business operations as currently conducted (sub-clauses (i) and (ii) above, collectively, “Security Incidents”);
(c) Audits and Testing. Except as set forth on Schedule 4.22(c) of the Disclosure Letter, Borrower and each of its Subsidiaries have conducted commercially reasonable efforts to verify that their respective service providers, that access, process or store Sensitive Information on their Systems, maintain effective control environments with independent audits and issue-related SOC 2 reports.
-42-
(d) Diligence. Except as set forth on Schedule 4.22(d) of the Disclosure Letter, Borrower and each of its Subsidiaries have conducted commercially reasonable privacy and data security diligence, consistent with generally accepted practices, on all applicable service providers and other third parties that (i) collect, create, receive, access, maintain, store, or otherwise process Sensitive Information for or on behalf of Borrower or any of its Subsidiaries, or (ii) access or maintain the Systems.
(e) Security Incidents. Except as set forth on Schedule 4.22(e) of the Disclosure Letter, to the Knowledge of Borrower, neither Borrower nor any of its Subsidiaries nor any service provider (in the course of providing services for or on behalf of Borrower or any of its Subsidiaries), have in the past five (5) years suffered any Security Incidents which, individually or together with any other Security Incidents, could reasonably be expected to have a material and adverse effect on Borrower’s or any of its Subsidiaries’ business (including, but not limited to, causing a material disruption of development, manufacturing, or commercialization programs relating to any Product).
(f) Compliance. Except as set forth on Schedule 4.22(f) of the Disclosure Letter, Borrower and each of its Subsidiaries is in material compliance with the requirements of (i) their respective Security Programs, (ii) their respective contractual obligations regarding confidentiality, privacy, security, or notification of breaches of Personal Data, (iii) their respective publicly available privacy notices and policies; and (iv) PCI DSS, as applicable.
(g) Claims. Except as set forth on Schedule 4.22(g) of the Disclosure Letter, in the past five (5) years: (i) neither Borrower nor any of its Subsidiaries has received any written third-party claims or, to the Knowledge of such Credit Party, any threat (in writing) of a third-party claim, related to any Personal Data Breaches or other Security Incidents; and (ii) neither Borrower nor any of its Subsidiaries has received any written notice of any claims, actions, fines, penalties, or investigations (including investigations by any Governmental Authority) relating to any Personal Data Breaches or other Security Incidents, except, in each case of sub-clauses (i) and (ii) above as could not reasonably be expected to be material to Borrower and its Subsidiaries, taken as a whole.
(h) Artificial Intelligence Tools. Borrower and each of its Subsidiaries has established, maintained, and enforced industry-standard policies and procedures for the use of artificial intelligence and automated decision-making technology by such Borrower’s or Subsidiary’s employees, agents, and contractors.
4.23 Additional Representations and Warranties.
(a) As of the Effective Date and the Tranche A Closing Date, except as set forth on Schedule 4.23(a) of the Disclosure Letter, after giving effect to consummation of the transactions contemplated by this Agreement, there is no Indebtedness for borrowed money owed to Borrower or any of its Subsidiaries other than Permitted Indebtedness or Permitted Investments, or owed by Borrower or any of its Subsidiaries, other than Permitted Indebtedness (including, for the avoidance of doubt, Permitted Indebtedness then-outstanding under the 2030 Convertible Notes (and the Indenture)).
(b) As of each Closing Date other than the Tranche A Closing Date, there is no Indebtedness for borrowed money (x) owed to Borrower or any of its Subsidiaries other than Permitted Indebtedness or Permitted Investments, or (y) owed by Borrower or any of its Subsidiaries other than Permitted Indebtedness (including, for the avoidance of doubt, Permitted Indebtedness then-outstanding under the 2030 Convertible Notes (and the Indenture)).
(c) As of the Effective Date and Tranche A Closing Date, except as set forth on Schedule 4.23(c) of the Disclosure Letter, neither Borrower nor any of its Subsidiaries are party to, or otherwise bound by, any Hedging Agreements.
(d) As of any Closing Date other than the Tranche A Closing Date, neither Borrower nor any of its Subsidiaries are party to, or otherwise bound by, any Hedging Agreements, except for Hedging Agreements expressly permitted by this Agreement.
-43-
(e) Except as has been disclosed in the Exchange Act Documents, as of the Effective Date and each Closing Date, there is no registration rights agreement, investors’ rights agreement or other similar agreement relating to, governing or otherwise affecting the ownership of any Equity Interest that is required to be pledged pursuant to the Collateral Documents.
(f) As of the Effective Date and each Closing Date, there is no Indebtedness owed by Borrower or any of its Subsidiaries that (i) conflicts with or results in any breach or contravention of, any of the terms or conditions set forth in this Agreement, (ii) adversely affects, or could reasonably be expected to adversely affect, the payment of any amounts owing under this agreement or any other Loan Document, or (iii) adversely affects, or could reasonably be expected to adversely affect, the perfection or priority of any Liens on or security interests in any Collateral pledged or granted (or purported to be pledged or granted) to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, pursuant to the Loan Documents.
(g) As of the Effective Date and each Closing Date, there is no guaranty or other similar obligation of Borrower or any of its Subsidiaries pursuant to or otherwise in connection with the 2030 Convertible Notes (or the Indenture), and there are no Liens on or security interests in any assets or properties of Borrower or any of its Subsidiaries securing the payment of any Indebtedness under the 2030 Convertible Notes (or the Indenture).
4.24 Permitted Royalty Agreement; Permitted Royalty Financing; Permitted Other Royalty Financing; Permitted Acquisition Royalty Documents.
(a) As of the Effective Date, except as set forth on Schedule 4.24(a) of the Disclosure Letter, neither Borrower nor any of its Subsidiaries is obligated to pay any royalty, revenue participation, milestone payment, deferred payment or any other contingent payment in respect of any Product except pursuant to the Permitted Royalty Agreements and the other Permitted Royalty Agreement Documents.
(b) As of any Closing Date, except as set forth on Schedule 4.24(a) of the Disclosure Letter, neither Borrower nor any of its Subsidiaries is obligated to pay any royalty, revenue participation, milestone payment, deferred payment or any other contingent payment in respect of any Product except pursuant to the Permitted Royalty Agreements and the other Permitted Royalty Agreement Documents, or pursuant to any Permitted Royalty Financing Agreements or other Permitted Royalty Financing Documents, or pursuant to any Permitted Other Royalty Financing Agreements or other Permitted Other Royalty Financing Documents, or pursuant to any Permitted Acquisition Royalty Agreements or other Permitted Acquisition Royalty Documents, as applicable.
(c) As of the Effective Date, except as set forth on Schedule 4.24(c) of the Disclosure Letter, there are no disputes between Borrower or any of its Subsidiaries, on the one hand, and any counterparty, on the other hand, under any Permitted Royalty Agreement Document that has not been completely resolved.
(d) As of any Closing Date, except as set forth on Schedule 4.24(c) of the Disclosure Letter, there are no disputes between Borrower or any of its Subsidiaries, on the one hand, and any counterparty, on the other hand, under any Permitted Royalty Agreement Document, or any Permitted Royalty Financing Document, or any Permitted Other Royalty Financing Document, or any Permitted Acquisition Royalty Document, as applicable, that has not been completely resolved.
5. AFFIRMATIVE COVENANTS
Each Credit Party covenants and agrees that until payment in full of all Obligations (other than contingent indemnification and reimbursement obligations to the extent no claims giving rise thereto have been asserted), each Credit Party shall, and shall cause each of its Subsidiaries to:
5.1 Maintenance of Existence.
(a) Preserve, renew and maintain in full force and effect its and all its Subsidiaries’ legal existence under the Requirements of Law in their respective jurisdictions of organization, incorporation or formation (other than as otherwise expressly permitted under Section 6.2(a)); (b) take all commercially reasonable action to maintain all rights, privileges (including its good standing (to the extent the concept is applicable in such jurisdiction)), permits, licenses and franchises necessary or desirable for it and all of its Subsidiaries in the ordinary course of its business, except in the case of clause (a) (other than with respect to Borrower) and clause (b) above, (i) to the extent that failure to do so could not reasonably be expected to result in a Material Adverse Change or (ii) pursuant to a transaction permitted by this Agreement; and (c) comply with all Requirements of Law of any Governmental Authority to which it is subject, except where the failure to do so could not reasonably be expected to result, individually or in the aggregate, in a Material Adverse Change.
-44-
5.2 Financial Statements, Notices. Deliver to the Collateral Agent:
(a) Financial Statements.
(i) Annual Financial Statements. Within ninety (90) days after the end of each fiscal year of Borrower (or such earlier date on which Borrower is required to file a Form 10-K under the Exchange Act, as applicable), beginning with the fiscal year ending December 31, 2026, a consolidated balance sheet of Borrower and its Subsidiaries, as of the end of such fiscal year, and the related consolidated statements of income, cash flows and stockholders’ equity for such fiscal year, setting forth in each case, certified by the Chief Financial Officer of Borrower, in comparative form the figures for the previous fiscal year, all prepared in accordance with GAAP, with such consolidated financial statements to be audited and accompanied by (x) a report and opinion of Ernst & Young LLC or other independent certified public accounting firm of recognized national standing (which report and opinion shall be prepared in accordance with GAAP and shall not be subject to any qualification as to “going concern” or “scope of audit,” stating that such financial statements fairly present, in all material respects, the consolidated financial condition, results of operations and cash flows of Borrower and its Subsidiaries as of the dates and for the periods specified in accordance with GAAP), and (y) if and only if Borrower is required to comply with the internal control provisions pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 requiring an attestation report of such independent certified public accounting firm, an attestation report of such independent certified public accounting firm as to Borrower’s internal controls pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 attesting to management’s assessment that such internal controls meet the requirements of the Sarbanes-Oxley Act of 2002;
(ii) Quarterly Financial Statements. Within forty-five (45) days after the end of each of the first three (3) Fiscal Quarters of each fiscal year of Borrower (or such earlier date on which Borrower is required to file a Form 10-Q under the Exchange Act, as applicable), beginning with respect to the Fiscal Quarter ending September 30, 2026, a consolidated balance sheet of Borrower and its Subsidiaries, as of the end of such Fiscal Quarter, and the related consolidated statements of income and cash flows and for such Fiscal Quarter and (in respect of the second and third Fiscal Quarters of such fiscal year) for the then-elapsed portion of Borrower’s fiscal year, setting forth in each case in comparative form the figures for the comparable period or periods in the previous fiscal year, all prepared in accordance with GAAP, subject to normal year-end audit adjustments and the absence of disclosures normally made in footnotes;
(iii) Quarterly Compliance Certificate. Upon delivery (or within five (5) Business Days following any deemed delivery) of financial statements pursuant to Section 5.2(a)(i) or Section 5.2(a)(ii), a duly completed Compliance Certificate signed by the Chief Financial Officer of Borrower, certifying, among other things, that (A) such financial statements fairly present, in all material respects, the consolidated financial condition, results of operations and cash flows of Borrower and its Subsidiaries as of the applicable dates and for the applicable periods in accordance with GAAP consistently applied and are not subject to any qualification or statement as to “going concern” or “scope of audit,” and (B) no Event of Default or Default has occurred or, if such an Event of Default or Default has occurred, specifying the nature and extent thereof and any corrective action taken or proposed to be taken with respect thereto; and
(iv) Other Information. Within five (5) Business Days after the reasonable request of the Collateral Agent therefor, such additional information regarding the operations, properties, business, liabilities or condition (financial or otherwise) of Borrower and its Subsidiaries (including with respect to the Collateral), or compliance with the terms of this Agreement or any other Loan Documents, in each case in a form reasonably acceptable to the Collateral Agent; provided, that, Borrower shall not be obligated to disclose any information that is restricted by Requirements of Law or contractual agreement with a third-party (so long as such contractual restriction was not agreed to for the specific purpose of preventing disclosure under this Agreement) or that is subject to the attorney-client privilege or constitutes attorney work product.
-45-
(b) Notice of Defaults or Events of Default, ERISA Events, Withdrawal Events and Material Adverse Changes. Written notice as promptly as practicable (and in any event within five (5) Business Days) after a Responsible Officer of any Credit Party shall have obtained Knowledge of (i) the receipt by Borrower or any of its Subsidiaries of any written notice from FDA or any other Regulatory Agency of a pending recommendation or a final decision to withdraw marketing authorization for any Product in the Territory, or (ii) the occurrence of, or the occurrence of any event which could reasonably be expected to result in, any (x) Default or Event of Default (including, for the avoidance of doubt, any Withdrawal Event or Material Adverse Change) or (y) ERISA Event.
(c) Legal Action Notice. Promptly (and in any event within five (5) Business Days) upon any Credit Party’s receipt or otherwise obtaining Knowledge thereof, written notice (which shall be deemed given to the extent timely reported in a Form 8-K under the Exchange Act and available on the SEC’s EDGAR system (or any successor system adopted by the SEC), provided, however, that such notice shall be deemed to have been so given with respect to additional information the Collateral Agent may reasonably request only if it includes such additional information) of: (i) correspondence received from the SEC (or comparable agency in any applicable foreign jurisdiction) concerning any investigation or possible investigation or other material inquiry by such agency regarding financial or other operational results of Borrower or any Subsidiary of Borrower; or (ii) any legal action, litigation, investigation or proceeding pending or threatened in writing against Borrower or any of its Subsidiaries or any material out-licensing partners (A) that could reasonably be expected to result in uninsured damages or costs to Borrower or any of its Subsidiaries in an amount in excess of the materiality thresholds applied by Borrower in accordance with the Exchange Act and related regulations and standards for purposes of its Exchange Act reporting or (B) that alleges violations of any Health Care Laws, FDA Laws, EU Laws, U.K. Laws, Data Protection Laws or any other applicable statutes, rules, regulations, standards, guidelines, policies and orders, or applicable foreign equivalents, administered or issued by any U.S. or foreign Governmental Authority, in each case of sub-clause (i) or (ii) above, which, individually or together with any other such allegations, could reasonably be expected to result in a Material Adverse Change; and in each case of sub-clause (i) or (ii) above, provide such additional information (including a description in reasonable detail regarding any material development) as the Collateral Agent may reasonably request in relation thereto; provided, however, that neither Borrower nor any other Credit Party shall be obligated to disclose any information that is reasonably subject to the assertion of attorney-client privilege or attorney work-product.
(d) Accounting Changes. Written notice within five (5) Business Days after any material change in accounting policies or financial reporting practices by Borrower or any Subsidiary.
(e) Material Statements and Reports.
(i) Promptly (and in no event later than ten (10) Business Days) after entering into the same, copies of any Permitted Royalty Financing Agreement or other Permitted Royalty Financing Documents, any Permitted Other Royalty Financing Agreements or other Permitted Other Royalty Financing Documents, or any Permitted Acquisition Royalty Agreement or other Permitted Acquisition Royalty Documents (and any amendments, restatements, amendment and restatements, supplements, modifications, consents, approvals or waivers to or otherwise in respect thereof), including a description in reasonable detail regarding any fees or payments made (or contemplated to be made) in connection therewith);
(ii) Promptly (and in no event later than ten (10) Business Days) after the furnishing thereof, copies of any material written statement or report or other material written correspondence furnished to counterparties pursuant to any Permitted Royalty Financing Document, or any Permitted Other Royalty Financing Document, or any Permitted Acquisition Royalty Document (it being understood and agreed that any statement, report or correspondence in relation to payments under any Permitted Royalty Financing Document, Permitted Other Royalty Financing Document or a Permitted Acquisition Royalty Document is material);
(iii) Promptly (and in no event later than ten (10) Business Days) after the receipt thereof, written notice of any accrual or payment of interest pursuant to any Permitted Royalty Financing Document or any Permitted Acquisition Royalty Document (including a description in reasonable detail regarding the underlying payment(s) in respect of which such interest has accrued or been paid);
-46-
(iv) Promptly (and in no event later than ten (10) Business Days) after obtaining Knowledge thereof, written notice of any assignment of any party’s obligations or rights under any Permitted Royalty Financing Agreement, or any Permitted Other Royalty Financing Agreement or any Permitted Acquisition Royalty Document, or of any acquisition of any interest in any counterparty’s rights under any Permitted Royalty Financing Agreement or any Permitted Other Royalty Financing Agreement or any Permitted Acquisition Royalty Document;
(v) Prompt written notice of any Credit Party’s obtaining Knowledge of any termination, in whole or in part, of any Permitted Royalty Financing Agreement, or any Permitted Other Royalty Financing Document or any Permitted Acquisition Royalty Document (including a description in reasonable detail regarding the rationale for such termination);
(vi) Promptly (and in no event later than ten (10) Business Days) after the furnishing thereof, copies of any material statement or report furnished to any holder of debt securities of Borrower or any of its Subsidiaries (including the 2030 Convertible Notes and the Working Capital Indebtedness) pursuant to the terms of any indenture (including the Indenture), loan or credit or similar agreement;
(vii) Within ten (10) Business Days after the request therefor by the Collateral Agent, copies of any material statement or report furnished to any holder of Permitted Indebtedness of Borrower or any of its Subsidiaries (other than any Permitted Indebtedness described in sub-clause (vi) above); and
(viii) Promptly (and in no event later than ten (10) Business Days) after the receipt thereof, copies of any Refuse-to-File (RTF) notification or Complete Response Letter (CRL) received from FDA (or similar notice or letter from any foreign equivalent) relating to any Product.
(f) Permitted Royalty Agreement.
(i) Prompt written notice of any Credit Party’s obtaining Knowledge of (A) any assignment of any counterparty’s obligations, rights, interests or benefits under any Permitted Royalty Agreement or any other Permitted Royalty Agreement Document to which Borrower or any of its Subsidiaries is a party, or (B) any acquisition of any interest in any of any counterparty’s rights, interests or benefits under any Permitted Royalty Agreement or any other Permitted Royalty Agreement Document to which Borrower or any of its Subsidiaries is a party, in either case together with a copy of any joinder or other agreement pursuant to which such assignee or acquirer agrees to be bound by the terms and obligations set forth in such Permitted Royalty Agreement;
(ii) Within ten (10) Business Days after entering into the same, copies of any amendments, restatements, amendment and restatements, supplements, modifications, consents, approvals or waivers to or otherwise in respect of any Permitted Royalty Agreement or any other Permitted Royalty Agreement Document, in each case that would (A) change the calculation or time of any Permitted Royalty Agreement Payment pursuant thereto, including any change to the basis or manner for calculating any late or overdue Permitted Royalty Agreement Payments (including any fees or interest payments thereon), (B) change any of the terms of any obligations thereunder with respect to any Permitted Royalty Agreement Payments, including any change to Borrower’s or any Subsidiary’s obligations to make any Permitted Royalty Agreement Payment relating to the occurrence of a change of control of Borrower or such Subsidiary, the termination of the Permitted Royalty Agreement or any other Permitted Royalty Agreement Document or if a specified amount of Permitted Royalty Agreement Payments are not received by a specified date by any counterparty, (C) contravene in any respect any of the terms or conditions set forth in Section 6.10 or Section 6.14(c), or (D) obligate Borrower or any of its Subsidiaries to make (or exercise any option with respect thereto), directly or indirectly through a Subsidiary, any payment or reimbursement of any kind to any counterparty pursuant to any Permitted Royalty Agreement or other Permitted Royalty Agreement Document other than Permitted Royalty Agreement Payments;
-47-
(iii) Within ten (10) Business Days of the making thereof, notice specifying in reasonable detail any (A) fees or payments made to any counterparty in connection with any amendment, restatement, amendment and restatement, supplement, modification, consent, approval or waiver to or otherwise in respect of any Permitted Royalty Agreement or any other Permitted Royalty Agreement Document or (B) any fees, payments or reimbursement made to any counterparty, including underpayments made by Borrower or any of its Subsidiaries following an audit, other than (1) reimbursements or payments to accounting firms and (2) Permitted Royalty Agreement Payments;
(iv) Within ten (10) Business Days after the furnishing thereof, copies of each material written report furnished to any counterparty pursuant to any Permitted Royalty Agreement or any other Permitted Royalty Agreement Document and any other written correspondence furnished to any counterparty or to Borrower or any of its Subsidiaries in connection with any such reports (it being understood and agreed that any statement, report or correspondence in relation to payments under a Permitted Royalty Agreement Document is material);
(v) Prompt written notice of any Credit Party’s obtaining Knowledge of any termination, in whole or in part, of any Permitted Royalty Agreement or any other Permitted Royalty Agreement Document (including a description in reasonable detail regarding the rationale for such termination); and
(vi) Within ten (10) Business Days thereof, notice of any accrual or payment of interest pursuant to any Permitted Royalty Agreement (including a description in reasonable detail regarding the underlying payment(s) in respect of which such interest has accrued or been paid).
(g) Sanctions and Anti-Money Laundering Laws Requirements.
(i) Credit Party Information. Promptly upon written request by the Collateral Agent or any Lender therefor, information and documentation that identifies each Credit Party and its principals and includes the legal name and address of each Credit Party and its principals and such other reasonably requested information that will allow the Collateral Agent and each Lender to identify each such party in accordance with Sanctions and Anti-Money Laundering Laws.
(ii) Blocked Person Notice. Notification to the Collateral Agent and each Lender in writing promptly (but in any event within three (3) Business Days) upon any Responsible Officer of any Credit Party becoming aware that any Credit Party or any Subsidiary or Affiliate of any Credit Party is a Blocked Person.
(h) Notice of Strategic Marketing Suspension or Cessation. Written notice promptly (and in any event within ten (10) Business Days) after the commencement thereof of a Strategic Marketing Suspension or Cessation with respect to any Key Product.
Notwithstanding the foregoing, any documents, materials, notices or other information, that Borrower, any Credit Party or any Subsidiary of Borrower is required to deliver under Sections 5.2(a)(i), (a)(ii), (b), (c), (d), (e) and (f) above shall be deemed to have been made if such item shall have been made available within the time period specified above on the SEC’s EDGAR system (or any successor system adopted by the SEC), provided, however, that in the case of any notice required to be delivered under Section 5.2(c) above, such notice shall be deemed to have been so made with respect to additional information the Collateral Agent may reasonably request only if it includes such additional information.
5.3 Taxes. Timely file (taking into account valid extensions) all required income and other material Tax returns and reports or extensions therefor and timely pay all Taxes, assessments, deposits and contributions imposed upon it or any of its properties or assets or in respect of any of its income, businesses or franchises before any penalty or fine accrue thereon; provided, however, that no such Tax or any claim for Taxes that has become due and payable and has or may become a Lien on any Collateral shall be required to be paid if (a) it is being contested in good faith by appropriate proceedings promptly instituted and diligently conducted, so long as adequate reserves therefor have been set aside on its books and maintained in conformity with GAAP, (b) solely in the case of a Tax or claim that has or may become a Lien against any Collateral, such contest proceedings conclusively operate to stay the sale or forfeiture of any portion of any Collateral to satisfy such Tax or claim, or (c) the failure to pay such Taxes, individually or in the aggregate, does not result or could not reasonably be expected to result in a Material Adverse Change.
-48-
5.4 Insurance. Maintain with financially sound and reputable independent insurance companies or underwriters, insurance with respect to its properties and business against loss or damage of the kinds customarily insured against by Persons of comparable size engaged in the same or similar business, of such types and in such amounts (after giving effect to any self-insurance reasonable and customary for similarly situated Persons of comparable size engaged in the same or similar businesses as Borrower and its Subsidiaries) as are customarily carried under similar circumstances by such other Persons. For the avoidance of doubt, this includes cyber liability insurance. Subject to the timing requirements of Section 5.14 (solely with respect to any such policies in effect as of the First Closing Date), any products liability or general liability insurance maintained in the United States regarding Collateral shall name the Collateral Agent, on behalf of the Lenders and the other Secured Parties, as additional insured or loss payee, as applicable (the additional insured clauses or endorsements for which, in form and substance reasonably satisfactory to the Collateral Agent). So long as no Event of Default shall have occurred and be continuing, with respect to the Borrower’s and its Subsidiaries’ property and general liability policies, and at all times with respect to any other policies (including any product liability policies) the Borrower and its Subsidiaries may retain all or any portion of the proceeds of any such insurance of the Borrower and its Subsidiaries (and the Collateral Agent and each Lender shall promptly remit to Borrower any proceeds received by it with respect to any such insurance).
5.5 Operating Accounts.
(a) In the case of any Credit Party, following the establishment of any new Collateral Account at or with any bank or other depository or financial institution located in (i) the United States, subject such account to a Control Agreement or other appropriate instrument that is reasonably acceptable to the Collateral Agent, within the time period provided in the following sentence, and (ii) any jurisdiction other than the United States, comply with requirements set forth in the applicable Collateral Document in relation to Collateral Accounts in such jurisdiction. For each Collateral Account that each Credit Party at any time maintains in the United States, such Credit Party shall, within forty-five (45) days (plus an additional fifteen (15) days so long as such Credit Party is using reasonable good faith efforts) (or such later time as the Collateral Agent may agree in writing in its sole discretion) of establishing such Collateral Account, cause the applicable bank or other depository or financial institution located in the United States, at or with which any Collateral Account is maintained to execute and deliver, and such Credit Party shall execute and deliver, to the Collateral Agent, a Control Agreement or other appropriate instrument with respect to such Collateral Account to perfect the Collateral Agent’s Lien, for the benefit of Lenders and the other Secured Parties, in such Collateral Account in accordance with the terms hereunder, which Control Agreement may not be terminated by any Credit Party without the prior written consent of the Collateral Agent.
(b) The provisions of the previous clause (a) shall not apply to (1) accounts exclusively used for payroll, payroll Taxes and other employee wage and benefit payments to or for the benefit of any Credit Party’s employees, (2) zero balance accounts, provided, that, within two (2) Business Days of any deposit made into any such zero balance account, such deposit is swept in full to an account subject to a Control Agreement, (3) accounts (including trust accounts) used exclusively for escrow, customs, insurance or fiduciary purposes, (4) merchant accounts, (5) accounts used exclusively for compliance with any Requirements of Law to the extent such Requirements of Law prohibit the granting of a Lien thereon, (6) accounts which constitute cash collateral in respect of a Permitted Lien, (7) any other account established and maintained in the ordinary course of business or in furtherance of a bona fide general corporate purpose and designated as an Excluded Account by a Responsible Officer of Borrower in writing delivered to the Collateral Agent, the cash balance of which, individually or together with all other such accounts excluded pursuant to this sub-clause (7), does not exceed $5,000,000 at any time, provided, that, if the cash balance of such account, individually or together with all other such accounts excluded pursuant to this sub-clause (7), exceeds $5,000,000 at any time, (x) such account shall no longer be deemed to be an Excluded Account hereunder as of such time, with the effect that the accounts which remain as Excluded Accounts pursuant to sub-clause (7) are in compliance with the requirements for exclusion under sub-clause (7), and (y) such account shall be deemed to be a Collateral Account on such date and Borrower shall comply with the requirements of this Section 5.5 with respect to such account as if such account was established as of such date, and (8) accounts not otherwise described in sub-clauses (1) through (7) above constituting Excluded Property (all such accounts in sub-clauses (1) through (8) above, collectively, the “Excluded Accounts”).
-49-
(c) Notwithstanding the foregoing, the Credit Parties shall have until the date that is forty-five (45) days (plus an additional fifteen (15) days (or such later time as the Collateral Agent may agree in writing in its sole discretion) so long as such Credit Party is using reasonable good faith efforts) following the closing date of any Acquisition or other Investment, to comply with the provisions of this Section 5.5 with regards to Collateral Accounts (other than Excluded Accounts) of the Credit Parties acquired in connection with such Acquisition or other Investment.
5.6 Compliance with Laws.
(a) Comply, and use commercially reasonable efforts to ensure that licensing partners comply (such efforts to be limited to requiring by contract such licensing partners to comply), in all respects with the Requirements of Law and all orders, writs, injunctions, decrees and judgments applicable to it or to its business or its assets or properties (including applicable Environmental Laws, ERISA, Health Care Laws, FDA Laws, Data Protection Laws, the Federal Fair Labor Standards Act, EU Laws, and any foreign equivalents thereof), including in connection with governing any aspect of the research, development, testing, approval, licensure, clearance, authorization, exclusivity, licensure, designation, post-approval (or post-licensure, post-authorization, or post-clearance, as applicable) monitoring or commitments, reporting, (including post-marketing safety reports, if any), manufacture, production, packaging, labeling, use, commercialization, marketing, promotion, advertising, importing, exporting, storage, transport, offer for sale, distribution (including for investigational use) or sale of any Product in the Territory, except, in each case, if the failure to comply therewith individually or taken together with any other such failures, could not reasonably be expected to result in a Material Adverse Change.
(b) Subject to Schedule 4.18(d) of the Disclosure Letter, implement and maintain policies and procedures reasonably designed to ensure compliance with applicable Sanctions, Anti-Money Laundering Laws, Export and Import Laws, Anti-Corruption Laws, Health Care Laws, Data Protection Laws and PCI DSS (as applicable). Comply with all Sanctions, Anti-Money Laundering Laws, Export and Import Laws and Anti-Corruption Laws.
5.7 Protection of Intellectual Property Rights.
(a) Except as expressly permitted under clause (b) below or with respect to the Company IP set forth on Schedule 4.6(g) of the Disclosure Letter, use commercially reasonable efforts to:
(i) protect, defend and maintain the validity and enforceability of Company IP material to any aspect of the research, development, manufacture, production, use, commercialization, marketing, import, storage, transport, offer for sale, distribution or sale of any Product in the Territory, including defending any future or current oppositions, interference proceedings, reissue proceedings, reexamination proceedings, inter partes review proceedings, derivative proceedings, post-grant review proceedings, cancellation proceedings, injunctions, lawsuits, paragraph IV patent certifications or lawsuits under the Hatch-Waxman Act, hearings, investigations, complaints, arbitrations, mediations, demands, International Trade Commission investigations, decrees, or any other disputes, disagreements, or claims, challenging the legality, validity, patentability, enforceability, inventorship or ownership of any such Company IP;
(ii) (A) maintain the confidential nature of any material trade secrets and material trade secret rights used in any aspect of the research, development, manufacture, production use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of any Key Product in the Territory, and (B) maintain the confidential nature of any material trade secrets and trade secret rights material to any material aspect of the research, development, manufacture, production use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of any other Product in the Territory;
-50-
(iii) not allow any Company IP material to any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of any Product in the Territory, to be abandoned, disclaimed, forfeited or dedicated to the public (other than in accordance with its statutory term or the exercise of the Credit Parties’ normal prosecution practices and reasonable business judgment, e.g., the abandonment of a continuation application that is no longer needed to maintain the pendency of another patent application) or allow any Company IP Agreement to be terminated by any Credit Party or any of its Subsidiaries, as applicable, without the Collateral Agent’s prior written consent (such consent not to be unreasonably withheld, conditioned or delayed);
provided, however, that with respect to any such Company IP that is not owned by a Credit Party or any of its Subsidiaries, the obligations in sub-clauses (i) and (iii) above shall apply only to the extent a Credit Party or any of its Subsidiaries have the right to take such actions or to cause any licensee or other third-party to take such actions pursuant to applicable agreements or contractual rights.
(b) Except as a Credit Party may otherwise determine in its reasonable business judgment: (i) use commercially reasonable efforts, either directly or indirectly, to take any and all actions (including taking legal action to specifically enforce the applicable terms of any Company IP Agreement or other license agreement) and prepare, execute, deliver and file agreements, documents or instruments which are necessary to (A) prosecute and maintain the Current Company IP or other Company IP material to any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of any Product in the Territory and (B) diligently defend or assert the Company IP material to any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of any Product in the Territory against material infringement, misappropriation, violation or interference by any other Persons and, in the case of the Company IP, against any claims of invalidity, unpatentability or unenforceability (including by bringing any legal action for infringement, dilution, violation, derivation or defending any counterclaim of invalidity or action of a non-Affiliate third-party for declaratory judgment of non-infringement or non-interference); (ii) use commercially reasonable efforts to cause any licensee or licensor of any Current Company IP not to disclaim, forfeit, dedicate to the public or abandon, or fail to take any action necessary to prevent the disclaimer, forfeiture or abandonment of Company IP necessary to any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of any Product in the Territory; and (iii) use commercially reasonable efforts to cause any licensee or licensor of any Company IP not to disclaim, forfeit, dedicate to the public or abandon, or fail to take any action necessary to prevent the disclaimer, forfeiture or abandonment of Company IP otherwise material to any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of any Product in the Territory (other than in accordance with the applicable licensor’s normal prosecution practices and reasonable business judgment). Each Credit Party agrees to (1) notify the Collateral Agent in writing, promptly (and in any event within ten (10) Business Days) after a Credit Party or any of its Subsidiaries first becomes aware of, and thereafter (2) keep the Collateral Agent reasonably informed regarding, (x) any infringement or violation of any of the rights of any Credit Party or its Subsidiary in or to any Company IP, or any misappropriation by any Person of any Company IP or any of the subject matter thereof, and (y) if any Product infringes or violates any Third-Party IP or constitutes a misappropriation of any Third-Party IP.
(c) Save as contemplated by any Permitted License, use commercially reasonable efforts (in its commercially reasonably business judgement) to protect, defend and maintain, and assert against any biosimilar, bioequivalent or interchangeable version of any Product in the Territory, market, data and any other applicable regulatory exclusivity provided under Requirements of Law for the manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of any Product in the Territory through the Term Loan Maturity Date and use commercially reasonable efforts to otherwise not allow for the manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of any biosimilar, bioequivalent or interchangeable version of any Product in the Territory before the Term Loan Maturity Date. Borrower agrees to, in each case, provided that no Credit Party or third-party confidential information will be shared that violates trade secret protection or a court order, (i) promptly notify the Collateral Agent in writing of, (ii) keep the Collateral Agent reasonably informed of, and (iii) at the reasonable request of the Collateral Agent in writing, consult with and consider in good faith any reasonable comments of the Collateral Agent, regarding the commencement of any filings or submissions in any opposition, interference proceeding, reissue proceeding, reexamination proceeding, inter partes review proceeding, post-grant review proceeding, derivation proceeding, cancellation proceeding, injunction, lawsuit, hearing, investigation, complaint, arbitration, mediation, demand, International Trade Commission investigation, decree, or any other dispute, disagreement, or claim, in each case challenging the legality, validity, patentability, enforceability, inventorship or ownership of any Current Company IP or other material; Company IP (including any claim in any Patent within the Company IP that is material to any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, packaging, labelling, promotion, advertising, offer for sale, distribution or sale of any Product in the Territory).
-51-
5.8 Books and Records. Maintain proper Books, in which entries that are full, true and correct in all material respects and are in conformity with GAAP consistently applied shall be made of all material financial transactions and matters involving the assets, properties and business of such Credit Party (or such Subsidiary).
5.9 Access to Collateral; Audits. Allow the Collateral Agent, or its agents or representatives, at any time after the occurrence and during the continuance of an Event of Default, during normal business hours and upon reasonable advance notice, to visit and inspect any of the Collateral or to inspect and copy and (at the sole discretion of the Collateral Agent) audit any Credit Party’s Books. The foregoing inspections and audits, if any, shall be at the relevant Credit Party’s expense.
5.10 Use of Proceeds. (a) Use the proceeds of (i) the Tranche A Loan solely to fund the Heron Acquisition Transaction, and (ii) the Tranche B Loan solely to fund the Other Acquisition Transaction (if any), the in-licensing of commercial-stage pharmaceutical product(s) or the acquisition (whether by merger, purchase or otherwise) of commercial-stage pharmaceutical product(s) constituting a Permitted Acquisition; and (b) not use the proceeds of the Term Loans or any other Credit Extensions, directly or indirectly, for the purpose of purchasing or carrying any Margin Stock, for the purpose of reducing or retiring any Indebtedness that was originally incurred to purchase or carry any Margin Stock, for the purpose of extending credit to any other Person for the purpose of purchasing or carrying any Margin Stock or for any other purpose that might cause any Term Loan or other Credit Extension to be considered a “purpose credit” within the meaning of Regulation T, U or X of the Federal Reserve Board. If requested by the Collateral Agent, Borrower shall complete and sign Part I of a copy of Federal Reserve Form G-3 referred to in Regulation U and deliver such copy to the Collateral Agent.
5.11 Further Assurances. Promptly upon the reasonable written request of the Collateral Agent, execute, acknowledge and deliver such further documents and do such other acts and things in order to effectuate or carry out more effectively the purposes of this Agreement and the other Loan Documents at its expense, including after the Effective Date taking such steps as are reasonably deemed necessary or desirable by the Collateral Agent to maintain, protect and enforce its Lien, for the benefit of Lenders and the other Secured Parties, on Collateral securing the Obligations created under the Collateral Documents and the other Loan Documents in accordance with the terms of the Collateral Documents and the other Loan Documents, subject to Permitted Liens. Notwithstanding the foregoing, no perfection steps shall be required outside of the United States or the jurisdiction of organization of a Credit Party (and, if different, the jurisdiction of the principal place of business of such Credit Party).
5.12 Additional Collateral.
(a) From and after the First Closing Date:
(i) each Credit Party (other than Borrower) shall, and Borrower and each other Credit Party shall cause each of its Subsidiaries (other than Excluded Subsidiaries) to, grant to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, a first priority security interest in and Lien upon (subject to Permitted Liens, the limitations set forth herein and the limitations set forth in the other Loan Documents), and pledge to the Collateral Agent for the benefit of Lenders and the other Secured Parties, all of such Credit Party’s or Subsidiary’s properties and assets constituting Collateral, whether now existing or hereafter acquired or existing (including in connection with an Asset Acquisition), to secure such guaranty; provided, that, Borrower’s and each such other Credit Party’s obligations to take the foregoing actions shall in each case be subject to the timing requirements of Section 5.5, Section 5.13, Section 5.14 or any applicable section of the Collateral Documents (as applicable);
-52-
(ii) additionally, Borrower shall grant to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, a first priority security interest in and Lien upon (subject to Permitted Liens, the limitations set forth herein and the limitations set forth in the other Loan Documents), and pledge to the Collateral Agent for the benefit of Lenders and the other Secured Parties, all of Borrower’s properties and assets constituting Collateral, whether now existing or hereafter acquired or existing (including in connection with an Asset Acquisition), to secure the payment and performance in full of all of the Obligations; provided, that, Borrower’s obligations to take the foregoing actions shall in each case be subject to the timing requirements of Section 5.5, Section 5.13, Section 5.14 or any applicable section of the Collateral Documents (as applicable);
(iii) further, Borrower and each other Credit Party shall, and shall cause each of its Subsidiaries (other than Excluded Subsidiaries) to, grant to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, a first priority security interest in and Lien upon (subject to Permitted Liens, the limitations set forth herein and the limitations set forth in the other Loan Documents), and pledge to the Collateral Agent for the benefit of Lenders and the other Secured Parties, all of the Equity Interests (other than Excluded Equity Interests) in each of its Subsidiaries (other than Excluded Subsidiaries) (and to execute and deliver to the Collateral Agent a joinder or pledge amendment to the Security Agreement (in the form(s) attached thereto) and a joinder to any other Collateral Document, as applicable); provided, that, Borrower’s obligations to take the foregoing actions shall in each case be subject to the timing requirements of Section 5.5, Section 5.13, Section 5.14 or any applicable section of the Collateral Documents (as applicable).
(b) Any document, agreement or instrument executed or issued pursuant to this Section 5.12 shall be a Loan Document for all purposes under this Agreement and the other Loan Documents.
(c) In the event after the First Closing Date any Credit Party acquires any fee title to real estate in the U.S. with a fair market value (reasonably determined in good faith by a Responsible Officer of such Credit Party) in excess of $5,000,000, unless otherwise agreed by the Collateral Agent, such Person shall execute or deliver, or cause to be executed or delivered, to the Collateral Agent, (i) within sixty (60) days (or such longer period as the Collateral Agent may agree in writing and in its sole discretion, taking into account reasonable good faith efforts) after such acquisition, an appraisal complying with the Financial Institutions Reform, Recovery and Enforcement Act of 1989, (ii) within forty-five (45) days (or such longer period as the Collateral Agent may agree in writing and in its sole discretion, taking into account reasonable good faith efforts) after receipt of notice from the Collateral Agent that such real estate is located in a Special Flood Hazard Area, Federal Flood Insurance, (iii) within sixty (60) days (or such longer period as the Collateral Agent may agree in writing and in its sole discretion, taking into account reasonable good faith efforts) after such acquisition, a fully executed Mortgage, in form and substance reasonably satisfactory to the Collateral Agent, together with an A.L.T.A. lender’s title insurance policy issued by a title insurer reasonably satisfactory to the Collateral Agent, in form and substance (including any endorsements) and in an amount reasonably satisfactory to the Collateral Agent insuring that the Mortgage is a valid and enforceable first priority Lien on the respective property, free and clear of all defects, encumbrances and Liens (other than Permitted Liens), (iv) simultaneously with such acquisition, then-current A.L.T.A. surveys, certified to the Collateral Agent by a licensed surveyor sufficient to allow the issuer of the lender’s title insurance policy to issue such policy without a survey exception and (v) within sixty (60) days (or such longer period as the Collateral Agent may agree in writing and in its sole discretion, taking into account reasonable good faith efforts) after such acquisition, an environmental site assessment prepared by a qualified firm reasonably acceptable to the Collateral Agent, in form and substance reasonably satisfactory to the Collateral Agent.
-53-
5.13 Formation or Acquisition of Subsidiaries; Designated Guarantors. If (a) any Credit Party or any of its Subsidiaries at any time after the Effective Date incorporates, organizes, forms or acquires (including by a Stock Acquisition or an Asset Acquisition) a Subsidiary (including by division), other than an Excluded Subsidiary (a “New Subsidiary”) or (b) Borrower elects, in its sole discretion, to designate an Excluded Subsidiary as a Credit Party (such designated Subsidiary, a “Designated Guarantor”) or (c) any Excluded Subsidiary ceases to be an Excluded Subsidiary (a “Non-Excluded Subsidiary”), then in each such case such Credit Party shall (i) (x) notify the Collateral Agent in writing promptly, and in no event later than five (5) Business Days after such incorporation, organization, formation or acquisition, designation, or cessation, as applicable, and (y) with respect to a Domestic Subsidiary, within thirty (30) days after such incorporation, organization, formation or acquisition, designation, or cessation, and with respect to a Foreign Subsidiary, within thirty (30) days (plus an additional thirty (30) days so long as such Credit Party is using reasonable good faith efforts) (or, in each case, such later time as the Collateral Agent may agree in writing in its sole discretion) after such incorporation, organization, formation or acquisition, designation, or cessation, as applicable (or, if later, by the First Closing Date): (1) without limiting the generality of sub-clause (ii) below, cause such New Subsidiary, Designated Guarantor or Non-Excluded Subsidiary, as applicable, to the extent required or applicable, to execute and deliver to the Collateral Agent a joinder to the Security Agreement (in the form attached thereto), any relevant IP Agreement or other Collateral Documents, and such other Collateral Documents or other documents as the Collateral Agent may reasonably request; (2) cause such New Subsidiary, Designated Guarantor or Non-Excluded Subsidiary, as applicable, to deliver (or cause to be delivered) to the Collateral Agent (A) true, correct and complete copies of the Operating Documents of such New Subsidiary, Designated Guarantor or Non-Excluded Subsidiary, as applicable, (B) a Secretary’s Certificate, certifying that the copies of the Operating Documents of such New Subsidiary, Designated Guarantor or Non-Excluded Subsidiary, as applicable, are true, correct and complete (such Secretary’s Certificate to be in form and substance reasonably satisfactory to the Collateral Agent) and (C) a good standing certificate for such New Subsidiary, Designated Guarantor or Non-Excluded Subsidiary, as applicable, certified by the Secretary of State (or the equivalent thereof) of its jurisdiction of organization, incorporation or formation (where applicable in the subject jurisdiction); and (ii) cause such New Subsidiary, Designated Guarantor or Non-Excluded Subsidiary, as applicable, to satisfy all collateral requirements contained in this Agreement (including Section 5.12) and each other Loan Document if and to the extent applicable to such New Subsidiary, Designated Guarantor or Non-Excluded Subsidiary. The parties hereto agree that any New Subsidiary, Designated Guarantor or Non-Excluded Subsidiary, as applicable, shall constitute a Credit Party for all purposes hereunder as of the date of the execution and delivery of any joinder contemplated by clause (a)(y)(1) above or the date such New Subsidiary, Designated Guarantor or Non-Excluded Subsidiary, as applicable, provides any guarantee of the Obligations as contemplated by Section 5.12. Any document, agreement or instrument executed or issued pursuant to this Section 5.13 shall be a Loan Document for all purposes under this Agreement and the other Loan Documents.
5.14 Post-Closing Requirements. Borrower will, and will cause each of its Subsidiaries, as applicable, to take each of the actions set forth on Schedule 5.14 of the Disclosure Letter within the time period prescribed therefor on such schedule, which shall include, among other things, that: (a) notwithstanding anything to the contrary in Section 3.1(g) or Section 5.4, the Credit Parties shall have until the date that is thirty (30) days following the First Closing Date (or such longer period as the Collateral Agent may agree in writing in its sole discretion) to comply with the provisions of Section 5.4 with regards to naming the Collateral Agent, on behalf of the Lenders and the other Secured Parties, as additional insured or loss payee, as applicable, on any products liability or general liability insurance policies maintained in the United States regarding any Collateral in effect on the First Closing Date; (b) notwithstanding anything to the contrary in Section 5.5, the Credit Parties shall have until the date that is thirty (30) days following the First Closing Date (plus an additional thirty (30) days so long as such Credit Party is using reasonable good faith efforts) to comply with the provisions of Section 5.5 with regards to Collateral Accounts of the Credit Parties in existence on the First Closing Date; and (c) notwithstanding anything to the contrary in Section 6.2(b), the Credit Parties shall have until the date that is thirty (30) days following the First Closing Date (plus an additional thirty (30) days so long as such Credit Party is using reasonable good faith efforts) to comply with the provisions of Section 6.2(b) with regards to the location of the primary Books of any Credit Party or the location of any Collateral on the First Closing Date. All representations and warranties and covenants contained in this Agreement and the other Loan Documents shall be deemed modified to the extent necessary to take the actions set forth on Schedule 5.14 of the Disclosure Letter within the time periods set forth therein, rather than elsewhere provided in the Loan Documents, such that to the extent any such action set forth in Schedule 5.14 of the Disclosure Letter is not overdue, the applicable Credit Party shall not be in breach of any representation or warranty or covenant contained in this Agreement or any other Loan Document applicable to such action for the period from the First Closing Date until the date on which such action is required to be fulfilled as set forth on Schedule 5.14 of the Disclosure Letter.
-54-
5.15 Environmental.
(a) Deliver to the Collateral Agent:
(i) as soon as practicable following receipt thereof, copies of all environmental audits, investigations, analyses and reports of any kind or character, whether prepared by personnel of Borrower or any of its Subsidiaries or by independent consultants, governmental authorities or any other Persons, with respect to any significant environmental matter at any Facility or with respect to any Environmental Claim that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Change;
(ii) promptly upon a Responsible Officer of any Credit Party or any of its Subsidiaries obtaining knowledge of the occurrence thereof, written notice describing in reasonable detail (A) any Release required to be reported to any federal, state, local or foreign governmental or regulatory agency under any applicable Environmental Laws that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Change, (B) any remedial action taken by (or on behalf of) any Credit Party or any other Person in response to (x) any Hazardous Materials Activities, the existence of which, individually or in the aggregate, could reasonably be expected to result in one or more Environmental Claims resulting in a Material Adverse Change, or (y) any Environmental Claims that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Change, and (C) any Credit Party’s discovery of any occurrence or condition on any real property adjoining or in the vicinity of any Facility that could cause such Facility or any part thereof to be subject to any material restrictions on the ownership, occupancy, transferability or use thereof under any Environmental Laws, provided, that, with respect to real property adjoining or in the vicinity of any Facility, Borrower shall have no duty to affirmatively investigate or make any efforts to become or stay informed regarding any such adjoining or nearby properties;
(iii) as soon as practicable following the sending or receipt thereof by any Credit Party, a copy of any and all written communications with respect to (A) any Environmental Claims that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Change, (B) any Release required to be reported to any federal, state, local or foreign governmental or regulatory agency that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Change, and (C) any request for information from any Governmental Authority that suggests such Governmental Authority is investigating whether any Credit Party or any of its Subsidiaries may be potentially responsible for any Hazardous Materials Activity that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Change;
(iv) prompt written notice describing in reasonable detail of (A) any proposed acquisition of stock, assets, or property by Borrower or any of its Subsidiaries that, individually or in the aggregate, could reasonably be expected to (x) expose Borrower or any of its Subsidiaries to, or result in, Environmental Claims which could reasonably be expected to result in a Material Adverse Change or (y) affect the ability of Borrower or any of its Subsidiaries to maintain in full force and effect all material Governmental Approvals required under any Environmental Laws for their respective operations, and (B) any proposed action to be taken by Borrower or any of its Subsidiaries to modify current operations, in each case of sub-clause (A) and (B) above, that, individually or taken together with any other such proposed acquisitions or actions, expose Borrower or any of its Subsidiaries to, or result in, Environmental Claims that could reasonably be expected to result in a Material Adverse Change; and
(v) with reasonable promptness, such other documents and information as from time to time may be reasonably requested by the Collateral Agent in relation to any matters disclosed pursuant to this Section 5.15(a).
(b) Each Credit Party shall, and shall cause each of its Subsidiaries to, promptly take any and all actions reasonably necessary to (i) cure any violation of applicable Environmental Laws by Borrower or any of its Subsidiaries that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Change, and (ii) make an appropriate response to any Environmental Claim against Borrower or any of its Subsidiaries and discharge any obligations it may have to any Person thereunder where failure to do so, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Change.
-55-
5.16 Inventory; Returns; Maintenance of Properties. Keep all Inventory that constitutes any Product in good and marketable condition, free from material defects and otherwise keep all Inventory that constitutes any Product in compliance with all applicable FDA Laws, EU Laws, U.K. Laws, and all other foreign equivalents, as applicable, except where the failure to do so could not reasonably be expected to result in a Material Adverse Change. Returns and allowances between a Credit Party and its Account Debtors shall follow such Credit Party’s customary practices. Each Credit Party will, and will cause each of its Subsidiaries to, maintain or cause to be maintained in good repair, working order and condition, ordinary wear and tear, casualty and condemnation excepted, all material tangible properties used or useful in its respective business, and from time to time will make or cause to be made all commercially reasonable repairs, renewals and replacements thereof except where failure to do so could not reasonably be expected to result in a Material Adverse Change.
5.17 Regulatory Obligations; Maintenance of Regulatory Approval; Manufacturing, Marketing and Distribution.
(a) (i) Comply in all material respects with Governmental Authority research, development, testing, post-marketing approval, authorization, clearance, or licensure requirements for any Product in the Territory, as applicable, (ii) maintain all Regulatory Approvals or Licensures required or otherwise material to manufacture, market, and distribute any Product in the Territory (including meeting the supplier standards of Medicare, Medicaid, and other federal healthcare programs), and (iii) with respect to each calendar year commencing with calendar year 2026, maintain manufacturing capacity to sell any Product in the Territory in sufficient quantities to satisfy or exceed either (x) current or future demand of such Product in the Territory, except as could not reasonably be expected to have a Material Adverse Change, or (y), solely with respect to any Product that has been designated as an Orphan Drug in the Territory, the expected needs of patients with the disease or condition for which such Product was designated as an Orphan Drug for such calendar year, as reasonably determined by Responsible Officers of the Credit Parties in good faith.
(b) Deliver to the Collateral Agent, as promptly as practicable after a Responsible Officer of Borrower shall have obtained Knowledge thereof, written notice describing in reasonable detail any instance where any Credit Party or any of its Subsidiaries or licensing partners, with respect to any Product: (i) has a reasonable expectation that there are grounds for imposition of a clinical hold, as described in 21 C.F.R. § 312.42 or foreign equivalent, withdrawal of an investigational new drug application, as defined in 21 C.F.R. § 312.38 or foreign equivalent, withdrawal or suspension of any Product approval or licensure, as described in 21 C.F.R. Part 314 or foreign equivalent, or a recall, as defined in 21 C.F.R. § 7.3 or foreign equivalent, in each case with respect to any Product; (ii) has been issued a Warning Letter or Untitled Letter or Form FDA-483 from FDA (or equivalent communication from any other Regulatory Agency) with respect to any Product; (iii) has received notice from a Regulatory Agency (including the EMA) that an application for any Product will not be approved in its present form; or (iv) has a reasonable expectation that any Product will lose its designation under 21 C.F.R. Part 316 or any foreign equivalent or face a supply shortage materially impacting any Product.
5.18 Material Contracts; Collateral Documents; Permitted Royalty Agreement Documents; Permitted Royalty Financing Documents; Permitted Acquisition Royalty Documents. Comply with all of its covenants, agreements, undertakings and obligations arising under, and fulfill all of its obligations under, (a) subject to clause (b) below, each Material Contract to which it is a party, except as could not reasonably be expected to have a Material Adverse Change, (b) any Permitted Royalty Agreement Document, Permitted Royalty Financing Document, Permitted Other Royalty Financing Document or Permitted Acquisition Royalty Document to which it is a party, except, in each case, to the extent prohibited by or as would contravene in any respect any of the terms or conditions set forth in this Agreement (including Section 6.10 and Section 6.14(c)), or (c) each Collateral Document to which it is a party.
-56-
5.19 Protection of Regulatory Materials.
(a) Except as expressly permitted under clause (b) below, use commercially reasonable efforts to (i) protect, defend and maintain the validity and enforceability of Covered Regulatory Materials material to any aspect of the research, development, manufacture, production, use, commercialization, marketing, import, storage, transport, offer for sale, distribution or sale of any Product in the Territory, including defending any future or current cancellation proceedings, injunctions, lawsuits, hearings, investigations, complaints, arbitrations, mediations, demands, decrees, or any other disputes, disagreements, or claims, challenging the legality, validity, enforceability or ownership of any such Covered Regulatory Materials; and (ii) not allow any Covered Regulatory Materials material to any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of any Product in the Territory, to be abandoned, disclaimed, forfeited or dedicated to the public (other than in accordance with its statutory term or the exercise of the Credit Parties’ reasonable business judgment).
(b) Except as a Credit Party may otherwise determine in its reasonable business judgment, (i) use commercially reasonable efforts to cause any licensee or licensor of any Covered Regulatory Materials not to disclaim, forfeit, dedicate to the public or abandon, or fail to take any action necessary to prevent the disclaimer, forfeiture or abandonment of Covered Regulatory Materials necessary to any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of any Product in the Territory, and (ii) use commercially reasonable efforts to cause any licensee or licensor of any Covered Regulatory Materials not to disclaim, forfeit, dedicate to the public or abandon, or fail to take any action necessary to prevent the disclaimer, forfeiture or abandonment of Covered Regulatory Materials otherwise material to any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of any Product in the Territory (other than in accordance with the applicable licensor’s reasonable business judgment).
5.20 Privacy, Cybersecurity, and Data Protection.
(a) Maintain, implement, and comply in all material respects with the requirements of (i) a commercially reasonable, enterprise-wide Security Program, and (ii) reasonable and appropriate policies and procedures for the use of artificial intelligence and automated decision-making technology by Credit Party employees, agents, and contractors.
(b) Conduct, and require service providers to conduct, commercially reasonable cybersecurity audits and penetration tests at reasonable intervals on all Systems that maintain, store, access, or process Sensitive Information, as applicable, in each case consistent with generally accepted practices for similarly situated companies in the pharmaceutical industry and in accordance with any applicable Requirements of Law, and promptly remediate any critical or high vulnerabilities or deficiencies identified in any such audit or test.
(c) Conduct commercially reasonable cybersecurity diligence, consistent with generally accepted practices in the pharmaceutical industry, on all service providers that (i) collect, create, receive, access, maintain, store, or otherwise process Sensitive Information for or on behalf of any Credit Party or Subsidiary, or (ii) access or maintain the Systems.
(d) Deliver to the Collateral Agent, as reasonably promptly as practicable after Responsible Officers of any Credit Party gains Knowledge thereof, written notice describing in reasonable detail any instance where any Credit Party or any of its Subsidiaries discovers any material Security Incident that requires notice to affected Persons or Governmental Authorities under applicable Requirements of Law, that materially disrupts any System, or that leads to, or could reasonably be expected to lead to, material losses or liabilities.
-57-
6. NEGATIVE COVENANTS
Each Credit Party covenants and agrees that until payment in full of all Obligations (other than contingent indemnification obligations to the extent no claims giving rise thereto has been asserted), such Credit Party shall not, and shall cause each of its Subsidiaries not to:
6.1 Dispositions. Convey, sell, lease, transfer, exchange, assign, covenant not to sue, enter into a coexistence agreement, exclusively or nonexclusively license out, or otherwise dispose of (including any sale-leaseback or any transfer of assets pursuant to a plan of division), directly or indirectly and whether in one or a series of transactions (collectively, “Transfer”), all or any part of its properties or assets constituting Collateral (including, for the avoidance of doubt, any Equity Interests constituting Collateral issued by any Subsidiary which are owned or otherwise held by such Credit Party) or any Current Company IP that does not constitute Collateral under the Loan Documents but related to any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of any Product in the Territory; except, in each case of this Section 6.1, for Permitted Transfers.
6.2 Fundamental Changes; Location of Collateral.
(a) Without at least ten (10) days prior written notice to the Collateral Agent, solely in the case of a Credit Party: (i) change its jurisdiction of organization, incorporation or formation, (ii) change its organizational structure or type, (iii) change its legal name, or (iv) change any organizational number (if any) assigned by its jurisdiction of organization, incorporation or formation.
(b) Maintain its primary Books at or deliver any Collateral with a fair market value or, if less, replacement cost (in each case, as reasonably determined in good faith by a Responsible Officer of Borrower), individually or together with any other Collateral, in excess of $5,000,000 to, one or more leased locations or one or more warehouses, processors or bailees, as applicable, unless, subject to the timing requirements of Section 5.12, 5.13 or 5.14 if and only to the extent applicable (solely with respect to such leased locations, warehouses, processors or bailees where such Books or Collateral is located on the applicable Closing Date (or during the 30-day period following such applicable Closing Date), such Credit Party uses commercially reasonable efforts to obtain, within thirty (30) days (plus an additional thirty (30) days so long as such Credit Party is using reasonable good faith efforts) after such Books are maintained or such Collateral is delivered, a Collateral Access Agreement for such leased location or such warehouse, processor or bailee governing such Books or such Collateral (as applicable), in form and substance reasonably satisfactory to the Collateral Agent, to the extent such Books or such Collateral is located in the United States or the jurisdiction of organization of such Credit Party (or, if different, the jurisdiction of the principal place of business of such Credit Party)). Notwithstanding anything to the contrary herein, such obligation to deliver Collateral Access Agreements will not apply to any inventory or assets while in transit (including such assets stored at any temporary location pending transit) or with an employee in the ordinary course of business and consistent with past practices.
(c) Establish or maintain any bank account of any Credit Party other than the bank accounts set forth on Schedule 6.2(c) of the Disclosure Letter (which bank accounts constitute all of the deposit accounts, securities accounts or other similar accounts maintained by any Credit Party on the applicable Closing Date), unless, in the case of any bank account that is not an Excluded Account, (i) the Collateral Agent is provided at least ten (10) Business Days’ written notice from such Credit Party prior to the establishment or maintenance of such account and (ii) such account is or is made subject to a Control Agreement or an applicable Collateral Document to the extent required by Section 5.5 hereof.
(d) Maintain cash in any bank account located outside of the United States or with respect to bank accounts of Foreign Subsidiaries, the jurisdiction of the organization of such Credit Party (or, if different, its principal place of business) that, in each case would be in excess of the amount of cash that would be appropriate for (i) the continued operations in the ordinary course of business of such Credit Party or Subsidiary and (ii) such other business needs of such Person, as reasonably determined by a Responsible Officer of Borrower in good faith, consistent with prudent cash management practices and not with an intent to hinder the security interests available under the Loan Documents.
(e) Take any action or engage in any transaction (or series of actions or transactions), whether by reorganization, sale of assets, merger, dissolution, amendment of Operating Documents or otherwise, the primary purpose of which is to evade, avoid or seek to avoid the performance or observance of any of the covenants, agreements or obligations of any Credit Party under the Loan Documents (including under the Collateral Documents).
-58-
6.3 Mergers, Acquisitions, Liquidations or Dissolutions.
(a) Merge, divide itself into two (2) or more entities, consolidate, liquidate or dissolve, or permit any of its Subsidiaries to merge, divide itself into two (2) or more entities, consolidate, liquidate or dissolve with or into any other Person, except that:
(i) (x) any Subsidiary of Borrower may merge or consolidate with or into a Credit Party, provided, that, the Credit Party is the surviving entity and (y) any Subsidiary of Borrower may liquidate or dissolve, provided, that, prior to or concurrent with such liquidation or dissolution, the remaining assets of such Subsidiary shall be distributed to another Subsidiary, provided, further, that if the liquidating or dissolving Subsidiary is a Credit Party, all of the assets and business of such Subsidiary shall be distributed to an existing or newly-formed Credit Party, and if the liquidating or dissolving Subsidiary is not a Credit Party, all of the assets and business of such Subsidiary are transferred to a Credit Party or another Subsidiary; provided, finally, that neither such dissolution or liquidation nor such transfer could reasonably be expected to result in a Material Adverse Change;
(ii) any Subsidiary of Borrower may merge or consolidate with any other Subsidiary of Borrower, provided, that, if any party to such merger or consolidation is a Credit Party then either (x) such Credit Party is the surviving entity or (y) the surviving or resulting entity executes and delivers to the Collateral Agent a joinder to the Security Agreement in the form attached thereto, a joinder to any relevant IP Agreement, and such other Collateral Documents or other documents required under the terms of the Loan Documents or as the Collateral Agent may reasonably request, as applicable, and otherwise satisfies the requirements of Section 5.13 as promptly as practicable but in no event later than thirty (30) days (or such longer period as the Collateral Agent may agree in writing in its sole discretion) following the completion of such merger or consolidation;
(iii) any Subsidiary of Borrower may divide itself into two (2) or more entities or be dissolved or liquidated, provided, that, if such Subsidiary is a Credit Party, the properties and assets of such Subsidiary are allocated or distributed to an existing or newly formed or newly joined Credit Party; and
(iv) any Permitted Acquisition, Permitted Transfer of Equity Interests or Permitted Investment may be structured as a merger or consolidation.
(b) Make, or permit any of its Subsidiaries to make, Acquisitions outside the ordinary course of business, including any purchase of all or substantially all of the assets of, or any division or line of business of, any other Person, other than Permitted Acquisitions or Permitted Investments.
For the avoidance of doubt, nothing in this Section 6.3 shall prohibit any Credit Party or its Subsidiaries from entering into in-licensing agreements; provided, however, that in each case no Indebtedness that is not Permitted Indebtedness hereunder is incurred or assumed in connection therewith.
6.4 Indebtedness. Directly or indirectly, create, incur, assume or guaranty or otherwise become or remain liable with respect to, any Indebtedness that is not Permitted Indebtedness hereunder; provided, however, that the accrual of interest, the accretion of accreted value and the payment of interest in the form of additional Indebtedness shall not be deemed to be an incurrence of Indebtedness for purposes of this Section 6.4.
6.5 Encumbrances. Except for Permitted Liens, (a) create, incur, allow, or suffer to exist any Lien on any Collateral, or (b) permit (other than pursuant to the terms of the Loan Documents) any material portion of the Collateral (including, for the avoidance of doubt, any Equity Interests constituting Collateral issued by any Subsidiary which are owned or otherwise held by such Credit Party) not to be subject to the first priority security interest (subject to Permitted Liens, the limitations expressly set forth herein and the limitations expressly set forth in the other Loan Documents) granted in the Loan Documents or otherwise pursuant to the Collateral Documents, in each case of this clause (b), other than as a direct result of any action by the Collateral Agent or any Lender or failure of the Collateral Agent or any Lender to perform an obligation thereof under the Loan Documents.
-59-
6.6 No Further Negative Pledges; Negative Pledge.
(a) Enter into any agreement, document or instrument directly or indirectly prohibiting (or having the effect of prohibiting) or limiting the ability of such Credit Party or Subsidiary to create, incur, assume or suffer to exist any Lien upon any Collateral, whether now owned or hereafter acquired, in favor of the Collateral Agent, for the benefit of Lenders and the other Secured Parties, with respect to the Obligations or under the Loan Documents, in each case of this Section 6.6, other than Permitted Negative Pledges.
(b) Notwithstanding Sections 6.1 and 6.5, no Credit Party will Transfer, or create, incur, allow or suffer to exist any Lien on, any Equity Interests owned or otherwise held by such Credit Party that is issued by any Subsidiary that owns or otherwise holds any interest in Current Company IP registered, issued or filed for, as applicable, in the Territory, except for: (i) Permitted Liens and Permitted Transfers that, in each case, would not interfere with or impede the ability of Borrower or any Subsidiary of Borrower to conduct the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of any Product in the Territory or enforce its rights with respect to any of the foregoing within the Territory; and (ii) sales, assignments, transfers, exchanges or other dispositions to qualify directors if required by Requirements of Law, provided, that, such sale, assignment, transfer, exchange or other disposition shall be for the minimum number of Equity Interests as are necessary for such qualification under Requirements of Law.
6.7 Maintenance of Collateral Accounts. Maintain any Collateral Account except in accordance with the terms of Section 5.5 hereof.
6.8 Distributions; Investments.
(a) Pay any dividends or make any distribution or payment on, or redeem, retire or repurchase any of its Equity Interests (collectively, “Restricted Payments”), except, in each case of this Section 6.8, for Permitted Distributions, Permitted Transactions and Permitted Equity Derivatives.
(b) Directly or indirectly, make any Investment other than Permitted Acquisitions and Permitted Investments.
For the avoidance of doubt, nothing in this Section 6.8 shall prohibit any Credit Party or its Subsidiaries from entering into in-licensing agreements; provided, however, that in each case no Indebtedness that is not Permitted Indebtedness is incurred or assumed in connection therewith.
6.9 No Restrictions on Subsidiary Distributions. Enter into any agreement, document or instrument directly or indirectly prohibiting (or having the effect of prohibiting) or limiting the ability of any Subsidiary of Borrower to (a) pay dividends or make any other distributions on any of such Subsidiary’s Equity Interests owned by Borrower or any of its other Subsidiaries, (b) repay or prepay any Indebtedness owed by such Subsidiary to Borrower or any of its other Subsidiaries, (c) make loans or advances to Borrower or any of its other Subsidiaries, or (d) transfer, lease or license any Collateral to Borrower or any of its other Subsidiaries, except, in each case of this Section 6.9, for Permitted Subsidiary Distribution Restrictions.
-60-
6.10 Subordinated Debt; Permitted Convertible Indebtedness; Permitted Royalty Agreement Documents; Permitted Royalty Financing; Permitted Other Royalty Financing; Permitted Acquisition Royalty Documents. Notwithstanding anything to the contrary in this Agreement:
(a) Make or permit any voluntary or optional prepayment or repayment of the outstanding principal amount of any Subordinated Debt other than in accordance with the express terms of a subordination, intercreditor or other similar agreement relating to such Subordinated Debt, if any, that is in form and substance reasonably satisfactory to the Collateral Agent;
(b) Make or permit any payment of interest (including accrued and unpaid interest) in cash on or in respect of any Subordinated Debt at any time that a Default or Event of Default shall have occurred and be continuing other than in accordance with the express terms of a subordination, intercreditor or other similar agreement relating to such Subordinated Debt, if any, that is in form and substance reasonably satisfactory to the Collateral Agent;
(c) Directly or indirectly, create, incur, assume or guaranty, or otherwise become directly or indirectly liable with respect to, any Subordinated Debt except as expressly permitted hereunder;
(d) Amend, restate, supplement or otherwise modify any terms, conditions or other provisions of any Subordinated Debt, or any agreement, instrument or other document relating thereto, in any manner which would contravene in any respect any of the foregoing clauses of this Section 6.10 or adversely affect the payment or priority subordination thereof (as applicable) to Obligations owed to Lenders, in each case except under the terms of the subordination, intercreditor, or other similar agreement to which such Subordinated Debt, if any, is subject, without the prior written consent of the Collateral Agent (in its sole discretion);
(e) Amend, restate, supplement, modify or replace, or renew or alter any terms, conditions or other provisions of any Permitted Royalty Agreement or any other Permitted Royalty Agreement Document (in each case, as in effect on the Effective Date or the date acquired or assumed), in any manner that would: (i) change the calculation or time of any Permitted Royalty Agreement Payment pursuant thereto, including any change to the basis or manner for calculating any late or overdue Permitted Royalty Agreement Payments (including any fees or interest payments thereon), (ii) change any of the terms of any obligations thereunder with respect to any Permitted Royalty Agreement Payments, including any change to Borrower’s or any Subsidiary’s obligations to make any Permitted Royalty Agreement Payment relating to the occurrence of a change of control of Borrower or such Subsidiary, the termination of such Permitted Royalty Agreement or any other Permitted Royalty Agreement Document or if a specified amount of Permitted Royalty Agreement Payments are not received by a specified date by any counterparty, (iii) contravene in any respect any of the terms or conditions set forth in clause (f) below or Section 6.14(c), or (iv) be materially adverse to the interest of Lenders;
(f) Make or permit (or exercise any option with respect thereto), directly or indirectly through a Subsidiary, any payment or reimbursement of any kind to any counterparty pursuant to any Permitted Royalty Agreement as in effect as of the Effective Date or the date acquired or assumed, or other Permitted Royalty Agreement Document as in effect as of the Effective Date or the date acquired or assumed (in each case as may be amended, restated, supplemented, modified or replaced, or renewed or altered (including pursuant to any waiver, consent or approval) from time to time in accordance with Section 6.10(e) above), in each case except for any Permitted Royalty Agreement Payments which are paid when due and payable under such Permitted Royalty Agreement, but including any Permitted Royalty Agreement Payment that Borrower or any of its Subsidiaries has the right, but not the obligation, to make pursuant to such Permitted Royalty Agreement or other Permitted Royalty Agreement Document (if any) or that Borrower or any of its Subsidiaries agrees to make pursuant to any amendment, restatement, amendment and restatement, supplement or modification thereto or any approval, consent or waiver in respect thereof;
-61-
(g) (i) Make or permit (or exercise any option with respect thereto), directly or indirectly, any payment, prepayment, repurchase or redemption for cash of any Permitted Convertible Indebtedness, provided, however, that nothing in this Section 6.10(g) shall prohibit or otherwise restrict (A) any Permitted Transaction, (B) scheduled cash interest payments, (C) required cash payments of accrued but unpaid interest upon repurchase, redemption or conversion thereof, (D) cash payments in lieu of any fractional share issuable upon conversion thereof, or (E) any ordinary course fees or other expenses in connection therewith; or (ii) amend, restate, supplement or otherwise modify any terms, conditions or other provisions of the 2030 Convertible Notes as in force and effect as of the Effective Date, or any agreement, instrument or other document relating thereto (including the Indenture), in any manner which would contravene in any respect any of clauses (a) through (e) and (g) of the definition of Permitted Convertible Indebtedness or any of sub-clause (i) of this Section 6.10(g);
(h) (i) Make or permit, directly or indirectly through a Subsidiary, any voluntary or optional prepayment or repayment of any outstanding amount of any Indebtedness under any Permitted Royalty Financing Document, or any Permitted Other Royalty Financing Document or any Permitted Acquisition Royalty Document (including any principal or interest) (for the avoidance of doubt, excluding regularly scheduled Permitted Royalty Financing Agreement Payments due and payable to such counterparty pursuant to such Permitted Royalty Financing Document, or regularly scheduled Permitted Other Royalty Financing Agreement Payments due and payable to such counterparty pursuant to such Permitted Other Royalty Financing Document or regularly scheduled Permitted Acquisition Royalty Payments due and payable to such counterparty pursuant to such Permitted Acquisition Royalty Document (as applicable)), (ii) exercise or consummate any call option, change of control call option or similar right, or (iii) amend, restate, supplement or otherwise modify any terms, conditions or other provisions of such Indebtedness, Permitted Royalty Financing Document or Permitted Acquisition Royalty Document (for the avoidance of doubt, excluding regularly scheduled royalty payments due and payable to such counterparty pursuant to such Permitted Royalty Financing Document or Permitted Acquisition Royalty Document (as applicable)) in any manner which would contravene in any respect any of the foregoing in this clause (h) or Section 6.14(c), or adversely affect the payment or priority subordination thereof (as applicable) to Obligations owed to Lenders or otherwise be materially adverse to the interest of Lenders, in each case other than to the extent permitted by the express terms of the Permitted Royalty Financing Intercreditor Agreement in respect of such Indebtedness under such Permitted Royalty Financing Document or the express terms of such Permitted Acquisition Royalty Document, as applicable; or
(i) Without limiting the generality of clause (h) above, without the written consent of the Collateral Agent (acting in its sole discretion), make or permit (or exercise any option with respect thereto), directly or indirectly through a Subsidiary, any payment or reimbursement of any kind to any counterparty pursuant to any Permitted Royalty Financing Document, or any Permitted Other Royalty Financing Document or any Permitted Acquisition Royalty Document, in each case except for any customary indemnification obligations and any regularly scheduled royalty payments due and payable to such counterparty pursuant to such Permitted Royalty Financing Document, or such Permitted Other Royalty Financing Document or such Permitted Acquisition Royalty Document (as applicable), and, for the avoidance of doubt, excluding in all cases (other than for customary indemnification obligations and any such regularly scheduled Permitted Royalty Financing Agreement Payments pursuant to such Permitted Royalty Financing Document, or regularly scheduled Permitted Other Royalty Financing Agreement Payments due and payable to such counterparty pursuant to such Permitted Other Royalty Financing Document or regularly scheduled Permitted Acquisition Royalty Payments pursuant to such Permitted Acquisition Royalty Document (as applicable)), any advance payment, prepayment or similar payment that Borrower or any of its Subsidiaries has the right, but not the obligation, to make pursuant to such Permitted Royalty Financing Document, or such Permitted Other Royalty Financing Document or such Permitted Acquisition Royalty Document (if any) or that Borrower or any of its Subsidiaries agrees to make pursuant to any amendment, restatement, amendment and restatement, supplement or modification thereto or any approval, consent or waiver in respect thereof;
provided, that, subject to Sections 6.10(e) and 6.10(f) above, Borrower or any of its Subsidiaries shall be permitted to make any Permitted Royalty Agreement Payments, Permitted Other Royalty Agreement Payments and Permitted Royalty Financing Agreement Payments.
-62-
6.11 Amendments or Waivers of Organizational Documents. Amend, restate, supplement or otherwise modify, or waive, any provision of its Operating Documents in a manner that would reasonably be expected to result in a Material Adverse Change.
6.12 Compliance.
(a) Become an “investment company” under the Investment Company Act of 1940, or undertake as one of its important activities extending credit to purchase or carry margin stock (as defined in Regulation U of the Board of Governors of the Federal Reserve System), or use the proceeds of any Credit Extension for that purpose;
(b) With respect to any ERISA Affiliate, cause or suffer to exist (i) any event that would result in the imposition of a Lien under ERISA on any assets or properties of any Credit Party or a Subsidiary of a Credit Party with respect to any Plan or (ii) any other ERISA Event that, in the case of sub-clauses (i) and (ii) above, could reasonably be expected to, individually or in the aggregate, result in a Material Adverse Change; or
(c) Permit the occurrence of any other event with respect to any present pension, profit sharing or deferred compensation plan which could reasonably be expected to result in a Material Adverse Change.
6.13 Compliance with Sanctions, Export and Import Laws, Anti-Corruption Laws and Anti-Money Laundering Laws.
(a) Permit any of its Subsidiaries or controlled Affiliates to, directly or indirectly, enter into any documents or contracts with any Blocked Person except as permitted by applicable Sanctions laws.
(b) Fail to notify the Collateral Agent and each Lender in writing promptly (but in any event within three (3) Business Days) upon any Responsible Officer of any Credit Party becoming aware that any Credit Party or any Subsidiary or Affiliate of any Credit Party is a Blocked Person or that any Credit Party or any Subsidiary or Affiliate of any Credit Party or any of their respective directors, officers or employees (i) is convicted on, (ii) pleads nolo contendere to, (iii) is indicted on, or (iv) is arraigned and held over on charges involving money laundering or predicate crimes to money laundering.
(c) Permit any of its Subsidiaries or controlled Affiliates to, directly or indirectly, (i) conduct any prohibited business or engage in any prohibited investment, activity, transaction or dealing with any Blocked Person, including the making or receiving of any contribution of funds, goods or services to or for the benefit of any Blocked Person, (ii) deal in, or otherwise engage in any investment, activity, transaction or dealing relating to, any property or interests in property blocked pursuant to Sanctions, or (iii) engage in or conspire to engage in any investment, activity, transaction or dealing that evades or avoids or violates, or has the purpose of evading or avoiding, or attempts to violate, any prohibitions under Sanctions, Export and Import Laws, Anti-Corruption Laws or Anti-Money Laundering Laws.
(d) Permit any of its Subsidiaries or controlled Affiliates to, directly or, to the Knowledge of Borrower, indirectly through a non-controlled Affiliate or an agent or any other third Person, use any of the proceeds of any Credit Extension, or lend, contribute or otherwise make available such proceeds of any Credit Extension to any Subsidiary, joint venture partner or other Person, (i) for any payments to any government official or employee, political party, official of a political party, candidate for political office or anyone else, in order to obtain, retain or direct business, or to obtain any improper advantage, in violation in any respect of Anti-Corruption Laws, (ii) in violation in any respect of any Anti-Money Laundering Laws, or (iii) in violation of Export and Import Laws.
-63-
(e) Permit any of its Subsidiaries or controlled Affiliates to, directly or indirectly through a non-controlled Affiliate or an agent or any other third Person, use any of the proceeds of any Credit Extension, or lend, contribute or otherwise make available such proceeds of any Credit Extension to any Subsidiary, joint venture partner or other Person in violation of Sanctions.
(f) Permit any of its Subsidiaries or controlled Affiliates to, directly or, to the Knowledge of Borrower, indirectly through a non-controlled Affiliate or an agent or any other third Person, fund all or part of any repayment of the Credit Extensions or other payments under this Agreement out of proceeds derived from criminal activity or activity or transactions in violation in any respect of Anti- Corruption Laws, Export and Import Laws, Anti-Money Laundering Laws or Sanctions, or that would otherwise cause any Person (including any Person participating in the Credit Extensions, whether as agent, lender, sponsor, underwriter, advisor, investor, or otherwise) to be in violation in any respect of Anti-Corruption Laws, Export and Import Laws, Anti-Money Laundering Laws or Sanctions.
The Collateral Agent and each Lender hereby notifies each Credit Party that pursuant to the requirements of Sanctions and Anti-Money Laundering Laws, and their respective policies and practices, the Collateral Agent and each Lender is required to obtain, verify and record certain information and documentation that identifies each Credit Party and its principals, which information includes the name and address of each Credit Party and its principals and such other information that will allow the Collateral Agent and each Lender to identify such party in accordance with Sanctions and Anti-Money Laundering Laws.
6.14 Material Contracts.
(a) (i) Waive, amend, cancel or terminate, exercise or fail to exercise, any rights constituting or relating to any of the Material Contracts or (ii) breach, default under, or take any action or fail to take any action that, with the passage of time or the giving of notice or both, would constitute a default or event of default under any of the Material Contracts, in each case of this Section 6.14, which, individually or taken together with any other such waivers, amendments, cancellations, terminations, exercises or failures, could reasonably be expected to have a Material Adverse Change.
(b) From and after the Effective Date, enter into any Manufacturing Agreement (excluding, for the avoidance of doubt, any Manufacturing Agreement listed on Schedule 13.2 of the Disclosure Letter and all amendments, restatements, amendment and restatements, extensions, supplements or other modifications thereto) relating to active pharmaceutical ingredients or finished products relating to any Product (i) that cannot be collaterally assigned to secure the Obligations, (ii) that cannot be assigned to a purchaser in a foreclosure sale of all or any portion of the Collateral (subject to assumption by the purchaser of all obligations under such Material Contract) in the event of any exercise of rights or remedies under the Loan Documents, or (iii) that contains provisions that restrict or penalize the granting of a security interest in or Lien on such Material Contract or the assignment of such Material Contract upon the sale or other disposition of all or a portion of a product to which such Material Contract relates, in each case without using its commercially reasonable efforts to ensure such Manufacturing Agreement does not contain the terms listed in sub-clauses (i) to (iii) above.
-64-
(c) Except, in each case, as otherwise permitted by Section 6.10 and Section 6.14(c), and without limitation to any other provision herein or in any other Loan Document, until all of the Obligations have been paid, performed or discharged in full and Borrower has no further right to obtain any Credit Extension hereunder, make, and such Credit Party shall cause its Affiliates not to: (i) make (w) any payment (whether of principal, interest or otherwise) under any Permitted Royalty Agreement Document, Permitted Royalty Financing Document, Permitted Other Royalty Financing Document or Permitted Acquisition Royalty Document, other than any regularly scheduled Permitted Royalty Agreement Payments due and payable to any counterparty pursuant to such Permitted Royalty Agreement Document, regularly scheduled Permitted Royalty Financing Agreement Payments due and payable to any counterparty pursuant to such Permitted Royalty Financing Document, regularly scheduled Permitted Other Royalty Financing Agreement Payments due and payable to any counterparty pursuant to such Permitted Other Royalty Financing Document, or regularly scheduled Permitted Acquisition Royalty Payments due and payable to any counterparty pursuant to such Permitted Acquisition Royalty Document, as applicable, so long as such regularly scheduled royalty payment is not in contravention with any other term or condition of this Agreement, but excluding, for the avoidance of doubt (unless otherwise permitted by Section 6.10 and Section 6.14(c)), (x) any advance payment, accelerated payment, prepayment or similar payment that such Credit Party or Subsidiary has the right, but not the obligation, to make pursuant to such Permitted Royalty Agreement Document, Permitted Royalty Financing Document or Permitted Acquisition Royalty Document (if any), (y) any payment for any amendment, restatement, amendment and restatement, supplement or modification thereto or any replacement, renewal or alteration thereof, including in connection with any approval, consent or waiver in respect thereof, or (z) any payment pursuant to the exercise by any counterparty of any put option, change in control purchase option or other similar right; or (ii) exercise any call option, change of control call option or similar right pursuant to the terms of any Permitted Royalty Agreement Document, Permitted Royalty Financing Document, Permitted Other Royalty Financing Document or Permitted Acquisition Royalty Document.
(d) Prepay, repay, convert, repurchase, redeem or otherwise settle, or refinance any or all Indebtedness or any or all other amounts outstanding under the 2030 Convertible Notes (and the Indenture) prior to the Term Loan Maturity Date, other than pursuant to a Permitted Transaction or as permitted under Section 6.10(g) and otherwise in accordance with the terms of such convertible notes and the Indenture.
7. EVENTS OF DEFAULT
Any one of the following shall constitute an event of default (an “Event of Default”) under this Agreement:
7.1 Payment Default. Any Credit Party fails to (a) make any payment of any principal of the Term Loans when and as the same shall become due and payable, whether at the due date thereof (including pursuant to Section 2.2(c)) or at a date fixed for prepayment (whether voluntary or mandatory) thereof or by acceleration thereof or otherwise, or (b) within five (5) Business Days after the same becomes due and payable, any payment of interest or premium pursuant to Section 2.2, including any applicable Additional Consideration, Makewhole Amount or Prepayment Premium (which such five (5) Business Day cure period shall not apply to any such payments due on the Term Loan Maturity Date or an earlier date pursuant to Section 2.2(c) hereof or the date of acceleration pursuant to Section 8.1(a) hereof). A failure to pay any such interest, premium or Obligations pursuant to the foregoing clause (b) prior to the end of such five (5) Business Day-period shall not constitute an Event of Default (unless such payment is due on the Term Loan Maturity Date or such earlier date pursuant to Section 2.2(c) hereof or the date of acceleration pursuant to Section 8.1(a) hereof).
7.2 Covenant Default.
(a) The Credit Parties: (i) fail or neglect to perform any obligation in Sections 5.5, 5.10, 5.12, 5.13 or 5.14 or (ii) violate or breach any covenant or agreement in Section 6;
(b) The Credit Parties fail or neglect to perform any obligation in Section 5.2, 5.6, 5.7 or 5.17 and, in the case where such failure or neglect is capable of being cured such failure or neglect continues for ten (10) days after the earlier of the date on which (i) a Responsible Officer of any Credit Party becomes aware of such failure or neglect and (ii) written notice thereof shall have been delivered to Borrower by the Collateral Agent or any Lender. Cure periods provided under this Section 7.2(b) shall not apply, among other things, to any of the covenants referenced in clause (a) above; or
(c) The Credit Parties fail or neglect to perform, keep, or observe any other term, provision, condition, covenant or agreement contained in this Agreement or any Loan Documents on its part to be performed, kept or observed and, where such failure or neglect is capable of being cured such failure or neglect continues for twenty (20) days after the earlier of the date on which (i) a Responsible Officer of any Credit Party becomes aware of such failure or neglect and (ii) written notice thereof shall have been delivered to Borrower by the Collateral Agent or any Lender. Cure periods provided under this Section 7.2(c) shall not apply, among other things, to any of the covenants referenced in clauses (a) or (b) above.
-65-
7.3 Withdrawal Event; Material Adverse Change. (a) A Withdrawal Event occurs with respect to any Key Product (including, for the avoidance of doubt, Rezzayo), or (b) a Material Adverse Change occurs.
7.4 Attachment; Levy; Restraint on Business.
(a) (i) The service of process seeking to attach, by trustee or similar process, any funds of any Credit Party or of any entity under the control of any Credit Party (including a Subsidiary) in excess of $10,000,000 on deposit or otherwise maintained with the Collateral Agent, or (ii) a notice of Lien or levy is filed against any material portion of Collateral by any Governmental Authority, and the same under sub-clauses (i) or (ii) hereof are not, within thirty (30) days after the occurrence thereof, discharged or stayed (whether through the posting of a bond or otherwise); provided, however, that no Credit Extensions shall be made during any thirty (30) day cure period (unless earlier cured); or
(b) (i) Any material portion of Collateral is attached, seized, levied on, or comes into possession of a trustee or receiver, or (ii) any court order enjoins, restrains, or prevents Borrower and its Subsidiaries from conducting any material part of their business, taken as a whole.
7.5 Insolvency.
(a) An involuntary proceeding shall be commenced or an involuntary petition shall be filed in a court of competent jurisdiction seeking: (i) relief in respect of any Credit Party, or of a substantial part of the property of any Credit Party, under Title 11 of the United States Code, as now constituted or hereafter amended, or any other federal, state or foreign bankruptcy, insolvency, receivership or other similar law; (ii) the voluntary or involuntary appointment of a receiver, interim receiver, receiver and manager, administrative receiver, administrator, trustee, custodian, sequestrator, conservator or other similar official for or in respect of any Credit Party or for all or a substantial part of the property or assets or undertakings of any Credit Party; (iii) issuance of a warrant of attachment, execution, distraint or similar process against all or a substantial part of the property or assets or undertakings of any Credit Party; or (iv) the winding-up or liquidation of any Credit Party; and in each case of sub-clause (i) through (iv) above, such proceeding or petition shall continue undismissed or unstayed for sixty (60) days or an order or decree approving or ordering any of the foregoing shall be entered;
(b) Any Credit Party shall: (i) voluntarily commence any proceeding or file any petition seeking relief under Title 11 of the United States Code, as now constituted or hereafter amended, or any other existing or future federal, state or foreign bankruptcy, insolvency, receivership, relief of debtors or similar law; (ii) consent to the institution of, or fail to contest in a timely and appropriate manner, any proceeding or the filing of any petition described in clause (a) above; (iii) apply for or consent to the appointment of a receiver, interim receiver, receiver and manager, administrative receiver, administrator, trustee, custodian, sequestrator, conservator or other similar official for or in respect of any Credit Party or for any portion of the property or assets or undertakings of any Credit Party; (iv) file an answer admitting the material allegations of a petition filed against it in any such proceeding; (v) make a general assignment for the benefit of creditors, or enter into a composition, compromise, assignment or arrangement with any of its creditors (whether by way of a voluntary arrangement, schedule of arrangement, deed of compromise or otherwise); (vi) become unable to, admit in writing its inability to or fail to, generally pay its debts as they become due; (vii) take any corporate action (including, for the avoidance of doubt, an affirmative vote by the applicable Board of Directors) for the purpose of effecting any of the foregoing; or (viii) wind up or liquidate (except as otherwise expressly permitted hereunder);
(c) Any Credit Party shall be insolvent as defined in any statute of the Bankruptcy Code or in the fraudulent conveyance or fraudulent transfer statutes of the State of Delaware or other applicable jurisdiction of organization; and
(d) An affirmative vote by the applicable Board of Directors to cause, consent to, approve or acquiesce in any of the acts described in clauses (a) or (c) above.
-66-
7.6 Other Agreements.
(a) Any Credit Party or any of its Subsidiaries fails to pay any Indebtedness (other than the Indebtedness represented by this Agreement and the other Loan Documents), including, for the avoidance of doubt, any Permitted Indebtedness that constitutes Subordinated Debt, Working Capital Indebtedness or Permitted Convertible Indebtedness, within any applicable grace period after such payment is due and payable (including at final maturity) or after the acceleration of any such Indebtedness by the holder(s) thereof because of a default, in each case, if the total amount of such Indebtedness unpaid or accelerated exceeds $10,000,000;
(b) Without limiting the generality of clause (a) above, an event of default occurs under any Hedging Agreement as to which any Credit Party or any of its Subsidiaries is the defaulting party or any termination event occurs under any Hedging Agreement as to which any Credit Party or any of its Subsidiaries is a party, in either case if, in respect of such Hedging Agreement and as a result of such occurrence, the Hedge Termination Value owed by any such Credit Party or Subsidiary is greater than $5,000,000;
(c) (i) A put option or a change in control purchase option or similar right is exercised by the counterparty to any Permitted Royalty Agreement Document, Permitted Royalty Financing Document, Permitted Other Royalty Financing Document or Permitted Acquisition Royalty Document pursuant to the terms thereof, (ii) a call option or a change of control call option or similar right is exercised by Borrower or any Subsidiary pursuant to the terms of any Permitted Royalty Agreement Document, Permitted Royalty Financing Document, Permitted Other Royalty Financing Document or Permitted Acquisition Royalty Document, or (iii) upon the occurrence of a put option event or any other event that would give the counterparty to any Permitted Royalty Agreement Document, Permitted Royalty Financing Document, Permitted Other Royalty Financing Document or Permitted Acquisition Royalty Document the right to require Borrower or any of its Subsidiaries to purchase all or any part of the Indebtedness under such Permitted Royalty Agreement Document, Permitted Royalty Financing Document, Permitted Other Royalty Financing Document or Permitted Acquisition Royalty Document (as applicable);
(d) Without limiting the generality of clause (a) above, Borrower or any of its Subsidiaries fails to timely pay, in accordance with the terms and conditions of any Permitted Royalty Agreement Document, Permitted Royalty Financing Document, Permitted Other Royalty Financing Document or Permitted Acquisition Royalty Document, after the same becomes due any amount owing under such Permitted Royalty Agreement Document, Permitted Royalty Financing Document, Permitted Other Royalty Financing Document or Permitted Acquisition Royalty Document (as applicable), including, for the avoidance of doubt, any such failure that would obligate Borrower or any of its Subsidiaries to pay interest to any counterparty to such Permitted Royalty Agreement Document, Permitted Royalty Financing Document, Permitted Other Royalty Financing Document or Permitted Acquisition Royalty Document (as applicable), unless (x) such payment is subject to an Adverse Proceeding that has been commenced or brought by any counterparty against Borrower or such Subsidiary; or (y) the amount of such payment, individually or when aggregated with any other amounts due under any Permitted Royalty Agreement Document, Permitted Royalty Financing Document, Permitted Other Royalty Financing Document or Permitted Acquisition Royalty Document and unpaid, is less than $5,000,000;
(e) With respect to any Permitted Royalty Agreement or other Permitted Royalty Agreement Documents, Borrower or any of its Subsidiaries makes or permits (or exercises any option with respect thereto), directly or indirectly through a Subsidiary, any payment or reimbursement of any kind to any counterparty pursuant to such Permitted Royalty Agreement or other Permitted Royalty Agreement Document other than any Permitted Royalty Agreement Payment; or
-67-
(f) With respect to any Permitted Royalty Financing Document, Permitted Other Royalty Financing Document or any Permitted Acquisition Royalty Document, makes or permits (or exercises any option with respect thereto), directly or indirectly through a Subsidiary: (i) any (x) advance payment, prepayment or accelerated payment of any royalty payments or similar payments owed under the terms of such Permitted Royalty Financing Document, such Permitted Other Royalty Financing Document or such Permitted Acquisition Royalty Document or any minimum amount payment in the form of a true up, any payment relating to a change of control, any late or overdue payments in excess of shortfalls discovered through an audit, any payment of fees or interest payments with respect to any such shortfalls, or any payment of fees relating to the termination of the underlying Permitted Royalty Financing, or the underlying Permitted Other Royalty Financing Document or the underlying Permitted Acquisition Royalty Obligations, as applicable, (y) any payment that Borrower or such Subsidiary has the right, but not the obligation, to make or to make more frequently pursuant to such Permitted Royalty Financing Document or such Permitted Other Royalty Financing Document or such Permitted Acquisition Royalty Document, or (z) any deposit into any collateral or similar account established and maintained in connection with the transactions contemplated under such Permitted Royalty Financing Document, or such Permitted Other Royalty Financing Document or such Permitted Acquisition Royalty Document other than in the minimum amount and in the manner expressly required in accordance with the terms and conditions of such Permitted Royalty Financing Document, or such Permitted Other Royalty Financing Document or such Permitted Acquisition Royalty Document; or (ii) any payment pursuant to any amendment, restatement, supplement, modification or replacement, or any renewal or alteration, of such Permitted Royalty Financing Document, or such Permitted Other Royalty Financing Document or such Permitted Acquisition Royalty Document, including pursuant to any waiver, consent or approval, which such payment or deposit, as applicable, in each case of foregoing sub-clauses (i) and (ii), that is not a Permitted Royalty Financing Agreement Payment, Permitted Other Royalty Financing Agreement Payment or Permitted Acquisition Royalty Agreement Payment and is not permitted under Section 6.10 or Section 6.14(c).
7.7 Judgments. One or more final, non-appealable judgments, orders, or decrees for the payment of money, or one or more settlement agreements requiring the payment of money, in an amount in excess of $5,000,000 (but excluding any final judgments, orders, or decrees for the payment of money, or settlement agreements requiring the payment of money, in each case that is covered by a policy from an independent third-party insurance carrier as to which such insurance carrier has not excluded or denied liability or by an indemnification claim against a solvent and unaffiliated Person that is not a Credit Party or a Subsidiary of a Credit Party as to which such Person has not denied liability for such claim), shall be rendered against or entered into by one or more Credit Parties and the same are not, within thirty (30) days after the entry thereof, discharged or execution thereof stayed or bonded pending appeal, or such judgments are not discharged prior to the expiration of any such stay.
7.8 Misrepresentations. Any Credit Party or any Person acting for any Credit Party makes or is deemed to make any representation, warranty, or other statement now or later in this Agreement, any other Loan Document or in any writing delivered to the Collateral Agent or any Lender or to induce the Collateral Agent or any Lender to enter this Agreement or any other Loan Document, and such representation, warranty, or other statement is incorrect in any material respect (or, to the extent any such representation, warranty or other statement is qualified by materiality or Material Adverse Change, in any respect) when made or deemed to be made.
7.9 Loan Documents; Collateral. Any material provision of any Loan Document shall for any reason cease to be valid and binding on or enforceable against any Credit Party, or any Credit Party shall so state in writing or bring an action to limit its obligations or liabilities thereunder; or any Collateral Document shall for any reason (other than pursuant to or expressly permitted by the terms thereof) cease to create a valid security interest in any material portion of the Collateral purported to be covered thereby or such security interest shall for any reason (other than pursuant to or expressly permitted by the terms of the Loan Documents) cease to be a perfected and first priority security interest in any material portion of the Collateral subject thereto, subject only to Permitted Liens, in each case, other than as a direct result of any action by the Collateral Agent or any Lender or failure of the Collateral Agent or any Lender to perform an obligation thereof under the Loan Documents.
7.10 ERISA Event. An ERISA Event occurs that, individually or taken together with any other ERISA Events, results or could reasonably be expected to result in a Material Adverse Change or the imposition of a Lien under Section 303(k) of ERISA on any Collateral that, individually or taken together with any other such Liens, could reasonably be expected to result in a Material Adverse Change.
-68-
7.11 Intercreditor Agreements. (i) A default or breach on the part of a Credit Party occurs under any other subordination, intercreditor or other similar agreement with respect to any Permitted Indebtedness that constitutes Subordinated Debt, Working Capital Indebtedness or Permitted Convertible Indebtedness, or with respect to any Permitted Royalty Financing or any Permitted Other Royalty Financing, or (ii) any creditor party to such an agreement with the Collateral Agent (or Lenders) and any Credit Party breaches any of the terms of such agreement, in each case of sub-clauses (i) and (ii) above, to the extent such breach or default results or could reasonably be expected to result in a Material Adverse Change. For the avoidance of doubt, default or breaches by any Secured Party shall not constitute an Event of Default hereunder.
8. RIGHTS AND REMEDIES UPON AN EVENT OF DEFAULT
8.1 Rights and Remedies. While an Event of Default occurs and continues, the Collateral Agent may, or at the request of the Required Lenders, will, without notice or demand:
(a) declare all Obligations (including, for the avoidance of doubt, any and all amounts payable pursuant to Section 2.2(e) and Section 2.2(f), as applicable) immediately due and payable (but if an Event of Default described in Section 7.5 occurs, all Obligations, including any and all amounts payable pursuant to Section 2.2(e) and Section 2.2(f), as applicable, are automatically and immediately due and payable without any notice, demand or other action by the Collateral Agent or any Lender), whereupon all Obligations for principal, interest, premium or otherwise (including, for the avoidance of doubt, any and all amounts payable pursuant to Section 2.2(e) and Section 2.2(f), as applicable) shall become due and payable by Borrower without presentment for payment, demand, notice of protest or other demand or notice of any kind, which are all expressly waived by the Credit Parties hereby;
(b) stop advancing money or extending credit for Borrower’s benefit under this Agreement;
(c) settle or adjust disputes and claims directly with Account Debtors for amounts on terms and in any order that the Collateral Agent considers advisable, notify any Person owing Borrower money of the Collateral Agent’s security interest, for the benefit of the Lenders and the other Secured Parties, in such funds, and verify the amount of the Collateral Accounts;
(d) make any payments and do any acts it considers necessary or reasonable to protect the Collateral or the Collateral Agent’s security interest, for the benefit of Lenders and the other Secured Parties, in the Collateral. Borrower shall assemble the Collateral if the Collateral Agent or the Required Lenders requests and make it available as the Collateral Agent designates or the Required Lenders designate. The Collateral Agent or its agents or representatives may enter premises where the Collateral is located, take and maintain possession of any part of the Collateral, and pay, purchase, contest, or compromise any Lien that appears to be prior or superior to its security interest, for the benefit of Lenders and the other Secured Parties, and pay all expenses incurred. Effective solely while an Event of Default occurs and continues, Borrower grants the Collateral Agent an irrevocable, royalty-free license or other right to enter, use, operate and occupy (and for its agents or representatives to enter, use, operate and occupy), without charge, any such premises to exercise any of the Collateral Agent’s or any Lender’s rights or remedies under this Section 8.1 (including in order to take possession of, collect, receive, assemble, process, appropriate, remove, realize upon, advertise for sale, sell, assign, license out, convey, transfer or grant options to purchase any Collateral);
(e) apply to the Obligations (i) any balances and deposits of Borrower it holds, (ii) any amount held by the Collateral Agent owing to or for the credit or the account of Borrower or (iii) any balance from any Collateral Account of any Credit Party or instruct the bank at which any such Collateral Account is maintained to pay the balance of any such Collateral Account to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, or to any Lender on behalf of itself and the other Secured Parties, as the Collateral Agent shall direct;
-69-
(f) ship, reclaim, recover, store, finish, maintain, repair, prepare for sale, advertise for sale, and sell the Collateral; and in connection therewith, while an Event of Default occurs and continues, with respect to any and all Intellectual Property owned or held by any Credit Party and included in Collateral, each Credit Party hereby grants to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, to the maximum extent permitted: an irrevocable, non-exclusive, assignable, royalty-free license or other right to use (and for its agents or representatives to use), without charge, including the right to sublicense, use and practice, any and all of such Credit Party’s rights to such Intellectual Property for the purpose of taking possession of, collecting, receiving, assembling, processing, appropriating, removing, realizing upon, advertising for sale, selling, assigning, licensing out, conveying, transferring or granting options to purchase any Collateral, and access to all media in which any of the licensed items may be recorded or stored and to all Software and programs used for the compilation or printout thereof; and in connection with the Collateral Agent’s exercise of its rights or remedies under this Section 8.1 (including in order to take possession of, collect, receive, assemble, process, appropriate, remove, realize upon, sell, assign, license out, convey, transfer or grant options to purchase any Collateral), each Credit Party’s rights under all licenses for rights to any Intellectual Property included in the Collateral will (to the maximum extent permitted) be exercisable and enforceable directly by the Collateral Agent for the benefit of all Secured Parties as if the Collateral Agent were a third-party beneficiary for such purpose under such licenses;
(g) place a “hold” on any account maintained with the Collateral Agent or deliver a notice of exclusive control, any entitlement order, or other directions or instructions pursuant to any Control Agreement or similar agreements providing control of any Collateral;
(h) demand and receive possession of the Books of any Credit Party regarding Collateral; and
(i) exercise all rights and remedies available to the Collateral Agent or any Lender under the Collateral Documents or any other Loan Documents or at law or equity, including all remedies provided under the Code (including disposal of the Collateral pursuant to the terms thereof).
(j) Each of the Collateral Agent and Lender agrees that in connection with any foreclosure or other exercise of rights under this Agreement or any other Loan Document with respect to any Intellectual Property included in the Collateral, the rights of the licensees under any license of such Intellectual Property will not be terminated, limited or otherwise adversely affected so long as no default exists thereunder in a way that would permit the licensor to terminate such license (commonly termed a non-disturbance). Without limitation to any other provision herein or in any other Loan Document, while an Event of Default occurs and continues, at the Collateral Agent’s or the Required Lenders’ request, representatives from Borrower and the Collateral Agent shall promptly meet (in person or telephonically) to discuss in good faith how to collect, receive, appropriate and realize upon Borrower’s rights and interests in, to and under any Company IP Agreement, including in connection with any foreclosure or other exercise of the Collateral Agent’s or any Lender’s rights with respect thereto. If Borrower and the Collateral Agent do not mutually agree with respect thereto within ten (10) Business Days after such request by the Collateral Agent (or such later date as agreed by the Collateral Agent), then the Collateral Agent may request Borrower to, and Borrower (promptly following the receipt of such request) shall, use reasonable best efforts to obtain the written consent of any counterparty to the exercise by the Collateral Agent or any Lender of any and all rights and remedies under this Agreement or any other Loan Document with respect to any Company IP Agreement, in form and substance reasonably satisfactory to the Collateral Agent.
-70-
8.2 Power of Attorney. Borrower hereby irrevocably appoints the Collateral Agent and any Related Party thereof as its lawful attorney-in-fact, exercisable solely upon the occurrence and during the continuance of an Event of Default, to: (a) endorse Borrower’s name on any checks or other forms of payment or security; (b) sign Borrower’s name on any invoice or bill of lading for any Account or drafts against Account Debtors; (c) settle and adjust disputes and claims about the Collateral Accounts directly with depository banks where the Collateral Accounts are maintained, for amounts and on terms the Collateral Agent determines reasonable; (d) make, settle, and adjust all claims under Borrower’s products liability or general liability insurance policies maintained in any jurisdiction regarding Collateral; (e) pay, contest or settle any Lien, charge, encumbrance, security interest, and adverse claim in or to the Collateral, or any judgment based thereon, or otherwise take any action to terminate or discharge the same; and (f) transfer the Collateral into the name of the Collateral Agent or a third-party as the Code permits. Borrower hereby appoints the Collateral Agent and any Related Party thereof as its lawful attorney-in-fact solely to file or record any documents necessary to perfect or continue the perfection of the Collateral Agent’s security interest, for the benefit of Lenders and the other Secured Parties, in the Collateral regardless of whether an Event of Default has occurred until all Obligations (other than contingent indemnification and reimbursement obligations to the extent no claim giving rise thereto has been asserted) have been satisfied in full and no Lender is under any further obligation to make Credit Extensions hereunder. The foregoing appointment of the Collateral Agent and any Related Party thereof as Borrower’s attorney in fact, and all of the Collateral Agent’s (or such Related Party’s) rights and powers, coupled with an interest, are irrevocable until all Obligations (other than contingent indemnification and reimbursement obligations to the extent no claim giving rise thereto has been asserted) have been fully repaid and performed and each Lender’s obligation to provide Credit Extensions terminates.
8.3 Application of Payments and Proceeds Upon Default. If an Event of Default has occurred and is continuing, the Collateral Agent shall apply any funds in its possession, whether from Borrower account balances, payments, proceeds realized as the result of any collection of Collateral Accounts or disposition of any other Collateral, or otherwise, to the Obligations in such order as the Collateral Agent shall determine in its sole discretion. Any surplus shall be paid to Borrower or other Persons legally entitled thereto; Borrower shall remain liable to Lenders for any deficiency. If the Collateral Agent or any Lender directly or indirectly enters into a deferred payment or other credit transaction with any purchaser at any sale of Collateral, the Collateral Agent or such Lender, as applicable, shall have the option, exercisable at any time, of either reducing the Obligations by the principal amount of the purchase price or deferring the reduction of the Obligations until the actual receipt by the applicable Lender(s) of cash therefor.
8.4 Collateral Agent’s Liability for Collateral. So long as the Collateral Agent complies with Requirements of Law regarding the safekeeping of the Collateral in the possession or under the control of the Collateral Agent and absent bad faith, gross negligence or willful misconduct of the Collateral Agent (as determined by a court of competent jurisdiction by final and nonappealable judgment), the Collateral Agent shall not be liable or responsible for: (a) the safekeeping of the Collateral; (b) any loss or damage to the Collateral; or (c) any act or default of any other Person. In no event shall the Collateral Agent or any Lender have any liability for any diminution in the value of the Collateral for any reason except as a result of the Collateral Agent’s bad faith, gross negligence or willful misconduct (as determined by a court of competent jurisdiction by final and nonappealable judgment). Subject to the foregoing, Borrower bears all risk of loss, damage or destruction of the Collateral.
8.5 No Waiver; Remedies Cumulative. The Collateral Agent’s or any Lender’s failure, at any time or times, to require strict performance by Borrower or any other Person of any provision of this Agreement or any other Loan Document shall not waive, affect, or diminish any right of the Collateral Agent or any Lender thereafter to demand strict performance and compliance herewith or therewith. No waiver hereunder shall be effective unless signed by the party granting the waiver and then is only effective for the specific instance and purpose for which it is given. Each of the Collateral Agent’s and Lender’s rights and remedies under this Agreement and the other Loan Documents are cumulative. Each of the Collateral Agent and Lenders has all rights and remedies provided under the Code, by law, or in equity. The exercise by the Collateral Agent or any Lender of one right or remedy is not an election and shall not preclude the Collateral Agent or any Lender from exercising any other remedy under this Agreement or other remedy available at law or in equity, and the waiver by the Collateral Agent or any Lender of any Event of Default is not a continuing waiver. The Collateral Agent’s or any Lender’s delay in exercising any remedy is not a waiver, election, or acquiescence.
-71-
8.6 Demand Waiver; Makewhole Amount; Prepayment Premium; Additional Consideration. Borrower waives demand, notice of default or dishonor, notice of payment and nonpayment, notice of any default, nonpayment at maturity, release, compromise, settlement, extension, or renewal of accounts, documents, instruments, chattel paper, and guarantees held by the Collateral Agent on which Borrower is liable. Borrower acknowledges and agrees that if the Obligations shall be or are prepaid or repaid pursuant to Section 2.2(c) or the maturity of the Obligations shall be accelerated pursuant to Section 8.1(a), each of the applicable Makewhole Amount and Prepayment Premium that is payable pursuant to Section 2.2(e) and Section 2.2(f), as applicable, shall become due and payable by Borrower upon such prepayment or repayment, whether such prepayment or repayment is voluntary or mandatory (as provided in Section 2.2(c)) or such acceleration, whether automatic or effected by the Collateral Agent’s or any Lender’s declaration thereof (as provided in Section 8.1(a)), and shall also become due and payable by Borrower in the event the Obligations are satisfied or released by foreclosure (whether by power of judicial proceeding), deed in lieu of foreclosure or by any other similar means, and in all such cases Borrower shall pay each of the Makewhole Amount and Prepayment Premium that is payable pursuant to Section 2.2(e) and Section 2.2(f), as applicable, as well as any accrued Additional Consideration that is payable pursuant to Section 2.7, as compensation to Lenders for the loss of its investment opportunity and not as a penalty, and Borrower waives any right to object thereto in any voluntary or involuntary bankruptcy, insolvency or similar proceeding or otherwise.
9. NOTICES
All notices, consents, requests, approvals, demands, or other communication by any party to this Agreement or any other Loan Document must be in writing and shall be deemed to have been validly served, given, or delivered: (a) upon the earlier of actual receipt and three (3) Business Days after deposit in the U.S. mail, first class, registered or certified mail return receipt requested, with proper postage prepaid; (b) upon transmission, when sent by electronic mail; (c) one (1) Business Day after deposit with a reputable overnight courier with all charges prepaid; or (d) when delivered, if hand-delivered by messenger, all of which shall be addressed to the party to be notified and sent to the address, or email address (if any) indicated below. Any party to this Agreement may change its mailing or electronic mail address by giving all other parties hereto written notice thereof in accordance with the terms of this Section 9.
If to Borrower or any other Credit Party:
CorMedix Inc.
389 Interpace Pkwy.
Suite 450
Parsippany, NJ 07054
Attn: Chief Financial Officer
Email: [***]
with a copy to (which shall not constitute notice) to:
Willkie Farr & Gallagher LLP
787 Seventh Avenue
New York, NY 10019 6099
Attn: Sarah B. Gelb
Phone: [***]
Email: [***]
If to Collateral Agent: BioPharma Credit PLC
c/o MUFG Corporate Governance Limited
51 Lime Street
19th Floor
London, United Kingdom
EC3M 7DQ
Attn: Company Secretary
Email: [***]
-72-
with a copy to (which shall not constitute notice) to:
BioPharma Credit PLC
c/o Pharmakon Advisors, LP
110 East 59th Street, # 2800
New York, NY 10022
Attn: Pedro Gonzalez de Cosio
Phone: [***]
Fax: [***]
Email: [***]
and
Akin Gump Strauss Hauer & Feld LLP
One Bryant Park
New York, NY 10036-6745
Attn: Geoffrey E. Secol
Phone: [***]
Email: [***]
If to any Lender: To the address of such Lender set forth on Exhibit D attached hereto
with a copy to (which shall not constitute notice) to:
Pharmakon Advisors, LP
110 East 59th Street, #2800
New York, NY 10022
Attn: Pedro Gonzalez de Cosio
Phone: [***]
Fax: [***]
Email: [***]
and
Akin Gump Strauss Hauer & Feld LLP
One Bryant Park
New York, NY 10036-6745
Attn: Geoffrey E. Secol
Phone: [***]
Email: [***]
-73-
10. CHOICE OF LAW, VENUE, AND JURY TRIAL WAIVER
THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS (EXCLUDING THOSE LOAN DOCUMENTS THAT BY THEIR OWN TERMS ARE EXPRESSLY GOVERNED BY THE LAWS OF ANOTHER JURISDICTION) SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, PROVIDED, HOWEVER, THAT IF THE LAWS OF ANY JURISDICTION OTHER THAN NEW YORK SHALL GOVERN IN REGARD TO THE VALIDITY, PERFECTION OR EFFECT OF PERFECTION OF ANY LIEN OR IN REGARD TO PROCEDURAL MATTERS AFFECTING THE ENFORCEMENT OF ANY LIENS IN COLLATERAL, SUCH LAWS OF SUCH OTHER JURISDICTIONS SHALL APPLY TO THAT EXTENT. Each party hereto submits to the exclusive jurisdiction of the courts of the State of New York sitting in New York County, and of the United States District Court of the Southern District of New York, and any appellate court from any thereof, and agrees that all claims in respect of any such action, litigation or proceeding may be heard and determined in such New York State court or, to the fullest extent permitted by Requirements of Law, in such Federal court; provided, however, that nothing in this Agreement shall be deemed to operate to preclude the Collateral Agent or any Lender from bringing suit or taking other legal action in any other jurisdiction to realize on the Collateral or any other security for the Obligations, or to enforce a judgment or other court order in favor of the Collateral Agent or any Lender. Each Credit Party expressly submits and consents in advance to such jurisdiction in any action or suit commenced in any such court, and each Credit Party hereby waives any objection that it may have based upon lack of personal jurisdiction, improper venue, or forum non conveniens and hereby consents to the granting of such legal or equitable relief as is deemed appropriate by such court. Each Credit Party hereby waives personal service of the summons, complaints, and other process issued in such action or suit and agrees that service of such summons, complaints, and other process may be made by registered or certified mail addressed to such party at the address set forth in (or otherwise provided in accordance with the terms of) Section 9 of this Agreement and that service so made shall be deemed completed upon the earlier to occur of such party’s actual receipt thereof or three (3) days after deposit in the U.S. mails, proper postage prepaid.
TO THE FULLEST EXTENT PERMITTED BY REQUIREMENTS OF LAW, EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES ITS RIGHT TO A JURY TRIAL IN ANY CLAIM, SUIT, ACTION OR PROCEEDING WITH RESPECT TO, OR DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH, THIS AGREEMENT, ANY OTHER LOAN DOCUMENT OR THE TRANSACTIONS CONTEMPLATED HEREIN AND THEREIN OR RELATED HERETO OR THERETO (WHETHER FOUNDED IN CONTRACT, TORT OR ANY OTHER THEORY). EACH PARTY HERETO (A) CERTIFIES THAT NO OTHER PARTY AND NO RELATED PARTY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 10 AND (C) HAS REVIEWED THIS WAIVER WITH ITS COUNSEL.
11. GENERAL PROVISIONS
11.1 Successors and Assigns.
(a) This Agreement binds and is for the benefit of the parties hereto and their respective successors and permitted assigns.
(b) No Credit Party may transfer, pledge or assign this Agreement or any other Loan Document or any rights or obligations hereunder or thereunder without the prior written consent of each Lender. Subject to Section 11.1(d), any Lender may at any time sell, transfer, assign or pledge this Agreement or any other Loan Document or any of its rights or obligations hereunder or thereunder, or grant a participation in all or any part of, or any interest in, such Lender’s obligations, rights or benefits under this Agreement and the other Loan Documents, including with respect to any Term Loan (or any portion thereof), to any other Lender, any Affiliate of any Lender or any third Person without Borrower’s consent (any such sale, transfer, assignment, pledge or grant of a participation, a “Lender Transfer”), including, for the avoidance of doubt, in furtherance of, as contemplated under or otherwise in connection with any Lender’s credit facility (including any exercise of rights or remedies thereunder or any actions as a result of any such exercise); provided, however, that no Lender may make a Lender Transfer to a Disqualified Assignee without Borrower’s prior written consent except after the occurrence and during the continuance of an Event of Default (in which case such consent is not required).
-74-
(c) In the case of a Lender Transfer in the form of a participation granted by any Lender to any third Person, (i) such Lender’s obligations under this Agreement shall remain unchanged, (ii) such Lender shall remain solely responsible to the other parties hereto for the performance of its obligations hereunder, (iii) Borrower shall continue to deal solely and directly with such Lender in connection with such Lender’s rights and obligations under this Agreement and (iv) any agreement or instrument pursuant to which such Lender sells such participation shall provide that such Lender shall retain the sole right to enforce this Agreement and to approve any amendment, restatement, amendment and restatement, supplement or other modification hereto, in each case subject to the terms and conditions of this Agreement. Borrower agrees that each participant shall be entitled to the benefits of Sections 2.5 and 2.6 (subject to the requirements and limitations therein, including the requirements under Section 2.6(d) (it being understood that the documentation required under Section 2.6(d) shall be delivered to the applicable Lender)) to the same extent as if it were a Person that had acquired its interest by assignment pursuant to clause (b) above; provided that, with respect to any participation, such participant shall not be entitled to receive any greater payment under Sections 2.5 or 2.6 than the applicable Lender (i.e., the party that participated the interest) would have been entitled to receive, except to the extent of any entitlement to receive a greater payment resulting from a Change in Law that occurs after such participant acquired the applicable participation.
(d) Borrower shall record any Lender Transfer in the Note Register. Each Lender shall provide Borrower and the Collateral Agent with written notice of a Lender Transfer delivered no later than five (5) Business Days (or immediately if known fewer than five (5) Business Days) prior to the date on which such Lender Transfer is proposed to be consummated. If any Lender sells a participation, such Lender shall, acting solely for this purpose as a non-fiduciary agent of Borrower, maintain a register on which it enters the name and address of each participant and principal amounts (and stated interest) of each participant’s interest in the Term Loans or other obligations under the Loan Documents (the “Participant Register”); provided, however, that such Lender shall have no obligation to disclose all or any portion of the Participant Register (including the identity of any participant or any information relating to a participant’s interest in any commitments, loans or its other obligations under any Loan Document) to any Person except to the extent that such disclosure is necessary to establish that such commitment, loan, letter of credit or other obligation is in “registered form” within the meaning of Section 5f.103-1(c) of the United States Treasury regulations (or any amended or successor version) or Section 163(f), 871(h)(2) and 881(c)(2) of the IRC and any related regulations (and any other relevant or successor provisions of the IRC or such regulations). The entries in the Participant Register shall be conclusive absent manifest error, and the Collateral Agent and each Lender shall treat each Person whose name is recorded in the Participant Register as the owner of such participation for all purposes of this Agreement notwithstanding any notice to the contrary. For avoidance of doubt, no Lender Transfer shall be made to a Blocked Person.
(e) Any attempted transfer, pledge or assignment of this Agreement or any other Loan Document or any rights or obligations hereunder or thereunder in violation of this Section 11.1 shall be null and void.
11.2 Indemnification.
(a) Borrower agrees to indemnify and hold harmless each of the Collateral Agent, Lenders and its and their respective Affiliates (and its or their respective successors and assigns) and each manager, member, partner, controlling Person, director, officer, employee, agent or sub-agent, advisor and affiliate thereof (each such Person, an “Indemnified Person”) from and against any and all Indemnified Liabilities; provided, however, that Borrower shall have no obligation to any Indemnified Person hereunder with respect to any Indemnified Liabilities to the extent such Indemnified Liabilities (i) are determined by a court of competent jurisdiction by final and nonappealable judgment to have resulted from the bad faith, gross negligence or willful misconduct of such Indemnified Person (or the bad faith, gross negligence or willful misconduct of such Indemnified Person’s affiliates or controlling Persons or any of their respective managers, members, partners, controlling Persons, directors, officers, employees, agents or sub-agents, advisors or affiliates), (ii) result from a claim brought by Borrower against an Indemnified Person for material breach in bad faith of any of such Indemnified Person’s obligations hereunder or under any other Loan Document, if Borrower has obtained a final and nonappealable judgment in its favor on such claim as determined by a court of competent jurisdiction, or (iii) result from a claim not involving an act or omission of Borrower or any of its Subsidiaries that is brought by an Indemnified Person against another Indemnified Person (other than against the Collateral Agent in its capacity as such). This Section 11.2(a) shall not apply with respect to Taxes other than any Taxes that represent liabilities, obligations, losses, damages, penalties, claims, costs, expenses and disbursements arising from any non-Tax claim.
-75-
(b) To the extent permitted by Requirements of Law, no party to this Agreement shall assert, and each party to this Agreement hereby waives, any claim against any other party hereto (and its or their successors and assigns), and each manager, member, partner, controlling Person, director, officer, employee, agent or sub-agent, advisor and affiliate thereof, on any theory of liability, for special, indirect, consequential or punitive damages (as opposed to direct or actual damages) (whether or not the claim therefor is based on contract, tort or duty imposed by any applicable legal requirement) arising out of, in connection with, arising out of, as a result of, or in any way related to, this Agreement or any Loan Document or any agreement or instrument contemplated hereby or thereby or referred to herein or therein, the transactions contemplated hereby or thereby, any Credit Extension or the use of the proceeds thereof or any act or omission or event occurring in connection therewith, and each party to this Agreement hereby waives, releases and agrees not to sue upon any such claim or any such damages, whether or not accrued and whether or not known or suspected to exist in its favor.
(c) Any action taken by any Credit Party under or with respect to any Loan Document, even if required under any Loan Document, or at the request of the Collateral Agent or any Lender, shall be at the expense of such Credit Party, and neither the Collateral Agent nor any Secured Party shall be required under any Loan Document to reimburse any Credit Party or any Subsidiary of any Credit Party therefor except as expressly provided therein. In addition, and without limiting the generality of Section 2.4, Borrower agrees to pay or reimburse promptly upon demand each of the Collateral Agent and Lenders (and their respective successors and assigns) and each of their respective Related Parties, if applicable, for any and all fees, expenses and disbursements of the kind or nature described in clause (b) of the definition of “Lender Expenses” or described in the definition of “Indemnified Liabilities” incurred by it.
11.3 Severability of Provisions. In case any provision in or obligation hereunder or under any other Loan Document shall be invalid, illegal or unenforceable in any jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby.
11.4 Correction of Loan Documents. The Collateral Agent or Required Lenders may correct patent errors and fill in any blanks in the Loan Documents consistent with the agreement of the parties hereto so long as the Collateral Agent or Required Lenders, as applicable, provides the Credit Parties and the other parties hereto with written notice of such correction and allows the Credit Parties at least ten (10) days to object to such correction in writing delivered to the Collateral Agent and each Lender. In the event of such objection, such correction shall not be made except by an amendment to this Agreement in accordance with Section 11.5.
11.5 Amendments in Writing; Integration.
(a) No amendment, restatement, amendment and restatement or other modification of or supplement to any provision of this Agreement or any other Loan Document, or waiver, discharge or termination of any obligation hereunder or thereunder, no approval or consent hereunder or thereunder (including any consent to any departure by Borrower or any other Credit Party herefrom or therefrom), shall in any event be effective unless the same shall be in writing and signed by Borrower (on its own behalf and on behalf of each other Credit Party) and the Required Lenders; provided, however, that no such amendment, restatement, amendment and restatement, modification, supplement, waiver, discharge, termination, approval or consent shall, unless in writing and signed by the Collateral Agent and the Required Lenders, affect the rights or duties of, or any amounts payable to, the Collateral Agent under this Agreement or any other Loan Document. Any such waiver, approval or consent granted shall be limited to the specific circumstance expressly described in it and shall not apply to any subsequent or other circumstance, whether similar or dissimilar, or give rise to, or evidence, any obligation or commitment to grant any further waiver, approval or consent.
-76-
(b) This Agreement and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements. All prior agreements, understandings, representations, warranties, and negotiations among the parties hereto about the subject matter of this Agreement and the Loan Documents merge into this Agreement and the Loan Documents.
11.6 Counterparts. This Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one Agreement.
11.7 Survival; Termination. All covenants, representations and warranties made in this Agreement continue in full force until this Agreement has terminated pursuant to this Section 11.7 and all Obligations (other than contingent indemnification and reimbursement obligations to the extent no claim giving rise thereto has been asserted and any other obligations which, by their terms, are to survive the termination of this Agreement) have been paid in full and satisfied in accordance with the terms of this Agreement. The obligation of Borrower or any other the Credit Parties in Section 11.2 to indemnify Indemnified Persons shall survive until the statute of limitations with respect to such claim or cause of action shall have run. So long as all Obligations (other than contingent indemnification and reimbursement obligations to the extent no claim giving rise thereto has been asserted and any other obligations which, by their terms, are to survive the termination of this Agreement and for which no claim has been made) have been paid in full and satisfied in accordance with the terms of this Agreement, this Agreement and the other Loan Documents shall be terminated automatically upon payment in full of all Obligations.
11.8 Confidentiality. Any information regarding the Credit Parties and their Subsidiaries and their businesses provided to the Collateral Agent or any Lender by or on behalf of any Credit Party pursuant to the Loan Documents shall be deemed “Confidential Information”; provided, however, that Confidential Information does not include information that is either: (i) in the public domain or in the possession of the Collateral Agent, any Lender or any of their respective Affiliates or when disclosed to the Collateral Agent, any Lender or any of their respective Affiliates, or becomes part of the public domain after disclosure to the Collateral Agent, any Lender or any of their respective Affiliates, in each case, other than as a result of a breach by the Collateral Agent, any Lender or any of their respective Affiliates of the obligations under this Section 11.8; or (ii) disclosed to the Collateral Agent, any Lender or any of their respective Affiliates by a third-party if the Collateral Agent, such Lender or such Affiliate, as applicable, does not know (following reasonable inquiry) that the third-party is prohibited from disclosing the information. Neither the Collateral Agent nor any Lender shall disclose any Confidential Information to a third-party or use Confidential Information for any purpose other than the administration of the Loan Documents, the exercise of its rights or remedies under the Loan Documents or the performance of its duties or obligations under the Loan Documents. The foregoing in this Section 11.8 notwithstanding, the Collateral Agent and each Lender may disclose Confidential Information: (a) to any of its Subsidiaries or Affiliates; (b) to prospective transferees, purchasers or participants of any interest in the Term Loans (including, for the avoidance of doubt, in connection with any proposed Lender Transfer), provided, that, no such disclosure to any Disqualified Assignee shall be permitted hereunder without Borrower’s prior written consent (which consent shall not be required after the occurrence and during the continuance of an Event of Default); (c) as required by any legal, judicial or administrative proceeding or as otherwise required by or as necessary to comply with Requirements of Law (including, for the avoidance of doubt, any Sanctions, Anti-Money Laundering Laws, Anti-Corruption Laws or Export and Import Laws) or compulsory legal process, provided, that, (x) prior to any disclosure under this clause (c), the Collateral Agent or such Lender, as applicable, agrees to endeavor to provide Borrower with prior written notice thereof, to the extent that the Collateral Agent or such Lender is permitted to provide such prior notice to Borrower pursuant to such proceeding, law or process and if the Collateral Agent or such Lender is unable to notify Borrower prior to such disclosure, to inform Borrower promptly thereafter to the extent reasonably practicable and permitted by such proceeding, law or process, and (y) any disclosure under this clause (c) shall be limited solely to that portion of the Confidential Information as may be specifically compelled by such proceeding, law, or other process; (d) to the extent requested by regulators having jurisdiction over the Collateral Agent or such Lender or as otherwise required in connection with the Collateral Agent’s or such Lender’s examination or audit by such regulators (including any self-regulatory authority, such as the National Association of Insurance Commissioners); (e), as the Collateral Agent or such Lender considers reasonably necessary in exercising any rights or remedies under the Loan Documents or in connection with any proceeding relating to the Agreement or any other Loan Documents; (f) to any party hereto; (g) to third-party service providers of the Collateral Agent or such Lender; (h) to any of the Collateral Agent’s or such Lender’s Related Parties; (i) to the limited partners or investors (including any potential limited partners or investors) of any Lender or any fund managed by any Lender or any of its Affiliates, to the extent reasonably necessary for such Lender's ordinary course reporting and communications with such limited partners or investors; and (j) as the Collateral Agent or any Lender (or any of its or their Affiliates) considers reasonably necessary in connection with any regulatory notification or mandatory or voluntary disclosure applicable to the Collateral Agent or such Lender (or Affiliate), including any notice or disclosure under OFAC regulations or the United Kingdom’s Financial Conduct Authority’s Listing Rules or Disclosure Guidance and Transparency Rules (or any equivalent rules applicable in any other jurisdiction); provided, however, that the third parties to which Confidential Information is disclosed pursuant to clauses (a), (b), (g), (h) and (i) above are bound by obligations of confidentiality and non-use that are no less restrictive than those contained herein.
The provisions of this Section 11.8 shall survive the termination of this Agreement.
-77-
11.9 Attorneys’ Fees, Costs and Expenses. In any action or proceeding between, on the one hand, any Credit Party and, on the other hand, the Collateral Agent or any Lender, arising out of or relating to the Loan Documents other than in connection with the enforcement against any Credit Party of this Agreement or any other Loan Document, the prevailing party shall be entitled to recover its reasonable attorneys’ fees and other costs and expenses incurred, in addition to any other relief to which it may be entitled.
11.10 Right of Setoff. In addition to any rights now or hereafter granted under Requirements of Law and not by way of limitation of any such rights, upon the occurrence of an Event of Default and at any time thereafter during the continuance of any Event of Default, each Lender is hereby authorized by each Credit Party at any time or from time to time, without prior notice to any Credit Party, any such notice being hereby expressly waived by Borrower (on its own behalf and on behalf of each other Credit Party), to set off and to appropriate and to apply any and all deposits (general or special, including Indebtedness evidenced by certificates of deposit, whether matured or unmatured, but not including trust accounts) and any other Indebtedness at any time held or owing by such Lender to or for the credit or the account of any Credit Party against and on account of the obligations and liabilities of any Credit Party to such Lender hereunder and under the other Loan Documents, including all claims of any nature or description arising out of or connected hereto or with any other Loan Document, irrespective of whether or not (a) the Collateral Agent or such Lender shall have made any demand hereunder or (b) the principal of or the interest on the Term Loans or any other amounts due hereunder shall have become due and payable pursuant to Section 2 and although such obligations and liabilities, or any of them, may be contingent or unmatured. Each Lender agrees promptly to notify Borrower and the Collateral Agent after any such set-off and application made by such Lender; provided, that, the failure to give such notice shall not affect the validity of such set off and application.
11.11 Marshalling; Payments Set Aside. Neither the Collateral Agent nor any Lender shall be under any obligation to marshal any assets in favor of any Credit Party or any other Person or against or in payment of any or all of the Obligations. To the extent that any Credit Party makes a payment or payments to any Lender, or the Collateral Agent or any Lender enforces any Liens or exercises its rights of setoff, and such payment or payments or the proceeds of such enforcement or setoff or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside or required to be repaid to a trustee, receiver or any other party under any bankruptcy law, any other state or federal law, common law or any equitable cause, then, to the extent of such recovery, the obligation or part thereof originally intended to be satisfied, and all Liens, rights and remedies therefor or related thereto, shall be revived and continued in full force and effect as if such payment or payments had not been made or such enforcement or setoff had not occurred.
11.12 Electronic Execution of Documents. The words “execution,” “signed,” “signature,” and words of like import in this Agreement and the other Loan Documents shall be deemed to include electronic signatures or electronic records, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any Requirements of Law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.
11.13 Captions. Section headings herein are included herein for convenience of reference only and shall not constitute a part hereof for any other purpose or be given any substantive effect.
-78-
11.14 Construction of Agreement. The parties hereto mutually acknowledge that they and their respective attorneys have participated in the preparation and negotiation of this Agreement. In cases of uncertainty, this Agreement shall be construed without regard to which of the parties hereto caused the uncertainty to exist.
11.15 Third Parties. Nothing in this Agreement, whether express or implied, is intended to: (a) except as expressly provided in Section 11.2(a), confer any benefits, rights or remedies under or by reason of this Agreement on any Persons other than the express parties to it and their respective successors and permitted assigns; (b) relieve or discharge the obligation or liability of any Person not an express party to this Agreement; or (c) give any Person not an express party to this Agreement any right of subrogation or action against any party to this Agreement. Unless expressly provided to the contrary in this Agreement, a Person who is not a party to this Agreement has no rights under the Contracts (Rights of Third Parties) Act 1999 to enforce or enjoy the benefit of any term of this Agreement. Notwithstanding any term of any Loan Document, the consent of any Person who is not a party to this Agreement is not required to rescind or vary this Agreement at any time.
11.16 No Advisory or Fiduciary Duty. The Collateral Agent and each Lender may have economic interests that conflict with those of the Credit Parties. Each Credit Party agrees that nothing in the Loan Documents or otherwise will be deemed to create an advisory, fiduciary or agency relationship or fiduciary or other implied duty between any Lender or the Collateral Agent, on the one hand, and such Credit Party, its Subsidiaries, and any of their respective stockholders or affiliates, on the other hand. Each Credit Party acknowledges and agrees that (i) the transactions contemplated by the Loan Documents are arm’s-length commercial transactions between each Lender and the Collateral Agent, on the one hand, and such Credit Party, its Subsidiaries and their respective affiliates, on the other hand, (ii) in connection therewith and with the process leading to such transaction, the Collateral Agent and each Lender is acting solely as a principal and not the advisor, agent or fiduciary of such Credit Party, its Subsidiaries or their respective affiliates, management, stockholders, creditors or any other Person, (iii) neither the Collateral Agent nor any Lender has assumed an advisory or fiduciary responsibility in favor of any Credit Party, its Subsidiaries or their respective affiliates with respect to the transactions contemplated hereby or the process leading thereto (irrespective of whether the Collateral Agent or any Lender or any of their respective affiliates has advised or is currently advising such Credit Party, its Subsidiaries or their respective affiliates on other matters) or any other obligation to such Credit Party, its Subsidiaries or their respective affiliates except the obligations expressly set forth in the Loan Documents, and (iv) each Credit Party, its Subsidiaries and their respective affiliates have consulted their own legal and financial advisors to the extent each deemed appropriate. Each Credit Party further acknowledges and agrees that it is responsible for making its own independent judgment with respect to such transactions and the process leading thereto. Each Credit Party agrees that it will not claim that the Collateral Agent or any Lender has rendered advisory services of any nature or respect or owes a fiduciary or similar duty to such Credit Party, its Subsidiaries or their respective affiliates in connection with such transaction or the process leading thereto.
11.17 Credit Parties’ Agent. Each of the Credit Parties hereby irrevocably appoints Borrower, as its agent, attorney-in-fact and legal representative for all purposes, including requesting disbursement of the Term Loans and receiving account statements and other notices and communications to Credit Parties (or any of them) from the Collateral Agent or the Lenders, executing amendments, waivers or other modifications of or supplements to Loan Documents and executing or designating new Loan Documents. The Collateral Agent or the Lenders may rely, and shall be fully protected in relying, on any request for the Term Loans, disbursement instruction, report, information or any other notice or communication made or given by Borrower and any amendment, restatement, amendment and restatement, waiver or other modification of or supplement to a Loan Document or the execution or designation of new Loan Documents executed or made by Borrower, whether in its own name or on behalf of one or more of the other Credit Parties, and the Collateral Agent or the Lenders shall not have any obligation to make any inquiry or request any confirmation from or on behalf of any other Credit Party as to the binding effect on it of any such request, instruction, report, information, other notice, communication, amendment, restatement, amendment and restatement, supplement, waiver, other modification, execution or designation, nor shall the joint and several character of the Credit Parties’ obligations hereunder be affected thereby.
-79-
12. COLLATERAL AGENT
12.1 Appointment and Authority . Each of the Lenders hereby irrevocably appoints BioPharma Credit PLC to act on its behalf as the Collateral Agent hereunder and under the other Loan Documents and authorizes the Collateral Agent to take such actions on its behalf and to exercise such powers as are delegated to the Collateral Agent by the terms hereof or thereof, together with such actions and powers as are reasonably incidental thereto. Except for the first two (2) sentences of Section 12.6 and the penultimate paragraph of Section 12.8, the provisions of this Section 12 are solely for the benefit of the Collateral Agent and Lenders, and neither Borrower nor any other Credit Party shall have rights as a third-party beneficiary of any of such provisions. Subject to Section 12.8 and Section 11.5, any action required or permitted to be taken by the Collateral Agent hereunder shall be taken with the prior approval of the Required Lenders.
12.2 Rights as a Lender . The Person serving as the Collateral Agent hereunder shall have the same rights and powers in its capacity as a Lender as any other Lender and may exercise the same as though it were not the Collateral Agent and the term “Lender” or “Lenders” shall, unless otherwise expressly indicated or unless the context otherwise requires, include the Person serving as the Collateral Agent hereunder in its individual capacity. Such Person and its Affiliates may lend money to, own securities of, act as the financial advisor or in any other advisory capacity for and generally engage in any kind of business with Borrower or any Subsidiary or other Affiliate thereof as if such Person were not the Collateral Agent hereunder and without any duty to account therefor to any Lender.
12.3 Exculpatory Provisions .
(a) The Collateral Agent shall not have any duties or obligations to the Lenders except those expressly set forth herein and in the other Loan Documents to which it is a party. Without limiting the generality of the foregoing, with respect to the Lenders, the Collateral Agent:
(i) shall not be subject to any fiduciary or other implied duties, regardless of whether a Default or Event of Default has occurred and is continuing;
(ii) shall not have any duty to take any discretionary action or exercise any discretionary powers, except discretionary rights and powers expressly contemplated hereby or by the other Loan Documents to which it is a party that the Collateral Agent is required to exercise as directed in writing by the Required Lenders (or such other number or percentage of the Lenders as shall be expressly provided for herein or in such other Loan Documents), provided that the Collateral Agent shall not be required to take any action that, in its opinion or the opinion of its counsel, may expose the Collateral Agent to liability or that is contrary to any Loan Document or Requirements of Law; and
(iii) shall not, except as expressly set forth herein and in the other Loan Documents to which it is a party, have any duty to disclose, and shall not be liable for the failure to disclose, any information relating to any Credit Party or any of its Affiliates that is communicated to or obtained by the Person serving as the Collateral Agent or any of its Affiliates in any capacity.
-80-
(b) The Collateral Agent shall not be liable for any action taken or not taken by it (i) with the consent or at the request of the Required Lenders (or such other number or percentage of the Lenders as shall be necessary, or as the Collateral Agent shall believe in good faith shall be necessary, under the circumstances as provided in Section 11.5) or (ii) in the absence of its own gross negligence or willful misconduct as determined by a court of competent jurisdiction by final and nonappealable judgment. The Collateral Agent shall be deemed not to have knowledge of any Default or Event of Default unless and until notice describing such Default or Event of Default is given to the Collateral Agent in writing by Borrower or a Lender.
(c) The Collateral Agent shall not be responsible for or have any duty to ascertain or inquire into (i) any statement, warranty or representation made in or in connection with this Agreement or any other Loan Document, (ii) the contents of any certificate, report or other document delivered hereunder or thereunder or in connection herewith or therewith, (iii) the performance or observance of any of the covenants, agreements or other terms or conditions set forth herein or therein or the occurrence of any Default or Event of Default, (iv) the validity, enforceability, effectiveness or genuineness of this Agreement, any other Loan Document or any other agreement, instrument or document or (v) the satisfaction of any condition set forth in Section 3 or elsewhere herein, other than to confirm receipt of items expressly required to be delivered to the Collateral Agent.
12.4 Reliance by Collateral Agent. The Collateral Agent shall be entitled to rely upon, and shall not incur any liability for relying upon, any notice, request, certificate, consent, statement, instrument, document or other writing (including any electronic message, internet or intranet website posting or other distribution) believed by it to be genuine and to have been signed, sent or otherwise authenticated by the proper Person. The Collateral Agent also may rely upon any statement made to it orally or by telephone and believed by it to have been made by the proper Person and shall not incur any liability for relying thereon. The Collateral Agent may consult with legal counsel (who may be counsel for Borrower), independent accountants, manufacturing consultants and other experts selected by it, and shall not be liable for any action taken or not taken by it in accordance with the advice of any such counsel, accountants, consultants or experts.
12.5 Delegation of Duties. The Collateral Agent may perform any and all of its duties and exercise its rights and powers hereunder or under any other Loan Document by or through any one or more sub-agents appointed by the Collateral Agent. The Collateral Agent and any such sub-agent may perform any and all of its duties and exercise its rights and powers by or through their respective Related Parties. The exculpatory provisions of this Section 12 shall apply to any such sub-agent and to the Related Parties of the Collateral Agent and any such sub-agent. The Collateral Agent shall not be responsible for the negligence or misconduct of any sub-agent except to the extent that a court of competent jurisdiction determines in a final and nonappealable judgment that the Collateral Agent acted with gross negligence or willful misconduct in the selection of such sub-agent.
12.6 Resignation of Collateral Agent. The Collateral Agent may at any time give notice of its resignation to the Lenders and Borrower. Upon the receipt of any such notice of resignation, the Required Lenders shall have the right, with the prior written consent of Borrower (not to be unreasonably delayed, withheld or conditioned) so long as no Default or Event of Default has occurred and is continuing, to appoint a successor (which shall not be a Disqualified Assignee except after the occurrence and during the continuation of an Event of Default). If no successor shall have been so appointed by the Required Lenders and shall have accepted such appointment within thirty (30) days after the retiring Collateral Agent gives notice of its resignation, then the retiring Collateral Agent may, on behalf of the Lenders, appoint a successor Collateral Agent that is a Related Party of the Collateral Agent or any Lender; provided, that, whether or not a successor has been appointed or has accepted such appointment, such resignation shall become effective upon delivery of the notice thereof. Upon the acceptance of a successor’s appointment as Collateral Agent hereunder, such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring (or retired) Collateral Agent, and the retiring Collateral Agent shall be discharged from all of its duties and obligations under the Loan Documents (if not already discharged therefrom as provided above in this Section 12.6), other than, for the avoidance of doubt, its obligations under Section 11.8. After the retiring Collateral Agent’s resignation, the provisions of Section 12 and Section 10 shall continue in effect for the benefit of such retiring Collateral Agent, its sub-agents and their respective Related Parties in respect of any actions taken or omitted to be taken by any of them while the retiring Collateral Agent was acting as Collateral Agent. Upon any resignation by the Collateral Agent, all payments, communications and determinations provided to be made by, to or through the Collateral Agent shall instead be made by, to or through each Lender directly, until such time as a Person accepts an appointment as Collateral Agent in accordance with this Section 12.6.
-81-
12.7 Non-Reliance on Collateral Agent and Other Lenders. Each Lender acknowledges that it has, independently and without reliance upon the Collateral Agent or any other Lender or any of their respective Related Parties and based on such documents and information as it has deemed appropriate, made its own credit analysis and decision to enter into this Agreement and make Credit Extensions hereunder. Each Lender also acknowledges that it will, independently and without reliance upon the Collateral Agent or any other Lender or any of their respective Related Parties and based on such documents and information as it shall from time to time deem appropriate, continue to make its own decisions in taking or not taking action under or based upon this Agreement, any other Loan Document or any related agreement or any document furnished hereunder or thereunder.
12.8 Collateral and Guaranty Matters. Each Lender agrees that any action taken by the Collateral Agent or the Required Lenders in accordance with the provisions of this Agreement or of the other Loan Documents, and the exercise by the Collateral Agent or Required Lenders of the powers set forth herein or therein, together with such other powers as are reasonably incidental thereto, shall be authorized and binding upon all of the Lenders. Without limiting the generality of the foregoing, the Lenders irrevocably authorize and instruct the Collateral Agent, and the Collateral Agent agrees:
(a) to release any Lien on any property granted to or held by the Collateral Agent under any Collateral Document (i) upon payment and satisfaction in full of the Obligations (other than contingent indemnification and reimbursement obligations to the extent no claim giving rise thereto has been asserted) in accordance with the terms of this Agreement, (ii) that is sold, transferred, disposed or to be sold, transferred, disposed as part of or in connection with any sale, transfer or other disposition (other than any sale to a Credit Party) permitted hereunder, (iii) subject to Section 11.5, if approved, authorized or ratified in writing by the Required Lenders, or (iv) to the extent such property is owned by a Guarantor upon the release of such Guarantor from its obligations under the Loan Documents pursuant to clause (c) below;
(b) to subordinate any Lien on any property granted to or held by the Collateral Agent under any Loan Document to the holder of any Lien on such property that is permitted by clauses (d), (i), (j), (m), (n), (r), or (v) of the definition of “Permitted Liens”, and, solely with respect to modifications, replacements, extensions or renewals of Liens permitted under clauses (d), (i), (j), (m), (n) or (v) of the definition of “Permitted Liens”, clause (y) of the definition of “Permitted Liens”;
(c) to release any Guarantor from its obligations under the Security Agreement (and other applicable Collateral Documents) if such Person ceases to be a Subsidiary (or becomes an Excluded Subsidiary (to the extent not designated by Borrower to be a Designated Guarantor)) as a result of a transaction permitted hereunder or upon payment and satisfaction in full of the Obligations (other than contingent indemnification and reimbursement obligations);
(d) to enter into non-disturbance and similar agreements in connection with the licensing of Intellectual Property permitted pursuant to the terms of this Agreement, including any agreement that makes the Lien of the Collateral Agent expressly subject to all rights of any such licensee under any such license; and
-82-
(e) to enter into a subordination, intercreditor, or other similar agreement with respect to (i) any Permitted Indebtedness that constitutes Subordinated Debt, Working Capital Indebtedness or Permitted Convertible Indebtedness, or (ii) any Indebtedness under any Permitted Royalty Financing Document or any Permitted Other Royalty Financing Document.
Upon request by the Collateral Agent at any time, the Required Lenders will confirm in writing the Collateral Agent’s authority to release or subordinate its interest in particular types or items of property, or to release any Guarantor from its obligations under the Security Agreement (and other applicable Collateral Documents), pursuant to this Section 12.8.
In each case as specified in this Section 12.8, the Collateral Agent will (and each Lender irrevocably authorizes and instructs the Collateral Agent to), at Borrower’s expense, (A) deliver to Borrower any Collateral that is in the Collateral Agent’s possession (if any) in connection with the release of the Collateral Agent’s Lien thereon, and (B) execute and deliver to the applicable Credit Party such documents as such Credit Party may reasonably request (i) to evidence the release or subordination of such item of Collateral from the Liens and security interests granted under the Collateral Documents, (ii) to enter into non-disturbance or similar agreements in connection with the licensing of Intellectual Property, including any agreement that makes the Lien of the Collateral Agent expressly subject to all rights of any such licensee under any such license, (iii) to enter into a subordination, intercreditor, or other similar agreement with respect to any Indebtedness that constitutes Subordinated Debt to the extent such Subordinated Debt is permitted under the definition of Permitted Indebtedness or (iv) to evidence the release of any Guarantor from its obligations under the Security Agreement (and other applicable Collateral Documents), in each case in accordance with the terms of the Loan Documents and this Section 12.8 and in form and substance reasonably acceptable to the Collateral Agent.
Without limiting the generality of Section 12.10 below, the Collateral Agent shall deliver to the Lenders notice of any action taken by it under this Section 12.8 promptly after the taking thereof; provided, that, delivery of or failure to deliver any such notice shall not affect the Collateral Agent’s rights, powers, privileges and protections under this Section 12.
12.9 Reimbursement by Lenders. To the extent that Borrower for any reason fails to indefeasibly pay any amount required under Section 2.4 to be paid by it to the Collateral Agent (or any sub-agent thereof) or any Related Party of any of the foregoing, each Lender severally agrees to pay to the Collateral Agent (or any such sub-agent) or such Related Party, as the case may be, such Lender’s pro rata share (based upon the percentages as used in determining the Required Lenders as of the time that the applicable unreimbursed expense or indemnity payment is sought) of such unpaid amount; provided that the unreimbursed expense or indemnified loss, damage, liability or related expense, as the case may be, was incurred by or asserted against the Collateral Agent (or any such sub-agent) in its capacity as such or against any Related Party of any of the foregoing acting for the Collateral Agent (or any sub-agent) in connection with such capacity.
12.10 Notices and Items to Lenders. The Collateral Agent shall deliver to the Lenders each notice, report, statement, approval, direction, consent, exemption, authorization, waiver, certificate, filing or other item received by it pursuant to this Agreement or any other Loan Document (including any item received by it pursuant to Section 3 or set forth on Schedule 5.14 of the Disclosure Letter); provided, that, any delivery of or failure to deliver any such notice, report, statement, approval, direction, consent, exemption, authorization, waiver, certificate, filing or item shall not otherwise alter or effect the rights of the Lenders or the Collateral Agent under this Agreement or any other Loan Document or the validity of such item. In addition, to the extent the Collateral Agent or the Required Lenders deliver any notices, approvals, authorizations, directions, consents or waivers to Borrower pursuant to this Agreement or any other Loan Document, the Collateral Agent or the Required Lenders, as applicable, will also deliver such notice, approval, authorization, direction, consent or waiver to the other Lenders on or about the same time such notice, approval, authorization, direction, consent or waiver is provided to Borrower; provided, that, the delivery of or failure to deliver such notice, approval, authorization, direction, consent or waiver to the other Lenders shall not in any way effect the obligations of Borrower, or the rights of the Collateral Agent or the Required Lenders, in respect of such notice, approval, authorization, direction, consent or waiver or the validity thereof.
-83-
13. DEFINITIONS
13.1 Definitions. For the purposes of and as used in the Loan Documents: (a) references to any Person include its successors and assigns and, in the case of any Governmental Authority, any Person succeeding to its functions and capacities; (b) except as the context otherwise requires (including to the extent otherwise expressly provided in any Loan Document), (i) references to any law, statute, treaty, order, policy, rule or regulation include any amendments, supplements and successors thereto and (ii) references to any contract, agreement, consent, waiver, instrument or other document include any amendments, restatements, amendments and restatements, supplements or other modifications thereto or thereof from time to time to the extent permitted by or otherwise not in contravention of this Agreement or any other Loan Documents; (c) the words “shall” and “will” are interchangeable and will be understood to be imperative or mandatory in nature; (d) the word “may” is permissive; (e) the word “or” has the inclusive meaning represented by the phrase “and/or”; (f) the words “include”, “includes” and “including” are not limiting; (g) the singular includes the plural and the plural includes the singular; (h) numbers denoting amounts that are set off in parentheses are negative unless the context dictates otherwise; (i) each authorization herein shall be deemed irrevocable and coupled with an interest; (j) all accounting terms shall be interpreted, and all determinations relating thereto shall be made, in accordance with GAAP; (k) references to any time of day shall be to New York time; (l) the words “herein”, “hereof”, “hereby”, “hereto” and “hereunder” refer to this Agreement as a whole; and (m) unless otherwise expressly provided, references to specific sections, articles, clauses, sub-clauses, annexes and exhibits are to this Agreement and references to specific schedules are to the Disclosure Letter. The provisions of this Section 13.1 shall survive the termination of this Agreement. As used in this Agreement, the following capitalized terms have the following meanings:
“2030 Convertible Notes” means the $150,000,000 4.00% convertible senior notes due August 1, 2030, with cash interest payments commencing on February 1, 2026, issued by Borrower at par pursuant to that certain Indenture, dated August 12, 2025, by and between Borrower and U.S. Bank Trust Company, National Association, as trustee (the “Indenture”).
“Account” means any “account” as defined in the Code with such additions to such term as may hereafter be made, and includes all accounts receivable, book debts, and other sums owing to Credit Parties.
“Account Debtor” means any “account debtor” as defined in the Code with such additions to such term as may hereafter be made.
“Acquisition” means (a) any Stock Acquisition, or (b) any Asset Acquisition.
“Additional Consideration” means, individually or collectively, as the context dictates, the Tranche A Additional Consideration or the Tranche B Additional Consideration.
“Advance Request Form” means a Loan Advance Request Form in substantially the form attached hereto as Exhibit A.
“Adverse Proceeding” means any action, suit, proceeding, hearing (whether administrative, judicial or otherwise), governmental investigation or arbitration (whether or not purportedly on behalf of any Credit Party or any of its Subsidiaries) at law or in equity, or before or by any Governmental Authority, domestic or foreign (including any Environmental Claims), whether pending or, to the Knowledge of such Credit Party, threatened against or adversely affecting any Credit Party or any of its Subsidiaries or any property of Borrower or any of its Subsidiaries. For the avoidance of doubt, an action, suit, proceeding, hearing, or arbitration that follows or precedes an investigation shall be treated as a new and separate Adverse Proceeding from the investigation, whether or not such action, suit, proceeding, hearing, or arbitration is brought by any Governmental Authority.
-84-
“Affiliate” means, with respect to any Person, each other Person that owns or controls, directly or indirectly, such Person, any other Person that controls or is controlled by or is under common control with such Person, and each of that Person’s senior executive officers, directors, partners and, for any Person that is a limited liability company or limited liability partnership, that Person’s managers and members. As used in this definition, “control” means (a) direct or indirect beneficial ownership of at least fifty percent (50%) (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other equity interest in a Person or (b) the power to direct or cause the direction of the management of such Person by contract or otherwise. In no event shall the Collateral Agent or any Lender be deemed to be an Affiliate of Borrower or any of its Subsidiaries.
“Agreement” is defined in the preamble hereof.
“Amortization Adjustment Trigger” means, with respect to Borrower’s right to elect to adjust the amortization schedule of the Term Loans as described in the proviso contained in Section 2.2(b)(i) by delivery of written notice to the Collateral Agent, accompanied by evidence in reasonable detail of the underlying financial calculations, no later than November 30, 2029, (a) of either (i) TTM Net Rezzayo Revenues having equaled or exceeded $95,000,000 for the trailing twelve-month period ended September 30, 2029, on the basis of information contained in the most recent financial statements that have been delivered pursuant to Section 5.2(a)(i) or Section 5.2(a)(ii) and filed with the SEC, or, alternatively, (ii) the Consolidated Total Gross Leverage Ratio does not exceed 3.0x for the Test Period ended on September 30, 2029 (on the basis of information contained in the most recent financial statements that have been delivered pursuant to Section 5.2(a)(i) or Section 5.2(a)(ii) and filed with the SEC), that (b) no Default or Event of Default shall have occurred and be continuing, and (c) as certified to the Collateral Agent by the Chief Financial Officer of Borrower; provided, that, to the extent the financial statements referred to in clause (a) above do not clearly delineate the satisfaction of the condition set forth in clause (a)(i) or clause (a)(ii) above, as applicable, Borrower shall deliver to the Collateral Agent, together with such certification, supporting documentation and calculations in reasonable detail, reasonably satisfactory to the Collateral Agent, evidencing the satisfaction of such condition. For the avoidance of doubt, only TTM Net Rezzayo Revenues calculated on the basis of information contained in Borrower’s financial statements that have been delivered pursuant to Section 5.2(a)(i) or Section 5.2(a)(ii) and filed with the SEC shall be considered for purposes of determining whether the Amortization Adjustment Trigger has been achieved.
“Anti-Corruption Laws” is defined in Section 4.18(a).
“Anti-Money Laundering Laws” is defined in Section 4.18(b).
“Applicable Margin” means, for any day, as to any Term Loan, a rate per annum equal to five and three-quarters percent (5.75%).
“Applicable Percentage” means at any time: (a) with respect to the Tranche A Loan or the Tranche A Loan Amount, the percentage equal to a fraction, the numerator of which is (i) on or prior to the Tranche A Closing Date, the amount of such Lender’s Tranche A Commitment applicable thereto at such time and the denominator of which is the Tranche A Loan Amount at such time or (ii) thereafter, the outstanding principal amount of such Lender’s portion of the Tranche A Loan at such time, and the denominator of which is the aggregate outstanding principal amount of the Tranche A Loan at such time; (b) with respect to the Tranche B Loan or the Tranche B Loan Amount, the percentage equal to a fraction, the numerator of which is (i) on or prior to the Tranche B Closing Date, the amount of such Lender’s Tranche B Commitment at such time and the denominator of which is the Tranche B Loan Amount at such time or (ii) thereafter, the outstanding principal amount of such Lender’s portion of the Tranche B Loan at such time, and the denominator of which is the aggregate outstanding principal amount of the Tranche B Loan at such time; and (c) with respect to the Term Loans and the Term Loan Commitments, the percentage equal to a fraction, the numerator of which is, the sum of the amount of such Lender’s outstanding Term Loan Commitments and the amount of such Lender’s portion of the outstanding principal amount of the Term Loans at such time, and the denominator of which is the sum of the amount of all outstanding Term Loan Commitments and the aggregate outstanding principal amount of the Term Loans at such time.
-85-
“ASC” is defined in Section 1.
“Asset Acquisition” means, with respect to Borrower or any of its Subsidiaries, any purchase, in-license or other acquisition of properties or assets (other than properties or assets from third parties used in the ordinary course of business, including inventory, raw materials, vehicles, equipment, office supplies, software and other similar assets) of any other Person (including any purchase or other acquisition of any entire business unit, line of business or division of such Person). For the avoidance of doubt, “Asset Acquisition” includes any co-promotion or co-marketing arrangement pursuant to which Borrower or any Subsidiary acquires rights to promote or market the products of another Person.
“Available Tenor” means, as of any date of determination and with respect to the then-current Benchmark, as applicable, (a) if such Benchmark is a term rate, any tenor for such Benchmark (or component thereof) that is or may be used for determining the length of an interest period pursuant to this Agreement, or (b) otherwise, any payment period for interest calculated with reference to such Benchmark (or component thereof) that is or may be used for determining any frequency of making payments of interest calculated with reference to such Benchmark pursuant to this Agreement, in each case, as of such date and not including, for the avoidance of doubt, any tenor for such Benchmark that is then-removed from the definition of “Interest Period” pursuant to Section 2.3(f).
“Bankruptcy Code” means Title 11 of the United States Code entitled “Bankruptcy,” as now and hereafter in effect, or any successor statute (and any foreign equivalent).
“Benchmark” means, initially, the Term SOFR Reference Rate; provided that if a Benchmark Transition Event has occurred with respect to the Term SOFR Reference Rate or the then-current Benchmark, then “Benchmark” means the applicable Benchmark Replacement to the extent that such Benchmark Replacement has replaced such prior benchmark rate pursuant to Section 2.3(f).
“Benchmark Replacement” means, with respect to any Benchmark Transition Event, the first alternative set forth in the order below that can be determined by the Collateral Agent for the applicable Benchmark Replacement Date:
(a) Daily Simple SOFR; and
(b) the sum of: (i) the alternate benchmark rate that has been selected by the Collateral Agent and Borrower giving due consideration to (A) any selection or recommendation of a replacement benchmark rate or the mechanism for determining such a rate by the Relevant Governmental Body or (B) any evolving or then-prevailing market convention for determining a benchmark rate as a replacement to the then-current Benchmark for Dollar-denominated syndicated credit facilities and (ii) the related Benchmark Replacement Adjustment;
provided that, if the Benchmark Replacement as determined pursuant to clause (a) or (b) above would be less than the Floor, the Benchmark Replacement will be deemed to be the Floor for the purposes of this Agreement and the other Loan Documents.
-86-
“Benchmark Replacement Adjustment” means, with respect to any replacement of the then-current Benchmark with an Unadjusted Benchmark Replacement (other than Daily Simple SOFR), the spread adjustment, or method for calculating or determining such spread adjustment, (which may be a positive or negative value or zero) that has been selected by the Collateral Agent and Borrower giving due consideration to (a) any selection or recommendation of a spread adjustment, or method for calculating or determining such spread adjustment, for the replacement of such Benchmark with the applicable Unadjusted Benchmark Replacement by the Relevant Governmental Body or (b) any evolving or then-prevailing market convention for determining a spread adjustment, or method for calculating or determining such spread adjustment, for the replacement of such Benchmark with the applicable Unadjusted Benchmark Replacement for Dollar-denominated syndicated credit facilities at such time.
“Benchmark Replacement Date” means a date and time determined by the Collateral Agent in its reasonable discretion, which date shall be no later than the earliest to occur of the following events with respect to the then-current Benchmark:
(a) in the case of clause (a) or (b) of the definition of “Benchmark Transition Event,” the later of (i) the date of the public statement or publication of information referenced therein and (ii) the date on which the administrator of such Benchmark (or the published component used in the calculation thereof) permanently or indefinitely ceases to provide all Available Tenors of such Benchmark (or such component thereof); and
(b) in the case of clause (c) of the definition of “Benchmark Transition Event,” the first date on which such Benchmark (or the published component used in the calculation thereof) has been determined and announced by the regulatory supervisor for the administrator of such Benchmark (or such component thereof) to be non-representative; provided that such non-representativeness will be determined by reference to the most recent statement or publication referenced in such clause (c) and even if any Available Tenor of such Benchmark (or such component thereof) continues to be provided on such date.
For the avoidance of doubt, the “Benchmark Replacement Date” will be deemed to have occurred in the case of clause (a) or (b) above with respect to any Benchmark upon the occurrence of the applicable event or events set forth therein with respect to all then-current Available Tenors of such Benchmark (or the published component used in the calculation thereof).
“Benchmark Transition Event” means the occurrence of one or more of the following events with respect to the then-current Benchmark:
(a) a public statement or publication of information by or on behalf of the administrator of such Benchmark (or the published component used in the calculation thereof) announcing that such administrator has ceased or will cease to provide all Available Tenors of such Benchmark (or such component thereof), permanently or indefinitely; provided, that, at the time of such statement or publication, there is no successor administrator that will continue to provide any Available Tenor of such Benchmark (or such component thereof);
(b) a public statement or publication of information by the regulatory supervisor for the administrator of such Benchmark (or the published component used in the calculation thereof), the Federal Reserve Board, the Federal Reserve Bank of New York, an insolvency official with jurisdiction over the administrator for such Benchmark (or such component), a resolution authority with jurisdiction over the administrator for such Benchmark (or such component) or a court or an entity with similar insolvency or resolution authority over the administrator for such Benchmark (or such component), which states that the administrator of such Benchmark (or such component) has ceased or will cease to provide all Available Tenors of such Benchmark (or such component thereof) permanently or indefinitely; provided, that, at the time of such statement or publication, there is no successor administrator that will continue to provide any Available Tenor of such Benchmark (or such component thereof); or
-87-
(c) a public statement or publication of information by the regulatory supervisor for the administrator of such Benchmark (or the published component used in the calculation thereof) announcing that all Available Tenors of such Benchmark (or such component thereof) are not, or as of a specified future date will not be, representative.
For the avoidance of doubt, a “Benchmark Transition Event” will be deemed to have occurred with respect to any Benchmark if a public statement or publication of information set forth above has occurred with respect to each then-current Available Tenor of such Benchmark (or the published component used in the calculation thereof).
“Benchmark Unavailability Period” means, the period (if any) (a) beginning at the time that a Benchmark Replacement Date has occurred if, at such time, no Benchmark Replacement has replaced the then-current Benchmark for all purposes hereunder and under any Loan Document in accordance with Section 2.3(f) and (b) ending at the time that a Benchmark Replacement has replaced the then-current Benchmark for all purposes hereunder and under any Loan Document in accordance with Section 2.3(f).
“Blocked Person” means an individual or entity that is, or is collectively 50% or more owned or, where applicable, controlled by one or more Persons that are: (i) identified on the list of Specially Designated Nationals and Blocked Persons maintained by OFAC, the Consolidated List of Financial Sanctions Targets in the UK maintained by His Majesty’s Treasury, the Consolidated List of Persons, Groups, and Entities Subject to EU Financial Sanctions, or any other Person listed on any Sanctions-related list administered or maintained by the United States, the United Kingdom, the European Union or any other applicable Sanctions authority; (ii) the subject or target of blocking or asset-freezing Sanctions; or (iii) located, organized or ordinarily resident in a Sanctioned Country.
“Board of Directors” means, with respect to any Person, (i) in the case of any corporation, the board of directors of such Person, (ii) in the case of any limited liability company, the board of managers, the board of directors or the managing member of such Person, (iii) in the case of any partnership, the Board of Directors of the general partner of such Person and (iv) in any other case, the functional equivalent of the foregoing.
“Board of Governors” means the Board of Governors of the United States Federal Reserve System, or any successor thereto.
“Books” means all books and records including ledgers, records regarding a Credit Party’s assets or liabilities, the Collateral, business operations or financial condition, and all computer programs or storage or any equipment containing such information.
“Borrower” is defined in the preamble hereof.
“Borrowing Resolutions” means, with respect to any Person, those resolutions adopted by such Person’s Board of Directors or other competent corporate body, as required pursuant to Requirements of Law and delivered by such Person to the Collateral Agent pursuant to Section 3.1 approving the Loan Documents to which such Person is a party and the transactions contemplated thereby (including the Term Loan).
“Business Day” means any day that is not a Saturday or a Sunday or a day on which banks are authorized or required to be closed in New York, New York, London, England or Georgetown, Grand Cayman.
-88-
“Capital Lease” means, as applied to any Person, any lease of, or other arrangement conveying the right to use, any property by that Person as lessee which, in accordance with GAAP, is required to be accounted for as a finance lease (and not an operating lease) on a balance sheet of that Person (subject to Section 1 hereof).
“Capital Lease Obligations” means, at any time, with respect to any Capital Lease, any lease entered into as part of any sale leaseback transaction of any Person or any synthetic lease, the amount of all obligations of such Person that is (or that would be, if such synthetic lease or other lease were accounted for as a Capital Lease) capitalized on a balance sheet of such Person prepared in accordance with GAAP.
“Cash Equivalents” means:
(a) securities issued or directly and fully guaranteed or insured by the United States government or any agency or instrumentality of the United States government or by the government of any other member country of the Organisation for Economic Co-operation and Development (“OECD”) (provided that the full faith and credit of the United States or such other member country of OECD, as applicable, is pledged in support of those securities) or any agency or instrumentality of the OECD, in each case, having maturities of not more than two (2) years from the date of acquisition;
(b) certificates of deposit, time deposits with maturities of one year or less from the date of acquisition, bankers’ acceptances with maturities not exceeding one year and overnight bank deposits and demand deposits, in each case, with any commercial bank having (i) capital and surplus in excess of $500,000,000 in the case of U.S. banks or (ii) capital and surplus in excess of $100,000,000 (or the U.S. dollar equivalent as of the date of determination) in the case of non-U.S. banks or a rating for its long-term unsecured and noncredit enhanced debt obligations of “A” or higher by Standard & Poor’s Rating Services or Fitch Ratings Ltd or “A2” or higher by Moody’s Investors Service Limited;
(c) commercial paper or marketable short-term money market or readily marketable direct obligations and similar securities having a credit rating of either A-1 or higher by Standard & Poor’s Rating Service or F1 or higher by Fitch Ratings Ltd or P-1 or higher Moody’s Investors Service Limited, and, in each case, maturing within two (2) years after the date of acquisition;
(d) repurchase obligations with a term of not more than seven (7) days for underlying securities of the types described in clauses (a) and (c) above entered into with any financial institution meeting the qualifications specified in clause (b) above;
(e) investment funds investing ninety-five percent (95.0%) of their assets in securities of the types described in clauses (a) through (d) above and clause (f) below;
(f) investments in money market funds which have a credit rating of either A-1 or higher by Standard & Poor’s Rating Service or F1 or higher by Fitch Ratings Ltd or P-1 or higher by Moody’s Investors Service Limited (or, if at any time none of Fitch Ratings Ltd, Moody’s Investors Service Limited or Standard & Poor’s Rating Service shall be rating such obligations, an equivalent rating from another rating agency) and that have portfolio assets of at least $1,000,000,000; and
(g) other investments in accordance with Borrower’s investment policy as of the Effective Date or otherwise approved in writing (which may be by email) by the Collateral Agent (such approval not to be unreasonably withheld, conditioned or delayed).
-89-
“CCPA” means the provisions of the California Consumer Privacy Act, as amended by the California Privacy Rights Act and codified at Cal. Civ. Code § 1798.100 et seq., together with any effective implementing regulations.
“Change in Control” means: (a) a transaction or series of transactions (including any merger or consolidation involving Borrower) whereby any “person” or “group” (within the meaning of Section 13(d) or 14(d) of the Exchange Act, but excluding any employee benefit plan of such Person or its Subsidiaries, and any Person acting in its capacity as trustee, agent or other fiduciary or administrator of any such plan) (i) is or becomes the “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of more than fifty percent (50.0%) of the voting power of outstanding Equity Interests of Borrower ordinarily entitled to vote in the election of directors (or compatible voting Equity Interests), or (ii) obtains the power (whether or not exercised) to elect a majority of directors of Borrower; (b) a sale, directly or indirectly, of all or substantially all of the consolidated assets of Borrower and its Subsidiaries in one transaction or a series of transactions (whether by way of merger, stock purchase, asset purchase or otherwise); or (c) a merger or consolidation involving Borrower in which Borrower is not the surviving Person or in which Persons holding more than fifty percent (50.0%) of the power to elect a majority of directors of Borrower immediately prior to such merger or consolidation do not continue to hold at least fifty percent (50.0%) of such power immediately after such merger or consolidation. For the avoidance of doubt, an underwriter, initial purchaser, investor or holder of any Permitted Convertible Indebtedness or Permitted Equity Derivative shall, in each case, be deemed to not directly or indirectly own the Equity Interests of Borrower or any Subsidiary of Borrower underlying such transactions unless and until such Equity Interests are delivered upon settlement thereof.
“Change in Control Notice” is defined in Section 2.2(c)(ii).
“Change in Law” means the occurrence, after the date of this Agreement, of any of the following: (a) the adoption or taking into effect of any law, treaty, order, policy, rule or regulation, (b) any change in any law, treaty, order, policy, rule or regulation or in the administration, interpretation or application thereof by any Governmental Authority or (c) the making or issuance of any request, guideline or directive (whether or not having the force of law) by any Governmental Authority; provided that notwithstanding anything herein to the contrary, (x) the regulations promulgated under the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued in connection therewith and (y) all requests, rules, guidelines or directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities, in each case pursuant to Basel III, shall be deemed to be a “Change in Law”, regardless of the date enacted, adopted or issued.
“Cinvanti” is defined in clause (a) of the definition of Heron Acquisition Products.
“Clause (u) Product” has the meaning ascribed to such term in clause (u) of the definition of “Permitted Transfer.”
“Clause (v) Product” has the meaning ascribed to such term in clause (v) of the definition of “Permitted Transfer.”
“Closing Date” means the Tranche A Closing Date, or the Tranche B Closing Date, as the context dictates.
“Code” means the Uniform Commercial Code, as the same may, from time to time, be enacted and in effect in the State of New York; provided, that, to the extent that the Code is used to define any term herein or in any Loan Document and such term is defined differently in different Articles of the Code, the definition of such term contained in Article 9 of the Code shall govern; provided, further, that in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection, or priority of, or remedies with respect to, the Collateral Agent’s Lien, for the benefit of Lenders and the other Secured Parties, on any Collateral is governed by the Uniform Commercial Code in effect in a jurisdiction other than the State of New York, the term “Code” shall mean the Uniform Commercial Code as enacted and in effect in such other jurisdiction solely for purposes of the provisions thereof relating to such attachment, perfection, priority, or remedies and for purposes of definitions relating to such provisions.
-90-
“Collateral” means, collectively, “Collateral”, as such term is defined in the Security Agreement and any and all other assets and properties of whatever kind and nature subject or purported to be subject from time to time to a Lien under any Collateral Document, but in any event excluding all Excluded Property.
“Collateral Access Agreement” means an agreement, in form and substance reasonably satisfactory to the Collateral Agent and to which the Collateral Agent is a party, pursuant to which a mortgagee or lessor of real property on which Collateral is stored or otherwise located, or a warehouseman, processor or other bailee of Inventory (other than work-in-process Inventory held by a contract manufacturer for which a Credit Party may hold title) or other property owned by any Credit Party, acknowledges the Liens and security interests of the Collateral Agent, for the benefit of Lenders and the other Secured Parties, and waives (or, if approved by the Collateral Agent in its sole discretion, subordinates) any Liens or security interests held by such Person on any such Collateral, and, in the case of any such agreement with a mortgagee or lessor, permits the Collateral Agent and any Lender (and its representatives and designees) reasonable access to any Collateral stored or otherwise located thereon.
“Collateral Account” means any Deposit Account of a Credit Party maintained with a bank or other depository or financial institution located in the United States, and any Securities Account of a Credit Party maintained with a securities intermediary located in the United States or any Commodity Account of a Credit Party maintained with a commodity intermediary located in the United States, in each case, other than an Excluded Account.
“Collateral Agent” is defined in the preamble hereof.
“Collateral Documents” means the Security Agreement, the Control Agreements, the IP Agreements, any Mortgages and all other instruments, documents and agreements delivered by any Credit Party pursuant to or incidental to this Agreement or any of the other Loan Documents, in each case, in order to grant to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, or perfect a Lien on any Collateral as security for the Obligations, and all amendments, restatements, amendments and restatements, modifications or supplements thereof or thereto.
“Commodity Account” means any “commodity account” as defined in the Code with such additions to such term as may hereafter be made.
“Company IP” means any and all of the following, as they exist in and throughout the Territory to the extent owned by or licensed to Borrower or any of its Subsidiaries: (a) Current Company IP; (b) improvements, continuations, continuations-in-part, divisions, provisionals or any substitute applications with respect to any of the Current Company IP, any patent issued with respect to any of the Current Company IP, including any patent right claiming the apparatus, system, component or composition of matter of, or the method of making or using, any Product in the Territory, any reissue, reexamination, renewal or patent term extension or adjustment (including any supplementary protection certificate) of any such patent and all foreign and international counterparts of any of the foregoing, and any confirmation patent or registration patent or patent of addition based on any such patent; (c) trade secrets or trade secret rights, including any rights to unpatented inventions, know-how, show-how, operating manuals, confidential or proprietary information, research in progress, algorithms, data, databases, data collections, designs, processes, procedures, methods, protocols, materials, formulae, drawings, schematics, blueprints, flow charts, models, strategies, prototypes, techniques, and the results of experimentation and testing, including samples, in each case, as specifically related to (i) the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of any Key Product in the Territory or (ii) any material aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of any other Product in the Territory; (d) to the extent not described in clauses (a), (b) or (c) above, any and all IP Ancillary Rights specifically relating to any of the foregoing (other than all income, royalties, proceeds and liabilities at any time due and payable or asserted under or with respect to any of the foregoing), including, for the avoidance of doubt, all rights to sue or recover at law or in equity for any past, present or future infringement, misappropriation, dilution, violation or other impairment thereof, and, in each case, all rights to obtain any other intellectual property right ancillary to any Copyright, Trademark, Patent, Software, trade secrets or trade secret rights in the Territory; (e) rights in all data provided in any regulatory filings, submissions and approvals related to any research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of any Key Product; and (f) rights in all material data provided in any regulatory filings, submissions and approvals related to any research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of any other Product.
-91-
“Company IP Agreement” means each contract or agreement, pursuant to which Borrower or any of its Subsidiaries has the legal right to exploit Current Company IP or other Intellectual Property that is owned by another Person and is material to any aspect of the research, development, manufacture, production, use, supply, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of any Product in the Territory, including each Permitted Royalty Agreement and each other Permitted Royalty Agreement Document, and any other license and collaboration agreements for the research and development or commercialization of any Product.
“Competitor” means, at any time of determination, any Person (and each other Person that owns or controls, directly or indirectly, such Person, or that controls or is controlled by or is under common control with such Person) that is directly and primarily engaged in the same, substantially the same, or similar line of business as Borrower and its Subsidiaries, taken as a whole, as of such time (any such Person so engaged, an “Operating Competitor”); provided, however, that in no event shall any Diversified Institutional Investor constitute a Competitor, so long as (i) such Diversified Institutional Investor is not itself an Operating Competitor, (ii) no Operating Competitor (or any of its personnel) directs or controls (or would direct or control) the investment decisions of such Diversified Institutional Investor in respect of the Term Loans, and (iii) such Diversified Institutional Investor maintains customary information barriers between the Persons managing its investment in the Term Loans and any Operating Competitor in which it holds an investment. As used in this definition, “Diversified Institutional Investor” means any bona fide asset manager, fund, investment vehicle, commercial bank, insurance company, finance company, financial institution or other institutional investor that makes, purchases or holds investments in pharmaceutical and biopharmaceutical companies or in companies across multiple industries in the ordinary course of business.
“Compliance Certificate” means that certain certificate in the form attached hereto as Exhibit E.
“Conforming Changes” means, with respect to either the use or administration of Term SOFR or the use, administration, adoption or implementation of any Benchmark Replacement, any technical, administrative or operational changes (including changes to the definition of “Business Day,” the definition of “U.S. Government Securities Business Day,” the definition of “Interest Period” or any similar or analogous definition (or the addition of a concept of “interest period”), timing and frequency of determining rates and making payments of interest, timing of borrowing requests or prepayment, conversion or continuation notices, the applicability and length of lookback periods and other technical, administrative or operational matters) that the Collateral Agent decides (after consultation with Borrower) may be appropriate to reflect the adoption and implementation of any such rate or to permit the use and administration thereof by the Collateral Agent in a manner substantially consistent with market practice (or, if the Collateral Agent decides that adoption of any portion of such market practice is not administratively feasible or if the Collateral Agent determines that no market practice for the administration of any such rate exists, in such other manner of administration as the Collateral Agent decides is reasonably necessary in connection with the administration of this Agreement and the other Loan Documents).
“Connection Income Taxes” means Other Connection Taxes that are imposed on or measured by net income (however denominated) or that are franchise Taxes or branch profits Taxes.
-92-
“Consolidated EBITDA” means, for any Test Period with respect to Borrower and its Subsidiaries on a consolidated basis, net income (or loss) for such period, calculated on a pro forma basis after giving effect to any Permitted Acquisition consummated during such Test Period, as if such transaction occurred on the first day of such period, and including the amount of cost savings and cost synergies reasonably determined by Borrower in good faith to have resulted from actions which have been taken (or which have been substantially taken) in connection with such Permitted Acquisition, calculated on a run-rate basis as though such cost savings and cost synergies had been realized on the first day of such Test Period, net of the amount of actual benefits realized during such Test Period, and determined in accordance with GAAP, excluding, without duplication, (w) any revenue participation, milestone payment, deferred payment or any other contingent payment received in respect of any Product (other than the $6,000,000 milestone payment received from A. Menarini Industrie Farmaceutiche Riunite S.r.l. or its Affiliates in respect of the regulatory approval of Vabomere in China) for such Test Period, (x) extraordinary, unusual or non-recurring gains and extraordinary, unusual or non-recurring losses (other than such $6,000,000 milestone payment received from A. Menarini Industrie Farmaceutiche Riunite S.r.l. or its Affiliates in respect of the regulatory approval of Vabomere in China), including any remeasurement or true-up related revenues or sales allowances (solely to the extent such remeasurement or true-up constitutes a change in estimate disclosed in Borrower's quarterly or annual financial statements filed with the SEC), for such Test Period and (y) to the extent not otherwise deducted in calculating such consolidated net income (or loss) for such Test Period, any royalty payments made by Borrower or any of its Subsidiaries during such Test Period that, as a result of the application of purchase accounting or for any other reason, are not included in Cost of Goods Sold, plus, without duplication, the following to the extent deducted in calculating such consolidated net income (or loss) for such Test Period: (a) interest expense, net of interest income, for such Test Period, (b) the provision for Federal, state, local and foreign income taxes payable for such Test Period, (c) depreciation and amortization expense for such Test Period, (d) non-cash, stock-based compensation expenses for such Test Period, (e) non-cash asset impairment expenses for such Test Period (net of any non-cash gains resulting from the write-up of assets or the reversal of any prior impairment), (f) other non-operating expenses for such Test Period (net of other non-operating income), including foreign exchange losses (net of gains), accretion expense and changes in the fair value of contingent consideration, (g) any reorganization or restructuring costs or expenses for such Test Period, (h) transaction costs, fees and expenses incurred during such Test Period in connection with such Permitted Acquisition (whether or not consummated), (i) integration costs and expenses incurred during such Test Period in connection with such Permitted Acquisition, and (j) severance costs and expenses incurred during such Test Period in connection with such Permitted Acquisition, in each case of clauses (g) through (j) above, to the extent non-recurring and incurred during such Test Period (and not, for the avoidance of doubt, outside of such Test Period) in connection with such Permitted Acquisition, provided, however, that the aggregate amount added back to consolidated net income (or loss) for any Test Period pursuant to clauses (g) through (j) above (other than third-party fees and expenses described in clause (h) and severance costs described in clause (j), in each case related to a Permitted Acquisition consummated within the twelve (12) months preceding the last day of such Test Period and without duplication of any amounts added back in any prior Test Period) shall not exceed fifteen percent (15%) of Consolidated EBITDA for such Test Period (calculated prior to giving effect to such add-backs), and in each case of clauses (a) through (j) above, determined in accordance with GAAP and in an amount no greater than the amount actually deducted from consolidated net income (or loss) for such Test Period.
“Consolidated Interest Charges” means, for any Test Period with respect to Borrower and its Subsidiaries on a consolidated basis, the sum of all interest, premium payments, debt discount, debt issuance, fees, charges and related expenses in connection with Indebtedness (including capitalized interest) for such period, determined in accordance with GAAP.
“Consolidated Product Adjusted EBITDA” means, for any applicable Test Period, the Consolidated EBITDA of Borrower and its Subsidiaries, minus (without duplication) the sum of the Product Gross Profit of (a) any and all Clause (u) Product(s) or Clause (v) Product(s) that have been or will be Transferred pursuant to clause (u) or clause (v), as applicable, of the definition of “Permitted Transfers” during such Test Period, and (b) any and all Products that have or will become Withdrawn Products during such Test Period, in each case of clauses (a) and (b) above, determined in accordance with GAAP and on a pro forma basis after giving effect to each such Transfer of a Clause (u) Product or a Clause (v) Product, and any other Transfer of a Clause (u) Product or a Clause (v) Product occurring during such Test Period, as if each such Transfer had occurred on the first day of such Test Period, and after giving effect to each such Withdrawn Product, and any other Withdrawal Event occurring during such Test Period, as if the applicable Withdrawal Event occurred on the first day of such Test Period.
-93-
“Consolidated Total Debt” means, as of any time of determination or for any Test Period (and without duplication), as the context dictates, all then-outstanding Indebtedness of Borrower and its Subsidiaries of the types described in clauses (a), (d), (f) and (j) of the definition of “Indebtedness,” including the face value of any Indebtedness under the 2030 Convertible Notes (and the Indenture), any other Permitted Convertible Indebtedness (if any), and any Working Capital Indebtedness (and, in the case of clause (j) of such definition, solely to the extent the primary obligation guaranteed is of a type described in clause (a), (d) or (f) of such definition); provided, that, Consolidated Total Debt shall exclude (i) Indebtedness under any Permitted Royalty Agreement Document, Permitted Royalty Financing Document, Permitted Other Royalty Financing Document or Permitted Acquisition Royalty Document, (ii) undrawn letters of credit, surety bonds, performance bonds and similar instruments, (iii) obligations in respect of deferred purchase price, earn-outs, milestones and other Contingent Obligations, (iv) Disqualified Equity Interests, and (v) obligations under Hedging Agreements and Permitted Equity Derivatives.
“Consolidated Total Gross Leverage Ratio” means, with respect to any Test Period, the ratio of (a) Consolidated Total Debt as of the last day of such Test Period to (b) Consolidated Product Adjusted EBITDA for such Test Period, in each case of clauses (a) and (b) above, on the basis of information contained in the most recent financial statements that have been delivered pursuant to Section 5.2(a)(i) or Section 5.2(a)(ii) and filed with the SEC (and, to the extent such financial statements do not expressly set forth the applicable amounts, supporting documentation and calculations in reasonable detail, reasonably satisfactory to the Collateral Agent and certified by the Chief Financial Officer of Borrower, evidencing such amounts). For the avoidance of doubt and notwithstanding anything herein to the contrary, for purposes of determining Consolidated Total Gross Leverage Ratio in the context of Section 7.3(a) or clause (u) or clause (v) of the definition of Permitted Transfers, as applicable, Consolidated Product Adjusted EBITDA shall be calculated on a pro forma basis after giving effect to the subject Withdrawal Event or Transfer of a Clause (u) Product or a Clause (v) Product, respectively, and any other Withdrawal Events, Transfers of Clause (u) Products or Transfers of Clause (v) Products occurring during such Test Period (if any), as if such Withdrawal Event or Transfer occurred on the first day of such Test Period.
“Contingent Obligation” means, for any Person, (a) any direct or indirect liability, contingent or not, of that Person for any indebtedness, lease, dividend, letter of credit or other obligation of another Person directly or indirectly guaranteed, endorsed, co-made, discounted or sold with recourse by that Person, or for which that Person is directly or indirectly liable (other than by endorsements of instruments in the course of collection) and (b) any obligation of that Person to pay an earn-out payment, milestone payment or similar contingent payment or contingent compensation (including purchase price adjustments but excluding license fees, royalties payable and milestones based on net sales) to a counterparty incurred or created in connection with an Acquisition, Transfer, or Investment or otherwise in connection with any collaboration, development or similar agreement, in each instance where such contingent payment or compensation becomes due and payable upon the occurrence of an event or the performance of an act (and not solely with the passage of time). The amount of a Contingent Obligation is the stated or determined amount of the primary obligation for which the Contingent Obligation is made or, if not determinable by a Responsible Officer of such Person, the amount required to be shown as a liability on the balance sheet of such Person in accordance with GAAP (or, if not required to be so shown, the maximum reasonably anticipated amount reasonably determined by a Responsible Officer of such Person in good faith); but the amount may not exceed the maximum of the obligations under any guarantee or other support arrangement. Notwithstanding anything to the contrary in the foregoing, Permitted Equity Derivatives shall not constitute a Contingent Obligation.
“Contract Research Agreement” means an arrangement under which the Borrower or any of its Subsidiaries engages with another party such as a university, research institution, or contract research organization or similar entity to perform specific research activities in connection with any Product.
-94-
“Control Agreement” means, with respect to any Credit Party, any control agreement entered into among such Credit Party, the Collateral Agent and, in the case of a Deposit Account, the bank or other depository or financial institution located in the United States, at which such Credit Party maintains such Deposit Account, or, in the case of a Securities Account or a Commodity Account, the securities intermediary or commodity intermediary located in the United States, at which such Credit Party maintain such Securities Account or Commodities Account, in either case pursuant to which the Collateral Agent obtains control (within the meaning of the Code) pursuant to a “springing” control agreement, or otherwise has a perfected first priority security interest (subject to any Permitted Liens), over such Collateral Account.
“Copyrights” means any and all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret (and all related IP Ancillary Rights).
“Cost of Goods Sold” means, for any Test Period, the aggregate of all direct costs incurred by Borrower and its Subsidiaries in the manufacture, production, importing, storage and packaging of the Clause (u) Product, Clause (v) Product, or the Withdrawn Product, as applicable, in the Territory during such Test Period, as adjusted to account for (without duplication) extraordinary, unusual or non-recurring gains during such Test Period and extraordinary, unusual or non-recurring losses during such Test Period, plus (without duplication), to the extent deducted in calculating consolidated net income (or loss) of Borrower and its Subsidiaries for such Test Period, the items set forth in clauses (a) through (j) of the definition of Consolidated EBITDA, in each case determined on a consolidated basis in accordance with GAAP and on the basis of information contained in the most recent financial statements that have been delivered pursuant to Section 5.2(a)(i) or Section 5.2(a)(ii) and filed with the SEC (and, to the extent such financial statements do not expressly set forth the applicable amounts, supporting documentation and calculations in reasonable detail, reasonably satisfactory to the Collateral Agent and certified by the Chief Financial Officer of Borrower, evidencing such amounts).
“Covered Regulatory Materials” is defined in Section 4.20(a).
“Credit Extension” means any Term Loan or any other extension of credit by any Lender for Borrower’s benefit pursuant to this Agreement.
“Credit Party” means Borrower and each Guarantor (including any Designated Guarantor).
“Current Company IP” is defined in Section 4.6(c).
“Daily Simple SOFR” means, for any day, SOFR, with the conventions for this rate (which will include a lookback) being established by the Collateral Agent in accordance with the conventions for this rate recommended by the Relevant Governmental Body for determining “Daily Simple SOFR” for bilateral business loans; provided, that, if the Collateral Agent decides that any such convention is not administratively feasible for the Collateral Agent, then the Collateral Agent may establish another convention in its reasonable discretion.
“Data Protection Laws” means any and all applicable foreign or domestic (including U.S. federal, state and local), statutes, ordinances, orders, rules, regulations, judgments, Governmental Approvals, or any other requirements of Governmental Authorities relating to privacy, security, notification of breaches, data transfers, confidentiality of any Personal Data or any other Sensitive Information or to any database registration or data localization requirements, in each case, in any manner applicable to Borrower or any of its Subsidiaries, including, to the extent applicable, Section 5 of the FTC Act and other consumer protection laws, HIPAA, GDPR, PIPEDA, U.S. state comprehensive privacy laws (including CCPA and the Connecticut Data Privacy Act (CGS 42-515 et seq.)), other U.S. state health information privacy laws (including the Washington My Health My Data Act (RCW 19.373.005 et seq.), Nevada SB 370 (NRS 603A.400 et seq.), and the California Confidentiality of Medical Information Act (Cal. Civ. Code pt. 2.6 § 56 et seq.)), genetic privacy laws, and state breach notification laws, and including any required policies and procedures.
-95-
“DEA” means the United States Drug Enforcement Administration (and foreign equivalents).
“DEA Laws” means all applicable statutes (including the CSA), rules, regulations, and orders implemented, administered, enforced, or issued by DEA (and any foreign or United States state equivalents).
“Default” means any breach of or default under any term, provision, condition, covenant or agreement contained in this Agreement or any other Loan Document or any other event, in each case that, with the giving of notice or the lapse of time or both, would constitute an Event of Default.
“Default Rate” is defined in Section 2.3(b).
“DefenCath” is defined in clause (a)(i) of the definition of Products.
“Deposit Account” means any “deposit account” as defined in the Code with such additions to such term as may hereafter be made.
“Designated Guarantor” is defined in Section 5.13.
“Disclosure Letter” means the disclosure letter to this Agreement, dated the Effective Date and delivered by the Credit Parties to the Collateral Agent pursuant to Section 3.1(a) hereof, as updated on each subsequent Closing Date (if required and as expressly permitted hereunder).
“Disqualified Assignee” means (a) any Competitor; (b) any vulture or loan-to-own fund; or (c) any other Person listed on Schedule 13.1 of the Disclosure Letter as of the Effective Date delivered pursuant to Section 3.1(a).
“Disqualified Equity Interest” means any Equity Interest that, by its terms (or by the terms of any security or other Equity Interests into which it is convertible or for which it is exchangeable) or upon the happening of any event or condition: (a) matures or is mandatorily redeemable, pursuant to a sinking fund obligation or otherwise (except if redeemable or convertible into other Equity Interest that would not constitute a Disqualified Equity Interest or as a result of a change of control, asset sale or similar event so long as any and all rights of the holders thereof upon the occurrence of a change of control, asset sale or similar event shall be subject to the prior repayment in full in cash of the Term Loans and the satisfaction in full of all other Obligations (other than contingent indemnification and reimbursement obligations) in accordance with the terms of this Agreement); (b) is redeemable at the option of the holder thereof, in whole or in part (except if redeemable or convertible into other Equity Interest that would not constitute a Disqualified Equity Interest or as a result of a change of control, asset sale or similar event so long as any rights of the holders thereof upon the occurrence of a change of control, asset sale or similar event shall be subject to the prior repayment in full in cash of the Term Loans and the satisfaction in full of all other Obligations (other than contingent indemnification and reimbursement obligations) in accordance with this Agreement); (c) provides for the scheduled payments of dividends or distributions in cash; or (d) is convertible into or exchangeable for (i) Indebtedness which is not Permitted Indebtedness or (ii) any other Equity Interest that would constitute a Disqualified Equity Interest; in each case described in clauses (a) through (d) above, prior to the date that is 180 days after the Term Loan Maturity Date; provided that, if any such Equity Interest is issued pursuant to any plan for the benefit of any employee, director, manager or consultant of Borrower or its Subsidiaries or by any such plan to such employee, director, manager or consultant, such Equity Interest shall not constitute a “Disqualified Equity Interest” solely because it may be required to be repurchased by Borrower or its Subsidiaries in order to satisfy applicable statutory or regulatory obligations or as a result of the termination, death or disability of such employee, director, manager or consultant.
-96-
“Distribution Agreement” means any agreement with a wholesaler or distributor under which such wholesaler or distributor (i) purchases or has the option to purchase any Product in finished form from or at the direction of Borrower or any of its Affiliates (or its licensee), (ii) has the right, option or obligation to distribute, market and sell any Product (with or without packaging rights), and (iii) does not make any royalty, milestone, profit share, or other similar payments to Borrower or its Affiliates (or its licensee) based on such wholesaler’s or distributor’s sale of any Product.
“Dollars,” “dollars” or use of the sign “$” means only lawful money of the United States and not any other currency, regardless of whether that currency uses the “$” sign to denote its currency or may be readily converted into lawful money of the United States.
“Domestic Subsidiary” means, with respect to any Credit Party, a Subsidiary of such Credit Party that is incorporated or organized under the laws of the United States.
“Effective Date” is defined in the preamble hereof.
“Effective Date Products” means, collectively, each Product owned or controlled by Borrower or any of its Subsidiaries as of the Effective Date.
“EMA” means the European Medicines Agency.
“Environmental Claim” means any investigation, notice, notice of violation, claim, action, suit, proceeding, demand, abatement order or other order or directive (conditional or otherwise), by any Governmental Authority or any other Person, arising (i) pursuant to or in connection with any actual or alleged violation of any Environmental Law; (ii) in connection with any Hazardous Material or any actual or alleged Hazardous Materials Activity; or (iii) in connection with any actual or alleged damage, injury, threat or harm to health, safety, natural resources or the environment.
“Environmental Laws” means any and all current or future, foreign or domestic, statutes, ordinances, orders, rules, regulations, judgments, Governmental Approvals, or any other requirements of Governmental Authorities relating to (i) environmental matters, including those relating to any Hazardous Materials Activity; (ii) the generation, use, storage, transportation or disposal of Hazardous Materials; or (iii) occupational safety and health, industrial hygiene, land use or the protection of human, plant or animal health or welfare, in each case, in any manner applicable to any Credit Party or any of its Subsidiaries or any Facility.
“Equity Interests” means collectively, with respect to any Person, any and all shares, interests, participations or other equivalents (however designated) of capital stock of a corporation, any and all equivalent ownership interests in such Person (other than a corporation), including partnership interests and membership interests, and any and all warrants, rights or options to purchase or other arrangements or rights to acquire (by purchase, conversion, dividend, distribution or otherwise) any of the foregoing (and all other rights, powers, privileges, interests, claims and other property in any manner arising therefrom or relating thereto); provided, however, that (i) any Permitted Convertible Indebtedness or other Indebtedness convertible into Equity Interests (or into any combination of cash and Equity Interests based on the value of such Equity Interests) shall not constitute Equity Interests unless and until (and solely to the extent) so converted into Equity Interests and (ii) any Permitted Equity Derivative shall not constitute Equity Interests unless and until (and solely to the extent) any Equity Interests have been issued pursuant to the terms thereof.
-97-
“ERISA” means the Employee Retirement Income Security Act of 1974, and the regulations promulgated thereunder.
“ERISA Affiliate” means, with respect to any Person, any trade or business (whether or not incorporated) that, together with such Person, is treated as a single employer under Section 414(b) or (c) of the IRC or, solely for purposes of Section 302 of ERISA or Section 412 of the IRC, Section 414(m) or (o) of the IRC.
“ERISA Event” means (a) any “reportable event,” as defined in Section 4043 of ERISA or the regulations issued thereunder, with respect to a Plan (other than an event for which the 30-day notice period is waived by regulation); (b) with respect to a Plan, the failure by Borrower or its Subsidiaries or their ERISA Affiliates to satisfy the minimum funding standard of Section 412 of the IRC and Section 302 of ERISA, whether or not waived; (c) the failure by Borrower or its Subsidiaries or their ERISA Affiliates to make by its due date a required installment under Section 430(j) of the IRC with respect to any Plan or to make any required contribution to a Multiemployer Plan; (d) the filing pursuant to Section 412(c) of the IRC or Section 302(c) of ERISA of an application for a waiver of the minimum funding standard with respect to any Plan; (e) the incurrence by Borrower or any of its ERISA Affiliates of any liability under Title IV of ERISA with respect to the termination of any Plan; (f) the receipt by Borrower or its Subsidiaries or any of their respective ERISA Affiliates from the Pension Benefit Guaranty Corporation (referred to and defined in ERISA) or a plan administrator of any notice relating to the intention to terminate any Plan under Section 4041 or any Multiemployer Plan under 4041A of ERISA or to appoint a trustee to administer any Plan under Section 4042 of ERISA, or the occurrence of any event or condition which could reasonably be expected to constitute grounds under ERISA for the termination of, or the appointment of a trustee to administer, any Plan under Section 4041 Section or 4042 of ERISA; (g) the incurrence by Borrower or its Subsidiaries or any of their respective ERISA Affiliates of any liability with respect to the withdrawal from any Plan pursuant to Section 4063 of ERISA or Multiemployer Plan; (h) the receipt by Borrower or its Subsidiaries or any of their respective ERISA Affiliates of any notice, concerning the imposition of Withdrawal Liability or a determination that a Multiemployer Plan is, or is expected to be, insolvent, within the meaning of Section 4245 of ERISA; (i) the “substantial cessation of operations” by Borrower or its Subsidiaries or their ERISA Affiliates within the meaning of Section 4062(e) of ERISA with respect to a Plan; or (j) the occurrence of a nonexempt prohibited transaction (within the meaning of Section 4975 of the IRC or Section 406 of ERISA) with respect to a Plan which could reasonably be expected to result in a material liability to Borrower or its Subsidiaries.
“EU Laws” means all applicable statutes, rules and regulations implemented administered or enforced by the European Commission, the EMA or the competent authorities of the EU Member States including, but not limited to, the EU Community Code on medicinal products (Directive 2001/83/EC), the EMA Regulation (Regulation (EC) No 726/2004), the Manufacturing Directive (Commission Directive 2003/94/EC), the Clinical Trials Regulation (Regulation (EU) No 536/2014), and related implementing legislation of individual EU Member States and related guidance at EU level and national level in individual EU Member States.
“EU Member State” means a country that is (a) included in the Territory and (b) a member state of the European Union.
“European Union” means, collectively, the individual Member States of the European Union.
“Event of Default” is defined in Section 7.
“Exchange Act” means the Securities Exchange Act of 1934.
“Exchange Act Documents” means any and all documents filed by Borrower with the SEC pursuant to the Exchange Act.
“Excluded Accounts” is defined in Section 5.5.
-98-
“Excluded Equity Interests” means, collectively: (i) any Equity Interests in any Subsidiary with respect to which the grant to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, of a security interest in and Lien upon, and the pledge to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, of, such Equity Interests, to secure the Obligations (and any guaranty thereof) are validly prohibited by Requirements of Law; (ii) any Equity Interests in any Subsidiary with respect to which the grant to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, of a security interest in and Lien upon, and the pledge to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, of, such Equity Interests, to secure the Obligations (and any guaranty thereof) require the consent, approval or waiver of any Governmental Authority or other third-party and such consent, approval or waiver has not been obtained by Borrower following Borrower’s commercially reasonable efforts to obtain the same; (iii) any Equity Interests in any Subsidiary that is a non-Wholly-Owned Subsidiary that the grant to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, of a security interest in and Lien upon, and the pledge to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, of, such Equity Interests, to secure the Obligations (and any guaranty thereof) are validly prohibited by, or would give any third-party (other than Borrower or an Affiliate of Borrower) the right to terminate its obligations under, the Operating Documents or the joint venture agreement or shareholder agreement with respect to, or any other contract with such third-party relating to such non-Wholly-Owned Subsidiary, including any contract evidencing Indebtedness of such non-Wholly-Owned Subsidiary (other than customary non-assignment provisions which are ineffective under Article 9 of the Code or other Requirements of Law), but only, in each case, to the extent, and for so long as such Operating Document, joint venture agreement, shareholder agreement or other contract is in effect; (iv) all or a portion of the Equity Interests in any Foreign Subsidiary or FSHCO, the pledge of which would, in the reasonable determination of a Responsible Officer of Borrower in good faith, reasonably be expected to result in a tax liability for Borrower or its Subsidiaries under Section 956 of the IRC (or a successor or similar provision) or Treasury Regulations promulgated thereunder as a result of a change in Requirements of Law occurring after the date hereof that causes a material adverse tax consequence to Borrower or its Subsidiaries; and (v) any Equity Interests in any other Subsidiary with respect to which, Borrower and the Collateral Agent reasonably determine by mutual agreement that the cost (including material adverse tax consequences) of granting the Collateral Agent, for the benefit of Lenders and the other Secured Parties, a security interest in and Lien upon, and pledging to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, such Equity Interests, to secure the Obligations (and any guaranty thereof) are excessive, relative to the value to be afforded to the Secured Parties thereby.
“Excluded License” means any license or sublicense by a Credit Party to a Person other than Borrower or any Subsidiary of Borrower, of any Company IP: (a) covering any Product that is tantamount to a sale of substantially all rights to the Intellectual Property covering such Product because it conveys to the licensee or sublicensee exclusive rights to practice all or substantially all rights to such Intellectual Property anywhere in the Territory for consideration that is not based upon (i) the future development or commercialization of such Product in the Territory (e.g., pursuant to so-called earn-out payments or royalties based on net sales), or (ii) the performance of services by the licensee or sublicensee (other than transition services) with no anticipated subsequent payments or only de minimis subsequent payments to Borrower or any of its Subsidiaries; provided, that, solely for purposes of this clause (a), no Distribution Agreement, Manufacturing Agreement, Logistics Agreement, Contract Research Agreement or other similar agreement shall constitute an Excluded License; (b) except as expressly permitted hereunder, within the Territory covering any Key Product that could reasonably be expected to interfere with or impede the ability of Borrower or any Subsidiary of Borrower to conduct any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of such Product in the Territory or to enforce its rights with respect to any of the foregoing within the Territory; (c) except as expressly permitted hereunder, within the Territory covering any Product other than a Key Product that could reasonably be expected to interfere with or impede the ability of Borrower or any Subsidiary of Borrower to conduct any material aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of such Product in the Territory or to enforce its rights with respect to any of the foregoing within the Territory; or (d) except as expressly permitted hereunder, that requires any Credit Party or any Subsidiary of a Credit Party to pay to the licensee any royalties, milestones or similar payments that are based on the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of any Product in the Territory.
-99-
“Excluded Property” has the meaning set forth for such term in the Security Agreement.
“Excluded Subsidiaries” means, collectively: (i) any Subsidiary with respect to which the grant to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, of a security interest in and Lien upon, and the pledge to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, of, such Subsidiary’s properties and assets subject or purported to be subject from time to time to a Lien under any Collateral Document and the Equity Interests in such Subsidiary to secure the Obligations (and any guaranty thereof) are validly prohibited by Requirements of Law; (ii) any Subsidiary with respect to which the grant to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, of a security interest in and Lien upon, and the pledge to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, of, such Subsidiary’s properties and assets subject or purported to be subject from time to time to a Lien under any Collateral Document and the Equity Interests in such Subsidiary to secure the Obligations (and any guaranty thereof) require the consent, approval or waiver of any Governmental Authority or other third-party (other than Borrower or an Affiliate of Borrower) and any such consent, approval or waiver has not been obtained, directly or indirectly, by Borrower following Borrower’s direct and indirect commercially reasonable efforts to obtain the same; (iii) any Subsidiary that is a non-Wholly Owned Subsidiary, with respect to which, the grant to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, of a security interest in and Lien upon, and the pledge to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, of, the properties and assets of such non-Wholly Owned Subsidiary, to secure the Obligations (and any guaranty thereof) are validly prohibited by, or would give any third-party (other than Borrower or an Affiliate of Borrower) the right to terminate its obligations under, such non-Wholly Owned Subsidiary’s Operating Documents or the joint venture agreement or shareholder agreement with respect thereto or any other contract with such third-party relating to such non-Wholly Owned Subsidiary, including any contract evidencing Indebtedness of such non-Wholly Owned Subsidiary (other than customary non-assignment provisions which are ineffective under Article 9 of the Code or other Requirements of Law), but only, in each case, to the extent, and for so long as such Operating Document, joint venture agreement, shareholder agreement or other contract is in effect; (iv) any Foreign Subsidiary that owns properties and assets with an aggregate fair market value (as reasonably determined in good faith by a Responsible Officer of Borrower), individually and when aggregated together with all other Subsidiaries excluded solely under this sub-clause (iv), of less than $5,000,000; and (v) any Foreign Subsidiary with respect to which, Borrower and the Collateral Agent reasonably determine by mutual agreement that the cost (including adverse tax consequences) of granting the Collateral Agent, for the benefit of Lenders and the other Secured Parties, a security interest in and Lien upon, and pledging to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, such Subsidiary’s properties and assets subject or purported to be subject from time to time to a Lien under any Collateral Document and the Equity Interests of such Subsidiary to secure the Obligations (and any guaranty thereof) are excessive relative to the value to be afforded to the Secured Parties thereby. Notwithstanding the foregoing or any other provision of this Agreement, the parties hereto hereby agree that without the prior written consent of the Collateral Agent or the Required Lenders, no Subsidiary existing as of the Effective Date or organized, formed or acquired, directly or indirectly, by any Credit Party from and after the Effective Date, that at any time (A) owns or co-owns any material Company IP or that holds rights in or to any Covered Regulatory Materials, (B) is party to any Company IP Agreement, (C) enters into any Material Contract or otherwise becomes a party thereto or bound thereby or (D) engages in any business operations material to any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, packaging, labelling, promotion, advertising, offer or sale, distribution or sale of any Product in the Territory and owns properties and assets with an aggregate fair market value (as reasonably determined in good faith by a Responsible Officer of Borrower) equal to or greater than $5,000,000, individually and when aggregated together with all other Subsidiaries excluded under sub-clause (iv) above, shall, in any such case, be (or be deemed to be) an Excluded Subsidiary for any purpose under the Loan Documents and, therefore, such Subsidiary shall constitute a Credit Party for all purposes under the Loan Documents, as of the date of such ownership, co-ownership, maintenance, license, entry or becoming so bound or engagement, and, additionally, in each case, Borrower shall cause such entity, within the time periods required by Section 5.12, 5.13, or 5.14, as and to the extent applicable, to become a Guarantor in accordance therewith.
-100-
“Excluded Taxes” means any of the following Taxes imposed on or with respect to Lender or required to be withheld or deducted from a payment to Lender, (a) Taxes imposed on or measured by net income (however denominated), franchise Taxes, and branch profits Taxes, in each case, (i) imposed by the United States or as a result of Lender being organized under the laws of, or having its principal office or its applicable lending office located in, the jurisdiction imposing such Tax (or any political subdivision thereof) or (ii) that are Other Connection Taxes, (b) U.S. federal withholding Taxes imposed on amounts payable to or for the account of Lender with respect to any Obligation pursuant to a law in effect on the date on which (i) Lender acquires such interest in any Obligation or (ii) Lender changes its lending office, except in each case to the extent that, pursuant to Section 2.6, amounts with respect to such Taxes were payable either to Lender’s assignor immediately before Lender became a party hereto or to Lender immediately before it changed its lending office, (c) Taxes attributable to Lender’s failure to comply with Section 2.6(d), and (d) any U.S. federal withholding Taxes imposed under FATCA.
“Export and Import Laws” means any applicable law, regulation, order or directive that applies to the import, export, re-export, transfer, disclosure or provision of goods, software, technology or technical assistance including restrictions or controls administered pursuant to the U.S. Export Administration Regulations, 15 C.F.R. Parts 730-774, administered by the U.S. Department of Commerce, Bureau of Industry and Security; U.S. Customs regulations; and similar import and export laws, regulations, orders and directives of other jurisdictions to the extent applicable.
“Facility” means, with respect to any Credit Party, any real property (including all buildings, fixtures or other improvements located thereon) now, hereafter or heretofore owned, leased, operated or used by such Credit Party or any of its Subsidiaries or any of their respective predecessors or Affiliates.
“FATCA” means Sections 1471 through 1474 of the IRC, as of the date of this Agreement (including, for the avoidance of doubt, any agreements between the governments of the United States and the jurisdiction in which the applicable Lender is resident implementing such provisions), or any amended or successor version that is substantively comparable and not materially more onerous to comply with, and any current or future regulations promulgated thereunder or official interpretations thereof, any agreements entered into pursuant to Section 1471(b)(1) of the IRC, any intergovernmental agreement entered into in connection with the implementation of the foregoing sections of the IRC and any fiscal or regulatory legislation, regulations, rules or practices adopted pursuant to, or official interpretations implementing such Sections of the IRC or intergovernmental agreements.
“FCPA” is defined in Section 4.18(a).
“FDA” means the United States Food and Drug Administration (and any United States state and foreign equivalents).
“FDA Good Clinical Practices” means the good clinical practice requirements set forth in 21 C.F.R. Parts 50, 54, 56, 312, 314, 812, and 45 C.F.R. Part 46 (and any foreign equivalents).
“FDA Good Laboratory Practices” means the applicable good laboratory practice requirements set forth in 21 C.F.R. Part 58 (and any foreign equivalents).
“FDA Good Manufacturing Practices” means the good manufacturing practice requirements set forth in 21 C.F.R. Parts 4, 210, 211, 803, and 820 (and any foreign equivalents).
-101-
“FDA Laws” means all statutes (including the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 301 et seq.)) and rules and regulations implemented, administered, or enforced by FDA and any United States state and foreign equivalents), and as interpreted through FDA’s applicable guidance documents (and foreign equivalents).
“Federal Reserve Board” means the Board of Governors of the Federal Reserve System.
“First Closing Date” means the earlier to occur of the Tranche A Closing Date and the Tranche B Closing Date.
“Fiscal Quarter” means a fiscal quarter of any Fiscal Year, ending March 31, June 30, September 30 or December 31, as applicable, of each calendar year.
“Fiscal Year” means the fiscal year of Borrower and its Subsidiaries ending on December 31 of each calendar year.
“Floor” means a rate of interest equal to three and one-half percent (3.50%) per annum.
“Foreign Lender” means a Lender that is not a “United States person” as defined in Section 7701(a)(30) of the IRC.
“Foreign Subsidiary” means, with respect to any Credit Party, any Subsidiary of such Credit Party that is not a Domestic Subsidiary.
“FSHCO” means any Subsidiary that has no material assets other than equity (or debt treated for U.S. federal income tax purposes as equity) of one or more Foreign Subsidiaries or other FSHCOs.
“GAAP” means with respect to Borrower and its Subsidiaries, generally accepted accounting principles in the United States as set forth in the opinions and pronouncements of the Accounting Principles Board of the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or in such other statements by such other Person as may be approved by a significant segment of the accounting profession, which are applicable to the circumstances as of the date of determination, consistently applied.
“GDPR” means, as amended and restated from time to time, collectively, (i) Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation) (the “EU GDPR”) and (ii) the UK Data Protection Act 2018 and the EU GDPR as it forms part of the laws of the United Kingdom by virtue of section 3 of the European Union (Withdrawal) Act 2018 and as amended by the Data Protection, Privacy and Electronic Communications (Amendments etc.) (EU Exit) Regulations 2019 (the “UK GDPR”).
“Governmental Approval” means any consent, authorization, approval, licensure, clearance, order, license, franchise, permit, certificate, accreditation, registration, filing or notice, of, issued by, from or to, or other act by or in respect of, any Governmental Authority.
“Governmental Authority” means any nation or government, any supranational organization, any state or other political subdivision thereof, any agency (including Regulatory Agencies, data protection authorities, and agencies acting as supervisory governmental organizations on issues of privacy protection), government department (including the U.S. Department of Justice), authority (including state attorneys general), instrumentality, regulatory body, ministry, board, commission, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative functions of or pertaining to government, any securities exchange and any self-regulatory organization.
“Governmental Payor Programs” means any and all governmental third-party payor programs in which any Credit Party or its Subsidiaries participates, including Medicare, Medicaid, TRICARE, or any other state or federal health care program as that term is defined in 42 U.S.C. 1320a–7b(f).
-102-
“Guarantor” means, at any time, any Person that is, pursuant to the terms of any Loan Document, a guarantor of any of the Obligations at that time, including any Designated Guarantor.
“Hazardous Materials” means any chemical, material or substance, exposure to which is prohibited, limited or regulated by any Governmental Authority or which may or could pose a hazard to the health and safety of the owners, occupants or any Persons in the vicinity of any Facility or to the indoor or outdoor environment.
“Hazardous Materials Activity” means any past, current, proposed or threatened activity, event or occurrence involving any Hazardous Materials, including the use, manufacture, possession, storage, holding, presence, existence, location, Release, threatened Release, discharge, placement, generation, transportation, processing, construction, treatment, abatement, removal, remediation, disposal, disposition or handling of any Hazardous Materials, and any corrective action or response action with respect to any of the foregoing.
“Health Care Laws” means, collectively, and to the extent applicable: (a) applicable federal, state or local laws, rules, regulations, orders, ordinances, codes, statutes, standards, and requirements issued under or in connection with Medicare, Medicaid or any other Governmental Payor Programs or issued in connection with or otherwise governing commercial third-party payor programs; (b) applicable federal and state laws and regulations governing health information, including HIPAA; (c) federal, state and local fraud and abuse laws of any Governmental Authority, including the federal Anti-Kickback Statute (42 U.S.C. § 1320a-7(b)), the Stark law (42 U.S.C. § 1395nn and 1396b(s)), the civil False Claims Act (31 U.S.C. § 3729 et seq.), Sections 1320a-7 and 1320a-7a of Title 42 of the United States Code and the regulations promulgated pursuant to such statutes, and also any other U.S. or foreign laws or regulations that are applicable to health care fraud, abuse, corruption, waste, bribery, inducements, false statements, or false claims; (d) the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Pub. L. No. 108-173) and the regulations promulgated thereunder and any other federal, state or local laws or regulations (or foreign equivalents thereof) governing the disclosure of payments or providing other items of value or remuneration or drug product samples to health care professionals, to the extent applicable; (e) the Physician Payment Sunshine Act (42 U.S.C. § 1320a-7h); (f) reporting and disclosure requirements, including any arising under the Medicaid Drug Rebate Program (e.g., Monthly and Quarterly Average Manufacturer Price, Baseline Average Manufacturer Price, and Rebate Per Unit, as applicable), Medicare Part B (Quarterly Average Sales Price), Section 602 of the Veteran’s Health Care Act (Public Health Service 340B Quarterly Ceiling Price), Section 603 of the Veteran’s Health Care Act (Quarterly and Annual Non-Federal Average Manufacturer Price and Federal Ceiling Price), Best Price, Federal Supply Schedule Contract Prices and Tricare Retail Pharmacy Refunds, and Medicare Part D; (g) applicable federal, state or local laws, rules, regulations, ordinances, statutes and requirements relating to (i) the regulation of managed care, third-party payors and Persons bearing the financial risk for the provision or arrangement of health care services, (ii) billings to insurance companies, health maintenance organizations and other Managed Care Plans or otherwise relating to insurance fraud and (iii) any insurance, health maintenance organization or managed care Requirements of Law; (h) laws and regulations for the protection of human research subjects (including 45 C.F.R. part 46, and any foreign or United States state equivalents); (i) requirements for licensure or permitting of personnel who are engaged in marketing, sales, or medical activities under federal, state, or local laws (or foreign equivalents); (j) requirements concerning disclosure of drug pricing information and other company information to the public, customers, prescribers or to state and local agencies under federal, state, or local laws (or foreign equivalents); (k) laws and regulations requiring the adoption of compliance codes or policies; and (l) any other applicable Requirements of Law (including any applicable EU Laws or other foreign equivalents) relating to research, development, testing, approval, exclusivity, licensure, clearance, authorization, designation, post-approval (or post-licensure, post-clearance, or post-approval, as applicable) monitoring or commitments, reporting, manufacture, production, packaging, labeling, use, commercialization, marketing, promotion, advertising, importing, exporting, storage, transport, distribution, sale or offer for sale or lease, or payment of or for any Product.
“Hedge Termination Value” means, with respect to any Hedging Agreement, after taking into account the effect of any legally enforceable netting agreement relating to such Hedging Agreement (if any), (a) for any date occurring on or after the date such Hedging Agreement has been closed out and termination value determined in accordance therewith, such termination value, and (b) for any date occurring prior to the date referenced in cause (a) above, the amount determine as the mark-to-market value for such Hedging Agreement, as determined based upon one or more mid-market or other readily available quotation(s) provided by any recognized dealer in such Hedging Agreement (which may include a Lender or any Affiliate of a Lender).
-103-
“Hedging Agreement” means any interest rate, currency, commodity or equity swap, collar, cap, floor or forward rate agreement, or other agreement or arrangement designed to protect a Person against fluctuations in interest rates, currency exchange rates or commodity or equity prices or values (including any option with respect to any of the foregoing and any combination of the foregoing agreements or arrangements), and any confirmation execution in connection with any such agreement or arrangement. Notwithstanding anything to the contrary in the foregoing, no Permitted Equity Derivative shall constitute a Hedging Agreement.
“Heron Acquisition Agreement” means, collectively, the acquisition agreement governing or evidencing the Heron Acquisition Transaction and the transactions contemplated thereunder (including the schedules and exhibits thereto), together with all other documents delivered or filed pursuant to the Heron Acquisition Transaction, in each case in the most recent forms delivered to the Collateral Agent and Lenders pursuant to Section 3.1(a), Section 3.1(j), Section 3.2(b) or Section 3.2(c), as applicable.
“Heron Acquisition Products” means, collectively:
(a) CINVANTI® (aprepitant) injectable emulsion as approved by FDA under NDA No. 209296 (“Cinvanti”);
(b) ZYNRELEF® (bupivacaine and meloxicam) extended-release solution as approved by FDA under NDA No. 211988 (“Zynrelef”);
(c) APONVIE® (aprepitant) injectable emulsion as approved by FDA under NDA No. 216457;
(d) SUSTOL® (granisetron) extended-release injection as approved by FDA under NDA No. 022445; and
(e) any other biopharmaceutical or other product acquired by Borrower or any of its Subsidiaries in connection with the Heron Acquisition Transaction.
“Heron Acquisition Transaction” means the acquisition of the Heron Acquisition Products by Borrower or any of its Subsidiaries from Heron Therapeutics, Inc. on or concurrently with, the Tranche A Closing Date, pursuant to the Heron Acquisition Agreement.
“HIPAA” means the Health Insurance Portability and Accountability Act of 1996, as amended and supplemented by the Health Information Technology for Economic and Clinical Health (HITECH) Act of 2009, any and all rules or regulations promulgated from time to time thereunder (including the regulations codified in 45 C.F.R. Parts 160, 162, and 164).
“IFRS” means international accounting standards within the meaning of IAS Regulation 1606/2002 to the extent applicable to the relevant financial statements.
“Indebtedness” means, with respect to any Person, without duplication: (a) all indebtedness for advanced or borrowed money of, or credit extended to, such Person; (b) all obligations issued, undertaken or assumed by such Person as the deferred purchase price of assets, properties, services or rights (other than (i) accrued expenses and trade payables entered into in the ordinary course of business that are not more than one hundred and eighty (180) days past due or subject to a bona fide dispute, (ii) obligations to pay for services provided by employees and individual independent contractors in the ordinary course of business which are not more than one hundred twenty (120) days past due or subject to a bona fide dispute, (iii) liabilities associated with customer prepayments and deposits and (iv) prepaid or deferred revenue arising in the ordinary course of business), including (A) any obligation or liability to pay deferred purchase price or other similar deferred consideration for such assets, properties, services or rights where such deferred purchase price or consideration becomes due and payable solely upon the passage of time, and (B) any obligation described in clause (b) of the definition of Contingent Obligation that becomes due and payable solely with the passage of time (and not the occurrence of an event or the performance of an act); (c) the face amount of all letters of credit issued for the account of such Person and, without duplication, all drafts drawn thereunder and all reimbursement or payment obligations with respect to letters of credit, surety bonds, performance bonds and other similar instruments issued by such Person; (d) all obligations of such Person evidenced by notes, bonds, debentures or other debt securities or similar instruments (including debt securities convertible into Equity Interests (including Permitted Convertible Indebtedness)), including obligations so evidenced incurred in connection with the acquisition of properties, assets or businesses; (e) all indebtedness of such Person created or arising under any conditional sale or other title retention agreement or incurred as financing, in either case with respect to property acquired by such Person (even though the rights and remedies of the seller or bank under such agreement in the event of default are limited to repossession or sale of such property); (f) all Capital Lease Obligations of such Person; (g) the principal balance outstanding under any synthetic lease, off-balance sheet loan or similar off balance sheet financing product by such Person; (h) Disqualified Equity Interests; (i) all indebtedness referred to in clauses (a) through (h) above of other Persons secured by (or for which the holder of such indebtedness has an existing right, contingent or otherwise, to be secured by) any Lien upon or in assets or properties (including accounts and contracts rights) owned by such Person, even though such Person has not assumed or become liable for the payment of such indebtedness of such other Persons (limited to the fair market value of the assets subject to such Lien); and (j) any obligation of such Person described in clause (a) of the definition of Contingent Obligation. For the avoidance of doubt, “Indebtedness” shall include Permitted Convertible Indebtedness but shall not include any Permitted Equity Derivatives.
-104-
“Indemnified Liabilities” means, collectively, any and all liabilities, obligations, losses, damages (including natural resource damages), penalties, claims, actions, judgments, suits, costs, reasonable and documented out-of-pocket fees, expenses and disbursements of any kind or nature whatsoever (including the reasonable and documented fees and disbursements of one primary legal counsel for Indemnified Persons plus, as applicable, one local legal counsel in each relevant material jurisdiction and one intellectual property legal counsel, and in the case of an actual or perceived conflict of interest, one additional legal counsel for such affected Indemnified Persons), incurred by any Indemnified Person or asserted against any Indemnified Person by any Person (including Borrower or any other Credit Party) relating to or arising out of or in connection with, or as a result of, this Agreement or the other Loan Documents or the transactions contemplated hereby or thereby (including any Lender’s agreement to make Credit Extensions or the use or intended use of the proceeds thereof, or any enforcement of any of the Loan Documents (including any sale of, collection from, or other realization upon any of the Collateral or the enforcement of any guaranty of the Obligations)), including (i) the execution or delivery of this Agreement, any other Loan Document or any agreement or instrument contemplated hereby or thereby, the performance by the parties hereto of their respective obligations hereunder or thereunder or the consummation of the transactions contemplated hereby or thereby, (ii) any Term Loan or the use or proposed use of the proceeds therefrom, (iii) any actual or alleged presence or release of Hazardous Materials on or from any property owned or operated by Borrower or any of its Subsidiaries, or any liability relating to any Environmental Law, any Release of Hazardous Materials or any Hazardous Materials Activity, (iv) any actual or prospective claim, suit, litigation, investigation, hearing or proceeding relating to any of the foregoing, whether based on contract, tort or any other theory, whether brought by, commenced or threatened in writing by any Person (including Borrower or any of its affiliates), and regardless of whether any Indemnified Person is or is designated as a party or a potential party thereto, and (v) the enforcement of the indemnity hereunder, in each case whether direct, indirect or consequential and whether based on any federal, state or foreign laws, statutes, rules or regulations, on common law or equitable cause or on contract or otherwise, that may be imposed on, incurred by, or asserted against any such Indemnified Person, in any manner.
“Indemnified Person” is defined in Section 11.2(a).
“Indemnified Taxes” means (a) Taxes, other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any obligation of any Credit Party under any Loan Document and (b) to the extent not otherwise described in clause (a) above, Other Taxes.
“Initial Payment Date” means the last day of the Fiscal Quarter ending on or immediately following the third (3rd) anniversary of the First Closing Date; provided, however, that if the Amortization Adjustment Trigger occurs and Borrower elects to postpone the Initial Payment Date pursuant to Section 2.2(b)(i), the Initial Payment Date means the last day of the Fiscal Quarter ending on or immediately following the fourth (4th) anniversary of the First Closing Date.
“Insolvency Proceeding” means, with respect to any Person, any proceeding by or against such Person under the Bankruptcy Code, or any other domestic or foreign bankruptcy or insolvency law, including assignments for the benefit of creditors, compositions, extensions generally with its creditors, or proceedings seeking reorganization, arrangement, rescue process or other relief; provided, however, that, solely with respect to any Person incorporated, organized or formed in any jurisdiction other than the United States, “Insolvency Proceeding” shall not include any winding-up petition against such Credit Party which is frivolous or vexatious and is discharged or dismissed within thirty (30) days of the commencement thereof or any step or procedure in connection with any transaction otherwise permitted under this Agreement.
-105-
“Intellectual Property” means all:
(a) Copyrights, Trademarks, and Patents;
(b) trade secrets and trade secret rights, including any rights to unpatented inventions, know-how, show-how and operating manuals;
(c) rights in (i) all computer programs, including source code and object code versions, (ii) all data, databases and compilations of data, whether machine readable or otherwise, and (iii) all documentation, training materials and configurations related to any of the foregoing (collectively, “Software”);
(d) all right, title and interest arising under any contract or Requirements of Law in or relating to Internet Domain Names;
(e) design rights;
(f) IP Ancillary Rights (including all IP Ancillary Rights related to any of the foregoing); and
(g) any similar or equivalent rights to any of the foregoing anywhere in the world.
“Interest Date” means the last day of each calendar quarter, commencing with the last Business Day occurring in the first full calendar quarter after the First Closing Date occurs.
“Interest Period” means, as to each Term Loan: (a)(i) with respect to the Tranche A Loan, the period commencing on (and including) the Tranche A Closing Date and ending on (and including) the first Interest Date following the Tranche A Closing Date, and (ii) with respect to the Tranche B Loan, the period commencing on (and including) the Tranche B Closing Date and ending on (and including) the first Interest Date following the Tranche B Closing Date; and (b) thereafter, with respect to each Term Loan, each period beginning on (and including) the first day following the end of the preceding Interest Period and ending on the earlier of (and including) (x) the next Interest Date and (y) the Term Loan Maturity Date.
“Internet Domain Name” means all right, title and interest (and all related IP Ancillary Rights) arising under any contract or Requirements of Law in or relating to Internet domain names.
“Inventory” means all “inventory” as defined in the Code in effect on the date hereof with such additions to such term as may hereafter be made, and includes all merchandise (including inventory of any Product), materials (including raw materials), parts, components (including component materials and component raw materials), supplies, packing and shipping materials, work in process and finished products, technology (including software, systems, and solutions), and all elements needed to fulfill obligations related to any Product under any Manufacturing Agreements including such inventory as is temporarily out of a Credit Party’s or Subsidiary’s custody or possession or in transit (prior to title having transferred) and including any returned goods and any documents of title representing any of the above.
-106-
“Investment” means (a) any beneficial ownership interest in any Person (including Equity Interests), (b) any Acquisition or (c) the making of any advance, loan, extension of credit or capital contribution in or to, any Person. The amount of an Investment shall be the amount actually invested (which, in the case of any Investment by a Credit Party or any of its Subsidiaries constituting the contribution of an asset or property, shall be based on the good faith estimate of the fair market value of such asset or property at the time such Investment is made as reasonably determined in good faith by a Responsible Officer of such Credit Party), less the amount of cash received or returned for such Investment, without adjustment for subsequent increases or decreases in the value of such Investment or write-ups, write-downs or write-offs with respect thereto; provided that in no event shall such amount be less than zero.
“IP Agreements” means, collectively, (a) those certain IP Security Agreement(s) entered into by and between Borrower or another Credit Party, on the one hand, and the Collateral Agent, on the other hand, dated as of the Effective Date, and (b) any IP Security Agreement entered into by and between any relevant Credit Party and the Collateral Agent after the Effective Date in accordance with the Loan Documents.
“IP Ancillary Rights” means, with respect to any Copyright, Trademark, Patent, Software, trade secrets or trade secret rights, including any rights to unpatented inventions, know-how, show-how and operating manuals, all income, royalties, proceeds and liabilities at any time due or payable or asserted under or with respect to any of the foregoing or otherwise with respect thereto, including all rights to sue or recover at law or in equity for any past, present or future infringement, misappropriation, dilution, violation or other impairment thereof, and, in each case, all rights to obtain any other intellectual property right ancillary to any Copyright, Trademark, Patent, Software, trade secrets or trade secret rights.
“IP Security Agreement” means “IP Security Agreement”, as such term is defined in the Security Agreement.
“IRC” means the Internal Revenue Code of 1986, as amended, or any successor statute.
“IRS” means the United States Internal Revenue Service or any successor agency.
“Key Product” means, as of any time of determination or any Test Period, (a) DefenCath, (b) Rezzayo, (c) Minocin, (d) Cinvanti, (e) Zynrelef, (f) for any Test Period, any other Product in respect of which Net Product Revenues for such Test Period exceed ten percent (10%) of the Net Product Revenues from all Products for such Test Period, on the basis of information contained in the most recent financial statements that have been delivered pursuant to Section 5.2(a)(i) or Section 5.2(a)(ii) and filed with the SEC (and, to the extent such financial statements do not expressly set forth the applicable amounts, supporting documentation and calculations in reasonable detail, reasonably satisfactory to the Collateral Agent and certified by the Chief Financial Officer of Borrower, evidencing such amounts), and (g) any Product acquired by Borrower or any of its Subsidiaries after the First Closing Date that Borrower and the Collateral Agent, each acting reasonably and in good faith, agree in writing, on or prior to the consummation of such acquisition, shall constitute a Key Product; provided, however, that the preceding shall exclude any Heron Acquisition Products at any time prior to the consummation of the Heron Acquisition Transaction on the Tranche A Closing Date.
“Knowledge” means, with respect to any Person, the actual knowledge, after reasonable investigation, of the Responsible Officers of such Person; provided, that, with respect to Borrower, reasonable investigation means that Borrower has also affirmatively sought out information from its Subsidiaries; provided, further, that with respect to each representation and warranty in Section 4.6 relating to Intellectual Property, including Company IP, Current Company IP, Current Product IP and Third-Party IP, to the extent made as of the Tranche A Closing Date with respect to any Heron Acquisition Product acquired by Borrower or any of its Subsidiaries pursuant to the Heron Acquisition Agreement on or concurrently with the Tranche A Closing Date, “Knowledge” shall mean knowledge of the Credit Parties as obtained through the due diligence conducted by or on behalf of Borrower and its Subsidiaries in connection with the acquisition of such Heron Acquisition Product, which such diligence was conducted on a commercially reasonable basis for a product in the biopharmaceutical market, including the representations, warranties, disclosure schedules and other information provided by or on behalf of the seller or licensor of such Heron Acquisition Product in the Heron Acquisition Agreement; provided, finally, that that with respect to each representation and warranty in Section 4.6 relating to Intellectual Property, including Company IP, Current Company IP, Current Product IP and Third-Party IP, to the extent made as of the Tranche B Closing Date with respect to any Other Acquisition Product acquired by Borrower or any of its Subsidiaries pursuant to the Other Acquisition Agreement on or concurrently with the Tranche B Closing Date, “Knowledge” shall mean knowledge of the Credit Parties as obtained through the due diligence conducted by or on behalf of Borrower and its Subsidiaries in connection with the acquisition of such Other Acquisition Product, which such diligence was conducted on a commercially reasonable basis for a product in the biopharmaceutical market, including the representations, warranties, disclosure schedules and other information provided by or on behalf of the seller or licensor of such Other Acquisition Product in the Other Acquisition Agreement.
-107-
“Lender” means each Person signatory hereto as a “Lender” and its successors and assigns.
“Lender Expenses” means, collectively (without duplication):
(a) all reasonable and documented out-of-pocket fees and expenses of the Collateral Agent and, as applicable, each Lender (and their respective successors and assigns) and their respective Related Parties (including the reasonable and documented out-of-pocket fees, expenses and disbursements of any legal counsel or other professional advisors (it being agreed that such legal counsel fees, expenses and disbursements shall be limited to one primary legal counsel, one local legal counsel in each applicable jurisdiction and one intellectual property legal counsel (as and to the extent applicable) for the Collateral Agent, Lenders and Related Parties, taken as a whole and in the case of an actual or perceived conflict of interest, one additional legal counsel for such affected Indemnified Person)), manufacturing consultants, safety consultants or intellectual property experts (it being agreed that such consultant or expert fees, expenses and disbursements shall be limited to one of each such consultant and one such expert for the Collateral Agent, Lenders and such Related Parties, taken as a whole) therefor, (i) incurred in connection with developing, preparing, negotiating, syndicating, executing and delivering, and interpreting, investigating and administering, the Loan Documents (or any term or provision thereof), any commitment, proposal letter, letter of intent or term sheet therefor or any other document prepared in connection therewith, (ii) incurred in connection with the consummation and administration of any transaction contemplated therein, (iii) incurred in connection with the performance of any obligation or agreement contemplated therein, (iv) incurred in connection with any modification or amendment or restatement of any term or provision of, or any supplement to, or the termination (in whole or in part) of, any Loan Document, (v) incurred in connection with internal audit reviews and Collateral audits, or (vi) otherwise incurred with respect to the Credit Parties in connection with the Loan Documents, including any filing or recording fees and expenses; and
(b) all reasonable and documented out-of-pocket costs and expenses incurred by the Collateral Agent and each Lender (and their respective successors and assigns) and their respective Related Parties (limited to the reasonable and documented out-of-pocket fees, expenses and disbursements of any one primary legal counsel, one local legal counsel to each applicable jurisdiction and one intellectual property legal counsel (as of and to the extent applicable) therefor for the Collateral Agent, Lenders and such Related Parties taken as a whole and in the case of an actual or perceived conflict of interest, one additional legal counsel for such affected Indemnified Person) in connection with (i) any refinancing or restructuring of the credit arrangements provided hereunder in the nature of a “work-out,” (ii) the enforcement or protection or preservation of any right or remedy under any Loan Document, any Obligation, with respect to any of the Collateral or any other related right or remedy, or (iii) the commencement, defense, conduct of, intervention in, or the taking of any other action with respect to, any proceeding (including any Insolvency Proceeding) related to any Credit Party or any Subsidiary of any Credit Party in respect of any Loan Document or Obligation, or otherwise in connection with any Loan Document or Obligation (or the response to and preparation for any subpoena or request for document production relating thereto).
“Lender Transfer” is defined in Section 11.1(b).
“Lien” means a claim, mortgage, deed of trust, levy, charge, pledge, security interest or other encumbrance of any kind or assignment for security purposes, whether voluntarily incurred or arising by operation of law or otherwise against any property or assets.
“Liquidity” means, at any time of determination, an amount equal to the sum of unrestricted cash and Cash Equivalents (including the proceeds of the Term Loans) that, from and after the date Control Agreements are required hereunder to be obtained, are maintained by the Credit Parties in accounts which have been granted as security in favor of the Collateral Agent pursuant to Control Agreements or other applicable Collateral Documents.
“Loan Documents” means, collectively, this Agreement, the Disclosure Letter, the Term Loan Notes, the Security Agreement, the IP Agreements, the Perfection Certificate, any Control Agreement, any Collateral Access Agreement, any other Collateral Document, any guaranties executed by a Guarantor in favor of the Collateral Agent for the benefit of Lenders and the other Secured Parties in connection with this Agreement, and any other present or future agreement between or among a Credit Party, the Collateral Agent and any Lender in connection with this Agreement, including in each case, for the avoidance of doubt, any annexes, exhibits (it being understood that exhibits of “forms” are not Loan Documents until signed and delivered) or schedules thereto, and any related ancillary documents, accessions, agreements, waivers or consents.
-108-
“Logistics Agreement” means any agreement between the Borrower or its Subsidiaries, on the one hand, and a Person acting solely as a Logistics Provider, on the other hand, including agreements with specialty pharmacies and specialty distributors, in each case (x) entered into in the ordinary course of business and (y) that does not substantively constitute an out-licensing or sale transaction with respect to any Product.
“Logistics Provider” means a Person that has the right, option or obligation to distribute, transport, warehouse, package, import, or provide similar logistics services with respect to any Product pursuant to a Logistics Agreement.
“Makewhole Amount” means the Tranche A Makewhole Amount or the Tranche B Makewhole Amount, (as applicable) or the combination thereof, as the context dictates.
“Managed Care Plans” means all health maintenance organizations, preferred provider organizations, individual practice associations, competitive medical plans and similar arrangements.
“Manufacturing Agreement” means (a) any manufacturing or supply contract or agreement entered into by any Credit Party or any of its Subsidiaries with third parties for (i) the commercial supply in the Territory of any Product for any indication or (ii) the commercial manufacture or in-bound supply of any raw materials or component(s) (including component raw materials and other component materials) incorporated into any Product which such raw materials or component(s) are not readily replaceable (with the Manufacturing Agreements in effect as of the Effective Date being set forth in Schedule 13.2 of the Disclosure Letter), and (b) any future contract or agreement entered into after the Effective Date by any Credit Party or any of its Subsidiaries with third parties for (i) the clinical or commercial manufacture or in-bound supply in the Territory of any Product for any indication or (ii) the commercial manufacture or in-bound supply of any raw materials or component(s) (including component raw materials and other component materials) incorporated into any Product which such raw materials or component(s) are not readily replaceable. Notwithstanding the foregoing, agreements or contracts entered into by any Credit Party or any of its Subsidiaries with third parties for the performance of services relating to the manufacture or supply of any Product for any indication or the commercial manufacture or in-bound supply of any raw materials or component(s) incorporated into any Product are not Manufacturing Agreements hereunder.
“Margin Stock” means “margin stock” within the meaning of Regulations U and X of the Federal Reserve Board as now and from time-to-time hereafter in effect.
“Material Adverse Change” means any material adverse change in or material adverse effect on: (a) the business, financial condition, properties or assets (including all or any material portion of the Collateral), liabilities (actual or contingent), operations or performance of the Credit Parties, taken as a whole, since December 31, 2025; (b) without limiting the generality of clause (a) above, (i) any of the rights or remedies of the Credit Parties, taken as a whole, in or related to the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of the Key Products in the Territory, taken as a whole, or (ii) the period of regulatory exclusivity granted by the applicable Regulatory Agency for the Key Products in the Territory, taken as a whole; (c) without limiting the generality of clause (a) or (b) above, the period of regulatory exclusivity granted by the applicable Regulatory Agency for Rezzayo or the other Key Products in the Territory, taken as a whole (including Orphan Drug exclusivity, if any); (d) without duplication of clauses (a) through (c) above, the business, rights or remedies of the Credit Parties in or related to the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of the Key Products in the Territory, taken as a whole, or the period of regulatory exclusivity granted by the applicable Regulatory Agency for the Key Products in the Territory, taken as a whole; (e) any ability of the Credit Parties, taken as a whole, to fulfill the payment or performance obligations under this Agreement or any other Loan Document; (f) any ability of the Credit Parties, taken as a whole, to fulfill the payment or performance obligations under any Permitted Royalty Agreement Document, Permitted Royalty Financing Document, Permitted Other Royalty Financing Document or Permitted Acquisition Royalty Document; (g) the binding nature or validity of, or the ability of the Collateral Agent or any Lender to enforce, any of the Loan Documents or any of its material rights or remedies under any of the Loan Documents; or (h) the validity, perfection (except to the extent expressly permitted under the Loan Documents) or priority of Liens in favor of the Collateral Agent, for the benefit of the Lenders and the other Secured Parties. Notwithstanding the foregoing, none of the following events shall, in and of itself, constitute a Material Adverse Change: (x) adverse results or delays in any nonclinical or clinical trial or (y) any event described in clause (i) of the definition of “Withdrawal Event” if such event does not result in a Withdrawal Event.
-109-
“Material Contract” means any contract or other arrangement to which any Credit Party or any of its Subsidiaries is a party (other than the Loan Documents) or by which any of its assets or properties are bound, in each case, relating to any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of any Product in the Territory, for which the breach of, default or nonperformance under, cancellation or termination of or the failure to renew could reasonably be expected to result in a Material Adverse Change. For the avoidance of doubt, (i) each Manufacturing Agreement and each Distribution Agreement, in each case under which the total aggregate amount payable over the applicable fiscal year could reasonably be expected to exceed $1,000,000 (as reasonably determined in good faith by a Responsible Officer of Borrower), (ii) each Company IP Agreement, (iii) each Permitted Royalty Agreement Document, (iv) each Permitted Royalty Financing Document, (v) each Permitted Other Royalty Financing Document and (vi) each Permitted Acquisition Royalty Document is in all cases deemed to be a Material Contract for all purposes hereunder. Notwithstanding the foregoing, the following agreements are not Material Contracts: (a) any customer contracts, (b) any purchase orders or statements of work entered into from time to time in the ordinary course of business pursuant to Manufacturing Agreements, except, in each case if any such order or statement is in the form of an amendment to or otherwise amends any material terms of any Manufacturing Agreement, (c) agreements or other contractual arrangements in connection with capital expenditures in the ordinary course of business, and (d) agreements or other contractual arrangements entered into in the ordinary course of business in connection with the purchase of materials or the sale of third-party products for further distribution.
“Maturity Date Acceleration Trigger” means, as of the date that is ninety (90) days prior to the stated maturity date of the 2030 Convertible Notes (that is, August 1, 2030, as such date may be extended pursuant to and in accordance with the terms and conditions of such convertible notes (including the Indenture)), (a) the Consolidated Total Gross Leverage Ratio exceeds 3.0x for the Test Period most recently ended on or prior to such date, and (b) the aggregate principal amount of the 2030 Convertible Notes then-outstanding exceeds $25,000,000; provided, however, that, notwithstanding the foregoing, the Maturity Date Acceleration Trigger shall not be deemed to occur (and shall not occur) at any time that the maturity date of the 2030 Convertible Notes is a date occurring after the Term Loan Maturity Date.
“Medicaid” means the health care assistance program established by Title XIX of the SSA (42 U.S.C. § 1396 et seq.).
“Medicare” means the health insurance program for the aged and disabled established by Title XVIII of the SSA (42 U.S.C. 1395 et seq.).
“MHRA” means The Medicines and Healthcare products Regulatory Agency that regulates medicinal products, medical devices and blood components for transfusion in the U.K.
“Mortgage” means any deed of trust, leasehold deed of trust, mortgage, leasehold mortgage, deed to secure debt, leasehold deed to secure debt or other document creating a Lien on real estate or any interest in real estate.
“Multiemployer Plan” means a multiemployer plan within the meaning of Section 4001(a)(3) or Section 3(37) of ERISA (a) to which Borrower or its Subsidiaries or their respective ERISA Affiliates is then making or accruing an obligation to make contributions; (b) to which Borrower or its Subsidiaries or their respective ERISA Affiliates has within the preceding five (5) plan years made contributions; or (c) with respect to which Borrower or its Subsidiaries could incur material liability.
“NDA” means a new drug application, submitted to FDA pursuant to 21 U.S.C. § 355, seeking authorization to market a new drug in the United States, or any foreign equivalents.
-110-
“Net Product Revenues” means, with respect to any Product for any Test Period, net sales of such Product in the Territory, on the basis of information contained in the most recent financial statements that have been delivered pursuant to Section 5.2(a)(i) or Section 5.2(a)(ii) and filed with the SEC (and, to the extent such financial statements do not expressly set forth the applicable amounts, supporting documentation and calculations in reasonable detail, reasonably satisfactory to the Collateral Agent and certified by the Chief Financial Officer of Borrower, evidencing such amounts); provided, however, that Net Product Revenues shall exclude any milestone payments, any non-recurring payments and any non-sales-based revenues or proceeds, or any payments, revenues or proceeds from products which are not such Product.
“Note Register” is defined in Section 2.8(a).
“Obligations” means, collectively, the Credit Parties’ obligations to pay when due any and all debts, principal, interest, Lender Expenses, the Additional Consideration, the Makewhole Amount, the Prepayment Premium and any other fees, expenses, indemnities and amounts any Credit Party owes any Lender or the Collateral Agent now or later, under this Agreement or any other Loan Document, including interest accruing after Insolvency Proceedings begin (whether or not allowed), and to perform Borrower’s duties under the Loan Documents.
“OFAC” is defined in Section 4.18(c).
“Operating Documents” means, collectively with respect to any Person, such Person’s formation and constitutional documents and, (a) if such Person is a corporation, its bylaws (or similar organizational regulations), (b) if such Person is an exempted company or a company limited by shares, its memorandum and articles of association (or similar organizational regulations), (c) if such Person is a limited liability company, its limited liability company agreement (or similar agreement), and (d) if such Person is a partnership, its partnership agreement (or similar agreement), in each case including all amendments, restatements, amendment and restatements, supplements and other modifications thereto.
“ordinary course of business” means, in respect of any transaction involving any Person, the ordinary course of such Person’s business, undertaken by such Person in good faith and not for purposes of evading any covenant, prepayment obligation or restriction in any Loan Document.
“Orphan Drug” means a drug or biologic that meets the definition for “orphan drug” provided in 21 C.F.R. § 316.3(b)(10) that has been granted an orphan drug designation by the Secretary of U.S. Department of Health and Human Services under 21 U.S.C. § 360bb, and any foreign equivalents granted by any other Governmental Authorities (it being understood and agreed that, as of the Effective Date, Rezzayo is the only Orphan Drug).
“Other Acquisition Agreement” means, collectively, the acquisition agreement governing or evidencing any Other Acquisition Transaction and the transactions contemplated thereunder (including the schedules and exhibits thereto), together with all other documents delivered or filed pursuant to such Other Acquisition Transaction, in each case in the forms most recently delivered to the Collateral Agent and Lenders delivered to the Collateral Agent and Lenders pursuant to Section 3.1(a), Section 3.1(k), Section 3.2(b) or Section 3.2(d), as applicable.
“Other Acquisition Products” means, collectively, any pharmaceutical or biopharmaceutical product acquired by Borrower or any of its Subsidiaries pursuant to any Other Acquisition Agreement in connection with any Other Acquisition Transaction.
“Other Acquisition Transaction” means an acquisition of any Other Acquisition Products by Borrower or any of its Subsidiaries on or concurrently with, the Tranche B Closing Date, pursuant to the Other Acquisition Agreement; provided, that, if the Tranche B Closing Date precedes the Tranche A Closing Date, the cash consideration payable by Borrower or such Subsidiary is greater than or equal to $50,000,000.
“Other Connection Taxes” means, with respect to any Lender, Taxes imposed as a result of a present or former connection (including present or former connection of its agents) between such Lender and the jurisdiction imposing such Tax (other than connections arising solely from such Lender having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in any Term Loan or Loan Document).
-111-
“Other Royalty Product” is defined in the definition of Permitted Other Royalty Financing.
“Other Taxes” means all present or future stamp, court or documentary, intangible, recording, filing, charges or similar Taxes that arise from any payment made hereunder, from the execution, delivery, performance, enforcement or registration of, from the receipt or perfection of a security interest under, or otherwise with respect to, any Loan Document, except any such Taxes that are Other Connection Taxes imposed with respect to a Lender Transfer.
“Participant Register” is defined in Section 11.1(d).
“Patents” means all patents and patent applications (including any improvements, continuations, continuations-in-part, divisionals, provisionals or any substitute applications), any patent issued with respect to any of the foregoing patent applications, any reissue, reexamination, renewal or patent term extension or adjustment (including any supplementary protection certificate) of any such patent, and any confirmation patent or registration patent or patent of addition based on any such patent, and all foreign and international counterparts of any of the foregoing. For the avoidance of doubt, patents and patent applications under this definition include individual patent claims and include all those filed with the U.S. Patent and Trademark Office or which could be nationalized in the United States.
“Patriot Act” is defined in Section 3.1(h).
“Payment Date” means the last Business Day of each March, June, September and December of each year, commencing on the Initial Payment Date and continuing quarterly through and including the Term Loan Maturity Date (provided that if such date is not a Business Day, then on the immediately preceding Business Day).
“PCI Cap” means, as of any date of determination, an amount not to exceed $150,000,000 in the aggregate outstanding at any time (including, for the avoidance of doubt, the aggregate original principal amount of Indebtedness then-outstanding under the 2030 Convertible Notes (and the Indenture) and the aggregate original principal amount of Indebtedness (if any) incurred to refinance the 2030 Convertible Notes pursuant to clause (w) of the definition of Permitted Indebtedness).
“PCI DSS” means the Payment Card Industry Data Security Standard, issued by the Payment Card Industry Security Standards Council, as revised from time to time.
“Perfection Certificate” is defined in Section 4.6.
“Periodic Term SOFR Determination Day” has the meaning specified in the definition of “Term SOFR”.
“Permitted Acquisition” means any Acquisition, so long as:
(a) no Default or Event of Default shall have occurred and be continuing as of the date the purchase or other acquisition agreement underlying such Acquisition has been executed and delivered by all parties thereto;
(b) the properties or assets being acquired or licensed, or the Person whose Equity Interests are being acquired, are useful in or engaged in, as applicable, (i) the same, similar or a related line of business as that then-conducted by Borrower or its Subsidiaries, or (ii) a line of business that is related or ancillary to or in furtherance of a line of business as that then-conducted by Borrower or its Subsidiaries;
(c) in the case of an Asset Acquisition, the subject assets are being acquired or licensed by a Credit Party, and within the timeframes expressly set forth in Section 5.12 with respect to all assets constituting Collateral, such Credit Party shall have executed and delivered or authorized, as applicable, any and all security agreements, financing statements and any other documentation required by Section 5.12 or reasonably requested by the Collateral Agent, in order to include the newly acquired or licensed assets within the Collateral, as applicable, to the extent required by Section 5.12;
-112-
(d) in the case of a Stock Acquisition, the subject Equity Interests are being acquired in such Acquisition directly or indirectly by a Credit Party, and such Credit Party shall have complied with its obligations under Section 5.13; and
(e) any Indebtedness or Liens assumed in connection with such Acquisition are otherwise permitted under Section 6.4 or 6.5, respectively.
“Permitted Acquisition Royalty Agreement” means the primary agreement (which may be a purchase and sale agreement, an asset purchase agreement or similar acquisition agreement) governing any Permitted Acquisition Royalty Obligation (including the schedules and exhibits thereto), in each case in the forms delivered to the Collateral Agent and Lenders pursuant to Section 3.1(m) or Section 3.2(f), as applicable, or, with respect to any Permitted Acquisition consummated after the First Closing Date, in the forms delivered to the Collateral Agent pursuant to Section 5.2(e)(i), and not prohibited under Section 6.10 or Section 6.14(c) hereof, as may be amended, restated, supplemented, modified or replaced, or renewed or altered from time to time in accordance with Section 6.10 hereof.
“Permitted Acquisition Royalty Documents” means, collectively, the Permitted Acquisition Royalty Agreement and each other document related to any Permitted Acquisition Royalty Obligation (including all documents delivered or filed in connection with the underlying Acquisition), in each case in the forms delivered to the Collateral Agent and Lenders pursuant to Section 3.1(m) or Section 3.2(f), as applicable, or, with respect to any Permitted Acquisition consummated after the First Closing Date, in the forms delivered to the Collateral Agent pursuant to Section 5.2(e)(i), as may be amended, restated, supplemented, modified or replaced, or renewed or altered from time to time in accordance with Section 6.10 hereof.
“Permitted Acquisition Royalty Obligation” means any direct or indirect obligation of Borrower or any of its Subsidiaries to pay any royalty or milestone payment to a third party based on net sales of a product, that is assumed, incurred or created in connection with an Acquisition involving such product that constitutes a Permitted Acquisition hereunder; provided, however, that:
(a) Any such product shall constitute a “Product” under clause (i) or (j) of the definition thereof;
(b) No such obligation requires Borrower or any of its Subsidiaries to pay an earn-out payment, milestone payment or similar contingent payment or contingent compensation to a third party, including any contingent payment or compensation that becomes due and payable solely with the passage of time, other than (i) royalties or milestones based on net sales of the product(s) that are the subject of such Permitted Acquisition Royalty Obligation and (ii) any Contingent Obligation constituting Permitted Indebtedness under clause (j) of the definition thereof (it being understood that the existence of any such Contingent Obligation or other obligation in the same Permitted Acquisition Royalty Agreement shall not cause such Permitted Acquisition Royalty Obligation to fail to satisfy this clause (b));
(c) No such obligation requires Borrower or any of its Subsidiaries to make any payment relating to a change of control (other than a customary call option (and not requirement) upon the change of control of Borrower or any Subsidiary, provided, however, that the Obligations are prepaid in full pursuant to Section 2.2(c)(ii) before any amounts payable upon exercise of such call option are paid to any Person), any late or overdue payments in excess of shortfalls discovered through an audit plus any interest payment with respect to such shortfall that does not exceed an interest rate that is permitted under applicable law, any other fees with respect to any such shortfalls, or any fees relating to the termination of such royalty;
(d) No such obligation requires Borrower or any of its Subsidiaries to make any advance payment before such payment is due and payable, any prepayment or accelerated payment of any royalty payments or similar payments owed under the terms of such royalty or similar financing, or any minimum amount payment in the form of a true up;
-113-
(e) No such obligation involves the incurrence of any Indebtedness in connection therewith or otherwise pursuant to any Permitted Acquisition Royalty Documents, other than Permitted Indebtedness;
(f) No such obligation requires or contemplates the pledge of or granting of any Lien on or any security interest in any Collateral (other than the revenue or royalty permitted to be transferred pursuant to such royalty or similar financing), including, for the avoidance of doubt, any Lien on or any security interest in any right, title or interest in or to, or any products or proceeds of, the revenues (and the right to receive the same) relating to the remaining percentage of aggregate Net Product Revenues of the product(s) that are the subject of such Permitted Acquisition Royalty Obligation (which shall remain as Collateral); and
(g) No such obligation includes any sale or other transfer of any right, title or interest in or to, or any products or proceeds of, the revenues (and the right to receive the same) relating to the remaining percentage of aggregate Net Product Revenues of the product(s) that are the subject of such Permitted Acquisition Royalty Obligation (which shall remain as Collateral).
“Permitted Acquisition Royalty Payments” means all payments that are due and payable under any Permitted Acquisition Royalty Documents.
“Permitted Convertible Indebtedness” means Indebtedness of Borrower or any Subsidiary of Borrower that is a Credit Party having a feature which entitles the holder thereof in certain circumstances to convert or exchange all or a portion of such Indebtedness into Equity Interests in Borrower or such Subsidiary (or other securities or property following a merger event or other change of the common stock of Borrower or such Subsidiary), cash or any combination of cash and such Equity Interests (or such other securities or property) based on the market price of such Equity Interests (or such other securities or property); provided, however, that (a) such Indebtedness shall be unsecured, (b) such Indebtedness shall not be guaranteed by any Subsidiary of Borrower (including, for the avoidance of doubt, any Excluded Subsidiary), (c) such Indebtedness shall bear interest at a rate per annum not to exceed five percent (5.0%), (d) such Indebtedness shall not include covenants and defaults (other than covenants and defaults customary for convertible indebtedness but not customary for loans, as determined by Borrower in its good faith judgment) that are, taken as a whole, more restrictive on the Credit Parties than the provisions of this Agreement (as determined by Borrower in its good faith judgment), (e) immediately prior to and after giving effect to the incurrence or issuance of such Indebtedness, no Default or Event of Default shall have occurred and be continuing or could reasonably be expected to occur as a result therefrom (after giving effect to this Agreement), (f) such Indebtedness shall not (i) mature or be mandatorily redeemable, pursuant to a sinking fund obligation or otherwise, (ii) be redeemable at the option of the holder thereof, in whole or in part or (iii) provide for the scheduled payment of dividends or distributions (other than scheduled cash interest payments) in cash, in each case of the foregoing sub-clauses (i), (ii) and (iii), earlier than twelve (12) months after the Term Loan Maturity Date (it being understood, for the avoidance of doubt, that (w) a redemption right of Borrower or such Subsidiary in respect of such Indebtedness, (x) conversion rights of holders in respect of such Indebtedness, (y) acceleration rights of holders of such Indebtedness upon the occurrence of an event of default specified in the agreement governing such Indebtedness and (z) the obligation to pay customary amounts to holders of such Indebtedness in connection with a “change of control” or “fundamental change”, in each case, shall not be considered in connection with the determination of scheduled maturity date for purposes of this clause (f)); (g) immediately after giving effect to the incurrence of such Indebtedness (and any prepayment, repurchase or redemption of any existing Permitted Convertible Indebtedness using cash proceeds of the issuance of such Indebtedness (and any cash proceeds received pursuant to the exercise, early unwind or termination of any Permitted Equity Derivatives in connection with such prepayment, repurchase or redemption)), the amount of all Permitted Convertible Indebtedness permitted hereunder (together with any Indebtedness incurred to refinance Permitted Convertible Indebtedness pursuant to clause (w) of the definition of Permitted Indebtedness) and then-outstanding shall not exceed the PCI Cap; and (h) Borrower shall have delivered to the Collateral Agent a certificate of a Responsible Officer of Borrower certifying as to the foregoing clauses (a) through (g) with respect to any such Indebtedness. For the avoidance of doubt, Indebtedness under the 2030 Convertible Notes (and the Indenture) constitutes Permitted Convertible Indebtedness hereunder if and only to the extent such Indebtedness does not contravene in any respect any of clauses (a), (b), (c), (d), (e) or (g) above.
“Permitted Distributions” means, in each case subject to Section 6.8 if applicable:
(a) dividends, distributions or other payments by any Wholly Owned Subsidiary of Borrower on its Equity Interests to, or the redemption, retirement or purchase by any Wholly Owned Subsidiary of Borrower of its Equity Interests from, Borrower or any other Wholly Owned Subsidiary of Borrower;
-114-
(b) dividends, distributions or other payments by any non-Wholly Owned Subsidiary on its Equity Interests to, or the redemption, retirement or purchase by any non-Wholly Owned Subsidiary of its Equity Interests from, Borrower or any other Subsidiary or each other owner of such non-Wholly Owned Subsidiary’s Equity Interests based on their relative ownership interests of the relevant class of such Equity Interests;
(c) exchanges, redemptions or conversions by Borrower in whole or in part any of its Equity Interests for or into another class of its Equity Interests or rights to acquire its Equity Interests or with proceeds from substantially concurrent equity contributions or issuances of new Equity Interests;
(d) any such payments arising from (i) a Permitted Acquisition or (ii) other Permitted Investment, in each case of this clause (d) by Borrower or any of its Subsidiaries;
(e) the payment of dividends by Borrower solely in non-cash pay and non-redeemable capital stock (including, for the avoidance of doubt, dividends and distributions payable solely in Equity Interests);
(f) cash payments in lieu of the issuance of fractional shares arising out of stock dividends, splits or combinations or in connection with the exercise of warrants, options or other securities convertible into or exchangeable for Equity Interests, including Permitted Convertible Indebtedness;
(g) in connection with any Acquisition or other Investment by Borrower or any of its Subsidiaries, (i) the receipt or acceptance of the return to Borrower or any of its Subsidiaries of Equity Interests of Borrower constituting a portion of the purchase price consideration in settlement of indemnification claims, or as a result of a purchase price adjustment (including earn-outs or similar obligations) and (ii) payments or distributions to equity holders pursuant to appraisal rights required under Requirements of Law;
(h) the distribution of rights pursuant to any shareholder rights plan or the redemption of such rights for nominal consideration in accordance with the terms of any shareholder rights plan;
(i) dividends, distributions or payments on its Equity Interests by any Subsidiary to any Credit Party;
(j) dividends, distributions or payments on its Equity Interests by any Subsidiary that is not a Credit Party to any other Subsidiary that is not a Credit Party;
(k) purchases of Equity Interests of Borrower or its Subsidiaries in connection with net settlements, the exercise of stock options by way of cashless exercise, or in connection with the satisfaction of withholding tax obligations;
(l) issuance to current or former directors, officers, employees, consultants or contractors of Borrower or its Subsidiaries of awards or common stock of Borrower pursuant to awards, of restricted stock, restricted stock units, or other rights to acquire common stock of Borrower, in each case pursuant to plans or agreements approved by Borrower’s Board of Directors (or committee thereof) or stockholders;
(m) the repurchase, retirement or other acquisition or retirement for value of Equity Interests of Borrower or any of its Subsidiaries held by any future, present or former employee, consultant, officer or director (or spouse, ex-spouse or estate of any of the foregoing or trust for the benefit of any of the foregoing or any lineal descendants thereof) of Borrower or any of its Subsidiaries pursuant to any management equity plan or stock option plan or any other management or employee benefit plan or agreement, or any stock subscription or shareholder agreement or employment agreement; provided, however, that, with respect to any calendar year, the aggregate payments made under this clause (m) do not exceed the sum of (i) $6,000,000 plus (ii) any unused amounts permitted under this clause (m) during the two (2) immediately preceding calendar years, plus (iii) amount of any payments received in such calendar year under key-man life insurance policies;
-115-
(n) dividends or distributions on its Equity Interests by Borrower or any of its Subsidiaries payable solely in additional shares of its common stock;
(o) additional Restricted Payments in an aggregate amount not to exceed $5,000,000 in the aggregate; and
(p) solely in connection with Permitted Convertible Indebtedness, the Credit Parties or its Subsidiaries may enter into Permitted Equity Derivatives (and may settle, terminate or unwind any such Permitted Equity Derivatives in connection with any refinancing, repurchase, redemption, early conversion or maturity of such Permitted Convertible Indebtedness).
“Permitted Equity Derivative” means any call or capped call option (or substantively equivalent equity derivative transaction) or “call spread” transaction (which consists of separate call option and warrant transactions) relating to the Equity Interests of Borrower or any other Credit Party purchased by Borrower or such Credit Party in connection with the issuance or incurrence of Permitted Convertible Indebtedness by Borrower or such other Credit Party, provided, that, the purchase price for such call or capped call option or such other transaction (net of any proceeds received from the issuance of any related warrant transactions) does not exceed the net cash proceeds received by Borrower or such other Credit Party from the issuance or incurrence of such Permitted Convertible Indebtedness.
“Permitted Indebtedness” means:
(a) Indebtedness of the Credit Parties to Secured Parties under this Agreement and the other Loan Documents;
(b) Indebtedness existing on the First Closing Date and set forth on Schedule 13.3 of the Disclosure Letter, including Indebtedness under the 2030 Convertible Notes (and the Indenture) if and only to the extent such Indebtedness does not contravene in any respect any of clauses (a) through (e) and (g) of the definition of “Permitted Convertible Indebtedness;”
(c) (i) Indebtedness incurred to finance the purchase, construction, repair, or improvement of fixed assets and (ii) Capital Lease Obligations; provided, however, that all such Indebtedness and Capital Lease Obligations (other than that which directly relates to the purchase, construction, repair, leasing or improvement of manufacturing facilities) shall not exceed $10,000,000 in the aggregate at any time outstanding;
(d) Indebtedness in connection with trade credit, corporate credit cards, purchasing cards or bank card products, provided, that, any such Indebtedness that is secured shall not exceed $5,000,000 in the aggregate at any time outstanding;
(e) guarantees of Permitted Indebtedness by any Credit Party;
(f) Indebtedness assumed in connection with any Permitted Acquisition or Permitted Investment, so long as (i) such Indebtedness was not incurred in connection with, or in anticipation of, such Acquisition or Investment and (ii) such Indebtedness is at all times Subordinated Debt or Capital Lease Obligations;
(g) Indebtedness of Borrower or any of its Subsidiaries with respect to letters of credit, bank guarantees, bankers’ acceptances, warehouse receipts or similar instruments outstanding and to the extent secured, secured solely by cash or Cash Equivalents, in each case entered into in the ordinary course of business;
(h) Indebtedness owed: (i) by a Credit Party to another Credit Party; (ii) by a Subsidiary of Borrower that is not a Credit Party to another Subsidiary of Borrower that is not a Credit Party; (iii) by a Credit Party to a Subsidiary of Borrower that is not a Credit Party; or (iv) by a Subsidiary of Borrower that is not a Credit Party to a Credit Party, not to exceed $10,000,000 in the aggregate at any time outstanding;
-116-
(i) Indebtedness consisting of Contingent Obligations described in clause (a) of the definition thereof: (i) of a Credit Party of Permitted Indebtedness of another Credit Party (or obligations that do not constitute Indebtedness hereunder and are not prohibited hereunder); (ii) of a Subsidiary of Borrower which is not a Credit Party of Permitted Indebtedness (or obligations that do not constitute Indebtedness hereunder and are not prohibited hereunder) of another Subsidiary of Borrower which is not a Credit Party; (iii) of a Subsidiary of Borrower which is not a Credit Party of Permitted Indebtedness (or obligations that do not constitute Indebtedness hereunder and are not prohibited hereunder) of a Credit Party; or (iv) of a Credit Party of Permitted Indebtedness (or obligations that do not constitute Indebtedness hereunder and are not prohibited hereunder) of a Subsidiary of Borrower which is not a Credit Party not to exceed $10,000,000 in the aggregate at any time outstanding;
(j) Indebtedness consisting of Contingent Obligations described in clause (b) of the definition thereof, incurred in connection with any Permitted Acquisition, Permitted Transfer, Permitted Investment or any in-licensing or any collaboration, co-promotion or co-marketing arrangement; provided such Indebtedness is due and payable upon the occurrence of an event or the performance of an act (and not solely with the passage of time);
(k) (i) Indebtedness with respect to workers’ compensation claims, payment obligations in connection with health, disability or other types of social security benefits, unemployment or other insurance obligations, reclamation and statutory obligations or (ii) Indebtedness related to employee benefit plans, including annual employee bonuses, accrued wage increases and 401(k) plan matching obligations; in each case, incurred in the ordinary course of business;
(l) Indebtedness in respect of performance bonds, bid bonds, appeal bonds, surety bonds and completion guarantees and similar obligations arising in the ordinary course of business;
(m) Indebtedness in respect of netting services, overdraft protection and other cash management services, in each case in the ordinary course of business;
(n) Indebtedness consisting of the financing of insurance premiums in the ordinary course of business;
(o) Indebtedness consisting of guarantees resulting from endorsement of negotiable instruments for collection by any Credit Party in the ordinary course of business;
(p) unsecured Indebtedness incurred in connection with any items of Permitted Distributions in clause (m) of the definition of Permitted Distributions;
(q) Indebtedness under any (i) unsecured Hedging Agreements entered into for hedging and not speculative purposes, and (ii) Hedging Agreements with respect to interest rates that are secured only by cash or Cash Equivalents and entered into for hedging and not speculative purposes;
(r) Permitted Convertible Indebtedness, including Indebtedness under the 2030 Convertible Notes (and the Indenture) if and only to the extent such Indebtedness does not contravene in any respect any of clauses (a) through (g) (other than, with respect to the 2030 Convertible Notes (and Indenture), clause (f)) of the definition of “Permitted Convertible Indebtedness,” in an aggregate original principal amount not to exceed the PCI Cap at the time of any issuance or incurrence thereof;
(s) to the extent constituting Indebtedness, Permitted Equity Derivatives;
(t) Indebtedness under (i) any Permitted Royalty Agreement Document, (ii) any Permitted Royalty Financing Document, (iii) any Permitted Other Royalty Financing Document and (iv) any Permitted Acquisition Royalty Document;
-117-
(u) Indebtedness in the form of a working capital line of credit in an amount not to exceed $15,000,000 at any one time outstanding (the “Working Capital Credit Line” and the Indebtedness to be incurred thereunder, the “Working Capital Indebtedness”), subject to the satisfaction of the following conditions:
(i) such Working Capital Credit Line is entered into, and any Working Capital Indebtedness incurred under such Working Capital Credit Line, after the Tranche A Closing Date;
(ii) in the event such Working Capital Indebtedness is secured, such Working Capital Indebtedness shall be secured only by a Lien on inventory and accounts receivable;
(iii) such Working Capital Indebtedness shall be subject to a subordination, intercreditor or other similar agreement that is in form and substance satisfactory to the Collateral Agent;
(iv) the Consolidated Total Gross Leverage Ratio does not exceed 3.0x for the Test Period most recently ended on or prior to the date such Working Capital Credit Line is entered into, after giving pro forma effect thereto; and
(v) no Default shall have occurred and be continuing or Event of Default shall have occurred both immediately before and immediately after giving pro forma effect to (x) the applicable Credit Party’s entry into such Working Capital Credit Line, and (y) each incurrence of Working Capital Indebtedness under such Working Capital Credit Line;
(v) other unsecured Indebtedness in an aggregate principal amount not to exceed $5,000,000 at any time outstanding; and
(w) subject to the proviso immediately below, extensions, refinancings, renewals, modifications, amendments, restatements and, in the case of any items of Permitted Indebtedness in clause (b) of the definition thereof or Permitted Indebtedness constituting notes governed by an indenture, exchanges, of any items of Permitted Indebtedness in clauses (a) through (v) above, including, for the avoidance of doubt, Indebtedness under the 2030 Convertible Notes (and the Indenture); provided, that, in the case of clause (b) above, the principal amount thereof is not increased (other than by any reasonable amount of premium (if any), interest (including post-petition interest), fees, expenses, charges or additional or contingent interest reasonably incurred in connection with the same and the terms thereof); provided, further, that in the case of any Indebtedness permitted under clause (r) of the definition of Permitted Indebtedness (including, for the avoidance of doubt, Indebtedness under the 2030 Convertible Notes (and the Indenture)), (w) the maturity thereof is not shortened to before the Term Loan Maturity Date, (x) the amount of all Permitted Convertible Indebtedness permitted hereunder and then-outstanding does not exceed the PCI Cap, (y) there is no change to or addition of any direct or indirect obligor with respect thereto, and (z) immediately before and immediately after giving effect to any such extensions, refinancings, renewals, modifications, amendments or restatements, such Indebtedness constitutes Permitted Convertible Indebtedness in accordance with the definition thereof.
Notwithstanding the foregoing or anything in this Agreement to the contrary, except with respect to any Permitted Royalty Agreement Document, any Permitted Royalty Financing Document, Permitted Other Royalty Financing Document or any Permitted Acquisition Royalty Document, (x) no direct or indirect synthetic royalty or similar financing transaction involving the sale of revenues or royalties, in each case, based on net sales of any product (including any Product) in the Territory (including, for the avoidance of doubt, any Indebtedness constituting such synthetic royalty or other similar payment), and (y) except to the extent incurred in connection with any Permitted Acquisitions, Permitted Investments, Permitted Licenses, in-licensing agreements or any collaboration, co-promotion or co-marketing arrangements, no Indebtedness constituting royalty payments or milestone payments based on net sales or similar payments, in each case based on the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of any product (including any Product) in the Territory, that is, directly or indirectly, created, incurred, assumed or guaranteed after the Effective Date, in each case of sub-clause (x) or (y) above, by a Credit Party or any of its Subsidiaries, shall in any instance be permitted under this Agreement without the prior written consent of the Collateral Agent or the Required Lenders.
-118-
“Permitted Investments” means:
(a) Investments (including Investments in Borrower and Subsidiaries) existing on the First Closing Date and shown on Schedule 13.4 of the Disclosure Letter, and any extensions, renewals or reinvestments thereof;
(b) Investments consisting of cash and Cash Equivalents;
(c) Investments consisting of the endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business;
(d) Investments consisting of deposit accounts or securities accounts;
(e) Investments in connection with Permitted Transfers;
(f) Investments consisting of (i) travel advances and employee relocation loans and other employee advances in the ordinary course of business, and (ii) loans to employees, officers or directors relating to the purchase of equity securities of Borrower pursuant to employee stock purchase plans or agreements approved by Borrower’s Board of Directors (or committee thereof);
(g) Investments (including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent obligations of, and other disputes with, customers or suppliers arising in the ordinary course of business;
(h) Investments consisting of accounts or notes receivable of, or prepaid royalties and other credit extensions, to customers, suppliers and manufacturers who are not Affiliates, in the ordinary course of business; provided that this clause (h) shall not apply to Investments of any Credit Party in any of its Subsidiaries;
(i) Investments (i) required in connection with a Permitted Acquisition (including the formation of any Subsidiary for the purpose of effectuating such Permitted Acquisition, the capitalization of such Subsidiary whether by capital contribution or intercompany loans, in each case, to the extent otherwise permitted by the terms of this Agreement, related Investments in Subsidiaries necessary to consummate such Permitted Acquisition, and the receipt of any non-cash consideration in a Permitted Acquisition), and (ii) consisting of earnest money deposits required in connection with a Permitted Acquisition or other acquisition of properties or assets not otherwise prohibited hereunder;
(j) Investments constituting the formation of any Subsidiary for the purpose of consummating a merger or acquisition transaction permitted by Section 6.3(a)(i) through (iii) hereof, which such transaction is otherwise a Permitted Investment;
(k) Investments of any Person that (i) becomes a Subsidiary of Borrower (or of any Person not previously a Subsidiary of Borrower that is merged or consolidated with or into a Subsidiary of Borrower in a transaction permitted hereunder) after the Effective Date, (ii) are assumed as of the Tranche A Closing Date by any Subsidiary of Borrower in connection with the Heron Acquisition Transaction, or (iii) are assumed after the Effective Date by any Subsidiary of Borrower in connection with an acquisition of assets from such Person by such Subsidiary, including in connection with an Acquisition in connection with the Tranche B Closing Date (if any), in each case, in a Permitted Acquisition; provided, that, in each case any such Investment (w) does not constitute Indebtedness of such Person, (x) exists at the time such Person becomes a Subsidiary of Borrower (or is merged or consolidated with or into a Subsidiary of Borrower) or such assets are acquired, (y) was not made in contemplation of or in connection with such Person becoming a Subsidiary of Borrower (or merging or consolidating with or into a Subsidiary of Borrower) or such acquisition of assets, and (z) could not reasonably be expected to result in a Default or an Event of Default;
(l) Investments arising as a result of the licensing of Company IP in the ordinary course of business and not otherwise prohibited hereunder;
(m) Investments by: (i) any Credit Party in any other Credit Party; (ii) any Subsidiary of Borrower which is not a Credit Party in another Subsidiary of Borrower which is not a Credit Party; (iii) any Subsidiary of Borrower which is not a Credit Party in any Credit Party; and (iv) any Credit Party in any Subsidiary of Borrower which is not a Credit Party not to exceed $10,000,000 in the aggregate outstanding at any time.
-119-
(n) repurchases of capital stock of Borrower or any of its Subsidiaries deemed to occur upon the exercise of options, warrants or other rights to acquire capital stock of Borrower or such Subsidiary solely to the extent that shares of such capital stock represent a portion of the exercise price of such options, warrants or such rights;
(o) Investments consisting of non-cash consideration received for any Permitted Transfer;
(p) Investments consisting of acquisitions of assets from third parties used in the ordinary course of business, including inventory, raw materials, vehicles, equipment, office supplies, software and other similar assets;
(q) Investments consisting of in-licensing agreements, provided, that, no Indebtedness that is not Permitted Indebtedness is incurred or assumed in connection therewith;
(r) to the extent constituting an Investment, any Permitted License;
(s) (i) unsecured Hedging Agreements entered into for hedging and not speculative purposes, and (ii) Hedging Agreements with respect to interest rates that are secured only by cash or Cash Equivalents and entered into for hedging and not speculative purposes;
(t) to the extent constituting an Investment, any Permitted Equity Derivatives, including the payment of premium by any Credit Party in connection therewith; and
(u) other Investments, not to exceed $5,000,000 in the aggregate;
provided, however, that, none of the foregoing Investments shall be a “Permitted Investment” if any Indebtedness or Liens assumed in connection with such Investment are not otherwise permitted under Section 6.4 or 6.5, respectively.
“Permitted Licenses” means, collectively: (a) any exclusive license, non-exclusive license, covenant not to sue, or similar agreement with respect to any Product or any other product in any geography outside the Territory; (b) subject to clause (c) below, any exclusive license, covenant not to sue or similar agreement with respect to any Intellectual Property (including, for clarity, any Company IP) solely for the purpose of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale or lease, distribution or sale or lease of products that are not (i) any Product or (ii) products which compete with any Product within the Territory, provided, that, such license, covenant or agreement does not, and could not reasonably be expected to, interfere with or impede the ability of, or interfere with the rights or ability of, Borrower or any of its Subsidiaries, to conduct the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution, sale of, or to otherwise exploit, any Product in the Territory or to enforce its rights with respect to any of the foregoing; (c) without limiting the generality of clause (b) above, any non-exclusive license with respect to any Product within the Territory to Intellectual Property or any non-exclusive grant of rights for development, manufacture, production, commercialization, marketing, co-promotion, distribution, sale or similar commercial rights with respect to any Product within the Territory, in each case in the ordinary course of business (each, a “Co-Promotion Arrangement”), provided, that, the primary purpose of such license or grant is to further a co-development, co-promotion or similar commercial arrangement with respect to such Product within the Territory; provided, further, that as a result of any such license or grant, (i) one hundred percent (100%) of the Net Product Revenues of such Product must be reported in the financial statements of Borrower and its Subsidiaries in accordance with GAAP, (ii) Borrower or its Subsidiaries must retain (x) the right to control pricing authorization, if any, and (y) decision-making of pricing of such Product, in each case, within the Territory, (iii) either (1) the Net Product Revenues of such Product for the Test Period most recently ended prior to entry into such Co-Promotion Arrangement are less than $20,000,000, or (2) the Consolidated Total Gross Leverage Ratio, calculated on a pro forma basis, does not exceed 3.0x for the Test Period most recently ended on or prior to the date of entry into such Co-Promotion Arrangement, and (iv) no Event of Default shall have occurred and be continuing at the time of entry into the definitive agreement therefor; (d) licenses pursuant to any Logistics Agreements, Manufacturing Agreements, or otherwise with a logistics provider, or contract manufacturer, in each case solely with respect to the services provided under such agreement, within the Territory; (e) any non-exclusive licenses with respect to any research and development (including Contract Research Agreements or similar agreements with contract researchers), including with respect to any Product within the Territory; (f) any intercompany license or other similar arrangement described in clause (k) of the definition of Permitted Transfers among Credit Parties and Subsidiaries within the Territory; (g) any intercompany license or other similar arrangement among Credit Parties within the Territory; (h) Distribution Agreements; and (i) any exclusive license, non-exclusive license, covenant not to sue or similar agreement existing as of the Effective Date and listed on Schedule 13.5 of the Disclosure Letter delivered on the Effective Date (as such schedule may be updated on any Closing Date solely to reflect any such license, covenant not to sue or similar agreement entered into after the Effective Date in compliance with this Agreement, it being understood and agreed that no such update shall cause any license, covenant not to sue or similar agreement that would not otherwise constitute a Permitted License to constitute a Permitted License), and any amendment, extension or replacement thereof. Notwithstanding the foregoing or any other provision of this Agreement, no Excluded License with respect to any Product entered into after the Effective Date shall be a “Permitted License” hereunder without the prior written consent of the Collateral Agent or the Required Lenders.
-120-
“Permitted Liens” means:
(a) Liens in favor and for the benefit of any Lender and the other Secured Parties securing the Obligations pursuant to any Loan Document;
(b) Liens existing on the Effective Date and set forth on Schedule 13.6 of the Disclosure Letter;
(c) Liens for Taxes, assessments or governmental charges which (i) are not yet due and payable or (ii) if due and payable, are being contested in good faith and by appropriate proceedings; provided that, in each case, adequate reserves therefor have been set aside on the books of the applicable Person and maintained in conformity with GAAP;
(d) (i) pledges or deposits made in the ordinary course of business (other than Liens imposed by ERISA) in connection with workers’ compensation, payroll taxes, unemployment insurance, old-age pensions, or other similar social security legislation, (ii) pledges or deposits made in the ordinary course of business securing liability for reimbursement or indemnification obligations of (including obligations in respect of letters of credit or bank guarantees for the benefit of) insurance carriers providing property, casualty or liability insurance to Borrower or any of its Subsidiaries, (iii) subject to Section 6.2(b), statutory or common law Liens of landlords, (iv) pledges or deposits to secure performance of tenders, bids, leases, statutory or regulatory obligations, surety and appeal bonds, government contracts, performance and return-of-money bonds and other obligations of like nature, in each case other than for borrowed money and entered into in the ordinary course of business, (v) Liens otherwise arising by operation of law in favor of the owner or sublessor of leased premises and confined to the property rented, (vi) Liens that are restrictions on transfer of securities imposed by applicable securities laws, and (vii) Liens resulting from a filing by a lessor as a precautionary filing for a true lease;
(e) Liens arising from attachments or judgments, orders, or decrees in circumstances not constituting an Event of Default under either Section 7.4 or Section 7.7;
(f) Liens (including the right of setoff) in favor of banks or other financial institutions incurred on deposits made in accounts held at such institutions in the ordinary course of business; provided that such Liens (i) are not given in connection with the incurrence of any Indebtedness, (ii) relate solely to obligations for administrative and other banking fees and expenses incurred in the ordinary course of business in connection with the establishment or maintenance of such accounts and (iii) are within the general parameters customary in the banking industry;
(g) Liens that are contractual rights of setoff (i) relating to pooled deposit or sweep accounts of Borrower or any of its Subsidiaries to permit satisfaction of overdraft or similar obligations incurred in the ordinary course of business or (ii) relating to purchase orders and other agreements entered into with customers of Borrower or any of its Subsidiaries in the ordinary course of business, including vendors’ liens to secure payment arising under Article 2 of the Code or similar provisions of Requirements of Law in the ordinary course of business, covering only the goods sold and securing only the unpaid purchase price for such goods and related expenses;
(h) Liens solely on any cash earnest money deposits made by Borrower or any of its Subsidiaries in connection with any Permitted Acquisition, Permitted Investment or other acquisition of assets or properties not otherwise prohibited under this Agreement;
-121-
(i) Liens existing on assets or properties at the time of its acquisition or existing on the assets or properties of any Person at the time such Person becomes a Subsidiary of Borrower, in each case after the Effective Date; provided that (i) neither such Lien was created nor the Indebtedness secured thereby was incurred in contemplation of such acquisition or such Person becoming a Subsidiary of Borrower, (ii) such Lien does not extend to or cover any other assets or properties (other than the proceeds or products thereof and other than after-acquired assets or properties subject to a Lien securing Indebtedness and other obligations incurred prior to such time and which Indebtedness and other obligations are permitted hereunder that requires, pursuant to its terms and conditions in effect at such time, a pledge of after-acquired assets or properties, it being understood that such requirement shall not be permitted to apply to any assets or properties to which such requirement would not have applied but for such acquisition), (iii) the Indebtedness and other obligations secured thereby is permitted under Section 6.4 hereof and (iv) such Liens are of the type otherwise permitted under Section 6.5 hereof;
(j) Liens securing Indebtedness permitted under clause (c) of the definition of “Permitted Indebtedness” (including any extensions, refinancings, modifications, amendments or restatements of such Indebtedness permitted under clause (w) of the definition of Permitted Indebtedness); provided, that, such Lien does not extend to or cover any assets or properties other than those described in clause (c) of the definition of Permitted Indebtedness;
(k) servitudes, easements, rights-of-way, restrictions and other similar encumbrances on real property imposed by Requirements of Law and encumbrances consisting of zoning or building restrictions, easements, licenses, restrictions on the use of property or minor defects or other irregularities in title which, in the aggregate, are not material, and which do not in any case materially detract from the value of the property subject thereto or materially interfere with the ordinary conduct of the business of any Credit Party or any Subsidiary of any Credit Party;
(l) to the extent constituting a Lien, escrow arrangements securing purchase price adjustments, holdback amounts or indemnification obligations associated with any Permitted Acquisition or Permitted Investment;
(m) (i) leases or subleases of real property granted in the ordinary course of business (including, if referring to a Person other than a Credit Party or a Subsidiary, in the ordinary course of such Person’s business), (ii) licenses, sublicenses, leases or subleases of personal property (other than Intellectual Property) granted to third parties in the ordinary course of business, in each case which do not interfere in any material respect with the operations of the business of any Credit Party or any of its Subsidiaries and do not prohibit granting the Collateral Agent a security interest in any Credit Party’s personal property held at such location for the benefit of the Lenders and other Secured Parties, (iii) Permitted Licenses, and (iv) retained interests of lessors or licensors or similar parties under any in-licenses;
(n) Liens on cash or other current assets pledged to secure: (i) Indebtedness in respect of corporate credit cards, purchasing cards or bank card products, provided, that, the portion of such Indebtedness secured pursuant to this clause (n) shall not exceed $5,000,000 in the aggregate at any time outstanding; or (ii) Indebtedness in the form of letters of credit or bank guarantees entered into in the ordinary course of business, provided, that, any such Indebtedness is secured solely by cash or Cash Equivalents;
(o) Liens on any properties or assets of Borrower or any of its Subsidiaries which do not constitute Collateral under the Loan Documents, other than (i) Liens on Equity Interests of any Subsidiary that does not constitute Collateral under the Loan Documents, or (ii) Liens that interfere with or impede the ability of Borrower or any Subsidiary of Borrower to conduct the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of any Product in the Territory or enforce its rights with respect to any of the foregoing within the Territory;
(p) Liens on any properties or assets of Borrower or any of its Subsidiaries imposed by law or regulation which were incurred in the ordinary course of business, including landlords’, carriers’, warehousemen’s, mechanics’, materialmen’s, contractors’, suppliers of materials’, architects’ and repairmen’s Liens, and other similar Liens arising in the ordinary course of business; provided that such Liens (i) do not materially detract from the value of such properties or assets subject thereto or materially impair the use of such properties or assets subject thereto in the operations of the business of Borrower or such Subsidiary or (ii) are being contested in good faith by appropriate proceedings, which conclusively operate to stay the sale or forfeiture of any portion of such properties or assets subject thereto and for which adequate reserves have been set aside on the books of the applicable Person and maintained in conformity with GAAP, if required;
-122-
(q) Liens in favor of customs and revenue authorities arising as a Requirement of Law which were incurred in the ordinary course of business, to secure payment of customs duties in connection with the importation of goods in the ordinary course of business;
(r) Liens on any goods sold to Borrower or any of its Subsidiaries in the ordinary course of business in favor of the seller thereof, but only to the extent securing the unpaid purchase price for such goods and any related expenses;
(s) Liens securing Permitted Indebtedness of a Credit Party in favor of any other Credit Party;
(t) Liens securing Indebtedness owed by a Subsidiary of Borrower that is not a Credit Party permitted under clause (h) of the definition of Permitted Indebtedness, in favor of a Credit Party or another Subsidiary of Borrower that is not a Credit Party;
(u) Liens on insurance policies and the proceeds thereof; provided, that, such Liens are not given in connection with the incurrence of any Indebtedness, secure only the financing of the insurance premiums with respect thereto, and are within the general parameters customary in the insurance industry;
(v) Liens solely on cash and Cash Equivalents in each case securing Hedging Agreements with respect to interest rates that are entered into for hedging and not speculative purposes;
(w) Liens on inventory and accounts receivable securing Working Capital Indebtedness permitted under clause (u) of the definition of Permitted Indebtedness;
(x) additional Liens on assets or properties, in each case so long as the aggregate principal amount of the Indebtedness and other obligations secured thereby do not exceed $2,500,000 in the aggregate for all such Liens at any time outstanding; and
(y) subject to the provisos immediately below, the modification, replacement, extension or renewal of the Liens described in clauses (a) through (x) above; provided, however, that any such modification, replacement, extension or renewal must (i) be limited to the assets or properties encumbered by the existing Lien (and any additions, accessions, parts, improvements and attachments thereto and the proceeds thereof) and (ii) not increase the principal amount of any Indebtedness secured by the existing Lien (other than by any reasonable premium or other reasonable amount paid and fees and expenses reasonably incurred in connection therewith); provided, further, that to the extent any of the Liens described in clauses (a) through (x) above secure Indebtedness of a Credit Party, such Liens, and any such modification, replacement, extension or renewal thereof, shall constitute Permitted Liens if and only to the extent that such Indebtedness is permitted under Section 6.4 hereof.
“Permitted Negative Pledges” means:
(a) prohibitions or limitations with regard to specific properties or assets encumbered by Permitted Liens, if and only to the extent each such prohibition or limitation applies only to such properties or assets;
(b) prohibitions or limitations set forth in any lease, license or other similar agreement entered into in the ordinary course of business and not prohibited hereunder;
(c) prohibitions or limitations relating to Permitted Indebtedness, in each case if and only to the extent such prohibitions or limitations, taken as a whole, are not materially more restrictive than the prohibitions and limitations set forth in this Agreement and the other Loan Documents, taken as a whole (as reasonably determined by a Responsible Officer of Borrower in good faith);
-123-
(d) customary provisions restricting assignments, subletting, sublicensing or other transfer of properties or assets subject thereto set forth in leases, subleases, licenses (including Permitted Licenses) and other similar agreements that are not otherwise prohibited under this Agreement or any other Loan Document, if and only to the extent each such restriction applies only to the properties or assets subject to such leases, subleases, licenses or agreements, and customary provisions restricting assignment, pledges or transfer of any agreement entered into in the ordinary course of business;
(e) prohibitions or limitations imposed by Requirements of Law;
(f) prohibitions or limitations that exist as of the Effective Date under Indebtedness existing on the Effective Date;
(g) customary prohibitions or limitations arising in connection with any Permitted Transfer or contained in any agreement relating to any Permitted Transfer pending the consummation of such Permitted Transfer;
(h) customary provisions in shareholders’ agreements, joint venture agreements, organizational documents or similar binding agreements relating to, or any agreement evidencing Indebtedness of, any joint venture entity or non-Wholly Owned Subsidiary and applicable solely to such joint venture entity or non-Wholly Owned Subsidiary and the Equity Interests issued thereby;
(i) customary net worth provisions set forth in real property leases entered into by Subsidiaries of Borrower, so long as such net worth provisions could not reasonably be expected to impair the ability of Borrower or its Subsidiaries to meet their ongoing obligations (as reasonably determined by a Responsible Officer of Borrower in good faith);
(j) customary net worth provisions set forth in customer agreements entered into in the ordinary course of business that are not otherwise prohibited under this Agreement or any other Loan Document, so long as such net worth provisions could not reasonably be expected to impair the ability of Borrower or its Subsidiaries to meet their ongoing obligations (as reasonably determined by a Responsible Officer of Borrower in good faith);
(k) restrictions on cash or other deposits (including escrowed funds) imposed by agreements entered into in the ordinary course of business that are not otherwise prohibited under this Agreement or any other Loan Document;
(l) prohibitions or limitations set forth in any agreement in effect at the time any Person becomes a Subsidiary (but not any amendment, modification, restatement, renewal, extension, supplement or replacement expanding the scope of any such restriction or condition); provided that such agreement was not entered into in contemplation of such Person becoming a Subsidiary and each such prohibition or limitation does not apply to Borrower or any other Subsidiary (other than such Person and any other Person that is a Subsidiary of such first Person at the time such first Person becomes a Subsidiary);
(m) prohibitions or limitations imposed by (i) any Loan Document, (ii) any Permitted Royalty Agreement Document, (iii) any Permitted Royalty Financing Document, (iv) any Permitted Other Royalty Financing Document, or (v) any Permitted Acquisition Royalty Document;
(n) customary provisions set forth in joint venture agreements or agreements governing minority investments that are not otherwise prohibited under this Agreement or any other Loan Document, if and only to the extent each such prohibition or limitation applies only to the joint venture entity or minority investment that is the subject of such agreement;
(o) limitations imposed with respect to any license acquired in a Permitted Acquisition;
-124-
(p) customary provisions restricting assignments or other transfer of properties or assets subject thereto set forth in any agreement entered into in the ordinary course of business, if and only to the extent each such restriction applies only to the properties or assets subject to such agreement;
(q) prohibitions or limitations imposed by any agreement evidencing any Permitted Indebtedness of the type described in clause (c) of the definition of Permitted Indebtedness; and
(r) prohibitions or limitations imposed by any amendments, modifications, restatements, renewals, extensions, supplements or replacements of any of the agreements referred to in clauses (a) through (q) above, except to the extent that any such amendment, modification, restatement, renewal, extension, supplement or replacement expands the scope of any such prohibition or limitation.
“Permitted Other Royalty Financing” means any direct or indirect royalty or similar financing (including any royalty sale or any synthetic royalty financing) for the sale of revenues or royalties relating to any Product that is not a Heron Acquisition Product or subject to any Permitted Royalty Agreement or Permitted Acquisition Royalty Agreement (any such Product, an “Other Royalty Product”), entered into after the Effective Date and effective as of (and no earlier than) the First Closing Date, not prohibited under Section 6.10 or Section 6.14(c) hereof;
provided, however, that any such royalty or similar financing:
(i) is structured as a “true sale” of revenues or royalties (and not as a lending transaction or the grant of a security interest in such revenues or royalties (other than a customary back-up security interest in form and substance acceptable to the Collateral Agent));
(ii) does not obligate Borrower or any of its Subsidiaries to make any payment relating to a change of control (other than a customary call option (and not requirement) upon the change of control of Borrower or any Subsidiary, provided, however, that the Obligations are prepaid in full pursuant to Section 2.2(c)(ii) before any amounts payable upon exercise of such call option are paid to any Person), any late or overdue payments in excess of shortfalls discovered through an audit plus any interest payment with respect to such shortfall that does not exceed an interest rate that is permitted under applicable law, any other fees with respect to any such shortfalls, or any fees relating to the termination of such royalty or similar financing;
(iii) does not require Borrower or any of its Subsidiaries to make any advance payment before such payment is due and payable, any prepayment or accelerated payment of any royalty payments or similar payments owed under the terms of such royalty or similar financing, or any minimum amount payment in the form of a true up;
(iv) does not require or contemplate the pledge of or granting of any Lien on or any security interest in any Collateral (other than the revenue or royalty permitted to be transferred pursuant to such royalty or similar financing), including, for the avoidance of doubt, any Lien on or any security interest in any right, title or interest in or to, or any products or proceeds of, the revenues (and the right to receive the same) relating to the remaining percentage of aggregate Net Product Revenues of the applicable Other Royalty Product(s) in excess of the Net Product Revenues which are subject to such royalty or similar financing (which shall remain as Collateral);
(v) does not include any sale or other transfer of any right, title or interest in or to, or any products or proceeds of, the revenues (and the right to receive the same) relating to the remaining percentage of aggregate Net Product Revenues of the applicable Other Royalty Product(s) in excess of the Net Product Revenues which are subject to such royalty or similar financing (which shall remain as Collateral); and
(vi) shall be subject to a subordination, intercreditor or other similar agreement (a “Permitted Other Royalty Financing Intercreditor Agreement”) in form and substance reasonably acceptable to the Collateral Agent (which agreement shall include turnover provisions that are satisfactory to the Collateral Agent).
“Permitted Other Royalty Financing Agreement” means the primary agreement (which may be a purchase and sale agreement, a royalty purchase agreement or similar agreement) governing any Permitted Other Royalty Financing (including the schedules and exhibits thereto), in each case in the forms delivered to the Collateral Agent and Lenders pursuant to Section 3.1(l) or Section 3.2(e), as applicable, and not prohibited under Section 6.10 or Section 6.14(c) hereof, as may be amended, restated, supplemented, modified or replaced, or renewed or altered from time to time in accordance with Section 6.10 hereof.
-125-
“Permitted Other Royalty Financing Agreement Payments” means all regularly scheduled royalty payments that are due and payable under any Permitted Other Royalty Financing Agreement, together with customary indemnification obligations thereunder, in each case, to the extent not prohibited by Section 6.10 or Section 6.14(c) hereof.
“Permitted Other Royalty Financing Documents” means, collectively, the Permitted Other Royalty Financing Agreement and each other document related to such Permitted Other Royalty Financing Agreement (including all documents delivered or filed pursuant to each such Permitted Other Royalty Financing Agreement), in each case in the forms delivered to the Collateral Agent and Lenders pursuant to Section 3.1(l) or Section 3.2(e), as applicable, and not prohibited under Section 6.10 or Section 6.14(c) hereof, as may be amended, restated, supplemented, modified or replaced, or renewed or altered from time to time in accordance with Section 6.10 hereof.
“Permitted Royalty Agreements” means, collectively:
(a) that certain License Agreement, dated July 26, 2022, between Napp Pharmaceutical Group Limited (“Mundi”), a member of Mundipharma independent associated companies (as successor in interest to Cidara Therapeutics, Inc.) and Melinta Therapeutics, LLC, relating to Rezzayo, as amended pursuant to Amendment No. 1 to License Agreement, dated April 23, 2024, and as may be further amended, restated, supplemented, modified or replaced, or renewed or altered (including pursuant to any waiver, consent or approval) from time to time in accordance with Section 6.10 hereof (the “Mundipharma Royalty Agreement”);
(b) that certain Amended and Restated License Agreement, dated May 1, 2017, between Wakunaga Pharmaceutical Co., Ltd. (“Wakunaga”) and Melinta Therapeutics, LLC, as may be amended, restated, supplemented, modified or replaced, or renewed or altered (including pursuant to any waiver, consent or approval) from time to time in accordance with Section 6.10 hereof (the “Wakunaga Royalty Agreement”);
(c) those certain license and other agreements listed in on Schedule 2.1.1(a) of the Asset Purchase Agreement, dated as of August 29, 2025, between AstraZeneca AB (“AZ”) and Aralez Pharmaceutical Trading DAC and the other partiers thereto, relating to TOPROL-XL® (metoprolol succinate), as approved by FDA under NDA No. 206334, as may be amended, restated, supplemented, modified or replaced, or renewed or altered (including pursuant to any waiver, consent or approval) from time to time in accordance with Section 6.10 hereof (collectively, the “AZ Royalty Agreement”);
(d) that certain License and Supply Agreement, dated November 30, 2010, between CyDex Pharmaceuticals, Inc. (now a wholly-owned subsidiary of Ligand Pharmaceuticals Incorporated, both hereafter referred to as “Ligand”) and Melinta Therapeutics, LLC, as may be amended, restated, supplemented, modified or replaced, or renewed or altered (including pursuant to any waiver, consent or approval) from time to time in accordance with Section 6.10 hereof (the “Ligand Royalty Agreement”); and
(e) that certain Contingent Payment Agreement, dated as of August 29, 2025, among Deerfield Private Design Fund IV, L.P. and Deerfield Private Design Fund III, L.P. (together, “Deerfield”), CorMedix Inc. and Melinta Therapeutics, LLC, relating to Rezzayo or MINOCIN® (minocycline) as approved by FDA under NDA No. 050444, as applicable, as may be amended, restated, supplemented, modified or replaced, or renewed or altered (including pursuant to any waiver, consent or approval) from time to time in accordance with Section 6.10 hereof (the “Deerfield Royalty Agreement”).
“Permitted Royalty Agreement Documents” means, collectively, each Permitted Royalty Agreement as in effect as of the Effective Date, and each other document related to each such Permitted Royalty Agreement (including all documents delivered or filed pursuant to each such Permitted Royalty Agreement), in each case as may be amended, restated, supplemented, modified or replaced, or renewed or altered from time to time in accordance with Section 6.10 hereof.
-126-
“Permitted Royalty Agreement Payments” means all regularly scheduled payments that are due and payable under each Permitted Royalty Agreement Document.
“Permitted Royalty Financing” means any direct or indirect royalty or similar financing (including any royalty sale or any synthetic royalty financing) for the sale of revenues or royalties relating to CINVANTI® (aprepitant) injectable emulsion as approved by FDA under NDA No. 209296 (and any 505(b)(2) product as successor of the foregoing) and SUSTOL® (granisetron) extended-release injection as approved by FDA under NDA No. 022445, entered into after the Effective Date and effective as of (and no earlier than) the Tranche A Closing Date, not prohibited under Section 6.10 or Section 6.14(c) hereof; provided, that, such royalty or similar financing(s) shall not exceed the PRF Cap;
provided, however, that any such royalty or similar financing:
(i) is structured as a “true sale” of revenues or royalties (and not as a lending transaction or the grant of a security interest in such revenues or royalties (other than a customary back-up security interest in form and substance acceptable to the Collateral Agent));
(ii) does not obligate Borrower or any of its Subsidiaries to make any payment relating to a change of control (other than a customary call option (and not requirement) upon the change of control of Borrower or any Subsidiary, provided, however, that the Obligations are prepaid in full pursuant to Section 2.2(c)(ii) before any amounts payable upon exercise of such call option are paid to any Person), any late or overdue payments in excess of shortfalls discovered through an audit plus any interest payment with respect to such shortfall that does not exceed an interest rate that is permitted under applicable law, any other fees with respect to any such shortfalls, or any fees relating to the termination of such royalty or similar financing;
(iii) does not require Borrower or any of its Subsidiaries to make any advance payment before such payment is due and payable, any prepayment or accelerated payment of any royalty payments or similar payments owed under the terms of such royalty or similar financing, or any minimum amount payment in the form of a true up;
(iv) does not require or contemplate the pledge of or granting of any Lien on or any security interest in any Collateral (other than the revenue or royalty permitted to be transferred pursuant to such royalty or similar financing), including, for the avoidance of doubt, any Lien on or any security interest in any right, title or interest in or to, or any products or proceeds of, the revenues (and the right to receive the same) relating to the remaining percentage of aggregate Net Product Revenues of CINVANTI® (aprepitant) injectable emulsion as approved by FDA under NDA No. 209296 (and any 505(b)(2) product as successor of the foregoing) and SUSTOL® (granisetron) extended-release injection as approved by FDA under NDA No. 022445 in excess of the PRF Cap (which shall remain as Collateral);
(v) does not include any sale or other transfer of any right, title or interest in or to, or any products or proceeds of, the revenues (and the right to receive the same) relating to the remaining percentage of aggregate Net Product Revenues of CINVANTI® (aprepitant) injectable emulsion as approved by FDA under NDA No. 209296 (and any 505(b)(2) product as successor of the foregoing) and SUSTOL® (granisetron) extended-release injection as approved by FDA under NDA No. 022445 in excess of the PRF Cap (which shall remain as Collateral); and
(vi) shall be subject to a subordination, intercreditor or other similar agreement (a “Permitted Royalty Financing Intercreditor Agreement”) in form and substance reasonably acceptable to the Collateral Agent (which agreement shall include turnover provisions that are satisfactory to the Collateral Agent).
“Permitted Royalty Financing Agreement” means the primary agreement (which may be a purchase and sale agreement, a royalty purchase agreement or similar agreement or, with respect to the Heron Acquisition Transaction, which is set forth within the Heron Acquisition Agreement) governing any Permitted Royalty Financing (including the schedules and exhibits thereto), in each case in the forms delivered to the Collateral Agent and Lenders pursuant to Section 3.1(l) or Section 3.2(e), as applicable, and not prohibited under Section 6.10 or Section 6.14(c) hereof, as may be amended, restated, supplemented, modified or replaced, or renewed or altered from time to time in accordance with Section 6.10 hereof.
-127-
“Permitted Royalty Financing Agreement Payments” means all regularly scheduled royalty payments that are due and payable under the Permitted Royalty Financing Agreement, together with customary indemnification obligations thereunder, in each case, to the extent not prohibited by Section 6.10 or Section 6.14(c) hereof.
“Permitted Royalty Financing Documents” means, collectively, the Permitted Royalty Financing Agreement and each other document related to such Permitted Royalty Financing Agreement (including all documents delivered or filed pursuant to each such Permitted Royalty Financing Agreement), in each case in the forms delivered to the Collateral Agent and Lenders pursuant to Section 3.1(l) or Section 3.2(e), as applicable, and not prohibited under Section 6.10 or Section 6.14(c) hereof, as may be amended, restated, supplemented, modified or replaced, or renewed or altered from time to time in accordance with Section 6.10 hereof.
“Permitted Subsidiary Distribution Restrictions” means, in each case notwithstanding Section 6.8:
(a) prohibitions or limitations with regard to specific properties or assets encumbered by Permitted Liens, if and only to the extent each such prohibition or limitation applies only to such properties or assets;
(b) prohibitions or limitations set forth in any lease, license or other similar agreement entered into in the ordinary course of business;
(c) prohibitions or limitations relating to Permitted Indebtedness, in each case if and only to the extent such prohibitions or limitations, taken as a whole, are not materially more restrictive than the prohibitions and limitations set forth in this Agreement and the other Loan Documents, taken as a whole (as reasonably determined by a Responsible Officer of Borrower in good faith);
(d) customary provisions restricting assignments, subletting, sublicensing or other transfer of properties or assets subject thereto set forth in leases, subleases, licenses (including Permitted Licenses) and other similar agreements that are not otherwise prohibited under this Agreement or any other Loan Document, if and only to the extent each such restriction applies only to the properties or assets subject to such leases, subleases, licenses or agreements, and customary provisions restricting assignment, pledges or transfer of any agreement entered into in the ordinary course of business;
(e) prohibitions or limitations on the transfer or assignment of any properties, assets or Equity Interests set forth in any agreement entered into in the ordinary course of business that is not otherwise prohibited under this Agreement or any other Loan Document, if and only to the extent each such prohibition or limitation applies only to such properties, assets or Equity Interests;
(f) prohibitions or limitations imposed by Requirements of Law;
(g) prohibitions or limitations that exist as of the Effective Date under Indebtedness existing on the Effective Date;
(h) customary prohibitions or limitations arising in connection with any Permitted Transfer or contained in any agreement relating to any Permitted Transfer pending the consummation of such Permitted Transfer;
(i) customary provisions in shareholders’ agreements, joint venture agreements, organizational documents or similar binding agreements relating to, or any agreement evidencing Indebtedness of, any joint venture entity or non-Wholly Owned Subsidiary and applicable solely to such joint venture entity or non-Wholly Owned Subsidiary and the Equity Interests issued thereby;
(j) customary net worth provisions set forth in real property leases entered into by Subsidiaries of Borrower, so long as such net worth provisions could not reasonably be expected to impair the ability of Borrower or its Subsidiaries to meet their ongoing obligations (as reasonably determined by a Responsible Officer of Borrower in good faith);
-128-
(k) customary net worth provisions set forth in customer agreements entered into in the ordinary course of business that are not otherwise prohibited under this Agreement or any other Loan Document, so long as such net worth provisions could not reasonably be expected to impair the ability of Borrower or its Subsidiaries to meet their ongoing obligations (as reasonably determined by a Responsible Officer of Borrower in good faith);
(l) restrictions on cash or other deposits (including escrowed funds) imposed by agreements entered into in the ordinary course of business that are not otherwise prohibited under this Agreement or any other Loan Document;
(m) prohibitions or limitations set forth in any agreement in effect at the time any Person becomes a Subsidiary (but not any amendment, modification, restatement, renewal, extension, supplement or replacement expanding the scope of any such restriction or condition); provided that such agreement was not entered into in contemplation of such Person becoming a Subsidiary and each such prohibition or limitation does not apply to Borrower or any other Subsidiary (other than such Person and any other Person that is a Subsidiary of such first Person at the time such first Person becomes a Subsidiary);
(n) prohibitions or limitations imposed by (i) any Loan Document, (ii) any Permitted Royalty Agreement Document, (iii) any Permitted Royalty Financing Document; or (iv) any Permitted Acquisition Royalty Document;
(o) customary provisions set forth in joint venture agreements or agreements governing minority investments that are not otherwise prohibited under this Agreement or any other Loan Document, if and only to the extent each such prohibition or limitation applies only to the joint venture entity or minority investment that is the subject of such agreement;
(p) customary provisions restricting assignments or other transfer of properties or assets subject thereto set forth in any agreement entered into in the ordinary course of business, if and only to the extent each such restriction applies only to the properties or assets subject to such agreement;
(q) prohibitions or limitations imposed by any agreement evidencing any Permitted Indebtedness of the type described in clause (c) of the definition of Permitted Indebtedness; and
(r) prohibitions or limitations imposed by any amendments, modifications, restatements, renewals, extensions, supplements or replacements of any of the agreements referred to in clauses (a) through (q) above, except to the extent that any such amendment, modification, restatement, renewal, extension, supplement or replacement expands the scope of any such prohibition or limitation.
“Permitted Transaction” is defined in Section 2.2(c)(iii).
“Permitted Transfers” means:
(a) Transfers of any properties or assets that do not constitute Collateral under the Loan Documents, other than any Company IP that does not constitute Collateral under the Loan Documents but is necessary or material to any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of any Product in the Territory;
(b) Transfers of Inventory in the ordinary course of business;
(c) Transfers of surplus, damaged, worn out or obsolete equipment or immaterial property or assets that is, in the reasonable judgment of a Responsible Officer of Borrower exercised in good faith, no longer economically practicable to maintain or useful in the ordinary course of business, and Transfers of other properties or assets in lieu of any pending or threatened institution of any proceedings for the condemnation or seizure of such properties or assets or for the exercise of any right of eminent domain;
-129-
(d) Transfers made in connection with, or constituting, Permitted Liens, Permitted Acquisitions, Permitted Investments or Permitted Transactions;
(e) Transfers of cash and Cash Equivalents in the ordinary course of business for equivalent value and in a manner that is not prohibited under this Agreement or the other Loan Documents;
(f) Transfers: (i) to a Credit Party, provided that, with respect to any properties or assets constituting Collateral under the Loan Documents, any and all steps as may be required to be taken in order to create and maintain a first priority security interest in and Lien upon such properties and assets in favor of the Collateral Agent for the benefit of Lenders and the other Secured Parties, including as required pursuant to Section 5.12, are taken contemporaneously with the completion of any such Transfer; (ii) between or among non-Credit Parties; or (iii) to a non-Credit Party, so long as such Transfer (x) is on arm’s length terms, (y) constitutes an Investment that is otherwise permitted hereunder and (z) does not include or otherwise involve the transfer of any Current Company IP to a non-Credit Party;
(g) the sale or issuance of Equity Interests of any Subsidiary of Borrower to any Credit Party or Subsidiary, provided, that, any such sale or issuance by a Credit Party shall be to another Credit Party;
(h) the discount without recourse or sale or other disposition of unpaid and overdue accounts receivable arising in the ordinary course of business in connection with the compromise, collection or settlement thereof and not part of a financing transaction;
(i) any abandonment, disclaimer, forfeiture, dedication to the public, cancellation, non-renewal or discontinuance of use or maintenance of Intellectual Property (including, for clarity, any Company IP) that a Responsible Officer of Borrower reasonably determines in good faith (i) is no longer economically practicable to maintain or useful in the ordinary course of business and that (ii) could not reasonably be expected to be adverse to the rights, remedies and benefits available to, or conferred upon, the Collateral Agent or any Lender under any Loan Document in any material respect;
(j) without limiting clause (a) above, Transfers by Borrower or any of its Subsidiaries pursuant to any Permitted License;
(k) (A) intercompany licenses or grants of rights of distribution, co-promotion or similar commercial rights: (i) between or among the Credit Parties; (ii) between or among the Credit Parties and Subsidiaries that are not Credit Parties and, in the case of any such licenses or grant of rights that relates to any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, packaging, labeling, promotion, advertising, offer for sale, distribution or sale of any Product within the Territory entered into prior to the Effective Date, listed on Schedule 13.7 of the Disclosure Letter; and (iii) between or among Subsidiaries that are not Credit Parties, and (B) Distribution Agreements between or among Borrower and any of its Subsidiaries, in each case together with renewals, replacements and extensions thereof (including additional licenses or grants in relation to new territories) on comparable terms in the ordinary course of business;
(l) any involuntary loss, damage or destruction of property or any involuntary condemnation, seizure or taking, by exercise of the power of eminent domain or otherwise, or confiscation or requisition of use of property;
(m) licenses, sublicenses, leases or subleases, in each case other than relating to any Company IP, granted to third parties in the ordinary course of business;
(n) the abandonment disclaimer, forfeiture, dedication to the public, or other disposition of any Intellectual Property (including, for clarity, any Company IP) that is (i) not material to any aspect of the research, development, manufacture, production, use (by any Credit Party or its Subsidiaries), commercialization, marketing, importing, storage, transport, packaging, labelling, promotion, advertising, offer for sale, distribution or sale of any Product in the Territory, (ii) expiring in accordance with its statutory term or (iii) no longer economically practicable or commercially desirable to maintain, or used or useful in any material respect in any Product line of business of Borrower and its Subsidiaries;
-130-
(o) any involuntary disposition or any sale, lease, license or other disposition of property (other than, for the avoidance of doubt, any Company IP or Covered Regulatory Materials) in settlement of, or to make payment in satisfaction of, any property or casualty insurance;
(p) sales, leases, licenses, transfers or other dispositions of property to the extent that (i) such property is exchanged for credit against the purchase price of similar replacement property or (ii) the proceeds of such sale, lease, license, transfer or other disposition are promptly applied to the purchase price of similar replacement property;
(q) other Transfers on commercially reasonable arm’s length terms (i) made in the ordinary course of business or (ii) that otherwise do not interfere with or impede the ability of Borrower or any Subsidiary of Borrower to conduct the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of any Product in the Territory or enforce its rights with respect to any of the foregoing within the Territory;
(r) other Transfers of properties or assets, in each case so long as (i) the fair market value of such properties or assets (as reasonably determined in good faith by a Responsible Officer of Borrower) does not exceed, individually or together with any other such Transfers under this clause (r), $5,000,000 at any time and (ii) such Transfer is not otherwise prohibited hereunder;
(s) (i) Transfers entered into in connection with any Permitted Royalty Agreement Document and (ii) Transfers in connection with any Permitted Royalty Financing Document or any Permitted Acquisition Royalty Document, in each case if and to the extent not otherwise prohibited under Section 6.10 or Section 6.14(c) hereof;
(t) Transfers by Borrower or any of its Subsidiaries of any assets or rights with respect to TOPROL-XL® (metoprolol succinate);
(u) Transfers of any Product, other than a Key Product, owned by Borrower or any of its Subsidiaries as of the Effective Date, the Tranche A Closing Date or the Tranche B Closing Date, as applicable, including any Heron Acquisition Product, in each case, so long as: (x) the Consolidated Total Gross Leverage Ratio does not exceed 3.0x for the Test Period most recently ended on or prior to the date such Transfer is consummated; (y) no Default or Event of Default shall have occurred; and (z) no later than ten (10) Business Days prior to entering into or consummating such Transfer, (1) Borrower shall have delivered to the Collateral Agent notice regarding such Transfer, describing such Transfer in reasonable detail (including the identity of the parties thereto and the material economic terms thereof), (2) the Collateral Agent shall be given the opportunity to reasonably request, and Borrower shall deliver to the Collateral Agent, any additional information regarding such Transfer, and (3) Borrower shall have delivered to the Collateral Agent a certificate of the Chief Financial Officer of Borrower certifying as to the foregoing clause (x) (with evidence in reasonable detail supporting such certification) and (y) with respect to such Transfer (any such Product, a “Clause (u) Product”);
(v) Transfers of any Product acquired by Borrower or any of its Subsidiaries after the First Closing Date (excluding, for the avoidance of doubt, any Clause (u) Product) occurring within twelve (12) months of the acquisition thereof by Borrower or such Subsidiary, in each case, so long as: (x) TTM Net Product Revenues of such Product as of the date of acquisition thereof is less than twenty-five percent (25%) of the aggregate TTM Net Product Revenues for all Products acquired by Borrower or any of its Subsidiaries in the same transaction or in the series of related transactions pursuant to which Borrower or such Subsidiary acquired such Product, as of the date of acquisition(s) thereof; (y) no Default or Event of Default shall have occurred; and (z) no later than ten (10) Business Days prior to entering into or consummating such Transfer, (1) Borrower shall have delivered to the Collateral Agent notice regarding such Transfer, describing such Transfer in reasonable detail (including the identity of the parties thereto and the material economic terms thereof), (2) the Collateral Agent shall be given the opportunity to reasonably request, and Borrower shall deliver to the Collateral Agent, any additional information regarding such Transfer, and (3) Borrower shall have delivered to the Collateral Agent a certificate of the Chief Financial Officer of Borrower certifying as to the foregoing clauses (x) (with evidence in reasonable detail supporting such certification) and (y) with respect to such Transfer (any such Product, a “Clause (v) Product”);
-131-
(w) subject to clause (a) above, other Transfers of properties or assets not constituting Collateral (including, for clarity, Intellectual Property or Equity Interests which do not constitute Collateral) made on arms’ length terms.
“Person” means any individual, sole proprietorship, partnership, limited liability company, joint venture, company, trust, unincorporated organization, association, corporation, exempted company, institution, public benefit corporation, firm, joint stock company, estate, entity or government agency.
“Personal Data” means information protected under applicable Data Protection Laws as “personal data,” “personal information,” “personally identifiable information,” “protected health information,” “medical information,” “health information,” “sensitive information,” “individually identifiable health information,” “identifiable private information,” “bulk sensitive personal data,” or any similar terms under applicable Data Protection Laws, including customer, consumer, patient, clinical trial participant and employee information collected, created, received, maintained, stored, transmitted, or otherwise processed by or for Borrower or any of its Subsidiaries.
“Personal Data Breach” is defined in Section 4.22(b).
“PIPEDA” means the Personal Information Protection and Electronic Documents Act (Canada) and the regulations promulgated thereunder, and any other applicable Canadian federal or provincial privacy, security, or breach notification laws, in each case as amended or supplemented from time-to-time.
“Plan” means any employee pension benefit plan (other than a Multiemployer Plan) subject to the provisions of Title IV of ERISA or Section 412 of the IRC or Section 302 of ERISA which is maintained or contributed to by Borrower or its Subsidiaries or their respective ERISA Affiliates or with respect to which Borrower or its Subsidiaries have any liability (including under Section 4069 of ERISA).
“Prepayment Premium” means the Tranche A Prepayment Premium or the Tranche B Prepayment Premium, (as applicable) or the combination thereof, as the context dictates.
“PRF Cap” means, with respect to any sale of revenues or royalties relating to the purported Permitted Royalty Financing, five percent (5.0%) of the aggregate Net Product Revenues of Cinvanti® (aprepitant) (and any 505(b)(2) product as successor of the foregoing) and Sustol (granisetron extended-release injection) for sales in excess of $25,000,000.
“Product Gross Profit” means, with respect to any Product for any applicable Test Period, the difference between (a) the total revenue of Borrower and its Subsidiaries for such Test Period directly attributable to the sale of such Product in the Territory occurring during such Test Period and (b) Cost of Goods Sold of Borrower and its Subsidiaries directly attributable to such Product in the Territory for such Test Period, in each case of clauses (a) and (b) above, (i) as adjusted to account for (without duplication) extraordinary, unusual or non-recurring gains during such Test Period and extraordinary, unusual or non-recurring losses during such Test Period, plus (without duplication), to the extent deducted in calculating consolidated net income (or loss) of Borrower and its Subsidiaries for such Test Period, the items set forth in clauses (a) through (j) of the definition of Consolidated EBITDA and (ii) determined in accordance with GAAP and on a pro forma basis as if each such transaction occurred on the first day of such Test Period, and on the basis of information contained in the most recent financial statements that have been delivered pursuant to Section 5.2(a)(i) or Section 5.2(a)(ii) and filed with the SEC (and, to the extent such financial statements do not expressly set forth the applicable amounts, supporting documentation and calculations in reasonable detail, reasonably satisfactory to the Collateral Agent and certified by the Chief Financial Officer of Borrower, evidencing such amounts).
-132-
“Products” means, collectively:
(a)(i) DefenCath® (taurolidine and heparin) in any form, dosage form, dosing regimen, strength or route of administration, for any indication, including as approved by FDA under NDA No. 214520 (“DefenCath”), (ii) any biopharmaceutical product (whether in development or approved) owned or controlled by Borrower or any of its Subsidiaries for commercialization in the Territory that comprises or contains taurolidine or heparin in any form (including salt forms), dosage form, dosing regimen, strength or route of administration, for any indication and (iii) any successor product(s) of the foregoing, in any form, dosage form, dosing regimen, strength or route of administration, under development or hereinafter developed, including in conjunction with out-licensing partners, and owned or controlled by Borrower or its Subsidiaries, for use in one or more of the same indications for which any product described in sub-clause (i) or (ii) above is in development or has been developed or approved;
(b)(i) REZZAYO® (rezafungin) in any form, dosage form, dosing regimen, strength or route of administration, for any indication, including as approved by FDA under NDA No. 217417 (“Rezzayo”), (ii) any biopharmaceutical product (whether in development or approved) owned or controlled by Borrower or any of its Subsidiaries for commercialization in the Territory that comprises or contains rezafungin in any form (including salt forms), dosage form, dosing regimen, strength or route of administration, for any indication and (iii) any successor product(s) of the foregoing, in any form, dosage form, dosing regimen, strength or route of administration, under development or hereinafter developed, including in conjunction with out-licensing partners, and owned or controlled by Borrower or its Subsidiaries, for use in one or more of the same indications for which any product described in sub-clause (i) or (ii) above is in development or has been developed or approved;
(c)(i) MINOCIN® (minocycline) in any form, dosage form, dosing regimen, strength or route of administration, for any indication, including as approved by FDA under NDA No. 050444 (“Minocin”); (ii) any biopharmaceutical product (whether in development or approved) owned or controlled by Borrower or any of its Subsidiaries for commercialization in the Territory that comprises or contains minocycline in any form (including salt forms), dosage form, dosing regimen, strength or route of administration, for any indication and (iii) any successor product(s) of the foregoing, in any form, dosage form, dosing regimen, strength or route of administration, under development or hereinafter developed, including in conjunction with out-licensing partners, and owned or controlled by Borrower or its Subsidiaries, for use in one or more of the same indications for which any product described in sub-clause (i) or (ii) above is in development or has been developed or approved;
(d)(i) VABOMERE® (meropenem and vaborbactam) in any form, dosage form, dosing regimen, strength or route of administration, for any indication, including as approved by FDA under NDA No. 209776 (“Vabomere”), (ii) any biopharmaceutical product (whether in development or approved) owned or controlled by Borrower or any of its Subsidiaries for commercialization in the Territory that comprises or contains meropenem or vaborbactam in any form (including salt forms), dosage form, dosing regimen, strength or route of administration, for any indication and (iii) any successor product(s) of the foregoing, in any form, dosage form, dosing regimen, strength or route of administration, under development or hereinafter developed, including in conjunction with out-licensing partners, and owned or controlled by Borrower or its Subsidiaries, for use in one or more of the same indications for which any product described in sub-clause (i) or (ii) above is in development or has been developed or approved;
(e)(i) KIMYRSA® (oritavancin) in any form, dosage form, dosing regimen, strength or route of administration, for any indication, including as approved by FDA under NDA No. 214155 (“Kimyrsa”), (ii) any biopharmaceutical product (whether in development or approved) owned or controlled by Borrower or any of its Subsidiaries for commercialization in the Territory that comprises or contains oritavancin in any form (including salt forms), dosage form, dosing regimen, strength or route of administration, for any indication and (iii) any successor product(s) of the foregoing, in any form, dosage form, dosing regimen, strength or route of administration, under development or hereinafter developed, including in conjunction with out-licensing partners, and owned or controlled by Borrower or its Subsidiaries, for use in one or more of the same indications for which any product described in sub-clause (i) or (ii) above is in development or has been developed or approved;
(f)(i) ORBACTIV® (oritavancin) in any form, dosage form, dosing regimen, strength or route of administration, for any indication, including as approved by FDA under NDA No. 206334 (“Orbactiv”), (ii) any biopharmaceutical product (whether in development or approved) owned or controlled by Borrower or any of its Subsidiaries for commercialization in the Territory that comprises or contains oritavancin in any form (including salt forms), dosage form, dosing regimen, strength or route of administration, for any indication and (iii) any successor product(s) of the foregoing, in any form, dosage form, dosing regimen, strength or route of administration, under development or hereinafter developed, including in conjunction with out-licensing partners, and owned or controlled by Borrower or its Subsidiaries, for use in one or more of the same indications for which any product described in sub-clause (i) or (ii) above is in development or has been developed or approved;
-133-
(g)(i) BAXDELA® (delafloxacin) in any form, dosage form, dosing regimen, strength or route of administration, for any indication, including as approved by FDA under NDA Nos. 208611 and 208610 (“Baxdela”) (ii) any biopharmaceutical product (whether in development or approved) owned or controlled by Borrower or any of its Subsidiaries for commercialization in the Territory that comprises or contains delafloxacin in any form (including salt forms), dosage form, dosing regimen, strength or route of administration, for any indication and (iii) any successor product(s) of the foregoing, in any form, dosage form, dosing regimen, strength or route of administration, under development or hereinafter developed, including in conjunction with out-licensing partners, and owned and controlled by Borrower or its Subsidiaries, for use in one or more of the same indications for which any product described in sub-clause (i) or (ii) above is in development or has been developed or approved;
(h) as of the Tranche A Closing Date (if any), (i) each of the Heron Acquisition Products for commercialization in the Territory, (ii) any biopharmaceutical product (whether in development or approved) owned or controlled by Borrower or any of its Subsidiaries for commercialization in the Territory that comprises or contains any of the active ingredients, or any of the active moieties used in any of the active ingredients, used in manufacturing any of the Heron Acquisition Products in any form (including salt forms), dosage form, dosing regimen, strength or route of administration, for any indication and (iii) any successor product(s) of the foregoing, in any form, dosage form, dosing regimen, strength or route of administration, under development or hereinafter developed, including in conjunction with out-licensing partners, and owned or controlled by Borrower or its Subsidiaries, for use in one or more of the same indications for which any product described in sub-clause (i) or (ii) above is in development or has been developed or approved;
(i) as of the Tranche B Closing Date and only if the Other Acquisition Transaction is consummated thereon, (i) each of the Other Acquisition Products, (ii) any biopharmaceutical product (whether in development or approved) owned or controlled by Borrower or any of its Subsidiaries that comprises or contains any of the active ingredients, or any of the active moieties used in any of the active ingredients, used in manufacturing any of the Other Acquisition Products in any form (including salt forms), dosage form, dosing regimen, strength or route of administration, for any indication and (iii) any successor product(s) of the foregoing, in any form, dosage form, dosing regimen, strength or route of administration, under development or hereinafter developed, including in conjunction with out-licensing partners, and owned or controlled by Borrower or its Subsidiaries, for use in one or more of the same indications for which any product described in sub-clause (i) or (ii) above is in development or has been developed or approved; and
(j)(i) any other biopharmaceutical product from time to time manufactured, developed or acquired by Borrower or any of its Subsidiaries for commercialization in the Territory after the Effective Date (excluding, for the avoidance of doubt, any Heron Acquisition Product or Other Acquisition Product), (ii) any biopharmaceutical product (whether in development or approved) owned or controlled by Borrower or any of its Subsidiaries for commercialization in the Territory that comprises or contains any active pharmaceutical ingredient used in manufacturing any product described in sub-clause (i) above, and (iii) any successor product(s) of the foregoing, in any form, dosage form, dosing regimen, strength or route of administration, under development or hereinafter developed, including in conjunction with out-licensing partners, and owned and controlled by Borrower or its Subsidiaries, for use in one or more of the same indications for which any product described in sub-clause (i) or (ii) above is in development or has been developed or approved.
For the avoidance of doubt, the product TOPROL-XL® (metoprolol succinate), as approved by FDA under NDA No. 206334, in any form, dosage form, dosing regimen, strength or route of administration, for any indication, shall not constitute a Product for all purposes hereunder.
-134-
“Registered Organization” means any “registered organization” as defined in the Code with such additions to such term as may hereafter be made.
“Regulatory Agency” means a U.S. or foreign Governmental Authority with responsibility for the approval of the marketing and sale of drugs or other regulation of drugs or otherwise having authority to regulate any Product.
“Regulatory Approvals or Licensures” means all approvals, authorizations, designations, licensures or clearances and any product or establishment licenses, registrations or authorizations of any Regulatory Agency necessary for the manufacture, use, storage, import, export, transport, offer for sale, or distribution (including for investigational use) or sale of any Product in the Territory.
“Regulatory Submission Material” means all regulatory filings, submissions, approvals, licensures, and authorizations related to any research, development, manufacture, production, use, commercialization, post-approval (or post-licensure, post-authorization, or post-clearance, as applicable) monitoring and reporting (including post-marketing safety reports), marketing, importing, storage, transport, offer for sale, distribution (including for investigational use) or sale of any Product in the Territory, including all data and information provided in, and used to develop, any of the foregoing, and any other material that is exempt from disclosure under 5 U.S.C. § 552.
“Related Parties” means, with respect to any Person, such Person’s Affiliates and the partners, directors, officers, employees, agents, trustees, administrators, managers, advisors and representatives of such Person and of such Person’s Affiliates.
“Release” means any release, spill, emission, leaking, pumping, pouring, injection, escaping, deposit, disposal, discharge, dispersal, dumping, leaching or migration of any Hazardous Material into the indoor or outdoor environment (including the abandonment or disposal of any barrels, containers or other closed receptacles containing any Hazardous Material), including the movement of any Hazardous Material through the air, soil, surface water or groundwater.
“Relevant Governmental Body” means the Board of Governors of the Federal Reserve System or the Federal Reserve Bank of New York, or a committee officially endorsed or convened by the Board of Governors of the Federal Reserve System or the Federal Reserve Bank of New York, or any successor thereto.
“Required Lenders” means Lenders representing greater than fifty percent (50%) of the principal amount of the Term Loans outstanding as of such date.
“Requirements of Law” means, as to any Person, the organizational or governing documents of such Person, and any law (statutory or common, foreign or domestic), treaty, order, rule or regulation, legally binding policy, or determination of an arbitrator or a court or other Governmental Authority (including Environmental Laws, Health Care Laws, Data Protection Laws, FDA Laws, EU Laws, and all other applicable statutes, rules, regulations, standards or orders, or legally binding guidelines or legally binding policies, administered or issued by any foreign Governmental Authority), in each case, applicable to and binding upon such Person or any of its assets or properties or to which such Person or any of its assets or properties are subject, including, with respect to Borrower, the rules or requirements of any applicable U.S. national securities exchange applicable to Borrower or any of its Equity Interests.
“Responsible Officers” means, with respect to any Credit Party or any of its Subsidiaries, collectively, each of the Chief Executive Officer, Chief Medical Officer, Chief Financial Officer, Chief Operating & Commercial Officer, Chief Legal and Compliance Officer, Corporate Secretary, any Executive Vice President, Head of Information Technology, and General Counsel of such Credit Party or, in each case, if none, of Borrower.
-135-
“Restricted License” means any material license or other material agreement of the kind or nature subject or purported to be subject from time to time to a Lien under any Collateral Document, with respect to which a Credit Party is the licensee and pursuant to which such Credit Party in-licenses any of the Company IP that is necessary or otherwise material for any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage transport, packaging, labeling, promotion, advertising, offer for sale, distribution or sale of any Product in the Territory, (a) that prohibits or otherwise restricts such Credit Party from granting a security interest in its interest therein to the Collateral Agent, for the benefit of Lenders and the other Secured Parties (other than as a result of customary anti-assignment provisions) in a manner enforceable under Requirements of Law, or (b) for which a breach of or default thereunder remains uncured and could reasonably be expected to materially interfere with the Collateral Agent’s or any Lender’s right to sell or otherwise dispose of any Collateral (other than the license or agreement itself). For the avoidance of doubt, (i) software, open source code, application programming interfaces or trademarks, copyrights or patents of others that are commercially available to the public under the shrinkwrap licenses, clickwrap licenses, online terms of service or other terms of use or similar agreements, (ii) intellectual property rights of customers used by Borrower in the course of providing service to third parties in the ordinary course of business, and (iii) each Permitted Royalty Agreement, in each case, shall not constitute a Restricted License.
“Restricted Payments” is defined in Section 6.8(a).
“Rezzayo” is defined in clause (b)(i) of the definition of Products.
“Sanctioned Country” means, at any time, a country or territory which is itself the subject or target of comprehensive Sanctions (including Cuba; Iran; North Korea; and the Crimea, so-called Donetsk People’s Republic, so-called Luhansk People’s Republic, Kherson, Zaporizhzhia, and other regions of Ukraine that are the subject or target of comprehensive Sanctions).
“Sanctions” is defined in Section 4.18(c).
“SEC” means the Securities and Exchange Commission and any analogous Governmental Authority.
“Second Closing Date” means the later to occur of the Tranche A Closing Date and the Tranche B Closing Date.
“Secretary’s Certificate” means, with respect to any Person, a certificate of such Person executed by its Secretary, authorized signatory or director certifying as to the various matters set forth therein.
“Section 5 of the FTC Act” means the Section 5(a) of the U.S. Federal Trade Commission Act (15 U.S.C. § 45), which prohibits unfair and deceptive acts or practices in or affecting commerce and serves as the primary basis for U.S. Federal Trade Commission authority on privacy and security.
“Secured Parties” means each Lender, each other Indemnified Person and each other holder of any Obligation of a Credit Party.
“Securities Account” means any “securities account” as defined in the Code with such additions to such term as may hereafter be made.
“Security Agreement” means the Guaranty and Security Agreement, dated as of the First Closing Date, by and among the Credit Parties and the Collateral Agent, in form and substance substantially similar to Exhibit C attached hereto or in such form or substance as the Credit Parties and the Collateral Agent may otherwise agree.
“Security Incidents” is defined in Section 4.22(b).
“Security Program” is defined in Section 4.22(b).
“Sensitive Information” means, collectively, (a) any Personal Data collected, created, received, maintained, stored, transmitted, or otherwise processed by Borrower or any of its Subsidiaries that is subject to any Data Protection Law(s), (b) any material confidential or proprietary information in which Borrower or any of its Subsidiaries have IP Ancillary Rights or any other material confidential Company IP, including trade secrets, (c) any information with respect to which Borrower or any of its Subsidiaries have contractual non-disclosure obligations, and (d) Regulatory Submission Materials.
-136-
“SOC 2” means an independent, third-party audit report performed by a Certified Public Accountant in accordance with the American Institute of Certified Public Accountants Trust Services Criteria, that evaluates the design and operating effectiveness of a service provider’s internal controls, systems, and processes relating to security, availability, processing integrity, confidentiality, and privacy.
“SOFR” means a rate equal to the secured overnight financing rate as administered by the SOFR Administrator.
“SOFR Administrator” means the Federal Reserve Bank of New York (or a successor administrator of the secured overnight financing rate).
“Software” is defined in the definition of “Intellectual Property”.
“Solvent” means as of any date of determination, that, as of such date, (a) the value of the assets (including goodwill minus disposition costs) of such Person (both at fair value and present fair saleable value), on a going concern basis, is greater than the total amount of liabilities (including contingent and unliquidated liabilities) of such Person, (b) such Person is able to generally pay all liabilities (including trade debt) of such Person as such liabilities become absolute and mature in the ordinary course of business consistent with past practice and (c) such Person does not have unreasonably small capital after giving due consideration to the prevailing practice in the industry in which it is engaged or will be engaged. In computing the amount of contingent or unliquidated liabilities at any time, such liabilities shall be computed at the amount that, in light of all the facts and circumstances existing at such time, represents the amount that can reasonably be expected to become an actual or matured liability.
“SSA” means the Social Security Act of 1935, codified at Title 42, Chapter 7, of the United States Code.
“Stock Acquisition” means the purchase or other acquisition by Borrower or any of its Subsidiaries of (or resulting in the ownership of) any Equity Interests (by merger, stock purchase or otherwise) in any other Person (other than purchases or acquisitions of Equity Interests held in securities accounts in the ordinary course of business and consistent with past practices).
“Strategic Marketing Suspension or Cessation” means a temporary suspension or a cessation of no more than eight (8) months in the aggregate by Borrower or any of its Subsidiaries of the commercial marketing, promotion or sale of any Product or any successor Product, undertaken in Borrower’s reasonable business judgment for bona fide commercial or strategic reasons (including to reset the pricing or average selling price of such Product), and not in connection with any safety, efficacy or quality concern or any request, requirement or action of any Regulatory Agency.
“Subordinated Debt” means any Indebtedness in the form of or otherwise constituting term debt incurred by any Credit Party or any Subsidiary thereof (including any Indebtedness incurred in connection with any Acquisition or other Investment) that: (a) is subordinated in right of payment to the Obligations at all times until all of the Obligations have been paid, performed or discharged in full and Borrower has no further right to obtain any Credit Extension hereunder, pursuant to a subordination, intercreditor or other similar agreement that is in form and substance reasonably satisfactory to the Collateral Agent (which agreement shall include turnover provisions that are reasonably satisfactory to the Collateral Agent); (b) except as permitted by clause (d) below, is not subject to scheduled amortization, redemption (mandatory), sinking fund or similar payment and does not have a final maturity, in each case, before a date that is at least 180 days following the Term Loan Maturity Date; (c) does not include covenants (including financial covenants) and agreements (excluding agreements with respect to maturity, amortization, pricing and other economic terms) that, taken as a whole, are more restrictive or onerous on the Credit Parties in any material respect than the comparable covenants and agreements, taken as a whole, in the Loan Documents (as reasonably determined by a Responsible Officer of such Credit Party in good faith); (d) is not subject to repayment or prepayment, including pursuant to a put option exercisable by the holder of any such Indebtedness, prior to a date that is at least 180 days following the Term Loan Maturity Date except in the case of an event of default, change of control or asset sale (or, in each case, the equivalent thereof, however described); and (e) does not provide or otherwise include provisions having the effect of providing that a default or event of default (or the equivalent thereof, however described) under or in respect of such Indebtedness shall exist, or such Indebtedness shall otherwise become due prior to its scheduled maturity or the holder or holders thereof or any trustee or agent on its or their behalf shall be permitted (with or without the giving of notice, the lapse of time or both) to cause any such Indebtedness to become due, or to require the prepayment, repurchase, redemption or defeasance thereof, prior to its scheduled maturity, in any such case upon the occurrence of a Default or Event of Default hereunder unless and until the Obligations have been declared, or have otherwise automatically become, immediately due and payable pursuant to Section 8.1(a). Notwithstanding the foregoing, Permitted Convertible Indebtedness, Indebtedness under any Permitted Royalty Agreement Document, any Permitted Royalty Financing Document and any Permitted Acquisition Royalty Document shall not constitute Subordinated Debt.
-137-
“Subsidiary” means, (a) with respect to any Person not incorporated in England and Wales, a corporation, partnership, limited liability company or other entity of which more than fifty percent (50.0%) of whose shares of stock or other ownership interests having ordinary voting power (other than stock or such other ownership interests having such power only by reason of the happening of a contingency) to elect a majority of the Board of Directors (or similar body) of such corporation, partnership or other entity are at the time owned, directly or indirectly through one or more intermediaries, or both, by such Person, and (b) with respect to any Person incorporated in England and Wales, any subsidiary incorporated in England and Wales within the meaning of section 1159 of the Companies Act 2006. Unless the context otherwise requires, each reference to a Subsidiary herein shall be a reference to a Subsidiary of a Credit Party.
“Systems” is defined in Section 4.22(a).
“Tax” means any present or future taxes, levies, imposts, duties, deductions, withholdings (including backup withholding), assessments, fees or other charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto.
“Term Loan” means each of the Tranche A Loan or the Tranche B Loan, as applicable, and “Term Loans” means, collectively, the Tranche A Loan and the Tranche B Loan, in each case, to the extent funded.
“Term Loan Commitment” means, each of the Tranche A Commitment or the Tranche B Commitment, as applicable, and “Term Loan Commitments” means, collectively, the Tranche A Commitment and the Tranche B Commitment.
“Term Loan Maturity Date” means the 5th-year anniversary of the First Closing Date; provided, however, that, notwithstanding the foregoing, upon the occurrence of the Maturity Date Acceleration Trigger, the Term Loan Maturity Date will be the date that is ninety (90) days prior to the stated maturity date of the 2030 Convertible Notes (that is, August 1, 2030, as such date may be extended pursuant to and in accordance with the terms and conditions of such convertible notes (including the Indenture)). For the avoidance of doubt, in no event shall the Term Loan Maturity Date occur on a date later than the 5th-year anniversary of the First Closing Date.
“Term Loan Note” means each Tranche A Note or Tranche B Note, as applicable, and “Term Loan Notes” means collectively, the Tranche A Notes and the Tranche B Notes (to the extent the Tranche A Loan and the Tranche B Loan, respectively, is funded hereunder).
“Term Loan Rate” is defined in Section 2.3(a)(i).
“Term SOFR” means, for any day in any calendar month, the Term SOFR Reference Rate for a tenor of three (3) months to the applicable Interest Period on the day (such day, the “Periodic Term SOFR Determination Day”) that is two (2) U.S. Government Securities Business Days’ prior to the first day of such Interest Period, as such rate is published by the Term SOFR Administrator; provided, however, that if as of 5:00 p.m. (New York City time) on any Periodic Term SOFR Determination Day the Term SOFR Reference Rate for the applicable tenor has not been published by the Term SOFR Administrator and a Benchmark Replacement Date with respect to the Term SOFR Reference Rate has not occurred, then Term SOFR will be the Term SOFR Reference Rate for such tenor as published by the Term SOFR Administrator on the first preceding U.S. Government Securities Business Day for which such Term SOFR Reference Rate for such tenor was published by the Term SOFR Administrator so long as such first preceding U.S. Government Securities Business Day is not more than three (3) U.S. Government Securities Business Days prior to such Periodic Term SOFR Determination Day; provided, further, that if Term SOFR determined as provided above (including pursuant to the proviso above) shall ever be less than the Floor, then Term SOFR shall be deemed to be the Floor.
-138-
“Term SOFR Administrator” means CME Group Benchmark Administration Limited (CBA) (or a successor administrator of the Term SOFR Reference Rate selected by the Collateral Agent in its reasonable discretion).
“Term SOFR Reference Rate” means the forward-looking term rate based on SOFR.
“Territory” means the United States.
“Test Period” means, for any date of determination under this Agreement, the most recent period of four consecutive Fiscal Quarters of Borrower ended on or prior to such time in respect of which financial statements for each quarter or Fiscal Year in such period have been or are required to be delivered pursuant to Section 5.2(a)(i) or Section 5.2(a)(ii), as applicable, and filed with the SEC; provided, that, prior to the first date that financial statements have been or are required to be delivered pursuant to Section 5.2(a)(i) or Section 5.2(a)(ii), the Test Period in effect shall be the period of four consecutive full Fiscal Quarters of Borrower ended on June 30, 2026.
“Third-Party IP” is defined in Section 4.6(l).
“Third-Party Regulatory Materials” is defined in Section 4.20(a)(iii).
“Trademarks” means (a) all trademarks, trade names, corporate names, company names, business names, fictitious business names, service marks, elements of trade dress, logos and other source or business identifiers, together with the goodwill associated therewith, including all registrations and recordings thereof, and all applications in connection therewith, in the United States Patent and Trademark Office or in any similar office or agency of the United States or any state thereof or in any similar office or agency anywhere in the world in which foreign counterparts are registered or issued, and (b) all renewals thereof.
“Tranche A Additional Consideration” is defined in Section 2.7(a). For the avoidance of doubt, and notwithstanding anything to the contrary herein, in the event that, pursuant to Sections 2.2(a)(i), 2.2(h) and 3.5, Borrower is deemed to have requested the Tranche A Loan, each Lender is deemed to have advanced its Applicable Percentage of the Tranche A Loan Amount to Borrower, and Borrower is deemed to have prepaid in full the Tranche A Loan pursuant to Section 2.2(c)(i), the Tranche A Additional Consideration shall be due and payable in accordance with Sections 2.2(h) and 2.7(a) hereof.
“Tranche A Closing Date” means the date on which the Tranche A Loan is advanced by Lenders, which, subject to the satisfaction of the conditions precedent to the Tranche A Loan set forth in Section 3.1, Section 3.3, Section 3.4 and Section 3.5, shall be no earlier than thirty (30) days following the delivery to the Collateral Agent and Lenders of the completed and duly executed Advance Request Form in the form of Exhibit A hereto for the Tranche A Loan pursuant to Section 3.5 (or such earlier date as determined by the Lenders in their reasonable discretion) and in no event (deemed or otherwise) later than the Tranche A Commitment End Date; provided, however, that in the event Borrower does not deliver such completed and duly executed Advance Request Form pursuant to Section 3.1(a)(ii) and Borrower or any of its Subsidiaries consummates the Heron Acquisition Transaction or any other transaction involving the acquisition, directly or indirectly, of one or more of the Heron Acquisition Products on or before the Tranche A Commitment End Date, and Borrower is deemed to have requested the Tranche A Loan and each Lender is deemed to have advanced its Applicable Percentage of the Tranche A Loan Amount to Borrower on the Business Day immediately preceding the Tranche A Loan Trigger Date, the Tranche A Closing Date shall be such Tranche A Loan Trigger Date.
“Tranche A Commitment” means, with respect to any Lender, the commitment of such Lender to make the Credit Extensions relating to the Tranche A Loan on the Tranche A Closing Date in the aggregate principal amount set forth opposite such Lender’s name on Exhibit D attached hereto; provided, however, that the parties hereto hereby agree that such commitment, and any obligations of such Lender hereunder with respect thereto, shall terminate automatically without any further action by any party hereto and be of no further force and effect if (w) the Tranche B Closing Date occurs prior to the Tranche A Closing Date and the Term Loans funded on the Tranche B Closing Date are prepaid or repaid in whole or in part prior to the Tranche A Closing Date (other than any deemed prepayment pursuant to Section 2.2(h)), (x) the Tranche A Closing Date does not occur (deemed or otherwise) on or before the Tranche A Commitment End Date, (y) the Heron Acquisition Transaction is not consummated pursuant to the Heron Acquisition Agreement on or before the Tranche A Commitment End Date, or (z) the Heron Acquisition Agreement (and the underlying Heron Acquisition Transaction) is terminated by any party thereto on or before the Tranche A Commitment End Date (at any such time, for purposes of this Agreement, such Lender’s Tranche A Commitment equals zero). Notwithstanding anything herein to the contrary, in the event any of Heron Acquisition Products are acquired by Borrower or any of its Subsidiaries pursuant to any agreement that is not the Heron Acquisition Agreement, the parties hereto hereby agree that the Tranche A Commitment, and any obligations of each Lender hereunder with respect thereto, shall terminate automatically without any further action by any party hereto and be of no further force and effect.
-139-
“Tranche A Commitment End Date” means May 8, 2027.
“Tranche A Loan” is defined in Section 2.2(a)(i).
“Tranche A Loan Amount” means an original principal amount of Seventy-Five Million Dollars ($75,000,000.00).
“Tranche A Loan Trigger Date” is defined in Section 2.2(h).
“Tranche A Makewhole Amount” means, as of the date of any prepayment of the Tranche A Loan pursuant to Section 2.2(c) or as a result of the acceleration of the maturity of the Term Loans pursuant to Section 8.1(a) (but not, for the avoidance of doubt, as a result of the acceleration of the maturity of the Term Loans upon the occurrence of the Maturity Date Acceleration Trigger), in each case, occurring prior to the 2nd-year anniversary of the Tranche A Closing Date, an amount equal to the sum of all interest that would have accrued and been payable from such date of prepayment through the 2nd-year anniversary of the Tranche A Closing Date on the amount of principal prepaid. For purposes of calculating the Tranche A Makewhole Amount: (a) the date of determination shall be such date of prepayment, using the interest rate as in effect on such date, provided, that, for purposes of any such prepayment pursuant to Section 2.2(c)(ii), the date of determination shall be the date on which the Change in Control is consummated; and (b) the Default Rate shall not apply to any interest that would have accrued and been payable from and after such date of determination. For the avoidance of doubt, and notwithstanding anything to the contrary herein, in the event the Tranche A Loan is deemed to have been requested by Borrower and to have been advanced by Lenders pursuant to Sections 2.2(a)(i), 2.2(h) and 3.5, and is deemed to have been prepaid by Borrower pursuant to Section 2.2(h), the Tranche A Makewhole Amount shall be due and payable in accordance with Sections 2.2(e) and 2.2(h) hereof.
“Tranche A Note” means a promissory note in substantially the form attached hereto as Exhibit B-1, as it may be amended, restated, supplemented or otherwise modified from time to time.
“Tranche A Prepayment Premium” means, with respect to any prepayment of the Tranche A Loan by Borrower pursuant to Section 2.2(c), or as a result of the acceleration of the maturity of the Term Loans pursuant to Section 8.1(a) (including, for the avoidance of doubt, as a result of the acceleration of the maturity of the Term Loans upon the occurrence of the Maturity Date Acceleration Trigger), an amount equal to the product of the amount of any principal so prepaid, multiplied by:
(a) if such prepayment occurs prior to the 3rd-year anniversary of the Tranche A Closing Date, 0.03;
(b) if such prepayment occurs on or after the 3rd-year anniversary of the Tranche A Closing Date but prior to the 4th-year anniversary of the Tranche A Closing Date, 0.02; and
(c) if such prepayment occurs on or after the 4th-year anniversary of the Tranche A Closing Date but prior to the Term Loan Maturity Date, 0.01.
-140-
For the avoidance of doubt, (x) no Tranche A Prepayment Premium shall be due and owing for any repayment of principal of the Tranche A Loan made on the Term Loan Maturity Date, or the date of any repayment of the Tranche A Loan pursuant to Section 2.2(b)(i), and (y) notwithstanding anything to the contrary herein, in the event the Tranche A Loan is deemed to have been requested by Borrower and to have been advanced by Lenders pursuant to Sections 2.2(a)(i), 2.2(h) and 3.5, and is deemed to have been prepaid by Borrower pursuant to Section 2.2(h), the Tranche A Prepayment Premium shall be due and payable in accordance with Sections 2.2(f) and 2.2(h) hereof.
“Tranche B Additional Consideration” is defined in Section 2.7(b). For the avoidance of doubt, and notwithstanding anything to the contrary herein, in the event that, pursuant to Sections 2.2(a), 2.2(h) and 3.5, Borrower is deemed to have requested the Tranche B Loan, each Lender is deemed to have advanced its Applicable Percentage of the Tranche B Loan Amount to Borrower, and Borrower is deemed to have prepaid in full the Tranche B Loan pursuant to Section 2.2(c)(i), the Tranche B Additional Consideration shall be due and payable in accordance with Sections 2.2(h) and 2.7(b) hereof.
“Tranche B Closing Date” means the date on which the Tranche B Loan is advanced by Lenders, which, subject to the satisfaction (or waiver) of the conditions precedent to the Tranche B Loan set forth in Section 3.2, Section 3.3, Section 3.4 and Section 3.5, shall be no earlier than thirty (30) days (or such shorter period as may be agreed to by Lenders in their reasonable discretion) following the delivery to the Collateral Agent and Lenders of the completed and duly executed Advance Request Form in the form of Exhibit A hereto for the Tranche B Loan pursuant to Sections 2.2(a)(ii) and 3.5 and in no event (deemed or otherwise) later than the Tranche B Commitment End Date; provided, however, that, if the Tranche B Closing Date is the First Closing Date and the use of proceeds thereof is for the Other Acquisition Transaction, in the event Borrower does not deliver such completed and duly executed Advance Request Form pursuant to Section 3.1(a)(ii) and Borrower or any of its Subsidiaries consummates the Other Acquisition Transaction or any other transaction involving the acquisition, directly or indirectly, of one or more of the Other Acquisition Products on or before the Tranche B Commitment End Date, and Borrower is deemed to have requested the Tranche B Loan and each Lender is deemed to have advanced its Applicable Percentage of the Tranche B Loan Amount to Borrower on the Business Day immediately preceding the Tranche B Loan Trigger Date, the Tranche B Closing Date shall be such Tranche B Loan Trigger Date.
“Tranche B Commitment” means, with respect to any Lender, the commitment of such Lender to make the Credit Extensions relating to the Tranche B Loan on the Tranche B Closing Date in the aggregate principal amount set forth opposite such Lender’s name on Exhibit D attached hereto; provided, however, that the parties hereto hereby agree that such commitment, and any obligations of such Lender hereunder with respect thereto, shall terminate automatically without any further action by any party hereto and be of no further force and effect if (w) the Tranche A Closing Date occurs prior to the Tranche B Closing Date and the Term Loans funded on the Tranche A Closing Date are prepaid or repaid in whole or in part prior to the Tranche B Closing Date (other than any deemed prepayment pursuant to Section 2.2(h)), (x) the Tranche B Closing Date does not occur (deemed or otherwise) on or before the Tranche B Commitment End Date, (y) the Other Acquisition Transaction (if any) is not consummated pursuant to the Other Acquisition Agreement on or before the Tranche B Commitment End Date, or (z) the Other Acquisition Agreement (and the underlying Other Acquisition Transaction) is terminated by any party thereto on or before the Tranche B Commitment End Date (at any such time, for purposes of this Agreement, such Lender’s Tranche B Commitment equals zero). Notwithstanding anything herein to the contrary, in the event any of the Other Acquisition Products are acquired by Borrower or any of its Subsidiaries pursuant to any agreement that is not the Other Acquisition Agreement, the parties hereto hereby agree that the Tranche B Commitment, and any obligations of each Lender hereunder with respect thereto, shall terminate automatically without any further action by any party hereto and be of no further force and effect.
“Tranche B Commitment End Date” means, (a) if the Tranche A Closing Date does not occur by the Tranche A Commitment End Date, May 8, 2027, and (b) if the Tranche A Closing Date occurs on or before the Tranche A Commitment End Date, the date that is thirty (30) days after June 30, 2028.
“Tranche B Loan” is defined in Section 2.2(a)(ii).
“Tranche B Loan Amount” means an original principal amount, (a) if funded hereunder on the First Closing Date and the First Closing Date is the Tranche B Closing Date, of not less than Fifty Million Dollars ($50,000,000.00) and not more than Seventy-Five Million Dollars ($75,000,000.00), and (b) if funded hereunder on the Second Closing Date, elected by Borrower pursuant to Section 3.5, of not less than Twenty-Five Million Dollars ($25,000,000.00) and not more than Seventy-Five Million Dollars ($75,000,000.00); provided, however, that if the Tranche B Closing Date does not occur on or before the Tranche B Commitment End Date, then the Tranche B Loan Amount, from and after such time for purposes of this Agreement, equals zero.
-141-
“Tranche B Loan Trigger Date” is defined in Section 2.2(h).
“Tranche B Makewhole Amount” means, as of the date of any prepayment of the Tranche B Loan pursuant to Section 2.2(c) or as a result of the acceleration of the maturity of the Term Loans pursuant to Section 8.1(a) (but not, for the avoidance of doubt, as a result of the acceleration of the maturity of the Term Loans upon the occurrence of the Maturity Date Acceleration Trigger), in each case, occurring prior to the 2nd-year anniversary of the Tranche B Closing Date, an amount equal to the sum of all interest that would have accrued and been payable from such date of prepayment through the 2nd-year anniversary of the Tranche B Closing Date on the amount of principal prepaid. For purposes of calculating the Tranche B Makewhole Amount: (a) the date of determination shall be such date of prepayment, using the interest rate as in effect on such date, provided, that, for purposes of any such prepayment pursuant to Section 2.2(c)(ii), the date of determination shall be the date on which the Change in Control is consummated; and (b) the Default Rate shall not apply to any interest that would have accrued and been payable from and after such date of determination. For the avoidance of doubt, and notwithstanding anything to the contrary herein, in the event the Tranche B Loan is deemed to have been requested by Borrower and to have been advanced by Lenders pursuant to Sections 2.2(a), 2.2(h) and 3.5, and is deemed to have been prepaid by Borrower pursuant to Section 2.2(h), the Tranche B Makewhole Amount shall be due and payable in accordance with Sections 2.2(e) and 2.2(h) hereof.
“Tranche B Note” means a promissory note in substantially the form attached hereto as Exhibit B-2, as it may be amended, restated, supplemented or otherwise modified from time to time.
“Tranche B Prepayment Premium” means, with respect to any prepayment of the Tranche B Loan by Borrower pursuant to Section 2.2(c) or as a result of the acceleration of the maturity of the Term Loans pursuant to Section 8.1(a) (including, for the avoidance of doubt, as a result of the acceleration of the maturity of the Term Loans upon the occurrence of the Maturity Date Acceleration Trigger), an amount equal to the product of the amount of any principal so prepaid, multiplied by:
(a) if such prepayment occurs prior to the 3rd-year anniversary of the Tranche B Closing Date, 0.03;
(b) if such prepayment occurs on or after the 3rd-year anniversary of the Tranche B Closing Date but prior to the 4th-year anniversary of the Tranche B Closing Date, 0.02; and
(c) if such prepayment occurs on or after the 4th-year anniversary of the Tranche B Closing Date but prior to the Term Loan Maturity Date, 0.01.
For the avoidance of doubt: (x) no Tranche B Prepayment Premium shall be due and owing for any repayment of principal of the Tranche B Loan made on the Term Loan Maturity Date, or the date of any repayment of the Tranche B Loan pursuant to Section 2.2(b)(i), and (y) notwithstanding anything to the contrary herein, in the event the Tranche B Loan is deemed to have been requested by Borrower and to have been advanced by Lenders pursuant to Sections 2.2(a), 2.2(h) and 3.5, and is deemed to have been prepaid by Borrower pursuant to Section 2.2(h), the Tranche B Prepayment Premium shall be due and payable in accordance with Sections 2.2(f) and 2.2(h) hereof.
“Transfer” is defined in Section 6.1.
“Treasury Regulations” mean those regulations promulgated pursuant to the IRC.
“TRICARE” means, collectively, a program of medical benefits covering former and active members of the uniformed services and certain of their dependents, financed and administered by the United States Departments of Defense, Health and Human Services and Transportation, and all laws applicable to such programs.
“TTM Net Product Revenues” means, with respect to any Product acquired by Borrower or any of its Subsidiaries after the Effective Date (excluding, for the avoidance of doubt, any Heron Acquisition Product), and for the trailing twelve month period preceding the date on which Borrower or any of its Subsidiaries acquired such Product, net sales of such Product in the Territory occurring during such trailing twelve month period, as reflected in the financial statements made available to Borrower or such Subsidiary in connection with such acquisition; provided, however, that TTM Net Product Revenues shall exclude any milestone payments, any non-recurring payments and any non-sales-based revenues or proceeds, or any payments, revenues or proceeds from products which are not such Product.
-142-
“TTM Net Rezzayo Revenues” means, as of any date of determination and solely with respect to Rezzayo, trailing twelve months net sales of such Product in the Territory, on the basis of information contained in the most recent financial statements that have been delivered pursuant to Section 5.2(a)(i) or Section 5.2(a)(ii) and filed with the SEC (and, to the extent such financial statements do not expressly set forth the applicable amounts, supporting documentation and calculations in reasonable detail, reasonably satisfactory to the Collateral Agent and certified by the Chief Financial Officer of Borrower, evidencing such amounts); provided, however, that TTM Net Rezzayo Revenues shall exclude any milestone payments, any non-recurring payments and any non-sales-based revenues or proceeds, or any payments, revenues or proceeds from products which are not Rezzayo.
“U.K. Laws” means all applicable statutes, rules and regulations implemented administered or enforced by the MHRA, the National Health Services (NHS), or the competent authorities of the United Kingdom’s constituent countries, including, but not limited to, the Human Medicines Regulations 2012 (SI 2012/1916), and related implementing legislation.
“Unadjusted Benchmark Replacement” means the applicable Benchmark Replacement excluding the related Benchmark Replacement Adjustment.
“United States” or “U.S.” means the United States of America, its fifty (50) states, the District of Columbia, Puerto Rico and any other jurisdiction within the United States of America.
“U.S. Government Securities Business Day” means any day except for (a) a Saturday, (b) a Sunday or (c) a day on which the Securities Industry and Financial Markets Association recommends that the fixed income departments of its members be closed for the entire day for purposes of trading in United States government securities.
“U.S. Tax Compliance Certificate” is defined in Section 2.6(d)(ii)(3).
“Wholly Owned Subsidiary” means, with respect to any Person, a Subsidiary of such Person, all of the Equity Interests of which (other than directors’ qualifying shares or nominee or other similar shares required pursuant to Requirements of Law) are owned by such Person or another Wholly Owned Subsidiary of such Person. Unless the context otherwise requires, each reference to a Wholly Owned Subsidiary herein shall be a reference to a Wholly Owned Subsidiary of a Credit Party.
“Withdrawal Event” means: (i) as applicable, (a) any voluntary withdrawal or removal of any Key Product in the Territory by any Credit Party or any of its Subsidiaries, (b) the loss of marketing authorization for any Key Product in the Territory, (c) the receipt by any Credit Party or any of its Subsidiaries of any written notice from FDA or any other Regulatory Agency of pending recommendation to withdraw marketing authorization for any Key Product in the Territory, or (d) the receipt by any Credit Party or any of its Subsidiaries of any written notice from FDA or any other Regulatory Agency of final decision to withdraw marketing authorization for any Key Product in the Territory; provided, however, that no Strategic Marketing Suspension or Cessation with respect to any Key Product shall constitute a Withdrawal Event; and (ii) as of the date of such withdrawal, removal or other event and with respect to any Key Product other than Rezzayo, the Consolidated Total Gross Leverage Ratio with respect to such Key Product exceeds 3.0x for the Test Period most recently ended on or prior to the applicable withdrawal, removal or other event set forth in clause (i) above.
“Withdrawal Liability” means liability to a Multiemployer Plan as a result of a complete or partial withdrawal from such Multiemployer Plan, as such terms are defined in Part I of Subtitle E of Title IV of ERISA.
“Withdrawn Product” means any Product with respect to which an event described in clause (i) of the definition of “Withdrawal Event” has occurred (whether or not such event has resulted in a Withdrawal Event or an Event of Default under Section 7.3(a)).
“Withholding Agent” is defined in Section 2.6(b).
“Working Capital Credit Line” is defined in clause (u) of the definition of “Permitted Indebtedness.”
“Working Capital Indebtedness” is defined in clause (u) of the definition of “Permitted Indebtedness.”
“Zynrelef” is defined in clause (b) of the definition of Heron Acquisition Products.
[Signature page follows]
-143-
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the Effective Date.
| CORMEDIX INC., | ||
| as Borrower and a Credit Party | ||
| By | /s/ Joseph Todisco | |
| Name: | Joseph Todisco | |
| Title: | Chief Executive Officer | |
| MELINTA THERAPEUTICS, LLC, | ||
| as an additional Credit Party | ||
| By | /s/ Joseph Todisco | |
| Name: | Joseph Todisco | |
| Title: | Chief Executive Officer | |
| MELINTA SUBSIDIARY CORP., | ||
| as an additional Credit Party | ||
| By | /s/ Joseph Todisco | |
| Name: | Joseph Todisco | |
| Title: | Chief Executive Officer | |
| REMPEX PHARMACEUTICALS, INC., | ||
| as an additional Credit Party | ||
| By | /s/ Joseph Todisco | |
| Name: | Joseph Todisco | |
| Title: | Chief Executive Officer | |
Signature Page to Loan Agreement
| TARGANTA THERAPEUTICS CORPORATION, | ||
| as an additional Credit Party | ||
| By | /s/ Joseph Todisco | |
| Name: | Joseph Todisco | |
| Title: | Chief Executive Officer | |
| CEM-102 PHARMACEUTICALS, INC., | ||
| as an additional Credit Party | ||
| By | /s/ Joseph Todisco | |
| Name: | Joseph Todisco | |
| Title: | Chief Executive Officer | |
| CEMPRA PHARMACEUTICALS, INC., | ||
| as an additional Credit Party | ||
| By | /s/ Joseph Todisco | |
| Name: | Joseph Todisco | |
| Title: | Chief Executive Officer | |
Signature Page to Loan Agreement
| BIOPHARMA CREDIT PLC, | ||
as Collateral Agent |
||
| By: | Pharmakon Advisors, LP, | |
| its Investment Manager | ||
| By: Pharmakon Management I, LLC, | ||
| its General Partner | ||
| By | /s/ Pedro Gonzalez de Cosio | |
| Name: | Pedro Gonzalez de Cosio | |
| Title: | Managing Member |
| BPCR LIMITED PARTNERSHIP, | ||
| as a Lender | ||
| By: | Pharmakon Advisors, LP, | |
| its Investment Manager | ||
| By: Pharmakon Management I, LLC, | ||
| its General Partner | ||
| By | /s/ Pedro Gonzalez de Cosio | |
| Name: | Pedro Gonzalez de Cosio | |
| Title: | Managing Member |
| BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP, | ||
| as Lender | ||
| By: | BioPharma Credit Investments V GP LLC, | |
| its General Partner | ||
| By: Pharmakon Advisors, LP, | ||
| its Investment Manager | ||
| By | /s/ Pedro Gonzalez de Cosio | |
| Name: | Pedro Gonzalez de Cosio | |
| Title: | Managing Member |
Signature Page to Loan Agreement
EXHIBIT A
LOAN ADVANCE REQUEST FORM
[Intentionally Omitted.]
EXHIBIT B-1
[Intentionally Omitted.]
EXHIBIT B-2
[Intentionally Omitted.]
EXHIBIT
C
FORM OF SECURITY AGREEMENT
[Intentionally Omitted.]
EXHIBIT
D
COMMITMENTS; NOTICE ADDRESSES
Lender |
Commitments | Notice Address |
| BPCR Limited Partnership |
Tranche A Loan Commitment: $25,000,000.00
Tranche B Loan Commitment: $25,000,000.00
|
BPCR LIMITED PARTNERSHIP c/o MUFG Corporate Governance Limited 51 Lime Street 19th Floor London, United Kingdom EC3M 7DQ Attn: Company Secretary Email: biopharmacreditplc@cm.mpms.mufg.com
with copies (which shall not constitute notice) to:
PHARMAKON ADVISORS, LP 110 East 59th Street, #2800 New York, NY 10022 Attn: Pedro Gonzalez de Cosio Tel: [***] Fax: [***] Email: [***]
and
AKIN GUMP STRAUSS HAUER & FELD LLP One Bryant Park New York, NY 10036-6745 Attn: Geoffrey E. Secol Tel: [***] Email: [***] |
| BioPharma Credit Investments V (Master) LP |
Tranche A Loan Commitment: $50,000,000.00
Tranche B Loan Commitment: $50,000,000.00
|
BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP c/o BioPharma Credit Investments V GP LLC c/o Walkers Corporate Limited 190 Elgin Avenue, George Town Grand Cayman KY1-9008 Attn: Pedro Gonzalez de Cosio
with copies (which shall not constitute notice) to:
PHARMAKON ADVISORS, LP 110 East 59th Street, #2800 New York, NY 10022 Attn: [***] Tel: [***] Fax: [***] Email: [***]
and
AKIN GUMP STRAUSS HAUER & FELD LLP One Bryant Park New York, NY 10036-6745 Attn: Geoffrey E. Secol Tel: [***] Email: [***]
|
EXHIBIT
E
form of COMPLIANCE CERTIFICATE
[Intentionally Omitted.]
EXHIBIT F-1
FORM OF U.S. TAX COMPLIANCE CERTIFICATE
[Intentionally Omitted.]
EXHIBIT F-2
FORM OF U.S. TAX COMPLIANCE CERTIFICATE
[Intentionally Omitted.]
EXHIBIT F-3
FORM OF U.S. TAX COMPLIANCE CERTIFICATE
[Intentionally Omitted.]
EXHIBIT F-4
FORM OF U.S. TAX COMPLIANCE CERTIFICATE
[Intentionally Omitted.]
Exhibit 99.1
CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of Care
Adds four commercial-stage products — ZYNRELEF®, APONVIE®, CINVANTI® and SUSTOL® — to CorMedix’s hospital- and acute-care-focused commercial platform
Upfront consideration consisting of $145 million in cash, subject to customary purchase price adjustments, plus 14,583,333 shares of CorMedix common stock
Additional consideration of up to $55 million in earn-out payments to Heron tied to calendar year 2028 ZYNRELEF net sales plus a royalty on net sales of certain products above a sales threshold
Transaction expected to be immediately accretive to CorMedix earnings and free cash flow, as well as estimated to generate $45-$60 million in near-term total operating cost synergies
CorMedix entered into a new senior secured term loan facility with funds managed by Pharmakon Advisors and will draw $75 million of non-dilutive financing to support the transaction
Heron to remain a publicly traded company with its credit facility repaid, a significant position in CorMedix common stock and rights to earn-out and royalty payments
Transaction expected to close in the first quarter of 2027, subject to regulatory clearance and approval by Heron stockholders and other customary closing conditions
CorMedix to host a conference call and webcast today at 4:30 p.m. Eastern Time
PARSIPPANY, N.J. and CARY, N.C., November 9, 2026 — CorMedix Therapeutics (Nasdaq: CRMD) (“CorMedix”) and Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron”) today announced that they have entered into a definitive asset purchase agreement (the “Agreement”) under which CorMedix will acquire substantially all of the assets of Heron, and assume certain of Heron’s liabilities, for upfront consideration consisting of $145 million in cash, subject to customary purchase price adjustments, plus 14,583,333 shares of CorMedix common stock, plus up to $55 million in contingent earn-out payments and royalties on net sales of certain Heron products. The transaction has been unanimously approved by the Boards of Directors of both companies.
The acquisition adds four commercial-stage products to CorMedix’s portfolio: ZYNRELEF (bupivacaine and meloxicam) extended-release solution for postoperative pain; APONVIE (aprepitant) injectable emulsion for the prevention of postoperative nausea and vomiting; CINVANTI (aprepitant) injectable emulsion and SUSTOL (granisetron) extended-release injection for the prevention of chemotherapy-induced nausea and vomiting. Each is administered in hospitals, ambulatory surgical centers or infusion centers — the institutional settings of care where CorMedix has built its commercial infrastructure. The transaction also includes the assumption of Heron’s rights with respect to products covered by Heron’s multi-product Development and License Agreement.
Management Commentary
“This acquisition is a meaningful step forward in our strategy to build a diversified portfolio of products used in institutional settings of care, which creates substantial value for CorMedix shareholders,” said Joseph Todisco, Chairman & Chief Executive Officer of CorMedix. “Heron’s products are a natural fit for the commercial platform we have built, and we see ZYNRELEF in particular as an asset with significant untapped potential as hospitals and surgery centers increasingly adopt non-opioid approaches to postsurgical pain. We expect to realize $45-$60 million in operating cost synergies by leveraging our existing infrastructure, and we have structured this transaction in a manner which will be immediately accretive to earnings and free cash flow. Importantly, the Pharmakon facility gives us an efficient source of non-dilutive capital to fund this transaction while preserving dry powder for additional growth-oriented business development opportunities, including the flexibility of a second $75 million tranche to fund further growth.”
“Following a thorough review of strategic alternatives, our Board concluded that this transaction offers the most compelling path forward for Heron stockholders,” said Craig Collard, Chief Executive Officer of Heron. “The transaction provides substantial consideration through a combination of cash, CorMedix stock and earn-out payments, enabling Heron to complete the repayment of its outstanding credit facility with Hercules and become a significant stockholder of a company we believe is well-positioned for future growth and value creation. In addition, the earn-out and royalties provide the opportunity for Heron and our stockholders to further benefit from the success of the products our team has built. I am deeply grateful to the entire Heron team for their hard work advancing the standard of care for patients, and I believe that CorMedix has the scale, financial strength and institutional commercial focus to accelerate the growth of ZYNRELEF and APONVIE and to help ensure that CINVANTI continues to reach the patients who rely on it.”
Transaction Terms
Under the terms of the Agreement, CorMedix will pay upfront consideration consisting of $145 million in cash, subject to customary purchase price adjustments, and issue 14,583,333 shares of CorMedix common stock. The number of shares was determined by dividing $105 million by $7.20 per share and is fixed, subject to customary adjustment for stock splits and similar events; it will not be adjusted for changes in CorMedix’s share price prior to closing. Based on the closing price of CorMedix common stock of $5.32 on November 6, 2026, the stock consideration has a value of approximately $77.6 million, and the upfront consideration has an aggregate value of approximately $222.6 million.
In addition to the upfront consideration, Heron will be eligible to receive:
| ● | Total earn-out payments of up to $55 million: $25 million if ZYNRELEF net sales equal or exceed $65 million for calendar year 2028, plus an additional $30 million if ZYNRELEF net sales equal or exceed $95 million for calendar year 2028; and |
| ● | A 5% royalty on the portion of combined annual net sales of CINVANTI, SUSTOL and the products covered by Heron’s multi-product Development and License Agreement which exceed $25 million in calendar year 2027, calendar year 2028 and calendar year 2029. |
In connection with the transaction, Rubric Capital Management LP (“Rubric”), the holder of Heron’s senior unsecured convertible notes due 2031, has agreed to exchange this debt, consisting of $35.0 million in aggregate principal amount of such notes plus accrued and unpaid interest (approximately $37.8 million in the aggregate as of September 30, 2026), for shares of CorMedix common stock received by Heron (the “Exchange”). This Exchange between Heron and Rubric is expected to occur in four quarterly tranches following the closing, subject to the terms and conditions of the exchange agreement.
Both Heron and Rubric have entered into respective governance agreements with CorMedix, wherein Heron shall have the right to name one new member to the CorMedix Board of Directors for so long as Heron continues to hold at least 10% of the outstanding shares of CorMedix and where each of Heron and Rubric have agreed to prohibitions on certain conduct and limitations on trading in CorMedix shares.
2
The transaction is subject to approval by Heron stockholders, the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, and other customary closing conditions. The transaction is not subject to any financing contingency and is expected to close in the first quarter of 2027.
In connection with the transaction, certain Heron stockholders holding approximately 22% of Heron’s outstanding common stock, including Rubric, have entered into voting agreements with Heron and CorMedix pursuant to which they have agreed to vote their shares in favor of the transaction.
Strategic Rationale
The acquisition advances CorMedix’s strategy of expanding its portfolio with differentiated products used in institutional settings of care. Following its acquisition of Melinta Therapeutics, CorMedix has assembled a commercial organization focused on hospitals, infusion centers, dialysis clinics and other institutional settings of care. The Heron portfolio is highly complementary to this footprint, sharing overlapping call points across hospital pharmacy and therapeutics committees, group purchasing organizations, integrated delivery networks and ambulatory surgical centers.
| ● | Scale and diversification: Adds an established revenue base of approximately $150 million on September 30, 2026, trailing twelve-month net product revenue across acute care and oncology supportive care, further broadening CorMedix’s revenue mix. |
| ● | Commercial and operational leverage: Deploys Heron’s products through CorMedix’s existing institutional commercial, market access, medical affairs and supply chain infrastructure, driving the $45–$60 million in total expected operating cost synergies. |
| ● | Growth from the acute care franchise: ZYNRELEF and APONVIE represent the fastest-growing products in the Heron portfolio and are positioned for continued expansion in the hospital and ambulatory surgical center settings. |
| ● | Expanded hematology/oncology presence: CINVANTI, SUSTOL and products covered by Heron’s multi-product Development and License Agreement complement CorMedix’s emerging position in the space with REZZAYO® (rezafungin for injection), which is currently indicated for treating candidemia and invasive candidiasis and in development for prophylaxis of invasive fungal disease in allogeneic stem cell transplant patients. |
Expected Pro Forma Financial Profile and Financing1
CorMedix expects the transaction to be immediately accretive to earnings and free cash flow upon closing and to generate operating cost synergies of an estimated $45-$60 million on an annualized run-rate basis by year-end 2027, driven primarily by the elimination of redundant commercial, general and administrative, and public company expenses.
CorMedix expects pro forma 2026 estimated revenue for the combined business to be $465-$490 million. In addition, CorMedix expects the acquired Heron assets to generate approximately $125–150 million of estimated pro forma revenue in 2027.
Concurrent with the signing of the Agreement, CorMedix entered into a new $150 million senior secured term loan facility with funds managed by Pharmakon Advisors, LP (“Pharmakon”). Under the facility, CorMedix expects to draw $75 million at the closing of the Heron asset acquisition, and an additional $75 million tranche may be drawn at CorMedix’s discretion through June 30, 2028 to support future business development transactions.
| 1 | The pro forma results and the non-GAAP measures were prepared by combining the estimated financial results of CorMedix and Heron without further adjustment. As such, the foregoing includes non- GAAP financial measures. CorMedix has not provided a reconciliation of the applicable non-GAAP measures to the most directly comparable GAAP measures because certain items excluded from GAAP cannot be reasonably calculated or predicted at this time. Accordingly, a quantitative reconciliation is not available without unreasonable effort. |
3
Pharmakon Advisors, LP is a leading investor in non-dilutive debt for the life sciences industry and serves as the investment manager for the BioPharma Credit funds. Established in 2009, funds managed by Pharmakon Advisors have committed $12.9 billion across 82 investments.
Key terms of the asset purchase agreement with Heron, the loan facility and other agreements referenced herein will be described in a Current Report on Form 8-K to be filed by CorMedix with the Securities and Exchange Commission.
Heron Commentary
Following the closing, Heron will exit the operation of its current biotechnology business and other historical operations, but it does not intend to liquidate and will remain a publicly traded company. Heron will retain significant federal and state net operating loss carryforwards (approximately $2.3 billion as of September 30, 2026), certain other tax attributes and other material assets, including the shares of CorMedix common stock issued to Heron, the right to receive future royalties and earn-out payments, and cash on hand. Following the closing, the Heron Board of Directors intends to actively evaluate various strategic transactions and opportunities for the use of the proceeds of the transaction, including acquiring or investing in additional businesses or assets, which may or may not be pharmaceutical or biotechnology businesses or assets. Such opportunities may include, but are not limited to, the acquisition of products, product candidates, milestone payments and royalty streams, programs or technologies as well as pursuing strategic alliances, joint ventures, investments in complementary businesses, out-licensing and in-licensing agreements, divestitures or other transactions. It is currently uncertain what businesses or assets Heron may acquire or invest in following the closing of the transaction, and the Heron Board of Directors intends to evaluate opportunities to create value for the benefit of stockholders.
Key terms of the asset purchase agreement with CorMedix and other agreements referenced herein will be described in a Current Report on Form 8-K to be filed by Heron with the Securities and Exchange Commission.
Third Quarter 2026 Financial Results
CorMedix will report third quarter 2026 financial results on November 12, 2026. Please refer to CorMedix’s press release issued here to register and for more information.
Heron reports its third quarter 2026 financial results today, November 9, 2026. In light of the transaction with CorMedix, Heron will not hold an associated conference call.
Advisors
Moelis & Company LLC is serving as exclusive financial and financing advisor to CorMedix, and Willkie Farr & Gallagher LLP is serving as legal counsel. Leerink Partners is serving as exclusive financial advisor to Heron, and DLA Piper LLP (US) is serving as legal counsel.
Conference Call and Webcast
CorMedix will host a conference call and webcast today at 4:30 p.m. EST to discuss the transaction. To participate by telephone, please see information listed below. The live webcast will also be available on the Presentations and Events page within the Investors section of the CorMedix website at https://www.cormedix.com. A replay will be available on the CorMedix website following the call.
4
Investor Call Information: Monday, November 9th at 4:30 p.m. EST
| Domestic: | 1-800-715-9871 |
| International: | 1-646-307-1963 |
| Webcast: | Webcast Link |
About CorMedix
CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases in the United States. CorMedix is focused on selling and marketing products in institutional care settings in the U.S. and has field-based medical and commercial infrastructure deployed in hospitals, clinics and infusion centers. For more information visit: www.cormedix.com.
About Heron Therapeutics
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “guidance,” “intend,” “may,” “plan,” “potential,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions. All statements, other than statements of historical facts, should be considered forward-looking statements, including, but not limited to, statements regarding the proposed transaction by CorMedix to purchase substantially all of the assets of Heron (the “Proposed Transaction”); Heron’s ability to provide an additional revenue base of four FDA-approved commercial brands, with opportunities to drive future growth; the expected timing of closing; the anticipated benefits of the Proposed Transaction, including expected synergies, diversification of revenue base and the expectation that the Proposed Transaction will be accretive to earnings; statements regarding product strategy, growth and label expansion opportunities; development and expectations of CorMedix’s and Heron’s product pipeline, results of real-world studies, expectations regarding product utilization, reimbursement rates, and market access, including changes in CMS reimbursement methodology; the potential achievement of earn-out milestones and royalty payments; the commercial potential of ZYNRELEF and the other acquired products; the development of the acquired pipeline program; the terms, funding and availability of the Pharmakon term loan facility; CorMedix’s ability to pursue future business development transactions; estimates of total addressable market size; and Heron’s plans following the closing, including its expectation to remain a publicly traded company.
5
These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including: the failure to obtain Heron stockholder approval or required regulatory clearances, or to satisfy other closing conditions, on a timely basis or at all; CorMedix’s ability to successfully integrate the acquired assets, achieve anticipated synergies, accretion, and EBITDA or Adjusted EBITDA on a timely basis or at all; the amount of any adjustments to the consideration under the asset purchase agreement; the occurrence of any event that could give rise to termination of the asset purchase agreement, including circumstances requiring Heron to pay a termination fee; the risk that CorMedix’s or Heron’s stock price may decline if the Proposed Transaction is not completed; fluctuations in the price of CorMedix common stock; dilution to CorMedix’s stockholders; disruption to CorMedix’s and Heron’s business relationships with customers, suppliers and employees, including as a result of the announcement or pendency of the Proposed Transaction, and diversion of management’s attention; restrictions on the conduct of Heron’s business while the Proposed Transaction is pending; unexpected costs, liabilities or delays relating to the Proposed Transaction and the acquired products; market acceptance and reimbursement of the acquired products, including continued eligibility for separate payment under the NOPAIN Act; changes to reimbursement rates and methodology, customer utilization, and other factors impacting the demand for CorMedix’s and Heron’s products; competition; manufacturing and supply risks; the incurrence of indebtedness and compliance with covenants under the Pharmakon facility; litigation relating to the Proposed Transaction; uncertainty about CorMedix’s or Heron’s business, operations and strategy after the consummation of the Proposed Transaction, including (i) the risk that Heron may not identify, pursue or complete an acquisition of, or investment in, another business, (ii) the risk that Heron may not find opportunities to utilize its NOLs after the consummation of the Proposed Transaction or that its ability to use its NOLs may be limited or lost, (iii) Heron’s plans with respect to shares of CorMedix common stock received by Heron as consideration in the Proposed Transaction, including uncertainty and timing of any sales, transfers or other distributions of such shares, (iv) the risk that the value of CorMedix common stock received by Heron as consideration in the Proposed Transaction may decline and that Heron may be unable to sell or otherwise monetize such shares when or at the price it expects and (v) Heron’s lack of operating revenues or material operations following the closing, the risk that Heron may not regain or maintain compliance with Nasdaq’s continued listing requirements, and the risk that Heron may be deemed an investment company under the Investment Company Act of 1940; and the other risks described in the periodic reports filed by CorMedix and Heron with the Securities and Exchange Commission (“SEC”), including their most recent Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, copies of which are available free of charge at the SEC’s website at www.sec.gov or upon request from CorMedix and Heron, as applicable. All forward-looking statements are expressly qualified in their entirety by this cautionary statement, and readers are cautioned not to place undue reliance on them. Forward-looking statements speak only as of the date of this press release, and neither CorMedix nor Heron undertakes any obligation to update them, except as required by law.
Non-GAAP Financial Information
This press release includes financial measures that do not conform to generally accepted accounting principles (“GAAP”). These measures should not be viewed as an alternative to GAAP measures of performance. Furthermore, these measures may not be consistent with similar measures provided by other companies. CorMedix does not provide reconciliations for non-GAAP estimates on a forward-looking basis when it is unable to provide a meaningful or accurate calculation or estimation of reconciling items or the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of various items that have not yet occurred, are out of CorMedix’s control and/or cannot be reasonably predicted. For the same reasons, CorMedix is unable to address the probable significance of the unavailable information.
Additional Information and Where to Find It
In connection with the Proposed Transaction, Heron intends to file with the SEC a proxy statement on Schedule 14A. Each of CorMedix and Heron may also file other relevant documents with the SEC regarding the Proposed Transaction. This press release is not a substitute for the proxy statement or any other document that Heron may file with the SEC. Heron will mail the definitive proxy statement to its stockholders. INVESTORS AND STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, as well as any amendments or supplements to those documents, CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and stockholders may obtain these documents free of charge at the SEC’s website, www.sec.gov, and on the Investors section of the CorMedix’s investor relations website at https://cormedix.com/investors/ and Heron’s investor relations website at https://ir.herontx.com/.
6
Participants in the Solicitation
CorMedix, Heron and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from Heron’s stockholders in connection with the Proposed Transaction. Information about the directors and executive officers of Heron, including a description of their direct or indirect interests, by security holdings or otherwise, is set forth in its proxy statement for its 2026 annual meeting of stockholders, filed with the SEC on April 30, 2026, which is available online at https://www.sec.gov/ix?doc=/Archives/edgar/data/818033/000119312526196306/hrtx-20260430.htm, under the headings “Information Concerning the Board of Directors,” “Information Concerning Executive Officers,” “Corporate Governance – 2025 Director Compensation,” “Security Ownership of Certain Beneficial Owners and Management,” “Certain Relationships and Related Person Transactions” and “Executive Compensation,” and information about the directors and executive officers of CorMedix, including a description of their direct or indirect interests, by security holdings or otherwise, is set forth in its proxy statement for its 2026 annual meeting of stockholders, filed with the SEC on April 29, 2026, which is available online at https://www.sec.gov/ix?doc=/Archives/edgar/data/1410098/000121390026049311/ea0286136-05.htm, under the headings “Proposal No. 1 – Approval of the Director Election Proposal,” “Corporate Governance – Executive Officers,” “Security Ownership of Certain Beneficial Owners and Management,” “Director Compensation,” “Executive Compensation” and “Certain Relationships and Related Transactions,” and, in each case, in subsequently filed Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Forms 3, 4 and 5. Additional information regarding the interests of such participants will be included in the proxy statement and other relevant materials to be filed with the SEC when they become available.
Other information regarding the participants in the solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be set forth in Heron’s definitive proxy statement and other relevant materials to be filed with the SEC regarding the Proposed Transaction when such materials become available. Investors and stockholders should read the proxy statement carefully when it becomes available before making any voting or investment decisions. Copies of these documents may be obtained, free of charge, from the sources indicated above.
No Offer or Solicitation
This press release is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The shares of CorMedix common stock to be issued to Heron in the Proposed Transaction will be issued in a private placement in reliance on an exemption from the registration requirements of the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration.
Contacts
CorMedix —
Investors:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
Heron Therapeutics —
Investor Relations and Media:
Ira Duarte
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
iduarte@herontx.com
858-251-4400
7